<SEC-DOCUMENT>0001213900-21-050881.txt : 20211001
<SEC-HEADER>0001213900-21-050881.hdr.sgml : 20211001
<ACCEPTANCE-DATETIME>20210930190714
ACCESSION NUMBER:		0001213900-21-050881
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		89
FILED AS OF DATE:		20211001
DATE AS OF CHANGE:		20210930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NutriBand Inc.
		CENTRAL INDEX KEY:			0001676047
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				811118176
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259833
		FILM NUMBER:		211296301

	BUSINESS ADDRESS:	
		STREET 1:		121 S. ORANGE AVE.
		STREET 2:		SUITE 1500
		CITY:			ORLANDO
		STATE:			FL
		ZIP:			32801
		BUSINESS PHONE:		407 377-6695

	MAIL ADDRESS:	
		STREET 1:		121 S. ORANGE AVE.
		STREET 2:		SUITE 1500
		CITY:			ORLANDO
		STATE:			FL
		ZIP:			32801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nutriband Inc.
		DATE OF NAME CHANGE:	20160601
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ea148206-s1a2_nutriband.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Sep 30 22:42:50 UTC 2021 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ntrb="http://nutriband.com/20210731" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the Securities and Exchange
Commission on&#160;October 1, 2021</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <b>Registration No. 333-259833&#160;</b> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription"><b>AMENDMENT NO. 2</b></ix:nonNumeric></p><div>

</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"> <b>TO</b> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span style="-sec-ix-hidden: hidden-fact-0">S-1</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REGISTRATION STATEMENT<br/>
UNDER THE SECURITIES ACT OF 1933 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>Nutriband Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2834</b></span></td> <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>81-1118176</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or jurisdiction of <br/>
incorporation or organization)</span></td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary Standard Industrial <br/>
Classification Code Number)</span></td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.&#160;Employer <br/>
Identification&#160;No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">121 South Orange Ave., Suite 1500</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Orlando, Florida 32801</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(407) 377-6695</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address and telephone number of principal executive
offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Gareth Sheridan, Chief Executive Officer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nutriband Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">121 South Orange Ave., Suite 1500</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Orlando, Florida 32801</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(407) 377-6695</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copies to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 51%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Michael Paige</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Michael Paige Law PLLC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2300 N Street, NW, Suite 300</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, DC 20037</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(202) 363-4791</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fax: (202) 457-1678</p></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="width: 48%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ross D. Carmel, Esq.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jeffrey P. Wofford, Esq.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carmel, Milazzo&#160;&amp; Feil LLP</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">55 West 39<sup>th</sup> Street, 18<sup>th</sup>
    Floor</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, NY 10018</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APPROXIMATE DATE OF PROPOSED SALE TO PUBLIC:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As soon as practicable after this registration
statement becomes effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any securities being registered on this Form
are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered
only in connection with dividend or interest reinvestment plans, check the following box: &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non- accelerated filer</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:booleantrue" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided to Section 7(a)(2)(B) of the Securities Act. <ix:nonNumeric contextRef="c0" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CALCULATION OF REGISTRATION FEE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Title
    of Each Class of Securities to be Registered</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Proposed
    <br/>
    Maximum <br/>
    Aggregate <br/>
    Offering Price <br/>
    (1)(2)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Amount
    of <br/>
    Registration <br/>
    Fee</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Registration
    Fee </b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 64%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Units
    (3)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6,600,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">720.06</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Common
    Stock included in the Units (4)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Paid:&#160;$1,538.19&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Common
    Stock issuable upon exercise of the Warrants, which are included in the Units (5)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">7,920,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">864.07</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Fee Due:</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Representative&#8217;s
    Warrants (6)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Common
    Stock underlying Representative&#8217;s Warrants (5)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">990,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">98.07</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Total</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,692.14</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">153.95</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed maximum aggregate offering price. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes the price of additional shares of common stock and warrants to purchase common stock that the underwriters have the option to purchase to cover over-allotments, if any, within 45 days after the date of this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Unit includes (i) one share of common stock and (ii) one Warrant.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in the price of the units. No separate registration fee is required pursuant to Rule 457(g) under the Securities Act. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, pursuant to Rule 416 under the Securities Act of 1933, this Registration Statement includes an indeterminate number of additional shares as may be issuable as a result of stock splits or stock dividends which occur during this continuous offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required pursuant to Rule 457(g).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section
8(a) may determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Red"><b>The information in
this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer
to buy these securities in any state where the offer or sale is not permitted.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PRELIMINARY PROSPECTUS, SUBJECT TO COMPLETION,
DATED OCTOBER 1, 2021</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>1,056,000 Units, Each Consisting of One
Share of Common Stock and a</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant to Purchase One Share of Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Nutriband Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OTCQB trading symbol for the common stock: NTRB</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering 1,056,000 units (each a &#8220;Unit&#8221;),
each Unit consisting of one share of common stock, par value $0.001 per share, and one warrant (each a &#8220;Warrant&#8221;) at a price
of $6.25 per Unit. Each Warrant is immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise
price of $7.50 and will expire five (5) years from the date of issuance. The shares of common stock and Warrants may be transferred separately
immediately upon issuance. The public offering price per share of common stock will be determined by us at the time of pricing, may be
at a discount to the current market price, and the assumed offering price used throughout this prospectus may not be indicative of the
final offering price. All of the shares included in this offering are being sold by us.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our symbol on the OTCQB is NTRB. We have applied
for listing of our common stock and Warrants on the NASDAQ Capital Market under the symbols &#8220;NTRB&#8221; and &#8220;NTRBW,&#8221;
respectively and such listings are a condition to closing. On September 29, 2021, the last reported sale price of our common stock was
$9.575 per share.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company&#8221;
as that term is used in the Jumpstart Our Business Startups Act of 2012, and as such, we have elected to take advantage of certain reduced
public company reporting requirements for this prospectus and future filings. See &#8220;Risk Factors&#8221; and &#8220;Prospectus Summary
&#8212;Implications of Being an Emerging Growth Company.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing in our common stock involves risks.
See &#8220;Risk Factors&#8221; beginning on page 8.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Per
    Unit</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Price
    to the public</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6.25</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6,600,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Underwriting
    discounts and commissions</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">0.50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">528,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Proceeds
    to us (before expenses)<sup>(1)(2)</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">5.75</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6,072,000</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The
    public offering price and underwriting discount and commissions in respect of each Unit corresponds to the public offering price
    per share of common stock of $6.24 and the public offering price per accompanying Warrant of $0.01.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include a non-accountable expense allowance equal to 1.7% of the gross proceeds of this offering payable to the underwriters, or the reimbursement of certain expenses of the underwriters. We refer you to &#8220;Underwriting&#8221; beginning on page 63 of this prospectus for additional information regarding underwriting compensation.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriters the option
for a period of 45 days to purchase up to an additional 158,400 shares of common stock and/or 158,400 warrants to purchase shares of
common stock (equal to 15% of the number of shares of common stock and Warrants underlying the Units sold in the offering) from us in
any combination thereof at the public offering price per share of common stock and per Warrant, less underwriting discounts and commissions,
solely to cover over-allotments, if any.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters expect to deliver the shares
of common stock and warrants to purchasers in the offering against payment on&#160;xxx&#160;x, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WallachBeth
    Capital, LLC</b></span></td>
    <td style="width: 50%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WestPark Capital,
    Inc.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;,
2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 93%; text-align: justify"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offering</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Consolidated Financial Data</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Common Stock and Related Stockholder Matters</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Stockholders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Party Transactions</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Eligible for Future Sale</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index to Consolidated Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this prospectus and in any free writing prospectus prepared by or on behalf of us and delivered or made available to you. Neither we
nor the underwriters have authorized anyone to provide you with additional or different information. We are offering to sell, and seeking
offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this
prospectus or a free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of
our common stock. Our business, financial condition, operating results, and prospects may have changed since that date, and neither the
delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implication
that there has been no change in our affairs since the date of this prospectus or that the information contained by reference to this
prospectus is correct as of any time after its date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">References to &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our&#8221; and words of like import refer to us and our subsidiaries, including 4P Therapeutics LLC following our acquisition of
4P Therapeutics on August 1, 2018, and certain assets of Pocono Coated Products, LLC, on August 31, 2020, unless the context indicates
otherwise. References to 4P Therapeutics or Pocono Coated Products, LLC refer to the business and operations of 4P Therapeutics or Pocono
Coated Products, LLC, as the case may be, prior to acquisition by us unless the context indicates otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For investors outside the United States: Neither
we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in
any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares
of common stock and the distribution of this prospectus outside of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Industry and Market Data</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market data and certain other statistical
information used throughout this prospectus are based on independent industry publications, government publications and other published
independent sources. Some data is also based on our good faith estimates. The industry in which we operate is subject to a high degree
of uncertainty and risk due to a variety of factors, including those described in the section entitled &#8220;Risk Factors.&#8221; These
and other factors could cause results to differ materially from those expressed in these publications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<a id="a_001"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary highlights information contained
elsewhere in this prospectus. This summary does not contain all the information you should consider before investing in the securities.
However, you should read the entire prospectus carefully, including the &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations,&#8221; and our financial statements, including the notes thereto, appearing
elsewhere in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are primarily engaged in the development of
a portfolio of transdermal pharmaceutical products, contract research and development services and the manufacture of transdermal, topical
and coated products. Following our acquisition of 4P Therapeutics on August 1, 2018, we are planning to develop, and seek FDA approval
of, a number of transdermal pharmaceutical products under development by 4P Therapeutics. With the acquisition of the transdermal, topical,
cosmetic and nutraceutical business of Pocono Coated Products, LLC effective August 31, 2020, we manufacture on a contract basis transdermal,
topical, coated and consumer products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead product is our abuse deterrent fentanyl
transdermal system which we are developing to provide clinicians and patients with an extended-release transdermal fentanyl product for
use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis
by deterring the abuse and misuse of these fentanyl patches. We believe that our abuse deterrent technology, AVERSA, can also be utilized
in transdermal patches to deter the abuse of other drugs and we are exploring follow-on applications. In addition, we are also exploring
the development of generic transdermal patches and the application of our transdermal technology for the transdermal delivery of commercially
available drugs or biologics that are typically delivered by injection.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the acquisition of 4P Therapeutics, 4P Therapeutics&#8217;
drug development business became our principal business. 4P Therapeutics was engaged in developing a series of transdermal pharmaceutical
products that are all in the preclinical stage of development. Prior to our acquisition of 4P Therapeutics, 4P Therapeutics developed
abuse deterrent technology upon which our lead product is based. Prior to our acquisition, 4P Therapeutics filed an international patent
application under the Patent Cooperation Treaty for worldwide prosecution of the abuse deterrent transdermal technology used in our abuse
deterrent fentanyl transdermal system. The patent is being prosecuted in the United States and in other countries throughout the world.
We have received patent protection from the European Patent Office, Mexico&#8217;s patent office, Korea&#8217;s patent office, Russia&#8217;s
patent office, Australia&#8217;s patent office and the Japan patent office for the patent applications filed by 4P Therapeutics entitled
&#8220;Abuse and Misuse Deterrent Transdermal System.&#8221; In addition to applying the technology to developing an abuse deterrent fentanyl
transdermal system, we believe that the abuse deterrent patch technology can be applied to other opioids and pain medication patches where
there is a risk of abuse and overdose, as well as other transdermal pharmaceuticals where we believe our technology can help prevent abuse
or accidental exposure. The principal asset that we acquired with our acquisition of 4P Technology is the abuse deterred technology, which
included the patent applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general approach is to use generic drugs that
are off patent and incorporate them into our transdermal drug delivery system. Although these medications have received FDA approval in
oral or injectable form, we need to conduct a transdermal product development program which will include the preclinical and clinical
trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead product under development is our abuse
deterrent fentanyl transdermal system. We believe that our abuse deterrent technology can reduce the abuse (both intentional and accidental)
and misuse potential of the fentanyl patch thereby reducing the liability associated with the manufacture, sales and marketing and prescribing
of fentanyl patches while maintaining the same chronic pain management associated with conventional fentanyl patches. In 2017, according
to a report from the National Institute on Drug Abuse, of the more than 72,000 drug overdose deaths in the United States, nearly 30,000
occurred due to overdoses of fentanyl and fentanyl analogues. Although fentanyl patches are available on the market, we believe that none
of the currently available fentanyl patches have technology designed to reduce abuse or misuse and we believe that our technology is designed
to reduce the ability of recreational users to abuse or misuse the patch. Further, FDA has introduced a label warning of fatal accidental
pediatric exposure to discarded fentanyl patches following more than 20 such cases in the past decade. Basic transdermal fentanyl patch
technology offers no safeguard against this accidental pediatric exposure, and we believe our technology will reduce the risk of these
very unfortunate accidents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the acquisition of 4P Therapeutics,
we also acquired a pipeline of transdermal biologic products, including exenatide for type 2 diabetes and FSH for infertility, that leverage
our novel delivery technology. These large molecule and peptide drugs are off-patent and are currently available only as injectables.
We are evaluating the possibility of developing a transdermal delivery system for these drugs using our delivery technology as an alternative
to injection but with improved compliance and patient outcomes. In addition, we may develop certain generic transdermal products where
we think we can efficiently make an improvement to existing patches where we believe that we will have the opportunity to take significant
market share with good profit margins. One example of such a product candidate is the development of a generic scopolamine patch. The
prioritization of our portfolio product candidates will be reviewed on an ongoing basis and will take into account technical progress,
market potential, and commercial interest. We cannot assure you that we will be able to develop and obtain FDA approval for any of these
potential products or that we can be successful in marketing any such products. The FDA approval process can take many years to complete
and we will require substantial funding for each product that goes through the process. We cannot assure you that we will obtain FDA marketing
approval for any of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no current plans to market our
own branded consumer products. Following the acquisition of Pocono our focus has turned to contract manufacturing primarily in the Asia
region with our partner Best Choice Inc. Best Choice Inc. currently works with a number of brands to whom we now provide consulting for
and contract manufacturing services. The terms of our distribution agreement with Best Choice dated April 13, 2018. remain in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Selected Risks Associated with our Business
and Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to significant risks,
which are disclosed in more detail under &#8220;Risk Factors,&#8221; which begins on page&#160;8, as a result of which an investment in
our common stock is highly speculative and could result in the loss of your entire investment. Significant risks include, but are not
limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the recent outbreak of COVID-19, which was declared by the World Health Organization as a global pandemic, and is resulting in travel and other restrictions to reduce the spread of the disease, including state and local orders across the country, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. The effects of these orders, government-imposed quarantines and measures we would take, such as work-from-home policies, may negatively impact productivity, disrupt our business and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not raise substantial funds subsequent to the completion of this offering, we may not be able to develop our lead product and we may have to grant rights to our product on unfavorable terms in order to complete the development of this product. The completion of the development of our lead product may take longer or be more expensive than we anticipate.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA regulatory process may take longer and be more expensive than we anticipate without any assurance that we will obtain FDA approval.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are not able to obtain FDA approval for our lead product, we may not have the resources to develop any other product, and we may not be able to continue in business.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to launch any products for which we receive FDA marketing approval.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to establish a distribution network for the marketing and sale of any products for which we receive FDA approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to establish manufacturing facilities in compliance with FDA good manufacturing practices or to enter into manufacturing agreements for the manufacture of our products in an FDA approved manufacturing facility.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It may be necessary to us to enter into a joint venture or other strategic relationship in order to develop, perform clinical testing for, manufacture or market any of our proposed products. We may not be able to enter into such a relationship, and any relationship may not be successful, and the other party may have business interests and priorities that are different from ours.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are party to a settlement agreement with the SEC resulting from statements in our SEC filings that did not accurately reflect the FDA&#8217;s jurisdiction over our consumer products and did not disclose that we could not legally market these products in the United States. The settlement included a cease-and-desist order against violating the provisions of the Securities Exchange Act which require us to file accurate registration statements and annual reports with the SEC. Our failure to comply with our obligations under the settlement agreement could result in enforcement proceedings against us or our officers.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to protect our rights in our intellectual property, and we may be subject to intellectual property litigation which would be expensive and disruptive of our operations even if we eventually prevail on the merits.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unanticipated side effects or other adverse events resulting from the use of our product could require a recall of our products and, even if no recall is required, our reputation could be impaired by side effects.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to evaluate potential acquisition candidates, with the result that we may not be able to benefit from the acquisition or integrate the acquired business with our business. We have recently incurred an impairment charge as a result of an acquisition when the intellectual property assets of the acquired company were not as represented. We cannot assure you that we will not incur similar or other problems with any future acquisitions.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may fail to comply with all applicable laws and regulations relating to our product. We may have to change or adapt our operations in the event of changes in national, regional and local government regulations, taxation, controls and political and economic developments that affect our products and the market for our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to accurately estimate anticipated expenses, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Best Choice or any other international distributor of our products may not be able to obtain any necessary regulatory approval necessary to market our product or, if they are able to obtain regulatory approval, they may not be successful in marketing our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms of our recent financing, including the antidilution provisions of the warrants, may impair our ability to raise funds for our operations during the term of the warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Organization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a Nevada corporation, incorporated on January
4, 2016. In January 2016, we acquired Nutriband Ltd, an Irish company which was formed by Gareth Sheridan, our chief executive officer,
in 2012 to enter the health and wellness market by marketing transdermal patches. Our corporate headquarters are located at 121 S. Orange
Ave. Suite 1500, Orlando, Florida 32765, telephone (407) 377-6695. Our website is <i>www.nutriband.com</i>. Information contained on or
available through our website or any other website does not constitute a portion of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Financings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a Stock Purchase Agreement (&#8220;SPA&#8221;),
dated December 7, 2020, with the Company, BPM Inno Ltd., Kiryat, Israel, purchased 81,395 shares of common stock at a price of $8.60 per
share, or $700,000. The transaction was completed at a closing on February 26, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 22, 2020, the Company issued in a private
placement 46,828 units at a price of $11 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share
of common stock at an exercise price of $14 per share. The warrants expire April 30, 2023. The Company issued a total of 46,828 shares
of common stock and warrants to purchase 46,828 shares of common stock. The Company received proceeds of $515,113.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, a minority stockholder who had
previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the total loans from the
stockholder to $275,000. See Note 4 in the attached Financial Statements. On March 27, 2020, the Company issued 25,000 shares upon conversion
of the notes in the principal balance of $275,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2020, the Company prepaid the convertible
notes in the principal amount of $270,000 from the proceeds of the private placement. The total payments, including the prepayment penalty
and accrued interest, was $345,565. As a result of the payment of the notes, the derivative liability, which was $928,774 at January 31,
2020, was reduced to zero. As a result of the terms of the private placement, the warrants to purchase 50,000 shares at lesser of (a)
$20.90 or (b) if the Company completes a private offering, 110% of the initial offering price of the common stock in the public offering,
became a warrant to purchase 95,000 shares at $11 per share, subject to adjustment pursuant to the antidilution provisions of the warrant.
See Notes 4 and 10 in the attached Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2019, we entered into a securities
purchase agreement with two investors pursuant to which we issued to the investor for $250,000 (i) 6% one-year convertible notes in the
principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise price equal to the lesser
of (i) $20.90 or (ii) if we complete this offering, 110% of the initial public offering price of the common stock in this offering, which,
based on an initial public offering price of the common stock in this offering of $12.00 per share, would be $13.20 per share. The net
proceeds from this financing, of approximately $203,000, were used for working capital. The notes are convertible at a conversion price
equal to the lesser of (i) the per share price of our common stock offered hereby or (ii) the variable conversion price, which is defined
as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion. The conversion price
and the percentage of the trading price is subject to downward adjustment in the event we fail to comply with its obligations under the
note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Implications of Being an Emerging Growth Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than $1.07 billion in revenue
during our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups
Act of 2012, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are otherwise generally
applicable to public companies, although as a smaller reporting company we are taking advantage of reduced reporting requirements. In
particular, as an emerging growth company, we:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may present only two years of audited financial statements and related disclosure under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, or MD&amp;A;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives, which is commonly referred to as &#8220;compensation discussion and analysis&#8221;;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to obtain an attestation and report from our auditors on our management&#8217;s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the &#8220;say-on-pay,&#8221; &#8220;say-on frequency&#8221; and &#8220;say-on-golden-parachute&#8221; votes);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and chief executive officer pay ratio disclosure;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">will not be required to conduct an evaluation of our internal control over financial reporting until two years after the effective date of the registration statement of which this prospectus is a part.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to take advantage of all of these reduced
reporting requirements and exemptions. However, since we have already adopted certain new or revised accounting standards under &#167;107
of the JOBS Act, we are not able to take advantage of the delayed phase in of the new or revised accounting standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the JOBS Act, we may take advantage of the
above-described reduced reporting requirements and exemptions for up to five years after our initial sale of common equity pursuant to
a registration statement declared effective under the Securities Act of 1933, as amended, or such earlier time that we no longer meet
the definition of an emerging growth company. The JOBS Act provides that we would cease to be an &#8220;emerging growth company&#8221;
if we have more than $1.07 billion in annual revenues (as adjusted for inflation), have more than $700 million in market value of our
common stock held by non-affiliates, or issue more than $1 billion in principal amount of non-convertible debt over a three-year period.
Under current Securities and Exchange Commission, or SEC, rules, however, we will continue to qualify as a &#8220;smaller reporting company&#8221;
for so long as we have either (i) a public float (i.e., the market value of common equity held by non-affiliates) of less than $250 million
as of the last business day of our most recently completed second fiscal quarter or (ii) annual revenues of less than $100 million and
a public float of less than $700 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<a id="a_002"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 31%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Units
    offered by us:</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td>
    <td style="width: 68%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">1,056,000
    Units, each consisting of one share of common stock and one Warrant, each whole Warrant exercisable for one share of common stock.
    The Warrants included with the Units are exercisable immediately, have an exercise price of $7.50 per share and expire five (5) years
    from the date of issuance. The shares of common stock and Warrants that are part of the Units are immediately separable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock outstanding prior to this offering: <sup>(1)</sup></span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,356,269 shares</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Common stock to be outstanding upon&#160;completion&#160;of&#160;this&#160;offering:<sup>(2)</sup></span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">7,412,269 shares (7,570,669&#160;shares
    if the underwriters&#8217; over-allotment option is exercised in full).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 17pt; padding-left: 10pt; text-indent: -0.15pt">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Option
    to purchase additional shares</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The underwriters have
    an option for a period of 45 days to purchase up to an additional 158,400 shares of our common stock and/or Warrants to purchase
    up to 158,400 additional shares of our common stock (equal to 15% of the number of shares of common stock and Warrants underlying
    the Units sold in the offering), from us in any combination thereof.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Use
    of proceeds:</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We intend to use the
    net proceeds of this offering, estimated at approximately $5.8 million primarily for research and development of our abuse deterrent
    fentanyl transdermal system and for working capital and other corporate purposes. See &#8220;Use of Proceeds.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend policy:</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not anticipate paying any cash dividends on our common stock. We expect that, for the foreseeable future, any earnings will be reinvested in our business.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing and trading symbol:</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our symbol on the OTCQB is NTRB. We have applied for listing of our common stock and Warrants on the NASDAQ Capital Market under the symbols &#8220;NTRB&#8221; and &#8220;NTRBW,&#8221; respectively and such listings are a condition to closing.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors:</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should carefully read and consider the information set forth under the heading &#8220;Risk Factors,&#8221; beginning on page 8 of this prospectus and all other information set forth in this prospectus before deciding to invest in our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 1, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares outstanding
does not include 141,830 shares which may be issued upon exercise of outstanding warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</div><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<a id="a_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SELECTED CONSOLIDATED FINANCIAL DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following information as of January 31, 2021 and 2020, and for
years then ended, has been derived from our audited consolidated financial statements which appear elsewhere in this prospectus. The following
information as of January 31, 2021 and 2020, and for six months ended July 31, 2021 and 2020, has been derived from our unaudited consolidated
financial statements which appear elsewhere in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Statement of Operations Information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Six Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>July 31, 2021 (Unaudited)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>January&#160;31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">647,227</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">203,814</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">943,702</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">370,647</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 0.25in">Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">582,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,088,827</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,957,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,790,980</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Derivative expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">767,650</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(835,880</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(638,063</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,932,828</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,721,627</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net (loss) per share of common stock (basic and diluted)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(.12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.51</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.50</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted average shares of common stock outstanding&#160;(basic and diluted)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,343,076</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,496,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,770,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,423,956</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Balance Sheet Information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">July 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">606,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">314,188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,181</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Working capital deficiency</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,048,806</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,254,418</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,979,141</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,670,985</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,835,105</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,902,277</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,316,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,111,946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,433</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>An investment in our common stock involves
a high degree of risk. You should carefully consider the risks described below together with all of the other information included in
this prospectus before making an investment decision with regard to our securities. The statements contained in this prospectus include
forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those
set forth in or implied by forward-looking statements. The risks set forth below are not the only risks facing us. Additional risks and
uncertainties may exist that could also adversely affect our business, prospects or operations. If any of the following risks actually
occurs, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock
could decline, and you may lose all or a significant part of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks Concerning our Business</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because of a lack of funds, we have suspended
our product development operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is the development of transdermal
systems for the delivery of pharmaceuticals. The development of pharmaceutical products is highly cash intensive, and many early-stage
drug development companies are unable to raise sufficient cash to complete the development and testing of their products and obtain regulatory
approval, with the result that they either obtain funding on very unfavorable terms, cease to conduct business or sell or license their
intellectual property on unfavorable terms. Because of our lack of cash and the absence of any significant financing, we have suspended
our development activities relating to our transdermal pharmaceutical products. Because of the anticipated lack of revenues until we have
an approved product that we can market and the time required to obtain FDA approval, which can take many years, we must rely on our ability
to raise money in the private or public equity market or enter into a joint venture relationship with a company that has the funds, the
willingness and the ability to fund or obtain funds for the project that is the subject of the joint venture. In March 2020, we withdrew
a registration statement relating to a proposed public offering. If we are able to raise funds or enter into a joint venture, it is likely
that the term will not be favorable to us. We cannot assure you that we will be able to raise funds in a public or private financing or
a joint venture, and, if we are unable to do so, we may cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because we are an early-stage company with
minimal revenue and a history of losses and we expect to continue to incur substantial losses for the foreseeable future, we cannot assure
you that we can or will be able to operate profitably.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not generate any revenue prior to the quarter
ended October 31, 2018 and since then, we have incurred losses as, 4P Therapeutics generated only modest revenue from contract research
and development services which are not related to our pharmaceutical transdermal patch business. Although we anticipate that, for the
near term, we will continue to perform research and development services for third parties, we do not expect to generate significant revenue
from performing contract research and development services for our clients and we have generated losses from operations from this business.
During the year ended January 31, 2020, we experienced a significant decline in revenue from 4P Therapeutics&#8217; largest customer.
We generated a negative gross margin and negative cash flow from operations for the years ended January 31, 2020 and 2019. We are subject
to the risks common to start-up, pre-revenue enterprises, including, among other factors, undercapitalization, cash shortages, limitations
with respect to personnel, financial and other resources and lack of revenues. Drug development companies typically incur substantial
losses during the product development and FDA testing phase of the business and do not generate revenues until after the drug has received
FDA approval, which cannot be assured, and until the company has started to sell the product. We can give no assurance that we can or
will ever be successful in achieving profitability and the likelihood of our success must be considered in light of our early stage of
operations. We cannot assure you that we will be able to operate profitably or generate positive cash flow. If we cannot achieve profitability,
we may be forced to cease operations and you may suffer a total loss of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business will be likely be adversely
affected by the COVID-19 pandemic.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The COVID-19 pandemic and the response to the
pandemic will affect our business in a number of ways, including, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to raise financing for our operations and to enter into a joint venture agreement may be affected by both the willingness and ability of potential financing sources and potential joint venture partners to invest in an undercapitalized business, particularly at a time when the potential financing source or joint venture partner may need to devote its resources to existing portfolio companies or joint ventures which may be in need of financing.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decision by investors who would invest in early-stage pharmaceutical companies to limit their financing efforts to companies that are dealing with products or services related to COVID-19 diagnosis or treatment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effect of recent stock market decline on the willingness of investors to make an investment in our securities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial health of our potential contract service customers.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to perform contract services.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain any goods or services which we may need to perform contract services.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of our foreign distributors to obtain regulatory approval, which may be affected by the regulatory agencies giving a low priority
to products such as our consumer patches.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial health of Best Choice.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval is obtained in South Korea, the extent to which consumers in South Korea purchase our products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent to which the purchase of our consumer products is a low priority item for a population whose disposable income may have decreased
as a result of COVID-19 and the steps taken by the South Korean government to curb the spread of infection.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because we do not have a product we can
market in the United States, we cannot predict when or whether we will operate profitably.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not completed the development of our lead
product, which is our abuse deterrent fentanyl transdermal system, and we do not have any product that we can market in the United States.
Because of the numerous risks and uncertainties associated with product development, we cannot assure you that we will be able to develop
and market any products or achieve or attain profitability. If we are able to obtain financing for our operations, we expect that we will
incur substantial expenses as we continue with our product development and clinical trials. Further, if we are required by applicable
regulatory authorities, including the FDA as well as the comparable regulatory agencies in other countries in which we may seek to market
product, to perform studies in addition to those we currently anticipate, our expenses will increase beyond expectations and the timing
of any potential product approval may be delayed. As a result, we expect to continue to incur substantial losses and negative cash flow
for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A number of factors, including, but not limited
to the following, may affect our ability to develop our business and operate profitably:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain necessary funding to develop our proposed products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
success of clinical trials for our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain FDA approval for us to market any proposed product in our pipeline in the United States;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
delays in regulatory review and approval of product in development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we obtain FDA approval to market our product, our ability to establish manufacturing and distribution operations or entering into manufacturing
and distribution agreements with qualified third parties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
acceptance of our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to establish an effective sales and marketing infrastructure;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to protect our intellectual property;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
from existing products or new products that may emerge;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
ability to commercialize our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
product liability claims and adverse events;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to adequately support future growth; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to attract and retain key personnel to manage our business effectively.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our failure to develop our abuse deterrent
fentanyl transdermal system will impair our ability to continue in business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead product is our abuse deterrent fentanyl
transdermal system, and we are devoting our resources primarily to developing this product, and, if we complete the development of this
product, we will conduct the clinical trials necessary to enable us to obtain FDA approval and to market the product. If we are not able
to obtain necessary financing to develop, obtain FDA marketing approval and market this product successfully, we may not have the resources
to develop additional products, and we may not be able to continue in business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Before we can market in the United States
any product which is classified by the FDA as a drug, we must obtain FDA marketing approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our proposed transdermal products are drug-device
combinations that are considered by the FDA to be drugs, which require approval by the FDA. In order to obtain FDA approval, it is necessary
to conduct a series of preclinical and clinical tests to confirm that the product is safe and effective. Even though the medication that
is being delivered through our transdermal patch may have already received FDA approval, because we are delivering the medication through
the skin, we will need to complete, to the FDA&#8217;s satisfaction, all of the required clinical testing steps to demonstrate safety
and efficacy. At any point, the FDA could ask us to perform additional tests or to refine and redo a test that we had previously completed.
The process of obtaining FDA approval could take many years, with no assurance that the FDA will approve the product. The FDA also will
need to approve the manufacturing process and the manufacturing facility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need to rely on a third-party contract
research organization to conduct our preclinical and clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we believe that we, through 4P Therapeutics,
have the capabilities to conduct preclinical studies and early stage clinical studies in house, we may need to rely on third party contract
research organizations to conduct our pivotal preclinical and clinical trials. Our failure or the failure of the contract research organization
to conduct the trials in compliance with FDA regulations could possibly derail our obtaining FDA approval, and could require us to redo
any preclinical or clinical trials which we or the organization administered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter delays in completing clinical
trials, which would increase our costs and delay market entry.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience delays in completing the clinical
trials necessary for FDA approval. These delays may result from a number of factors which could prevent us from starting the trial on
time or completing the study in a timely manner, which may include factors out of our control. Since we may need to rely on third parties
for supplying us with the drug and transdermal patches used in the trials, there may be various reasons for us to experience a delay in
obtaining the clinical materials required to start each clinical trial, which may include factors out of our control. Clinical trials
can be delayed or terminated for a number of reasons, including delay or failure to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
necessary financing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
regulatory approval to commence a trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reach
agreement on acceptable terms with prospective contract research organizations, investigators and clinical trial sites, the terms of
which may be subject to extensive negotiation and vary significantly among different research organizations and trial sites;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
institutional review board approval at each site;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enlist
suitable patients to participate in a trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
patients complete a trial or return for post-treatment follow-up;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure
clinical sites observe trial protocol or continue to participate in a trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address
any patient safety concerns that arise during the course of a trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address
any conflicts with new or existing laws or regulations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
a sufficient number of clinical trial sites; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
sufficient quantities of the product candidate for use in clinical trials.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patient enrolment is also a significant factor
in the timely completion of clinical trials and is affected by many factors, including the size and nature of the patient population,
the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical
trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to available
alternatives, including any new drugs or treatments that may be approved for the indications we are investigating.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also encounter delays if a clinical trial
is suspended or terminated by us, by the independent review boards of the institutions in which such trials are being conducted, by the
trial&#8217;s data safety monitoring board, or by the FDA. Such authorities may suspend or terminate one or more of our clinical trials
due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or
clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold,
unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations
or administrative actions or lack of adequate funding to continue the clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we experience delays in carrying out or completing
preclinical or clinical trials for any product candidates, the commercial prospects of our product candidates may be harmed, and our ability
to generate revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will
increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales
and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the
factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of
regulatory approval of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to finance our operations and
generate revenues depends on the clinical and commercial success of our abuse deterrent fentanyl transdermal system and our other product
candidates and failure to achieve such success will negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our prospects, including our ability to finance
our operations and generate revenues, depend on the successful development, regulatory approval and commercialization of our abuse deterrent
fentanyl transdermal system, which itself requires substantial financing, as well as our other product candidates. The clinical and commercial
success of our product candidates depends on a number of factors, many of which are beyond our control, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA&#8217;s acceptance of our parameters for regulatory approval relating to our product candidates, including our proposed indications,
primary endpoint assessments, primary endpoint measurements and regulatory pathways;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA&#8217;s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation
of data from preclinical studies or clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA&#8217;s acceptance of the sufficiency of the data we collect from our preclinical studies and pivotal clinical trials to support
the submission of a New Drug Application, known as an NDA, without requiring additional preclinical or clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA&#8217;s acceptance of our abuse deterrent labelling relating to our products, including our abuse deterrent fentanyl transdermal
system;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">when
we submit our NDA upon completion of our clinical trials, the FDA&#8217;s willingness to schedule an advisory committee meeting, if applicable,
in a timely manner to evaluate and decide on the approval of our NDA;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recommendation of the FDA&#8217;s advisory committee, if applicable, to approve our application without limiting the approved labelling, specifications, distribution or use of the products, or imposing other restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to satisfy any issued raised by the FDA in response to our test data;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA&#8217;s satisfaction with the safety and efficacy of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
prevalence and severity of adverse events associated with our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timely and satisfactory performance by third party contractors of their obligations in relation to our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we receive FDA approval, our success in educating physicians and patients about the benefits, administration and use our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to raise additional capital on acceptable terms in order to achieve conduct the necessary clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
availability, perceived advantages and relative cost of alternative and competing treatments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
effectiveness of our marketing, sales and distribution strategy and operations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing
practices;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain, protect and enforce our intellectual property rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to bring an action timely for patent infringement arising out of the filing of ANDAs by generic companies seeking approval to
market generic versions of our products, if applicable, before the expiry of our patents; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to avoid third party claims of patent infringement or intellectual property violations.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to achieve these objectives or to overcome
the challenges presented above, many of which are beyond our control, in a timely manner, we could experience significant delays or an
inability to successfully commercialize our product candidates. Accordingly, even if we obtain FDA approval to market our products, we
may not be able to generate sufficient revenues through the sale of our products to enable us to continue our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Since we do not have commercial drug manufacturing
capabilities, if we are unable to establish manufacturing facilities, we may have to enter into a manufacturing agreement with a manufacturer
that has been approved by the FDA.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any commercial manufacturer of our products and
the manufacturing facilities where we make our commercial products will be subject to FDA approval. Part of the process of seeking FDA
approval to market our products is the FDA&#8217;s approval of the manufacturing process and facility. Although we recently added certain
manufacturing capabilities through our acquisition of Pocono, the establishment of a manufacturing facility at the level required for
prescription medication&#8217;s is very costly, and, unless we obtain funding for that purpose, it would be necessary for us to engage
a third party who has experience is manufacturing transdermal patches for FDA approved products. By relying on a third-party manufacturer,
we will be dependent upon the manufacturer, whose interests may be different from ours. Any third-party contract manufacturer will be
responsible for quality control and for meeting our requirements. If the manufacturer does not meet our quality standards and delivers
products that do not meet our specifications, we may both incur liability for breach of our warranty to our customer, as well as liability
for any damage, including death, that may result from the use, abuse or accidental misuse of the product. Regardless of whether we are
able to make a claim against the manufacturer, our reputation may be impaired and we may lose business as a result. Further, the contract
manufacturer may have other customers and may allocate its resources based on the contract manufacturer&#8217;s interest rather than our
interest. Furthermore, we may not be able to assure ourselves that we will get favorable pricing. We have previously had problems with
our manufacturer of our consumer over-the-counter transdermal patches, and we cannot assure you that we will not have the same, similar
or other problems with the manufacturer of our FDA approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we or any third-party manufacturer fails
to comply with FDA current good manufacturing practices, we may not be able to sell our products until and unless the manufacture becomes
compliant.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All FDA approved drugs, including our proposed
transdermal products, must be manufactured in accordance with good manufacturing practices. All manufacturing facilities are inspected
by the FDA as a matter of routine inspection or for a specific cause. If a manufacturer fails to comply with all applicable regulations,
the FDA can prohibit us from distributing products manufactured in those facilities, whether they are a contract manufacturer or own facility.
A failure to be in compliance with good manufacturing practices could result in the FDA closing the facilities or limiting our use of
the facilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the FDA implements Risk Evaluation and
Mitigation Strategies policies for any of our proposed products, we will need to comply with such policies before we can obtain FDA approval
or the product.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Food and Drug Administration Amendments Act
of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy from manufacturers to ensure that the benefits of
a drug or biological product outweigh its risks. The FDA has issued a Risk Evaluation Mitigation Strategy for a fentanyl iontophoretic
transdermal system. Before we can receive FDA approval for any product for which the FDA has issued a Risk Evaluation Mitigation Strategy,
we must satisfy the FDA that we have complied with the Risk Evaluation Mitigation Strategy. If one of our products becomes subject to
a Risk Evaluation and Mitigation Strategy policy after receiving FDA approval, it will need to comply with such policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products will continue to be subject
to FDA review after FDA approval is given.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discovery of previously unknown problems with
our products or unanticipated problems with the manufacturing processes and facilities, even after FDA and other regulatory approvals
of the product for commercial sale, may result in the imposition of significant restrictions, including withdrawal of the product from
the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and other regulatory agencies continue
to review products even after the products receive agency approval. If and when the FDA approves one of our products, its manufacture
and marketing will be subject to ongoing regulation, which could include compliance with current good manufacturing practices, adverse
event reporting requirements and general prohibitions against promoting products for unapproved or &#8220;off-label&#8221; uses. We are
also subject to inspection and market surveillance by the FDA for compliance with these and other requirements. Any enforcement action
resulting from the failure, even by inadvertence, to comply with these requirements could affect the manufacture and marketing of our
products. In addition, the FDA or other regulatory agencies could withdraw a previously approved product from the market upon receipt
of newly discovered information. The FDA or another regulatory agency could also require us to conduct additional, and potentially expensive,
studies in areas outside our approved indicated uses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We must continually monitor the safety of
our products once approved and marketed for potential adverse events which could jeopardize our ability to continue marketing the products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As with all medical products, the use of our products
could sometimes produce undesirable side effects or adverse reactions or events (referred to cumulatively as adverse events). Our consumer
products initially caused skin irritation because of certain of the ingredients in the patch, which we corrected by reformulating the
patches. For the most part, we expect these adverse events to be known and occur at some predicted frequency based on our experience in
the clinical development program. When adverse events are reported to us, we are required to investigate each event and the circumstances
surrounding it to determine whether it was caused by our product and whether a previously unrecognized safety issue exists. We will also
be required to periodically report summaries of these events to the applicable regulatory authorities. If the adverse effects are significant,
we may be required to recall our product. We cannot assure you that our medical products will not cause skin irritation or other adverse
events. Our ability to market our products may be impaired by unanticipated adverse events and any recall of our product. Because we are
an early-stage company, our reputation, and our ability to market products, could be affected more severely than a major pharmaceutical
company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the use of our products could be
associated with serious and unexpected adverse events, or with less serious reactions at a greater than expected frequency. Such issues
may arise when our products are used in critically ill or otherwise compromised patient populations. When unexpected events are reported
to us, we are required to make a thorough investigation to determine causality and the implications for product safety. These events must
also be specifically reported to the applicable regulatory authorities. If our evaluation concludes, or regulatory authorities perceive,
that there is an unreasonable risk associated with the product, we would be obligated to withdraw the impacted lot(s) of that product
or recall the product and discontinue marketing until all problems are satisfactorily resolved. Furthermore, an unexpected adverse event
of a new product could be recognized only after extensive use of the product, which could expose us to product liability risks, enforcement
action by regulatory authorities and damage to our reputation and public image.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A serious adverse finding concerning the risk
of any of our products by any regulatory authority could adversely affect our reputation, business and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we obtain FDA approval to market our
products, we expect to spend considerable time and money complying with federal and state laws and regulations governing their sale, and,
if we are unable to fully comply with such laws and regulations, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Health care providers, physicians and others will
play a primary role in the recommendation and prescription of our proposed products. Further, if we use third-party sales and marketing
providers, they may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the
business or financial arrangements and relationships through which we market, sell and distribute our products. Applicable federal and
state health care laws and regulations are expected to include, but not be limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal anti-kickback statute is a criminal statute that makes it a felony for individuals or entities knowingly and willfully to offer
or pay, or to solicit or receive, direct or indirect remuneration, in order to induce the purchase, order, lease, or recommending of
items or services, or the referral of patients for services, that are reimbursed under a federal health care program, including Medicare
and Medicaid;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal False Claims Act imposes liability on any person who knowingly submits, or causes another person or entity to submit, a false
claim for payment of government funds. Penalties include three times the government&#8217;s damages plus civil penalties of $5,500 to
$11,000 per false claim. In addition, the False Claims Act permits a person with knowledge of fraud, referred to as a qui tam plaintiff,
to file a lawsuit on behalf of the government against the person or business that committed the fraud, and, if the action is successful,
the qui tam plaintiff is rewarded with a percentage of the recovery;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
Insurance Portability and Accountability Act, known as HIPAA, imposes obligations, including mandatory contractual terms, with respect
to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Social Security Act contains numerous provisions allowing the imposition of a civil money penalty, a monetary assessment, exclusion from
the Medicare and Medicaid programs, or some combination of these penalties; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have analogous state laws and regulations, such as state anti-kickback and false claims laws. In some cases, these state laws
impose more strict requirements than the federal laws. Some state laws also require pharmaceutical companies to comply with certain price
reporting and other compliance requirements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our failure to comply with any of these federal
and state health care laws and regulations, or health care laws in foreign jurisdictions, could have a material adverse effect on our
business, financial condition, result of operations and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Before we can market our product outside
of the United States, we will need to obtain regulatory approval in each country in which we propose to sell our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to market and sell our products in jurisdictions
other than the United States, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements.
The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA and can involve
additional testing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in many countries worldwide, it is
required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain
approvals from regulatory authorities outside the United States on a timely basis, if at all. Even if we were to receive approval in the
United States, approval by the FDA does not ensure approval by regulatory authorities in other countries. Similarly, approval by one regulatory
authority outside the United States would not ensure approval by regulatory authorities in other countries. We may not be able to file
for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain
approval of our product candidates by regulatory authorities in foreign jurisdictions, the commercial prospects of those product candidates
may be significantly diminished, and our business prospects could be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, particularly in member
states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations
or the successful completion of health technology assessment procedures with governmental authorities can take considerable time after
receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on
prices and reimbursement levels, including as part of cost containment measures. Certain countries allow companies to fix their own prices
for medicines but monitor the pricing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to regulations in the United States,
if we market outside of the United States, we will be subject to a variety of regulations governing, among other things, clinical trials
and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the requisite
approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in
those countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not have sufficient product liability
insurance, we may be subject to claims that are in excess of our net worth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we market any pharmaceutical product, we
will need to purchase significant product liability insurance. However, in the event of major claims from the use of our products, it
is possible that our product liability insurance will not be sufficient to cover claims against us. We cannot assure you that we will
not face liability arising out of the use of our products which is significantly in excess of the limits of our product liability insurance.
In such event, if we do not have the funds or access to the funds necessary to satisfy such liability, we may be unable to continue in
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because some of the patches we are developing,
such as our abuse deterrent fentanyl patch, have potential severe side effects, we may face liability in the event patients suffer serious,
possibly life-threatening, side effects from our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fentanyl patches have known side effects and may
cause serious or life-threatening breathing problems due to opioid-induced respiratory depression. In addition, taking certain medications
with fentanyl may increase the risk of serious or life-threatening breathing problems, sedation or coma. Because of the seriousness of
the side effects, fentanyl patches should only be used in accordance labelling approved by the FDA or by the applicable regulatory authorities
outside of the United States. Fentanyl patches are only indicated for the treatment of people who are tolerant to opioid medications because
they have taken this type of medication for at least one week and should not be used to treat mild or moderate pain, short-term pain,
pain after an operation or medical or dental procedure, or pain that can be controlled by medication that is taken on an as-needed basis.
Although we will include all warnings on the packaging that are required by the FDA or foreign regulatory authorities, claims may be made
against us in the event that death or serious side effects result from the use of our abuse deterrent fentanyl transdermal system, even
if prescribed for a patient for whom fentanyl patches should not be prescribed. We cannot assure you that we will not face significant
liability as a result of such side effects, and we may not have sufficient product liability insurance to cover any damages that may be
assessed against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Because of our lack of funds, we may have to enter into a joint
venture or strategic relationship or licensing agreement with a third party to develop and seek to obtain FDA approval of our potential
products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our present efforts are directed to developing
and seeking FDA approval for our pipeline of transdermal pharmaceutical products including our lead product, the abuse deterrent fentanyl
transdermal system. The development of pharmaceutical products including a new delivery system for an already approved drug, is very expensive
with no assurance of obtaining FDA approval. Because of the costs involved, we may need to enter into a joint venture or strategic alliance
or licensing or similar agreement with a third party to bring our products to market, in which event we would have to give up a significant
percentage of the equity in or rights to the product and require the other party to provide the necessary financing and personnel and
to take a significant role in making the decisions relating to the development, testing, marketing and manufacturing of the product. The
third party may have interests which are different from, and possibly in conflict with, our own. If we are unable to attract competent
parties to distribute and market any product which we may develop, or if such parties&#8217; efforts are inadequate, we will not be able
to implement our business strategy and may have to cease operations. We cannot assure you that we will be successful in entering into
joint ventures or other strategic relationships or that any relationship into which we may enter will develop a marketable product or
that we will generate any revenue or net income from such a venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may decide not to continue developing
or commercializing any products at any time during development or after approval, which would reduce or eliminate our potential return
on investment for those product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may decide to discontinue the development of
our abuse deterrent fentanyl transdermal system or any other product in our pipeline or not to continue to commercialize any potential
product for a variety of reasons, such as the appearance of new technologies that make our product less commercially viable, an increase
in competition, changes in or failure to comply with applicable regulatory requirements, the discovery of unforeseen side effects during
clinical development or after the approved product has been marketed or the occurrence of adverse events at a rate or severity level that
is greater than experienced in prior clinical trials. If we discontinue a program in which we have invested significant resources, we
will not receive any return on our investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If any of our potential products are approved
for marketing but fail to achieve the broad degree of physician or market acceptance necessary for commercial success, our operating results
and financial condition will be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the products in our pipeline receives
FDA approval for us to market the product in the United States, it will be necessary for us to generate acceptance of our product for
the indications covered by the FDA approval. In order to generate acceptance in the marketplace, we will need to demonstrate to physicians
that our product provides a distinct advantage or better outcome at a price that reflects the value of our product as compared with existing
products. We will need to develop and implement a marketing program directed at both physicians and the general public. Since we do not
presently have the resources necessary to develop or implement an in-house marketing program and we may not have the funds to do so if
and when we obtain FDA approval to market our product, we will need to establish a distribution network though license and distribution
agreements with third parties who have the capability to market our product to physicians and emergency service organizations, and we
will be dependent upon the ability of these third parties to market our products effectively. We cannot assure you that we will be able
to negotiate license and distribution agreements with terms that are acceptable to us. Since we do not have an established track record
and our product pipeline is relatively small, we may be at a disadvantage in negotiating the terms of license and distribution agreements.
Further, we may have little control over the development and implementation of our licensee&#8217;s marketing program, and our licensees
may have interests that are inconsistent with ours with respect to the allocation of resources and implementation of the marketing program.
We cannot assure you that a marketing program for any of our products can or will be implemented effectively or that we will be successful
in developing physician and emergency service acceptance of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we seek to market any products in our
pipeline in countries other than the United States, we will need to comply with the regulations of each country in which we seek to market
our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our pharmaceutical products are currently
approved for sale by any government authority in any jurisdiction. If we fail to comply with regulatory requirements in any market we
decide to enter, or to obtain and maintain required approvals, or if regulatory approvals in the relevant markets are delayed, our target
market will be reduced and our ability to realize the full market potential of our products will be harmed. Marketing approval in one
jurisdiction, including the United States, does not ensure marketing approval in another, but a failure or delay in obtaining marketing
approval in one jurisdiction may have a negative effect on the regulatory process in others. Failure to obtain a marketing approval in
countries in which we seek to market our products or any delay or setback in obtaining such approval would impair our ability to develop
foreign markets for any of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The drug delivery industry is subject to rapid technological
change and, our failure to keep up with technological developments may impair our ability to market our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products use technology which we developed
for the transdermal delivery of drugs. The field of drug delivery is subject to rapid technological changes. Our future success will depend
upon our ability to keep abreast of the latest developments in the industry and to keep pace with advances in technology and changing
customer requirements. If we cannot keep pace with such changes and advances, our proposed products could be rendered obsolete, which
would result in our having to cease its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we obtain FDA approval, we will face
significant competition from better known and better capitalized companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we obtain FDA approval for any of our products,
we expect to face significant competition from existing companies, which are better known and already have developed relationships with
physicians within the healthcare system. Any product we may develop will compete with existing medications performing the same medicinal
functions, which may include transdermal patches. We cannot assure you that we will be able to compete successfully. In addition, even
if we are able to commercialize our product candidates, we may not be able to price them competitively with current standard of care products
or their price may drop considerably due to factors outside our control. If this happens or the price of materials and manufacture increases
dramatically, our ability to continue to operate our business would be materially harmed and we may be unable to commercialize any products
successfully. In addition, other pharmaceutical companies may be engaged in developing, patenting, manufacturing and marketing products
that compete with those that we are developing. These potential competitors may include large and experienced companies that enjoy significant
competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources,
greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare reforms by governmental authorities,
court decisions affecting health care policies and related reductions in pharmaceutical pricing, reimbursement and coverage by third-party
payors may adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect the healthcare industry to face increased
limitations on reimbursement, rebates and other payments as a result of healthcare reform, which could adversely affect third-party coverage
of our proposed products and how much or under what circumstances healthcare providers will prescribe or administer our products, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In both the U.S. and other countries, sales of
our products, if approved for marketing, will depend in part upon the availability of reimbursement from third-party payors, which include
governmental authorities, managed care organizations and other private health insurers. Third-party payors are increasingly challenging
the price and examining the cost effectiveness of medical products and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Increasing expenditures for healthcare have been
the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or
contain healthcare costs. Numerous proposals that would effect changes in the United States healthcare system have been introduced or
proposed in Congress and in some state legislatures, including reducing reimbursement for prescription products and reducing the levels
at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost reduction initiatives and changes in coverage
implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products, which in turn
would affect the price we can receive for those products. Any reduction in reimbursement that results from federal legislation or regulation
may also result in a similar reduction in payments from private payors, since private payors often follow Medicare coverage policy and
payment limitations in setting their own reimbursement rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant developments that may adversely affect
pricing in the United States include the enactment of federal healthcare reform laws and regulations, including the Affordable Care Act,
or ACA, which is popularly known as Obamacare, and the Medicare Prescription Drug Improvement and Modernization Act of 2003. A recent
district court decision which struck down Obamacare, if upheld, could have a material adverse effect upon reimbursement and payment for
products such as our proposed products. Changes to the healthcare system enacted as part of any healthcare reform in the United States,
as well as the increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries,
may result in increased pricing pressure by influencing, for instance, the reimbursement policies of third-party payors. Regulatory changes
which have the effect of decreasing the use of opioids has resulted in a decrease in the size of the market for opioid products, including
fentanyl, could impact the market for our abuse deterrent fentanyl transdermal system or any other opioid-based transdermal product we
may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2017, a new administration, which had promised
to repeal and replace the ACA, took office in the United States. Although we cannot predict the form any such replacement of the ACA may
take or the full effect on our business of&#160;the enactment of additional legislation pursuant to healthcare and other legislative reform,
we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely
affect how much or under what circumstances healthcare providers prescribe or administer our products. This could materially and adversely
affect our business by reducing our ability to generate revenues, raise capital, obtain licensees and market our products. In addition,
we believe the increasing emphasis on managed care in the United States, has and will continue to put pressure on the price and usage
of pharmaceutical products, which may adversely impact product sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It will be difficult for us to profitably sell
any of our products if reimbursement for these products is limited by government authorities and third-party payor policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It is difficult and costly to protect our
proprietary rights, and we may not be able to ensure their protection.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success will depend in part on
obtaining and maintaining patent protection and trade secret protection for our technology which is incorporated in our products as well
as successfully defending these patents against third-party challenges, should any be brought. 4P Therapeutics originally filed an international
patent application under the Patent Cooperation Treaty for worldwide prosecution of the abuse deterrent transdermal technology patent
used in our lead product, the abuse deterrent fentanyl transdermal system. The patent is being prosecuted in the United&#160;States and
in other countries. Although the European Patent Office and the Japan patent office have approved our patent application, we have not
yet received any response from the United States Patent and Trademark Office. Our ability to stop third parties from making, using, selling,
offering to sell or importing products utilizing our proprietary or patented technology is dependent upon the extent to which we have
rights under valid and enforceable patents or trade secrets that cover these activities. We cannot assure you that a patent will be granted
in the United States or in any country in which the patent is being prosecuted. The patent positions of pharmaceutical and biopharmaceutical
companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved.
No consistent policy regarding the breadth of claims allowed in biopharmaceutical patents has emerged to date in the United States. The
biopharmaceutical patent situation outside the United States varies from country to country and is even more uncertain. Changes in either
the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual
property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in any patents we may be granted. Further,
if any patents are granted and are subsequently deemed invalid and unenforceable, it could impact our ability to license our technology
and, as noted previously, fend off competitive challenges. Patent litigation is very expensive, and we may not have sufficient funds to
defend our proprietary technology from infringement, either as a plaintiff in an action seeking to stop infringers from using our technology,
or as a defendant in an action against us alleging infringement by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The degree of future protection for our proprietary
rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain
or keep our competitive advantage. For example:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may be able to make compositions or formulations that are similar to our product s but that are not covered by the claims of our patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
persons may have filed patents covering inventions, technology or processes that we use, with the result that we may infringe upon the
prior patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may independently develop similar or alternative technologies or duplicate any of our technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
pending patent applications may not result in the grant of patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
patents which may be issued may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of
legal challenges by third parties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
inability to fund any litigation to defend our proprietary rights, either in defense of an action against us or a plaintiff to seek to
prevent infringement.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
failure to develop additional proprietary technologies that are patentable.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we seek to expand our business through
acquisition, we may not be successful in identifying acquisition targets or integrating their businesses with our existing business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have recently expanded our business by acquisition,
and we may make acquisitions in the future. In 2017, we issued 1,250,000 shares of common stock, valued at $2,500,000, in connection with
our proposed acquisition of Advanced Health Brands, Inc., but the stock of Advanced Health Brands was never transferred to us and the
value of the intellectual property we were to have acquired did not have the value we anticipated, with the result that we incurred a
$2,500,000 impairment loss in the year ended January 31, 2018. In September 2018, we entered into an agreement to acquire Carmel Biosciences
Inc., and in November 2018, we terminated the agreement. We previously entered into another acquisition agreement which was rescinded
shortly after the agreement was executed. We cannot assure you that any acquisition we complete will be successful or that any acquisition
agreement we may enter into will result in an acquisition. An acquisition can be unsuccessful for a number of reasons, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may incur significant expenses and devote significant management time to the acquisition, and we may be unable to consummate the acquisition
on acceptable terms.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we identify a potential acquisition, we may face competition from other companies in the industry or from financial buyers in seeking
to make the acquisition.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
integration of any acquisition with our existing business may be difficult and, if we are not able to integrate the business successfully,
we may not only be unable to operate the business profitably, but management may be unable to devote the necessary time to the development
of our existing business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key employees who operated the acquired business successfully prior to the acquisition may not be happy working for us and may resign,
thus leaving the business without the necessary continuity of management.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the business is successful, our senior executive officers may need to devote significant time to the acquired business, which may
distract them from their other management activities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the business does not operate as we expect, we may incur an impairment charge based on the value of the assets acquired.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The products or proposed products of the acquired company may have regulatory problems with the FDA or any other regulatory agency, including the need for additional and unanticipated testing or the need for a recall or a change in labeling.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may have difficulty maintaining the necessary quality control over the acquired business and its products and services.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that an acquired company operates at a loss prior to our acquisition, we may not be able to develop profitable operations
following the acquisition.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Problems
and claims relating to the acquired business that were not disclosed at the time of the acquisition may result in increased costs and
may impair our ability to operate the acquired company.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquired company may have liabilities or obligations which were not disclosed to us, or the acquired assets, including any intellectual
property, may not have the value we anticipated.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets, including intellectual property, of the acquired company may not have the value that we anticipated.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products may not perform as anticipated.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to fund the development of any assets we may acquire.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products may be subject to recall or the FDA may require additional trials for the product.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components
or ingredients for the product may become subject to tariffs which may increase manufacturing costs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may require significant capital both to acquire and to operate the business, and the capital requirements of the business may be greater
than we anticipated. Our failure to obtain funds on reasonable terms may impair the value of the acquisition.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquired company may not operate at the revenue level or with the gross margin shown in the financial statements or projections.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquired company may have granted rights to its intellectual property which decrease the value of the intellectual property to us.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
may not be granted for patent applications which the acquired company filed or patents may be successfully challenged.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be conflicts in management styles that prevent us from integrating the acquired company with us.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
former equity owners or officers may compete in violation of their non-competition covenants or the non-competition covenants may be
held to be unenforceable.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business of the acquired company may have problems of which management was unaware and which do not become evident until after the acquisition
and we may require significant funding to remedy the problem.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnification obligations of the seller under the purchase agreement, if any, may be inadequate to compensate us for any loss, damage
or expense which we may sustain, including undisclosed claims or liabilities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the acquired company is dependent upon its management to maintain relationships with existing customers, we may have
difficulty in retaining the business of these customers if there is a change in management.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
agencies may seek damages after we make the acquisition for conduct which occurred prior to the acquisition and we may not have adequate
recourse against the seller.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquired company may have operated in violation of laws which results significant expenditures for us to remedy as well as potential
penalties for the violations.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may have difficult collecting the acquired company&#8217;s accounts receivable and in selling the acquired company&#8217;s inventory.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sellers of the acquired company may be in breach of their representations and warranties and we may not be able to recover damages.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the foregoing or any other events which
we do not contemplate happen, we may incur significant expenses, which we may not be able to cover, and the development of our business
can be impaired. We cannot assure you that any acquisition we will make will be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have no current plans regarding the marketing
of our own consumer products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently sell or market our own branded
consumer transdermal products directly and have no such plans to do so. We cannot market our consumer transdermal patch products in the
United States without first obtaining FDA approval. We do not plan to seek FDA approval or market our own branded products in the United
States at this time. Following our acquisition of Pocono, our core focus is on contract manufacturing and consulting for third party brands
primarily in Asia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent upon our chief executive
officer and our chief operating officer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dependent upon Gareth Sheridan, our chief
executive officer, and Dr. Alan Smith, our chief operating officer who is president of 4P Therapeutics. Although Mr. Sheridan has an employment
agreement with us, the employment agreement does not guarantee that he will continue with us. We do not have an employment agreement with
Dr. Smith. The loss of Mr. Sheridan or Dr. Smith would materially impair our ability to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to attract, train and retain
technical and financial personnel, our business may be materially and adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success depends, to a significant extent,
on our ability to attract, train and retain key management, technical, regulatory and financial personnel. Recruiting and retaining capable
personnel with experience in pharmaceutical product development is vital to our success. There is substantial competition for qualified
personnel, and competition is likely to increase. We cannot assure you we will be able to attract or retain the personnel we require.
Our financial condition is likely to impair our ability to attract qualified candidates. If we are unable to attract and retain qualified
employees, our business may be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks Concerning our Securities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price for our common stock may
be volatile and your investment in our common stock could suffer a decline in value.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading volume in our stock is low, which
may result in volatility in our stock price. As a result, any reported prices may not reflect the price at which you would be able to
sell shares of common stock if you want to sell any shares you own or buy if you wish to buy shares. Further, stocks with a low trading
volume may be more subject to manipulation than a stock that has a significant public float and is actively traded. The price of our stock
may fluctuate significantly in response to a number of factors, many of which are beyond our control. These factors include, but are not
limited to, the following, in addition to the risks described above and general market and economic conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
market&#8217;s reaction to the offering, our financial condition and the general perception of our ability to raise necessary funding
or enter into a joint venture or partnering arrangement, given the economic environment resulting from the COVID-19 pandemic, as well
as its perception of the possible terms of any financing or joint venture;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
market&#8217;s perception as to our ability to generate positive cash flow or earnings;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in our or any securities analysts&#8217; estimate of our financial performance;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
perception of our ability to raise the necessary financing to complete the product development activities including preclinical and clinical
testing required for FDA approval and our ability to generate revenue and cash flow from our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
anticipated or actual results of our operations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in market valuations of other companies in our industry;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
or changes in regulations and insurance company reimbursement policies affecting prescription drugs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">concern
that our internal controls are ineffective;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
discrepancy between anticipated or projected results and actual results of our operations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
by third parties to either sell or purchase stock in quantities which would have a significant effect on our stock price; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
factors not within our control.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A market for our warrants may not develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no market for our warrants, we are not
applying for the listing or trading of the warrants on any exchange or market, neither we nor the underwriters are taking any steps to
create a market for the warrants, and we cannot assure that a market for our warrants will develop. The absence of a market could make
it difficult for you to sell or purchase any warrants, and if a market for the warrants develops, the market price for the warrants could
be more volatile that would be the case if there were an active market for the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have broad discretion in the use of the
proceeds from this offering, and we may invest or spend the proceeds of this offering in ways with which you may not agree or in ways
which may not yield a return.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the net proceeds from this offering
are expected to be used for general corporate purposes, work on the development of our lead product and working capital. Our management
will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment
decision, to assess whether the proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not
increase our operating results or market value. The net proceeds of this offering will not be sufficient to complete the development and
testing of our lead product. Until the net proceeds are used, they may be placed in investments that do not produce significant income
or that may lose value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising funds by issuing equity or convertible
debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that we will require funds in addition
to the net proceeds from this offering for our business. If we were to raise additional capital by issuing equity securities, either alone
or in connection with a non-equity financing, the net tangible book value of the then outstanding common stock could decline. If the additional
equity securities were issued at a per share price less than the market price, which is customary in the private placement of equity securities,
the holders of the outstanding shares would suffer dilution, which could be significant. Further, if we are able to raise funds from the
sale of debt securities, the lenders may impose restrictions on our operations and may impair our working capital as we service any such
debt obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Purchasers of common stock in this offering
will experience immediate and substantial dilution of $0.04 per share.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net tangible book value per share as of
July 31, 2021 is $0.26 per share. Based on an initial public offering price of $6.25 per share, purchasers of our common stock in this
offering will experience an immediate dilution of $0.04 per share in the net tangible book value per share of common stock from the initial
public offering price of the common stock (assuming that the underwriters do not exercise their over-allotment option or warrants), and
our net tangible book value as of&#160;July 31, 2021 after giving effect to this offering would be $0.22 per share. This dilution is
due in large part to sales of our common stock at a price which is less than the offering price of our common stock, our accumulated
deficit of $12,670,985 as of July 31, 2021, and $8,521,696 of our assets as of&#160;July 31, 2021, being intangible assets.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience future dilution as a
result of future equity offerings and other issuances of our common stock or other securities. In addition, this offering and future equity
offerings and other issuances of our common stock or other securities may adversely affect our common stock price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to raise funds in additional to the
net proceeds of this offering in order to develop our products. In order to raise additional capital, we may in the future offer additional
shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same
as the price per share in this offering. We may not be able to sell shares or other securities in any other offering at a price per share
that is equal o or greater than the price per share paid in this offering, and investors purchasing shares or other securities in the
future could have rights superior to those of existing stockholders. The price per share at which we sell additional shares of our common
stock or securities convertible into common stock in future transactions may be higher or lower than the price per share in this offering
and may be at a discount from the then current market price for the common stock. You will incur dilution upon exercise of any outstanding
stock options, warrants or upon the issuance of shares of common stock under our present and future stock incentive programs. In addition,
the sale of shares in this offering and any future sales of a substantial number of shares of our common stock in the public market, or
the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any,
that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market
price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders of our warrants will have no rights
as common stockholders until they exercise their warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until you acquire shares of our common stock upon
exercise of your warrants, you will have no rights with respect to shares of our common stock issuable upon exercise of your warrants.
Upon exercise of your warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record
date occurs after the exercise date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may issue preferred stock whose terms
could adversely affect the voting power or value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our articles of incorporation authorize us to
issue, without the approval of our stockholders, one or more classes or series of preferred stock having such designations, preferences,
limitations and relative rights, including preferences over our common stock respecting dividends and distributions, as our board of directors
may determine. The terms of one or more classes or series of preferred stock could adversely impact the voting power or value of our common
stock. For example, we might grant holders of preferred stock the right to elect a number of our directors in all events or on the happening
of specified events or the right to veto specified transactions. Similarly, the repurchase or redemption rights or liquidation preferences
we might assign to holders of preferred stock could affect the residual value of the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to recover the 1,200,000
shares of common stock we issued in connection with our proposed acquisition of Advanced Health Brands.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2018, we commenced an action in the
Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar, Paul
Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a Motion
for Prejudgment Writ of Replevin arising from our decision to seek to rescind for misrepresentation the agreement by which we acquired
advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of the shares. On August 2, 2018,
the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants. Defendants Kalmar, Murphy,
Polly-Murphy, and Baker filed a Motion to Dismiss our Verified Complaint, Motion to Dissolve Temporary Injunction Without Notice and Response
to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court dismissed our complaint with prejudice, and directed
the defendants to assign to us within 30 days, the six patents never duly transferred to us. On February 1, 2019, we appealed the court&#8217;s
order. Pursuant to a settlement agreement with one of the defendants, that defendant returned the 50,000 shares which had been issued
to her, and the shares were cancelled as of January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom
we have a settlement agreement), filed a motion for sanctions and civil contempt against us, which generally claimed that we failed to
comply with the Court&#8217;s January 4, 2019 order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer
their shares of common stock. On October 29, 2019, the Court denied the defendants&#8217; motion. On March 20, 2020, the Florida district
court of appeal reversed the lower court ruling in the Florida state court action that dismissed our complaint with prejudice# and gave
us leave to file an amended complaint. We cannot assure you that we will prevail in either action, that we will be able recover either
the 1,200,000 shares of common stock or any monetary damages from the Advanced Health Brands stockholders or that we will not incur any
liability as a result of either our issuance of the shares or our failure to provide the necessary documentation to permit the Advanced
Health Brands stockholders to sell their shares pursuant to Rule 144 or from our treating and announcing the acquisition as completed
or based on other claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>For as long as we are an emerging growth
company, we will not be required to comply with certain reporting requirements, including those relating to accounting standards and disclosure
about our executive compensation, that apply to other public companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are classified as an &#8220;emerging growth
company&#8221; under the JOBS Act. For as long as we are an emerging growth company, which may be up to five full fiscal years, we will
not be required to, among other things, (i)&#160;provide an auditor&#8217;s attestation report on management&#8217;s assessment of the
effectiveness of our system of internal control over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act, (ii)&#160;comply
with any new requirements adopted by the PCAOB requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report in
which the auditor would be required to provide additional information about the audit and the financial statements of the issuer, (iii)&#160;provide
certain disclosure regarding executive compensation, or (iv)&#160;hold nonbinding advisory votes on executive compensation. We will remain
an emerging growth company for up to five years, although we will lose that status sooner if we have more than $1.07 billion of revenues
in a fiscal year, have more than $700 million in market value of our common stock held by non-affiliates, or issue more than $1.07 billion
of non-convertible debt over a&#160;three-year&#160;period. To the extent that we rely on any of the exemptions available to emerging
growth companies, you will receive less information about our executive compensation and internal control over financial reporting than
issuers that are not emerging growth companies. If some investors find our common stock to be less attractive as a result, there may be
a less active trading market for our common stock and our stock price may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because the warrants provide that, in an
action, suit or proceeding the non-prevailing party will reimburse the prevailing party for its reasonable costs and expenses, holders
of the warrants may be reluctant to seek to enforce any rights they may have.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants provide that if either party shall
commence an action, suit or proceeding to enforce any provisions of the warrant, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding, which costs and expenses may be significant. As a result, holders of the warrants
may be reluctant to pursue any rights which they believe they have against the Company under the terms of the warrants. However, these
provisions do not apply to any action or proceeding brought by a holder of warrants against us under federal securities laws and the rules
and regulations of the Securities and Exchange Commission thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We and our senior executive officers settled
an SEC investigation, which may affect the market for and the market price of our common stock and our ability to list on a stock exchange.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following an investigation into the accuracy of
statements in our Form 10 registration statement filed June 2, 2016, as amended, and our Form 10-K annual report filed May 8, 2017 that
did not accurately reflect the FDA&#8217;s jurisdiction over our consumer products and did not disclose that we could not legally market
these products in the United States, a Wells notice which we, our chief executive officer and our chief financial officer received on
August 10, 2017 and a Wells submission which we and the officers submitted in response to the Wells notice, the SEC, on December 26, 2018,
announced that it has accepted our settlement offer and instituted settled an administrative cease-and-desist proceeding against us and
our chief executive officer and chief financial officer. The SEC&#8217;s administrative order, dated December 26, 2018, finds that we
and the officers consented &#8211; without admitting or denying any findings by the SEC &#8212; to cease-and-desist orders against them
for violations by us of Sections 12(g) and 13(a) of the Securities Exchange Act of 1934 and Rules 12b-20 and 13a-1 thereunder, which require
issuers to file accurate registration statements and annual reports with the Commission; violations by the officers for causing our violations
of the above issuer reporting provisions; and violations by the officers of Rule 13a-14 of the Exchange Act, which requires each principal
executive and principal financial officer of issuers to attest that annual reports filed with the SEC do not contain any untrue statements
of material fact. In addition to consenting to the cease-and-desist orders, the officers have each agreed to pay a $25,000 civil penalty
to resolve the investigation. The administrative order does not impose a civil penalty or any other monetary relief against us. The settlement
may affect the market for and the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our lack of internal controls over financial
reporting may affect the market for and price of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Section 404 of the Sarbanes-Oxley
Act, we are required to file a report by our management on our internal control over financial reporting. Our disclosure controls and
our internal controls over financial reporting are not effective. We do not have the financial resources or personnel to develop or implement
systems that would provide us with the necessary information on a timely basis so as to be able to implement financial controls. Our financial
condition together with the fact that we recently acquired 4P Therapeutics, which was a privately owned company prior to our acquisition
and did not have any internal controls over financial reporting in effect, makes it difficult for us to implement a system of internal
controls over financial reporting, and we cannot assure you that we will be able to develop and implement the necessary controls. The
absence of internal controls over financial reporting may inhibit investors from purchasing our stock and may make it more difficult for
us to raise capital or borrow money. Implementing any appropriate changes to our internal controls may require specific compliance training
of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period
of time to complete and divert management&#8217;s attention from other business concerns. These changes may not, however, be effective
in developing or maintaining internal control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The recently quoted price for the common
stock bears no relation to the offering price of the securities being offered in this offering or the price of the common stock following
this offering.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recent prices for our common stock reflect
the effects of the one-for-four reverse split on little or no volume. The offering price of the common stock and the exercise price of
the warrants do not bear a relationship to the recently reported price for the common stock. Therefore, the recent market price, which
is based on the absence of an active trading market in our common stock, is not to be indicative of the public offering price for our
common stock or of the market price for the common stock or warrants following this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have broad discretion in the use of the
proceeds from this offering, and we may invest or spend the proceeds of this offering in ways with which you may not agree or in ways
which may not yield a return.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the net proceeds from this offering
are expected to be used for general corporate purposes, work on the development of our lead product and working capital. Our management
will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment
decision, to assess whether the proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not
increase our operating results or market value. The net proceeds of this offering will not be sufficient to complete the development and
testing of our lead product. Until the net proceeds are used, they may be placed in investments that do not produce significant income
or that may lose value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because of our executive officers&#8217;
stock ownership, they have the power to elect all directors and to approve any action requiring stockholder approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our officers and directors as a group beneficially
own approximately 37% of our common stock. As a result, they have the effective power to elect all of our directors and to approve any
action requiring stockholder approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A market for our warrants may not develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no market for our warrants, we are not
applying for the listing or trading of the warrants on any exchange or market, neither we nor the underwriters are taking any steps to
create a market for the warrants, and we cannot assure that a market for our warrants will develop. The absence of a market could make
it difficult for you to sell or purchase any warrants, and if a market for the warrants develops, the market price for the warrants could
be more volatile that would be the case if there were an active market for the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders of our warrants will have no rights
as common stockholders until they exercise their warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until you acquire shares of our common stock upon
exercise of your warrants, you will have no rights with respect to shares of our common stock issuable upon exercise of your warrants.
Upon exercise of your warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record
date occurs after the exercise date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising funds by issuing equity or convertible
debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that we will require funds in addition
to the net proceeds from this offering for our business. If we were to raise additional capital by issuing equity securities, either alone
or in connection with a non-equity financing, the net tangible book value of the then outstanding common stock could decline. If the additional
equity securities were issued at a per share price less than the market price, which is customary in the private placement of equity securities,
the holders of the outstanding shares would suffer dilution, which could be significant. Further, if we are able to raise funds from the
sale of debt securities, the lenders may impose restrictions on our operations and may impair our working capital as we service any such
debt obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stockholders may experience significant
dilution as a result of future equity offerings and other issuances of our common stock or other securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to raise substantial funds in order
to develop our products. In order to raise additional capital, we may in the future offer additional shares of our common stock or other
securities convertible into or exchangeable for our common stock at prices that may not which is less than the market price and which
may be based on a discount from market at the time of issuance. Stockholders will incur dilution upon exercise of any outstanding stock
options, warrants or upon the issuance of shares of common stock under our present and future stock incentive programs. In addition, the
sale of shares and any future sales of a substantial number of shares of our common stock in the public market, or the perception that
such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of
those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common
stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may issue preferred stock whose terms
could adversely affect the voting power or value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our articles of incorporation authorize us to
issue, without the approval of our stockholders, one or more classes or series of preferred stock having such designations, preferences,
limitations and relative rights, including preferences over our common stock respecting dividends and distributions, as our board of directors
may determine. The terms of one or more classes or series of preferred stock could adversely impact the voting power or value of our common
stock. For example, we might grant holders of preferred stock the right to elect a number of our directors in all events or on the happening
of specified events or the right to veto specified transactions. Similarly, the repurchase or redemption rights or liquidation preferences
we might assign to holders of preferred stock could affect the residual value of the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants provide that if either party shall
commence an action, suit or proceeding to enforce any provisions of the warrant, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding, which costs and expenses may be significant. As a result, holders of the warrants
may be reluctant to pursue any rights which they believe they have against the Company under the terms of the warrants. However, these
provisions do not apply to any action or proceeding brought by a holder of warrants against us under federal securities laws and the rules
and regulations of the Securities and Exchange Commission thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay any cash dividends
in the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not paid any cash dividends on our common
stock and do not intend to pay cash dividends on our common stock in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains &#8220;forward-looking
statements,&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, all of which are subject to risks and uncertainties.
Forward-looking statements can be identified by the use of words such as &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221;
&#8220;forecasts,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; and other words of similar meaning. One
can identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address
our growth strategy, financial results and product and development programs. One must carefully consider any such statement and should
understand that many factors could cause actual results to differ from our forward-looking statements. These factors may include inaccurate
assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking
statement can be guaranteed and actual future results may vary materially.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These risks and uncertainties, many of which are
beyond our control, include, and are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to raise the necessary financing for the development of our business and the terms of any financing which we are able to raise;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to receive FDA marketing approval for any products we may develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain and enforce any United States and foreign patent we may seek;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to design and execute clinical trials to the satisfaction of regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to engage, if and when necessary, an independent preclinical or clinical testing organization to design and implement our trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to launch any products for which we receive FDA marketing approval;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate sufficient revenue from our contract services to cover our operating expenses;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to establish a distribution network for the marketing and sale of any products for which we receive FDA approval;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to establish manufacturing facilities in compliance with FDA good manufacturing practices or to enter into manufacturing agreements
for the manufacture of our products in an FDA approved manufacturing facility;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to enter into joint venture or other strategic relationship with respect to any of our proposed products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the other party to any joint venture or strategic relationship to implement successfully any plans for the development, clinical
testing, manufacturing and marketing of the products subject to the joint venture or strategic relationship;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to evaluate potential acquisitions, and the consequences of our failure to accurately evaluate the acquisitions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to integrate any business we acquire with our business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in national, regional and local government regulations, taxation, controls and political and economic developments that the market for
our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to develop and market products with the most current technology;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain and maintain any permits or licenses necessary for our business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to identify, hire and retain qualified executive, administrative, regulatory, research and development, and other personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to negotiate licenses on favorable terms with companies that have experience in marketing products such as ours;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs associated with defending and resolving pending and potential legal claims, even if such claims are without merit;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effects of the SEC settlement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effects of competition on our and our licensee&#8217;s ability to price, market and sell our product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to achieve favorable pricing for our products with third party reimbursement parties with respect to our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to accurately estimate anticipated expenses, capital requirements and needs for additional financing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to accurately estimate the timing, cost or other aspects of the commercialization of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure of Best Choice or any other international distributor to comply with applicable laws, including Best Choice&#8217;s failure to
obtain regulatory approval to market our consumer products in South Korea;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure or inability of Best Choice or any other international distributor to develop an effective marketing program or to sell our products
in any meaningful quantity;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actions
by third parties to either sell or purchase our common stock in quantities that would have a significant effect on our stock price;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks generally associated with pre-revenue development stage companies in the pharmaceutical industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current and future economic and political conditions;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of changes in accounting rules on our financial statements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
assumptions described in this prospectus; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
matters that are not within our control.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding market and industry statistics
contained in this prospectus is included based on information available to us that we believe is accurate. It is generally based on industry
and other publications that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included
data from all sources. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications
and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services.
We do not assume any obligation to update any forward-looking statement. As a result, you should not place undue reliance on these forward-looking
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this prospectus
speak only as of the date of this prospectus and you should not to place undue reliance on any forward-looking statements. Forward-looking
statements are subject to certain events, risks, and uncertainties that may be outside of our control. When considering forward-looking
statements, you should carefully review the risks, uncertainties and other cautionary statements in this prospectus as they identify certain
important factors that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements.
These factors include, among others, the risks described under in this prospectus, including those described under &#8220;Business,&#8221;
&#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
as well as in other reports and documents we file with the SEC. We undertake no obligation to revise or publicly release the results of
any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, you are cautioned not
to place undue reliance on such forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect the net proceeds from this offering
to be approximately $5,800,000, after deducting estimated underwriting discounts and commissions and the underwriters&#8217; non-accountable
expense allowance and estimated offering expenses of approximately $790,000 in the aggregate.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the proceeds of this offering
substantially as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(i)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Approximately
    $3 million (approximately 52% of the net proceeds) for research and development of our abuse deterrent fentanyl transdermal system,
    AVERSA. We believe that the proceeds of this offering will not be sufficient to enable us to complete the development of the product
    and FDA submission, and we estimate that we will require an at least $2 million to $3 million, in addition to the funds used from
    the proceeds of this offering, to complete the FDA clinical trial process, although it is possible that our costs may significantly
    exceed those amounts. We anticipate that we will also require additional funds to establish a marketing program, although we cannot
    estimate our required costs at this time. We do not have any formal or informal understandings or agreements with any person to provide
    us with any additional funds that we require; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(ii)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">$1.5
    million (approximately 26% of the net proceeds) will be used towards the completion of the acquisition of Pocono Coated Products
    Transdermal and Topical manufacturing business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(iii)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The
    balance of approximately $1.3 million (approximately 22%) for working capital and other corporate purposes, which may include, depending
    on the amount of available funds, the commencement of development efforts for our other transdermal products. Funds for working capital
    and general corporate purposes include amounts required to pay officers&#8217; compensation, consulting fees, professional fees,
    ongoing public reporting costs, office-related expenses and other corporate expenses and other costs incurred in connection with
    the operation of our business. To the extent that our working capital requirements exceed our estimate or to the extent that we continue
    to generate negative gross margins and negative cash flow from operations, we may need to allocate to working capital a portion of
    the proceeds otherwise allocated to the development of our abuse deterrent fentanyl transdermal system. If our operations do not
    generate a positive cash flow, we may need to devote a greater portion of the net proceeds to working capital, thereby reducing the
    funds available for product development.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriters a 45-day
option to purchase up to an aggregate of 158,400 additional shares of common stock and 158,400 additional warrants to cover over-allotments
of shares in this offering. If the underwriters exercise their over-allotment option, they are not required to purchase the same number
of shares of common stock and warrants. Any proceeds from the exercise of the over-allotment option will be used for working capital
and for the development our abuse deterrent fentanyl transdermal system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAPITALIZATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our capitalization
as of July 31, 2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
an actual basis</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">as
    adjusted for the sale of 1,056,000 Units at $6.25&#160;per Unit, after deducting the estimated underwriting discounts and commissions,
    the non-accountable expense allowance payable to the underwriters, and other estimated offering costs and reversal of our derivative
    liability resulting from the payment of convertible debt.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">July 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As<br/> adjusted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,356</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,412</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,980,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,789,743</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(304</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(304</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,670,985</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,670,985</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,316,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,125,866</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read the foregoing table in connection
with &#8220;Prospectus Summary &#8212; Selected Consolidated Financial Data,&#8221; &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations,&#8221; and our consolidated financial statements and related notes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has been traded on the OTCQB
market under the symbol NTRB since November 30, 2017. Any over-the-counter market quotations reflect inter-dealer prices, without retail
mark-up, mark-down or commission and may not necessarily represent actual transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 1, 2021, we had 83 holders of
record of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent for the common stock is American
Stock Transfer&#160;&amp; Trust Company, LLC, 6201 15th Ave, Brooklyn, NY, telephone (800) 937-5449.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any equity plans, except to the
extent that our employment agreements with Mr. Gallagher and Dr. Patrick may be deemed equity incentive plans since they give us the right
to pay their compensation in shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following discussion and analysis of financial
condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included
elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See &#8220;Note
Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially from those anticipated in the forward-looking
statements as a result of certain factors discussed in &#8220;Risk Factors&#8221; and elsewhere in this report.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It should be noted that current public health
threats could adversely affect our ongoing or planned business operations. In particular, the novel coronavirus (COVID-19) has resulted
in quarantines, restrictions on travel and other business and economic disruptions. We cannot presently predict the scope and severity
of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including the partners
and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct
our business in the manner and on the timelines presently planned could be materially and adversely impacted. The measures being taken
by service providers and government agencies to suppress the spread of COVID-19 infection may delay time to production of our planned
abuse deterrent fentanyl transdermal system product and therefor delay the time of filing with FDA for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary business is the development of a portfolio
of transdermal pharmaceutical products. Our lead product is our abuse deterrent fentanyl transdermal system which we are developing to
provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around
the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl
patches. We believe that our abuse deterrent technology can be broadly applied to various transdermal products and our strategy is to
follow the development of our abuse deterrent fentanyl transdermal system with the development of additional transdermal prescription
products for pharmaceuticals that have risks or a history of abuse. In addition, we are developing a portfolio of transdermal pharmaceutical
products to deliver commercially available drugs or biologics that are typically delivered by injection but with the potential to improve
compliance and therapeutic outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of our financial position, we have put
our development efforts with respect to these products on hold, and our only business is the performance of contract services for a small
number of customers. Because of both our financial position and the effects of the COVID-19 pandemic, our contract service business has
also been scaled back. The description of our business in this annual report is based on our ability to raise significant financing or
enter into a joint venture agreement with a third party that has the financial ability to fund the joint venture&#8217;s operations. We
cannot assure you that we will be able to obtain necessary financing or enter into a joint venture agreement on reasonable, if any, terms.
If we are not able to continue obtain financing or enter into a joint venture agreement, we may not be able to continue in business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through July 31, 2018, our business was the development
of a line of consumer and health products that are delivered through a transdermal patch which we plan to sell internationally. Consumer
products are products that are sold over the counter and do not require a prescription. Most of our consumer products require FDA approval
for sale in the United States, and we have not sought to obtain, and we do not plan to seek to obtain, FDA approval to market these products
in the United States at this time. Following our acquisition of Pocono, our focus is primarily now on providing contract manufacturing
services and consulting services to 3<sup>rd</sup> party brands with no intention at this time to launch our own consumer products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With our acquisition of 4P Therapeutics on August
1, 2018, our focus changed, and we are seeking to develop and seek FDA approval on a number of transdermal pharmaceutical products under
development by 4P Therapeutics. As a result of the acquisition of 4P Therapeutics, we have pipeline of potential products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4P Therapeutics has not generated any revenue
from any of its products under development. Rather, prior to our acquisition, 4P Therapeutics generated revenue to provide cash for its
operations through contract research and development and related services for a small number of clients in the life sciences field on
an as-needed basis. We are, for the near term, continuing this activity, although we do not anticipate that it will generate significant
revenues and, since our acquisition, it has generated a negative gross margin. We have no long-term contractual obligations, and either
party can terminate at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the change in our focus, our capital requirements
have increased substantially. The process of developing pharmaceutical products and submitting them for FDA approval is both time consuming
and expensive, with no assurance of obtaining approval from the FDA to market our product in the United States. We have budgeted $5.0
million for research and development of our abuse deterrent fentanyl transdermal system, including clinical manufacturing and clinical
trials that need to be completed in order to obtain FDA approval. However, the total cost could be substantially in excess of that amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2020, the Company formed Pocono
Pharmaceuticals Inc.(&#8220;Pocono&#8221;), a wholly owned subsidiary of the Company. Effective August 31, 2020, the Company entered into
a Purchase Agreement (&#8220;Agreement&#8221;) with Pocono Coated Products (&#8220;PCP&#8221;), a manufacturer of Topical and transdermal
products, pursuant to which PCP agreed to sell the Company certain of the assets and liabilities associated with its Transdermal, Topical,
Cosmetic and Nutraceutical business (the &#8220;Business&#8221;), including all related equipment, intellectual property and trade secrets,
cash balances, receivables, bank accounts and inventory. The net assets were contributed to Pocono. Included in the transaction, the Company
acquired 100% of the membership interests of Active Intelligence LLC (&#8220;Active Intelligence&#8221;). The purchase price for the assets
of the Business is (i) $6,000,000 paid in 608,519 shares of the Company&#8217;s common stock, based on the average price for the Company&#8217;s
common stock for the previous 90 days as of the date of Closing (the &#8220;Shares&#8221;); (ii) a promissory note of the Company in the
principal amount of $1,500,000, which is due upon the earlier of (a) twelve (12) months from issuance, or (b) immediately following a
capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financing Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2020, we issued in a private placement
46,828 units at a price of $11 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share of common
stock at an exercise price of $14 per share. The warrants expire April 30, 2023. We issued a total of 46,828 shares of common stock and
warrants to purchase 46,828 shares of common stock. We received proceeds of $515,113.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2020, we paid off the convertible
notes in the principal amount of $270,000 from the proceeds of the private placement. The total payments, including the prepayment penalty
and accrued interest, was $345,656. The payment was made from the proceeds of the private placement. As a result of the payment of the
notes, the derivative liability, which was $928,774 at January 31, 2020, was reduced to zero. As a result of a completed private placement,
the warrants to purchase 50,000 shares at the lesser of (i) $20.90 or, (ii) if the Company completes its public offering of its common
stock, 110% of the initial public offering price of the Common Stock in the public offering, became a warrant to purchase 95,000 warrants
at $11 per share, subject to adjustment pursuant to the antidilution provisions of the warrant. The Company recorded a derivative liability
for the warrants in the amount of $906,678 and reclassed the derivative liability to additional paid-in capital as of January 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, a minority stockholder who had
previously made loans to us in the total amount of $215,00, made an additional loan to us in the amount of $60,000, increasing the total
loans from the stockholder to $275,000. On March 27, 2020, we issued 25,000 shares of common stock upon conversion of the notes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2020, the Company entered into a
Purchase Agreement (&#8220;Agreement&#8221;), with Pocono Coated Products (&#8220;PCP&#8221;), pursuant to which PCP agreed to sell the
Company all of the assets associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the &#8220;Assets&#8221;). PCP
is the manufacturer of our transdermal products, and we bought that business from them. The purchase price for the Assets was (i) $6,000,000
paid in shares of the Company&#8217;s common stock at a value of the average price of the previous 90 days at the date of Closing (the
&#8220;Shares&#8221;); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a)
twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of
no less than $4,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2021 we entered into an amendment
to the Agreement with the parties to the Agreement that provides for an extension of the August 31, 2021 due date of the $1,500,000 note
issued in the transaction to September 30, 2021, and extends the time limit set forth in Section 5.3(a) of the Agreement for completion
of the Listing and for payment of the Note in full until September 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a Stock Purchase Agreement (&#8220;SPA&#8221;),
dated December 7, 2020, with the Company, BPM Inno Ltd., Kiryat, Israel, purchased 81,396 shares of common stock at a price of $8.60 per
share, or $700,000. The transaction was completed at a closing on February 26, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Years Ended January 31, 2021 and 2020</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended January 31, 2021, we generated
revenue of $943,702 and our costs of revenue were $582,378, resulting in a gross margin of $361,324. For the year ended January 31, 2020,
we generated revenue of $370,647 and our costs of revenue were $549,107, resulting in negative gross margin of $178,460. Our revenue for
January 31, 2021 was derived from three sources &#8211; (1) a continuation of research and development contracts of the type 4P Therapeutics
performed prior to our acquisition, which accounted for $206,183, (2) sales of our consumer transdermal product to or South Korean distributor,
which accounted for $583,324 which our distributor purchased for its preliminary marketing efforts since the product has not obtained
regulatory approval for retail sales in South Korea and (3) sales from our recent acquisition of transdermal patches, which accounted
for $154,195. Since we do not have the funds for development of our lead product, the 4P Therapeutics fixed costs are allocated to the
contract services that we perform for clients. Our cost of revenue for our contract research and development services represents basically
our labor cost plus a modest amount of material costs which we passed on to the client. The Company moved from the 4P facilities, and
many of the prior costs relating to the facility were not incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended January 31, 2021, our selling,
general and administrative expenses were $2,957,269 primarily legal, accounting and non-cash compensation expense compared to $1,790,980
for the year ended January 31, 2020.The increase from 2020 is primarily attributable to non-cash compensation to officers and directors
of $1,954,875 in 2021 offset by a decrease in professional fees. For the year ended January 31, 2020, $252,700 was stock-based compensation
comprised of a warrant granted to Dr. Jeff Patrick, our scientific officer, which expired unexercised, and $120,000 representing the value
of shares of common stock issued to our president, Sean Gallagher, and to an entity controlled by Dr. Patrick as compensation for services
during the year ended January 31, 2021 pursuant to employment agreements with Mr. Gallagher and Dr. Patrick. The agreements provide for
annual compensation of $60,000 to each of them, which may be paid in stock or cash, and the shares were issued for services rendered in
the years ended January 31, 2020 and 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended January 31, 2021, we incurred
gain on change in fair value of derivatives of $22,096 in connection with our October 2019 financing in which we raised gross proceeds
of $250,000 and net proceeds of approximately $230,000 from the sale of convertible notes and warrants. During the year ended January
31, 2020, we incurred derivative expense $767,650 and a gain on change of fair value of derivatives of $88,876 in connection with the
October 2019 financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incurred interest expense of $280,686, primarily
from the amortization of debt discounts for the year ended January 31, 2021 as compared to $73,413 for the year ended January 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the foregoing, we sustained a net
loss of $2,932,828 or $(0.51) per share (basic and diluted) for the year ended January 31, 2021, compared with a loss of $2,721,627, or
$(0.50) per share (basic and diluted) for the year ended January 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a Stock Purchase Agreement (&#8220;SPA&#8221;),
dated December 7, 2020, with the Company, BPM Inno Ltd., Kiryat, Israel, purchased 81,396 shares of common stock at a price of $8.60 per
share, or $700,000, which provided payment for the RamBam license. The transaction was completed at a closing on February 26, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Three Months Ended July 31, 2021 and 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended July 31, 2021, we generated
revenue of $213,739 and our costs of revenue were $186,762, resulting in a gross margin of $26,977. For the three months ended July 31,
2020, we generated revenue of $84,450 and our costs of revenue were $116,937, resulting in negative gross margin of $32,487. Our revenue
for July 31, 2021 was derived from sales from our recent acquisition of transdermal patches. Since we do not have the funds for development
of our lead product, the 4P Therapeutics fixed costs are allocated to the contract services that we perform for clients. Our cost of revenue
for our contract research and development services represents our labor cost plus a modest amount of material costs which we passed on
to the client. The Company moved from the 4P facilities, and many of the prior costs relating to the facility were not incurred. We did
not have any revenue from our South Korean customer but expect revenue will recommence during the third quarter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended July 31, 2021, our
selling, general and administrative expenses were $509,219 primarily legal, accounting and non-cash expenses compared to $193,331 for
the three months ended July 31, 2020.The increase from 2020 is primarily attributable to non-cash consulting expenses of $127,500 and
the inclusion of expenses of $151,278 of Active Intelligence in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incurred interest expense of $41,019, primarily
from the amortization of debt discounts for the three months ended July 31, 2021, as compared to $51 for the three months ended July 31,
2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the foregoing, we sustained a net
loss of $519,523 or $(0.08) per share (basic and diluted) for the three months ended July 31, 2021, compared with a loss of $225,869,
or $(0.04) per share (basic and diluted) for the three months ended July 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Six Months Ended July 31, 2021 and 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended July 31, 2021, we generated
revenue of $647,227 and our costs of revenue were $355,606, resulting in a gross margin of $291,621. For the six months ended July 31,
2020, we generated revenue of $203,814 and our costs of revenue were $191,876, resulting in a gross margin of $11,938. Our revenue for
July 31, 2021 was derived from three sources &#8211; (1) a continuation of research and development contracts of the type 4P Therapeutics
performed prior to our acquisition, which accounted for $105,976, (2) sales of our consumer transdermal product to or South Korean distributor,
which accounted for $86,600 which our distributor purchased for its preliminary marketing efforts since the product has not obtained regulatory
approval for retail sales in South Korea and (3) sales from our recent acquisition of transdermal patches, which accounted for $454,651.
Since we do not have the funds for development of our lead product, the 4P Therapeutics fixed costs are allocated to the contract services
that we perform for clients. Our cost of revenue for our contract research and development services represents basically our labor cost
plus a modest amount of material costs which we passed on to the client. The Company moved from the 4P facilities, and many of the prior
costs relating to the facility were not incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended July 31, 2021, our selling,
general and administrative expenses were $1,088,827 primarily legal, accounting and non-cash expenses compared to $355,248 for the six
months ended July 31, 2020.The increase from 2020 is primarily attributable to non-cash consulting expenses of $225,000 and the inclusion
of expenses of $315,915 of Active Intelligence in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended July 31, 2020, we
incurred gain on change in fair value of derivatives of $22,096 in connection with our October 2019 financing in which we raised gross
proceeds of $250,000 and net proceeds of approximately $230,000 from the sale of convertible notes and warrants. During the six months
ended July 31, 2021, the Company incurred a gain on extinguishment of debt of $43,214, consisting primarily of forgiveness of a PPP loan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incurred interest expense of $81,888, primarily
from the amortization of debt discounts for the six months ended July 31, 2021, as compared to $205,218 for the six months ended July
31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the foregoing, we sustained a net
loss of $835,880 or $(0.13) per share (basic and diluted) for the six months ended July 31, 2021, compared with a loss of $638,063, or
$(0.12) per share (basic and diluted) for the six months ended July 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 31, 2021, we had $304,258 in cash and
cash equivalents and a working capital deficiency of $2,048,806, as compared with cash and cash equivalents of $151,993 and working capital
deficiency of $2,254,418 as of January 31, 2021. The Company received proceeds of $583,000 from the sale of common stock during the six
months ended July 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended July 31, 2021, we used
cash of $367,944 in our operations. The principal adjustments to our net loss of $835,880 were amortization of debt discount of $73,108,
depreciation and amortization of $155,822, and stock-based compensation of $625,000, offset by a gain on extinguishment of debt of $43,214.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended July 31, 2021, we used
cash in investing activities of $49,396 primarily for the purchase of equipment. During the year ended July 31, 2020, we had no investing
activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended July 31, 2021, we had
cash flows of $569,605 from financing activities, primarily $583,000 from gross proceeds from the sale of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no off-balance sheet arrangements that
have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Going Concern</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 31, 2021, the Company believes the
substantial doubt about its status as a going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current quarter net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to
alleviate the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses,
equity funding that has been received and additional funding expected to be received, and the net revenue from its recent acquisitions.
These factors did not exist in prior years during its start-up operations. The Company&#8217;s recent history of losses has continued
but future positive cash flow projections due to its increased revenue commitments and decreases in overhead as well as future equity
funding will enable the Company to alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans have been currently implemented. The plans enable the Company to meet its obligations for at least one year from the date when the
financial statements are issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
&#8220;Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which amends the accounting standards for revenue
recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when
products are transferred to a customer. We adopted the guidance under the new revenue standards using the modified retrospective method
effective February 1, 2018. Topic 606 requires us to recognize revenues when control of the promised goods or services and receipt of
payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1)
identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price
among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenue Service Types</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a description of our revenue
service types, which include professional services and sales of goods:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
services include the contract of research and development related services with our clients in the life sciences field on an as-needed
basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project
engaged.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
revenues are generated from the sale of our products. Upon the receipt of a purchase order, we have the order filled and shipped.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Contracts with Customers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A contract with a customer exists when (i) we
enter into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred
and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine
that collection of substantially all consideration for services that are transferred is probable based on the customer&#8217;s intent
and ability to pay the promised consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred Revenue</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue is a liability related to a revenue
producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from
a contract before achieving certain criteria that must be met for revenue to be recognized in accordance with GAAP. As of July 31, 2021
and January 31, 2021, the balance of deferred revenue was $69,894 and $86,846, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Performance Obligations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A performance obligation is a promise in a contract
to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction
price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
For the Company&#8217;s different revenue service types, the performance obligation is satisfied at different times. Our performance obligations
include providing products and professional services in the area of research. We recognize product revenue performance obligations in
most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have
the right to invoice the customer for the work completed, which typically occurs on a monthly basis for work performed during that month.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All revenue recognized in the statement of operations
is considered to be revenue from contracts with customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock-Based Compensation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, &#8220;Compensation &#8212; Stock Compensation,&#8221;
prescribes accounting and reporting standards for all stock-based payment transactions in which employee services, and, since February
1, 2019, non-employee services, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options
and other equity instruments such as employee stock ownership plans and stock appreciation rights. Stock-based payments to employees,
including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values.
That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as
the requisite service period (usually the vesting period).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Intangible Assets</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets include trademarks, intellectual
property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance
of ASC 350, &#8220;Intangibles-Goodwill and Other.&#8221; The Company capitalizes certain costs related to patent technology. A substantial
component of the purchase price related to the Company&#8217;s acquisition has also been assigned to intellectual property and other intangibles.
Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with
indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their
estimated useful lives of ten years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Goodwill</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill represents the difference between the
total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed
for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the
recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August 31,
2020, in connection with the Company&#8217;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $5,810,640. As of July 31, 2021 and January 31, 2021, Goodwill amounted to $7,529,875.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Long-lived Assets</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management reviews long-lived assets for potential
impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An
impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.&#160;The carrying amount
of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use
and eventual disposition of the asset.&#160;If an impairment exists, the resulting write-down would be the difference between fair market
value of the long-lived asset and the related net book value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">New Financial Accounting Standards</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any other recently
issued, but not yet effective, accounting standard if currently adopted would have a material effect on the consolidated financial statements
included herewith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary business is the development of a portfolio
of transdermal pharmaceutical products. Our lead product is our abuse deterrent fentanyl transdermal system which we are developing to
provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around
the clock opioid therapy combined with our AVERSA&#174; technology which we plan to show can reduce the abuse and misuse of fentanyl patches.
We believe that AVERSA&#174; can be broadly applied to various transdermal products and our strategy is to follow the development of our
abuse deterrent fentanyl transdermal system with the development of additional transdermal prescription products for pharmaceuticals that
have risks or a history of abuse. In addition, we are developing a portfolio of transdermal pharmaceutical products to deliver commercially
available drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of our financial position, we have put
our development efforts with respect to these products on hold, and our only business is the performance of contract manufacturing and
R&amp;D services. The description of our business in this annual report is based on our ability to raise significant financing or enter
into a joint venture agreement with a third party that has the financial ability to fund the joint venture&#8217;s operations. We cannot
assure you that we will be able to obtain necessary financing or enter into a joint venture agreement on reasonable, if any, terms for
the development of our prescription pipeline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through July 31, 2018, we had not generated any
revenue from our business, which was the development of a range of transdermal consumer patches. Consumer products are products that can
be sold over-the-counter and do not require a prescription. Most transdermal patches are considered drugs in the United States and cannot
be marketed in the United States without approval from the FDA. We have not taken any steps to seek to obtain FDA approval for any of
our consumer products, and we have no plans to do so in the near term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Acquisition of 4P Therapeutics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to an acquisition agreement dated April
5, 2018 between us and 4P Therapeutics, on August 1, 2018, we acquired all of the equity interest in 4P Therapeutics from Steven Damon,
the owner of 4P Therapeutics. The purchase price of $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and
cash of $400,000, and are to pay Mr. Damon a 6% royalty on any revenue we receive or derive from our utilization or sale of the abuse
deterrent intellectual property that we acquired as a part of the assets 4P Therapeutics, including partner license milestones and development
payments. The royalty is payable pursuant to the acquisition agreement and continues as long as we generate revenue from our utilization
or sale of the abuse deterrent intellectual property we acquired as part of the acquisition of 4P Therapeutics. The 62,500 shares were
issued to Mr. Damon (41,750 shares) and Dr. Alan Smith (20,750 shares). In connection with the acquisition, Mr. Damon retained any cash
and accounts receivable and assumed any liabilities other than those relating to the ongoing business. Pursuant to the acquisition agreement,
we appointed Mr. Damon to our board of directors in April 2018, when we signed the acquisition agreement, and we agreed to pay Mr. Damon
the compensation received by independent board members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the acquisition, the focus of our
business has changed from the development and marketing of consumer transdermal products to the development of 4P Therapeutics&#8217;
portfolio of pharmaceutical transdermal system, with the lead product being the abuse deterrent fentanyl transdermal system, AVERSA&#174;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have received patent protection from the European
Patent Office, the patent offices for Japan, Australia and Russia and the patent office of Mexico -granted a notice of allowance for abuse
deterrent transdermal technology patent used in our lead product, an abuse deterrent fentanyl transdermal system. The patent is being
prosecuted in the United States and in other countries. The patent applications were filed by 4P Therapeutics prior to our acquisition
of 4P Therapeutics and any patents issued in respect of these applications will be in the name of 4P Therapeutics. In addition to applying
the technology to developing an abuse deterrent fentanyl transdermal system, we believe that the abuse deterrent patch technology can
be applied to other opioids and pain medication patches where there is a risk of abuse and overdose, as well as other transdermal pharmaceuticals
where we believe our technology can help prevent abuse or accidental misuse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead product under development is our abuse
deterrent fentanyl transdermal system which we plan to develop to deter the abuse and accidental misuse of fentanyl transdermal patches.
Fentanyl is a potent synthetic opioid that is marketed as a transdermal patch for chronic pain management. There are currently a number
of generic fentanyl patches on the market but we believe that none of them are abuse deterrent. We believe that our abuse deterrent technology,
AVERSA&#174;, containing aversive agents will significantly deter the abuse and accidental misuse of fentanyl from transdermal patches.
In 2017, according to a report from the National Institute on Drug Abuse, of the more than 72,000 drug overdose deaths in the United States,
nearly 30,000 occurred due to overdoses of fentanyl and fentanyl analogues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development of our abuse deterrent fentanyl
transdermal system requires preclinical and clinical trials to be conducted for the purposes of obtaining FDA approval. We require funds
for these trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the acquisition of 4P Therapeutics, we acquired
a pipeline of other transdermal products, including peptides and proteins such as exenatide for type 2 diabetes and FSH for infertility,
which we anticipate will be the next products for development. These drugs are off-patent but are currently only available as injections,
and we are evaluating the possibility of developing a transdermal delivery system for these drugs as an alternative to injection but with
improved compliance and safety. In addition, we may develop certain generic transdermal products where we think we can make an improvement
to existing patches and where we believe we can take significant market share with good profit margins. One example of such a product
candidate is the development of a generic scopolamine patch. The prioritization of our portfolio product candidates will be reviewed on
an ongoing basis and will take into account technical progress, market potential and commercial interest. We cannot assure you that we
will be able to develop and obtain FDA approval for any of these potential products or that we can be successful in marketing any such
products. The FDA approval process can take many years to complete successfully, and we will require substantial funding for each product
that goes through the process. We cannot assure you that we will obtain FDA marketing approval for any of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since 4P Therapeutics did not have any products
that it can market, its sole source of revenue to date was derived from the performance of contract research and development and other
services for a small number of clients in the life sciences field on an as-needed basis to support its ongoing operations. The work varied
in nature and includes early stage drug and device preclinical studies, commercial biologic manufacturing support, clinical-regulatory
consulting, drug or device clinical studies and formulation/analytical services relating to the chemistry, manufacturing and controls
function of drug manufacturing. The current continuing arrangements are varied, from purchase order supported per animal study fees, to
hourly rate research and development services, to flat rate contract research and development projects. Neither we nor current clients
have any long-term commitments, and either party can terminate at any time. If we raise financing we intend to devote our efforts toward
the development and testing of our lead product and other product candidates in our pipeline. However, for the near term, we are looking
to perform research and development services for third parties although we do not expect to generate significant revenues from these services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Acquisition of Pocono Coated Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2020, the Company formed Pocono
Pharmaceuticals Inc.(&#8220;Pocono&#8221;), a wholly owned subsidiary of the Company. Effective August 31, 2020, the Company entered into
a Purchase Agreement (&#8220;Agreement&#8221;) with Pocono Coated Products (&#8220;PCP&#8221;), a manufacturer of Topical and transdermal
products, pursuant to which PCP agreed to sell the Company certain of the assets and liabilities associated with its Transdermal, Topical,
Cosmetic and Nutraceutical business (the &#8220;Business&#8221;), including all related equipment, intellectual property and trade secrets,
cash balances, receivables, bank accounts and inventory. The net assets were contributed to Pocono. Included in the transaction, the Company
acquired 100% of the membership interests of Active Intelligence LLC (&#8220;Active Intelligence&#8221;). The purchase price for the assets
of the Business is (i) $6,000,000 paid in 608,519 shares of the Company&#8217;s common stock, based on the average price for the Company&#8217;s
common stock for the previous 90 days as of the date of Closing (the &#8220;Shares&#8221;); (ii) a promissory note of the Company in the
principal amount of $1,500,000, which is due upon the earlier of (a) twelve (12) months from issuance, or (b) immediately following a
capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a distribution agreement dated April 13,
2018 with EMI-Korea (Best Choice), Inc., whom we refer to as Best Choice, for marketing in certain regions in Asia. Pursuant to an exclusive
distribution agreement, we granted Best Choice exclusive distribution rights for all of our transdermal consumer products in South Korea,
Taiwan (the Republic of China), the People&#8217;s Republic of China and South Asia. We currently have no plans to market our own products
in these regions and following our acquisition of Pocono Pharma we are primarily focused on contract manufacturing services for Best Choice
and its partners. Best Choice is responsible for complying with all applicable regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Organization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a Nevada corporation, incorporated on January
4, 2016. In January 2016, we acquired Nutriband Ltd, an Irish company which was formed by Gareth Sheridan, our chief executive officer,
in 2012 to enter the health and wellness market by marketing transdermal patches. Our corporate headquarters are located at 121 S. Orange
Ave. Suite 1500, Orlando, Florida 32765, telephone (407) 377-6695. Our website is <i>www.nutriband.com</i>. Information contained on or
available through our website or any other website does not constitute a portion of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Implications of Being an Emerging Growth Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than $1.07 billion in revenue
during our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups
Act of 2012, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are otherwise generally
applicable to public companies, although as a smaller reporting company we are taking advantage of reduced reporting requirements. In
particular, as an emerging growth company, we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
present only two years of audited financial statements and related disclosure under Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations, or MD&amp;A;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing
how those elements fit with our principles and objectives, which is commonly referred to as &#8220;compensation discussion and analysis&#8221;;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
not required to obtain an attestation and report from our auditors on our management&#8217;s assessment of our internal control over
financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly
referred to as the &#8220;say-on-pay,&#8221; &#8220;say-on frequency&#8221; and &#8220;say-on-golden-parachute&#8221; votes);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and chief executive officer pay
ratio disclosure;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
not be required to conduct an evaluation of our internal control over financial reporting by our auditors.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to take advantage of all of these reduced
reporting requirements and exemptions. However, since we have already adopted certain new or revised accounting standards under &#167;107
of the JOBS Act, we are not able to take advantage of the delayed phase in of the new or revised accounting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the JOBS Act, we may take advantage of the
above-described reduced reporting requirements and exemptions for up to five years after our initial sale of common equity pursuant to
a registration statement declared effective under the Securities Act of 1933, as amended, or such earlier time that we no longer meet
the definition of an emerging growth company. The JOBS Act provides that we would cease to be an &#8220;emerging growth company&#8221;
if we have more than $1.07 billion in annual revenues (as adjusted for inflation), have more than $700 million in market value of our
common stock held by non-affiliates, or issue more than $1 billion in principal amount of non-convertible debt over a three-year period.
Under current Securities and Exchange Commission, or SEC, rules however, we will continue to qualify as a &#8220;smaller reporting company&#8221;
for so long as we have either (i) a public float (i.e., the market value of common equity held by non-affiliates) of less than $250 million
as of the last business day of our most recently completed second fiscal quarter or (ii) annual revenues of less than $100 million and
a public float of less than $700 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Effects of the COVID-19 Pandemic</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business may be affected by the COVID-19 pandemic
and the response to the pandemic. Factors which may affect our business include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to raise financing for our operations and to enter into a joint venture agreement may be affected by both the willingness and
ability of potential financing sources and potential joint venture partners to invest in an undercapitalized business, particularly at
a time when the potential financing source or joint venture partner may need to devote its resources to existing portfolio companies
or joint ventures which may be in need of financing decision by investors who would invest in early stage pharmaceutical companies to
limit their financing efforts to companies that are dealing with products or services related to COVID-19 diagnosis or treatment.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decision by investors who would invest in early-stage pharmaceutical companies to limit their financing efforts to companies that are
dealing with products or services related to COVID-19 diagnosis or treatment.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effect of recent stock market declines on the willingness of investors to make an investment in our securities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial health of our potential contract service customers.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to perform contract services.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain any goods or services which we may need to perform contract services.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of our foreign distributors to obtain regulatory approval, which may be affected by the regulatory agencies giving a low priority
to products such as our consumer patches.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial health of Best Choice.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval is obtained in South Korea, the extent to which consumers in South Korea purchase our products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent to which the purchase of our consumer products is a low priority item for a population whose disposable income may have decreased
as a result of COVID-19 and the steps taken by the South Korean government to curb the spread of infection.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pharmaceutical Products in Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a pipeline of transdermal pharmaceutical
products that are primarily in the early, preclinical, stages of development. Our pipeline consists primarily of drug compounds which
have been previously approved by the FDA and are now off-patent. In many cases, we are developing the first non-injectable version of
the drug utilizing our transdermal technology which represents a new route of administration. In most cases, we plan to utilize the 505(b)&#160;(2)
regulatory pathway provided by the FDA which allows us to reference the safety information on file at FDA for the approved drug or to
reference the published literature instead of having to generate new safety information that would typically be required for new chemical
entities. However, we cannot assure you that the FDA will concur with our approach or that we will be able to receive FDA approval to
market any of products that we develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead product under development is our abuse
deterrent fentanyl transdermal system. As the United States faces an epidemic of opioid abuse, fentanyl transdermal patches have become
an attractive target for recreational drug abusers due to the drug&#8217;s potency and its ease of abuse by the oral route. We are looking
to utilize our proprietary approach to incorporate aversive agents into the transdermal patch to deter the abuse of fentanyl patches by
the oral, buccal and inhaled routes, which represent as much as 70% of all transdermal fentanyl abuse. The technology is based on the
incorporation of taste and sensory aversive agents into the patch. We believe that the aversive agents we selected have several advantages,
such as their high potency, established safety, and the potential to prevent accidental misuse by children and pets. The aversive agents
are formulated in a controlled-release matrix that is coated onto the backing of a transdermal fentanyl patch. The controlled release
aspect of the technology is designed so that the abuse deterrent properties are maintained after normal use and during attempts to separate
the aversive agents from the fentanyl. We believe that this structure provides maximum exposure during oral abuse and during attempts
to extract the drug, while preventing exposure of the patient to the aversive agents during transdermal wear. We believe that a key differentiating
aspect of the technology is that the aversive agents are physically separated from the drug matrix, meaning that the aversive agents do
not have to be formulated in the fentanyl drug matrix and do not contact the skin. In addition to the fentanyl patch, this technology
has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our abuse deterrent technology
can be broadly applied to various transdermal products and our strategy is to follow the development of our abuse deterrent fentanyl transdermal
system with the development of additional products for pharmaceuticals that have risks or history of abuse. For example, we believe that
our technology can be utilized in other transdermal products to deter the abuse of other transdermal drugs such as buprenorphine, an opioid
used to treat acute pain and chronic pain, and methylphenidate, a central nervous system stimulant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Buprenorphine is an opioid used to treat opioid
addiction, acute pain and chronic pain. It can be used under the tongue, by injection, as a skin patch, or as an implant. For opioid addiction,
it is typically only started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a
health care provider. For longer term treatment of addiction, a combination formulation of buprenorphine/naloxone is recommended to prevent
misuse by injection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Methylphenidate, sold under various trade names,
such as Ritalin in oral form, and in transdermal patch form known as Daytrana, is a central nervous system stimulant of the phenethylamine
and Piperidine classes that is used in the treatment of attention deficit hyperactivity disorder and narcolepsy. We plan to follow up
with transdermal delivery systems for buprenorphine and methylphenidate after we make significant progress on our abuse deterrent fentanyl
transdermal system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also exploring product applications for
our transdermal technology to deliver proteins and peptides such as exenatide for type 2 diabetes and follicle stimulating hormone (FSH)
for infertility. Presently, these products are only available by injection or oral routes. We believe that transdermal delivery has the
potential to improve compliance, which can lead to improved therapeutic outcomes associated with these treatments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exenatide (exendin-4) is a glucagon-like peptide-1
(GLP-1) receptor agonist which is approved to improve glycemic control in patients with type 2 diabetes mellitus. Exenatide is currently
approved as a twice-daily subcutaneous injection or as a once-weekly injection. However, many patients have a strong aversion to needles,
resist initiation of injections even when oral agents are failing to control their diabetes and struggle with compliance after starting
therapy. We have performed pre-clinical work on the development of a novel transdermal patch for administration of exenatide to match
the therapeutic plasma levels achieved by subcutaneous injections of exenatide. However, we need substantial funds before we can continue
these efforts. In addition to being needle-free, painless and easy-to-use, our proposed exenatide transdermal system is being designed
to incorporate compliance tracking to help providers improve patient outcomes. We believe that the development of an exenatide patch matching
the profile of exenatide injections will follow the 505(b)(2) NDA regulatory pathway, thereby limiting the extent of safety and efficacy
trials required for FDA approval, although we cannot assure you that the FDA will agree. Transdermal exenatide is currently in the preclinical
phase of development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Follicle-stimulating hormone (FSH) is a gonadotropin,
a glycoprotein polypeptide hormone that is synthesized and secreted by the gonadotropic cells of the anterior pituitary gland. Follicle
stimulating hormone (FSH) is indicated for the treatment of infertility in women and is currently only approved and marketed as a subcutaneous
injection. FSH is mainly used for ovarian hyperstimulation as part of an in vitro fertilization (IVF) regimen. There are several purified
and recombinant FSH injections currently on the market. We are developing a novel transdermal patch to match the pharmacokinetic profile
of FSH subcutaneous injection but without the need for painful injections. Transdermal FSH is intended to offer a painless, easy to use
one-step application to improve patient compliance with FSH therapy. Transdermal FSH will be offered at multiple strengths to match the
typical doses prescribed to treat infertility. We plan to conduct a Phase 1 clinical trial to demonstrate that the transdermal patch can
match the pharmacokinetics of subcutaneous injection. Then we plan to conduct an irritation and sensitization study to demonstrate the
skin safety of the product and a pivotal clinical efficacy trial to demonstrate that transdermal FSH is not inferior to subcutaneous injection.
We intend to seek to utilize the 505(b)(2) NDA regulatory pathway to register the product with the FDA which allows us to reference the
know safety of FSH on file at FDA for the reference listed drug and the safety information that has been published in the literature.
We have not yet communicated with the FDA on our proposed development plan or registration plan and we cannot assure you that the FDA
will agree to our use of the 505(b)(2) pathway. Transdermal FSH is currently in the preclinical phase of development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may seek to develop certain generic
transdermal products where we think we can efficiently make an improvement to existing patches and potentially take significant market
share with good profit margins. One example of such a product candidate is the development of a generic scopolamine patch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transdermal scopolamine (Transderm Scop&#174;)
was developed in the 1970s by Alza Corporation for Ciba-Geigy (now Novartis) for prevention of nausea and vomiting associated with motion
sickness and recovery from anesthesia and surgery. The product was approved as the first modern transdermal therapeutic system by the
FDA in 1979. A generic transdermal scopolamine product was approved in 2015 (Perrigo) but was not marketed until 2017. As of November
2018, there was only one generic transdermal scopolamine approved and marketed. We are looking to develop what we believe is an improved
proprietary generic scopolamine patch. Product improvements include enhancements to the manufacturing processes to reduce the manufacturing
cost and optimization of the adhesive formulation to reduce cold flow and increase patient acceptability. We have performed pre-clinical
work on this proposed product, however, we cannot proceed further without significant funding. We plan to follow the FDA guidance on the
product development of a generic transdermal scopolamine patch and plan on utilizing the ANDA regulatory pathway to obtain FDA approval
for marketing. Transdermal scopolamine is currently in the preclinical phase of development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not yet determined which product we will
seek to develop after our abuse deterrent fentanyl transdermal system. The prioritization of our portfolio of product candidates will
be reviewed on an ongoing basis and will take into account technical progress, market potential, available funding and commercial interest.
Our ability to take any meaningful steps to the development of any of these products is determined by our ability to provide sufficient
funding for such purchase. As stated above, without significant financing or a joint venture agreement we will not be able to take any
steps to the development of any of these products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no branded OTC or Consumer products
nor do we plan to launch any OTC or Consumer products in the near term as our focus is primarily on our prescription pipeline and contract
services offered by both 4P Therapeutics and Pocono Pharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing of our pharmaceutical transdermal
products will be performed for clinical trials during the development program and for manufacturing of commercial products prior to FDA
approval and for sales and marketing. Clinical manufacturing for our early--stage clinical trials will most likely be performed at our
facilities at 4P Therapeutics. However, the manufacture of clinical products for later stage pivotal clinical trials and for commercial
manufacturing may either be done by contract manufacturers or done in our commercial facilities. Manufacture of clinical and commercial
product will be performed in compliance with current FDA Good Manufacturing Procedures (cGMP) and all applicable local regulations. All
manufacturing processes will be subject to review by the FDA during development, prior to approval and during subsequent routine FDA inspections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2020, the Company entered into
a License Agreement (the &#8220;License Agreement&#8221;) with Rambam Med-Tech Ltd., Haifa, Israel (&#8220;RamBam&#8221;), for us to develop
the RAMBAM Closed System Transfer Device (CSTD) the (&#8220;Medical Products&#8221;).&#160;As a part of the transaction with RamBam for
the License Agreement, and to assist in the development of the RAMBAM CSTD Device, on March 10, 2021, the Company finalized a Distribution
Agreement (&#8220;Distribution Agreement&#8221;)_with BPM Inno Ltd., Kiryat, Israel (&#8220;BPM&#8221;), providing for distribution of
the Medical Products developed and produced under the License Agreement and a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December
7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. The investment
by BPM in our common stock under the SPA was completed on February 26, 2021. Under the Distribution Agreement, BPM&#160;has the right
to distribute the Medical Products in Israel and has a right of first refusal in relation to all other countries/states, other than United
States, Korea, China, Vietnam, Canada and Ecuador, which are termed excluded countries.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2021, the Company has nine full
time employees, of which five are officers of the Company. None of our employees are engaged by a labor union, and we consider our employee
relations to be good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical business is subject to extensive
government regulation. In the United States, we must comply with the rules and regulations of the FDA. In other countries we must comply
with the laws and regulations of each country to legally market and sell our products. Obtaining FDA approval does not mean that the product
will be approved in other countries. Each country may require that additional clinical and nonclinical studies be conducted prior to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process required by the FDA to receive approval
prior to marketing and distributing a drug in the United States generally involves the following. The definition of drug is broadly defined
and includes our pharmaceutical products and most of our consumer transdermal patches. Even though the drug used in each of our proposed
products is currently approved by the FDA in oral or injectable dosage forms, we will still need to conduct a full development program
including preclinical and clinical trials before we receive FDA marketing approval. The FDA also has a number of abbreviated approval
pathways which, if we are eligible, could shorten the time for approval. However, we cannot be certain that we will be able to use any
abbreviated approval pathway, in which event we will need to comply with the full regulatory pathway.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Preclinical
phase</span>. Before a drug company can test an experimental treatment in humans, it must prove the drug is safe and effective in animals.
Scientists run tests in various animals before presenting the data to the FDA as an investigational new drug application. For already
approved drugs, an animal study may not be required prior to testing in humans. In most cases, the company must file an Investigational
New Drug (IND) submission to get clearance to test the product in humans.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Phase
one clinical trial</span>. In the first round of clinical trials, the drug company attempts to establish the drug&#8217;s safety in humans.
Drug researchers administer the treatment to healthy individuals &#8212; instead of patients suffering from the disease or condition
the drug is intended to treat &#8212; and gradually increase the dose to see if the drug is toxic at higher levels or if any possible
side effects occur. These drug trials are usually small, containing about 20 to 80 participants, according to the FDA. For drug delivery
products incorporating already approved drugs, Phase 1 studies involve measuring blood levels of the drug to understand the pharmacokinetics
for a new route of administration.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Phase
two clinical trial</span>. In the second round of clinical trials, researchers give the treatment to patients who have the disease to assess
the drug&#8217;s efficacy. The trial is randomized, meaning half of the study participants receive the drug and half receive a placebo.
These trials usually contain hundreds of participants, according to the FDA. There is about a 30 percent chance of a drug moving on to
a phase three clinical trial, according to data from the biotech trade organization BIO. For already approved drugs, as is the case with
drug delivery products, a Phase 2 trial may not be necessary as the therapeutic drug doses and blood concentrations are already known.
However, a Phase 2 may be conducted to inform the design of the Phase 3 clinical trial in regards to the safety and efficacy of the product
when used by patients.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Phase
three clinical trial</span>. In the third phase of clinical trials, researchers work with the FDA to design a larger trial to test the drug&#8217;s
ideal dosage, patient population and other factors that could decide whether the drug is approved, according to the report. These trials
usually contain a few hundred to thousands of participants. In the case of drug delivery products that utilize an approved drug, Phase
3 trials will typically include a comparison to the already approved reference product. For example a transdermal patch may be compared
to an injection.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">New
drug application</span>. Once a drug company collects and analyzes all data from the clinical trials, it submits a new drug application
to the FDA. The application includes trial data, preclinical information and details on the drug&#8217;s manufacturing process. If the
FDA accepts the application for review, the agency has ten months &#8212; or six months if the drug has priority review status &#8212;
to make a decision, according to the report. The FDA can hold an advisory committee meeting where independent experts assess the data
and recommend whether to approve the drug. From there, the FDA will either approve the drug or give the applicant a complete response
letter, which explains why the drug did not get approved and what steps the applicant must take before resubmitting the application for
approval.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may also require Human Abuse Liability
or Human Abuse Potential clinical studies to evaluate the abuse liability or abuse potential of a new chemical entity for drugs that affect
the central nervous system. If the abuse deterrent technology renders a product less desirable than conventional formulations, it is said
to convey abuse deterrent properties and can include specific label language indicating this difference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In other instances, sponsors are required to evaluate
the effectiveness of an Abuse Deterrent Formulation. For Abuse Deterrent Formulation trials, the objective is to assess the ability of
the new formulation to be tampered with and abused and is often pursuant to a 505(b)(2) strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving an NDA, the FDA may inspect the
facilities where the product is being manufactured or facilities that are significantly involved in the product development and distribution
process and will not approve the product unless compliance with current good manufacturing processes is satisfactory. The FDA may deny
approval of an NDA if applicable statutory or regulatory criteria are not satisfied, or may require additional testing or information,
which can delay the approval process. In pursuing FDA approval there may be various delays and it is possible that approval may never
be granted. In addition, new government requirements may be established that could delay or prevent regulatory approval of our product
candidates under development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a product is approved, the FDA may impose limitations
on the indications for use for which the product may be marketed, may require that warning statements be included in the product labeling,
may require that additional studies or trials be conducted following approval as a condition of the approval, may impose restrictions
and conditions on product distribution, prescribing or dispensing in the form of a risk management plan, or impose other limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once a product receives FDA approval, marketing
the product for other indicated uses or making certain manufacturing or other changes related to the product will require FDA review and
approval of a supplemental NDA or a new NDA, which may require additional clinical safety and efficacy data and may require additional
review fees. In addition, further post-marketing testing and surveillance to monitor the safety or efficacy of a product may be required.
Also, product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems
occur following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the labeling for our abuse deterrent
transdermal fentanyl system or any other opioid transdermal patch we develop, it is likely that we will need to disclose the risks of
improper use or abuse using language required by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>FDA Approval Pathways</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has several pathways that can be followed
to obtain FDA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
stand-alone NDA is an application submitted under Section 505(b)(1) of the Food, Drug and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and
approved under Section 505(c) of the FD&amp;C Act that contains full reports of investigations of safety and effectiveness that were
conducted by or for the applicant or for which the applicant has a right of reference or use. This is typically the pathway used for
new chemical entities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
505(b)(2) application is an NDA submitted under Section 505(b)(1) and approved under Section 505(c) of the FD&amp;C Act that contains
full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies
not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. This is the pathway typically
taken for off-patent drugs that are being development into alternate dosage forms or routes of administration.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
ANDA is an application for a duplicate of a previously approved drug product that was submitted and approved under Section 505(j) of
the FD&amp;C Act. An ANDA relies on the FDA&#8217;s finding that the previously approved drug product is safe and effective. An ANDA
generally must contain information to show that the proposed generic product (1) is the same as the drug with respect to the active ingredients,
conditions of use, route of administration, dosage form, strength and labeling (with certain permissible differences) and (2) is bioequivalent
to the referenced drug. An ANDA may not be submitted if studies are necessary to establish the safety and effectiveness of the proposed
product. This is the pathway taken for generic drugs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that we will be able to take
advantage of any of the available abbreviated approval pathways for any of our proposed products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Post-approval requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any drug products for which we receive FDA approval
will be subject to continuing regulation by the FDA. Certain requirements include, among other things, record-keeping requirements, reporting
of adverse events with the product, providing the FDA with updated safety and efficacy information on an annual basis or more frequently
for specific events, product sampling and distribution requirements, complying with certain electronic records and signature requirements
and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among others, standards
for direct-to-consumer advertising, prohibitions against promoting drugs for uses or patient populations that are not described in the
drug&#8217;s approved labeling, known as &#8220;off-label use,&#8221; and other promotional activities, such as those considered to be
false or misleading. Failure to comply with FDA regulations can have negative consequences, including the immediate discontinuation of
noncomplying materials, adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors,
and civil or criminal penalties. Such enforcement may also lead to scrutiny and enforcement by other government and regulatory bodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although physicians may prescribe legally available
drugs for off-label uses, manufacturers may not encourage, market or promote such off-label uses. As a result, &#8220;off-label promotion&#8221;
has formed the basis for litigation under the Federal False Claims Act, violations of which are subject to significant civil fines and
penalties. In addition, manufacturers of prescription products are required to disclose annually to the Center for Medicaid and Medicare
any payments made to physicians and teaching hospitals in the U.S. under the federal Physician Payment Sunshine Act. Reportable payments
may be direct or indirect, in cash or kind, for any reason, and are required to be disclosed even if the payments are not related to the
approved product. Failure to fully disclose or not in time reporting could lead to penalties up to $1.15 million per year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacturing of any of our products will
be required to comply with the FDA&#8217;s current good manufacturing process (cGMP) regulations. These regulations require, among other
things, quality control and quality assurance, as well as the corresponding maintenance of comprehensive records and documentation. Drug
manufacturers and other entities involved in the manufacture and distribution of approved drugs are also required to register with the
FDA their establishments and list any products they make and to comply with related requirements in certain states. These entities are
further subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with current good manufacturing
processes and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality
control to maintain cGMP compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discovery of problems with a product after approval
may result in serious and extensive restrictions on a product, manufacturer or holder of an approved NDA, as well as lead to potential
market disruptions. These restrictions may include recalls, suspension of a product until the FDA is assured that quality standards can
be met, and continuing oversight of manufacturing by the FDA under a &#8220;consent decree,&#8221; which frequently includes the imposition
of costs and continuing inspections over a period of many years, as well as possible withdrawal of the product from the market. In addition,
changes to the manufacturing process generally require prior FDA approval before being implemented. Other types of changes to the approved
product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also may require post-marketing testing,
or Phase IV testing, as well as risk minimization action plans and surveillance to monitor the effects of an approved product or place
conditions on an approval that could otherwise restrict the distribution or use of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Government Regulations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to government regulations that
are applicable to businesses generally, including those relating to workers&#8217; health and safety, environmental and waste disposal,
wage and hour and labor practices, including sexual harassment laws and regulations, and anti-discrimination laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we must comply with the laws and
regulations governing the research and manufacture of products containing controlled substances such as fentanyl and other opioids. We
must be licensed by the Drug Enforcement Agency (DEA) and the state(s) in which we conduct research and development activities. We currently
hold a DEA license and a Georgia State Board of Pharmacy license to support our current research activities at our facility in Georgia.
As a result we have been inspected by the DEA and the Georgia Board of Pharmacy. As we enter the manufacturing phase of development we
will need to obtain a DEA manufacturing license and a Georgia Board of Pharmacy manufacturing license and obtain production quota from
the DEA to allocate sufficient amounts of controlled substances to us to conduct our development program. There is no guarantee that we
will be able to obtain sufficient production quota from the DEA to support our manufacturing operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Europe and Other Countries</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we market our products in any countries other
than the United States, we would be subject to the laws of those countries. In order to obtain market our products in other countries
we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among
other things, clinical trials and commercial sales, pricing and distribution of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The European medicines regulatory system is based
on a network of around 50 regulatory authorities from the 31&#160;countries in the European Economic Area, the European Commission and
the European Medicines Agency. All medicines must be authorized before they can be placed on the market in the European Union. The European
system offers different routes for authorization. A centralized procedure allows the marketing of a medicine on the basis of a single
European Union assessment and marketing authorization which is valid throughout the European Union. However, a majority of medicines authorized
in the European Union do not fall within the scope of the centralized procedure, and we do not know whether our proposed products will
fall within the centralized authorization. We also do not know how the withdrawal of Great Britain from the European Union will affect
the procedure for approval of medicines in the United Kingdom. If we are not able to use the centralized procedure, we would need to use
one of the following procedures. One method is the decentralized procedure where we would apply for the simultaneous authorization in
more than one European Union member. The second method is the mutual-recognition procedure where we would have a medicine authorized in
one European Union country apply for authorization to be recognized in other European Union countries. In either case, we would be required
to complete clinical trials to demonstrate the safety and efficacy of the medicine and show and that the medicine is manufactured in accordance
with good manufacturing practice based upon European Union standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In countries other than the United States and
the European Union, we would be required to comply with the applicable laws of those countries, which may require us to perform additional
clinical testing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to obtain regulatory approval in any country
would prevent our product candidates from being marketed in those countries. In order to market and sell our products in jurisdictions
other than the United States and the European Union, we must obtain separate marketing approvals and comply with numerous and varying
regulatory requirements. The regulatory approval process outside the United States and the European Union generally includes all of the
risks associated with obtaining FDA and European Union approval but can involve additional testing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in many countries worldwide, it is
required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain
approvals from regulatory authorities outside the United States on a timely basis, if at all. Even if we were to receive approval in the
United States or the European Union, approval by the FDA or the European Medicines Agency does not ensure approval by regulatory authorities
in other countries or jurisdictions. Similarly, approval by one regulatory authority outside the United States would not ensure approval
by regulatory authorities in other countries or jurisdictions. We may not be able to file for marketing approvals and may not receive
necessary approvals to commercialize our products in any market. If we are unable to obtain approval of our product candidates by regulatory
authorities in other foreign jurisdictions, the commercial prospects of those product candidates may be significantly diminished and our
business prospects could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, particularly in member
states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations
or the successful completion of health technology assessment procedures with governmental authorities can take considerable time after
receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on
prices and reimbursement levels, including as part of cost containment measures. Certain countries allow companies to fix their own prices
for medicines but monitor the pricing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to regulations in the United States,
if we market outside of the United States, we will be subject to a variety of regulations governing, among other things, clinical trials
and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the requisite
approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in
those countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4P Therapeutics filed an international patent
application under the Patent Cooperation Treaty for worldwide prosecution of the abuse deterrent transdermal technology patent used in
our lead product, an abuse deterrent fentanyl transdermal system. The patent is being prosecuted in the United States and in other countries.
The European Patent Office and the patent offices for Japan, Australia and Russia had granted patent protection for the patent application
filed by 4P Therapeutics for its abuse deterrent transdermal technology and the patent office of Mexico has granted a notice of allowance.
In addition to applying the technology to developing an abuse deterrent fentanyl transdermal system, we believe that the abuse deterrent
patch technology can be applied to other opioids and pain medication patches where there is risk of abuse and overdose, as well as other
transdermal pharmaceuticals where we believe our technology can help prevent abuse or accidental misuse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have received a trademark and Wordmark for
the name Nutriband. We have also received a trademark for the name AVERSA&#174; which we use for our abuse deterrent technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our proposed pharmaceutical products deliver
a drug which is off patent and presently available, we will compete with a number of companies who are presently selling the drug which
is generally taken by injection. In addition, there are a number of companies that market generic transdermal patches, including fentanyl
transdermal patches, and we will compete against those companies that make products with the same drug. Further, as transdermal patches
become more popular, other companies, many of which have significantly greater resources and existing relationships with physicians and
medical personnel, may use their resources to develop improved transdermal delivery systems for the drugs that are in our pipeline. We
believe that competition is based on such factors as price, insurance/Medicaid and Medicare reimbursement rates and policies, safety and
efficacy, side effects or reduction in side effects and the reliability of the supplier or manufacturer. Since we are developing our products
to meet the needs of the patients, physicians, and the payers, we need to demonstrate advantages in terms of safety, efficacy, compliance
and cost. If we obtain regulatory approval to market our products, we cannot assure you that we will be successful in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not own any real property. We lease a shared
office space in Orlando for $ 149 per month. With the office lease, we have access to board rooms, kitchen facilities and administrative
support services. We lease manufacturing space in Cherryville, North Carolina, for $4,200 per month under a verbal agreement on a month-to-month
basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2018, we, our chief executive officer
and our chief financial officer received a Wells notice from the enforcement division staff of the Miami Regional Office of the SEC in
connection with an investigation into the accuracy of certain statements in our Form 10 registration statement filed June 2, 2016, as
amended, and our Form 10-K annual report filed May 8, 2017. The staff&#8217;s inquiry was focused on our disclosure language in those
filings relating to the FDA requirements for our consumer transdermal patch products in that our filings did not accurately reflect the
FDA&#8217;s jurisdiction over our consumer products and did not disclose that we could not legally market these products in the United
States. On September 7, 2018, we and the officers filed a Wells submission in response. After engaging in settlement discussions with
the staff about the matters under investigation, we and the officers submitted an offer of settlement to resolve the investigation without
admitting or denying any violations of the federal securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2018, the SEC announced that it
has accepted the settlement offer and instituted settled administrative cease-and-desist proceedings against us and the named officers.
The SEC&#8217;s administrative order, dated December 26, 2018, finds that we and the officers consented &#8211; without admitting or denying
any findings by the SEC&#8211; to cease-and-desist orders against them for violations by us of Sections 12(g) and 13(a) of the Exchange
Act 1934 and Rules 12b-20 and 13a-1 thereunder, which require issuers to file accurate registration statements and annual reports with
the SEC; violations by the officers for causing our violations of the above issuer reporting provisions; and violations by the officers
of Rule 13a-14 of the Exchange Act, which requires each principal executive and principal financial officer of issuers to attest that
annual reports filed with the SEC do not contain any untrue statements of material fact. In addition to consenting to the cease-and-desist
orders, the officers have each agreed to pay a $25,000 civil penalty to resolve the investigation. The administrative order does not impose
a civil penalty or any other monetary relief against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2018, we commenced an action in the
Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar, Paul
Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a Motion
for Prejudgment Writ of Replevin arising from our decision to seek to rescind for misrepresentation the agreement by which we acquired
advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of the shares. On August 2, 2018,
the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants. Defendants Kalmar, Murphy,
Polly-Murphy, and Baker filed a Motion to Dismiss our Verified Complaint, Motion to Dissolve Temporary Injunction Without Notice and Response
to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court dismissed our complaint with prejudice, and directed
the defendants to assign to us within 30 days, the six patents never duly transferred to us. On February 1, 2019, we appealed the court&#8217;s
order. Pursuant to a settlement agreement with one of the defendants, that defendant returned the 50,000 shares which had been issued
to her, and the shares were cancelled as of January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom
we have a settlement agreement), filed a motion for sanctions and civil contempt against us, which generally claimed that we failed to
comply with the Court&#8217;s January 4, 2019 order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer
their shares of common stock. On October 29, 2019, the Court denied the defendants motion. On March 20, 2020, the Florida district court
of appeal reversed the lower court ruling in the Florida state court action that dismissed our complaint with prejudice and gave us leave
to file an amended complaint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 22, 2018, four of the defendants in
the Florida action described in the previous paragraph filed a complaint against us in the Franklin County, Ohio Court of Common Pleas
seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement.
The parties have agreed to a stay pending the outcome of the Florida litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2019, we filed a securities fraud
action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Advanced
Health Brands and TD Therapeutic, Inc. In the complaint we allege that in 2017, the defendants fraudulently and deceitfully obtained 1,250,000
shares of common stock by orchestrating a months-long scheme to defraud us. We are seeking the return of the 1,200,000 shares of common
stock and monetary damages resulting from the defendants&#8217; fraudulent conduct. The defendants filed a motion to dismiss on August
23, 2019, and we filed our response on September 13, 2019. On July 20, 2020, the Court denied the defendant&#8217;s motion to dismiss
the complaint, and the parties have recently commenced the discovery phase of the litigation. No trial date has been scheduled by the
Court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below is certain information with respect
to our directors and executive officers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 35%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gareth Sheridan</span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="width: 53%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief executive officer and director</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean Gallagher</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman and director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serguei Melnik</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Myer</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President of Pocono Pharma and Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gerald Goodman</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Smith, Ph.D.</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief operating officer and president of 4P Therapeutics</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Ryan</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief technical officer</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Patrick, Pharm.D.</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief scientific officer</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radu Bujoreanu</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven P. Damon</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vsevolod Grigore</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Hamilton</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stefan Mancas</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyler Overk</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President of Active intelligence</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gareth Sheridan, our founder, has been chief executive
officer and a director since our organization in 2016. In 2012, Mr. Sheridan founded Nutriband Ltd., an Irish company which we acquired
in 2016. Mr. Sheridan was named Ireland&#8217;s &#8216;Young Entrepreneur of the Year&#8217; in 2014 in the National Bank of Ireland Startup
Awards for establishing Nutriband Ltd. Mr. Sheridan has further business awards from S. Dublin&#8217;s Best Young Entrepreneur and Nutriband
Ltd as S. Dublin&#8217;s Best Startup Company. Mr. Sheridan has also worked as a Business Mentor with 100 Minds, a social enterprise founded
in 2013, that brings together some of Ireland&#8217;s top college students and connects them with one cause to achieve large charitable
goals in a short space of time. Mr. Sheridan is also a past Nissan Generation Next Ambassador, receiving the acknowledgement in 2015 by
Nissan Ireland as one of Ireland&#8217;s future generational leaders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2019 Mr. Sheridan served on the Board of the
St. James Hospital foundation, the charitable foundation for Ireland&#8217;s largest public hospital. Mr. Sheridan received a B.Sc. in
Business and Management from Dublin Institute of Technology in 2012 where he concentrated on international economics, venture creation
and entrepreneurship.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sean Gallagher is an experienced businessman,
an inspiring speaker&#160;&amp; a highly regarded business writer. He also stood, as an Independent Candidate, and was runner up, in the
2011 Irish Presidential Election. Sean&#8217;s notable business ventures include Co Founding and serving as CEO of Clyde Real Estate,
Pharmaceutical Directorships and co-founding Ireland&#8217;s largest home technology company, Smarthomes. Sean has also served as a investor
in popular TV show, Dragon&#8217;s Den which is Ireland and UK&#8217;s version of popular US TV show Shark tank. Sean qualified with an
MBA from the University of Ulster and previously worked with one of Ireland&#8217;s Enterprise Agencies and has, over the past 20 years,
trained and mentored hundreds of emerging entrepreneurs. He has also served on a number of Irish State Boards including the National Training
and Employment Agency (FAS), the North South Trade Body (InterTrade Ireland) and was Chair of the State-owned Drogheda Port Company. Mr.
Gallagher works for us on a part-time basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Michael Myer, who was nominated as a director
for election at the November 12, 2020 annual meeting in connection with our acquisition, effective August 31, 2020, of Pocono Coated Products,
LLC&#8217;s Transdermal, Topical Cosmetic and Health business. Michael has been the Chief Quality Officer at Pocono Coated Products, LLC
from January 2015 to June 2019, and General Manager&#8212;Nutraceutical Division, from June 2019 to the present. Michael has substantial
experience as chief quality officer in manufacturing, quality systems, risk management, process engineering, lean practices, and financial
management. Michael has been acting as General Manager of the transdermal patch side of Pocono Coated Products, and&#160;the&#160;CEO
of its Active Intelligence subsidiary. He remains active in daily operations, as well as executive level decision making. Michael is also
a former Marine, CrossFit Level 1 Coach, and USAW Sport Performance Coach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Serguei Melnik serves as part a member of the
board of directors and is a co-founder of Nutriband Inc. Mr Melnik has previously served as our chief financial officer and a director
since January 2016. Mr. Melnik has been involved in general business consulting for companies in the U.S. financial markets and setting
up legal and financial framework for operations of foreign companies in the U.S. Mr. Melnik advised UNR Holdings, Inc. with regard to
the initiation of the trading of its stock in the over-the-counter markets in the U.S., and has provided general advice with respect to
the U.S. financial markets for companies located in the U.S. and abroad. From February 2003 to May 2005 he was the Chief Operations Officer
and a Board member of Asconi Corporation, Winter Park, Florida, with regard to restructuring the company and listing it on the American
Stock Exchange. Mr. Melnik from June 1995 to December 1996 was a lawyer in the Department of Foreign Affairs, JSC Bank &#8220;Inteprinzbanca,&#8221;,
Chisinau, Moldova, and prior thereto practiced law in Moldova in various positions. Mr. Melnik is fluent in Russian, Romanian, English
and Spanish.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gerald Goodman has been our chief accounting officer
since July 31, 2018 and was elected our Chief Financial Officer on November 12, 2020. Mr. Goodman is a certified public accountant and,
since 2014, has practiced with his own firm, Gerald Goodman CPA P.C. From January 1, 2010 until December 31, 2014, Mr. Goodman practiced
with Madsen&#160;&amp; Associates, CPA&#8217;s Inc., Murray, Utah, and was a non-equity partner and managed the firm&#8217;s SEC practice.
Mr. Goodman is a director of Lifestyle Medical Network, Inc., which provides management services to healthcare providers. From 1971 to
2010, Mr. Goodman was a partner in the accounting firm of Wiener, Goodman&#160;&amp; Company P.C. Mr. Goodman is a 1970 graduate of Pennsylvania
State University where he received a B.S. Degree in Accounting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alan Smith, Ph.D., co-founded 4P Therapeutics
in 2011 and serves as Head of 4P Theraputics, and Head of Clinical, Regulatory, Quality&#160;&amp; Operations at Nutriband. Previously,
he was with Altea Therapeutics, most recently serving as Vice President, Product Development and Head of Clinical R&amp;D, Regulatory
Affairs, and Project Management. At Altea, he led major research and development programs with pharmaceutical companies such as Eli Lilly,
Amylin, Hospira, Elan, and Novartis. He joined Altea as one of the first employees and spent 12 years growing its multidisciplinary drug
delivery research and development organization. Dr. Smith has 20 years of experience in the research and development of drug and biologic
delivery systems, diagnostics and medical devices for treatment and management of diabetes, chronic pain and cardiovascular disease. Prior
to joining Altea Therapeutics, he led the development of transdermal glucose monitoring systems at SpectRx, Inc., a publicly traded noninvasive
diagnostics company. Dr. Smith received Ph.D. and M.S. degrees in Biomedical Engineering from Rutgers University and the University of
Medicine and Dentistry of New Jersey. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Paddy Ryan has been chief technical officer since
February 2018. Having worked in the tech industry for 8 years, Paddy brings a fresh perspective and understanding to our team. From September
2019 to present Mr. Ryan served as director of digital agency for Trigger Media. From 2013 to 2016, Mr. Ryan worked as an online security
analyst with Paddy Power Betfair Plc. From 2016 to 2017, Mr. Ryan was general manager at CRS Events setting up and organising One-Zero,
the largest sports conference in Ireland. Mr Ryan served as head of technology for Irish agency Trigger Movement between 2017 and 2019.
Mr Ryan serves as technical advisor for sports media brand, Pundit Arena, where he has advised on their technical development since 2012.
Mr Ryan also served as a digital consultant for Irish Aid Charity, B&#243;thar, where he worked on the development of the charity&#8217;s
digital plans plans. Mr. Ryan has also consulted with Irish Local Government in County Limerick (Limerick County Council) regarding their
digital activity in September 2018. Mr. Ryan has also assisted Swiss Company, SEBA Crypto AG, to develop their online presence in October
2018. Mr. Ryan is also a technical advisor for Irish dairy company, Arrabawn where he has assisted them with online strategies since 2017.
Mr. Ryan has been involved in general technical consulting for startups and companies in Ireland for more than ten years. Mr. Ryan attended
University College Dublin where he studied engineering and is working towards his masters in data analytics from National College of Ireland.
Mr Ryan also assisted in the development and launch of the Pandemic Action Network website in early 2020. As CTO, Paddy is responsible
for Nutriband&#8217;s technology strategy and plays a key role in leading new initiatives. Mr. Ryan works for us on a part-time basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jeff Patrick Pharm.D. currently serves as Director
of Drug Development Institute at the Ohio State University Comprehensive Cancer Center. Dr. Patrick most recently serving as Chief Scientific
Officer for New Haven Pharmaceuticals. Prior roles included global vice president of professional affairs at Mallinckrodt Pharmaceuticals,
Inc.; and roles with ascending responsibilities at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo, Inc. Dr. Patrick is a residency-trained
clinical pharmacist with approximately 20 years of pharmaceutical industry experience. He brings expertise in executive leadership, scientific
and medical strategy, drug development and commercialization to the company. Prior to pursuing a career in research and development, Patrick
was an ambulatory care clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy
at the University of Tennessee College of Pharmacy, where he earned his doctorate in pharmacy. He also completed the Wharton School of
Business Pharmaceutical Executive Program. Dr. Patrick works for us on a part-time basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Radu Bujoreanu has been a director since June
2019. Mr. Bujoreanu has been the owner and executive director of Consular Assistance, Inc., which provides assistance in obtaining visas
for the Republic of Moldava and related services since December 2002, and he has been a real estate agent with Keller Williams Realty,
Inc. since May 2019. Mr. Bujoreanu received his Bachelor in International Public Law from the University of Moldova.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steven P. Damon has been a director since April
2018, when we signed the agreement to acquire 4P Therapeutics. Mr. Damon is a co-founder of 4P Therapeutics, which was formed in 2011,
and he has more than 20 years of experience with various business roles in the medical and pharmaceutical industries. Before founding
4P Therapeutics, Mr. Damon led the business development team at Altea Therapeutics as the company&#8217;s senior vice president of business
development. Mr. Damon is a director of Georgia BIO, a non-profit trade association that promotes Georgia&#8217;s life science industry.
Mr. Damon received is Bachelors in Business Administration and Associate in accounting from Colorado Mesa University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mark Hamilton, a director since July 2018, has
been at BDO Ireland, a major accounting firm, for more than nine years, held positions in Corporate Finance, Corporate Advisory, Restructuring
and Recovery, Client management and in his current role in Business Development. Mr. Hamilton is a Chartered Accountant and a member of
the Association of Chartered Accountants (ACA) qualifying in 2012. He is a chartered accountant and has been a member of the Association
of Chartered Accountants since 2012. Mr. Hamilton&#8217;s accounting background and experience in corporate finance, corporate advisory
and insolvency assists us in his role as an independent board member. Mr. Hamilton received a B.Sc. in Business and Management from Dublin
Institute of Technology in 2008 and subsequently received 1st class honors in his postgraduate degree specializing in Accountancy in 2009.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stefan Mancas, a director since July 2018, received
a Ph.D. in Applied Mathematics from the University of Central Florida in May 2007 under the supervision of Dr. Roy S. Choudhury, with
the dissertation topic &#8220;Dissipative Solitons in the cubic-quintic Complex Ginzburg Landau equation: Bifurcations and Spatiotemporal
Structure&#8221; for which he received the Outstanding Dissertation Award in 2008. Dr. Mancas is a professor and associate chair in the
department of mathematics at Embry-Riddle Aeronautical University. He is the co-founder of the nonlinear Waves Lab which contains a 10
m. long water tank used for research in water waves, solitons in shallow water, vortex solitons, soliton ships, surface waves and wind-wave
interaction, microcavitation, design and optimization, submarine currents, autonomous underwater vehicles, tractor beams, etc. He is also
the organizer of national and international conferences in applied mathematics, and has published more than 40 articles in refereed journals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vsevolod Grigore, age 62, is a seasoned executive
who managed to build careers in multiple fields. He is a former assistant professor and Head of Department at the Moldova State University
and Moldova Free International University. As a PhD in linguistics, he contributed to establishing many language services and conference
management businesses in his native country of Moldova.&#160;He then engaged in a prodigious diplomatic career, serving at high level
positions in the Ministry of Foreign Affairs of Moldova. From 1999 to 2002 he was Minister Counselor, Deputy Chief of Mission, then Charg&#233;
d&#8217;Affaires at Moldovan Embassy to the United States. From 2002 to 2006 he was Ambassador, Permanent Representative of Moldova to
the United Nations. During his tenure he served on the board of UNICEF and UNFPA. He currently resides in New York City, using his extensive
network of connections to provide a wide array of consultancy services, primarily in the legal and medical field. He graduated from Moldova
State University in 1979, received a PhD from Minsk State Linguistic University, Belorussia, in 1987.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tyler Overk, age 37, is the co-founder of Active
Intelligence, which was formed in 2017, and has more than 15 years of experience with various business roles in the Corporate Trade and
Health&#160;&amp; Wellness industries. Before Co-Founding Active Intelligence&#160;Mr. Overk spearheaded Business Development&#160;for
Active International as a Director of New Business Development and later as a member of the Corporate Development team tasked with leading
the company into new markets and developing new strategic offerings. Previously, Mr. Overk led a highly motivated sales team at Medi-One
LLC focused on high end Medical Diagnostic testing. He received a Bachelor&#8217;s degree from Ramapo College of New Jersey in Business
Administration with a concentration in Marketing and minor in Economics</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board of directors has created three
committees - the audit committee, the compensation committee and the nominating and corporate governance committee. Each of the
committees has a charter which meets the NASDAQ requirements and will be composed of three independent directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Audit Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit committee is comprised of Mr.&#160;Hamilton,
as chairman, Mr. Bujoreanu and Dr. Mancas. We believe that Mark Hamilton qualifies as an &#8220;audit committee financial expert&#8221;
under the rules of the Nasdaq Stock Market. The audit committee oversees, reviews, acts on and reports on various auditing and accounting
matters to the board, including: the selection of our independent accountants, the scope of our annual audits, fees to be paid to the
independent accountants, the performance of our independent accountants and our accounting practices, all as set forth in our audit committee
charter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The compensation committee is comprised of Mark
Hamilton and Mr. Bujoreanu. The compensation committee oversees the compensation of our chief executive officer and our other executive
officers and reviews our overall compensation policies for employees generally as set forth in the audit committee charter. If so authorized
by the board, the compensation committee may also serve as the granting and administrative committee under any option or other equity-based&#160;compensation
plans which we may adopt. The compensation committee will not delegate its authority to fix compensation; however, as to officers who
report to the chief executive officer, the compensation committee will consult with the chief executive officer, who may make recommendations
to the compensation committee. Any recommendations by the chief executive officer are accompanied by an analysis of the basis for the
recommendations. The committee will also discuss with the chief executive officer and other responsible officers the compensation policies
for employees who are not officers. The compensation committee has the responsibilities and authority relating to the retention, compensation,
oversight and funding of compensation consultants, legal counsel and other compensation advisers. The compensation committee members will
consider the independence of such advisors before selecting or receiving advice from such advisors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nominating and Corporate Governance Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The nominating and corporate governance committee,
which is comprised of Mr.&#160;Hamilton and Mr.&#160;Bujoreanu, will identify, evaluate and recommend qualified nominees to serve on our
board; develop and oversee our internal corporate governance processes, and maintain a management succession plan. An additional member
of this committee will be appointed, to bring the committee up to three members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Independent Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Five of our directors, Radu Bujoreanu, Steven
Damon, Mark Hamilton, Stefan Mancas and Vsevolod Grigore are independent directors based on the NASDAQ definition of independent director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;Family Relationships</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; ">There are no family relationships
among our directors and executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><b>&#160;</b>&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Compensation Committee Interlocks and Insider Participation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None of our executive officers serve on the board
of directors or compensation committee of a company that has an executive officer who serves on our board or compensation committee. No
member of our board is an executive officer of a company in which one of our executive officers serves as a member of the board of directors
or compensation committee of that company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary compensation table sets
forth information concerning compensation for services rendered in all capacities during the years ended January 31, 2021 and 2020, earned
by or paid to our chief executive officers and the two other officers receiving the greatest compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; text-align: left; font-weight: bold">Name and Principal&#160;Position</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Year &#160;</b></span></td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0">Salary<br/> $</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0">Bonus<br/> Awards<br/> $</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0">Stock<br/> Awards<br/> $</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option/<br/> Awards<sup>(1)</sup><br/> $ &#160; &#160;</b></span></td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0">Incentive<br/> Plan<br/> Compensation<br/> $</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0">Nonqualified<br/> Deferred<br/> Earnings<br/> $</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0">All Other<br/> Compensation<br/> $</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: center; font-weight: bold; padding-bottom: 1.5pt; text-indent: 0">&#160;</td>
    <td colspan="2" style="padding-left: 0; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; text-indent: 0">Total<br/> $</td><td style="padding-left: 0; text-align: center; padding-bottom: 1.5pt; font-weight: bold; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0; text-indent: 0; width: 11%; text-align: left">Gareth Sheridan,</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 7%; text-align: center; text-indent: 0">2021</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">60,000</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">150,000</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 1%; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; width: 7%; text-align: right; text-indent: 0">210,000</td><td style="padding-left: 0; width: 1%; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO<sup>3</sup></span></td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">2020</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">42,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">15,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">67,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0; text-indent: 0; text-align: left">Sean Gallagher,</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Executive Chairman<sup>1</sup></td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">2021</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">150,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">150,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">2020</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">60,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">60,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Jeff Patrick</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">2021</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">-</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer<sup>2</sup></span></td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: center; text-indent: 0">2020</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">60,000</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">252,700</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-indent: 0">&#160;</td>
    <td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: right; text-indent: 0">&#160;</td><td style="padding-left: 0; text-align: left; text-indent: 0">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended January 31, 2021, the Company issued Mr. Gallagher 10,000 shares of common stock, valued at $150,000, as compensation. During the year ended January 31, 2020, we issued to Mr. Gallagher 8,572 shares of common stock, valued at $120,000, representing his compensation for the years ended January 31, 2019 and 2018 pursuant to his employment agreement.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended January 31, 2020, we issued to Strategic Pharmaceutical Consulting LLC, a company controlled by Dr. Patrick 8,572 shares of common stock, valued at $120,000, representing Dr. Patrick&#8217;s compensation for the years ended January 31, 2020 and 2019. We also granted him to an option to purchase 25,000 shares of common stock at 75% of the market price. The option expired unexercised.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended January 31, 2021, we issued to Gareth Sheridan, our CEO, 10,000 shares of common stock valued at $150,000, representing compensation for the year ended January 31, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into a three-year employment agreement
with Gareth Sheridan, our CEO, effective April 25, 2019. The agreement also provides that the executive will continue as a director. The
Agreement provides for an initial term, commencing on the effective date of this Agreement and ending on January 31, 2024, and continuing
on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#8217; notice given prior to the expiration
of the initial term or any one-year extension. For his services to the Company during the term of the Agreement, Mr. Sheridan receives
an annual salary of $42,000 per annum, commencing on the effective date of the Agreement and increasing to $170,000 per annum commencing
in the month in which the Company shall have received not less than $2,500,000 from one or more public or private financings of the Company&#8217;s
equity securities subsequent to the date of the Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an employment agreement dated January
1, 2018 with Sean Gallagher pursuant to which we employed him as president for a term with no expiration date at an annual salary of $60,000,
which may be paid in stock or cash. The president serves on a part-time basis. The employment agreement terminated January 1, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an employment agreement dated
February 19, 2019 with its chief scientific officer pursuant to which the Company agrees to employ him as chief scientific officer for
annual compensation of $60,000, payable in cash or stock, as the Company may elect. The agreement has a term ending on February 13, 2021
and continues thereafter on a year to year basis unless terminated by either party on 30 days&#8217; notice. The chief scientific officer
series on a part-time basis. The employment agreement terminated January 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below sets forth the amounts of compensation paid to directors
of the Company in the fiscal year ended January 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Name</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Fees Earned or Paid in Cash <br/>($)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Stock Awards <br/>($)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Option Awards <br/>($)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Non-Equity Incentive Plan Compensation <br/>($)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Change in Pension Value and Nonqualified Deferred
    Compensation Earnings <br/>($)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>All Other Compensation <br/>($)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total <br/>($)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">(a)</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">(b)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">(c)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">(d)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">(e)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">(f)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">(g)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">(h)</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; padding-bottom: 1.5pt">Gareth Sheridan</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">150,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">210,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Serguei Melnik</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Sean Gallagher</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Michael Myer</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Mark Hamilton</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Radu Bujoreanu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Steven Damon</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Stefan Mancas</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Vsevolod Grigore</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pension Benefits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no plans that provide for payments
or other benefits at, following, or in connection with retirement of our officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year-End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no outstanding equity awards at January
31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PRINCIPAL STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information as to
shares of common stock beneficially owned as of September 1, 2021, by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
director;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
current officer named in the summary compensation table;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person owning of record or known by us, based on information provided to us by the persons named below, at least 5% of our common stock;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
directors and officers as a group.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the following table, &#8220;beneficial
ownership&#8221; means the sole or shared power to vote, or to direct the voting of, a security, or sole or shared investment power with
respect to a security, or any combination thereof, and the right to acquire such power (for example, through the exercise of warrants
granted by us) within 60 days of September 1, 2021. As of September 1, 2021, 6,356,269 shares of common stock were outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    and Address<sup>1</sup> of Beneficial Owner </b></span> </td>
    <td> &#160; </td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount<br/>
    and<br/>
    Nature of<br/>
    Beneficial<br/>
    Ownership</b></span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gareth Sheridan</span> </td>
    <td style="width: 1%"> &#160; </td>
    <td style="width: 1%"> &#160; </td>
    <td style="width: 9%; text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,510,000</span> </td>
    <td style="width: 1%"> &#160; </td>
    <td style="width: 1%"> &#160; </td>
    <td style="width: 1%"> &#160; </td>
    <td style="width: 9%; text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.76</span> </td>
    <td style="width: 1%"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span> </td></tr>
  <tr style="vertical-align: bottom; ">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vitalie Botgros</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">455,000</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.167</span> </td>
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span> </td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serguei Melnik<sup>2</sup></span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">717,500</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.29</span> </td>
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span> </td></tr>
  <tr style="vertical-align: bottom; ">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Damon</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,750</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean Gallagher</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,572</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; ">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stefan Mancas</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,500</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Hamilton</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,500</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; ">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radu Bujoreanu</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jeff Patrick<sup>3</sup></span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,072</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; ">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Ryan</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,500</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> </td>
    <td> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Myer(4)</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,641</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</span> </td>
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span> </td></tr>
  <tr style="vertical-align: bottom; ">
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All officers and directors as a group (14 individuals)<sup>2,3</sup></span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,596,163</span> </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td> &#160; </td>
    <td style="text-align: right"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.84</span> </td>
    <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span> </td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than One (1%) Percent.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The address is c/o Nutriband, Inc., 121 South Orange Ave., Suite 1500, Orlando, FL 32801.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 100,000 shares owned by Mr. Melnik&#8217;s wife, as to which Mr. Melnik disclaims beneficial interest, and 100,000 shares owned by each of his two minor children.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup>&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 21,072 shares owned by Strategic Pharmaceutical Consulting, with respect to which Dr. Jeff Patrick, chief scientific officer, has the power to vote and dispose of the shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(4)</sup></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>&#160;</sup></p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Myer owns 5,000 shares of common stock, and has the right to receive
188,641 shares in the acquisition of Pocono Coated Products, LLC, effective August 31, 2020 pursuant to the for the Purchase Agreement
for the acquisition (&#8220;Agreement&#8221;), that provided for payments under the Agreement to be held in escrow until August 31, 2021,
which escrow term was extended to September 30, 2021, pursuant to an Amendment to the Agreement effective August 31, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended January 31, 2021,
Serguei Melnik, a director and our former chief financial officer, and Dr. Alan Smith, our chief operating officer,
advanced us $18,128, all of which was repaid. As of January 31, 2021, the amount due each of these officers is $-0-.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2020, we issued 8,572 shares to
each of Sean Gallagher and to Strategic Pharmaceutical Consulting LLC, which is controlled by Jeff Patrick, for services rendered by Mr.
Gallaher and Dr. Patrick valued at $120,000. These issuances were made pursuant to employment agreements with Mr. Gallagher and Dr. Patrick
which provide for annual compensation of $60,000 and represented compensation for the years ended December 31, 2019 and 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company issued the following
numbers of shares common stock to Company officers and members of its Board of Directors. All stock issuances were valued by the Board
at $15.00 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Gareth Sheridan, CEO and Director</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sean Gallagher, Executive Chairman and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Serguei Melnik, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Michael Myer, President of Pocono Pharma and Director<sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Radu Bujoreanu, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Steven P. Damon, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Michael Doron, Director*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mark Hamilton, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stefan Mancass, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Vsevolod Grigore, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Patrick Ryan, Chief Technical Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gerald Goodman, Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alan Smith, Chief Operating Officer and President of 4P Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,825</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Vitalie Botgros, Consultant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thomas Cooney, Director*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jay Moore, Director*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Mr. Myer owns 188,641 shares of common stock, of which 5,000 were issued
on January 5, 2021, and 188,641 shares that he has the right to receive from the August 31, 2021 acquisition of Pocono Coated Products,
LLC, as a distribution from escrow terminating September 30, 2021, of certain distributions under the acquisition agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Former directors.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Five of our directors, Radu Bujoreanu, Steven
P. Damon, Mark Hamilton, Stefan Mancas and Vsevolod Grigore, are independent directors based on the NASDAQ definition of independent director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of 10,000,000
shares of preferred stock, par value $0.001 per share, none of which have been issued, and 250,000,000 shares of common stock, par value
$0.001 per share, of which 6,356,269 shares have been issued. Holders of our common stock are entitled to equal voting rights, consisting
of one vote per share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting rights. Therefore,
holders of a majority of the shares of common stock can elect all of our directors. The presence, in person or by proxy duly authorized,
of the holders of a majority of the outstanding shares of stock entitled to vote are necessary to constitute a quorum at any meeting of
our stockholders. A vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental corporate
changes such as liquidation, merger or an amendment to our articles of incorporation. In the event of liquidation, dissolution or winding
up of our company, either voluntarily or involuntarily, each outstanding share of the common stock is entitled to share equally in our
assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of our common stock have no pre-emptive
rights, no conversion rights and there are no redemption provisions applicable to our common stock. They are entitled to receive dividends
when and as declared by our board of directors, out of funds legally available therefore. We have not paid cash dividends in the past
and do not expect to pay any within the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors has broad powers to create
one or more series of preferred stock and to designate the voting powers, designations, preferences, limitations, restrictions and relative
right of each series.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants to Be Issued in the Offering</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The following summary of certain
terms and provisions of the Warrants included in the Units offered hereby is not complete and is subject to, and qualified in its entirety
by, the provisions of the warrant agent agreement between us and Computershare Inc., as warrant agent, and the form of Warrant, both of
which are filed as exhibits to the registration statement of which this prospectus is a part. Prospective investors should carefully review
the terms and provisions set forth in the warrant agent agreement, including the annexes thereto, and form of Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Exercisability.&#160;</i>The
Warrants are exercisable at any time after their original issuance and at any time up to the date that is five years after their original
issuance. The Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the warrants under
the Securities Act is effective and available for the issuance of such shares, or an exemption from registration under the Securities
Act is available for the issuance of such shares, by payment in full in immediately available funds for the number of shares of common
stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common stock underlying the
Warrants under the Securities Act is not effective or available and an exemption from registration under the Securities Act is not available
for the issuance of such shares, the holder may, in its sole discretion, elect to exercise the Warrant through a cashless exercise, in
which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set
forth in the Warrant. No fractional shares of common stock will be issued in connection with the exercise of a Warrant. In lieu of fractional
shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Exercise Limitation</i>.
A holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially
own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such
percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage
to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following
notice from the holder to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exercise Price.&#160;</i>The exercise price
per whole share of common stock purchasable upon exercise of the Warrants is $7.50 per share, which is 120% of public offering price
of the common stock. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets,
including cash, stock or other property to our stockholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Transferability.&#160;</i>Subject
to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Exchange Listing. </i>We
have applied for listing of our common stock and the Warrants on The NASDAQ Capital Market under the symbols &#8220;NTRB,&#8221; and &#8220;NTRBW,&#8221;
respectively.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Warrant Agent</i>. The
transfer agent for the common stock and warrant agent for the warrants is American Stock Transfer&#160;&amp; Trust Company, LLC (&#8220;AST&#8221;),
6201 15<sup>th</sup> Ave, Brooklyn, NY 11219, telephone (800) 937-5449.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Warrants will be issued in registered form
under a warrant agent agreement between AST, as warrant agent, and us. The Warrants shall initially be represented only by one or more
global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company (DTC) and registered in the name
of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Fundamental Transactions.&#160;</i>In
the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification
of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation
or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming
the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the warrants will be entitled
to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders would have received
had they exercised the warrants immediately prior to such fundamental transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Rights as a Stockholder.&#160;</i>Except
as otherwise provided in the Warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a Warrant
does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Governing Law</i>. The
Warrants and the warrant agent agreement are governed by Delaware law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Representative&#8217;s Warrants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">See &#8220;Underwriting &#8212;
Underwriters&#8217; Warrants&#8221; for a description of the warrants we have agreed to issue to the representative of the underwriters
in this offering, subject to the completion of the offering. We expect to enter into a warrant agreement in respect of the representative&#8217;s
warrants prior to the closing of this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nevada Law Provisions Relating to Certain Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sections 78.378 through 78.3793 of the Nevada
Revised Statutes contains voting limitations on certain acquisitions of control shares. Sections 78.411 through 78.444 contain restrictions
of combinations with interested stockholders. The Nevada law defines an interested stockholder as a beneficial owner (directly or indirectly)
of 10% or more of the voting power of the outstanding shares of the corporation. In addition, combinations with an interested stockholder
remain prohibited for three years after the person became an interested stockholder unless (i) the transaction is approved by the board
of directors or the holders of a majority of the outstanding shares not beneficially owned by the interested party, or (ii) the interested
stockholder satisfies certain fair value requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Limitation on liability of officers and directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nevada law provides that subject to certain very
limited statutory exceptions, a director or officer is not individually liable to the corporation or its stockholders or creditors for
any damages as a result of any act or failure to act in his or her capacity as a director or officer, unless it is proven that the act
or failure to act constituted a breach of his or her fiduciary duties as a director or officer and such breach of those duties involved
intentional misconduct, fraud or a knowing violation of law. The statutory standard of liability established by NRS Section 78.138 controls
even if there is a provision in the corporation&#8217;s articles of incorporation unless a provision in the corporation&#8217;s articles
of incorporation provides for greater individual liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nevada law permits broad provisions for indemnification
of officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws provide that each person who was or
is made a party or is threatened to be made a party to or is involved (including, without limitation, as a witness) in any threatened,
pending, or completed action, suit or proceeding, whether formal or informal, civil, criminal, administrative or investigative (hereinafter
a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director of or who is or was serving at our request as a
director, officer, employee or agent of this or another corporation or of a partnership, joint venture, trust, other enterprise, or employee
benefit plan (a &#8220;covered person&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a covered
person shall be indemnified and held harmless by us to the fullest extent permitted by applicable law, as then in effect, against all
expense, liability and loss (including attorneys&#8217; fees, costs, judgments, fines, ERISA excise taxes or penalties and amounts to
be paid in settlement) reasonably incurred or suffered by such person in connection therewith, and such indemnification shall continue
as to a person who ceased to be a covered person and shall inure to the benefit of his or her heirs, executors and administrators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, no indemnification shall be provided
hereunder to any covered person to the extent that such indemnification would be prohibited by Nevada state law or other applicable law
as then in effect, nor, with respect to proceedings seeking to enforce rights to indemnification, shall we indemnify any covered person
seeking indemnification in connection with a proceeding (or part thereof) initiated by such person except where such proceeding (or part
thereof) was authorized by our board of directors, nor shall we indemnify any covered person who shall be adjudged in any action, suit
or proceeding for which indemnification is sought, to be liable for any negligence or intentional misconduct in the performance of a duty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SEC Policy on Indemnification for Securities
Act liabilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions,
we have been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent and Warrant Agent</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent for the common stock and warrant
agent for the warrants is American Stock Transfer&#160;&amp; Trust Company, LLC, 6201 15<sup>th</sup> Ave, Brooklyn, NY 11219, telephone
(800) 937-5449.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SHARES ELIGIBLE FOR FUTURE SALE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sale of Restricted Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon consummation of this offering, we will have
7,106,269 shares of common stock outstanding, assuming that all shares are sold and there is no exercise of the underwriter&#8217;s over-allotment
option. Of these shares, all shares sold in this offering will be freely tradable without further restriction or registration under the
Securities Act, except that any shares purchased by our affiliates may generally only be sold in compliance with Rule 144, which is described
below. Of the remaining outstanding shares, the shares beneficially owned by our officers and directors, will be deemed &#8220;restricted
securities&#8221; under the Securities Act.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Rule 144</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of our common stock sold in this offering
will be freely transferable without restriction or further registration under the Securities Act. Any shares of our common stock held
by an &#8220;affiliate&#8221; of ours may not be resold publicly except in compliance with the registration requirements of the Securities
Act or under an exemption under Rule 144 or otherwise. Rule 144 permits our common stock that has been acquired by a person who is an
affiliate of ours, or has been an affiliate of ours within the three months of the date of sale, to be sold into the market in an amount
that does not exceed, during any three-month period, the greater of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
of the total number of shares of our common stock outstanding; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
average weekly reported trading volume of our common stock for the four calendar weeks prior to the sale.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such sales are also subject to specific manner
of sale provisions, a six-month holding period requirement, notice requirements and the availability of current public information about
us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximately 4,926,447 shares of our common stock
are eligible for sale under Rule 144. This number does not include the 1,200,000 shares held by the former stockholders of Advanced Health
Brands that are subject to lock-up arrangements and which are the subject of litigation described under &#8220;Business &#8212; Legal
Proceedings.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rule 144 also provides that a person who is
not deemed to have been an affiliate of ours at any time during the three months preceding a sale, and who has for at least six
months beneficially owned shares of our common stock that are restricted securities, will be entitled to freely sell such shares of
our common stock subject only to the availability of current public information regarding us. A person who is not deemed to have
been an affiliate of ours at any time during the three months preceding a sale, and who has beneficially owned for at least one year
shares of our common stock that are restricted securities, will be entitled to freely sell such shares of our common stock under
Rule 144 without regard to the current public information requirements of Rule 144.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNDERWRITING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WallachBeth Capital, LLC (&#8220;WallachBeth Capital&#8221;)
is acting as the representative of the underwriters and the book-running manager of this offering. Under the terms of an underwriting
agreement, which is filed as an exhibit to the registration statement, each of the underwriters named below has severally agreed to purchase
from us the respective number of shares of common stock shown opposite its name below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Underwriters</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">WallachBeth Capital, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">WestPark Capital, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriting agreement provides that the underwriters&#8217;
obligation to purchase Units depends on the satisfaction of the conditions contained in the underwriting agreement including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the representations and warranties made by us to the underwriters are true;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there is no material change in our business or the financial markets; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we deliver customary closing documents to the underwriters.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commissions and Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the public offering
price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the
underwriters of their over-allotment option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per<br/> Unit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total with <br/> no<br/> Over-<br/>
    Allotment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total with <br/> Over-<br/> Allotment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Public offering price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,600,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,590,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Underwriting discount (8.0%)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">528,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">607,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Proceeds, before expenses,
    to us <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,072,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,982,200</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate that the total
    expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, will be
    approximately $[*]. This figure includes expense reimbursements we have agreed to pay the Representative for reimbursement of its
    expenses related to the offering up to a maximum aggregate expense allowance of $150,000, $25,000 of which was paid at the time the
    engagement letter was executed. In accordance with FINRA Rule 5110, the reimbursement fee described in the preceding sentence is
    deemed underwriting compensation for this offering. This amount does not include the non-accountable expenses we agreed to pay in
    the amount of one-and seven-tenths percent (1.7%) of the aggregate sales price of securities sold in the Offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Option to Purchase Additional Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriters an option
exercisable for 45 days after the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of
(i) 158,400 shares of common stock included in the Units and/or (ii) Warrants to purchase 158,400 shares of common stock included in
the Units (15% of the shares of common stock and Warrants included in Units sold in this offering) from us in any combination thereof
to cover over allotments, if any. If the underwriters exercise all or part of this option, they will purchase shares and/or Warrants
covered by the option at the public offering price per share and Warrant, respectively, that appears on the cover page of this prospectus,
less the underwriting discount. To the extent that this option is exercised, each underwriter will be obligated, subject to certain conditions,
to purchase its pro rata portion of these additional shares or Warrants based on the underwriter&#8217;s percentage underwriting commitment
in this offering as indicated in the table at the beginning of this Underwriting Section.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consulting Agreement&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2020 we entered into a Consulting
Agreement (the &#8220;Consulting Agreement&#8221;) with WallachBeth Capital as amended on September 7, 2021, which was for a term of six
months. Pursuant to the Consulting Agreement, WallachBeth Capital agreed to assist us with our business plans and strategies, including
with respect to mergers and acquisitions. In consideration of these services, we issued WallachBeth Capital 5,602 shares of our common
stock. Such shares may not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the securities for a period of 180 days beginning
on the date of commencement of sales of this public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lock-Up Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our directors, executive officers and principal
shareholders have agreed that, for a period of 180 days after the date of this prospectus and subject to certain limited exceptions, we
and they will not directly or indirectly, without the prior written consent of WallachBeth Capital, (i) offer for sale, sell, pledge,
or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition
by any person at any time in the future of) any shares of common stock (including, without limitation, shares of common stock that may
be deemed to be beneficially owned by us or them in accordance with the rules and regulations of the SEC and shares of common stock that
may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock,
(ii) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits
or risks of ownership of shares of common stock, whether any such transaction described in clause (i) or (ii) above is to be settled by
delivery of common stock or other securities, in cash or otherwise, (iii) make any demand for or exercise any right or file or cause to
be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or
securities convertible into or exercisable or exchangeable for common stock or any of our other securities, or (iv) publicly disclose
the intention to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WallachBeth Capital, in its sole discretion, may
release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any time. When
determining whether or not to release common stock and other securities from lock-up agreements, WestPark Capital will consider, among
other factors, the holder&#8217;s reasons for requesting the release, the number of shares of common stock and other securities for which
the release is being requested and market conditions at the time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Underwriter&#8217;s Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> As additional compensation to the underwriters,
upon consummation of this offering, we will issue to the underwriters or their designees warrants to purchase an aggregate number of
shares of our common stock equal to 10.0% of the number of Units issued in this offering, at an exercise price per share equal to 120%
of the initial public offering price (the &#8220;Underwriters&#8217; Warrants&#8221;). The Underwriters&#8217; Warrants may not be sold,
transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the securities for a period of 180 days beginning on the date of commencement of
sales of this public offering.. The Underwriters&#8217; Warrants will be exercisable, in whole or in part, commencing six months after
the effective date of the registration statement related to this prospectus and will expire on the fifth anniversary of the effective
date of the registration statement related to this prospectus. The Underwriter&#8217;s Warrants expense, an additional demand registration
at the warrant holders&#8217; expense, which will expire on the fifth anniversary of the commencement of sales of this public offering
and unlimited &#8220;piggyback&#8221; registration rights at our expense that will expire on the fifth anniversary of the commencement
of sales of this public offering. </p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Right of First Refusal; Subsequent Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of this offering, in certain circumstances,
we have granted the representative a right of first refusal, with certain exceptions, to co-manage our next public underwriting or private
placement of debt or equity securities. This right of first refusal extends for 12 months from closing. The terms of any such engagement
of WallachBeth Capital will be determined by separate agreement. For any transaction resulting from any agreement for a merger, acquisition,
consolidation, or other business combination occurring at any time within 12 months from closing with any investor introduced by WallachBeth
to the Company during the term of their engagement (a &#8220;Transaction&#8221;), WallachBeth Capital shall receive 1% of the consideration
paid by us in the Transaction, paid in kind. Underwriter shall be entitled to 8% of the proceeds with respect to any public or private
offering or other financing or capital-raising transaction of any kind (&#8220;Tail Financing&#8221;) to the extent that such financing
or capital is provided to the Company by investors whom WallachBeth Capital had introduced to the Company during the term of its engagement
if such Tail Financing is consummated at any time within 12-months from closing.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Offering Price Determination</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The actual offering price of the Units we are
offering will be negotiated between us and the underwriter based upon, among other things, the trading of our shares prior to the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required
to make for these liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stabilization, Short Positions and Penalty
Bids</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representative may engage in stabilizing transactions,
short sales and purchases to cover positions created by short sales, and penalty bids or purchases for the purpose of pegging, fixing
or maintaining the price of the common stock, in accordance with Regulation M under the Exchange Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A short position involves a sale by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase in the offering, which creates the syndicate short position. This short position may be either a covered short position or a naked short position. In a covered short position, the number of shares involved in the sales made by the underwriters in excess of the number of shares they are obligated to purchase is not greater than the number of shares that they may purchase by exercising their option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in their option to purchase additional shares. The underwriters may close out any short position by either exercising their option to purchase additional shares and/or purchasing shares in the open market. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through their option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These stabilizing transactions, syndicate covering
transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding
a decline in the market price of the common stock. As a result, the price of the common stock may be higher than the price that might
otherwise exist in the open market. These transactions may be effected on The Nasdaq Capital Market or otherwise and, if commenced, may
be discontinued at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor any of the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price
of the common stock. In addition, neither we nor any of the underwriters make any representation that the representative will engage in
these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Electronic Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus in electronic format may be made
available on the Internet sites or through other online services maintained by one or more of the underwriters and/or selling group members
participating in this offering, or by their affiliates. In those cases, prospective investors may view offering terms online and, depending
upon the particular underwriter or selling group member, prospective investors may be allowed to place orders online. The underwriters
may agree with us to allocate a specific number of shares for sale to online brokerage account holders. Any such allocation for online
distributions will be made by the representative on the same basis as other allocations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the prospectus in electronic format,
the information on any underwriter&#8217;s or selling group member&#8217;s web site and any information contained in any other web site
maintained by an underwriter or selling group member is not part of the prospectus or the registration statement of which this prospectus
forms a part, has not been approved and/or endorsed by us or any underwriter or selling group member in its capacity as underwriter or
selling group member and should not be relied upon by investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Listing on The Nasdaq Capital Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied for listing of our common stock
and Warrants on the NASDAQ Capital Market under the symbols &#8220;NTRB&#8221; and &#8220;NTRBW,&#8221; respectively and such listings
are a condition to closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Discretionary Sales</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters have informed us that they do
not expect to sell more than 5% of the common stock in the aggregate to accounts over which they exercise discretionary authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of the underwriters and their affiliates
may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates for which
they may in the future receive customary fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WallachBeth Capital and certain of its officers
and principals hold, collectively,&#160;5,602&#160;shares of our common stock, representing less than 1% of our issued and outstanding
shares of common stock immediately prior to this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Selling&#160;Restrictions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than in the United States, no action has
been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction
where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly,
nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities
be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and
regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe
any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell
or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation
is unlawful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Notice to prospective investors in the European Economic
Area and the United Kingdom</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In relation to each Member State of the European
Economic Area and the United Kingdom (each a &#8220;Relevant State&#8221;), no shares have been offered or will be offered pursuant to
the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved
by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent
authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public
in that Relevant State at any time under the following exemptions under the Prospectus Regulation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>provided&#160;</i>that no such offer of shares
shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will
be deemed to have represented, acknowledged and agreed to and with each of the underwriters and us that it is a &#8220;qualified investor&#8221;
within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as
that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and
agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been
acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public
other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent
of the underwriters have been obtained to each such proposed offer or resale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of this provision, the expression
an &#8220;offer to the public&#8221; in relation to shares in any Relevant State means the communication in any form and by any means
of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Notice to prospective investors in the United
Kingdom</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in the United Kingdom, this document
is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified
investors&#8221; (as defined in the Prospectus Regulation) (i) who have professional experience in matters relating to investments falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#8220;Order&#8221;)
and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a)
to (d) of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;) or otherwise in circumstances which
have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial
Services and Markets Act 2000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any person in the United Kingdom that is not a
relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United
Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEGAL MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the issuance of the common stock
offered by us in this offering will be passed upon for us Michael Paige Law PLLC, Washington, D.C. Certain legal matters in connection
with this offering will be passed upon for the underwriters by Carmel, Milazzo&amp; Feil LLP, New York, New York.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPERTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial statements included in this prospectus
as of January 31, 2021 and 2020 have been included in reliance on the reports of Sadler, Gibb&#160;&amp; Associates, LLC, an independent
registered public accounting firm, given on the authority of such firm as experts in accounting and auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WHERE YOU CAN FIND MORE INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities and Exchange Commission maintains
an Internet site which contains reports, proxy and information statements, and other information regarding registrants that file electronically
with the Commission at the address: <i>www.sec.gov</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>January 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Index to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 95%; text-align: justify"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</span></a></td>
    <td style="vertical-align: bottom; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets at January 31, 2021 and 2020</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss for the years ended January 31, 2021 and 2020</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholder&#8217;s Equity (Deficit) for the years ended January 31, 2021 and 2020</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the years ended January 31, 2021 and 2020</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and the Board of Directors of Nutriband Inc.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Opinion on the Financial Statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Nutriband Inc. and Subsidiaries (&#8220;the Company&#8221;) as of January 31, 2021 and 2020, the related consolidated
statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the two-year period
ended January 31, 2021 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the
financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 31,
2021 and 2020, and the results of its operations and its cash flows for each of the years in the two-year period ended January 31, 2021,
in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Basis for Opinion</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Critical Audit Matters</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matters communicated below
are matters arising from the current-period audit of the consolidated financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our
opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a
separate audit opinion on the critical audit matters or on the accounts or disclosures to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-Lived Asset Impairment Assessment</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Critical Audit Matter Description</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As described in note 1 to the consolidated
financial statements, the Company performs impairment testing for its long-lived assets when events or changes in circumstances indicate
that its carrying amount may not be recoverable and exceeds its fair value. Due to challenging industry and economic conditions, the Company
tested its long-lived assets during the year ended January 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We identified the evaluation of the
impairment analysis for long-lived assets as a critical audit matter because of the significant estimates and assumptions management used
in the related cash flow analysis. Performing audit procedures to evaluate the reasonableness of these estimates and assumptions required
a high degree of auditor judgment and an increased extent of effort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>How the Critical Audit Matter Was
Addressed in the Audit</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Our audit procedures related to the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing management&#8217;s process for developing the fair value estimate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating the appropriateness of the cash flow model used by management.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing the completeness and accuracy of underlying data used in the fair value estimate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating the significant assumptions used by management related to revenues, gross margin, other operating expenses, income taxes and long-term growth rate to discern whether they are reasonable considering (i) the current and past performance of the entity; (ii) the consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professionals with specialized skill and knowledge were utilized by the Firm to assist in the evaluation of the discounted cash flow model and discount rate assumptions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill Impairment Assessment</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Critical Audit Matter Description</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As described in note 1 to the consolidated
financial statements, the Company tests goodwill for impairment annually at the reporting unit level, or more frequently, if events or
circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Reporting
units are tested for impairment by comparing the estimated fair value of each reporting unit with its carrying amount. If the carrying
amount of a reporting unit exceeds its estimated fair value, an impairment loss is recorded based on the difference between the fair value
and carrying amount, not to exceed the associated carrying amount of goodwill. The Company&#8217;s annual impairment test occurred on
January 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We identified the evaluation of the
impairment analysis for goodwill as a critical audit matter because of the significant estimates and assumptions management used in the
discounted cash flow analysis performed by management to determine fair value of the reporting unit. Performing audit procedures to evaluate
the reasonableness of these estimates and assumptions required a high degree of auditor judgment and an increased extent of effort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>How the Critical Audit Matter Was
Addressed in the Audit</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Our audit procedures related to the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing management&#8217;s process for developing the fair value estimate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating the appropriateness of the discounted cash flow model used by management.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing the completeness and accuracy of underlying data used in the fair value estimate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating the significant assumptions used by management related to revenues, gross margin, other operating expenses, income taxes, long-term growth rate, and discount rate to discern whether they are reasonable considering (i) the current and past performance of the entity; (ii) the consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professionals with specialized skill and knowledge were utilized by the Firm to assist in the evaluation of the discounted cash flow model and discount rate assumptions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Combinations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Description of the Critical Audit
Matter </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As described in note 2 to the consolidated
financial statements, the Company completed an acquisition agreement wherein the Company acquired the net assets from one entity and 100%
ownership of a second entity for total consideration of $7,418,073. The acquisition was accounted for a business combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The recognition, measurement and disclosure
of the Company&#8217;s business combination in the January 31, 2021 consolidated financial statements was considered especially challenging
and required significant auditor judgment due to the complex determination by management of the appropriate assumptions, such as discount
rates, revenue growth rates, and projected profit margins, for the valuation of acquired net assets and expected probabilities of key
outcomes for the valuation of assumed liabilities. The Company used income valuation models including Relief from Royalty, Multi-Period
Excess Earnings and With and Without Method to measure the Intellectual property, customer base and tradenames.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>How the Critical Audit Matter Was
Addressed in the Audit</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Our audit procedures related to the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing management&#8217;s process for developing the fair value estimate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating the appropriateness of the income valuation models used by management.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing the completeness and accuracy of underlying data used in the fair value estimate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating the significant assumptions used by management related to sales growth, discount rates, royalty rates cost of goods and operating overhead to discern whether they are reasonable considering (i) the current and past performance of the entity; (ii) the consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professionals with specialized skill and knowledge were utilized by the Firm to assist in the evaluation of the discounted cash flow model and discount rate assumptions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evaluation of a Going Concern</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Description of the Critical Audit
Matter </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As described further in Note 1 to the
financial statements, in the current year the Company has recorded operating losses, negative working capital, negative cash flows from
operations and an accumulated deficit, which raises doubt about its ability to continue as a going concern. Management has implemented
plans to alleviate the substantial doubt. Management plans to address the concerns, as needed, by (a) utilizing recent financing obtained
through equity issuances; (b) delaying planned expenditures and (c) relying on recent increases in revenues and positive cash flow trends.
When considering these factors in conjunction with the Company&#8217;s operating plan, management believes it has sufficient ability to
fund operations and satisfy the Company&#8217;s obligations as they come due for at least one year from the financial statement issuance
date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We determined the Company&#8217;s ability
to continue as a going concern is a critical audit matter due to the estimation and execution uncertainty regarding the Company&#8217;s
available capital and the risk of bias in management&#8217;s judgments and assumptions in their determination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>How the Critical Audit Matter Was
Addressed in the Audit</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Our audit procedures related to the
Company&#8217;s assertion on its ability to continue as a going concern included the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We performed testing procedures such as analytical procedures to identify conditions and events that indicate there could be substantial doubt about the entity&#8217;s ability to continue as a going concern for a reasonable period of time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We reviewed and evaluated management&#8217;s plans for dealing with adverse effect of these conditions and events that raised doubt about the Company&#8217;s ability to continue as a going concern. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We tested the reasonableness of management&#8217;s assessment of whether the Company has sufficient liquidity to fund operations for at least one year from the financial statement issuance date.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We assessed whether the Company&#8217;s determination that there is substantial doubt about its ability to continue as a going concern was adequately disclosed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>/s/ Sadler, Gibb&#160;&amp; Associates, LLC</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Draper, UT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 2, 2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="text-decoration:underline">ASSETS</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">151,993</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">10,181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">109,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">12,833</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">52,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">20,167</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">314,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">43,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">PROPERTY&#160;&amp; EQUIPMENT-net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,076,626</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">111,029</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">OTHER ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">7,529,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">1,719,235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Right of use operating lease asset-net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">9,610</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Intangible assets-net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">1,006,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">314,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" unitRef="usd">9,927,419</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" unitRef="usd">2,197,755</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">940,612</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">771,931</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd">928,774</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">10,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd">86,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Notes payable-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" scale="0" unitRef="usd">1,402,523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" scale="0" unitRef="usd">29,067</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Finance lease liabilities-current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd">24,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Notes payable-current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">113,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">215,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Convertible debt- net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="0" unitRef="usd">67,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,568,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,022,322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">LONG-TERM LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Notes payable-net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd">150,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Finance lease liabilities-net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" unitRef="usd">96,804</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,815,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,022,322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Commitments and Contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">STOCKHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><div style="-sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15">Preferred stock, $.001 par value, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, -<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction>- outstanding</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><div style="-sec-ix-hidden: hidden-fact-18; -sec-ix-hidden: hidden-fact-17">Common stock, $.001 par value, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">250,000,000</ix:nonFraction> shares and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">250,000,000</ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">6,256,772</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">5,441,100</ix:nonFraction></ix:nonFraction> shares issued and outstanding at January 31, 2021 and 2020, respectively</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">6,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">5,441</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in-capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">18,871,098</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">9,072,573</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Subscription payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscriptionPayables" scale="0" unitRef="usd">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">11,835,105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">8,902,277</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,111,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">175,433</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">9,927,419</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">2,197,755</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to consolidated financial statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended<br/> January&#160;31,</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt">Revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">943,702</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">370,647</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">582,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">549,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">2,957,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,790,980</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Costs and Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd">3,539,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd">2,340,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">2,595,945</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">1,969,440</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">12,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Early prepayment fee on convertible debenture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionExpense" scale="0" unitRef="usd">69,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Gain on forgiveness of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:GainOnForgivenessOfDebt" scale="0" unitRef="usd">3,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Derivative expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd">767,650</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Gain on change in fair value of derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfDerivatives" scale="0" unitRef="usd">22,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfDerivatives" scale="0" unitRef="usd">88,876</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">280,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">73,413</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total other income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">336,883</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">752,187</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations before provision for income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,721,627</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,721,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per share of common stock-basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.51</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.50</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted average shares of common stock outstanding - basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">5,770,944</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">5,423,956</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Comprehensive Loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">2,721,627</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" sign="-" unitRef="usd">252</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total Comprehensive Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,721,879</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to consolidated financial statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number&#160;of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid&#160;In</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Comprehensive</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subscription</b></span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Income (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Payable</b> &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 16%">Balance, February 1, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,404,612</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">5,423,956</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,424</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,579,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">52</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">6,180,650</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of warrants for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices" scale="0" unitRef="usd">252,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:numdotdecimal" name="ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices" scale="0" unitRef="usd">252,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">240,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">17,144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">239,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss for the year ended January 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,721,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,721,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance, January 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">175,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">5,441,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,072,573</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">8,902,277</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from sale of common stock and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" scale="0" unitRef="usd">515,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:numdotdecimal" name="ntrb:StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" scale="0" unitRef="shares">46,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:numdotdecimal" name="ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" scale="0" unitRef="usd">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:numdotdecimal" name="ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" scale="0" unitRef="usd">515,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">6,085,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">608,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">609</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">6,084,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">2,004,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">135,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">2,004,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassification of warrants from liability to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" scale="0" unitRef="usd">906,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:numdotdecimal" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" scale="0" unitRef="usd">906,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:IssuanceOfCommonStockForNotePayable" scale="0" unitRef="usd">287,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IssuanceOfCommonStockForNotePayableinShares" scale="0" unitRef="shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:numdotdecimal" name="ntrb:IssuanceOfCommonStockForNotePayable" scale="0" unitRef="usd">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:numdotdecimal" name="ntrb:IssuanceOfCommonStockForNotePayable" scale="0" unitRef="usd">287,475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Subscrption payable for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscrptionPayableForCash" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscrptionPayableForCash" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Subscrption payable for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscrptionPayableForServices" scale="0" unitRef="usd">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscrptionPayableForServices" scale="0" unitRef="usd">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss for the year ended January&#160;31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance, January 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,111,946</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">6,256,772</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,257</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">18,871,098</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c33" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">11,835,105</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">70,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to consolidated financial statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended<br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash flows from operating activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,721,627</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Expenses paid on behalf of the Company by related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="0" unitRef="usd">12,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="0" unitRef="usd">23,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">160,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">72,188</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Derivative expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreaseInDerivativeExpense" scale="0" unitRef="usd">767,650</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Early prepayment fee on convertible debentures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:EarlyPrepaymentFeeOnConvertibleDebentures" scale="0" unitRef="usd">69,131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">12,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Gain on forgiveness of loan payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:GainOnForgivenessOfLoanPayment" scale="0" unitRef="usd">3,338</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Gain on change in fair value of derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="0" unitRef="usd">22,096</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="0" unitRef="usd">88,876</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">272,130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">67,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Amortization of right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfLeasedAsset" scale="0" unitRef="usd">9,610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfLeasedAsset" scale="0" unitRef="usd">19,217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">2,004,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">252,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Subscription payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscriptionPayable" scale="0" sign="-" unitRef="usd">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">94,753</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">255</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">20,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">82,558</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">10,235</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInCustomerDeposits" scale="0" unitRef="usd">59,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInCustomerDeposits" scale="0" sign="-" unitRef="usd">71,225</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreaseOperatingLeaseLiability" scale="0" unitRef="usd">10,050</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreaseOperatingLeaseLiability" scale="0" unitRef="usd">18,777</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">145,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">720,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net Cash Used In Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">297,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">894,470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash received from acquisition</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="0" unitRef="usd">66,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd">66,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from sale of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">515,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd">194,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd">175,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from stock subscription</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Payment of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd">8,935</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Payment of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd">339,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Payment of finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd">8,345</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd">5,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd">34,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Payment of related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">47,194</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">29,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net Cash Provided by Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">371,873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">430,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" sign="-" unitRef="usd">252</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">141,812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">464,472</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents - Beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">10,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">474,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents - End of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">151,993</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">10,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplementary information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; padding-bottom: 4pt">Interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">11,555</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental disclosure of non-cash investing and financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Common stock and note issued for acquisition</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockAndNoteIssuedInAcquisitions" scale="0" unitRef="usd">7,418,073</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Adoption of ASC 842 Operating lease asset and liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:AdoptionOfASC842OperatingLeaseAssetAndLiability" scale="0" unitRef="usd">28,827</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Derivative liability warrant reclassed to equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:DerivativeLiabilityWarrantReclassedToEquity" scale="0" unitRef="usd">906,678</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Debt discount on convertible notes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:DebtDiscountOnConvertibleNotes" scale="0" unitRef="usd">270,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Common stock issued for accounts payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockIssuedForAccountsPayable" scale="0" unitRef="usd">240,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Common stock issued for settlement of debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockIssuedForSettlement" scale="0" unitRef="usd">287,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to consolidated financial statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF AND FOR THE YEARS ENDED JANUARY 31, 2021
AND 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i>&#160;</i></p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_1"><ix:nonNumeric contextRef="c4" continuedAt="_OrganizationPolicyTextBlock-c4_cont_1" escape="true" name="ntrb:OrganizationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Organization</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_2"><ix:continuation continuedAt="_OrganizationPolicyTextBlock-c4_cont_2" id="_OrganizationPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Nutriband Inc. (the &#8220;Company&#8221;)
is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which
was formed by the Company&#8217;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_3"><ix:continuation continuedAt="_OrganizationPolicyTextBlock-c4_cont_3" id="_OrganizationPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 1, 2018, <ix:nonNumeric contextRef="c78" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity">the Company acquired
4P Therapeutics LLC (&#8220;4P Therapeutics&#8221;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000,
and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been
developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of
the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_4"><ix:continuation continuedAt="_OrganizationPolicyTextBlock-c4_cont_4" id="_OrganizationPolicyTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#8217;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#8220;FDA&#8221;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_5"><ix:continuation continuedAt="_OrganizationPolicyTextBlock-c4_cont_5" id="_OrganizationPolicyTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">With the acquisition of 4P Therapeutics,
4P Therapeutics&#8217; drug development business became the Company&#8217;s principal business. The Company&#8217;s approach is to use
generic drugs that are off patent and incorporate them into the Company&#8217;s transdermal drug delivery system. Although these medications
have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will
include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical
products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_6"><ix:continuation continuedAt="_OrganizationPolicyTextBlock-c4_cont_6" id="_OrganizationPolicyTextBlock-c4_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 25, 2020, the Company formed
Pocono Pharmaceuticals Inc. (&#8220;Pocono Pharmaceuticals&#8221;), a wholly owned subsidiary of the Company. On August 31, 2020, the
Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono
Coated Products LLC (&#8220;PCP&#8221;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company
also acquired 100% of the membership interests of Active Intelligence LLC (&#8220;Active Intelligence&#8221;). See Note 2 for further
details of the acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_7"><ix:continuation continuedAt="_OrganizationPolicyTextBlock-c4_cont_7" id="_OrganizationPolicyTextBlock-c4_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Pocono Pharmaceuticals is a coated products
manufacturing entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product
design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#8217;s
competitive edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is the same as traditional kinesiology
tape.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_8"><ix:continuation id="_OrganizationPolicyTextBlock-c4_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, COVID-19 emerged and
has subsequently spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local
governments and private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay
at home orders and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed
quarantines and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business
and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_9"><ix:nonNumeric contextRef="c4" continuedAt="_ReverseStockSplitPolicyTextBlock-c4_cont_1" escape="true" name="ntrb:ReverseStockSplitPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Reverse Stock Split</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_10"><ix:continuation id="_ReverseStockSplitPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 25, 2019, the Company effected
one-for-four reverse split, pursuant to which each share of common stock became and was converted into <ix:nonFraction contextRef="c79" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">0.25</ix:nonFraction> share of common stock. The
reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements
retroactively reflect the reverse split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_11"><ix:nonNumeric contextRef="c4" continuedAt="_GoingConcernPolicyTextBlock-c4_cont_1" escape="true" name="ntrb:GoingConcernPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Going Concern</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_12"><ix:continuation id="_GoingConcernPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2021, the Company
believes the substantial doubt about going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current year net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to alleviate
the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses, equity
funding that has been received and the net revenue and positive cash flow from its recent acquisition. These factors did not exist in
prior years during its start-up operations. The Company&#8217;s recent history of losses has changed from prior periods due to its current
management&#8217;s plans including its acquisition in the latter part of 2020 to alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s plans have been currently implemented. The plans enable the Company to meet
its obligations for at least one year from the date when the financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_14" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_15" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_14"><ix:nonNumeric contextRef="c4" continuedAt="_ConsolidationPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_16" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_15"><ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c4_cont_2" id="_ConsolidationPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The consolidated financial statements
of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated.
The operations of 4P Therapeutics are included in the Company&#8217;s financial statements from the date of acquisition of August 1, 2018
and the operations of Pocono and Active Intelligence are included in the Company&#8217;s financial statements from the date of acquisition
of September 1, 2020. The wholly owned subsidiaries are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_17" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_16"><ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c4_cont_3" id="_ConsolidationPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Nutriband Ltd.</p></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_18" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_17"><ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c4_cont_4" id="_ConsolidationPolicyTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">4P Therapeutics LLC</p></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_19" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_18"><ix:continuation id="_ConsolidationPolicyTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pocono Pharmaceuticals Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_20" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_19"><ix:nonNumeric contextRef="c4" continuedAt="_UseOfEstimates-c4_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_21" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_20"><ix:continuation id="_UseOfEstimates-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of the consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related&#160;disclosure
of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related
to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_22" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_21"><ix:nonNumeric contextRef="c4" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Cash and Cash Equivalents</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_23" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_22"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Cash equivalents include short-term
investments in money-market funds and certificate of deposits with an original maturity of three months or less when purchased.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_24" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_23"><ix:nonNumeric contextRef="c4" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Foreign Currency Translation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_25" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_24"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The functional currency of the Company&#8217;s
Irish subsidiary is the Euro. The assets and liabilities of the subsidiary are translated into US dollars using the prevailing exchange
rate as of the balance sheet date and income and expenses are translated into US dollars using the average exchange rate during the reporting
period. Translation adjustments are recorded in other comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_26" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_25"><ix:nonNumeric contextRef="c4" continuedAt="_RevenueRecognitionPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Revenue Recognition</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_27" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_26"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c4_cont_2" id="_RevenueRecognitionPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In May 2014, the FASB issued ASU No.
2014-09, &#8220;Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which amends the accounting standards for
revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled
when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_28" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_27"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c4_cont_3" id="_RevenueRecognitionPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_29" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_28"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c4_cont_4" id="_RevenueRecognitionPolicyTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a description of the
Company&#8217;s revenue types, which include professional services and sale of goods:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_30" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_29"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c4_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service revenues include the contract of research and development related services with the Company&#8217;s clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product revenues are derived from the sale of the Company&#8217;s consumer transdermal and coated products. Upon the reception of a purchase order, we have the order filled and shipped.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_31" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_30"><ix:nonNumeric contextRef="c4" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_32" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_31"><ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A contract with a customer exists when
(i) we enter into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be
transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii)
we determine that collection of substantially all consideration for services that are transferred is probable based on the customer&#8217;s
intent and ability to pay the promised consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_33" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_32"><ix:nonNumeric contextRef="c4" continuedAt="_RevenueRecognitionDeferredRevenue-c4_cont_1" escape="true" name="us-gaap:RevenueRecognitionDeferredRevenue"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Deferred Revenue</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_34" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_33"><ix:continuation id="_RevenueRecognitionDeferredRevenue-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Deferred revenue is a liability related
to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration
from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_35" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_34"><ix:nonNumeric contextRef="c4" continuedAt="_PerformanceObligationsPolicyTextBlock-c4_cont_1" escape="true" name="ntrb:PerformanceObligationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_36" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_35"><ix:continuation continuedAt="_PerformanceObligationsPolicyTextBlock-c4_cont_2" id="_PerformanceObligationsPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A performance obligation is a promise
in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract
transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation
is satisfied. For the Company&#8217;s different revenue service types, the performance obligation is satisfied at different times. The
Company&#8217;s performance obligations include providing products and professional services in the area of research. The Company recognizes
product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service
work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on
a monthly basis for the work performed during that month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_37" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_36"><ix:continuation id="_PerformanceObligationsPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All revenue recognized in the income
statement is considered to be revenue from contracts with customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_38" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_37"><ix:nonNumeric contextRef="c4" continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c4_cont_1" escape="true" name="ntrb:DisaggregationOfRevenuesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_39" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_38"><ix:continuation continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c4_cont_2" id="_DisaggregationOfRevenuesPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company disaggregates its revenue
from contracts with customers by type and by geographical location. See the tables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_40" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_39"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"><ix:continuation continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c4_cont_3" id="_DisaggregationOfRevenuesPolicyTextBlock-c4_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalesRevenuesGoodsNet" scale="0" unitRef="usd">737,519</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalesRevenuesGoodsNet" scale="0" unitRef="usd">124,958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleOfGoodsAndServices" scale="0" unitRef="usd">206,183</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleOfGoodsAndServices" scale="0" unitRef="usd">245,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">943,702</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">370,637</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_41" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_40"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><ix:continuation id="_DisaggregationOfRevenuesPolicyTextBlock-c4_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographical location</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">360,378</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">245,679</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">583,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">124,958</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">943,702</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:DisaggregationOfRevenues" scale="0" unitRef="usd">370,637</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_42" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_41"><ix:nonNumeric contextRef="c4" continuedAt="_ReceivablesPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Accounts receivable</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_43" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_42"><ix:continuation id="_ReceivablesPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Trade accounts receivable are recorded
at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from
the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer
accounts where appropriate and the application of historical loss to non-specific accounts. For the years ended January 31, 2021 and 2020,
the Company recorded no bad debt expense and no allowance for doubtful accounts related to accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_44" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_43"><ix:nonNumeric contextRef="c4" continuedAt="_InventoryPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_45" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_44"><ix:continuation id="_InventoryPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Inventories are valued at the lower
of cost and realizable value determined using the first-in, first-out (FIFO) method. Net realizable value is the estimated selling price
in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in progress is comprised
of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_46" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_45"><ix:nonNumeric contextRef="c4" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_47" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_46"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c4_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Property and equipment represent an
important component of the Company&#8217;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated
useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and
replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements
are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range
from <ix:nonNumeric contextRef="c80" format="ixt-sec:duryear" name="ntrb:PropertyPlantAndEquipmentsUsefulLife">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c81" format="ixt-sec:duryear" name="ntrb:PropertyPlantAndEquipmentsUsefulLife">10</ix:nonNumeric> years as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_48" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_47"><ix:nonNumeric contextRef="c4" escape="true" name="ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c4_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c92" format="ixt-sec:duryear" name="us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c93" format="ixt-sec:duryear" name="us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c94" format="ixt-sec:duryear" name="us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c95" format="ixt-sec:duryear" name="us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_49" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_48"><ix:nonNumeric contextRef="c4" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c4_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Intangible Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_50" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_49"><ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Intangible assets include trademarks,
intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under
the guidance of ASC 350, &#8220;Intangibles-Goodwill and Other.&#8221; The Company capitalizes certain costs related to patent technology.
A substantial component of the purchase price related to the Company&#8217;s acquisition has also been assigned to intellectual property
and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives.
Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being
amortized over their estimated useful lives of ten years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_51" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_50"><ix:nonNumeric contextRef="c4" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Goodwill</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_52" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_51"><ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Goodwill represents the difference between
the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is
reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which
the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August
31, 2020, in connection with the Company&#8217;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">5,810,640</ix:nonFraction>. As of January 31, 2021, Goodwill amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">7,529,875</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_53" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_52"><ix:nonNumeric contextRef="c4" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Long-lived Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_54" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_53"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Management reviews long-lived assets
for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The
carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result
from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between
fair market value of the long-lived asset and the related net book value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_55" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_54"><ix:nonNumeric contextRef="c4" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c4_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Stock-Based Compensation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_56" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_55"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ASC 718, &#8220;Compensation - Stock
Compensation,&#8221; prescribes accounting and reporting standards for all share-based payment transactions in which employee services,
and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue
shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments
to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on
their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for
the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718
was applied to stock-based compensation for both employees and non-employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_57" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_56"><ix:nonNumeric contextRef="c4" continuedAt="_BusinessCombinationsPolicy-c4_cont_1" escape="true" name="us-gaap:BusinessCombinationsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Business Combinations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_58" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_57"><ix:continuation id="_BusinessCombinationsPolicy-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company recognizes the assets acquired,
the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values
as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related
costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That
replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated
to the individual assets acquired and liabilities assumed based on their estimated fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_59" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_58"><ix:nonNumeric contextRef="c4" continuedAt="_LesseeLeasesPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Leases</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_60" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_59"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c4_cont_2" id="_LesseeLeasesPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February 2016, the FASB issued ASU
2016-02, &#8220;Leases&#8221; (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and
lessors should apply a &#8220;right-of-use&#8221; model in accounting for all leases (including subleases) and eliminate the concept of
operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as
a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_61" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_60"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company adopted ASU 2016-02 as amended
effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize
the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under
ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates
the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company
completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_62" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_61"><ix:nonNumeric contextRef="c4" continuedAt="_ResearchAndDevelopmentExpensePolicy-c4_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Research and Development</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_63" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_62"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Research and developments costs are
expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_64" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_63"><ix:nonNumeric contextRef="c4" continuedAt="_IncomeTaxPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Income Taxes</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_65" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_64"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c4_cont_2" id="_IncomeTaxPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Taxes are calculated in accordance with
taxation principles currently effective in the United States and Ireland.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_66" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_65"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c4_cont_3" id="_IncomeTaxPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounts for income taxes
under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are
determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_67" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_66"><ix:continuation id="_IncomeTaxPolicyTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company records net deferred tax
assets to the extent they believe these assets will more-likely-than-not be realized. In making such determination, the Company considers
all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable
income, tax planning strategies and recent financial operations. In the event the Company was to determine that it would be able to realize
its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation
allowance which would reduce the provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_68" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_67"><ix:nonNumeric contextRef="c4" continuedAt="_ConcentrationRiskCreditRisk-c4_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Concentration of Credit Risk</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_69" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_68"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c4_cont_2" id="_ConcentrationRiskCreditRisk-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial instruments which potentially
subject the Company to concentrations of credit risk consist principally of cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_70" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_69"><ix:continuation id="_ConcentrationRiskCreditRisk-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s cash and cash equivalents
are concentrated primarily in banks. At times, such deposits could be in excess of insured limits. Management believes that the financial
institutions that hold the Company&#8217;s financial instruments are financially sound and, accordingly, minimal credit risk is believed
to exist with respect to these financial instruments. As of and for the year ended January 31, 2020, three customers accounted for <ix:nonFraction contextRef="c83" decimals="2" format="ixt:numdotdecimal" name="ntrb:ConcentrationRiskPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>%
of the Company&#8217;s revenues and two customers accounted for <ix:nonFraction contextRef="c84" decimals="2" format="ixt:numdotdecimal" name="ntrb:ConcentrationRiskPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of accounts receivable. As of and for the year ended January 31,
2021, one customer accounted for <ix:nonFraction contextRef="c85" decimals="2" format="ixt:numdotdecimal" name="ntrb:ConcentrationRiskPercentage" scale="-2" unitRef="pure">62</ix:nonFraction>% of the Company&#8217;s revenues and two customers accounted for <ix:nonFraction contextRef="c86" decimals="2" format="ixt:numdotdecimal" name="ntrb:ConcentrationRiskPercentage" scale="-2" unitRef="pure">67</ix:nonFraction>% and <ix:nonFraction contextRef="c87" decimals="2" format="ixt:numdotdecimal" name="ntrb:ConcentrationRiskPercentage" scale="-2" unitRef="pure">13</ix:nonFraction>% of accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_71" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_70"><ix:nonNumeric contextRef="c4" continuedAt="_EarningsPerSharePolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Earnings Per Share</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_72" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_71"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Basic earnings per share of common stock
is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings
per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common
stock outstanding during the period.&#160;Potential shares of common stock consist of outstanding common stock purchase warrants. For
the years ended January 31, 2021 and 2020 there were <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares">141,830</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares">70,000</ix:nonFraction> potential shares of common stock that were not included in the
calculation of diluted earnings per share as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_73" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_72"><ix:nonNumeric contextRef="c4" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_74" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_73"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements
and Disclosure&#8221; (&#8220;ASC 820&#8221;), defines fair value as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs
that may be to measure fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_75" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_74"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company utilizes the accounting
guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities
that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.
The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier
value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_76" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_75"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 -&#160;Observable inputs such
as quoted market prices in active markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_77" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_76"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 -&#160;Inputs other than quoted
prices in active markets that are either directly or indirectly observable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_78" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_77"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 -&#160;Unobservable inputs
about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_79" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_78"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The carrying value of the Company&#8217;s
financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their
fair value due to the short maturities of these financial instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_80" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_79"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c4_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Derivative liabilities are determined
based on &#8220;Level 3&#8221; inputs, which are significant and unobservable and have the lowest priority. The recorded values of all
other financial instruments approximate their current fair value because of their nature and respective short maturity dates or durations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_81" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_80"><ix:nonNumeric contextRef="c4" continuedAt="_DerivativeLiabilitiesPolicyTextBlock-c4_cont_1" escape="true" name="ntrb:DerivativeLiabilitiesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Derivative Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_82" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_81"><ix:continuation continuedAt="_DerivativeLiabilitiesPolicyTextBlock-c4_cont_2" id="_DerivativeLiabilitiesPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounts for derivative
instruments in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; and all derivative instruments are reflected as either
assets or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments.
Fair value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market
participants. In general, the Company&#8217;s policy in estimating fair values is to first look at observable market prices for identical
assets and liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such
as prices of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable
data from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of January 31, 2021, and 2020, the Company had a $-<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" unitRef="usd">0</ix:nonFraction>-
and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" unitRef="usd">928,774</ix:nonFraction> derivative liability, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_83" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_82"><ix:continuation id="_DerivativeLiabilitiesPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Fair value estimates are made at a specific
point in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve
uncertainties and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly
affect the estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_84" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_83"><ix:nonNumeric contextRef="c4" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c4_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Recent Accounting Standards</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_85" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_84"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c4_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August 2018, the FASB issued ASU
2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements&#8221;. The updated
guidance improves the disclosure requirements on fair value measurement. The updated guidance is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. The Company adopted the provisions effective February 1, 2020. The
adoption did not have a material impact on the Company&#8217;s consolidated financial position or consolidated results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_86" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_85"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c4_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, the FASB issued ASU
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which modifies ASC 740 to reduce complexity while maintaining
or improving the usefulness of the information provided to the users of financial statements. ASU 209-12 is effective for annual reporting
periods beginning after December 15, 2021. The Company is currently assessing the impact of ASU 209-12, but it is not expected to have
a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c4_cont_86"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has reviewed all other FASB-issued
ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods.
The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles
will have a material impact on the company&#8217;s reported financial position or operations in the near term. The applicability of any
standard is subject to the formal review of the Company&#8217;s financial management and certain standards are under consideration.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACQUISITION OF BUSINESS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_2" id="_BusinessCombinationDisclosureTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 31, 2020, the Company entered
into a Purchase Agreement (&#8220;Agreement&#8221;), with Pocono Coated Products (&#8220;PCP&#8221;), pursuant to which PCP agreed to
sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business,
including: (1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free
and clear of all liens, except for certain lease obligations, and (2), a <ix:nonFraction contextRef="c82" decimals="2" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired" scale="-2" unitRef="pure">100</ix:nonFraction>% membership interest in Active Intelligence, LLC (collectively
the &#8220;Assets&#8221;). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary
of the Company. The purchase price for the Assets was (i) $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="0" unitRef="usd">6,085,180</ix:nonFraction> paid with the issuance of <ix:nonFraction contextRef="c98" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares">608,519</ix:nonFraction> shares in the Company&#8217;s common
stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the &#8220;Shares&#8221;), and (ii)
a promissory note of the Company, net of debt discount, in the principal amount, of $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="ntrb:DebtInstrumentAnnualPrincipalPayments" scale="0" unitRef="usd">1,332,893</ix:nonFraction> (the Note&#8221;) which is due upon the
earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd">4,000,000</ix:nonFraction> and/or a public
offering of no less than $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" unitRef="usd">4,000,000</ix:nonFraction>. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period
of <ix:nonNumeric contextRef="c100" format="ixt-sec:durwordsen" name="ntrb:AnnualMeetingOfShareholdersTerm">one year</ix:nonNumeric> at the annual meeting of shareholders of the Company held in October 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_3" id="_BusinessCombinationDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Agreement provides that it is effective
August 31, 2020, on which date the parties also entered into an escrow agreement (the &#8220;Escrow Agreement&#8221;), with legal counsel
serving as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special
purpose subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also
entered into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_4" id="_BusinessCombinationDisclosureTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The purpose of the Company entering
into the transaction is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated
to the net tangible assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and,
as such, the transaction was accounted for under the acquisition method of accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_5" id="_BusinessCombinationDisclosureTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Details of the net assets acquired are
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_6" id="_BusinessCombinationDisclosureTextBlock-c4_cont_5"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/> Recognized<br/> on<br/> Acquisition</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionCommonStockIssued" scale="0" unitRef="usd">6,085,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Note payable issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:NotePayableIssued" scale="0" unitRef="usd">1,332,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockAndNoteIssuedInAcquisition" scale="0" unitRef="usd">7,418,073</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" unitRef="usd">66,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" unitRef="usd">1,761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" unitRef="usd">42,613</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equipment and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" scale="0" unitRef="usd">1,056,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Customer base</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" scale="0" unitRef="usd">177,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intellectual property and trademarks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" scale="0" unitRef="usd">583,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" unitRef="usd">5,810,640</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="0" unitRef="usd">26,104</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="0" unitRef="usd">26,851</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="0" unitRef="usd">268,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" unitRef="usd">7,418,073</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_7" id="_BusinessCombinationDisclosureTextBlock-c4_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following unaudited pro forma condensed
financial information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and
Active Intelligence, as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed
financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would
have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation
of the future consolidated results of operations of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c4_cont_8" id="_BusinessCombinationDisclosureTextBlock-c4_cont_7"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proforma</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proforma</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">943,702</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" unitRef="usd">1,369,761</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">370,647</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" unitRef="usd">1,993,472</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">2,932,828</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" sign="-" unitRef="usd">3,001,178</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">2,766,627</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" sign="-" unitRef="usd">2,732,727</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.51</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" scale="0" unitRef="usdPershares">0.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.50</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" scale="0" sign="-" unitRef="usdPershares">0.45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BusinessCombinationDisclosureTextBlock-c4_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Since the date of acquisition, Pocono
and Active Intelligence had net revenues of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionRevenue" scale="0" unitRef="usd">154,195</ix:nonFraction> and incurred a net loss of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionNetProfit" scale="0" unitRef="usd">40,068</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPERTY AND EQUIPMENT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c4_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c4_cont_1"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:numdotdecimal" name="ntrb:PropertyPlantAndEquipmentsGross" scale="0" unitRef="usd">144,585</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:numdotdecimal" name="ntrb:PropertyPlantAndEquipmentsGross" scale="0" unitRef="usd">144,585</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:numdotdecimal" name="ntrb:PropertyPlantAndEquipmentsGross" scale="0" unitRef="usd">1,053,966</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:numdotdecimal" name="ntrb:PropertyPlantAndEquipmentsGross" scale="0" unitRef="usd">22,612</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:numdotdecimal" name="ntrb:PropertyPlantAndEquipmentsGross" scale="0" unitRef="usd">19,643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:PropertyPlantAndEquipmentsGross" scale="0" unitRef="usd">1,221,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:PropertyPlantAndEquipmentsGross" scale="0" unitRef="usd">164,228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="0" unitRef="usd">144,537</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="0" unitRef="usd">53,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Property and Equipment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,076,626</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">111,029</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expense amounted to $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">91,338</ix:nonFraction>
and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">35,118</ix:nonFraction> for the years ended January 31, 2021 and 2020, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCOME TAXES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_2" id="_IncomeTaxDisclosureTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company adopted the provisions of
ASC 740, &#8220;Income Taxes, (&#8220;ASC 740&#8221;). As a result of the implementation of ASC 740, the Company recognized no adjustment
in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all
tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize
the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will
also setup a liability for interest and penalties. The Company&#8217;s policy is to recognize interest and penalties related to uncertain
tax positions as a component of the current provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_3" id="_IncomeTaxDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">There is no U.S. tax provision due to
losses from U.S. operations for the years ended January 31, 2021 and 2020. Deferred income taxes are provided for the temporary differences
between the financial reporting and tax basis of the Company&#8217;s assets and liabilities. The principal item giving rise to deferred
taxes is the net operating loss carryforward in the U.S. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes
may not be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_4" id="_IncomeTaxDisclosureTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The provision for income taxes consists
of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_5" id="_IncomeTaxDisclosureTextBlock-c4_cont_4"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Years Ended<br/> January&#160;31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_6" id="_IncomeTaxDisclosureTextBlock-c4_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A reconciliation of taxes on income
computed at the federal statutory rate to amounts provided is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_7" id="_IncomeTaxDisclosureTextBlock-c4_cont_6"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended<br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Book income (loss) from operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="0" unitRef="usd">615,894</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="0" unitRef="usd">580,992</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Common stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" unitRef="usd">421,024</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" unitRef="usd">52,931</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Unused operating losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="0" unitRef="usd">194,870</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="0" unitRef="usd">528,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_8" id="_IncomeTaxDisclosureTextBlock-c4_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2021, the Company
recorded a deferred tax asset associated with a net operating loss (&#8220;NOL&#8221;) carryforward of approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="0" unitRef="usd">5,300,000</ix:nonFraction> that was
fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize
those benefits in the foreseeable future. <ix:nonNumeric contextRef="c4" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse">The Company&#8217;s NOL expires in 2038.</ix:nonNumeric> The valuation allowance increased by approximately
$<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd">810,000</ix:nonFraction> during the year ended January 31, 2021. <ix:nonNumeric contextRef="c106" name="ntrb:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax">On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) significantly
revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%.</ix:nonNumeric> Because the Company recognizes
a valuation allowance for the entire balance, there is no net impact to the Company&#8217;s balance sheet or results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c4_cont_9" id="_IncomeTaxDisclosureTextBlock-c4_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The types of temporary differences between
tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax
asset and their approximate tax effects are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c4_cont_9"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforwards (expire through 2038)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">1,106,339</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">698,308</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="ntrb:DeferredTaxAssetAndLiabilityStockIssuedForServices" scale="0" sign="-" unitRef="usd">844,520</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="ntrb:DeferredTaxAssetAndLiabilityStockIssuedForServices" scale="0" sign="-" unitRef="usd">436,904</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" scale="0" unitRef="usd">525,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" scale="0" unitRef="usd">525,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">2,475,859</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">1,660,212</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_DebtDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES PAYABLE/CONVERTIBLE DEBT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_2" id="_DebtDisclosureTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notes Payable</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_3" id="_DebtDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 21, 2020, <ix:nonNumeric contextRef="c107" name="ntrb:NotePayablesDescription">the Coronavirus Aid
Relief and Economic Security Act (&#8220;CARES ACT&#8221; was enacted. The CARES ACT established the Paycheck Protection Program (&#8220;PPP&#8221;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#8217;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was outstanding as of January 31, 2021. The note matures June 17, 2022
and accrues interest at 0.98% per year.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_4" id="_DebtDisclosureTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2020, a minority shareholder
who had previously made loans of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FederalHomeLoanBankAdvances" scale="0" unitRef="usd">215,000</ix:nonFraction> as of January 31, 2020, made an additional loan to the Company in the amount of $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLoanOriginations1" scale="0" unitRef="usd">60,000</ix:nonFraction>, increasing
the total loans from the stockholder to $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:numdotdecimal" name="ntrb:ProceedsFromLoanOriginationsTotal" scale="0" unitRef="usd">275,000</ix:nonFraction>. The loans are interest free and due upon demand. On March 27, 2020, the Company issued
<ix:nonFraction contextRef="c109" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">25,000</ix:nonFraction> shares of common stock upon reaching a settlement with the noteholder to convert the notes in the principal balance of $<ix:nonFraction contextRef="c110" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd">275,000</ix:nonFraction>.
The transaction resulted in a loss on extinguishment of $<ix:nonFraction contextRef="c109" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" scale="0" unitRef="usd">12,500</ix:nonFraction>. In July 2020, the minority shareholder made an additional loan to the
Company in the amount of $<ix:nonFraction contextRef="c111" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLoanOriginations1" scale="0" unitRef="usd">100,000</ix:nonFraction>. The loan is interest free and due upon demand. The loan was outstanding as of January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_5" id="_DebtDisclosureTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Active Intelligence, the Company&#8217;s
newly acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="0" unitRef="usd">160,000</ix:nonFraction>
due <ix:nonNumeric contextRef="c4" name="us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">October 16, 2029</ix:nonNumeric> with interest of <ix:nonFraction contextRef="c1" decimals="2" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure">5</ix:nonFraction>% per year. The amount assumed in Note 2 was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtDefaultLongtermDebtAmount" scale="0" unitRef="usd">139,184</ix:nonFraction>. The loan requires monthly payments of principal
and interest of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="0" unitRef="usd">1,697</ix:nonFraction>. During the year ended January 31, 2021, Active Intelligence made payments of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityAnnualPrincipalPayment" scale="0" unitRef="usd">3,351</ix:nonFraction>, and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="0" unitRef="usd">2,217</ix:nonFraction> were principal
payments advanced under the Cares Act. As of January 31, 2020, the amount due was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">129,078</ix:nonFraction>, of which $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd">13,885</ix:nonFraction> is current.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_6" id="_DebtDisclosureTextBlock-c4_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Pocono has two finance leases secured
by equipment. <ix:nonNumeric contextRef="c5" name="us-gaap:DebtInstrumentMaturityDateDescription">The leases mature in 2025 and 2026.</ix:nonNumeric> The incremental borrowing rate is <ix:nonFraction contextRef="c5" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" unitRef="pure">5.0</ix:nonFraction>%. As of January 31, 2021, the minimum lease payments
are as follow:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_7" id="_DebtDisclosureTextBlock-c4_cont_6"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; width: 13%">Years Ending</td>
    <td style="width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 75%">January 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" scale="0" unitRef="usd">24,738</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" scale="0" unitRef="usd">26,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree" scale="0" unitRef="usd">27,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour" scale="0" unitRef="usd">26,361</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">January 31, 2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive" scale="0" unitRef="usd">16,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right; padding-left: 0.125in; padding-bottom: 4pt">Total</td>
    <td>&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">121,543</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_8" id="_DebtDisclosureTextBlock-c4_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Related Party Payable</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_9" id="_DebtDisclosureTextBlock-c4_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2020, the Company
owed its chief financial officer and chief operating officer $<ix:nonFraction contextRef="c112" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">29,067</ix:nonFraction> from advances made to the Company. During the year ended January
31, 2021, the Company&#8217;s chief financial officer paid expenses of $<ix:nonFraction contextRef="c113" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralExpense" scale="0" unitRef="usd">12,628</ix:nonFraction> on behalf of the Company, the Company&#8217;s chief executive
officer and chief operating officer advanced the Company $<ix:nonFraction contextRef="c114" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralExpense" scale="0" unitRef="usd">5,500</ix:nonFraction> and the officers were repaid $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">40,194</ix:nonFraction>. As of January 31, 2021, the amount
the officers were fully repaid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_10" id="_DebtDisclosureTextBlock-c4_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 31, 2020, in connection with
the Company&#8217;s acquisition of Pocono Products LLC, <ix:nonNumeric contextRef="c99" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">the Company issued to Pocono Coated Products LLC a promissory note, net of debt
discount, in the amount of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021 or immediately following
the earlier of a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products
LLC, a related party, is a shareholder of the Company.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_11" id="_DebtDisclosureTextBlock-c4_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Convertible Debt</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_12" id="_DebtDisclosureTextBlock-c4_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On October 30, 2019, <ix:nonNumeric contextRef="c116" name="ntrb:NotePayableConvertibleDebtDescription">the Company entered
into a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible
promissory notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise
price equal to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price
of the common stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from
this financing of $250,000.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_13" id="_DebtDisclosureTextBlock-c4_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The notes are convertible at a conversion
price equal to <ix:nonNumeric contextRef="c116" name="us-gaap:DebtInstrumentDescription">the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion
price, which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion.
The conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply
with the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the
notes at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which
percentage increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after
the closing of the first to occur of (a) the next public offering of the Company&#8217;s securities or (b) the next private placement
of the Company&#8217;s equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of
securities pursuant to an equity line of credit or (d) a financing with a bank or other institutional lender.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_14" id="_DebtDisclosureTextBlock-c4_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The embedded conversion option qualified
for derivative accounting and bifurcation under ASC 815-15 Derivative and Hedging. The initial fair of the conversion feature was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:FairValueOfConversionPrice" scale="0" unitRef="usd">128,870</ix:nonFraction>
and the fair value of the warrants in connection with the notes were valued at $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">888,789</ix:nonFraction> and were recorded based on their relative fair
values. A debt discount to the note payables of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd">270,000</ix:nonFraction> and an initial derivative discount of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" unitRef="usd">767,650</ix:nonFraction> was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_15" id="_DebtDisclosureTextBlock-c4_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The debt discount will be amortized
over the life of the note. Amortization of the debt discount for the year ended January 31, 2020 was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd">67,500</ix:nonFraction>. As of January 31, 2020,
the debt discount remaining was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:DiscountRemainingAmount" scale="0" unitRef="usd">202,500</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c4_cont_16" id="_DebtDisclosureTextBlock-c4_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 25, 2020, the Company prepaid
the convertible notes in the principal amount of $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction> from the proceeds of a private placement. The total payments, including a prepayment
fee of $<ix:nonFraction contextRef="c118" decimals="0" format="ixt:numdotdecimal" name="ntrb:PrepaymentFee" scale="0" unitRef="usd">69,131</ix:nonFraction> and accrued interest, was $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" unitRef="usd">345,565</ix:nonFraction>. As a result of the payment of the notes, the derivative liability, which was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:DerivativeLiabilitiesTotal" scale="0" unitRef="usd">928,774</ix:nonFraction>
as of January 31, 2021, was reduced to zero. The warrants are no longer a derivative liability based on the notes being paid in full.
See Note 7 for further information. The total loss of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" unitRef="usd">81,631</ix:nonFraction> was recorded as a result of early prepayment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c4_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Interest expense for the year ended
January 31, 2021 was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:InterestExpensesDebt" scale="0" unitRef="usd">280,686</ix:nonFraction> including the amortization of the debt discounts of was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:AmortizationOfDebtDiscountsPremium" scale="0" unitRef="usd">272,130</ix:nonFraction> and interest expense of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">8,566</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTANGIBLE ASSETS AND GOODWILL</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_2" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2021, and 2020, intangible
assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_3" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_2"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">January&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">January&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">314,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">136,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Intellectual property and trademarks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">817,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">234,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,131,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">370,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">124,770</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">56,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">1,006,730</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">314,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_4" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The value of the intangible assets,
consisting of intellectual property and customer base has been recorded at their fair value by the Company after completing a valuation
and are being amortized over a period of <ix:nonNumeric contextRef="c4" format="ixt-sec:durwordsen" name="ntrb:amortizedOverPeriod">ten years</ix:nonNumeric>. Amortization expense for the year ended January 31, 2021 and 2020 was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">68,770</ix:nonFraction> and
$<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">37,070</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_5" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Estimated Amortization:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c4_cont_5"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Year Ended January 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd">113,150</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd">113,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd">113,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd">113,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2026 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd">554,130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">1,006,730</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DERIVATIVE LIABILITIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_2" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The embedded conversion option of the
convertible debentures described in Note 4 contain conversion features that qualify for embedded derivative classification. The fair value
of the liabilities will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement
of operations as a gain or loss on derivative financial instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_3" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The table below sets forth a summary
in the fair value of the Company&#8217;s Level 3 financial liabilities:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_4" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_3"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Balance at the beginning of the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd">928,774</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative liability warrants reclassed to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c126" decimals="0" format="ixt:numdotdecimal" name="ntrb:DerivativeLiabilityWarrantsReclassedToEquity" scale="0" sign="-" unitRef="usd">906,678</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in value of embedded conversion option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c126" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" sign="-" unitRef="usd">22,096</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_5" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company uses Level 3 inputs for
its valuation methodology for the embedded conversion option and warrant liabilities as their fair value were determined by using the
Monte Carlo Model based on various assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_6" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At issuance, the expected volatility
was <ix:nonFraction contextRef="c4" decimals="3" format="ixt:numdotdecimal" name="ntrb:FairValueAssumptionsWeightedAverageVolatilityRates" scale="-2" unitRef="pure">158.3</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction contextRef="c4" decimals="4" format="ixt:numdotdecimal" name="ntrb:FairValueAssumptionsRiskFreeInterestRates" scale="-2" unitRef="pure">1.58</ix:nonFraction>%; and expected term of <ix:nonNumeric contextRef="c4" format="ixt-sec:durwordsen" name="ntrb:ExpectedTerm">one year</ix:nonNumeric>. For the revaluation at January 31, 2020, the expected volatility
was <ix:nonFraction contextRef="c123" decimals="3" format="ixt:numdotdecimal" name="ntrb:FairValueAssumptionsWeightedAverageVolatilityRates" scale="-2" unitRef="pure">184.4</ix:nonFraction>%; risk-free rate of return of <ix:nonFraction contextRef="c123" decimals="4" format="ixt:numdotdecimal" name="ntrb:FairValueAssumptionsRiskFreeInterestRates" scale="-2" unitRef="pure">1.43</ix:nonFraction>%; and expected term of <ix:nonNumeric contextRef="c123" name="ntrb:ExpectedTerms">nine months</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c4_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Reclassification at March 25, 2020 to
settle the liabilities, the expected volatility was <ix:nonFraction contextRef="c124" decimals="4" format="ixt:numdotdecimal" name="ntrb:FairValueAssumptionsWeightedAverageVolatilityRates" scale="-2" unitRef="pure">147.47</ix:nonFraction>%; risk-free rate of return of <ix:nonFraction contextRef="c124" decimals="4" format="ixt:numdotdecimal" name="ntrb:FairValueAssumptionsRiskFreeInterestRates" scale="-2" unitRef="pure">0.36</ix:nonFraction>%; exercise price of $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">11</ix:nonFraction>; and expected term
of <ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="ntrb:ExpectedTerm">2.6</ix:nonNumeric> months.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RELATED PARTY TRANSACTIONS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c4_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c4_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c128" continuedAt="_SaleOfStockDescriptionOfTransaction-c128_cont_1" name="us-gaap:SaleOfStockDescriptionOfTransaction"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></ix:nonNumeric></td> <td style="text-align: justify"><ix:continuation id="_SaleOfStockDescriptionOfTransaction-c128_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company&#8217;s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise.</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c4_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the warrant on the
date of grant using the Black Scholes model was $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:numdotdecimal" name="ntrb:FairValueOfWarrantExpense" scale="0" unitRef="usd">252,700</ix:nonFraction> and was expensed during the six months ended July 31, 2019. <ix:nonNumeric contextRef="c4" name="us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized">The warrant expired
unexercised on May 19, 2019.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c4_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had related party notes with its Chief Financial Officer and Chief Operating Officer. See footnote 5 for further discussion.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisition of Pocono, the Company recorded various transactions and operations through Pocono Coated Products LLC, a related entity. The transactions included revenue of $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrincipalTransactionsRevenue" scale="0" unitRef="usd">68,780</ix:nonFraction>, purchase of materials of $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:numdotdecimal" name="ntrb:PurchaseOfMaterials" scale="0" unitRef="usd">33,479</ix:nonFraction>, paid expenses of $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:numdotdecimal" name="ntrb:ExpensesPaid" scale="0" unitRef="usd">23,310</ix:nonFraction>, and finance payments of $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd">6,763</ix:nonFraction>. As of January 31, 2021, <ix:nonNumeric contextRef="c130" name="ntrb:RelatedPartyTransactionDescriptionOfTransactions">Pocono Coated Products LLC owed the Company $5,228. The Company also issued a note in the amount $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.</ix:nonNumeric></span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended January 31, 2021, the Company issued <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="ntrb:CommonStockIssued" scale="0" unitRef="shares">51,825</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">777,375</ix:nonFraction>, to executive officers of the Company, based on the market price at the date of issuance, and <ix:nonFraction contextRef="c131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">78,500</ix:nonFraction> shares of common stock, valued at <ix:nonFraction contextRef="c131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">1,221,500</ix:nonFraction>, to the Company&#8217;s current and former independent directors, based on the market price at the date of issuance. The shares were issued on December 31, 2020 at a stock price of $<ix:nonFraction contextRef="c132" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">15</ix:nonFraction> per share.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDER&#8217;S EQUITY</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Preferred Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 15, 2016, the board of directors
of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company
to include and authorize <ix:nonFraction contextRef="c133" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction> shares of Preferred Stock, par value $<ix:nonFraction contextRef="c133" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On May 24, 2019, the board of directors
created a series of preferred stock consisting of <ix:nonFraction contextRef="c134" decimals="INF" format="ixt:numdotdecimal" name="ntrb:DesignatedSharesOfPreferredStocks" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares designated as the Series A Convertible Preferred Stock (&#8220;Series
A Preferred Stock&#8221;). On June 20, 2019, the Series A preferred Stock was terminated, and the <ix:nonFraction contextRef="c135" decimals="INF" format="ixt:numdotdecimal" name="ntrb:DesignatedSharesOfPreferredStocks" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares were restored to the
status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated
as part of a particular series by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c136" name="ntrb:CommonStockOfDescription"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 25, 2019, the Company effected
a one-for four reverse split, pursuant to which each share of common stock became converted into <ix:nonFraction contextRef="c137" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">0.25</ix:nonFraction> shares of common stock, and the
Company decreased its authorized common stock from <ix:nonFraction contextRef="c138" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">100,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c139" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">25,000,000</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 27, 2020, the Company amended
its articles of incorporation to increase its authorized common shares from <ix:nonFraction contextRef="c140" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">25,000,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c141" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">250,000,000</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Activity during the Year Ended January
31, 2021</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 22, 2020, the Company issued
in a private placement <ix:nonFraction contextRef="c142" decimals="INF" format="ixt:numdotdecimal" name="ntrb:PrivatePlacement" scale="0" unitRef="shares">46,828</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:numdotdecimal" name="ntrb:WarrantsToPurchaseOfCommonStockShare" scale="0" unitRef="usdPershares">11</ix:nonFraction> per unit. Each unit consisted of one share of common stock and a warrant to purchase
one share of common stock at an exercise price of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:numdotdecimal" name="ntrb:InvestmentWarrantExercisePrice" scale="0" unitRef="usdPershares">14</ix:nonFraction> per share. The warrants expire April 30, 2023. The Company issued a total of <ix:nonFraction contextRef="c142" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">46,828</ix:nonFraction>
shares of common stock and warrants to purchase <ix:nonFraction contextRef="c142" decimals="INF" format="ixt:numdotdecimal" name="ntrb:WarrantsToPurchaseOfCommonStockShares" scale="0" unitRef="shares">46,828</ix:nonFraction> shares of common stock. The Company received proceeds of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">515,108</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c143" name="ntrb:CommonStockOfDescription"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2020, a minority shareholder
who had previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 30, 2020, the Company issued
<ix:nonFraction contextRef="c144" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">5,000</ix:nonFraction> shares to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">50,000</ix:nonFraction>,
all of which is included in selling and general administrative expense for the year ended January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 31, 2020, the Company acquired
the membership interests in Pocono Coated Products LLC and issued <ix:nonFraction contextRef="c145" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">608,519</ix:nonFraction> shares of its common stock, valued at $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">6,085,180</ix:nonFraction>, and issued
a promissory note, net of debt discount, in the amount of $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" unitRef="usd">1,332,893</ix:nonFraction>. See Note 2 for further information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On December 31, 2020, the Company issued
<ix:nonFraction contextRef="c146" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">130,325</ix:nonFraction> shares of common stock for services, valued at $<ix:nonFraction contextRef="c146" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">1,954,875</ix:nonFraction>, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c147" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">51,825</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">777,375</ix:nonFraction>, issued to executive officers.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c148" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">78,500</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction contextRef="c148" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">1,177,500</ix:nonFraction>, issued to the Company&#8217;s current and former independent directors.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Subscription Payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (&#8220;BPM&#8221;), the Company issued <ix:nonFraction contextRef="c149" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">81,396</ix:nonFraction> shares of common stock to BPM and received proceeds of $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">700,000</ix:nonFraction> to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInterestReceived" scale="0" unitRef="usd">60,000</ix:nonFraction> which is included in Stockholders&#8217; Equity as Subscription in the Company&#8217;s consolidated balance sheet as of January 31, 2021. The balance of the funds was received in February 2021.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25,2021, the Company issued <ix:nonFraction contextRef="c151" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">5,602</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">60,000</ix:nonFraction>, for consulting services pursuant to a consultant agreement commencing December 1, 2020. The Company has reflected $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd">10,000</ix:nonFraction> representing <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="ntrb:CommonStockShareSubscribedButUnissuedSubscriptionsShares" scale="0" unitRef="shares">934</ix:nonFraction> shares as Subscription Payable in the Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Activity during the Year Ended January
31, 2020</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c4_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the year ended January 31, 2020,
the Company issued <ix:nonFraction contextRef="c15" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">17,144</ix:nonFraction> shares of common stock to extinguish accounts payable in the amount of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd">240,000</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_WarrantsAndOptionsTextBlock-c4_cont_1" escape="true" name="ntrb:WarrantsAndOptionsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANTS AND OPTIONS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c4_cont_2" id="_WarrantsAndOptionsTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes the changes
in warrants outstanding and the related price of the shares of the Company&#8217;s common stock issued to non-employees of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c4_cont_3" id="_WarrantsAndOptionsTextBlock-c4_cont_2"><ix:nonNumeric contextRef="c4" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">&#160;&#160;<b>Remaining</b> </span></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Life</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">182,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c155" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" scale="0" unitRef="usdPershares">6.32</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c156" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">0.35</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c155" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">4,101,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">20.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;<ix:nonNumeric contextRef="c156" format="ixt-sec:duryear" name="ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted">3.00</ix:nonNumeric>&#160;years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c156" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" sign="-" unitRef="shares">162,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.38</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" scale="0" unitRef="usdPershares">18.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;<ix:nonNumeric contextRef="c156" format="ixt-sec:duryear" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne">2.08</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">91,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">12.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;<ix:nonNumeric contextRef="c158" format="ixt-sec:duryear" name="ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted">3.00</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Expired/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c158" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" sign="-" unitRef="shares">20,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">14.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding-period ending January 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">141,828</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" scale="0" unitRef="usdPershares">11.99</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c158" format="ixt-sec:duryear" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne">2.16</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">853,311</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable - period ending January 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">141,828</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">11.99</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c158" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.16</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">853,311</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c4_cont_4" id="_WarrantsAndOptionsTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As a result of a completed private placement,
the warrants to purchase <ix:nonFraction contextRef="c152" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" scale="0" unitRef="shares">50,000</ix:nonFraction> shares at the lesser of (i) $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">20.90</ix:nonFraction> or, (ii) if the Company completes its public offering of its common
stock, <ix:nonFraction contextRef="c4" decimals="2" format="ixt:numdotdecimal" name="ntrb:InitialPublicOfferingPricePercentage" scale="-2" unitRef="pure">110</ix:nonFraction>% of the initial public offering price of the Common Stock in the public offering, became a warrant to purchase <ix:nonFraction contextRef="c153" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" scale="0" unitRef="shares">95,000</ix:nonFraction> warrants
at $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">11</ix:nonFraction> per share, subject to adjustment pursuant to the antidilution provisions of the warrant. The Company recorded a derivative liability
for the warrants in the amount of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:ReclassOfWarrantsFromLiabilityToEquity" scale="0" unitRef="usd">906,678</ix:nonFraction> and reclassed the derivative liability to additional paid-in capital as of January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c4_cont_5" id="_WarrantsAndOptionsTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes additional
information relating to the warrants outstanding at January31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c4_cont_6" id="_WarrantsAndOptionsTextBlock-c4_cont_5"><ix:nonNumeric contextRef="c4" escape="true" name="ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Range of <br/> Exercise <br/> Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining <br/> Contractual <br/> Life(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price <br/> for Shares <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price <br/> for Shares <br/> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">11.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" scale="0" unitRef="shares">95,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonNumeric contextRef="c158" format="ixt-sec:duryear" name="ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2">1.75</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c158" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">11.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" scale="0" unitRef="shares">95,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">11.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">14.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" scale="0" unitRef="shares">46,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2">2.24</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">14.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" scale="0" unitRef="shares">46,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">14.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c4_cont_7" id="_WarrantsAndOptionsTextBlock-c4_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes the changes
in options outstanding and the related price of the shares of the Company&#8217;s common stock issued to non-employees of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_WarrantsAndOptionsTextBlock-c4_cont_7"><ix:nonNumeric contextRef="c160" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c163" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">25,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">25.64</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c163" format="ixt-sec:duryear" name="ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted">0.05</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usd">232,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c163" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitRef="shares">25,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">25.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding-period ending January 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable - period ending January 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_LesseeOperatingLeasesTextBlock-c4_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEASES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c4_cont_2" id="_LesseeOperatingLeasesTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company had operating leases for
its facilities used for research and development, sales and administration. These leases have been terminated. The Company is currently
operating its manufacturing operations on a month-to-month basis in a North Carolina facility under a verbal commitment. The monthly rent
is $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:MonthlyRent" scale="0" unitRef="usd">4,200</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">See financing leases for equipment in
Note 5.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMITMENTS AND CONTIGENCIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Legal Proceedings</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On July 27, 2018, the Company commenced
an action in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc.,
Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without
Notice and a Motion for Prejudgment Writ of Replevin arising from the Company&#8217;s decision to seek to rescind for misrepresentation
the agreement by which the Company acquired advanced Health Brands, Inc. for <ix:nonFraction contextRef="c164" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">1,250,000</ix:nonFraction> shares of common stock valued at $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">2,500,000</ix:nonFraction> and
seek return of the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against
the defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker filed a Motion to Dismiss the Company&#8217;s Verified Complaint, Motion
to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019,
the court dismissed the Company&#8217;s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the
six patents never duly transferred to the Company. On February 1, 2019, the Company appealed the court&#8217;s order. Pursuant to a settlement
agreement with one of the defendants, that defendant returned the <ix:nonFraction contextRef="c165" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" unitRef="shares">50,000</ix:nonFraction> shares which had been issued to her, and the shares were cancelled
as of January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom the Company has a settlement agreement),
filed a motion for sanctions and civil contempt against us, which generally claimed that we failed to comply with the Court&#8217;s January
4, 2019 order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer their shares of common stock. On
October 29, 2019, the Court denied the Defendants motion. On March 20, 2020, the Florida district court of appeal reversed the lower court
ruling in the Florida state court action that dismissed our complaint, with prejudice, and gave us leave to file an amended complaint.
On July 7, 2020, Defendants filed Notice for Trial, requesting the court to set a trial date. The Company and defendants have served their
first set of interrogatories on each other and have filed answers and responses to each other&#8217;s first set of interrogatories.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 22, 2018, four of the defendants
in the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of
Common Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition
agreement. The parties have agreed to a stay pending the outcome of the Florida litigation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 29, 2019, the Company filed
a securities fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle
Polly-Murphy, Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently
and deceitfully obtained <ix:nonFraction contextRef="c166" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">1,250,000</ix:nonFraction> shares of common stock by orchestrating a months-long scheme to defraud the Company. The Company is
seeking the return of the shares of common stock and monetary damages resulting from the defendants&#8217; fraudulent conduct. The defendants
filed a motion to dismiss the complaint on August 23, 2019, and on September 13, 2019 the Company filed its response. On July 20, 2020,
the Court denied the defendant&#8217;s motion to dismiss the complaint, and the parties have recently commenced the discovery phase of
the litigation. No trial date has been scheduled by the Court.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><i>Employment
Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company entered into a three-year
employment agreement with Gareth Sheridan, our CEO, effective April 25, 2019. The agreement also provides that the executive will continue
as a director. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31,
2024., and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#8217; notice given
prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement,
Mr. Sheridan receives an annual salary $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalaryPayment" scale="0" unitRef="usd">42,000</ix:nonFraction> per annum, commencing on the effective date of the agreement and increasing to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd">170,000</ix:nonFraction>
per annum in the month in which the Company shall have received not less than $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:numdotdecimal" name="ntrb:PublicOrPrivateFinancing" scale="0" unitRef="usd">2,500,000</ix:nonFraction> from one or more public or private financings
of the Company&#8217;s equity securities subsequent to the date of the agreement. During the year ended January 31, 2021, the salary was
increased to $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd">60,000</ix:nonFraction> per anum.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Rambam Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On December 9, 2020, the Company entered
into a License Agreement (the &#8220;License Agreement&#8221;) with Rambam Med-Tech Ltd. (&#8220;Rambam&#8221;), Haifa, Israel, to develop
the RAMBAM Closed System Transfer Device (&#8220;CTSD&#8221;) and such other products as the parties agree to develop/commercialize. The
Company will license from Rambam the full technology, IP, and title to CTSD in the field, with an Initial license fee of $<ix:nonFraction contextRef="c169" decimals="0" format="ixt:numdotdecimal" name="ntrb:PaymentForInitialLicenseFee" scale="0" unitRef="usd">50,000</ix:nonFraction> and running
royalties on net sales. The $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:numdotdecimal" name="ntrb:PaymentForInitialLicenseFee" scale="0" unitRef="usd">50,000</ix:nonFraction> license fee was paid in February 2021, at which time the agreement became effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c4" name="us-gaap:OtherCommitmentsDescription"><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company had entered into a prior
agreement, dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#8220;BPM&#8221;), that, in consideration of BPM&#8217;s introduction
of Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#8217;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>BPM Distribution and Stock Purchase
Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c4_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 10, 2021, the Company finalized the Distribution Agreement with BPM, providing for distribution of the medical products developed and produced under the License Agreement. Under the Distribution Agreement, BPM&#160;has the right to distribute the medical products in Israel and has a right of first refusal in relation to all other countries/states, other than United States, Korea, China, Vietnam, Canada and Ecuador, which are termed excluded countries.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c171" name="us-gaap:SignificantPurchaseCommitmentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and BPM entered into a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.</span></ix:nonNumeric></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c4" continuedAt="_SubsequentEventsTextBlock-c4_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUBSEQUENT EVENTS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c4_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 10, 2021, the Company issued <ix:nonFraction contextRef="c172" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">12,500</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction contextRef="c172" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">350,000</ix:nonFraction>, for consulting fee in connection with Rambam License Agreement.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25,2021, the Company issued <ix:nonFraction contextRef="c173" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">5,602</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction contextRef="c173" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">60,000</ix:nonFraction>, for consulting services pursuant to a consultant agreement commencing December 1, 2020.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>July 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Index to Unaudited Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Page No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 89%; text-indent: -0.125in; padding-left: 0.125in"><a href="#v_001">Condensed Consolidated Balance Sheets as of July 31, 2021 (unaudited) and January 31, 2021</a></td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">F-27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><a href="#v_002">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended July 31, 2021 and 2020 (unaudited)</a></td><td>&#160;</td>
    <td style="text-align: center">F-28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><a href="#v_003">Consolidated Statements of Stockholders&#8217; Equity for the three and six months ended Julyl 31, 2021 and 2020 (unaudited)</a></td><td>&#160;</td>
    <td style="text-align: center">F-29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><a href="#v_004">Condensed Consolidated Statements of Cash Flows for the six months ended July 31, 2021 and 2020 (unaudited)</a></td><td>&#160;</td>
    <td style="text-align: center">F-31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><a href="#v_005">Notes to Unaudited Consolidated Financial Statements</a></td><td>&#160;</td>
    <td style="text-align: center">F-32</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="v_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED
BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>July&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>January&#160;31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>(Unaudited)</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="text-decoration:underline">ASSETS</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">304,258</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">151,993</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">13,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">109,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">72,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">52,848</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">216,127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">606,750</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">314,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">PROPERTY &amp; EQUIPMENT-net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,035,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,076,626</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">OTHER ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">7,529,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">7,529,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Intangible assets-net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">991,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">1,006,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" unitRef="usd">10,163,555</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" unitRef="usd">9,927,419</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">975,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">940,612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd">64,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd">86,846</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Notes payable-related party, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" scale="0" unitRef="usd">1,475,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" scale="0" unitRef="usd">1,402,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Finance lease liabilities-current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd">25,506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd">24,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Notes payable-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">114,119</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">113,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,655,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,568,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LONG-TERM LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Note payable-net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd">108,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd">150,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Finance lease liabilities-net of currnt portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" unitRef="usd">83,856</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" unitRef="usd">96,804</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,847,489</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,815,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Commitments and Contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">STOCKHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><div style="-sec-ix-hidden: hidden-fact-20; -sec-ix-hidden: hidden-fact-19">Preferred stock, $.001 par value, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, -<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction>- outstanding</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><div style="-sec-ix-hidden: hidden-fact-22; -sec-ix-hidden: hidden-fact-21">Common stock, $.001 par value, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="ntrb:CommonStockShareIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="ntrb:CommonStockShareOutstanding" scale="0" unitRef="shares">6,356,270</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="ntrb:CommonStockShareIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:numdotdecimal" name="ntrb:CommonStockShareOutstanding" scale="0" unitRef="shares">6,256,770</ix:nonFraction></ix:nonFraction> shares issued and outstanding at July 31, 2021 and January 31, 2021, respectively</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">6,356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">6,257</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Additional paid-in-capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">19,980,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">18,871,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Subscription payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscriptionPayables" scale="0" unitRef="usd">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">12,670,985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">11,835,105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,316,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,111,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">10,163,555</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">9,927,419</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to unaudited condensed consolidated financial
statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="v_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>For the</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>For the</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 1.5pt">Revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">213,739</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">84,450</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">647,227</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">203,814</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">186,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">116,937</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">355,606</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">191,876</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">509,219</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">193,331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,088,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">385,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Costs and Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd">695,981</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd">310,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd">1,444,433</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd">577,124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">482,242</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">225,818</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">797,206</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">373,310</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Gain (loss) on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd">3,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd">43,214</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">12,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Early prepayment fee on convertible debentures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionExpense" scale="0" unitRef="usd">69,131</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Gain on change of fair value of derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfDerivatives" scale="0" unitRef="usd">22,096</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">41,019</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">81,888</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">205,218</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">37,681</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">38,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">264,753</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before provision for income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">519,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">225,869</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">835,880</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">519,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">225,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">835,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per share of common stock-basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.08</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.04</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.13</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.12</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average shares of common stock outstanding - basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">6,356,269</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">5,513,782</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">6,343,076</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">5,496,274</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Comprehensive Income (Loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">519,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">225,869</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">835,880</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Total Comprehensive Income (Loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">519,923</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">225,869</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">835,880</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to unaudited condensed consolidated financial
statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="v_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Six Months Ended July 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Common Stock</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Other</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Number&#160;of</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Paid In</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Comprehensive</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Subscription</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Total</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>shares</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Capital</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Income (Loss)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Deficit</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Payable</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-indent: -0.125in; padding-left: 0.125in">Balance, February 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,111,946</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c30" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">6,256,772</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,257</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">18,871,098</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c33" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">11,835,105</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">70,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued for proceeds and payment for license</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">81,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">699,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c39" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" sign="-" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">18,102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">409,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c39" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" sign="-" unitRef="usd">10,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss for the six months ended July 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">835,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c38" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">835,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance, July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,316,066</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">6,356,270</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,356</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">19,980,999</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">12,670,985</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Six Months Ended July 31, 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Common Stock</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Other</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Number&#160;of</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Paid In</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Comprehensive</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Subscription</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Total</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>shares</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Capital</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Income (Loss)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Deficit</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Payable</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-indent: -0.125in; padding-left: 0.125in">Balance, February 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">175,433</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">5,441,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,441</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,072,573</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">8,902,277</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">49,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleofCommonstockForCash" scale="0" unitRef="usd">515,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares">46,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleofCommonstockForCash" scale="0" unitRef="usd">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleofCommonstockForCash" scale="0" unitRef="usd">515,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Conversion of debt for common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">287,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">287,475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Reclassification of warrants from liability to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" scale="0" unitRef="usd">906,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:numdotdecimal" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" scale="0" unitRef="usd">906,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss for the six months ended July 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance, July 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,296,656</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c51" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">5,517,928</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,518</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,831,782</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c53" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c54" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">9,540,340</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Three Months Ended July 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Common Stock</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Other</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Number&#160;of</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Paid In</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Comprehensive</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Subscription</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Total</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>shares</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Capital</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Income (Loss)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Deficit</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Payable</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-indent: -0.125in; padding-left: 0.125in">Balance, April 30, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,835,989</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c57" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">6,356,270</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,356</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">19,980,999</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c59" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c60" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">12,151,062</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss for the three months ended July 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">519,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c65" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">519,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance, July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,316,066</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">6,356,270</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,356</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">19,980,999</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">12,670,985</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Three Months Ended July 31, 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Common Stock</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Other</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Number&#160;of</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Paid In</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Comprehensive</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Subscription</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Total</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>shares</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Capital</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Income (Loss)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Deficit</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Payable</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-indent: -0.125in; padding-left: 0.125in">Balance, April 30, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,472,525</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c68" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">5,512,928</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,513</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,781,787</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c70" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">9,314,471</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">49,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss for the three months ended July 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">225,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">225,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance, July 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,296,656</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c51" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">5,517,928</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,518</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,831,782</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c53" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c54" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">9,540,340</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to unaudited condensed consolidated financial
statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="v_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash flows from operating activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">835,880</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Expenses paid on behalf of the Company by related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="0" unitRef="usd">3,628</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">155,822</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">36,094</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">73,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">202,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Gain on change in fair value of derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="0" unitRef="usd">22,096</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Early prepayment fee on convertible debentures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:EarlyPrepaymentFeeOnConvertibleDebentures" scale="0" unitRef="usd">69,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Amortization of right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfLeasedAsset" scale="0" unitRef="usd">9,610</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">(Gain) loss on extinguisment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd">43,214</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">12,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">225,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">38,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">95,582</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">1,811</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">41,127</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">4,358</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">19,752</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Deposit on sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:increasedecreaseDepositOnSales" scale="0" unitRef="usd">22,142</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:increasedecreaseDepositOnSales" scale="0" sign="-" unitRef="usd">29,725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreaseOperatingLeaseLiability" scale="0" unitRef="usd">10,050</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">44,659</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd">38,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net Cash Used In Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">367,944</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">313,652</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Purchase of equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">49,396</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Proceeds from sale of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">583,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">515,108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd">194,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Payment on convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd">339,131</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Payment on note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd">1,213</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Payment on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd">12,182</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Proceeds from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd">5,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Payment of related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">33,628</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net Cash Provided by Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">569,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">342,719</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">152,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">29,067</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents - Beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">151,993</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">10,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents - End of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">304,258</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">39,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplementary information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">4,060</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Common stock issued for settlement of notes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockIssuedForSettlementOfNotesPayable" scale="0" unitRef="usd">287,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Common stock issued for prepaid consulting</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockIssuedForPrepaidConsulting" scale="0" unitRef="usd">400,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockIssuedForPrepaidConsulting" scale="0" unitRef="usd">12,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Non-cash payment for license agreement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:NoncashPaymentForLicenseAgreement" scale="0" unitRef="usd">57,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Derivative liability warrant reclassed to equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:DerivativeLiabilityWarrantReclassedToEquity" scale="0" unitRef="usd">906,678</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Common issued for subscription payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonIssuedForSubscriptionPayable" scale="0" unitRef="usd">70,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to unaudited condensed consolidated
financial statements</p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<span style="clear: both"><br/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUTRIBAND INC. AND SUBSIDIARIES</b></p><div>

</div><div><a id="v_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Unaudited Consolidated
Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of and for the Six Months Ended July 31,
2021 and 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORGANIZATION AND DESCRIPTION OF BUSINESS </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Organization</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nutriband Inc. (the &#8220;Company&#8221;) is
a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was
formed by the Company&#8217;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2018, <ix:nonNumeric contextRef="c78" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity">the Company acquired 4P Therapeutics
LLC (&#8220;4P Therapeutics&#8221;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000,
and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by
4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company
since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#8217;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#8220;FDA&#8221;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the acquisition of 4P Therapeutics, 4P Therapeutics&#8217;
drug development business became the Company&#8217;s principal business. The Company&#8217;s approach is to use generic drugs that are
off patent and incorporate them into the Company&#8217;s transdermal drug delivery system. Although these medications have received FDA
approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical
and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2020, the Company formed Pocono
Pharmaceuticals Inc. (&#8220;Pocono Pharmaceuticals&#8221;), a wholly owned subsidiary of the Company. On August 31, 2020, the Company
acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated
Products LLC (&#8220;PCP&#8221;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company also
acquired <ix:nonFraction contextRef="c174" decimals="2" format="ixt:numdotdecimal" name="ntrb:AcquiredPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the membership interests of Active Intelligence LLC (&#8220;Active Intelligence&#8221;). See Note 2 for further details
of the acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pocono Pharmaceuticals is a coated products manufacturing
entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product design and
development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#8217;s competitive
edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is used as the same as traditional
kinesiology tape.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, COVID-19 emerged and has subsequently
spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and
private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders
and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed quarantines
and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business and could
delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UnauditedInterimFinancialStatementsPolicyTextBlock-c0_cont_1" escape="true" name="ntrb:UnauditedInterimFinancialStatementsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Unaudited Interim Financial Statements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_UnauditedInterimFinancialStatementsPolicyTextBlock-c0_cont_2" id="_UnauditedInterimFinancialStatementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated balance sheet as of July 31,
2021, and the consolidated statements of operations, stockholders&#8217; equity, and cash flows for the periods presented have been prepared
by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary
to present fairly the financial position, results of operations, changes in stockholders&#8217; equity and cash flows for all periods
presented have been made. The results for the six months ended July 31, 2021, are not necessarily indicative of the results to be expected
for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and
footnotes thereto included in Nutriband&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_UnauditedInterimFinancialStatementsPolicyTextBlock-c0_cont_3" id="_UnauditedInterimFinancialStatementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain information and footnote disclosures required
under generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted
from these consolidated financial statements pursuant to the rules and regulations, including the interim reporting requirements of the
U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The preparation of consolidated financial statements in accordance with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts
in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UnauditedInterimFinancialStatementsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s significant accounting policies
are summarized in Note 1 in the Company&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant
changes to these accounting policies during the six months July 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_GoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="ntrb:GoingConcernPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Going Concern </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation id="_GoingConcernPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 31, 2021, the Company believes the
substantial doubt about its status as a going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current quarter net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to
alleviate the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses,
equity funding that has been received and additional funding expected to be received, and the net revenue from its recent acquisitions.
These factors did not exist in prior years during its start-up operations. The Company&#8217;s recent history of losses has continued
but future positive cash flow projections due to revenue commitments and decreases in overhead as well as expected equity funding will
enable the Company to alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans have been currently implemented. The plans enable the Company to meet its obligations for at least one year from the date when the
financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_2" id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of the Company
include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations
of 4P Therapeutics are included in the Company&#8217;s financial statements from the date of acquisition of August 1, 2018, and the operations
of Pocono and Active Intelligence are included in the Company&#8217;s financial statements from the date of acquisition of September 1,
2020. The wholly owned subsidiaries are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_3" id="_ConsolidationPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nutriband Ltd.</p></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_4" id="_ConsolidationPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4P Therapeutics LLC</p></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pocono Pharmaceuticals Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates
and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as
income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases
its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s significant policies are summarized
in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant changes to
the accounting policies during the six months ended July 31, 2021, and the Company does not expect that the adoption of other accounting
pronouncements will have a material impact on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Revenue Recognition </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
&#8220;Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which amends the accounting standards for revenue
recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when
products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a description of the Company&#8217;s
revenue types, which include professional services and sale of goods:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
    revenues include the contract of research and development related services with the Company&#8217;s clients in the life sciences
    field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for
    each given research project engaged.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    revenues are derived from the sale of the Company&#8217;s consumer transdermal and coated products. Upon the reception of a purchase
    order, we have the order filled and shipped.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A contract with a customer exists when (i) we
enter into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred
and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine
that collection of substantially all consideration for services that are transferred is probable based on the customer&#8217;s intent
and ability to pay the promised consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionDeferredRevenue-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionDeferredRevenue"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Deferred Revenue</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_RevenueRecognitionDeferredRevenue-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue is a liability related to a revenue
producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from
a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" continuedAt="_PerformanceObligationsPolicyTextBlock-c0_cont_1" escape="true" name="ntrb:PerformanceObligationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_PerformanceObligationsPolicyTextBlock-c0_cont_2" id="_PerformanceObligationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A performance obligation is a promise in a contract
to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction
price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
For the Company&#8217;s different revenue service types, the performance obligation is satisfied at different times. The Company&#8217;s
performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue
performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize
revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for
the work performed during that month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_PerformanceObligationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All revenue recognized in the income statement
is considered to be revenue from contracts with customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1" escape="true" name="ntrb:DisaggregationOfRevenuesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_2" id="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disaggregates its revenue from contracts
with customers by type and by geographical location. See the tables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"><ix:continuation continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_3" id="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalesRevenuesGoodsNet" scale="0" unitRef="usd">213,739</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalesRevenuesGoodsNet" scale="0" unitRef="usd">59,450</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalesRevenuesGoodsNet" scale="0" unitRef="usd">541,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalesRevenuesGoodsNet" scale="0" unitRef="usd">120,770</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleOfGoodsAndServices" scale="0" unitRef="usd">25,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleOfGoodsAndServices" scale="0" unitRef="usd">105,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:SaleOfGoodsAndServices" scale="0" unitRef="usd">83,044</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">213,739</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">84,450</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">647,227</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">203,814</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><ix:continuation id="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographic location:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">213,739</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">25,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c179" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">560,627</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">83,044</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">59,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">86,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">120,770</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">213,739</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">84,450</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">647,227</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" unitRef="usd">203,814</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Account receivable </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation id="_ReceivablesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivables are recorded at the
net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability
of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts
where appropriate and the application of historical loss to non-applicable accounts. For the six months ended July 31, 2021 and 2020,
the Company recorded no bad debt expense for doubtful accounts related to account receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are valued at the lower of cost and
reasonable value determined using the first-in, first-out (FIFO) method. Net reasonable value is the estimated selling price in the ordinary
course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material
costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of July 31,
2021, <ix:nonFraction contextRef="c0" decimals="2" format="ixt:numdotdecimal" name="ntrb:InventoryRawMaterialsPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the inventory consists of raw materials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment represent an important
component of the Company&#8217;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful
life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement
parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are
capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from
<ix:nonNumeric contextRef="c175" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c176" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> years as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:nonNumeric contextRef="c0" escape="true" name="ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c185" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c186" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c187" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c188" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c189" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Intangible Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets include trademarks, intellectual
property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance
of ASC 350, &#8220;Intangibles-Goodwill and Other.&#8221; The Company capitalizes certain costs related to patent technology. A substantial
component of the purchase price related to the Company&#8217;s acquisitions have also been assigned to intellectual property and other
intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible
assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized
over their estimated useful lives of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">ten years</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Goodwill</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill represents the difference between the
total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed
for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the
recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August 31,
2020, in connection with the Company&#8217;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">5,810,640</ix:nonFraction>. As of July 31, 2021, Goodwill amounted to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" unitRef="usd">7,529,875</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Long-lived Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management reviews long-lived assets for potential
impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount
of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use
and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market
value of the long-lived asset and the related book value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Earnings per Share</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic earnings per share of common stock is computed
by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per
share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock
outstanding during the period.&#160;Potential shares of common stock consist of shares issuable upon the exercise of outstanding options
and common stock purchase warrants. As of July 31, 2021, and 2020, there were <ix:nonFraction contextRef="c0" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares">141,830</ix:nonFraction></ix:nonFraction> common stock equivalents outstanding, that were
not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Stock-Based Compensation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, &#8220;Compensation - Stock Compensation,&#8221;
prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February
1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and
other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including
grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That
expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the
requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based
compensation for both employees and non-employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements and
Disclosure&#8221; (&#8220;ASC 820&#8221;), defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of
observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that
may be used to measure fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilizes the accounting guidance for
fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized
or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is
an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data
or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy,
which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs such as quoted market prices in active markets.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying value of the Company&#8217;s financial
instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their fair value
due to the short maturities of these financial instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Derivative Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates are made at a specific point
in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve uncertainties
and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect
the estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for derivative instruments
in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; and all 	derivative instruments are reflected as either assets
or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments. Fair
value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market participants.
In general, the Company&#8217;s policy in estimating fair values is to first look at observable market prices for identical assets and
liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such as prices
of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable data
from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of July 31, 2021, and January 31, 2021, the Company had
no derivative liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Recent Accounting Standards</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has implemented all new pronouncements,
including the adoption of ASU 2018-13 and ASU 2019-12, that are in effect and that may impact its consolidated financial statements and
does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its
consolidated financial statements or results of operations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACQUISITION OF BUSINESS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_2" id="_BusinessCombinationDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2020, the Company entered into a
Purchase Agreement (&#8220;Agreement&#8221;), with Pocono Coated Products (&#8220;PCP&#8221;), pursuant to which PCP agreed to sell the
Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business, including:
(1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free and clear
of all liens, except for certain lease obligations, and (2), a <ix:nonFraction contextRef="c82" decimals="2" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired" scale="-2" unitRef="pure">100</ix:nonFraction>% membership interest in Active Intelligence, LLC (collectively the
&#8220;Assets&#8221;). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary
of the Company. The purchase price for the Assets was (i) $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="0" unitRef="usd">6,085,180</ix:nonFraction> paid with the issuance of <ix:nonFraction contextRef="c98" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares">608,519</ix:nonFraction> shares in the Company&#8217;s common
stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the &#8220;Shares&#8221;), and (ii)
a promissory note of the Company, net of debt discount, in the principal amount, of $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="ntrb:DebtInstrumentAnnualPrincipalPayments" scale="0" unitRef="usd">1,332,893</ix:nonFraction> (the Note&#8221;) which is due upon the
earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd">4,000,000</ix:nonFraction> and/or a public
offering of no less than $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" unitRef="usd">4,000,000</ix:nonFraction>. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period
of <ix:nonNumeric contextRef="c100" format="ixt-sec:durwordsen" name="ntrb:AnnualMeetingOfShareholdersTerm">one year</ix:nonNumeric> at the annual meeting of shareholders of the Company held in October 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_3" id="_BusinessCombinationDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement provides that it is effective August
31, 2020, on which date the parties also entered into an escrow agreement (the &#8220;Escrow Agreement&#8221;), with legal counsel serving
as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special purpose
subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also entered
into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_4" id="_BusinessCombinationDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of the Company entering into the transaction
is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated to the net tangible
assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and, as such, the transaction
was accounted for under the acquisition method of accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_5" id="_BusinessCombinationDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the net assets acquired are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_6" id="_BusinessCombinationDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Fair value</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Recognized on</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Acquisition</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">Common stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionCommonStockIssued" scale="0" unitRef="usd">6,085,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Note payable issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:numdotdecimal" name="ntrb:NotePayableIssued" scale="0" unitRef="usd">1,332,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:numdotdecimal" name="ntrb:CommonStockAndNoteIssuedInAcquisition" scale="0" unitRef="usd">7,418,073</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" unitRef="usd">66,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" unitRef="usd">1,761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" unitRef="usd">42,613</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equipment and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" scale="0" unitRef="usd">1,056,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer base</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" scale="0" unitRef="usd">177,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intellectual property and trademarks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" scale="0" unitRef="usd">583,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" unitRef="usd">5,810,640</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="0" unitRef="usd">26,104</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="0" unitRef="usd">26,851</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="0" unitRef="usd">268,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" unitRef="usd">7,418,073</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_7" id="_BusinessCombinationDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following unaudited pro forma condensed financial
information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and Active Intelligence,
as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed financial information
is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had
the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated
results of operations of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BusinessCombinationDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>July 31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As Reported</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Proforma</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="0" unitRef="usd">203,814</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" unitRef="usd">629,873</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionsNetLossAsReported" scale="0" sign="-" unitRef="usd">638,063</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" sign="-" unitRef="usd">702,975</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:numdotdecimal" name="ntrb:LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" scale="0" sign="-" unitRef="usdPershares">0.12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:numdotdecimal" name="ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" scale="0" sign="-" unitRef="usdPershares">0.12</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPERTY AND EQUIPMENT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>July&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>January&#160;31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">144,585</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">144,585</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,097,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,056,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">28,442</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">19,643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,270,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,221,163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="0" unitRef="usd">235,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="0" unitRef="usd">144,537</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Property and Equipment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,035,109</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,076,626</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">90,913</ix:nonFraction> and <ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">17,558</ix:nonFraction>
for the six months ended July 31, 2021 and 2020, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES PAYABLE/CONVERTIBLE DEBT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Notes Payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2020, <ix:nonNumeric contextRef="c200" name="ntrb:NotePayablesDescription">the Coronavirus Aid Relief
and Economic Security Act (&#8220;CARES ACT&#8221; was enacted. The CARES ACT established the Paycheck Protection Program (&#8220;PPP&#8221;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#8217;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was forgiven as of April 30, 2021. The Company recorded a gain on the
extinguishment of debt of $34,870 during the six months ended July 31, 2021.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2020, a minority shareholder made an additional
loan to the Company in the amount of $<ix:nonFraction contextRef="c197" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLoanOriginations1" scale="0" unitRef="usd">100,000</ix:nonFraction>. The loan is interest-free and due upon demand. The loan was outstanding as July 31, 2021,
and January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Active Intelligence, the Company&#8217;s newly
acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="0" unitRef="usd">160,000</ix:nonFraction> due
<ix:nonNumeric contextRef="c0" name="us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">October 16, 2029</ix:nonNumeric>, with interest of <ix:nonFraction contextRef="c3" decimals="2" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure">5</ix:nonFraction>% per year. The amount assumed in Note 3 was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtDefaultLongtermDebtAmount" scale="0" unitRef="usd">139,184</ix:nonFraction>. The loan requires monthly payments of principal
and interest of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="0" unitRef="usd">1,697</ix:nonFraction>. During the six months ended July 31, 2021, principal and interest payments of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="0" unitRef="usd">8,344</ix:nonFraction> were forgiven under the Cares
Act. The amount, $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:GainOnExtinguishmentOfDebt" scale="0" unitRef="usd">8,344</ix:nonFraction>, has been recorded as a gain on the forgiveness of debt. As of July 31, 2021, the amount due was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">122,196</ix:nonFraction>, of
which $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd">14,119</ix:nonFraction> is current.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Finance Leases</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pocono has two finance leases secured by equipment.
<ix:nonNumeric contextRef="c0" name="us-gaap:DebtInstrumentMaturityDateDescription">The leases mature in 2025 and 2026.</ix:nonNumeric> The incremental borrowing rate is <ix:nonFraction contextRef="c0" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" unitRef="pure">5.0</ix:nonFraction>%. As of July 31, 2021, the minimum lease payments are as follow:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ending</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 75%">January 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" scale="0" unitRef="usd">12,557</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" scale="0" unitRef="usd">26,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree" scale="0" unitRef="usd">27,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour" scale="0" unitRef="usd">26,361</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">January 31, 2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive" scale="0" unitRef="usd">16,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">109,362</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Related Party Payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_10" id="_DebtDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2020, in connection with the Company&#8217;s
acquisition of Pocono Products LLC, <ix:nonNumeric contextRef="c201" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">the Company issued to Pocono Coated Products LLC a promissory note, net of debt discount, in the amount
of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021, or immediately following the earlier of a capital
raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products LLC, a related party, is
a shareholder of the Company.</ix:nonNumeric> During the six months ended July 31, 2021, the Company recorded amortization of debt discount of $<ix:nonFraction contextRef="c198" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">71,308</ix:nonFraction>.
As of July 31, 2021, the amount due was $<ix:nonFraction contextRef="c199" decimals="0" format="ixt:numdotdecimal" name="ntrb:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">1,475,631</ix:nonFraction>. The due date for the note has been extended to September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_11" id="_DebtDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Convertible Debt</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_12" id="_DebtDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2019, <ix:nonNumeric contextRef="c116" name="ntrb:NotePayableConvertibleDebtDescription">the Company entered into
a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible promissory
notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise price equal
to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price of the common
stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from this financing
of $250,000.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_13" id="_DebtDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The notes are convertible at a conversion price
equal to <ix:nonNumeric contextRef="c116" name="us-gaap:DebtInstrumentDescription">the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion price,
which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion. The
conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply with
the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the notes
at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which percentage
increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after the closing
of the first to occur of (a) the next public offering of the Company&#8217;s securities or (b) the next private placement of the Company&#8217;s
equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of securities pursuant to
an equity line of credit or (d) a financing with a bank or other institutional lender.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_14" id="_DebtDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The embedded conversion option qualified for derivative
accounting and bifurcation under ASC 815-15 Derivative and Hedging. The initial fair of the conversion feature was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:FairValueOfConversionPrice" scale="0" unitRef="usd">128,870</ix:nonFraction> and the fair
value of the warrants in connection with the notes were valued at $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">888,789</ix:nonFraction> and were recorded based on their relative fair values. A debt
discount to the note payables of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd">270,000</ix:nonFraction> and an initial derivative expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" unitRef="usd">767,650</ix:nonFraction> was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_15" id="_DebtDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The debt discount will be amortized over the life
of the note. Amortization of the debt discount for the six months ended July 31, 2020, was $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">202,500</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_16" id="_DebtDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2020, the Company prepaid the convertible
notes in the principal amount of $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction> from the proceeds of a private placement. The total payments, including a prepayment fee of
$<ix:nonFraction contextRef="c124" decimals="0" format="ixt:numdotdecimal" name="ntrb:PrepaymentFee" scale="0" unitRef="usd">69,131</ix:nonFraction> and accrued interest, was $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="0" unitRef="usd">345,565</ix:nonFraction>. As a result of the payment of the notes, the derivative liability, which was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:numdotdecimal" name="ntrb:DerivativeLiabilitiesTotal" scale="0" unitRef="usd">928,774</ix:nonFraction> as of
January 31, 2020, was reduced to zero. The warrants are no longer a derivative liability based on the notes being paid in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Interest expense for
the six months ended July 31, 2021was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="ntrb:InterestExpenseDebts" scale="0" unitRef="usd">81,888</ix:nonFraction> including the amortization of the debt discount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">73,108</ix:nonFraction> and interest expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">8,780</ix:nonFraction>.
Interest expense for the six months ended July 31, 2020, was $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="ntrb:InterestExpenseDebts" scale="0" unitRef="usd">205,218</ix:nonFraction> including the amortization of debt discount of $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="0" unitRef="usd">202,500</ix:nonFraction> and interest
expense of $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">2,718</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTANGIBLE ASSETS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 31, 2021, and January 31, 2021, intangible
assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>July&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>January&#160;31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">314,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">314,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">License agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Intellectual property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">817,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">817,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,181,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,131,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">189,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">124,770</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">991,821</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">1,006,730</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2021, the Company acquired an IP license
for $<ix:nonFraction contextRef="c202" decimals="0" format="ixt:numdotdecimal" name="ntrb:PaymentForInitialLicenseFee" scale="0" unitRef="usd">50,000</ix:nonFraction>, see Note 10- &#8220;Rambam Agreement&#8221; for further discussion regarding the license agreement. The value of the intangible
assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company
and are being amortized over a period of <ix:nonNumeric contextRef="c175" continuedAt="_amortizedOverPeriod-c175_cont_1" format="ixt-sec:durwordsen" name="ntrb:amortizedOverPeriod">three</ix:nonNumeric> to <ix:nonNumeric contextRef="c176" format="ixt-sec:durwordsen" name="ntrb:amortizedOverPeriod">ten<ix:continuation id="_amortizedOverPeriod-c175_cont_1"> years</ix:continuation></ix:nonNumeric>. Amortization expense for the six months ended July 31, 2021, and 2020 was
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">64,909</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">18,534</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimated Amortization:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0; text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended January 31,</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 89%; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remainder of 2022</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd">64,870</ix:nonFraction></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd">129,776</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2924</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd">129,776</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd">113,109</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 and thereafter</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd">554,290</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">991,821</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RELATED PARTY TRANSACTIONS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had related party notes with its former Chief Financial Officer and Chief Operating Officer. See footnote 5 for further discussion.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisition of Pocono, the Company recorded various transactions and operations through Pocono Coated Products LLC, a related entity. During the six months ended July 31, 2021, the Company was advanced $<ix:nonFraction contextRef="c207" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd">7,862</ix:nonFraction> in finance payments. <ix:nonNumeric contextRef="c207" name="ntrb:RelatedPartyTransactionDescriptionOfTransactions">As of July 31, 2021, the Company owed Pocono $2,634. The Company also issued a note in the amount of $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.</ix:nonNumeric></span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDERS&#8217; EQUITY</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Preferred Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 15, 2016, the board of directors of
the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company
to include and authorize <ix:nonFraction contextRef="c133" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction> shares of Preferred Stock, par value $<ix:nonFraction contextRef="c133" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2019, the board of directors created
a series of preferred stock consisting of <ix:nonFraction contextRef="c134" decimals="INF" format="ixt:numdotdecimal" name="ntrb:DesignatedSharesOfPreferredStocks" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares designated as the Series A Convertible Preferred Stock (&#8220;Series A Preferred
Stock&#8221;). On June 20, 2019, the Series A preferred Stock was terminated, and the <ix:nonFraction contextRef="c134" decimals="INF" format="ixt:numdotdecimal" name="ntrb:SharesWereRestored" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares were restored to the status of
authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part
of a particular series by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2019, the Company effected a one-for
four reverse stock splits, pursuant to which each share of common stock became converted into <ix:nonFraction contextRef="c208" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">0.25</ix:nonFraction> shares of common stock, and the Company
decreased its authorized common stock from <ix:nonFraction contextRef="c209" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">100,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c210" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">25,000,000</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2020, the Company amended its articles
of incorporation to increase its authorized common shares from <ix:nonFraction contextRef="c140" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">25,000,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c141" decimals="INF" format="ixt:numdotdecimal" name="ntrb:IncreaseDecreasedInAuthorizedCommonStock" scale="0" unitRef="shares">250,000,000</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Activity during the Six Months Ended July 31,
2020</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 22, 2020, the Company issued in a private
placement <ix:nonFraction contextRef="c142" decimals="INF" format="ixt:numdotdecimal" name="ntrb:PrivatePlacement" scale="0" unitRef="shares">46,828</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:numdotdecimal" name="ntrb:WarrantsToPurchaseOfCommonStockShare" scale="0" unitRef="usdPershares">11</ix:nonFraction> per unit. Each unit consisted of one share of common stock and a warrant to purchase one share
of common stock at an exercise price of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:numdotdecimal" name="ntrb:InvestmentWarrantExercisePrice" scale="0" unitRef="usdPershares">14</ix:nonFraction> per share. The warrants expire April 30, 2023. The Company issued a total of <ix:nonFraction contextRef="c142" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">46,828</ix:nonFraction> shares
of common stock and warrants to purchase <ix:nonFraction contextRef="c142" decimals="INF" format="ixt:numdotdecimal" name="ntrb:WarrantsToPurchaseOfCommonStockShares" scale="0" unitRef="shares">46,828</ix:nonFraction> shares of common stock. The Company received proceeds of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">515,108</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c211" name="ntrb:CommonStockOfDescription"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, a minority shareholder who had
previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30,2020, the Company issued <ix:nonFraction contextRef="c212" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">5,000</ix:nonFraction> shares
to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $<ix:nonFraction contextRef="c213" decimals="0" format="ixt:numdotdecimal" name="ntrb:FairValueOfTheCommonStocks" scale="0" unitRef="usd">50,000</ix:nonFraction>, of which
$<ix:nonFraction contextRef="c213" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">38,000</ix:nonFraction> is included in selling and general administrative expenses and $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd">12,000</ix:nonFraction> is included in prepaid expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Activity during the Six Months Ended July 31,
2021</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (&#8220;BPM&#8221;), the Company issued <ix:nonFraction contextRef="c215" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">81,396</ix:nonFraction> shares of common stock to BPM and received proceeds of $<ix:nonFraction contextRef="c215" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">700,000</ix:nonFraction> to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $<ix:nonFraction contextRef="c216" decimals="0" format="ixt:numdotdecimal" name="ntrb:SubscriptionPayable" scale="0" unitRef="usd">60,000</ix:nonFraction> which is included in Stockholders&#8217; Equity as Subscription Payable in the Company&#8217;s consolidated balance sheet as of January 31, 2021. In February 2021, BPM advanced a payment for the Company to Rambam in the amount of $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:numdotdecimal" name="ntrb:PaymentForInitialLicenseFee" scale="0" unitRef="usd">57,000</ix:nonFraction> for the license fee. The balance of the funds of $<ix:nonFraction contextRef="c218" decimals="0" format="ixt:numdotdecimal" name="ntrb:FundReceived" scale="0" unitRef="usd">583,000</ix:nonFraction> was received in February 2021. See footnote 10 for further discussion.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25,2021, the Company issued <ix:nonFraction contextRef="c219" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">5,602</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction contextRef="c219" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">60,000</ix:nonFraction>, for consulting services pursuant to a consultant agreement commencing December 1, 2020. The Company has reflected $<ix:nonFraction contextRef="c220" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd">10,000</ix:nonFraction> representing <ix:nonFraction contextRef="c220" decimals="INF" format="ixt:numdotdecimal" name="ntrb:CommonStockShareSubscribedButUnissuedSubscriptionsShares" scale="0" unitRef="shares">934</ix:nonFraction> shares as Subscription Payable in the Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2021, the Company issued <ix:nonFraction contextRef="c221" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">12,500</ix:nonFraction>
shares of common stock, valued at $<ix:nonFraction contextRef="c221" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">350,000</ix:nonFraction>, for consulting fees in connection with the Rambam License Agreement discussed in Note 10.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_WarrantsAndOptionsTextBlock-c0_cont_1" escape="true" name="ntrb:WarrantsAndOptionsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANTS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c0_cont_2" id="_WarrantsAndOptionsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the changes in
warrants outstanding and the related price of the shares of the Company&#8217;s common stock issued to non-employees of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c0_cont_3" id="_WarrantsAndOptionsTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Shares</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Exercise<br/> Price</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Remaining<br/> Life</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Intrinsic<br/> Value</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">141,828</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" scale="0" unitRef="usdPershares">11.99</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.16</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">285,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding-period ending July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">141,828</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" scale="0" unitRef="shares">11.99</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne">1.41</ix:nonNumeric> years</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable - period ending July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">141,828</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" scale="0" unitRef="shares">11.99</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.41</ix:nonNumeric> years</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_WarrantsAndOptionsTextBlock-c0_cont_4" id="_WarrantsAndOptionsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes additional information
relating to the warrants outstanding as of July 31, 2021:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_WarrantsAndOptionsTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
    of Exercise Prices</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/>

    Outstanding</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
    Contractual<br/>
 Life&#160;(Years)</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    <br/>
Price for<br/>
 Shares<br/>
 Outstanding</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/>

    Exercisable</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    <br/>
Price for<br/>
 Shares<br/>
 Exercisable</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic<br/>

    Value</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c222" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">11.00</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c222" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationNumberOutstanding" scale="0" unitRef="shares">95,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><ix:nonNumeric contextRef="c223" format="ixt-sec:duryear" name="ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</span></ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c223" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">11.00</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c223" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationNumberExercisable" scale="0" unitRef="shares">95,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c222" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">11.00</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">14.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationNumberOutstanding" scale="0" unitRef="shares">46,828</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">14.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationNumberExercisable" scale="0" unitRef="shares">46,828</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:numdotdecimal" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">14.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMITMENTS AND CONTIGENCIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal Proceedings</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2018, the Company commenced an action
in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar,
Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a
Motion for Prejudgment Writ of Replevin arising from the Company&#8217;s decision to seek to rescind for misrepresentation the agreement
by which the Company acquired advanced Health Brands, Inc. for <ix:nonFraction contextRef="c164" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">1,250,000</ix:nonFraction> shares of common stock valued at $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">2,500,000</ix:nonFraction> and seek return of
the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants.
Defendants Kalmar, Murphy, Polly-Murphy, and Baker filed a Motion to Dismiss the Company&#8217;s Verified Complaint, Motion to Dissolve
Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court
dismissed the Company&#8217;s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the six patents
never duly transferred to the Company. On February 1, 2019, the Company appealed the court&#8217;s order. Pursuant to a settlement agreement
with one of the defendants, that defendant returned the <ix:nonFraction contextRef="c165" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" unitRef="shares">50,000</ix:nonFraction> shares which had been issued to her, and the shares were cancelled as of
January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom the Company has a settlement agreement), filed
a motion for sanctions and civil contempt against us, which generally claimed that we failed to comply with the Court&#8217;s January
4, 2019, order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer their shares of common stock. On
October 29, 2019, the Court denied the Defendants motion. On March 20, 2020, the Florida district court of appeal reversed the lower court
ruling in the Florida state court action that dismissed our complaint, with prejudice, and gave us leave to file an amended complaint.
On July 7, 2020, Defendants filed Notice for Trial, requesting the court to set a trial date. The Company and defendants have served their
first set of interrogatories on each other and have filed answers and responses to each other&#8217;s first set of interrogatories.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 22, 2018, four of the defendants in
the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of Common
Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement.
The parties have agreed to a stay pending the outcome of the Florida litigation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2019, the Company filed a securities
fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy,
Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently and deceitfully
obtained <ix:nonFraction contextRef="c166" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">1,250,000</ix:nonFraction> shares of common stock by orchestrating a months-long scheme to defraud the Company. The Company is seeking the return
of the shares of common stock and monetary damages resulting from the defendants&#8217; fraudulent conduct. The defendants filed a motion
to dismiss the complaint on August 23, 2019, and on September 13, 2019, the Company filed its response. On July 20, 2020, the Court denied
the defendant&#8217;s motion to dismiss the complaint, and the parties have recently commenced the discovery phase of the litigation.
The Court has scheduled a trial date in November 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employment Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a three-year employment
agreement with Gareth Sheridan, our CEO, effective April 25, 2019. The agreement also provides that the executive will continue as a director.
The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2024, and continuing
on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#8217; notice given prior to the expiration
of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Sheridan receives
an annual salary $<ix:nonFraction contextRef="c224" decimals="0" format="ixt:numdotdecimal" name="ntrb:SalaryPayment" scale="0" unitRef="usd">42,000</ix:nonFraction> per annum, commencing on the effective date of the agreement and increasing to $<ix:nonFraction contextRef="c225" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd">170,000</ix:nonFraction> per annum in the month
in which the Company shall have received not less than $<ix:nonFraction contextRef="c226" decimals="0" format="ixt:numdotdecimal" name="ntrb:PublicOrPrivateFinancing" scale="0" unitRef="usd">2,500,000</ix:nonFraction> from one or more public or private financings of the Company&#8217;s
equity securities subsequent to the date of the agreement. During the year ended January 31, 2021, the salary was increased to $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd">60,000</ix:nonFraction>
per annum.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rambam Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2020, the Company entered into
a License Agreement (the &#8220;License Agreement&#8221;) with Rambam Med-Tech Ltd. (&#8220;Rambam&#8221;), Haifa, Israel, to develop
the RAMBAM Closed System Transfer Device (&#8220;CTSD&#8221;) and such other products as the parties agree to develop/commercialize. The
Company will license from Rambam the full technology, IP, and title to CTSD in the field, with an Initial license fee of $<ix:nonFraction contextRef="c169" decimals="0" format="ixt:numdotdecimal" name="ntrb:PaymentForInitialLicenseFee" scale="0" unitRef="usd">50,000</ix:nonFraction> and running
royalties on net sales. The $<ix:nonFraction contextRef="c218" decimals="0" format="ixt:numdotdecimal" name="ntrb:PaymentForInitialLicenseFee" scale="0" unitRef="usd">50,000</ix:nonFraction> license fee was paid by a third party at the direction of the Company in February 2021, at which time
the agreement became effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had entered into a prior agreement,
dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#8220;BPM&#8221;), that, in consideration of BPM&#8217;s introduction of
Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#8217;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>BPM Distribution and Stock Purchase Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 10, 2021, the Company finalized the Distribution Agreement with BPM, providing for distribution of the medical products developed and produced under the License Agreement. Under the Distribution Agreement, BPM&#160;has the right to distribute the medical products in Israel and has a right of first refusal in relation to all other countries/states, other than United States, Korea, China, Vietnam, Canada and Ecuador, which are termed excluded countries.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c227" name="us-gaap:SignificantPurchaseCommitmentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and BPM entered into a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.</span></ix:nonNumeric></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUBSEQUENT EVENTS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2020, the Company entered into a
Purchase Agreement (&#8220;Agreement&#8221;), with Pocono Coated Products (&#8220;PCP&#8221;), pursuant to which PCP agreed to sell the
Company all of the assets associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the &#8220;Assets&#8221;). PCP
is the manufacturer of our transdermal products, and we bought that business from them. The purchase price for the Assets was <ix:nonNumeric contextRef="c99" name="us-gaap:SubsequentEventDescription">(i) $6,000,000
paid in shares of the Company&#8217;s common stock at a value of the average price of the previous 90 days at the date of Closing (the
&#8220;Shares&#8221;); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a)
twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of
no less than $4,000,000.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2021 we entered into an amendment
to the Agreement with the parties to the Agreement that provides for an extension of the August 31, 2021 due date of the $<ix:nonFraction contextRef="c99" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" scale="0" unitRef="shares">1,500,000</ix:nonFraction> note
issued in the transaction to September 30, 2021, and extends the time limit set forth in Section 5.3(a) of the Agreement for completion
of the Listing and for payment of the Note in full until September 30, 2021.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.<sup>(1)</sup></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"> Nature of Expense: </td><td style="font-weight: bold; padding-bottom: 1.5pt"> &#160; </td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount </td><td style="padding-bottom: 1.5pt; font-weight: bold"> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"> SEC Registration Fee </td><td style="width: 1%"> &#160; </td>
    <td style="width: 1%; text-align: left"> $ </td><td style="width: 9%; text-align: right"> 1,538.19 </td><td style="width: 1%; text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"> NASDAQ initial listing fee </td><td> &#160; </td>
    <td style="text-align: left"> &#160; </td><td style="text-align: right"> 50,000.00 </td><td style="text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> FINRA filing fee </td><td> &#160; </td>
    <td style="text-align: left"> &#160; </td><td style="text-align: right"> 2,614.83 </td><td style="text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"> Accounting fees and expenses </td><td> &#160; </td>
    <td style="text-align: left"> &#160; </td><td style="text-align: right"> 6,400.00 </td><td style="text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> Legal fees and expenses </td><td> &#160; </td>
    <td style="text-align: left"> &#160; </td><td style="text-align: right"> 12,500.00 </td><td style="text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; ">
    <td> Printing </td><td> &#160; </td>
    <td style="text-align: left"> &#160; </td><td style="text-align: right"> 3,000.00 </td><td style="text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> Transfer Agent and Warrant Agent expenses </td><td> &#160; </td>
    <td style="text-align: left"> &#160; </td><td style="text-align: right"> 3,500.00 </td><td style="text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"> Miscellaneous </td><td style="padding-bottom: 1.5pt"> &#160; </td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"> &#160; </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> 2,946.98 </td><td style="padding-bottom: 1.5pt; text-align: left"> &#160; </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"> Total </td><td style="padding-bottom: 4pt"> &#160; </td>
    <td style="border-bottom: Black 4pt double; text-align: left"> $ </td><td style="border-bottom: Black 4pt double; text-align: right"> 76,000.00 </td><td style="padding-bottom: 4pt; text-align: left"> &#160; </td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All expenses, except the SEC registration fee, the NASDAQ initial listing fee and the FINRA filing fee are estimated.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14.&#160;INDEMNIFICATION OF DIRECTORS
AND OFFICERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nevada Revised Statutes 78.7502 and 78.751 provide
broad authority for the indemnification of directors, officers and certain other persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.7502 of the Nevada Revised Statutes
permits a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of
the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving
at the request of the corporation as a director, officer, employee or agent of another corporation, partnership joint venture, trust or
other enterprise, against expenses, including attorneys&#8217; fees, judgments, fines and amounts paid in settlement actually and reasonably
incurred by him in connection with the action, suit or proceeding if he:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is not liable pursuant to Nevada Revised Statute 78.138, or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Section 78.7502 permits a corporation
to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and
attorneys&#8217; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is not liability pursuant to Nevada Revised Statute 78.138; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;	</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that a director, officer, employee
or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to above,
or in defense of any claim, issue or matter, the corporation is required to indemnify him against expenses, including attorneys&#8217;
fees, actually and reasonably incurred by him in connection with the defense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 117; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.751 of the Nevada Revised Statutes
provides that such indemnification may also include payment by the Company of expenses incurred in defending a civil or criminal action
or proceeding in advance of the final disposition of such action or proceeding upon receipt of an undertaking by the person indemnified
to repay such payment if he shall be ultimately found not to be entitled to indemnification under Section 78.751. Indemnification may
be provided even though the person to be indemnified is no longer a director, officer, employee or agent of the Company or such other
entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.752 of the Nevada Revised Statutes
allows a corporation to purchase and maintain insurance or make other financial arrangements on behalf of any person who is or was a director,
officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him and liability
and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising out of his status as such, whether
or not the corporation has the authority to indemnify him against such liability and expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other financial arrangements made by the corporation
pursuant to Section 78.752 may include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the creation of a trust fund;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the establishment of a program of self-insurance;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the securing of its obligations of indemnification by granting a security interest or other lien on any assets of the corporation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the establishment of a letter of credit, guaranty or surety.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No financial arrangement made pursuant to Section
78.752 may provide protection for a person adjudged by a court of competent jurisdiction, after exhaustion of all appeals, to be liable
for intentional misconduct, fraud or a knowing violation of law, except with respect to the advancement of expenses of indemnification
ordered by a court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any discretionary indemnification pursuant to
Section 78.7502 of the Nevada Revised Statutes, unless ordered by a court or advanced pursuant to an undertaking to repay the amount if
it is determined by a court that the indemnified party is not entitled to be indemnified by the corporation, may be made by the corporation
only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper
in the circumstances. The determination must be made:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by the stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by the board of directors by a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion, or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsection 7 of Section 78.138 of the Nevada Revised
Statutes provides that, subject to certain very limited statutory exceptions, a director or officer is not individually liable to the
corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director
or officer, unless it is proven that the act or failure to act constituted a breach of his or her fiduciary duties as a director or officer
and such breach of those duties involved intentional misconduct, fraud or a knowing violation of law. The statutory standard of liability
established by Section 78.138 controls even if there is a provision in the corporation&#8217;s articles of incorporation unless a provision
in the corporation&#8217;s articles of incorporation provides for greater individual liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 118 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws provide that each person who was or
is made a party or is threatened to be made a party to or is involved (including, without limitation, as a witness) in any threatened,
pending, or completed action, suit or proceeding, whether formal or informal, civil, criminal, administrative or investigative (hereinafter
a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director of or who is or was serving at our request as a
director, officer, employee or agent of this or another corporation or of a partnership, joint venture, trust, other enterprise, or employee
benefit plan (a &#8220;covered person&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a covered
person shall be indemnified and held harmless by us to the fullest extent permitted by applicable law, as then in effect, against all
expense, liability and loss (including attorneys&#8217; fees, costs, judgments, fines, ERISA excise taxes or penalties and amounts to
be paid in settlement) reasonably incurred or suffered by such person in connection therewith, and such indemnification shall continue
as to a person who ceased to be a covered person and shall inure to the benefit of his or her heirs, executors and administrators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, no indemnification shall be provided
hereunder to any covered person to the extent that such indemnification would be prohibited by Nevada state law or other applicable law
as then in effect, nor, with respect to proceedings seeking to enforce rights to indemnification, shall we indemnify any covered person
seeking indemnification in connection with a proceeding (or part thereof) initiated by such person except where such proceeding (or part
thereof) was authorized by our board of directors, nor shall we indemnify any covered person who shall be adjudged in any action, suit
or proceeding for which indemnification is sought, to be liable for any negligence or intentional misconduct in the performance of a duty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors may cause us to purchase and maintain
insurance for the benefit of a person who is or was serving as a director, officer, employee or agent of us or of a corporation of which
we are or were a stockholder and his heirs or personal representatives against a liability incurred by him as a director, officer, employee
or agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions,
or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the organization of the Company in January 2016, on January 15, 2016, the Company issued 625,000 shares of common stock, valued at $13,094, to Gareth Sheridan in exchange for all of the issued and outstanding capital stock of Nutriband, Ltd., an Irish corporation. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also in connection with the organization of the Company, on January 16, 2016, the Company issued 4,843,750 shares of common stock at $0.001 per share to the following persons:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Gareth Sheridan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,875,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Serguei Melnik</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Vitali Botgrox</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Radim Kohot</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">218,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Victor Orindes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Simon McDonald</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,843,750</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The issuance of these shares was exempt
from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering. On November
30, 2016, Mr. Sheridan transferred 1,750,000 shares of common stock to the Company and such shares were cancelled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 119 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the Company issued to Nociota Holdings Limited, for $100,000, 125,000 shares of common stock and a warrant to purchase 125,000 shares of common stock at $2.80 per share. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June and July 2017, the Company issued for $40,000, 20,000 shares of common stock and three-year warrants to purchase 20,000 shares of common stock at $14.00 per share to Marc Angle, Jimmy Poirier, Jacques Poirier and George Pryor, each of whom purchased, for $10,000, (i) 5,000 shares of common stock and (ii) warrants to purchase 5,000 shares of common stock. The issuance of these shares and warrants was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2017, the Company we issued 25,000 shares to the Goldberg Law Firm for legal services. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2017, the Company issued a total of 1,250,000 shares of common stock to the stockholders of Advanced Health Brands, Inc. The shares were issued to the following former stockholders of Advanced Health Brands, Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">7.</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Ray Kalmar</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">525,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Paul Murphy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">525,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Michelle Poly Murphy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Laura Fillman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">John Baker</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The issuance of the shares was exempt
from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering. In connection
with litigation that the Company commenced seeking rescission of the acquisition agreement relating to Advanced Health Brands, Inc., pursuant
to a settlement agreement, Laura Fillman returned to us the 50,000 shares that we had issued to her pursuant to the acquisition agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 30, 2017, the Company sold 2,500 shares of common stock to the following purchasers at a purchase price of $4.00 per share:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Purchase Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Eric Williams</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Christopher Sims</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Kevin Kostenborder and Jenna Kostenborder</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The issuance of these shares was exempt
from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 120 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2018, the Company issued 25,000 shares of common stock to the following persons for services rendered.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Relationship</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left; text-indent: -9pt; padding-left: 9pt">IR Consulting Services LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">Investor&#160;relations</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Kazushige Okaniskhi and Phan Thi Okanishi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Consultant</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Jason Sakasci</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">Consultant</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 2, 2018, the Company sold to Barandnic Holdings Ltd. for $1.0 million, 62,500 shares stock and 30-day warrants to purchase 62,500 shares of common stock at $16.00 per share. On May 27, 2018, Barandnic Holdings Ltd. exercised warrants to purchase 31,250 shares of common stock and on June 2, 2018, warrants to purchase 31,250 shares of common stock expired unexercised. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as a transaction not involving a public offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended January 31, 2019, the Company issued 73,000 shares of common stock to executive officers and consultants as compensation. The following table sets forth the number of shares and the value of the shares, based on the market price at the date of issuance, of common stock issued to our executive officers and consultants:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; width: 41%">Sean Gallagher</td><td style="width: 1%">&#160;</td>
    <td style="width: 34%; text-align: left">Executive Chairman</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">402,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Larry Dillaha, MD</td><td>&#160;</td>
    <td style="text-align: left">Chief medical officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gerard Goodman</td><td>&#160;</td>
    <td style="text-align: left">Chief accounting officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Patrick, Pharm.D.<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">Chief scientific officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Patrick Ryan</td><td>&#160;</td>
    <td style="text-align: left">Chief technical officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Srinivas Nalamachu, MD</td><td>&#160;</td>
    <td style="text-align: left">Member, scientific advisory board</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Red Chip Companies</td><td>&#160;</td>
    <td style="text-align: left">Investor relations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,650</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trigger Movement Ltd.<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">Consultant</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,541,658</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issuable to Jeff Patrick were issued to Strategic Pharmaceutical Consulting LLC. Dr. Patrick has the sole right to vote and dispose of the shares owned by Strategic Pharmaceutical Consulting LLC.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The issuance of these shares was exempt
from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving a public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2018, the Company issued 62,500 shares of common stock to Steve Damon (41,750 shares) and Dr. Alan Smith (20,750 shares) as part of the purchase price for 4P Therapeutics. The issuance of these shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving a public offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2018, the Company issued 1,250 shares of common stock, valued at $37,000, based on the market price on the date of issuance, as compensation to each of the Company&#8217;s independent directors &#8212; Thomas Cooney, Michael Davidov, Michael Doron, Mark Hamilton, Stefan Mancas and Woody Jay Moore. The issuance of these shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving a public offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 23, 2018, the Company sold to TII Jetservices Lda., a Portuguese company, 17,857 shares of common stock for $500,000. The issuance of the shares was exempt from registration pursuant to Regulation S of the Securities and Exchange Commission pursuant to the Securities Act of 1933.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">No Underwriter was involved in any
of these issuances and the certificates for the shares bear a restricted stock legend.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 121 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 30, 2019, the Company entered into a securities purchase agreement dated October 29, 2019, with Jefferson Street Capital LLC and Platinum Point Capital LLC pursuant to which the Company issued to each investor for $125,000 (i) a 6% one-year convertible note in the principal amount of $135,000 and (ii) a three-year warrant to purchase 25,000 shares of common stock. The issuance of the notes and warrants was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving a public offering. In connection with the sale of the notes and warrants, the Company paid an investment banking fee to WallachBeth Capital, LLC of $28,500.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2020, we issued 8,572 shares of common stock to each of Sean Gallagher, president and a director, and Strategic Pharmaceutical Consulting LLC, which is controlled by Jeff Patrick, chief scientific officer, pursuant employment agreements with Mr. Gallagher and Dr. Patrick. The employment agreements provide that each of Mr. Gallagher and Dr. Patrick receive annual compensation of $60,000, which may be paid in cash or stock. The shares were issued as compensation of $120,000 for the years ended January 31, 2020 and 2019. The shares were exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On&#160;October 1, 2020, in connection with the Company&#8217;s acquisition of Pocono Coated Products, LLC (&#8220;Pocono&#8221;), that was effective August 31, 2020, the Company issued&#160;608,519 shares of its common stock to the owners of Pocono.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2021, the Company issued the following numbers of shares common stock to Company officers and members of its Board of Directors. All stock issuances were valued by the Board at $15.00 per share.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2020, the Company entered into a License Agreement (the &#8220;License Agreement&#8221;) with Rambam Med-Tech Ltd., Haifa, Israel (&#8220;RamBam&#8221;), for us to develop the RAMBAM Closed System Transfer Device (CSTD) the (&#8220;Medical Products&#8221;).&#160; As a part of the transaction with RamBam for the License Agreement, on March 10, 2021, the Company finalized a Distribution Agreement (&#8220;Distribution Agreement&#8221;)_with BPM Inno Ltd., Kiryat, Israel (&#8220;BPM&#8221;), providing for distribution of the Medical Products developed and produced under the License Agreement and a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000.&#160; The investment by BPM in our common stock under the SPA was completed on February 26, 2021.&#160;.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Gareth Sheridan, CEO and Director</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sean Gallagher, Executive Chairman and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Serguei Melnik, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Michael Myer, President of Pocono Pharma and Director(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Radu Bujoreanu, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Steven P. Damon, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Michael Doron, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Mark Hamilton, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stefan Mancas, Dlirector</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Vsevolod Grogore, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Patrick Ryan, Chief Technical Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gerald Goodman, Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Alan Smith, Chief Operating Officer and President of 4P Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,825</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Vitalie Botgros, Consultant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Thomas Cooney, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Jay Moore, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Mr. Myer owns 188,641 shares of common stock, of which 5,000 were issued
on January 5, 2021, and 188,641 shares that he has the right to receive from the August 31, 2021 acquisition of Pocono Coated Products,
LLC, as a distribution from escrow terminating September 30, 2021, of certain distributions under the acquisition agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuances to directors and management and
consultants are viewed by the Company as exempt from registration under the Securities Act, alternatively as transactions either not involving
any public offering, or as exempt under the provisions of Regulation D, Regulation S or Rule 701 promulgated by the SEC under the Securities
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 122 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16. Exhibits.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exhibit <br/> Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Description</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">1.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="ea148206ex1-1_nutriband.htm">Form of Underwriting Agreement, filed herewith.</a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; width: 9%; text-align: center">3.1A</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#160;</td>
    <td style="width: 89%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex3ia_nutriband.htm">Articles of Incorporation. (Filed as Exhibit 3.1A to the the Company&#8217;s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.)</a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">3.1B</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex3ib_nutriband.htm">Amendment to Articles of Incorporation, filed May 12, 2016. 2(Filed as Exhibit 3.1B to the the Company&#8217;s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.)</a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">3.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020001906/f8k012120ex3-1_nutribandinc.htm">Certificate of Amendment filed January 22, 2020. (Filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed January 27, 2020).</a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">3.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex3ii_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By-laws<sup>(1)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">4.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-1_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital&#160;LLC and Platinum Point Capital LLC<sup>(6)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">4.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-2_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of convertible 6% promissory note issued pursuant to Exhibit 4.3<sup>(6)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">4.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-3_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC<sup>(6)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">4.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="ea148206ex4-12_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Form of Warrant, filed herewith.</span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">4.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="ea148206ex4-13_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Form of Warrant Agent Agreement, filed herewith.</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">5.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="ea148206ex5-1_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Opinion of Counsel, filed herewith.</span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex10i_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and/or his nominee<sup>(1)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390018004227/f8k041018ex99-2_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition agreement dated April 5, 2018 between the Company and 4P Therepeutics LLC.<sup>(3)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390019006792/f10k2019ex10-4_nutribandinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of agreement with independent directors.<sup>(4)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390019006792/f10k2019ex10-5_nutribandinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea (Best&#160;Choice), Inc.<sup>(4)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-15_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company.<sup>(5)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-16_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company.<sup>(5)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-17_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company.<sup>(5)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-18_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company.<sup>(5)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020025377/ea126478ex10-19_nutribandinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC.<sup>(7)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020025377/ea126478ex10-20_nutribandinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Agreement, between the Company and Pocono Coated Products, LLC.<sup>(7)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390020025377/ea126478ex10-21_nutribandinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC.<sup>(7)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390021014753/ea137408ex10-22_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd.<sup>(8)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390021014753/ea137408ex10-23_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd.<sup>(8)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390021014753/ea137408ex10-24_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd.<sup>(8)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">10.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390021046170/ea146824ex10-25_nutriband.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC<sup>(8a)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ea148206ex23_nutriband.htm">Consent of Sadler, Gibb&#160;&amp; Associates, LLC, filed herewith</a>.</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: center">99.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390019006792/f10k2019ex99-1_nutribandinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Charter<sup>(4)</sup></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">99.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1676047/000121390019006792/f10k2019ex99-2_nutribandinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Committee Charter<sup>(4)</sup></span></a></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as exhibit to the Company&#8217;s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s report on Form 8-K, which was filed with the Commission on May 23, 2017 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s report on Form 8-K, which was filed with the Commission on November 4, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s report on form 8-K, which was filed with the Commission on September 4, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s report on Form 8-K, which was filed with the Commission on March 11, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to the Company&#8217;s report on Form 8-K, which was filed with the Commission on September 1, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by Amendment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 123 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(b) Financial Statement Schedules</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All schedules have been omitted because either
they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 17. Undertakings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) To file, during any period in which offers
or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by Section
10(a)(3) of the Securities Act of 1933; (ii) To reflect in the prospectus any facts or events arising after the effective date of the
registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from
the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; (iii) To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement; <i>provided, however</i>, that paragraphs (1)(i), (ii), and (iii) of
this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange
Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering
thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) To remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) That, for the purpose of determining liability
under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall
be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; <i>provided, however,</i>
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated
or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first
use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) That, for purposes of determining any liability
under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section
15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Act and will be governed by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 124 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized in the City of Orlando, State of Florida on&#160;October 1, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">NUTRIBAND INC. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 62%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">By: </span></td>
    <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Gareth Sheridan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Gareth Sheridan </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">By: </span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/ Gerald
    Goodman</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Gerald Goodman</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Financial Officer (Principal Financial and
    Accounting Officer) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Signature</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td>
    <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Title</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Gareth Sheridan</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Executive Officer
    and Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">October 1, 2021</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Gareth Sheridan</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/ Serguei
    Melnik</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">October 1, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Serguei Melnik</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/ Sean
    Gallagher</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Executive Chairman and
    Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">October 1, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Sean Gallagher</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Michael Myer</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">President of Pocono
    Pharma and Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Michael Myer</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Radu Bujoreanu</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Radu Bujoreanu</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Steven P. Samon</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Steven P. Damon</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Vsevolod Grigore</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Vsevolod Grigore</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Mark Hamilton</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Mark Hamilton</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/
    Stefan Mancas</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Director</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 1, 2021</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Stefan Mancas</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-9</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-1/A</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-2" name="us-gaap:PrepaidExpenseCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-4" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="us-gaap:DeferredRevenueCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-8" name="us-gaap:ConvertibleDebtCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-9" name="us-gaap:LongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-10" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-11" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-12" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-13" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-14" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" decimals="3" id="hidden-fact-15" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="3" id="hidden-fact-16" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c1" decimals="3" id="hidden-fact-17" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="3" id="hidden-fact-18" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="3" id="hidden-fact-19" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c1" decimals="3" id="hidden-fact-20" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="3" id="hidden-fact-21" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c1" decimals="3" id="hidden-fact-22" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-23" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-24" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-25" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-26" name="ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-27" name="ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-28" name="ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-29" name="ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-33" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-34" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-35" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-36" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-37" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-39" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-40" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-41" name="ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-42" name="ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-43" name="ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-45" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-46" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-50" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-51" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-52" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-53" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-54" name="ntrb:IssuanceOfCommonStockForNotePayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-55" name="ntrb:IssuanceOfCommonStockForNotePayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-56" name="ntrb:IssuanceOfCommonStockForNotePayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-57" name="ntrb:SubscrptionPayableForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-58" name="ntrb:SubscrptionPayableForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-59" name="ntrb:SubscrptionPayableForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-60" name="ntrb:SubscrptionPayableForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-61" name="ntrb:SubscrptionPayableForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-62" name="ntrb:SubscrptionPayableForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-63" name="ntrb:SubscrptionPayableForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-64" name="ntrb:SubscrptionPayableForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-65" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-66" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-67" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-68" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-69" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-70" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-71" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-72" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-73" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-74" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-75" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-76" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-77" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-78" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-82" name="ntrb:SaleofCommonstockForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-83" name="ntrb:SaleofCommonstockForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-84" name="ntrb:SaleofCommonstockForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-85" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-86" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-87" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-88" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-89" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-90" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-91" name="ntrb:ReclassificationOfWarrantsFromLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-92" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-93" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-94" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-95" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-96" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-97" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-98" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-99" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-100" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-101" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-102" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-103" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-104" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-105" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-106" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-107" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-108" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-109" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-110" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-111" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-112" name="ntrb:IncreaseDecreaseInDerivativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-113" name="ntrb:EarlyPrepaymentFeeOnConvertibleDebentures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-114" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-115" name="ntrb:GainOnForgivenessOfLoanPayment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-116" name="ntrb:SubscriptionPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-117" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-118" name="us-gaap:CashAcquiredFromAcquisition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-119" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-120" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-121" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-122" name="us-gaap:ProceedsFromOtherEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-123" name="us-gaap:RepaymentsOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-124" name="us-gaap:RepaymentsOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-125" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-126" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-127" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-128" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-129" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-130" name="ntrb:CommonStockAndNoteIssuedInAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-131" name="ntrb:AdoptionOfASC842OperatingLeaseAssetAndLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-132" name="ntrb:DerivativeLiabilityWarrantReclassedToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-133" name="ntrb:DebtDiscountOnConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-134" name="ntrb:CommonStockIssuedForAccountsPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-135" name="ntrb:CommonStockIssuedForSettlement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-136" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-137" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-138" name="ntrb:EarlyPrepaymentFeeOnConvertibleDebentures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-139" name="us-gaap:AmortizationOfLeasedAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-140" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-141" name="ntrb:IncreaseDecreaseOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-142" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-143" name="us-gaap:ProceedsFromNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-144" name="us-gaap:RepaymentsOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-145" name="us-gaap:RepaymentsOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-146" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-147" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-148" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-149" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-150" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-151" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-152" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-153" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-154" name="ntrb:CommonStockIssuedForSettlementOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-155" name="ntrb:NoncashPaymentForLicenseAgreement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-156" name="ntrb:DerivativeLiabilityWarrantReclassedToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-157" name="ntrb:CommonIssuedForSubscriptionPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-158" name="ntrb:PropertyPlantAndEquipmentsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-159" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-160" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-161" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-162" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-163" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-164" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-165" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-166" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-167" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-168" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-169" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-170" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-171" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-172" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-173" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-174" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c127" id="hidden-fact-175" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-176" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-177" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-178" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-179" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-180" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c157" id="hidden-fact-181" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-182" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-183" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-184" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-185" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-186" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-187" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c162" id="hidden-fact-188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c163" id="hidden-fact-189" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c162" id="hidden-fact-190" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c163" id="hidden-fact-191" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c163" id="hidden-fact-192" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-193" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-194" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c163" id="hidden-fact-195" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c163" id="hidden-fact-196" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-197" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c163" id="hidden-fact-199" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c161" id="hidden-fact-200" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-201" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-202" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c163" id="hidden-fact-203" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c161" id="hidden-fact-204" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-205" name="ntrb:SaleOfGoodsAndServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c181" id="hidden-fact-206" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c205" id="hidden-fact-207" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-208" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-209" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-210" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-211" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-212" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-213" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-214" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-215" name="ntrb:StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-216" name="ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-217" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-218" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-219" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-220" name="ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001676047</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="ntrb-20210731.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:TherapeuticsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-25</xbrli:startDate>
    <xbrli:endDate>2018-08-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:ThreeCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:TwoCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:OneCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:TwoCustomerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:TwoCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:BusinessCombinationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:BusinessCombinationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZzjdoIf697x9Ebb9RR62VzZ2moDN98hKYJqt0nOEvOJM3ovM/SXTjMP1Ald7slk0jhpkvJNEcZ22oENEU/pa+RGktyuYgAZpSzCvQD/cHd+rIAFOf0qxA58sbmcPw9UpSPh+OrTDXTmJ7VYjFEDe+x4Kv3wGjJ2krmmyw+NNN8s2/eDBLLdYlV6o0gz0biWHw=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-01</xbrli:startDate>
    <xbrli:endDate>2017-12-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-02</xbrli:startDate>
    <xbrli:endDate>2020-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-02</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-02</xbrli:startDate>
    <xbrli:endDate>2020-03-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2019-10-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-06</xbrli:startDate>
    <xbrli:endDate>2020-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">ntrb:RevaluedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-02</xbrli:startDate>
    <xbrli:endDate>2019-02-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:PoconoCoatedProductsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ntrb:FormerIndependentDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-01-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-02</xbrli:startDate>
    <xbrli:endDate>2019-05-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-07</xbrli:startDate>
    <xbrli:endDate>2019-06-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-07</xbrli:startDate>
    <xbrli:endDate>2019-06-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-17</xbrli:startDate>
    <xbrli:endDate>2020-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-17</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:PoconoCoatedProductsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:BPMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:BPMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2018-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ntrb:DefendantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:HealthsBrandsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-05</xbrli:startDate>
    <xbrli:endDate>2020-12-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ntrb:StockPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:ActiveIntelligenceLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-15</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-02</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:RelatedPartyPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:RelatedPartyPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:RelatedPartyPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-14</xbrli:startDate>
    <xbrli:endDate>2021-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:LicensingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:PoconoCoatedProductsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-17</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-17</xbrli:startDate>
    <xbrli:endDate>2020-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:BPMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:BPMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:BPMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676047</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ntrb:StockPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea148206ex1-1_nutriband.htm
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NUTRIBAND, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[*] Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consisting of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[*] Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>And</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[*] Warrants to Purchase [*] Shares of Common
Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[*], 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WallachBeth Capital, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Harborside Financial Plaza 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">185 Hudson St., Suite 1410</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jersey City, NJ 07311</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>As Representative of the </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><I>Several Underwriters Named on Schedule
I hereto</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NUTRIBAND, INC., a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), proposes, subject to the terms and conditions stated herein, to issue and sell to the
underwriters named in <B>Schedule I</B> hereto (the &ldquo;<U>Underwriters</U>,&rdquo; or each, an &ldquo;<U>Underwriter</U>&rdquo;),
for whom WallachBeth Capital, LLC is acting as representative (the &ldquo;<U>Representative</U>&rdquo;), an aggregate of [__] Units (the
&ldquo;<U>Firm Units</U>&rdquo;), each Firm Unit consisting of one share of the Company&rsquo;s common stock, $0.001 par value per share
(the &ldquo;<U>Common Stock</U>&rdquo;) and one warrant to purchase one share of Common Stock (the &ldquo;<U>Warrants</U>&rdquo; and each
a &ldquo;<U>Warrant</U>&rdquo;). The [__] shares of Common Stock referred to in this Section are hereinafter referred to as the &ldquo;<U>Firm
Shares</U>&rdquo; and the Warrants referred to in this Section are hereinafter referred to as the &ldquo;<U>Firm Warrants</U>,&rdquo;
and together with the Firm Units and the Firm Shares, the &ldquo;<U>Firm Securities</U>.&rdquo; The Firm Warrants shall be issued pursuant
to, and shall have the rights and privileges set forth in, a warrant agent agreement, dated on or before the Closing Date, between the
Company and Computershare, as warrant agent (the &ldquo;<U>Warrant Agreement</U>&rdquo;). The Company also proposes to sell to the Underwriters,
upon the terms and conditions set forth in Section 4 hereof, an option (the &ldquo;<U>Over-allotment Option</U>&rdquo;) to purchase up
to an additional [*] shares of Common Stock, representing up to fifteen percent (15%) of the Firm Shares sold in the offering (the &ldquo;<U>Option
Shares</U>&rdquo;), and/or [*] Warrants to purchase an additional [*] shares of Common Stock, representing up to 15% of the Firm Warrants
sold in the Offering (as defined below) (the &ldquo;<U>Option Warrants</U>&rdquo;), in each case for the purpose of covering over-allotments
of such securities, if any. The Over-allotment Option is, at the Underwriters&rsquo; sole discretion, for Option Shares and Option Warrants
together, solely Option Shares, solely Option Warrants, or any combination thereof (each, an &ldquo;<U>Option Security</U>&rdquo; and
collectively, the &ldquo;<U>Option Securities</U>&rdquo;). The Firm Securities and the Option Securities are collectively referred to
as the &ldquo;<U>Securities</U>.&rdquo; The Securities shall be issued directly by the Company and shall have the rights and privileges
described in the Registration Statement, the Pricing Prospectus and the Prospectus (as defined below). The offering and sale of the Securities
is herein referred to as the &ldquo;<U>Offering</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the several
Underwriters hereby confirm their agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>1. Registration Statement
and Prospectus</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has prepared and
filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) a registration statement covering the Securities
and Representative&rsquo;s Securities (as defined in Section 4(f) hereof) on Form S-1 (File No. 333- 259833) under the Securities Act
of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), and the rules and regulations (the &ldquo;<U>Rules and Regulations</U>&rdquo;)
of the Commission thereunder, including a preliminary prospectus relating to the Securities and such amendments to such registration statement
(including post effective amendments) as may have been required to the date of this Agreement. Such registration statement, as amended
(including any post effective amendments), has been declared effective by the Commission. Such registration statement, including amendments
thereto (including post effective amendments thereto) and all documents and information deemed to be a part of the Registration Statement
through incorporation by reference or otherwise at the time of effectiveness thereof (the &ldquo;<U>Effective Time</U>&rdquo;), the exhibits
and any schedules thereto at the Effective Time or thereafter during the period of effectiveness and the documents and information otherwise
deemed to be a part thereof or included therein by the Securities Act or otherwise pursuant to the Rules and Regulations at the Effective
Time or thereafter during the period of effectiveness, is herein called the &ldquo;<U>Registration Statement</U>.&rdquo; If the Company
has filed or files an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &ldquo;<U>Rule 462 Registration
Statement</U>&rdquo;), then any reference herein to the term Registration Statement shall include such Rule 462 Registration Statement.
Any preliminary prospectus included in the Registration Statement or filed with the Commission pursuant to Rule 424(a) under the Securities
Act is hereinafter called a &ldquo;<U>Preliminary Prospectus</U>.&rdquo; The Preliminary Prospectus relating to the Securities and Representative&rsquo;s
Securities that was included in the Registration Statement immediately prior to the pricing of the offering contemplated hereby is hereinafter
called the &ldquo;<U>Pricing Prospectus</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is filing with
the Commission pursuant to Rule 424 under the Securities Act a final prospectus covering the Securities, which includes the information
permitted to be omitted therefrom at the Effective Time by Rule 430A under the Securities Act. Such final prospectus, as so filed, is
hereinafter called the &ldquo;<U>Final Prospectus</U>.&rdquo; The Final Prospectus, the Pricing Prospectus and any preliminary prospectus
in the form in which they were included in the Registration Statement or filed with the Commission pursuant to Rule 424 under the Securities
Act is hereinafter called a &ldquo;<U>Prospectus</U>.&rdquo; Reference made herein to any Preliminary Prospectus, the Pricing Prospectus
or to the Prospectus shall be deemed to refer to and include any documents incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>2. Representations and
Warranties of the Company Regarding the Offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company represents and
warrants to, and agrees with, the several Underwriters, as of the date hereof and as of the Closing Date (as defined in Section 4(d) below)
and as of each Option Closing Date (as defined in Section 4(b) below), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) <B>No Material
Misstatements or Omissions</B>. At each time of effectiveness, at the date hereof, at the Closing Date, and at each Option Closing Date,
if any, the Registration Statement and any post-effective amendment thereto complied or will comply in all material respects with the
requirements of the Securities Act and the Rules and Regulations and did not, does not, and will not, as the case may be, contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. The Time of Sale Disclosure Package (as defined below) as of the date hereof and at the Closing Date and on each
Option Closing Date, any roadshow or investor presentations delivered to and approved by the Underwriter for use in connection with the
marketing of the offering of the Securities (the &ldquo;<U>Marketing Materials</U>&rdquo;), if any, and the Final Prospectus, as amended
or supplemented, as of its date, at the time of filing pursuant to Rule 424(b) under the Securities Act, at the Closing Date, and at each
Option Closing Date, if any, did not, does not and will not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The representations and warranties set forth in the two immediately preceding sentences shall not apply to statements
in or omissions from the Registration Statement, the Time of Sale Disclosure Package or any Prospectus in reliance upon, and in conformity
with, written information furnished to the Company by the Underwriter specifically for use in the preparation thereof, which written information
is described in Section 7(f). The Registration Statement contains all exhibits and schedules required to be filed by the Securities Act
or the Rules and Regulations. No order preventing or suspending the effectiveness or use of the Registration Statement or any Prospectus
is in effect and no proceedings for such purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated
or threatened by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii) <B>Marketing
Materials</B>. The Company has not distributed any prospectus or other offering material in connection with the offering and sale of the
Securities other than the Time of Sale Disclosure Package and the roadshow or investor presentations delivered to and approved by the
Representative for use in connection with the marketing of the offering of the Securities (the &ldquo;<U>Marketing Materials</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii) <B>Accurate
Disclosure</B>. (A) The Company has provided a copy to the Underwriters of each Issuer Free Writing Prospectus (as defined below) used
in the sale of Securities. The Company has filed all Issuer Free Writing Prospectuses required to be so filed with the Commission, and
no order preventing or suspending the effectiveness or use of any Issuer Free Writing Prospectus is in effect and no proceedings for such
purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission. When
taken together with the rest of the Time of Sale Disclosure Package or the Final Prospectus, no Issuer Free Writing Prospectus, as of
its issue date and at all subsequent times though the completion of the public offer and sale of the Securities, has, does or will include
(1) any untrue statement of a material fact or omission to state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading, or (2) information that conflicted, conflicts or will conflict
with the information contained in the Registration Statement or the Final Prospectus. The representations and warranties set forth in
the immediately preceding sentence shall not apply to statements in or omissions from the Time of Sale Disclosure Package, the Final Prospectus
or any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company by any Underwriter
specifically for use in the preparation thereof, which written information is described in Section 7(f). As used in this paragraph and
elsewhere in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(1) &ldquo;<U>Time of
Sale Disclosure Package</U>&rdquo; means the Prospectus most recently filed with the Commission before the time of this Agreement, including
any preliminary prospectus supplement deemed to be a part thereof, each Issuer Free Writing Prospectus, and the description of the transaction
provided by the Underwriters included on <B>Schedule II</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(2) &ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 under the Securities
Act, relating to the Securities that (A) is required to be filed with the Commission by the Company, or (B) is exempt from filing pursuant
to Rule 433(d)(5)(i) or (d)(8) under the Securities Act, in each case in the form filed or required to be filed with the Commission or,
if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(B) At the time of
filing of the Registration Statement and at the date hereof, the Company is an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(C) Each Issuer Free
Writing Prospectus listed on <B>Schedule III</B> satisfied, as of its issue date and at all subsequent times through the Prospectus Delivery
Period (as defined in Section 5(a) hereof), all other conditions as may be applicable to its use as set forth in Rules 164 and 433 under
the Securities Act, including any legend, record-keeping or other requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv) <B>Financial
Statements</B>. The financial statements of the Company, together with the related notes and schedules, included in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus comply in all material respects with the applicable requirements of the Securities
Act and the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and the rules and regulations of the
Commission thereunder, and fairly present in all material respects the financial condition of the Company as of the dates indicated and
the results of operations and changes in cash flows for the periods therein specified in conformity with U.S. generally accepted accounting
principles (&ldquo;<U>GAAP</U>&rdquo;) consistently applied throughout the periods involved (provided that unaudited interim financial
statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes
required by GAAP). No other financial statements, pro forma financial information or schedules are required under the Securities Act,
the Exchange Act, or the Rules and Regulations to be included in the Registration Statement, the Time of Sale Disclosure Package or the
Final Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v) <B>Pro Forma Financial
Information</B>. The pro forma financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the
Final Prospectus include assumptions that provide a reasonable basis for presenting the significant effects directly attributable to the
transactions and events described therein, the related pro forma adjustments give appropriate effect to those assumptions, and the pro
forma adjustments reflect the proper application of those adjustments to the historical financial statements amounts in the pro forma
financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. The pro forma
financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus comply as to
form in all material respects with the application requirements of Regulation S-X under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi) <B>Independent
Accountants.</B> To the Company&rsquo;s knowledge, Weinberg &amp; Company, P.A., which has expressed its opinion with respect to the audited
financial statements and schedules included as a part of the Registration Statement, the Time of Sale Disclosure Package and the Final
Prospectus, is an independent public accounting firm with respect to the Company within the meaning of the Securities Act and the Rules
and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii) <B>Accounting
Controls. </B>The Company will maintain a system of &ldquo;internal control over financial reporting&rdquo; (as defined under Rules 13a-15
and 15d-15 under the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by, or under the supervision
of, its principal executive and principal financial officer, or persons performing similar functions, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are
executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii) <B>Forward-Looking
Statements</B>. The Company had a reasonable basis for, and made in good faith, each &ldquo;forward-looking statement&rdquo; (within the
meaning of Section 27A of the Securities Act or Section 21E of the Exchange Act) contained or incorporated by reference in the Registration
Statement, the Time of Sale Disclosure Package, the Final Prospectus or the Marketing Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix) <B>Statistical
and Marketing-Related Data</B>. All statistical or market-related data included or incorporated by reference in the Registration Statement,
the Time of Sale Disclosure Package or the Final Prospectus, or included in the Marketing Materials, are based on or derived from sources
that the Company reasonably believes to be reliable and accurate, and the Company has obtained the written consent to the use of such
data from such sources, to the extent required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(x) <B>Pursuant to
the Exchange Act</B>. The Company has filed with the Commission a Form 8-A (File Number 001-[*]) providing for the registration pursuant
to Section 12(b) under the Exchange Act of the shares of Common Stock and Warrants. The registration of the shares of Common Stock and
Warrants under the Exchange Act has been declared effective by the Commission on or prior to the date hereof. The Company has taken no
action designed to, or likely to have the effect of, terminating the registration of the shares of Common Stock under the Exchange Act,
nor has the Company received any notification that the Commission is contemplating terminating such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xi) <B>Stock Exchange
Listing</B>. The shares of Common Stock have been approved for listing on The Nasdaq Capital Market (&ldquo;<U>Nasdaq</U>&rdquo;), and
the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from Nasdaq, nor has
the Company received any written notification that Nasdaq is contemplating terminating such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xii) <B>Absence of
Manipulation</B>. The Company has not taken, directly or indirectly, any action that is designed to or that has constituted or that would
reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xiii) <B>Investment
Company Act</B>. The Company is not and, after giving effect to the offering and sale of the Securities and the application of the net
proceeds thereof, will not be an &ldquo;investment company,&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Any certificate signed by
any officer of the Company and delivered to the Underwriters or to counsel for the Underwriters shall be deemed a representation and warranty
by the Company to the Underwriters as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>3. Representations and
Warranties Regarding the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company represents and
warrants to, and agrees with, the several Underwriters, as of the date hereof and as of the Closing Date and as of each Option Closing
Date, if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) <B>Good Standing</B>.
The Company has been duly organized and is validly existing as a corporation or other entity in good standing under the laws of its jurisdiction
of incorporation or organization. The Company has the power and authority (corporate or otherwise) to own its properties and conduct its
business as currently being carried on and as described in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus,
and is duly qualified to do business as a foreign corporation or other entity in good standing in each jurisdiction in which it owns or
leases real property or in which the conduct of its business makes such qualification necessary, except where the failure to so qualify
would not have or be reasonably likely to result in a material adverse effect upon the business, prospects, properties, operations, condition
(financial or otherwise) or results of operations of the Company, or in its ability to perform its obligations under this Agreement, the
Warrant, the Warrant Agreement or the Representative&rsquo;s Warrant (as defined in Section 4(f)) (&ldquo;<U>Material Adverse Effect</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii) <B>Validity and
Binding Effect of Agreements</B>. This Agreement, the Warrant, the Warrant Agreement and the Representative&rsquo;s Warrant have been
duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the
Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited
by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally; (ii) as enforceability of any indemnification
or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance
and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii) <B>Contracts</B>.
The execution, delivery and performance of this Agreement, the Warrant Agreement, the Warrant and the Representative&rsquo;s Warrant and
the consummation of the transactions herein and therein contemplated will not (A) result in a breach or violation of any of the terms
and provisions of, or constitute a default under, any law, order, rule or regulation to which the Company is subject, or by which any
property or asset of the Company is bound or affected, except to the extent that such conflict, breach or default is not reasonably likely
to result in a Material Adverse Effect, (B) conflict with, result in any violation or breach of, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, or give to others any right of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) (a &ldquo;<U>Default Acceleration Event</U>&rdquo;) of, any agreement,
lease, credit facility, debt, note, bond, mortgage, indenture or other instrument (the &ldquo;<U>Contracts</U>&rdquo;) or obligation or
other understanding to which the Company is a party or by which any property or asset of the Company is bound or affected, except to the
extent that such conflict, default, or Default Acceleration Event is not reasonably likely to result in a Material Adverse Effect, or
(C) result in a breach or violation of any of the terms and provisions of, or constitute a default under, the Company&rsquo;s Amended
and Restated Certificate of Incorporation, as amended (&ldquo;<U>Certificate of Incorporation</U>&rdquo;), or Amended and Restated Bylaws
(&ldquo;<U>Bylaws</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv) <B>No Violations
of Governing Documents</B>. The Company is not in violation, breach or default under its Certificate of Incorporation, Bylaws or other
equivalent organizational or governing documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v) <B>Consents</B>.
No consents, approvals, orders, authorizations or filings are required on the part of the Company in connection with the execution, delivery
or performance of this Agreement, the Warrant Agreement, the Warrant and the Representative&rsquo;s Warrant and the issue and sale of
the Securities and the Representative&rsquo;s Securities, except (A) the registration under the Securities Act of the Securities and Representative&rsquo;s
Securities, which has been effected, (B) the necessary filings and approvals from Nasdaq to list the Securities and the shares of Common
Stock underlying the Warrants and the Representative&rsquo;s Warrants, (C) such consents, approvals, authorizations, registrations or
qualifications as may be required under state or foreign securities or Blue Sky laws and the rules of the Financial Industry Regulatory
Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;) in connection with the purchase and distribution of the Securities by the several Underwriters,
(D) such consents and approvals as have been obtained and are in full force and effect, and (E) such consents, approvals, orders, authorizations
and filings the failure of which to make or obtain is not reasonably likely to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi) <B>Capitalization</B>.
The Company has an authorized capitalization as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final
Prospectus. All of the issued and outstanding shares of capital stock of the Company are duly authorized and validly issued, fully paid
and nonassessable, and have been issued in compliance with all applicable securities laws, and conform to the description thereof in the
Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. Since the respective dates as of which information
is provided in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, the Company has not entered into
or granted any convertible or exchangeable securities, options, warrants, agreements, contracts or other rights in existence to purchase
or acquire from the Company any shares of the capital stock of the Company. The Firm Securities, the Option Securities and the Representative&rsquo;s
Warrant have been duly authorized for issuance and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable,
free and clear of all liens imposed by the Company; the holders thereof are not and will not be subject to personal liability by reason
of being such holders; the Securities and Representative&rsquo;s Warrant are not and will not be subject to the preemptive rights of any
holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken
for the authorization, issuance and sale of the Securities and Representative&rsquo;s Warrant has been duly and validly taken; the shares
of Common Stock issuable upon exercise of the Warrants and the Representative&rsquo;s Warrant have been duly authorized and reserved for
issuance by all necessary corporate action on the part of the Company and when paid for and issued in accordance with the Warrant Agreement
or Representative&rsquo;s Warrant or exercised on a cashless basis as set forth in such Representative&rsquo;s Warrant, as the case may
be, such shares of Common Stock will be validly issued, fully paid and non-assessable; and the Securities, the Warrant Agreement and Representative&rsquo;s
Warrant conform in all material respects to all statements with respect thereto contained in the Registration Statement, the Time of Sale
Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii) <B>Taxes</B>.
The Company has (a) filed all foreign, federal, state and local tax returns (as hereinafter defined) required to be filed with taxing
authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof (except where the failure to file
would not, individually or in the aggregate, have a Material Adverse Effect) and (b) paid all taxes (as hereinafter defined) shown as
due and payable on such returns that were filed and has paid all taxes imposed on or assessed against the Company (except where the failure
to pay would not, individually or in the aggregate, have a Material Adverse Effect). The provisions for taxes payable, if any, shown on
the financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus are sufficient
for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial
statements. To the knowledge of the Company, no issues have been raised (and are currently pending) by any taxing authority in connection
with any of the returns or taxes asserted as due from the Company, and no waivers of statutes of limitation with respect to the returns
or collection of taxes have been given by or requested from the Company. The term &ldquo;<U>taxes</U>&rdquo; mean all federal, state,
local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease,
service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs,
duties or other taxes, fees, assessments, or charges of any kind whatever, together with any interest and any penalties, additions to
tax, or additional amounts with respect thereto. The term &ldquo;<U>returns</U>&rdquo; means all returns, declarations, reports, statements,
and other documents required to be filed in respect to taxes.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii) <B>Material
Change</B>. Since the respective dates as of which information is given in the Registration Statement, the Time of Sale Disclosure Package
or the Final Prospectus, and except as disclosed in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus,
(a) the Company has not incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions
other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any
kind with respect to its capital stock; (c) there has not been any change in the capital stock of the Company (other than a change in
the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise of outstanding options or warrants, upon
the conversion of outstanding shares of preferred stock or other convertible securities, due to the vesting of outstanding stock grants
or the issuance of restricted stock awards or restricted stock units under the Company&rsquo;s existing stock awards plan, or any new
grants thereof in the ordinary course of business), (d) there has not been any material change in the Company&rsquo;s long-term or short-term
debt, other than periodic accruals in the ordinary course pursuant to the terms of the Company&rsquo;s outstanding debt, and (e) there
has not been the occurrence of any Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix) <B>Absence of
Proceedings</B>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending
or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s knowledge, any executive
officer or director which has not been disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(x) <B>Regulatory</B>.
Except as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus: (i) the Company has not
received notice from any Governmental Entity (as defined below) alleging or asserting noncompliance with any Applicable Regulations (as
defined below) or Authorizations (as defined below); (ii) the Company is and has been in material compliance with federal, state or foreign
statutes, laws, ordinances, rules and regulations applicable to the Company (collectively, &ldquo;<U>Applicable Regulations</U>&rdquo;);
(iii) the Company possesses all licenses, certificates, approvals, clearances, consents, authorizations, qualifications, registrations,
permits, and supplements or amendments thereto required by any such Applicable Regulations and/or to carry on its businesses as now conducted
(&ldquo;<U>Authorizations</U>&rdquo;) and such Authorizations are valid and in full force and effect and the Company is not in violation
of any term of any such Authorizations; (iv) the Company has not received notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any Governmental Entity or third party alleging that any product, operation or activity
is in violation of any Applicable Regulations or Authorizations or has any knowledge that any such Governmental Entity or third party
is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, nor, has there been any material noncompliance
with or violation of any Applicable Regulations by the Company that could reasonably be expected to require the issuance of any such communication
or result in an investigation, corrective action, or enforcement action by any Governmental Entity; and (v) the Company has not received
notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations
or has any knowledge that any such Governmental Entity has threatened or is considering such action. Neither the Company nor, to the Company&rsquo;s
knowledge, any of its directors, officers, employees or agents has been convicted of any crime under any Applicable Regulations. &ldquo;<U>Governmental
Entity</U>&rdquo; shall be defined as any arbitrator, court, governmental body, regulatory body, administrative agency or other authority,
body or agency (whether foreign or domestic) having jurisdiction over the Company or any of its properties, assets or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xi) <B>Good Title</B>.
The Company has good and marketable title to all property (whether real or personal) described in the Registration Statement, the Time
of Sale Disclosure Package and the Final Prospectus as being owned by it that are material to the business of the Company, in each case
free and clear of all liens, claims, security interests, other encumbrances or defects, except those that are disclosed in the Registration
Statement, the Time of Sale Disclosure Package or the Final Prospectus and those that are not reasonably likely to result in a Material
Adverse Effect. The property held under lease by the Company is held by it under valid, subsisting and enforceable leases with only such
exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of the business of the Company.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xii) <B>Intellectual
Property</B>. The Company owns or possesses or has valid rights to use all patents, patent applications, trademarks, service marks, trade
names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (&ldquo;<U>Intellectual
Property Rights</U>&rdquo;) necessary for the conduct of the business of the Company as currently carried on and as described in the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus. To the knowledge of the Company, no action or use by the Company
necessary for the conduct of its business as currently carried on and as described in the Registration Statement and the Final Prospectus
will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. The Company
has not received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except
as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect (A) to the knowledge of
the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned
by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging
the rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable
basis for any such claim, that would, individually or in the aggregate, together with any other claims in this Section 3(a)(xii), reasonably
be expected to result in a Material Adverse Effect; (C) the Intellectual Property Rights owned by the Company and, to the knowledge of
the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction invalid
or unenforceable, in whole or in part, and there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding
or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts
which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in
this Section 3(a)(xii) reasonably be expected to result in a Material Adverse Effect; (D) there is no pending or, to the Company&rsquo;s
knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any
Intellectual Property Rights or other proprietary rights of others, the Company has not received any written notice of such claim and
the Company is unaware of any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate,
together with any other claims in this Section 3(a)(xii), reasonably be expected to result in a Material Adverse Effect; and (E) to the
Company&rsquo;s knowledge, no employee of the Company is in or has ever been in violation in any material respect of any term of any employment
contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure
agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s
employment with the Company, or actions undertaken by the employee while employed with the Company and could reasonably be expected to
result, individually or in the aggregate, in a Material Adverse Effect. To the Company&rsquo;s knowledge, all material technical information
developed by and belonging to the Company which has not been patented has been kept confidential. The Company is not a party to or bound
by any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required
to be set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus and are not described therein.
The Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus contain in all material respects the same description
of the matters set forth in the preceding sentence. None of the technology employed by the Company has been obtained or is being used
by the Company in violation of any contractual obligation binding on the Company or, to the Company&rsquo;s knowledge, any of its officers,
directors or employees, or otherwise in violation of the rights of any persons. To the Company&rsquo;s knowledge, there is no prior art
or public or commercial activity that may render any patent included in the Intellectual Property Rights invalid or that would preclude
the issuance of any patent on any patent application included in the Intellectual Property which has not been disclosed to the U.S. Patent
and Trademark Office or the relevant foreign patent authority, as the case may be. The Company has not, and to the Company&rsquo;s knowledge,
no third party has, committed any act or omitted to undertake any act the effect of such commission or omission would reasonably be expected
to result in a legal determination that any item of Intellectual Property Rights thereby was rendered invalid or unenforceable in whole
or in part. The manufacture, use and sale of the products or product candidates described in the Registration Statement, the Time of Sale
Disclosure Package and the Final Prospectus as under development by the Company fall within the scope of one or more claims of the patents
or patent applications included in the Intellectual Property Rights. Other than information disclosed in the Registration Statement, the
Time of Sale Disclosure Package and the Final Prospectus, no government funding, facilities or resources of a university, college, other
educational institution or research center was used in the development of any Intellectual Property Rights that are owned or purported
to be owned by the Company that would confer upon any governmental agency or body, university, college, other educational institution
or research center any claim or right in or to any such Intellectual Property Rights.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xiii) <B>Employment
Matters</B>. There is (A) no unfair labor practice complaint pending against the Company, nor to the Company&rsquo;s knowledge, threatened
against it, before the National Labor Relations Board, any state or local labor relation board or any foreign labor relations board, and
no grievance or arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company,
or, to the Company&rsquo;s knowledge, threatened against it and (B) no labor disturbance by the employees of the Company exists or, to
the Company&rsquo;s knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees
of any of its principal suppliers, manufacturers, customers or contractors, that could reasonably be expected, singularly or in the aggregate,
to have a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the Company plans
to terminate employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xiv) <B>ERISA Compliance</B>.
No &ldquo;prohibited transaction&rdquo; (as defined in Section 406 of the Employee Retirement Income Security Act of 1974, as amended,
including the regulations and published interpretations thereunder (&ldquo;<U>ERISA</U>&rdquo;), or Section 4975 of the Internal Revenue
Code of 1986, as amended from time to time (the &ldquo;<U>Code</U>&rdquo;)) or &ldquo;accumulated funding deficiency&rdquo; (as defined
in Section 302 of ERISA) or any of the events set forth in Section 4043(b) of ERISA (other than events with respect to which the thirty
(30)-day notice requirement under Section 4043 of ERISA has been waived) has occurred or could reasonably be expected to occur with respect
to any employee benefit plan of the Company which would reasonably be expected to, singularly or in the aggregate, have a Material Adverse
Effect. Each employee benefit plan of the Company is in compliance in all material respects with applicable law, including ERISA and the
Code. The Company has not incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect to the
termination of, or withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the Company would have any liability
that is intended to be qualified under Section 401(a) of the Code is so qualified, and, to the Company&rsquo;s knowledge, nothing has
occurred, whether by action or by failure to act, which could, singularly or in the aggregate, cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xv) <B>Environmental
Matters</B>. The Company is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the use,
treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment which
are applicable to their businesses (&ldquo;<U>Environmental Laws</U>&rdquo;), except where the failure to comply has not had and would
not reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect. There has been no storage, generation,
transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous
substances by, due to, or caused by the Company (or, to the Company&rsquo;s knowledge, any other entity for whose acts or omissions the
Company is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company, or upon any other property,
in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute,
ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, except for
any violation or liability which has not had and would not reasonably be expected to have, singularly or in the aggregate, a Material
Adverse Effect; and there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment
surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xvi) <B>SOX Compliance</B>.
The Company has taken all actions it deems reasonably necessary or advisable to take on or prior to the date of this Agreement to assure
that, upon and at all times after the Effective Date, it will be in compliance in all material respects with all applicable provisions
of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof. (the &ldquo;<U>Sarbanes-Oxley
Act</U>&rdquo;) that are then in effect and will take all action it deems reasonably necessary or advisable to assure that it will be
in compliance in all material respects with other applicable provisions of the Sarbanes-Oxley Act not currently in effect upon it and
at all times after the effectiveness of such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xvii) <B>Money Laundering
Laws</B>. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping
and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of
all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any Governmental Entity (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;); and no action, suit or proceeding
by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xviii) <B>Foreign
Corrupt Practices Act</B>. Neither the Company nor, to the knowledge of the Company, any director, officer, employee, representative,
agent, affiliate of the Company or any other person acting on behalf of the Company, is aware of or has taken any action, directly or
indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and
regulations thereunder (the &ldquo;<U>FCPA</U>&rdquo;), including, without limitation, making use of the mails or any means or instrumentality
of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or
other property, gift, promise to give, or authorization of the giving of anything of value to any &ldquo;foreign official&rdquo; (as such
term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention
of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the
FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure,
continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xix) <B>OFAC</B>.
Neither the Company nor, to the knowledge of the Company, any director, officer, employee, representative, agent or affiliate of the Company
or any other person acting on behalf of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;); and the Company will not directly or indirectly use the proceeds
of the offering of the Securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any person or
entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xx) <B>Insurance</B>.
Following the consummation of the offering contemplated hereby, the Company will carry insurance in such amounts and covering such risks
as is adequate for the conduct of its business and the value of its properties and as is customary for companies engaged in similar businesses
in similar industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxi) <B>Books and
Records</B>. The minute books of the Company have been made available to the Underwriters and counsel for the Underwriters, and such books
(i) contain a complete summary of all meetings and actions of the board of directors (including each board committee) and stockholders
of the Company (or analogous governing bodies and interest holders, as applicable), since the time of its incorporation or organization
through the date of the latest meeting and action, and (ii) accurately in all material respects reflect all transactions referred to in
such minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxii) <B>No Violation</B>.
Neither the Company nor, to its knowledge, any other party is in violation, breach or default of any Contract that has resulted in or
could reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxiii) <B>Continued
Business</B>. No supplier, customer, distributor or sales agent of the Company has notified the Company that it intends to discontinue
or decrease the rate of business done with the Company, except where such discontinuation or decrease has not resulted in and could not
reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxiv) <B>No Finder&rsquo;s
Fee</B>. There are no claims, payments, issuances, arrangements or understandings for services in the nature of a finder&rsquo;s, consulting
or origination fee with respect to the introduction of the Company to any Underwriter or the sale of the Securities hereunder or any other
arrangements, agreements, understandings, payments or issuances with respect to the Company that may affect the Underwriters&rsquo; compensation,
as determined by FINRA.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxv) <B>No Fees.</B>
Except as disclosed to the Representative in writing, the Company has not made any direct or indirect payments (in cash, securities or
otherwise) to (i) any person, as a finder&rsquo;s fee, investing fee or otherwise, in consideration of such person raising capital for
the Company or introducing to the Company persons who provided capital to the Company, (ii) any FINRA member, or (iii) any person or entity
that has any direct or indirect affiliation or association with any FINRA member within the twelve (12) month period prior to the date
on which the Registration Statement was filed with the Commission (&ldquo;<U>Filing Date</U>&rdquo;) or thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxvi) <B>Proceeds</B>.
None of the net proceeds of the offering will be paid by the Company to any participating FINRA member or any affiliate or associate of
any participating FINRA member, except as specifically authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxvii) <B>No FINRA
Affiliations</B>. To the Company&rsquo;s knowledge and except as disclosed to the Representative in writing, no (i) officer or director
of the Company or (ii) owner of 5% or more of any class of the Company&rsquo;s securities or (iii) owner of any amount of the Company&rsquo;s
unregistered securities acquired within the 180-day period prior to the Filing Date, has any direct or indirect affiliation or association
with any FINRA member. The Company will advise the Representative and counsel to the Underwriters if it becomes aware that any officer,
director of the Company or any owner of 5% or more of any class of the Company&rsquo;s securities is or becomes an affiliate or associated
person of a FINRA member participating in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxviii) <B>No Financial
Advisor</B>. Other than the Underwriters, no person has the right to act as an underwriter or as a financial advisor to the Company in
connection with the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxix) <B>Data Privacy
and Security Laws</B>. The Company is, and at all prior times was, in material compliance with all applicable state and federal data privacy
and security laws and regulations in the United States, including, without limitation, the Health Insurance Portability and Accountability
Act of 1996 (&ldquo;<U>HIPAA</U>&rdquo;) as amended by the Health Information Technology for Economic and Clinical Health Act, and all
applicable provincial and federal data privacy and security laws and regulations in Canada, including without limitation the Personal
Information Protection and Electronic Documents Act (S.C. 2000, c. 5) (&ldquo;<U>PIPEDA</U>&rdquo;); and the Company has taken commercially
reasonable actions to prepare to comply with, and have been and currently are in compliance with, the European Union General Data Protection
Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, the &ldquo;<U>Privacy Laws</U>&rdquo;). To ensure compliance with
the Privacy Laws, the Company has in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material
respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling,
and analysis of Personal Data (the &ldquo;<U>Policies</U>&rdquo;). &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s
name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&rsquo;s
license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would
qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) Protected Health
Information as defined by HIPAA; (iv) &ldquo;personal information&rdquo;, &ldquo;personal health information&rdquo;. and &ldquo;business
contact information&rdquo; as defined by PIPEDA; (v) &ldquo;personal data&rdquo; as defined by GDPR; and (vi) any other piece of information
that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related
to an identified person&rsquo;s health or sexual orientation. The Company has at all times made all disclosures to users or customers
required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to
the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material
respect. The Company further certifies: (i) it has not received notice of any actual or potential liability under or relating to, or actual
or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to
result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective
action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under
any Privacy Law.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxx) <B>No Registration
Rights</B>. Except as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, there are
no contracts, agreements or understandings between the Company and any person granting such person the right (other than rights which
have been waived in writing or otherwise satisfied) to require the Company to file a registration statement under the Securities Act with
respect to any securities of the Company owned or to be owned by such person or to require the Company to include such securities in the
securities registered pursuant to the Registration Statement or in any securities being registered pursuant to any other registration
statement filed by the Company under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxxi) <B>Prior Sales
of Securities</B>. Except as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the
Company has not sold or issued any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant
to Rule 144A under, or Regulations D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, stock option
plans or other employee compensation plans, pursuant to outstanding preferred stock, options, rights or warrants or other outstanding
convertible securities or in connection with the vesting of any outstanding stock grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxxii) <B>Compliance
with Laws.</B> The Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the
Company, including, without limitation, all statutes, rules, or regulations relating to the ownership, testing, development, manufacture,
packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of
any product manufactured or distributed by the Company and, without limiting the foregoing, include (i) the Federal Food, Drug, and Cosmetic
Act (the &ldquo;<U>FDCA</U>&rdquo;), (ii) the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances
Control Act and Laws applicable to hazardous or regulated substances and radioactive or biologic materials, (iii) the federal Anti-Kickback
Statute, (iv) the False Claims Act, (v) the Civil Monetary Penalties Law, (vi) the Physician Payments Sunshine Act, (vii) the criminal
False Claims Law, (viii) the HIPAA as amended by the Health Information Technology for Economic and Clinical Health Act and (ix) licensing
and certification laws covering any aspect of the business of the Company (&ldquo;<U>Applicable Laws</U>&rdquo;), except as could not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (B) has not received any warning letter, untitled
letter or other correspondence or notice from any other governmental authority alleging or asserting noncompliance with any Applicable
Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any
such Applicable Laws and/or to carry on its business as now conducted (&ldquo;<U>Applicable Authorizations</U>&rdquo;); (C) possesses
all material Application Authorizations and such Applicable Authorizations are valid and in full force and effect and are not in material
violation of any term of any such Applicable Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Applicable Authorizations and has no knowledge that any such Governmental Entity
or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding nor, to the Company&rsquo;s
knowledge, has there been any material noncompliance with or violation of any Applicable Laws by the Company that could reasonably be
expected to require the issuance of any such communication or result in an investigation, corrective action, or enforcement action by
any Governmental Entity; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit,
suspend, modify or revoke any Applicable Authorizations and has no knowledge that any such Governmental Entity has threatened or is considering
such action; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required by any Applicable Laws or Applicable Authorizations and that all such reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date
filed (or were corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated,
conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale
warning, &ldquo;dear doctor&rdquo; letter, or other notice or action relating to the alleged lack of safety or efficacy of any product
or any alleged product defect or violation and, to the Company&rsquo;s knowledge, no third party has initiated, conducted or intends to
initiate any such notice or action.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxxiii) <B>FDA</B>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company (each such product, a &ldquo;<U>FDA Product</U>&rdquo;),
such FDA Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with
all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket
clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product
listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have
or reasonably be expected to result in a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company, and the Company has not received any notice, warning letter or other communication from the FDA or any other Governmental
Entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing
or packaging of, the testing of, the sale of, or the labeling and promotion of any FDA Product, (ii) withdraws its approval of, requests
the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to,
any FDA Product, (iii) imposes a clinical hold on any clinical investigation by the Company, (iv) enjoins production at any facility of
the Company, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company, or (vi) otherwise alleges
any violation of any laws, rules or regulations by the Company, and which, either individually or in the aggregate, would not have or
reasonably be expected to result in a Material Adverse Effect. The properties, business and operations of the Company have been and are
being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not
been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to
be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any
product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xxxiv) <B>Clinical
and Preclinical Studies</B>. The studies, tests and preclinical and clinical trials conducted by or, to the Company&rsquo;s knowledge,
on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols,
procedures and controls pursuant to accepted professional scientific standards and all authorizations and applicable laws and the rules
and regulations promulgated thereunder and any applicable rules, regulations and policies of the jurisdiction in which such trials and
studies are being conducted; the descriptions of the results of such studies, tests and trials contained in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus are, to the Company&rsquo;s knowledge, accurate and complete in all material
respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus, the Company is not aware of any studies, tests or trials, the results of
which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus when viewed in the context in which such results are described
and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the Time of Sale Disclosure
Package or the Prospectus, the Company has not received any notices or correspondence from the FDA or any governmental entity requiring
the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>4. Purchase, Sale and
Delivery of Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) On the basis of the representations,
warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and
sell the Firm Shares to the several Underwriters, and the several Underwriters agree, severally and not jointly, to purchase the Firm
Shares set forth opposite the names of the Underwriters in Schedule I hereto. The purchase price for each Firm Share shall be $[*] per
share.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) The Company hereby grants
to the Underwriters the option to purchase some or all of the Option Securities and, upon the basis of the warranties and representations
and subject to the terms and conditions herein set forth, the Underwriter shall have the right, severally and not jointly, to purchase
all or any portion of the Option Shares and/or the Option Warrants as may be necessary to cover over-allotments made in connection with
the transactions contemplated hereby. The purchase price to be paid per Option Share shall be equal to $______ per Option Share. The purchase
price to be paid per Option Warrant shall be equal to $_____ per Option Warrant. The Underwriters shall not be under any obligation to
purchase any of the Option Securities prior to the exercise of the Over-allotment Option. This Over-Allotment Option may be exercised
by the Underwriters at any time and from time to time on or before the forty-fifth (45<SUP>th</SUP>) day following the date hereof, by
written notice to the Company (the &ldquo;<U>Option Notice</U>&rdquo;). The Option Notice shall set forth the aggregate number of Option
Shares and/or Option Warrants as to which the option is being exercised, and the date and time when the Option Shares and/or the Option
Warrants are to be delivered (such date and time being herein referred to as the &ldquo;<U>Option Closing Date</U>&rdquo;); <I>provided</I>,
<I>however</I>, that the Option Closing Date shall not be earlier than the Closing Date (as defined below) nor earlier than the first
business day after the date on which the option shall have been exercised nor later than the fifth business day after the date on which
the option shall have been exercised unless the Company and the Representative otherwise agree. Upon exercise of the Over-allotment Option
with respect to all or any portion of the Option Securities subject to the terms and conditions set forth herein, (i) the Company shall
become obligated to sell to the Underwriters the number of Option Securities specified in such notice; (ii) each of the Underwriters,
acting severally and not jointly, shall purchase that portion of the total number of Option Securities then being purchased as set forth
in Schedule 1 opposite the name of such Underwriter, subject to such adjustments as the Representative, in its sole discretion, shall
determine and (iii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the total number of Option
Warrants then being purchased that the number of Option Warrants as set forth in Schedule 1 opposite the name of such Underwriter bears
to the total number of Option Warrants, subject, in each case, to such adjustments as the Representative, in its sole discretion, shall
determine. The Representative may cancel the Over-Allotment Option at any time prior to the expiration of the Over-Allotment Option by
written notice to the Company (except to the extent the Representative has exercised the Over-Allotment Option in accordance herewith).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Payment of the purchase
price for and delivery of the Option Shares and/or the Option Warrants shall be made on an Option Closing Date in the same manner and
at the same office as the payment for the Firm Securities as set forth in subparagraph (d) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d) The Firm Securities will be delivered by the
Company to the Representative, for the respective accounts of the several Underwriters against payment of the purchase price therefor
by wire transfer of same day funds payable to the order of the Company at the offices of WallachBeth Capital, LLC, Harborside Financial
Plaza 5, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, or such other location as may be mutually acceptable, at 9:00 a.m. Eastern
Time, on the second (or if the Firm Securities are priced, as contemplated by Rule 15c6-1(c) under the Exchange Act, after 4:30 p.m. Eastern
time, the third) full business day following the date hereof, or at such other time and date as the Representative and the Company determine
pursuant to Rule 15c6-1(a) under the Exchange Act, or, in the case of the Option Securities, at such date and time set forth in the Option
Notice. The time and date of delivery of the Firm Shares is referred to herein as the &ldquo;<U>Closing Date</U>.&rdquo; On the Closing
Date, the Company shall deliver the Firm Securities which shall be registered in the name or names and shall be in such denominations
as the Representative may request on behalf of the Underwriters at least one (1) business day before the Closing Date, to the respective
accounts of the several Underwriters, which delivery shall with respect to the Firm Securities, be made through the facilities of the
Depository Trust Company&rsquo;s Deposit or Withdrawal at Custodian (&ldquo;<U>DWAC</U>&rdquo;) system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) It is understood that the
Representative has been authorized, for its own account and the accounts of the several Underwriters, to accept delivery of and receipt
for, and make payment of the purchase price for, the Firm Securities and any Option Securities the Underwriters have agreed to purchase.
The Representative, individually and not as the Representative of the Underwriters, may (but shall not be obligated to) make payment for
any Securities to be purchased by any Underwriter whose funds shall not have been received by the Representative by the Closing Date or
any Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter
from any of its obligations under this Agreement.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) The Company hereby agrees
to issue to the Underwriters (and/or its designees) on the Closing Date a five-year warrant (the &ldquo;<U>Representative&rsquo;s Warrant</U>&rdquo;)
for the purchase of an aggregate of [*] shares of Common Stock, representing up to 10% of the Firm Units. The Representative&rsquo;s Warrant,
in the form attached hereto as <U>Exhibit A</U>, shall be exercisable, in whole or in part, commencing on a date which is six (6) months
after the effective date (the &ldquo;<U>Effective Date</U>&rdquo;) of the Registration Statement and expiring on the five-year anniversary
of the Effective Date at an initial exercise price per share of Common Stock equal to 120% of the initial public offering price of the
Firm Shares (subject to adjustment as set forth therein). The Representative&rsquo;s Warrant and the shares of Common Stock issuable upon
exercise thereof are hereinafter referred to together as the &ldquo;<U>Representative&rsquo;s Securities</U>.&rdquo; The Representative
understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative&rsquo;s
Warrant and the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance
thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative&rsquo;s Warrant, or any portion
thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic
disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an
Underwriter or a selected dealer in connection with the offering of the Securities or (ii) a bona fide officer or partner of the Representative
or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions. Delivery
of the Representative&rsquo;s Warrant shall be made on the Closing Date and shall be issued in the name or names and in such authorized
denominations as the Representative may request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>5. Covenants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company covenants and
agrees with the Underwriters as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) The Company shall
prepare the Final Prospectus in a form approved by the Representative and file such Final Prospectus pursuant to Rule 424(b) under the
Securities Act not later than the Commission&rsquo;s close of business on the second business day following the execution and delivery
of this Agreement, or, if applicable, such earlier time as may be required by the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii) During the period
beginning on the date hereof and ending on the later of the Closing Date or such date as determined by the Representative the Final Prospectus
is no longer required by law to be delivered in connection with sales by an underwriter or dealer (the &ldquo;<U>Prospectus Delivery Period</U>&rdquo;),
prior to amending or supplementing the Registration Statement, including any Rule 462 Registration Statement, the Time of Sale Disclosure
Package or the Final Prospectus, the Company shall furnish to the Representative for review and comment a copy of each such proposed amendment
or supplement, and the Company shall not file any such proposed amendment or supplement to which the Representative reasonably objects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii) From the date
of this Agreement until the end of the Prospectus Delivery Period, the Company shall promptly advise the Representative in writing (A)
of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (B) of the time and date
of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Time of Sale Disclosure
Package, the Final Prospectus or any Issuer Free Writing Prospectus, (C) of the time and date that any post-effective amendment to the
Registration Statement becomes effective and (D) of the issuance by the Commission of any stop order suspending the effectiveness of the
Registration Statement or of any order preventing or suspending its use or the use of the Time of Sale Disclosure Package, the Final Prospectus
or any Issuer Free Writing Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Stock
from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation
of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time during the Prospectus Delivery
Period, the Company will use its reasonable efforts to obtain the lifting of such order at the earliest possible moment. Additionally,
the Company agrees that it shall comply with the provisions of Rules 424(b), 430A, 430B or 430C as applicable, under the Securities Act
and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely
manner by the Commission (without reliance on Rule 424(b)(8) or 164(b) of the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv) (A) During the
Prospectus Delivery Period, the Company will comply with all requirements imposed upon it by the Securities Act, as now and hereafter
amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act, as now and hereafter amended, so far
as necessary to permit the continuance of sales of or dealings in the Securities as contemplated by the provisions hereof, the Time of
Sale Disclosure Package, the Registration Statement and the Final Prospectus. If during the Prospectus Delivery Period any event occurs
the result of which would cause the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time
of Sale Disclosure Package ) to include an untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary or appropriate
in the opinion of the Company or its counsel or the Representative or counsel to the Underwriters to amend the Registration Statement
or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure
Package ) to comply with the Securities Act, the Company will promptly notify the Representative, allow the Representative the opportunity
to provide reasonable comments on such amendment, prospectus supplement or document, and will amend the Registration Statement or supplement
the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package)
or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(B) If at any time
during the Prospectus Delivery Period there occurred or occurs an event or development the result of which such Issuer Free Writing Prospectus
conflicted or would conflict with the information contained in the Registration Statement or any Prospectus or included or would include,
when taken together with the Time of Sale Disclosure Package, an untrue statement of a material fact or omitted or would omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time,
not misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer
Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v) The Company shall
take or cause to be taken all necessary action to qualify the Securities and Representative&rsquo;s Securities for sale under the securities
laws of such jurisdictions as the Representative reasonably designates and to continue such qualifications in effect so long as required,
except that the Company shall not be required in connection therewith to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified, to execute a general consent to service of process in any state or to subject itself
to taxation in respect of doing business in any jurisdiction in which it is not otherwise subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi) The Company will
furnish to the Underwriters and counsel to the Underwriters copies of the Registration Statement, each Prospectus, any Issuer Free Writing
Prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities as the Underwriters
may from time to time reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii) The Company
will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end
of the Company&rsquo;s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period that shall
satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii) The Company,
whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid all
expenses relating to the Offering, including, without limitation, (a) all filing fees and communication expenses relating to the registration
of the Securities with the Commission; (b) all filing fees associated with the review of the public offering of the Securities by FINRA;
(c) all fees and expenses relating to the listing of such Offered Securities on Nasdaq; (d) all fees, expenses and disbursements relating
to the registration, qualification or exemption of the Offered Securities under state &ldquo;blue sky&rdquo; securities laws and all other
jurisdictions as the Representatives may reasonably designate; (e) all fees, expenses and disbursements relating to the registration,
qualification or exemption of such Securities under the securities laws of such foreign jurisdictions as the Representatives may reasonably
designate; (f) the costs of all mailing and printing of the underwriting documents (including, without limitation, the Underwriting Agreement,
any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire
and Power of Attorney), Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary
and final Prospectuses as the Representative may reasonably deem necessary; (g) the costs and expenses of a public relations firm for
the Company mutually agreed upon by the Representative and the Company; (h) the costs of preparing, printing and delivering certificates
representing the Securities; (i) fees and expenses of the transfer agent for the Securities of the Company; (j) stock transfer and/or
stamp taxes, if any, payable upon the transfer of the Securities from the Company to the Underwriters; (k) the costs associated with post-closing
advertising; (l) the fees and expenses of the Company&rsquo;s accountants; (m) the fees and expenses of the Company&rsquo;s legal counsel
and other agents and representatives; (n) fees and expenses of legal counsel for the Underwriters; (o) the costs associated with Ipeo
book building, prospectus tracking and compliance software and (p) all reasonable road show expenses for the Offering. The Underwriters
may also deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or each Option Closing Date, if any,
all out-of-pocket fees, expenses and disbursements (including legal fees and expenses) of the Underwriters incurred as a result of providing
services related to the Offering to be paid by the Company to the Underwriters;&nbsp;<I>provided, however</I>, that all such costs and
expenses pursuant to this&nbsp;<U>subsection</U>, including those referenced in clauses (n), (o) and (p) above and legal expenses of counsel
to the Underwriters and otherwise, which are incurred by the Underwriters and for which the Company shall be responsible shall not exceed
$150,000 in the aggregate in the event of a Closing of the Offering. This $150,000 amount shall be inclusive of the Advance (as defined
in Section 5(a)(xvi).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix) The Company intends
to apply the net proceeds from the sale of the Securities to be sold by it hereunder for the purposes set forth in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus under the heading &ldquo;Use of Proceeds&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(x) The Company has
not taken and will not take, directly or indirectly, during the Prospectus Delivery Period, any action designed to or which might reasonably
be expected to cause or result in, or that has constituted, the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xi) The Company represents
and agrees that, unless it obtains the prior written consent of the Representative, and each Underwriter, severally, and not jointly,
represents and agrees that, unless it obtains the prior written consent of the Company, it has not made and will not make any offer relating
to the Securities that would constitute an Issuer Free Writing Prospectus; provided that the prior written consent of the parties hereto
shall be deemed to have been given in respect of the free writing prospectuses included in <B>Schedule III</B>. Any such free writing
prospectus consented to by the Company and the Representative is hereinafter referred to as a &ldquo;<U>Permitted Free Writing Prospectus</U>.&rdquo;
The Company represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer free
writing prospectus,&rdquo; as defined in Rule 433, and has complied or will comply with the requirements of Rule 433 applicable to any
Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record-keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xii) The Company
hereby agrees that, without the prior written consent of the Representative, it and any successors will not, during the period ending
one hundred and eighty 180 days after the date hereof (&ldquo;<U>Lock-Up Period</U>&rdquo;), (a) offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend,
or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock or the Company, (b) file or caused to be filed any registration statement
with the Commission relating to the offering of any shares of capital stock or any securities convertible into or exercisable or exchangeable
for shares of capital stock or (c) enter into any swap or other arrangement that transfers to another in whole or in part, any of the
economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (a), (b) or (c) above
is to be settled by delivery of shares of capital stock of the Company or any successors or such other securities, in cash or otherwise.
The restrictions contained in the preceding sentence shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the
issuance by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding
on the date hereof, which is disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the
terms of which option, warrant or other outstanding convertible security are not thereafter amended, (iii) the issuance by the Company
of shares of Common Stock upon the vesting of outstanding stock grants (iv) <FONT STYLE="background-color: white">grants of stock options,
stock awards, restricted stock, RSUs, or other equity awards and the issuance of Common Stock or securities convertible into or exercisable
or exchangeable for Common Stock (whether upon the exercise of stock options or otherwise) to the Company&rsquo;s employees, officers,
directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described
in the </FONT>Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus <FONT STYLE="background-color: white"><U>provided
</U>the grantee of any such equity award set forth in this Section enters into a Lock-Up Agreement (as defined below) </FONT>in the form
attached hereto as <U>Exhibit B</U> in connection with any such grant; and <FONT STYLE="background-color: white">(v) the filing by the
Company of any registration statement on Form S-8 or a successor form thereto relating to an equity compensation plan described in the
Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xiii) To engage and
maintain, at its expense, a registrar and transfer agent for the Common Stock (if other than the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xiv) To use its reasonable
best efforts to maintain the listing of the Common Stock on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xv) To not take,
directly or indirectly, any action designed to cause or result in, or that has constituted or might reasonably be expected to constitute,
under the Exchange Act or otherwise, the stabilization or manipulation of the price of any securities of the Company to facilitate the
sale or resale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xvi)
The Company further agrees that, in addition to the expenses payable pursuant to Section 5(a)(viii), on the Closing Date it shall pay
to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable expense allowance equal
to one and seven-tenth percent (1.7%) of the gross proceeds received by the Company from the sale of the Shares; provided, however, that
in the event that the Offering is terminated, the Company agrees to reimburse the Underwriters pursuant to Section 7 hereof. Notwithstanding
the foregoing, any advance previously paid by the Company to the Representative against the Representative&rsquo;s non-accountable expense
allowance actually anticipated to be incurred, which the Company and the Representative acknowledge is in the amount of $50,000 </FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">(the
&ldquo;<U>Advance</U>&rdquo;), shall be applied towards the accountable expenses set forth herein; provided that the Representative will
reimburse the Company for any remaining portion of the Advance to the extent amount of the Advance was not used for accountable expenses
actually incurred by the Representative in the offering in accordance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xvii) As of the Closing
Date, the Company shall have retained an investor relations advisory firm reasonably acceptable to the Representatives and the Company
and shall retain such firm or another firm reasonably acceptable to the Representatives for a period of not less than one (1) year after
the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xviii) On or prior
to the date of this Agreement, the Company will have appropriate Directors&rsquo; &amp; Officers&rsquo; (&ldquo;<U>D&amp;O&rdquo;</U>)
and Errors &amp; Omissions (&ldquo;<U>E&amp;O&rdquo;</U>) insurance with appropriate liability levels as reasonably determined by the
Company. The Company acknowledges and agrees that the Representative and their principal officers shall be named additional insureds of
the Company&rsquo;s D&amp;O and E&amp;O insurance policies. [NTD: has this been done?]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>6. Conditions of the
Underwriter&rsquo;s Obligations.</I></B> The respective obligations of the several Underwriters hereunder to purchase the Shares are subject
to the accuracy, as of the date hereof and at all times through the Closing Date, and on each Option Closing Date (as if made on the Closing
Date or such Option Closing Date, as applicable), of and compliance with all representations, warranties and agreements of the Company
contained herein, the performance by the Company of its obligations hereunder and the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) If filing of the Final Prospectus,
or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, is required under the Securities Act or the Rules and Regulations,
the Company shall have filed the Final Prospectus (or such amendment or supplement) or such Issuer Free Writing Prospectus with the Commission
in the manner and within the time period so required (without reliance on Rule 424(b)(8) or 164(b) under the Securities Act); the Registration
Statement shall remain effective; no stop order suspending the effectiveness of the Registration Statement or any part thereof, any Rule
462 Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Time of Sale Disclosure Package, any
Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus shall have been issued; no proceedings for the issuance of such
an order shall have been initiated or threatened by the Commission; any request of the Commission or the Representative for additional
information (to be included in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus,
any Issuer Free Writing Prospectus or otherwise) shall have been complied with to the satisfaction of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) The Common Stock and Warrants
shall be approved for listing on Nasdaq, and satisfactory evidence thereof shall have been provided to the Representative and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) FINRA shall have raised
no objection to the fairness and reasonableness of the underwriting terms and arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) The Representative shall
not have reasonably determined, and advised the Company, that the Registration Statement, the Time of Sale Disclosure Package, any Prospectus,
the Final Prospectus, or any amendment thereof or supplement thereto, or any Issuer Free Writing Prospectus, contains an untrue statement
of fact which, in the reasonable opinion of the Representative, is material, or omits to state a fact which, in the reasonable opinion
of the Representative, is material and is required to be stated therein or necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) On the Closing Date and
on each Option Closing Date, there shall have been furnished to the Representative on behalf of the Underwriter the opinion and negative
assurance letters of TroyGould PC, corporate counsel to the Company, dated the Closing Date or the Option Closing Date, as applicable,
and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) On the Closing Date and
on each Option Closing Date, there shall have been furnished to the Representative on behalf of the Underwriter the opinion and negative
assurance letters of Dechert LLP, intellectual property counsel to the Company, dated the Closing Date or the Option Closing Date, as
applicable, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representative</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) The Underwriters shall have
received a letter of Weinberg &amp; Company, P.A, on the date hereof and on the Closing Date and on each Option Closing Date, addressed
to the Underwriters, confirming that they are independent public accountants within the meaning of the Securities Act and are in compliance
with the applicable requirements relating to the qualifications of accountants under Rule 2-01 of Regulation S-X of the Commission, and
confirming, as of the date of each such letter (or, with respect to matters involving changes or developments since the respective dates
as of which specified financial information is given in the Registration Statement, the Time of Sale Disclosure Package and the Final
Prospectus, as of a date not prior to the date hereof or more than five (5) days prior to the date of such letter), the conclusions and
findings of said firm with respect to the financial information and other matters required by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j) On the Closing Date and
on each Option Closing Date, there shall have been furnished to the Underwriters a certificate, dated the Closing Date and on each Option
Closing Date and addressed to the Underwriters, signed by the chief executive officer and the chief financial officer of the Company,
in their capacity as officers of the Company, to the effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) The representations
and warranties of the Company in this Agreement that are qualified by materiality or by reference to any Material Adverse Effect are true
and correct in all respects, and all other representations and warranties of the Company in this Agreement are true and correct, in all
material respects, as if made at and as of the Closing Date and on the Option Closing Date, and the Company has complied in all material
respects with all the agreements and satisfied all the conditions on its part required to be performed or satisfied at or prior to the
Closing Date or on the Option Closing Date, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii) No stop order
or other order (A) suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof, (B) suspending
the qualification of the Securities for offering or sale, or (C) suspending or preventing the use of the Time of Sale Disclosure Package,
any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus, has been issued, and no proceeding for that purpose has been
instituted or, to their knowledge, is contemplated by the Commission or any state or regulatory body; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii) There has been
no occurrence of any event resulting or reasonably likely to result in a Material Adverse Effect during the period from and after the
date of this Agreement and prior to the Closing Date or on the Option Closing Date, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k) On or before the date hereof,
the Representative shall have received duly executed lock-up agreement, substantially in the form of <B>Exhibit B</B> hereto (each a &ldquo;<U>Lock-Up
Agreement</U>&rdquo;), by and between the Representative and each of the parties specified in <B>Schedule IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l) On the Closing Date, the
Company shall have delivered to the Representative executed copies of the Warrant Agreement and the Representative&rsquo;s Warrant<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m) The Company shall have furnished
to the Representative and its counsel such additional documents, certificates and evidence as the Representative and its counsel may have
reasonably requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any condition specified
in this Section 6 shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated by the Representative
by notice to the Company at any time at or prior to the Closing Date or on the Option Closing Date, as applicable, and such termination
shall be without liability of any party to any other party, except that Section 5(a)(viii), Section 7 and Section 8 shall survive any
such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>7. Indemnification and
Contribution</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company agrees to indemnify,
defend and hold harmless each Underwriter, its affiliates, directors and officers and employees, and each person, if any, who controls
such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any losses,
claims, damages or liabilities to which such Underwriter or such person may become subject, under the Securities Act or otherwise (including
in settlement of any litigation if such settlement is effected with the written consent of the Company), insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) an untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement, including the information deemed to be a part of the Registration Statement
at the time of effectiveness and at any subsequent time pursuant to Rules 430A and 430B of the Rules and Regulations, or arise out of
or are based upon the omission from the Registration Statement, or alleged omission to state therein, a material fact required to be stated
therein or necessary to make the statements therein not misleading (ii) an untrue statement or alleged untrue statement of a material
fact contained in the Time of Sale Disclosure Package, any <FONT STYLE="background-color: white">oral or written communication with potential
investors undertaken in reliance on Section 5(d) of the </FONT>Securities <FONT STYLE="background-color: white">Act</FONT> (<U>Written
Testing-the-Waters Communications</U>), any Prospectus, the Final Prospectus, or any amendment or supplement thereto, any Issuer Free
Writing Prospectus, or the Marketing Materials or in any other materials used in connection with the offering of the Securities, or arise
out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading, (iii) in whole or in part, any
inaccuracy in the representations and warranties of the Company contained herein, or (iv) in whole or in part, any failure of the Company
to perform its obligations hereunder or under law, and will reimburse each Underwriter for any legal or other expenses reasonably incurred
by it in connection with evaluating, investigating or defending against such loss, claim, damage, liability or action; <I>provided, however</I>,
that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out
of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement,
the Time of Sale Disclosure Package, any Written Testing-the-Waters Communications, any Prospectus, the Final Prospectus, or any amendment
or supplement thereto or any Issuer Free Writing Prospectus, in reliance upon and in conformity with written information furnished to
the Company by such Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Each Underwriter, severally
and not jointly, will indemnify, defend and hold harmless the Company, its affiliates, directors, officers and employees, and each person,
if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against
any losses, claims, damages or liabilities to which the Company may become subject, under the Securities Act or otherwise (including in
settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus,
or any amendment or supplement thereto or any Issuer Free Writing Prospectus, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in
each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission
was made in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus, or any amendment or
supplement thereto or any Issuer Free Writing Prospectus in reliance upon and in conformity with written information furnished to the
Company by such Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f), and
will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with evaluating, investigating,
and defending against any such loss, claim, damage, liability or action. The obligation of each Underwriter to indemnify the Company (including
any controlling person, director or officer thereof) shall be limited to the amount of the underwriting discount applicable to the Shares
to be purchased by such Underwriter hereunder actually received by such Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Promptly after receipt by
an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if a
claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing
of the commencement thereof, but the failure to notify the indemnifying party shall not relieve the indemnifying party from any liability
that it may have to any indemnified party except to the extent such indemnifying party has been materially prejudiced by such failure.
In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement
thereof, the indemnifying party shall be entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying
party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party, and after notice from the
indemnifying party to such indemnified party of the indemnifying party&rsquo;s election so to assume the defense thereof, the indemnifying
party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such
indemnified party in connection with the defense thereof; <I>provided</I>, <I>however</I>, that if (i) the indemnified party has reasonably
concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different
from or in addition to those available to the indemnifying party, (ii) a conflict or potential conflict exists (based on advice of counsel
to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have
the right to direct the defense of such action on behalf of the indemnified party), or (iii) the indemnifying party has not in fact employed
counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time after receiving
notice of the commencement of the action, the indemnified party shall have the right to employ a single counsel to represent it in any
claim in respect of which indemnity may be sought under subsection (a) or (b) of this Section 7, in which event the reasonable fees and
expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the indemnified party as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The indemnifying party under
this Section 7 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such
consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any
loss, claim, damage, liability or expense by reason of such settlement or judgment. No indemnifying party shall, without the prior written
consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action,
suit or proceeding in respect of which any indemnified party is a party or could be named and indemnity was or would be sought hereunder
by such indemnified party, unless such settlement, compromise or consent (a) includes an unconditional release of such indemnified party
from all liability for claims that are the subject matter of such action, suit or proceeding and (b) does not include a statement as to
or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) If the indemnification provided
for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under subsection (a) or (b) above, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages
or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate to reflect the relative benefits received
by the Company on the one hand and the Underwriters on the other from the offering and sale of the Shares or (ii) if the allocation provided
by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company on the one hand and the Underwriters on the other in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be
in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total
underwriting discount received by the Underwriters, in each case as set forth in the table on the cover page of the Final Prospectus.
The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters and
the parties&rsquo; relevant intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission.
The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this subsection (d) were to
be determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred
to in the first sentence of this subsection (d). The amount paid by an indemnified party as a result of the losses, claims, damages or
liabilities referred to in the first sentence of this subsection (d) shall be deemed to include any legal or other expenses reasonably
incurred by such indemnified party in connection with investigating or defending against any action or claim that is the subject of this
subsection (d). Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess
of the amount of the of the underwriting discount applicable to the Shares to be purchased by such Underwriter hereunder actually received
by such Underwriter. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&rsquo; respective
obligations to contribute as provided in this Section 7 are several in proportion to their respective underwriting commitments and not
joint.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) The obligations of the Company
under this Section 7 shall be in addition to any liability that the Company may otherwise have and the benefits of such obligations shall
extend, upon the same terms and conditions, to each person, if any, who controls any Underwriter within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act; and the obligations of each Underwriter under this Section 7 shall be in addition to
any liability that each Underwriter may otherwise have and the benefits of such obligations shall extend, upon the same terms and conditions,
to the Company and its officers, directors and each person who controls the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) For purposes of this Agreement,
each Underwriter severally confirms, and the Company acknowledges, that there is no information concerning such Underwriter furnished
in writing to the Company by such Underwriter specifically for preparation of or inclusion in the Registration Statement, the Time of
Sale Disclosure Package, any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus, other than the statement set forth
in the last paragraph on the cover page of the Prospectus, the marketing and legal names of each Underwriter, and the statements set forth
in the &ldquo;Underwriting&rdquo; section of the Registration Statement, the Time of Sale Disclosure Package, and the Final Prospectus
only insofar as such statements relate to the amount of selling concession and re-allowance, if any, or to over-allotment, stabilization
and related activities that may be undertaken by such Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>8. Representations and
Agreements to Survive Delivery</I></B>. All representations, warranties, and agreements of the Company contained herein or in certificates
delivered pursuant hereto, including, but not limited to, the agreements of the several Underwriters and the Company contained in Section
5(a)(viii) and Section 7 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf
of the several Underwriters or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons,
and shall survive delivery of, and payment for, the Shares to and by the Underwriters hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>9. Termination of this
Agreement</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Representative shall
have the right to terminate this Agreement by giving notice to the Company as hereinafter specified at any time at or prior to the Closing
Date or any Option Closing Date (as to the Option Shares to be purchased on such Option Closing Date only), if in the discretion of the
Representative, (i) there has occurred any material adverse change in the securities markets or any event, act or occurrence that has
materially disrupted, or in the opinion of the Representative, will in the future materially disrupt, the securities markets or there
shall be such a material adverse change in general financial, political or economic conditions or the effect of international conditions
on the financial markets in the United States is such as to make it, in the judgment of the Representative, inadvisable or impracticable
to market the Shares or enforce contracts for the sale of the Shares (ii) trading in the Company&rsquo;s Common Stock shall have been
suspended by the Commission or Nasdaq or trading in securities generally on the Nasdaq Stock Market, the NYSE or the NYSE MKT shall have
been suspended, (iii) minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have
been required, on the Nasdaq Stock Market, the NYSE or NYSE American, by such exchange or by order of the Commission or any other governmental
authority having jurisdiction, (iv) a banking moratorium shall have been declared by federal or state authorities, (v) there shall have
occurred any attack on, outbreak or escalation of hostilities or act of terrorism involving the United States any declaration by the United
States of a national emergency or war, any substantial change or development involving a prospective substantial change in United States
or other international political, financial or economic conditions or any other calamity or crisis, or (vi) the Company suffers any loss
by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, or (vii) in the judgment of the Representative,
there has been, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration
Statement, the Time of Sale Disclosure Package or the Final Prospectus, any material adverse change in the assets, properties, condition,
financial or otherwise, or in the results of operations, business affairs or business prospects of the Company, whether or not arising
in the ordinary course of business. Any such termination shall be without liability of any party to any other party except that the provisions
of Section 5(a)(viii) and Section 7 hereof shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) If the Representative elects
to terminate this Agreement as provided in this Section 9, the Company and the other Underwriters shall be notified promptly by the Representative
by telephone, confirmed by letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) If this Agreement is terminated
pursuant to any of its provisions, the Company shall not be under any liability to any Underwriter, and no Underwriter shall be under
any liability to the Company, except that (y) subject to a maximum reimbursement of $150,000, the Company will reimburse the Representative
only for all actual, accountable out-of-pocket expenses (including the reasonable fees and disbursements of its counsel) reasonably incurred
by the Representative in connection with the proposed purchase and sale of the Shares or in contemplation of performing their obligations
hereunder and (z) no Underwriter who shall have failed or refused to purchase the Shares agreed to be purchased by it under this Agreement,
without some reason sufficient hereunder to justify cancellation or termination of its obligations under this Agreement, shall be relieved
of liability to the Company, or to the other Underwriters for damages occasioned by its failure or refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>10. Substitution of
Underwriters</I></B>. If any Underwriter or Underwriters shall default in its or their obligations to purchase Shares hereunder on the
Closing Date or any Option Closing Date and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but
failed to purchase does not exceed ten percent (10%) of the total number of Shares to be purchased by all Underwriters on such Closing
Date or Option Closing Date, the other Underwriters shall be obligated severally, in proportion to their respective commitments hereunder,
to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed to purchase on such Closing Date or Option
Closing Date. If any Underwriter or Underwriters shall so default and the aggregate number of Shares with respect to which such default
or defaults occur is more than ten percent (10%) of the total number of Shares to be purchased by all Underwriters on such Closing Date
or Option Closing Date and arrangements satisfactory to the remaining Underwriters and the Company for the purchase of such Shares by
other persons are not made within forty-eight (48) hours after such default, this Agreement shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the remaining Underwriters
or substituted Underwriters are required hereby or agree to take up all or part of the Shares of a defaulting Underwriter or Underwriters
on such Closing Date or Option Closing Date as provided in this Section 10, (i) the Company shall have the right to postpone such Closing
Date or Option Closing Date for a period of not more than five (5) full business days in order to permit the Company to effect whatever
changes in the Registration Statement, the Final Prospectus, or in any other documents or arrangements, which may thereby be made necessary,
and the Company agrees to promptly file any amendments to the Registration Statement or the Final Prospectus which may thereby be made
necessary, and (ii) the respective numbers of Shares to be purchased by the remaining Underwriters or substituted Underwriters shall be
taken as the basis of their underwriting obligation for all purposes of this Agreement. Nothing herein contained shall relieve any defaulting
Underwriter of its liability to the Company or any other Underwriter for damages occasioned by its default hereunder. Any termination
of this Agreement pursuant to this Section 10 shall be without liability on the part of any non-defaulting Underwriters or the Company,
except that the obligations with respect to expenses to be paid or reimbursed pursuant to Section 5(a)(viii) and Section 7 and Sections
9 through 17, inclusive, shall not terminate and shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>11. [Intentionally Omitted]</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>12. Notices</I></B>. All notices and communications
hereunder shall be in writing and mailed or delivered or by telephone, electronic mail or telegraph if subsequently confirmed in writing,
(a) if to the Representative, WallachBeth Capital, LLC Harborside Financial Plaza 5, 185 Hudson St., Suite 1410, Jersey City, NJ 07311,
Kenneth Bantum, with a copy (which shall not constitute notice) to Carmel, Milazzo &amp; Feil LLP, 55 West 39<SUP>th</SUP> Street, 18<SUP>th</SUP>
Floor, New York, NY 10018, Attention: Ross Carmel and Jeffrey Wofford, and (b) if to the Company, to the Company&rsquo;s [*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>13. Persons Entitled
to Benefit of Agreement</I></B>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and assigns and the controlling persons, officers and directors referred to in Section 7. Nothing in this Agreement is intended
or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or claim under or in respect of this
Agreement or any provision herein contained. The term &ldquo;successors and assigns&rdquo; as herein used shall not include any purchaser,
as such purchaser, of any of the Shares from any Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>14. Absence of Fiduciary
Relationship</I></B>. The Company acknowledges and agrees that: (a) each Underwriter has been retained solely to act as underwriter in
connection with the sale of the Shares and that no fiduciary, advisory or agency relationship between the Company and any Underwriter
has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Underwriter has advised
or is advising the Company on other matters; (b) the price and other terms of the Shares set forth in this Agreement were established
by the Company following discussions and arms-length negotiations with the Underwriters and the Company is capable of evaluating and understanding
and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c) it has been advised
that the Underwriters and their affiliates are engaged in a broad range of transactions that may involve interests that differ from those
of the Company and that no Underwriter has any obligation to disclose such interest and transactions to the Company by virtue of any fiduciary,
advisory or agency relationship; and (d) it has been advised that each Underwriter is acting, in respect of the transactions contemplated
by this Agreement, solely for the benefit of such Underwriter, and not on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>15. Amendments and Waivers</I></B>.
No supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby.
The failure of a party to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future.
No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless
of whether similar), nor shall any such waiver be deemed or constitute a continuing waiver unless otherwise expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>16. Partial Unenforceability</I></B>.
The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability
of any other section, paragraph, clause or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>17. Governing Law</I></B>.
This Agreement shall be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>18. Submission to Jurisdiction</I></B>.
The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall
be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection
to such exclusive jurisdiction and that such courts represent an inconvenient forum. EACH OF THE COMPANY (ON BEHALF OF ITSELF AND, TO
THE FULLEST EXTENT PERMITTED BY LAW, ON BEHALF OF ITS RESPECTIVE EQUITY HOLDERS AND CREDITORS) AND THE UNDERWRITER HEREBY WAIVES ANY RIGHT
IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT, THE TIME OF SALE DISCLOSURE PACKAGE, ANY PROSPECTUS AND THE FINAL PROSPECTUS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>19. Counterparts.</I></B>
This Agreement may be executed and delivered (including by facsimile transmission or electronic mail) in one or more counterparts and,
if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall
together constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Please sign and return to the
Company the enclosed duplicates of this letter whereupon this letter will become a binding agreement between the Company and the several
Underwriters in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUTRIBAND, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed as of the date first above-mentioned by the Representative of the several Underwriters.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WALLACBETH CAPITAL, LLC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page to Underwriting Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number of Firm</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities to be</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Purchased</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Total Number of Option</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Securities to be</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Purchased</I></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Number of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Firm Units</P></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Number of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Option Shares</P></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Number&nbsp;of<BR>
</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Option Warrants</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wallachbeth Capital, LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WestPark Capital, Inc.</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Firm Units: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Option Shares: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Option Warrants: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Public Offering Price per Firm Unit: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Public Offering Price per Option Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Underwriting Discount per Firm Unit: $[&#9679;]
(__% per Firm Unit)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Underwriting non-accountable expense allowance
per Firm Unit: $[&#9679;] (1.7% per Firm Unit)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Free Writing Prospectus</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dr. John S. Kovach</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dr. James S. Miser</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Robert N. Weingarten</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eric Forman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dr. Philip F. Palmedo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dr. Stephen J. Forman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dr. Winson Sze Chun Ho</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dr. Yun Yen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Representative&rsquo;s Warrant </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2pt">THE REGISTERED HOLDER OF THIS
PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED
AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE
WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE LATER OF THE EFFECTIVE DATE (DEFINED BELOW) OR THE COMMENCEMENT OF
SALES OF THE OFFERING TO WHICH THIS PURCHASE WARRANT RELATES TO ANYONE OTHER THAN (I) WALLACHBETH CAPITAL, LLC, WESTPARK CAPITAL, INC.,
OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF WALLACHBETH CAPITAL,
LLC, WESTPARK CAPITAL, INC., OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2pt">THIS PURCHASE WARRANT IS NOT
EXERCISABLE PRIOR TO [<B>DATE THAT IS 180 DAYS FROM THE EFFECTIVE DATE OF THE OFFERING</B>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2pt">VOID AFTER 5:00 P.M., EASTERN
TIME, [<B>DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING</B>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANT TO PURCHASE COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NUTRIBAND, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant Shares: ________________<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initial Exercise Date: [<B>DATE THAT IS 180 DAYS
FROM THE EFFECTIVE DATE OF THE OFFERING</B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT TO PURCHASE COMMON
STOCK (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
_____________, 2021 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00
p.m. (New York time) on _____________, 2025 (the &ldquo;<U>Termination Date</U>&rdquo;), but not thereafter, to subscribe for and purchase
from Nutriband, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to _______________<SUP>1</SUP> shares of common stock,
par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company (the &ldquo;<U>Warrant Shares</U>&rdquo;), as subject
to adjustment hereunder. The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1 </SUP>10% of the total number of Units
sold in the offering, excluding shares sold in connection with exercise of the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effective Date</U>&rdquo;
means the effective date of the registration statement on Form S-1 (File No. 333-238829), including any related prospectus or prospectuses,
for the registration of the Company&rsquo;s Common Stock and the Warrant Shares under the Securities Act, that the Company has filed with
the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market located in the United States is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or
any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Underwriting Agreement</U>&rdquo;
means the underwriting agreement, dated ________________, 2020, by and between the Company and WallachBeth Capital, LLC, as representative
of the underwriters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the
Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if Common Stock is not
then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock are then reported in the &ldquo;Pink Sheets&rdquo;
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of the Common Stock as determined by
an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a. Exercise of the purchase
rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on
or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice
in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy
(or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within two (2) Trading Days following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or
cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified
in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the
amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b. <U>Exercise Price</U>. The
exercise price per share of the Common Stock under this Warrant shall be <B>$_______</B><SUP>2</SUP>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c. <U>Cashless Exercise</U>.
If at any time on or after the Initial Exercise Date, there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive the number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify; text-indent: -0.3in">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(64) of
Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the VWAP on the Trading Day immediately preceding
the date of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading
Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the
close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify; text-indent: -0.3in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify; text-indent: -0.3in">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If Warrant Shares are issued
in such a &ldquo;cashless exercise,&rdquo; the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrants
being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to
this Section 2(c).</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>2 </SUP>120% of the public offering price
per Unit in the offering.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d. <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i. <U>Delivery of Warrant
Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by its transfer agent to the
Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through
DWAC if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
of the Warrant Shares to or resale of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without
volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder prior to
the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to
such exercise to the address specified by the Holder in the Notice of Exercise by the date that is two (2) Trading Days after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). If the Warrant Shares can
be delivered via DWAC, the transfer agent shall have received from the Company, at the expense of the Company, any legal opinions or other
documentation required by it to deliver such Warrant Shares without legend (subject to receipt by the Company of reasonable back up documentation
from the Holder, including with respect to affiliate status) and, if applicable and requested by the Company prior to the Warrant Share
Delivery Date, the transfer agent shall have received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement
of the Holder to provide a confirmation as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant
Shares upon a cashless exercise of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant
Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become
a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the
Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares
subject to a Notice of Exercise by the second (2<SUP>nd</SUP>) Trading Day following the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth (5<SUP>th</SUP>) Trading Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading
Day following such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii. <U>Delivery of New Warrants
Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender
of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights
of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iii. <U>Rescission Rights</U>.
If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise; <U>provided</U>, <U>however</U>, that the Holder shall
be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently with the return to
Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder&rsquo;s right to acquire
such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iv. <U>Compensation for Buy-In
on Failure to Timely Deliver Warrant Shares upon Exercise</U>. In addition to any other rights available to the Holder, if the Company
fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share
Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or
the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the
Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay
in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company
was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise
to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to
the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery
obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with
respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000,
under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide
the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder,
at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">v. <U>No Fractional Shares
or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either
pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round
up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">vi. <U>Charges, Taxes and
Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">vii. <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant
to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">viii. <U>Signature</U>. This
Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to exercise this
Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any exercise form be required in order to exercise this Purchase Warrant. No additional
legal opinion, other information or instructions shall be required of the Holder to exercise this Purchase Warrant. The Company shall
honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant in accordance with the terms, conditions
and time periods set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e. <U>Holder&rsquo;s Exercise
Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion
of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group
together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and
its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Company&rsquo;s transfer agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two (2) Trading Days
confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this
Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99]% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial
Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a. <U>Stock Dividends and Splits</U>.
If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance
of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant
shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification. For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the
Company or any subsidiary thereof, as applicable, sells or grants any option to purchase, or sell or grant any right to reprice, or otherwise
dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock
equivalents, at an effective price per share less than the Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b. [RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c. <U>Subsequent Rights Offerings</U>.
In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock equivalents
or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock
(the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in
such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d. <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than cash dividends) or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of shares or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution&rdquo;</U>), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent
that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion
of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e. <U>Fundamental Transaction</U>.
If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable by holders of Common Stock as a result of such Fundamental Transaction for each share of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of
this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to
such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the Exercise Price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">f. <U>Calculations</U>. All
calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">g. <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i. <U>Adjustment to Exercise
Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the
Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and
setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii. <U>Notice to Allow Exercise
by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company
shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting
to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any
rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock,
any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company,
or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall
authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be mailed a notice to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least
20 calendar days prior to the applicable record or effective date hereinafter specified, stating (x) the date on which a record is to
be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are
to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to
become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; provided that the failure to provide such notice or any defect therein shall not affect the validity
of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a <U>Transferability</U>. Pursuant
to FINRA Rule 5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Effective Date
or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">i. by operation of law or by
reason of reorganization of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">ii. to any FINRA member firm
participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction
in this Section 4(a) for the remainder of the time period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">iii. if the aggregate amount
of securities of the Company held by the Holder or related person do not exceed one percent (1%) of the securities being offered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">iv. that is beneficially owned
on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments
by the fund, and participating members in the aggregate do not own more than ten percent (10%) of the equity in the fund; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">v. the exercise or conversion
of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the foregoing restriction,
any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b. <U>New Warrants</U>. This
Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with
a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice.
All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this
Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c. <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d. <U>Representation by the
Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof,
will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling
such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to
sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Registration
Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a. Demand Registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i. Grant of Right. The Company,
upon written demand (a &ldquo;<U>Demand Notice</U>&rdquo;) of the Holder(s) of at least 51% of the Warrants and/or the underlying Warrant
Shares, agrees to register on Form S-3 (if available) or Form S-1 (if Form S-3 is not available), on one occasion, all or any portion
of the Warrant Shares underlying the Warrants (collectively, the &ldquo;<U>Registrable Securities</U>&rdquo;). On such occasion, the Company
will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand
Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject to compliance
with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company
has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section 5(b)
hereof and either: (i) the Holder has elected to participate in the offering covered by such registration statement or (ii) if such registration
statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement
has been withdrawn or until thirty (30) days after such offering is consummated. The demand for registration may be made at any time beginning
on the Initial Exercise Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s)
to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of
any such Demand Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii. Terms. The Company shall
bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 5(a)(i), but the Holders shall
pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection
with the sale of the Registrable Securities. The Company agrees to use its best efforts to cause the filing required herein to become
effective promptly and to qualify or register the Registrable Securities in such States as are reasonably requested by the Holder(s);
provided, however, that in no event shall the Company be required to register the Registrable Securities in a State in which such registration
would cause: (i) the Company to be obligated to register or license to do business in such State or submit to general service of process
in such State or (ii) the principal shareholders of the Company to be obligated to escrow their shares of capital stock of the Company.
The Company shall cause any registration statement filed pursuant to the demand right granted under Section 5(a)(i) to remain effective
for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities covered by such
registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided
by the Company to sell the Warrant Shares covered by such registration statement, and will immediately cease to use any prospectus furnished
by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission.
Notwithstanding the provisions of this Section 5(a)(ii), the Holder shall be entitled to a demand registration under this Section 5(a)(ii)
on only one (1) occasion and such demand registration right shall terminate on the fifth (5<SUP>th</SUP>) anniversary of the Effective
Date or commencement of sales of the offering pursuant to which this Warrant is being issued in accordance with FINRA Rule 5110(g)(8)(C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b. <U>&ldquo;Piggy-Back&rdquo;
Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i. <U>Grant of Right</U>.
In addition to the demand right of registration described in Section 5(a) hereof, the Holder shall have the right, for a period of no
more than five years from the Effective Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable Securities as part
of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a)
promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely in connection
with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable
discretion, impose a limitation on the number of shares of Common Stock which may be included in the Registration Statement because, in
such underwriter(s)&rsquo; judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution,
then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities
with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable
Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless
the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such
Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii. <U>Terms</U>. The Company
shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5(b)(i) hereof, but the Holders
shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection
with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish the then Holders
of outstanding Registrable Securities with not less than fifteen (15) days written notice prior to the proposed date of filing of such
registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company during
the two (2) year period following the Initial Exercise Date until such time as all of the Registrable Securities have been sold by the
Holder. The holders of the Registrable Securities shall exercise the &ldquo;piggy-back&rdquo; rights provided for herein by giving written
notice within five (5) days of the receipt of the Company&rsquo;s notice of its intention to file a registration statement. Except as
otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration under this Section
5(b)(ii); provided, however, that such registration rights shall terminate on the fifth (5<SUP>th</SUP>) anniversary of the date of the
Underwriting Agreement in accordance with FINRA Rule 5110(g)(8)(D).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c. <U>General Terms</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i. <U>Indemnification</U>.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and
each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange
Act against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities
Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the
provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section 7(a) of the Underwriting Agreement.
The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall
severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo;
fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become
subject under the Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or
their successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect
as the provisions contained in Section 7(a) of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii. <U>Exercise of Warrants</U>.
Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or after the initial
filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iii. <U>Documents Delivered
to Holders</U>. The Company shall deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda
described below and to the managing underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel
or auditors and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and
permit each Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in
or omitted from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA.
Such investigation shall include access to books, records and properties and opportunities to discuss the business of the Company with
its officers and independent auditors, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iv. <U>Intentionally Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">v. <U>Documents to be Delivered
by Holder(s)</U>. Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company a completed and executed
questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">vi. <U>Damages</U>. Should
the registration or the effectiveness thereof required by Sections 5(a) or 5(b) hereof be delayed by the Company or the Company otherwise
fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s),
be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions
or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other
security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 6</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a. <U>No Rights as Stockholder
until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company
prior to the exercise hereof as set forth in Section 2(d)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b. <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares, and in case of loss, theft or
destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting
of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver
a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c. <U>Saturdays, Sundays, Holidays,
etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not
be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d. <U>Authorized Shares</U>.
The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock
a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that
all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the
purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain
all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e. <U>Jurisdiction</U>. All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with
the provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">f. <U>Restrictions</U>. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize
cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">g. <U>Nonwaiver and Expenses</U>.
No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right
or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Underwriting
Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">h. <U>Notices</U>. Any notice,
request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">i. <U>Limitation of Liability</U>.
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">j. <U>Remedies</U>. The Holder,
in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance
of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for
specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">k. <U>Successors and Assigns</U>.
Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and
be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">l. <U>Amendment</U>. This Warrant
may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">m. <U>Severability</U>. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if
any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">n. <U>Headings</U>. The headings
used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>NUTRIBAND, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">TO: <FONT STYLE="text-transform: uppercase">NUTRIBAND,
Inc. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase _____________ Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of
the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in lawful money of the United States; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please register and issue
said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[________________________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[________________________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[________________________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4) <U>Accredited Investor</U>.
If the Warrant is being exercised via cash exercise, the undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation
D promulgated under the Securities Act of 1933, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD STYLE="width: 65%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 93%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To assign the foregoing warrant, execute<BR>
this form and supply required information.<BR>
Do not use this form to exercise the warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, [&nbsp;&nbsp;] all of or [&nbsp;&nbsp;]
shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">whose address is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Dated: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 120px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE: The signature to this Assignment Form must
correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers
of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the
foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up<BR>
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">__________, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WallachBeth Capital, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Harborside Financial Center Plaza 5,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">185 Hudson Street, Suite 1410 Jersey City, New
Jersey 07311,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As Representative of the several Underwriters
named on Schedule 1 to the Underwriting Agreement referenced below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that WallachBeth Capital, LLC (the &ldquo;<B>Representative</B>&rdquo;), proposes to enter into an Underwriting Agreement (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;) with Nutriband, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), providing for the public offering
(the &ldquo;<B>Public Offering</B>&rdquo;) of shares of common stock, par value $0.001 per share, of the Company (the &ldquo;<B>Common
Shares</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To induce the Representative
to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent
of the Representative, the undersigned will not, during the period commencing on the date hereof and ending one hundred eighty (180) days
after the effective date of the Registration Statement on Form S-1 relating to the Public Offering (the &ldquo;<B>Lock-Up Period</B>&rdquo;),
(1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Shares
or any securities convertible into or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by the undersigned
or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;);
(2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities,
in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4)
publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other
arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may
transfer Lock-Up Securities without the prior written consent of the Representative in connection with (a) transactions relating to Lock-Up
Securities acquired in open market transactions after the completion of the Public Offering; <U>provided</U> that no filing under Section
13 or Section 16(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), or other public announcement
shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities acquired in such open market
transactions; (b) transfers of Lock-Up Securities as a <I>bona fide </I>gift, by will or intestacy or to a family member or trust for
the benefit of the undersigned (for purposes of this lock-up agreement, &ldquo;family member&rdquo; means any relationship by blood, marriage
or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution; (d) if the
undersigned is a corporation, partnership, limited liability company or other business entity, (i) any transfers of Lock-Up Securities
to another corporation, partnership or other business entity that controls, is controlled by or is under common control with the undersigned
or (ii) distributions of Lock-Up Securities to members, partners, stockholders, subsidiaries or affiliates (as defined in Rule 405 promulgated
under the Securities Act of 1933, as amended) of the undersigned; (e) if the undersigned is a trust, to a trustee or beneficiary of the
trust; <U>provided</U> that in the case of any transfer pursuant to the foregoing clauses (b), (c) (d) or (e), (i) any such transfer shall
not involve a disposition for value, (ii) each transferee shall sign and deliver to the Representative a lock-up agreement substantially
in the form of this lock-up agreement and (iii) no filing under Section 13 or Section 16(a) of the Exchange Act or other public announcement
shall be required or shall be voluntarily made during the Lock-Up Period; (f) the receipt by the undersigned from the Company of Common
Shares upon the vesting of restricted stock awards or stock units or upon the exercise of options to purchase the Company&rsquo;s Common
Shares issued under an equity incentive plan of the Company or an employment arrangement described in the Pricing Prospectus (as defined
in the Underwriting Agreement) (the &ldquo;<B>Plan Shares</B>&rdquo;) or the transfer or withholding of Common Shares or any securities
convertible into Common Shares to the Company upon a vesting event of the Company&rsquo;s securities or upon the exercise of options to
purchase the Company&rsquo;s securities, in each case on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis or to cover tax
obligations of the undersigned in connection with such vesting or exercise, <U>provided</U> that if the undersigned is required to file
a report under Section 13 or Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the
Lock-Up Period, the undersigned shall include a statement in such schedule or report to the effect that the purpose of such transfer was
to cover tax withholding obligations of the undersigned in connection with such vesting or exercise and, <U>provided further</U>, that
the Plan Shares shall be subject to the terms of this lock-up agreement; (g) the transfer of Lock-Up Securities pursuant to agreements
described in the Pricing Prospectus under which the Company has the option to repurchase such securities or a right of first refusal with
respect to the transfer of such securities, <U>provided </U>that if the undersigned is required to file a report under Section 13 or Section
16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned shall
include a statement in such schedule or report describing the purpose of the transaction; (h) the establishment of a trading plan pursuant
to Rule 10b5-1 under the Exchange Act for the transfer of Lock-Up Securities, <U>provided</U> that (i) such plan does not provide for
the transfer of Lock-Up Securities during the Lock-Up Period and (ii) to the extent a public announcement or filing under the Exchange
Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such
plan, such public announcement or filing shall include a statement to the effect that no transfer of Lock-Up Securities may be made under
such plan during the Lock-Up Period; (i) the transfer of Lock-Up Securities that occurs by operation of law, such as pursuant to a qualified
domestic order or in connection with a divorce settlement, <U>provided</U> that the transferee agrees to sign and deliver a lock-up agreement
substantially in the form of this lock-up agreement for the balance of the Lock-Up Period, and <U>provided further</U>, that any filing
under Section 13 or Section 16(a) of the Exchange Act that is required to be made during the Lock-Up Period as a result of such transfer
shall include a statement that such transfer has occurred by operation of law; and (j) the transfer of Lock- Up Securities pursuant to
a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Shares involving
a change of control (as defined below) of the Company after the closing of the Public Offering and approved by the Company&rsquo;s board
of directors; <U>provided</U> that in the event that the tender offer, merger, consolidation or other such transaction is not completed,
the Lock-Up Securities owned by the undersigned shall remain subject to the restrictions contained in this lock-up agreement. For purposes
of clause (j) above, &ldquo;change of control&rdquo; shall mean the consummation of any bona fide third party tender offer, merger, amalgamation,
consolidation or other similar transaction the result of which is that any &ldquo;person&rdquo; (as defined in Section 13(d)(3) of the
Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d- 5 of the Exchange Act) of a majority
of total voting power of the voting stock of the Company. The undersigned also agrees and consents to the entry of stop transfer instructions
with the Company&rsquo;s transfer agent and registrar against the transfer of the undersigned&rsquo;s Lock-Up Securities except in compliance
with this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the undersigned is an officer
or director of the Company, (i) the Representative agrees that, at least three (3) business days before the effective date of any release
or waiver of the foregoing restrictions in connection with a transfer of Lock-Up Securities, the Representative will notify the Company
of the impending release or waiver; and (ii) the Company has agreed in the Underwriting Agreement to announce the impending release or
waiver by press release through a major news service at least two (2) business days before the effective date of the release or waiver.
Any release or waiver granted by the Representative hereunder to any such officer or director shall only be effective two (2) business
days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is
effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound
by the same terms described in this lock-up agreement to the extent and for the duration that such terms remain in effect at the time
of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering.
The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned&rsquo;s heirs,
legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that, if the Underwriting Agreement is not executed by January 31, 2021 or if the Underwriting Agreement (other than the provisions thereof
which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder,
then this lock-up agreement shall be void and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not the Public
Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to
an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name - Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Signatory, in the case of entities - Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title of Signatory, in the case of entities - Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 228.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- 46 -</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



























































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea148206ex5-1_nutriband.htm
<DESCRIPTION>OPINION OF COUNSEL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Michael
Paige Law PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">2300 N Street,
N.W.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Washington,
D.C. 20037</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Telephone:
202-363-4791</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Facsimile:
202-457-1678</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">mpaigelaw@outlook.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">Admitted in the District of
Columbia</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">And New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">September 30, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nutriband Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">121 South Orange Ave., Suite 1500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Orlando, Florida 32801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>RE: Registration Statement on Form S-1 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is furnished to you in connection
with a Registration Statement on Form S-1 (File No. 333-259833, the &ldquo;Registration Statement&rdquo;) filed with the Securities and
Exchange Commission (the &ldquo;Commission&rdquo;) on September 27, 2021, for an public offering (&ldquo;Offering&rdquo;) through underwriters
(the &ldquo;Underwriters&rdquo;) of an aggregate of 1,056,000 shares (the &ldquo;Shares&rdquo;) of common stock, par value $0.001 per
share (&ldquo;Common Stock&rdquo;) and warrants (the &ldquo;Warrants&rdquo;) to purchase 1,056,000 Shares of Common Stock (the &ldquo;Warrant
Shares&rdquo;) of the Company, offered in 1,056,000 Units (the &ldquo;Units&rdquo;) at a price of $6.25 per Unit, under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), the prospectus that is part of the Registration Statement being herein referred
to as the &ldquo;Prospectus&rdquo;. The Company has granted the Underwriters the option for a period of 45 days after the effective date
under the Securities Act of the Registration Statement to purchase up to an additional 158,400 shares of Common Stock and/or 158,400 Warrants
(equal to 15% of the number of Shares and Warrants underlying the Units sold in the offering) from us in any combination thereof at the
public offering price per Share and per Warrant, less underwriting discounts and commissions, solely to cover over-allotments, if any.
Each Warrant is immediately exercisable, will entitle the holder to purchase one share of Common Stock at an exercise price of $7.50 and
will expire five (5) years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are acting as counsel for the Company in connection
with the registration for resale of the Shares and of the Warrant Shares in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have examined signed copies of the Registration
Statement filed with the Commission. We have also examined and relied upon minutes of meetings of the stockholders and the Board of Directors
of the Company as provided to us by the Company, stock record books of the Company as provided to us by the Company and its transfer agent,
the Articles of Incorporation and By-Laws of the Company, each as restated and/or amended to date, and such other documents as we have
deemed necessary for purposes of rendering the opinions hereinafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our examination of the foregoing documents,
we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original
documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence
of all signatories to such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We express no opinion herein as to the laws of
any state or jurisdiction other than the Chapter 78 Private Corporations of the Nevada Revised Statutes, and the federal laws of the United
States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon and subject to the foregoing, we are
of the opinion that the Shares, Warrants and Warrant Shares (the &ldquo;Securities&rdquo;) have been duly authorized for issuance, and
that, when (i)&nbsp;the Registration Statement, as finally amended, has become effective under the Securities Act, (ii)&nbsp;an appropriate
prospectus supplement with respect to the Securities has been prepared, filed and delivered in compliance with the Securities Act and
the applicable rules promulgated thereunder and (iii)&nbsp;the Shares and Warrants, and the Warrant Shares upon exercise of Warrants,
in accordance with the terms thereof, are issued and paid for as set forth herein, the Shares, Warrants and Warrant Shares, when issued,
will be duly and validly issued, and will be fully paid and nonassessable, and no opinion should be inferred as to any other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is based upon currently existing
statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources
of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this opinion
with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item&nbsp;601(b)(5) of Regulation
S-K under the Securities Act and to any reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MICHAEL PAIGE LAW PLLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 4%; padding-left: 12pt; text-indent: -12pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Paige</FONT></TD>
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>4
<FILENAME>ea148206ex4-12_nutriband.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 4.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>NUTRIBAND INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 12%">Warrant Shares:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 11%">&nbsp;</TD>
  <TD STYLE="width: 44%">&nbsp;</TD>
  <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>CUSIP:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"> ISIN:</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">THIS COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [&#9;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the initial exercise date first set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on September 30, 2026 (the &ldquo;Termination Date&rdquo;) but not thereafter, to subscribe for and purchase from Nutriband
Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to<U>&#9;</U>shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book- entry
form and the Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered holder of this
Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of that certain Warrant
Agent Agreement, dated September 30, 2021 (the &ldquo;<U>Warrant A</U>g<U>ent Agreement</U>&rdquo;), by and between American Stock Transfer&nbsp;&amp;
Trust Company, LLC, as warrant agent, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not listed or quoted on a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">&ldquo;<U>Board of Directors</U>&rdquo; means the board
of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT>&ldquo;<U>Business Da</U>y&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in
The City of New York are authorized or required by law to remain closed; p<U>rovided</U>, <U>however</U>, for clarification, commercial
banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;,
&ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations at the
direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial
banks in The City of New York generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">&ldquo;<U>Commission</U>&rdquo; means the United States
Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchan</U>g<U>e
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT>&ldquo;<U>Subsidiar</U>y&rdquo; means any subsidiary of the Company and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt">&ldquo;<U>Tradin</U>g <U>Day</U>&rdquo; means a day on
which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tradin</U>g
<U>Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
A</U>g<U>ent</U>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the current transfer agent of the Company, with a
mailing address of 6201 15th Ave, Brooklyn, NY 11219, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt">&ldquo;<U>Warrants</U>&rdquo; means this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">a) <U>Exercise of
Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company and the Warrant Agent of a duly
executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days
comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the
Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or
cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is
specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of
the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this
Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount
equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of
Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within
one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number
of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this
Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises
made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction
form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable),
subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agent Agreement,
in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $7.50, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of
Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP
on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the
principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise
if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours
thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section
2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day
and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo;
on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt">(B) = the Exercise Price of this Warrant, as adjusted hereunder;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in">(X) = the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a
cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing, and without limiting the rights of the Holder under Sections 2(d)(i) and 2(d)(iv), in no event will the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> d) <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">i. <U>Deliver</U>y <U>of
Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of
a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earliest of (i) two (2) Trading Days after the delivery to the Warrant Agent (with a copy to the Company) of
the Notice of Exercise and (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Warrant Agent (such date,
the &ldquo;<U>Warrant Share Deliver</U>y <U>Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed
for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been
exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other
than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to
deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay
to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $5 per Trading Day (increasing to $10 per
Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the
Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">ii. <U>Deliver</U>y
<U>of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Ri</U>g<U>hts</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Bu</U>y<U>-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of this Warrant to purchase shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts
payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">vi. <U>Char</U>g<U>es,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; p<U>rovided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">vii. <U>Closin</U>g
<U>of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">e) <U>Holder&rsquo;s Exercise Limitations</U>.
Neither the Company nor the Warrant Agent shall effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
&ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged and
accepted by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to
be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to
the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder shall be deemed to represent to the
Company and the Warrant Agent each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the
restrictions set forth in this paragraph, and the Company and the Warrant Agent shall have no obligation to verify or confirm the
accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section
2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of
Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case
may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company
shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In
any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which
such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be
4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The
Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61<FONT STYLE="font-size: 10pt">st </FONT>day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to
correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Section 3</U>. <U>Certain Ad</U>j<U>ustments</U>.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Ri</U>g<U>hts</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (p<U>rovided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of
its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other
disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of
50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock
held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a &ldquo;Fundamental Transaction&rdquo;), then, upon any
subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entit</U>y&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holders of a majority in interest of the Warrants then outstanding and approved
by such Holder or Holders (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holders of a majority in interest of the Warrants then
</FONT>outstanding. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> f) <U>Notice to Holder</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">i. <U>Ad</U>j<U>ustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise b</U>y <U>Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company
shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken as a whole) is a party, any
sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is
converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the
Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of
which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to
be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their
shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not
affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a) </FONT><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><FONT STYLE="font-size: 10pt"><U>Transferabilit</U>y. This Warrant and all rights hereunder (including, without limitation,
any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the office of the Warrant Agent designated
for such purpose, together with a written assignment of this Warrant substantially in the form attached hereto properly completed and
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer
accompanied by reasonable evidence of authority of the party making such request that may be required by the Warrant Agent. Upon such
surrender and, if required, such payment, the Company shall execute and deliver, and the Warrant Agent shall countersign, a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Warrant Agent unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this
Warrant to the Warrant Agent within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Warrant
Agent in accordance with this Section 4(a) assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may
be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined
with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names
and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section
4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver, and the Warrant
Agent shall countersign, a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Re</U>g<U>ister</U>. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose
(the &ldquo;<U>Warrant Re</U>g<U>ister</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and Warrant
Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. Notwithstanding the foregoing, nothing
herein shall prevent the Company or Warrant Agent or any agent of the Company or Warrant Agent from giving effect to any written certification,
proxy or other authorization furnished by DTC or any other depository governing the exercise of the rights of a holder of a beneficial
interest in any Warrant. The rights of beneficial owners in a Warrant held in global form shall be exercised by the Holder or a Participant
(as defined in the Warrant Agent Agreement) through the depository&rsquo;s system, except to the extent expressly set forth in the Warrant
Agent Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">a) <U>No
Ri</U>g<U>hts as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d) (i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company and the Warrant Agent of evidence
reasonably satisfactory to them of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the
Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to them (which, in the case
of a Warrant evidenced by a physical Warrant certificate, shall include the posting of a bond), and upon surrender and cancellation of
such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and
dated as of such cancellation, in lieu of such Warrant or stock certificate, which, in the case of the Warrant, shall include the posting
of a bond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">c) <U>Saturda</U>y<U>s,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who
are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company
covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon
exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Except and to
the extent as waived or consented to by the Holders of a majority in interest of the Warrants then outstanding, the Company shall not
by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of
this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">e) <U>Governin</U>g
<U>Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, stockholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
The Company and each Holder hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. As between the Company and any Holder, if either party shall commence an action, suit or proceeding to
enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party
for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of
such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at 121 South Orange Ave., Suite 1500, Orlando, Florida 32801, Attention: Chief Financial Officer, facsimile
number: [ ], email address: [ ], or such other facsimile number, email address or address as the Company may specify for such purposes
by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in
writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed to each
Holder at the facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New
York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via
facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or
later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.
To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any
Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)
<U>Limitation of Liabilit</U>y. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assi</U>g<U>ns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of
Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived in accordance with Section 8.8 of the Warrant Agent Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m) </FONT><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><FONT STYLE="font-size: 10pt"><U>Severabilit</U>y. Wherever possible, each provision of this Warrant shall be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder
of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)
<U>Headin</U>gs. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">o) <U>Warrant
A</U>g<U>ent Agreement</U>. This Warrant is issued subject to the Warrant Agent Agreement. To the extent any provision of this Warrant
conflicts with the express provisions of the Warrant Agent Agreement, the provisions of this Warrant shall govern and be controlling;
provided, however, that all provisions with respect to the rights, duties, obligations, protections, immunities and liability of the Warrant
Agent only shall be determined and interpreted solely by the provisions of the Warrant Agent Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">********************</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has
caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>NUTRIBAND INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Countersigned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3"><B>AMERICAN STOCK TRANSFER &amp; TRUST COMPANY, LLC</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">Title:</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">TO: <B>AMERICAN STOCK TRANSFER&nbsp;&amp; TRUST COMPANY,
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase_______Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt"> (2) Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt">[ &nbsp;&nbsp;&nbsp;] in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-indent: 0in; text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp; ] if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt"> (3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">The Warrant Shares shall be delivered to the following DWAC
Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Investing Entity:___________________________________________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>: ____________________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Authorized Signatory: ______________________________________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:_______________________________________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: __________________________________________________________________________________</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.25in; text-align: justify"><I>(To assign the foregoing Warrant, execute this form
and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in">FOR VALUE RECEIVED, the foregoing Warrant and all rights
evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-top: 4.55pt">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 60%; padding-top: 4.55pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.45pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.45pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.6pt">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 4.6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.45pt; width: 40%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.45pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.6pt">Phone Number:</TD>
    <TD STYLE="padding-top: 4.6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.05pt">Email Address:</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dated:________________ ,______ &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.6pt; width: 18%">Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 4.6pt; width: 22%">&nbsp;</TD>
    <TD STYLE="padding-top: 4.6pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.05pt">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>5
<FILENAME>ea148206ex4-13_nutriband.htm
<DESCRIPTION>FORM OF WARRANT AGENT AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.13</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;WARRANT AGENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Agent Agreement (&ldquo;<B>Warrant
Agreement</B>&rdquo;) is made as of September 30, 2020, by and between Nutriband Inc. (the &ldquo;<B>Company</B>&rdquo;), and American
Stock Transfer&nbsp;&amp; Trust Company, LLC (the &ldquo;<B>Warrant Agent</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Company is engaged in a public offering
(the &ldquo;<B>Public Offering</B>&rdquo;) of 1,056,000 shares of common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;)
and 1,056,000 warrants (the &ldquo;<B>Warrants</B>&rdquo;) entitling its holder to purchase one share Common Stock for each whole warrant,
subject to adjustment as set forth herein (the &ldquo;<B>Warrant Shares</B>&rdquo;) (including the additional shares of Common Stock and
Warrants issuable to the underwriter if the underwriter&rsquo;s over-allotment option is exercised);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Company has filed, with the Securities
and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;), a registration statement on Form S-1 (Registration No. 333-[*]) (as amended, the
&ldquo;<B>Registration Statement</B>&rdquo;), for the registration, under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;),
of Common Stock, the Warrants and the Warrant Shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Company desires the Warrant Agent
to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer,
exchange, redemption and exercise of the Warrants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Company desires to provide for the
form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of
rights and immunities of the Company, the Warrant Agent and the holders of the Warrants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, all acts and things have been done and
performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant
Agent, as provided herein, the legally valid and binding obligations of the Company, and to authorize the execution and delivery of this
Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, in consideration of the mutual
agreements herein contained, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <U>Appointment of Warrant Agent.</U> The Company
hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant Agent hereby accepts such appointment
and agrees to perform the same in accordance with the express terms and conditions set forth in this Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <U>Warrants.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.1 <U>Form of Warrant.</U> Each Warrant shall
be: (a) issued in registered form only, (b) in substantially the form of <U>Exhibit A</U> attached hereto (a &ldquo;<B>Warrant Certificate</B>&rdquo;),
the provisions of which are incorporated herein, (c) signed by, or bear the facsimile signature of, the Chairman of the Board of Directors
of the Company, the Chief Executive Officer, the President, the Chief Financial Officer, the Treasurer or Secretary of the Company, and
(d) signed manually or by facsimile signature by the Warrant Agent. In the event the person whose facsimile signature has been placed
upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it
may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.2 <U>Effect of Countersignature.</U> Unless
and until countersigned by the manual or facsimile signature of the Warrant Agent pursuant to this Warrant Agreement, a Warrant shall
be invalid and of no effect and may not be exercised by the holder thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.3 <U>Registration.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.3.1 <U>Warrant Register.</U> The Warrant Agent
shall maintain books (the &ldquo;<B>Warrant Register</B>&rdquo;), for the registration of the original issuance and transfers of the Warrants.
Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders
thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. Except as provided
in this <U>Section 2.3.1,</U> upon the initial issuance of the Warrants, to the extent the Warrants are DTC eligible as of such date,
all of the Warrants shall initially be represented by one or more Warrant Certificates reflecting book-entry of ownership (each a &ldquo;<B>Book-Entry
Warrant Certificate</B>&rdquo;), deposited with the Depository Trust Company (the &ldquo;<B>Depository</B>&rdquo;) and registered in the
name of Cede &amp; Co., a nominee of the Depository. Ownership of beneficial interests in the Book-Entry Warrant Certificates shall be
shown on, and the transfer of such ownership shall be effected through, records maintained (i) by the Depository or its nominee for each
Book-Entry Warrant Certificate; (ii) by institutions that have accounts with the Depository (such institution, with respect to a Warrant
in its account, a &ldquo;<B>Participant</B>&rdquo;); or (iii) directly on the book-entry records of the Warrant Agent with respect only
to owners of beneficial interests that request such direct registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Warrants are not DTC-eligible at the issuance
date or the Depository subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct
the Warrant Agent regarding making other arrangements for book-entry settlement within ten (10) Business Days (as defined below) after
the Depository ceases to make its book-entry settlement available. In the event that the Company does not make alternative arrangements
for book-entry settlement within ten (10) Business Days, or the Warrants are not eligible for, or it is no longer necessary to have the
Warrants available in, book-entry form, the Warrant Agent shall provide written instructions, upon receipt of instructions from the Company,
to the Depository to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct
the Warrant Agent to deliver to the Holder definitive Warrant Certificates in physical form evidencing such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the request of any Holder of Warrants, submitted
to the Warrant Agent via the Depositary as the initial Registered Holder as to Book-Entry Warrants, the Company and Warrant Agent shall
deliver to such purchaser definitive Warrant Certificates in physical form, registered in the name of such purchaser, evidencing the Warrants
purchased by such Holder. Such definitive Warrant Certificate shall be dated the original issue date of the Warrants, shall be executed
manually or by facsimile signature by an authorized signatory of the Company, and countersigned by the manual or facsimile signature of
the Warrant Agent, and shall be substantially in the form attached hereto as Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.3.2 <U>Registered Holder; Beneficial Owners.</U>
Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the Person
(as defined in the Warrant Certificate) in whose name such Warrant shall be registered upon the Warrant Register (&ldquo;<B>Registered
Holder</B>&rdquo;) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership
or other writing on the Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise
thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. The
term &ldquo;beneficial owner&rdquo; shall mean any Person in whose name ownership of a beneficial interest in the Warrants evidenced by
(a) a Book-Entry Warrant Certificate is recorded in the records maintained by the Depository or its nominee or a Participant or (b) a
definitive Warrant Certificate is recorded in the book-entry records of the Warrant Agent. Any reference herein to the term Holder or
Registered Holder shall include a beneficial owner who has received definitive Warrant Certificates registered in its name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.4 <U>Separate Issuance of Warrants.</U> The
Common Stock and the Warrants shall be issued separately and shall be transferable separately immediately upon issuance. The Common Stock
and the Warrants will begin to trade separately on or promptly after the date that is the effective date of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.5 <U>Uncertificated Warrants.</U> Notwithstanding
the foregoing and anything else herein to the contrary, the Warrants may be issued in uncertificated form if so specified by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.6 <U>Opinion of Counsel</U>. The Company shall
provide an opinion of counsel to the Warrant Agent prior to the issuance of the Warrants to set up a reserve of Warrants and related Warrant
Shares. The opinion shall state that all Warrants or Warrant Shares, as applicable, are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) registered under the Securities Act of 1933,
as amended, or are exempt from such registration, and all appropriate state securities law filings have been made with respect to the
warrants or shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <U>Terms and Exercise of Warrants.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.1 <U>Warrant Price.</U> Each Warrant shall,
when countersigned by the Warrant Agent, entitle the Registered Holder thereof, subject to the provisions of such Warrant and of this
Warrant Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $[_] per whole share
of Common Stock, subject to the adjustments provided in Section 4 hereof and in the last sentence of this <U>Section 3.1.</U> The term
&ldquo;<B>Warrant Price</B>&rdquo; as used in this Warrant Agreement refers to the price per whole share at which Common Stock may be
purchased at the time such Warrant is exercised. The Company, in its sole discretion, may lower the Warrant Price at any time prior to
the Expiration Date (as defined below); provided, that any such reduction remains in effect for no less than ten (10) Business Days and
shall be identical in percentage terms among all of the then outstanding Warrants. The Company shall promptly notify the Warrant Agent
of any Warrant Price reduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2 <U>Duration of Warrants.</U> A Warrant may
be exercised only during the period (&ldquo;<B>Exercise Period</B>&rdquo;) commencing on the Initial Exercise Date (as defined in the
Warrant Certificate) and terminating at 5:00 p.m., New York City time, on May [__], 2026 (&ldquo;<B>Expiration Date</B>&rdquo;). Each
Warrant not exercised on or before the Expiration Date shall become null and void, and all rights thereunder and all rights in respect
thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date. The Company may extend the duration
of the Warrants by delaying the Expiration Date; provided, however, that the Company will provide notice of not less than twenty (20)
days to the Warrant Agent and Registered Holders of such extension and that such extension shall be identical in duration among all of
the then outstanding Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.3 <U>Exercise of Warrants.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.1 <U>Payment.</U> Subject to the provisions
of the Warrant and this Warrant Agreement, a Warrant, when countersigned by the Warrant Agent, may be exercised by the Registered Holder
thereof by surrendering at the office of the Warrant Agent at 6201 15th Ave, Brooklyn, NY, or at the office of its successor as Warrant
Agent, (i) the Warrant Certificate evidencing the Warrants to be exercised, or, in the case of a Book-Entry Warrant Certificate, the Warrants
to be exercised (the &ldquo;<B>Book-Entry Warrants</B>&rdquo;) shall be exercised as described herein and Section 2(a) of the Warrant,
(ii) the subscription form, as set forth in the Warrant Certificate (the &ldquo;<B>Election to Purchase</B>&rdquo;), properly completed
and duly executed by the Registered Holder on the reverse of the Warrant Certificate or, in the case of a Book-Entry Warrant Certificate,
properly delivered by the Participant in accordance with the Depository&rsquo;s procedures, and (iii), unless the cashless exercise procedure
specified in Section 2(c) of the Warrant is specified in the applicable Notice of Exercise (a &ldquo;<B>Cashless Exercise</B>&rdquo;),
payment in full, in lawful money of the United States, in cash, by wire of same day funds or by certified or bank cashier&rsquo;s check
payable to the order of the Company, the Warrant Price for such number of Warrant Shares totaling whole shares of Common Stock as to which
the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant
for the Warrant Shares, and the issuance of the Warrant Shares.. Notwithstanding any other provision in this Warrant Agreement, a holder
whose interest in a Book-Entry Warrant is a beneficial interest in a Book-Entry Warrant held through the Depositary (or another established
clearing corporation performing similar functions), shall effect exercises by delivering to the Depositary (or such other clearing corporation,
as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by Depositary
(or such other clearing corporation, as applicable). Upon receipt of an Election to Purchase for a Cashless Exercise, the Company will
promptly calculate and transmit to the Warrant Agent the number of Warrant Shares issuable in connection with such Cashless Exercise.
The Warrant Agent shall have no duty or obligation to investigate or confirm whether the Company&rsquo;s determination of the number of
Warrant Shares to be issued on such exercise is accurate or correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.2 <U>Fractional Shares</U>. Notwithstanding
any provision to the contrary contained in this Warrant Agreement, the Company shall not be required to issue any fractional shares of
Common Stock in connection with the exercise of Warrants for Warrant Shares, and in any case where the Registered Holder would be entitled
under the terms of the Warrants to receive a fractional share of Common Stock as a Warrant Share upon the exercise of such Registered
Holder&rsquo;s Warrants, issue or cause to be issued only the largest whole number of aggregate Warrant Shares issuable on such exercise
(and such remaining fractional shares will be disregarded); provided, that if more than one Warrant Certificate is presented for exercise
at the same time by the same Registered Holder, the number of Warrant Shares which shall be issuable upon the exercise thereof shall be
computed on the basis of the aggregate number of Warrant Shares issuable on exercise of all such Warrants. The Company shall provide an
initial funding of one thousand dollars ($1,000) for the purpose of issuing cash in lieu of fractional shares. From time to time thereafter,
the Warrant Agent may request additional funding to cover payments for fractional Warrant Shares. The Warrant Agent shall have no obligation
to make such payments for fractional Warrant Shares unless the Company shall have provided the necessary funds to pay in full all amounts
due and payable with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.3 <U>Issuance of Certificates.</U> As soon
as practicable after the exercise of any Warrant and the clearance of the funds in payment of the Warrant Price, the Warrant Agent shall
advise the Company and its transfer agent regarding (i) the number of Warrant Shares issuable upon such exercise in accordance with the
terms and conditions of this Warrant Agreement, (ii) the instructions of each Holder or Participant, as they case may be, with respect
to delivery of the Warrant Shares issuable upon such exercise, and the delivery of definitive Warrant Certificates, as appropriate, evidencing
the balance, if any, of the Warrants remaining after such exercise, (iii) in case of a Book-Entry Warrant Certificate, the notation that
shall be made to the records maintained by the Depository, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate,
evidencing the balance, if any, of the Warrants remaining after such exercise and (iv) such other information as the Company or such transfer
agent and registrar shall reasonably require. Promptly thereafter and within the time period set forth in the Warrants, the Company shall
instruct its transfer agent to issue to the Registered Holder of such Warrant a certificate or certificates representing the number of
full shares of Common Stock to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it,
provided, in lieu of delivering physical certificates representing the Warrant Shares issuable upon exercise, and provided the Company&rsquo;s
transfer agent is participating in the Depository&rsquo;s Fast Automated Securities Transfer program, the Company shall use its commercially
reasonable efforts to cause its transfer agent to electronically transmit the Warrant Shares issuable upon exercise to the Registered
Holder by crediting the account of the Participant of record with the Depository or through its Deposit Withdrawal Agent Commission system.
If such Warrant shall not have been exercised or surrendered in full, a new countersigned Warrant Certificate for the number of shares
as to which such Warrant shall not have been exercised or surrendered, or, in case of a Book-Entry Warrant Certificate, a notation shall
be made to the records maintained by the Depository or nominee for each Book-Entry Warrant Certificate, as appropriate, evidencing the
balance, if any, of the Warrants remaining after such exercise. Notwithstanding the foregoing, the Company shall not be obligated to deliver
any securities pursuant to the exercise of a Warrant unless (a) a registration statement under the Act with respect to the Common Stock
issuable upon exercise of such Warrants is effective and a current prospectus relating to the shares of Common Stock issuable upon exercise
of the Warrants is available for delivery to the Registered Holder of the Warrant or (b) in the opinion of counsel to the Company, the
exercise of the Warrants is exempt from the registration requirements of the Act and such securities are qualified for sale or exempt
from qualification under applicable securities laws of the states or other jurisdictions in which the Registered Holder resides. Until
otherwise advised in writing by the Company, the Warrant Agent shall always be entitled to assume that either clause (a) or clause (b)
is in effect and shall incur no liability in making such assumption. Warrants may not be exercised by, or securities issued to, any Registered
Holder in any state in which such exercise or issuance would be unlawful. In the event a such exercise would be unlawful with respect
to a Registered Holder in any state, the Registered Holder shall not be entitled to exercise such Warrants and such Warrants may have
no value and expire worthless. In no event will the Company be obligated to pay such Registered Holder any cash consideration upon exercise
or otherwise &ldquo;net cash settle&rdquo; the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.4 <U>Valid Issuance.</U> The validity of any
exercise of Warrants will be determined by the Company in its reasonable discretion. The Warrant Agent shall notify a holder of any purported
invalidity of any exercise of Warrants. All shares of Common Stock issued upon the proper exercise or surrender of a Warrant in conformity
with this Warrant Agreement shall be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.5 <U>Date of Issuance.</U> Each Person in
whose name any shares of Common Stock is issued shall, for all purposes, be deemed to have become the holder of record of such shares
on the date on which the Warrant was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such
certificate, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed,
such Person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the
stock transfer books are open (the &ldquo;<B>Exercise Date</B>&rdquo;). If any of (i) the Warrant Certificate or the Book-Entry Warrants,
(ii) the Election to Purchase, or (iii) the Warrant Price therefor, is received by the Warrant Agent after 5:00 P.M., New York time, on
the specified Exercise Date, the Warrants will be deemed to be received and exercised on the Business Day next succeeding the Exercise
Date, subject to clearance of the funds. If the date specified as the Exercise Date is not a Business Day, the Warrants will be deemed
to be received and exercised on the next succeeding day that is a Business Day, subject to clearance of the funds. If the Warrants are
received or deemed to be received after the Expiration Date, the exercise thereof will be null and void and any funds delivered to the
Warrant Agent will be returned to the Registered Holder as soon as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.6 <U>Cost Basis Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) In the event of a cash exercise, the Company
hereby instructs the Warrant Agent to record cost basis for newly issued shares in a manner to be subsequently communicated by the Company
in writing to the Warrant Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) In the event of a Cashless Exercise, the Company
shall provide cost basis for shares issued pursuant to a cashless exercise at the time the Company confirms the number of Warrant Shares
issuable in connection with the cashless exercise to the Warrant Agent pursuant to Section 3.3.1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <U>Adjustments; Rights.</U> The Warrant Shares
and Warrant Price shall be subject to adjustment as provided for in the Warrant Certificate, and the rights of Warrant holders as provided
for in the Warrant Certificate are incorporated herein by reference and shall be adhered to by the Company and the Warrant Agent. The
Company hereby agrees that it will provide the Warrant Agent with reasonable notice of any adjustment events. The Company further agrees
that it will provide to the Warrant Agent with any new or amended exercise terms. Whenever the Warrant Shares or Warrant Price or the
number of shares of Common Stock issuable upon the exercise of each Warrant is adjusted, the Company shall (a) promptly prepare a certificate
setting forth the Warrant Price of each Warrant as so adjusted, and a brief statement of the facts accounting for such adjustment, (b)
promptly file with the Warrant Agent and with each transfer agent for the Common Stock a copy of such certificate and (c) instruct the
Warrant Agent to send a brief summary thereof to each Holder of a Warrant Certificate. The Warrant Agent shall be fully protected in relying
on any such certificate and on any adjustment or statement therein contained and shall have no duty or liability with respect to, and
shall not be deemed to have knowledge of any such adjustment or any such event unless and until it shall have received such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <U>Transfer and Exchange of Warrants.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.1 <U>Transfer of Warrants.</U> The Warrants
may be transferred or exchanged separately from shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.2 <U>Registration of Transfer.</U> The Warrant
Agent shall register the transfer, from time to time, of any outstanding Warrant into the Warrant Register, upon surrender of such Warrant
for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer, or properly
noticed by the Depositary as contemplated by <U>Section 5.3.</U> Upon any such transfer, a new Warrant, representing an equal aggregate
number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered
by the Warrant Agent to the Company from time to time upon the Company&rsquo;s request. A party requesting transfer of Warrants must provide
any evidence of authority that may be required by the Warrant Agent, including but not limited to, a signature guarantee from an eligible
guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.3 <U>Procedure for Surrender of Warrants.</U>
Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer reasonably acceptable to Warrant
Agent, duly executed by the registered holder thereof, or by a duly authorized attorney, and, thereupon, the Warrant Agent shall issue
in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered, representing an equal
aggregate number of Warrants; provided, however, that, except as otherwise provided herein or in any Book-Entry Warrant Certificate, each
Book-Entry Warrant Certificate may be transferred only in whole and only to the Depository, to another nominee of the Depository, to a
successor depository, or to a nominee of a successor depository; provided further, that in the event a Warrant surrendered for transfer
bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and shall issue new Warrants in exchange therefor until the
Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new
Warrants must also bear a restrictive legend. Notwithstanding anything else in this Section 5.3, in case of a Book-Entry Warrant, the
holder or Participant shall notify the Depositary in accordance with the Depository&rsquo;s procedures of a requested transfer and the
Depositary shall provide notice to an account of the Warrant Agent at the Depository designated for such purpose in writing by the Warrant
Agent to the Depository from time to time, of a transfer to be recorded in the records maintained by the Depository, its nominee for each
Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance, if any, of the Warrants remaining after such
transfer and the new name in which the transferred Book Entry Warrants are to be held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">5.4 <U>Fractional Warrants.</U> The Warrant Agent shall not be
required to effect any registration of transfer or exchange which will result in the issuance of a Warrant Certificate or a Book-Entry
Warrant Certificate for a fraction of a Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.5 <U>Warrant Execution and Countersignature.</U>
The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Warrant Agreement, the Warrants
required to be issued pursuant to the provisions of this <U>Section 5</U>, and the Company, whenever required by the Warrant Agent, will
supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <U>Other Provisions Relating to Rights of Registered
Holders of Warrants.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1 <U>No Rights as Stockholder.</U> A Warrant
does not entitle the Registered Holder thereof to any of the rights of a stockholder of the Company, including, without limitation, the
right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as stockholders
in respect of the meetings of stockholders or the election of directors of the Company or any other matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.2 <U>Lost, Stolen Mutilated or Destroyed Warrants.</U>
If any Warrant is lost, stolen, mutilated or destroyed, the Company and the Warrant Agent may, absent notice to Warrant Agent that such
certificates have been acquired by a bona fide purchaser, on such terms as to indemnity or otherwise as they may in their discretion impose
(which terms shall in all cases include posting of a lost security bond by or on behalf of the Registered Holder, and in the case of a
mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor and date as the Warrant so lost, stolen,
mutilated or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly
lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.3 <U>Reservation of Common Stock.</U> The Company
shall at all times reserve and keep available a number of its authorized but unissued shares of Common Stock that will be sufficient to
permit the exercise in full of all outstanding Warrants issued pursuant to this Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.4 <U>Registration of Common Stock.</U> The Company
agrees to use its commercially reasonable efforts to maintain the effectiveness of the Registration Statement until the expiration of
the Warrants in accordance with the provisions of this Warrant Agreement; provided, however, that the Company shall not have penalties
for failure to deliver Common Stock if a registration statement is not effective or a current prospectus is not on file with the SEC at
the time of exercise by the Registered Holder. In addition, to the extent not completed at the time of the initial issuance of the Warrants,
the Company agrees to use its reasonable efforts to register such securities under the blue sky laws of the states of residence of the
exercising Registered Holders to the extent an exemption under the Act is not available for the exercise of the Warrants. In no event
will the Registered Holder of a Warrant be entitled to receive a net-cash settlement or shares of Common Stock or other consideration
as of result of the Company&rsquo;s non-compliance with this <U>Section 6.4.</U> The provisions of this <U>Section 6.4</U> may not be
modified, amended or deleted without the prior written consent of WallachBeth Capital, LLC, the lead underwriter of the Public Offering
(the &ldquo;<B>Underwriter</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <U>Concerning the Warrant Agent and Other Matters.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.1 <U>Payment of Taxes.</U> The Company will,
from time to time, promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance
or delivery of shares of Common Stock upon the exercise of Warrants, but neither the Company nor the Warrant Agent shall be obligated
to pay any transfer taxes in respect of the Warrants or such shares. The Warrant Agent shall not register any transfer or issue or deliver
any Warrant Certificate(s) or Warrant Shares unless or until the Persons requesting the registration or issuance shall have paid to the
Warrant Agent for the account of the Company the amount of such tax, if any, or shall have established to the reasonable satisfaction
of the Company and the Warrant Agent that such tax, if any, has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2 <U>Resignation, Consolidation, or Merger of
Warrant Agent.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2.1 <U>Appointment of Successor Warrant Agent.</U>
The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities
hereunder after giving thirty (30) days&rsquo; notice in writing to the Company. If the office of the Warrant Agent becomes vacant by
resignation or incapacity to act or otherwise, the Company shall appoint, in writing, a successor Warrant Agent in place of the Warrant
Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified in writing of
such resignation or incapacity by the Warrant Agent or by the Registered Holder of the Warrant (who shall, with such notice, submit his,
her or its Warrant for inspection by the Company), then the Registered Holder of any Warrant may apply to the Supreme Court of the State
of New York for the County of New York for the appointment of a successor Warrant Agent. Any successor Warrant Agent, whether appointed
by the Company or by such court, shall be an entity authorized under applicable laws to exercise the powers of a transfer agent and subject
to supervision or examination by federal or state authorities. After appointment, any successor Warrant Agent shall be vested with all
the authority, powers, rights, immunities, duties and obligations of its predecessor Warrant Agent with like effect as if originally named
as Warrant Agent hereunder, without any further act or deed; but, if for any reason it becomes necessary or appropriate, the predecessor
Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all
the authority, powers, and rights of such predecessor Warrant Agent hereunder; and, upon request of any successor Warrant Agent, the Company
shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming
to such successor Warrant Agent all such authority, powers, rights, immunities, duties and obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2.2 <U>Notice of Successor Warrant Agent.</U>
In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and
the transfer agent for the Common Stock not later than thirty (30) days before the effective date of any such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2.3 <U>Merger or Consolidation of Warrant Agent.</U>
Any Person into which the Warrant Agent may be merged or with which it may be consolidated or any Person resulting from any merger or
consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Warrant Agreement without any
further act on the part of the Company or the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2.4 <U>Confidentiality.</U> The Warrant Agent
and the Company agree that all books, records, information and data pertaining to the business of the other party, including inter alia,
personal, non-public Holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this Warrant
Agreement shall remain confidential, and shall not be voluntarily disclosed to any other Person, except as may be required by law, including,
without limitation, pursuant to subpoenas from state or federal government authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.3 <U>Fees and Expenses of Warrant Agent.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.3.1 <U>Remuneration.</U> The Company agrees
to pay the Warrant Agent reasonable remuneration for its services as Warrant Agent hereunder as set forth on <U>Exhibit B</U> hereto and
will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its
duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.3.2 <U>Further Assurances.</U> The Company agrees
to perform, execute, acknowledge and deliver, or cause to be performed, executed, acknowledged and delivered, all such further and other
acts, instruments and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions
of this Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4 <U>Liability of Warrant Agent.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4.1 <U>Reliance on Company Statement.</U> Whenever,
in the performance of its duties under this Warrant Agreement, the Warrant Agent shall deem it necessary or desirable that any fact or
matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence
in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by
the Chief Executive Officer, Chief Financial Officer or Chairman of the Board of the Company and delivered to the Warrant Agent. The Warrant
Agent may rely upon, and be held harmless for such reliance, such statement for any action taken or suffered or omitted to be taken by
it in the absence of bad faith pursuant to the provisions of this Warrant Agreement, and shall not be held liable in connection with any
delay in receiving such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4.2 <U>Indemnity</U>. The Warrant Agent shall
be liable hereunder only for its own gross negligence, willful misconduct or bad faith (each as determined by a final judgment of a court
of competent jurisdiction). The Company covenants and agrees to indemnify the Warrant Agent and hold it harmless against any and all liabilities,
including judgments, losses, damages, costs, expenses, and reasonable counsel fees, which may be paid, incurred or suffered by or to which
it may become subject, arising from or out of, directly or indirectly, any claims or liability resulting from its actions as Warrant Agent
pursuant hereto; provided, that such covenant and agreement does not extend to, and the Warrant Agent shall not be indemnified with respect
to, such costs, expenses, losses and damages incurred or suffered by the Warrant Agent as a result of, or arising out of, its gross negligence,
willful misconduct or bad faith (each as determined by a final judgment of a court of competent jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4.3 <U>Exclusions. </U>The Warrant Agent shall
have no responsibility with respect to the validity of this Warrant Agreement or with respect to the validity or execution of any Warrant
(except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained
in this Warrant Agreement or in any Warrant; nor shall it be responsible to make any adjustments required under the provisions of <U>Section
4</U> hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that
would require any such adjustment; nor shall it, by any act hereunder, be deemed to make any representation or warranty as to the authorization
or reservation of any shares of Common Stock to be issued pursuant to this Warrant Agreement or any Warrant or as to whether any shares
of Common Stock will when issued be valid and fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4.4 <U>Instructions</U>. From time to time,
the Company may provide the Warrant Agent with instructions concerning the services performed by the Warrant Agent hereunder. In addition,
at any time the Warrant Agent may apply to any officer of Company for instruction, and may consult with legal counsel for the Warrant
Agent or the Company with respect to any matter arising in connection with the services to be performed by the Warrant Agent under this
Warrant Agreement. Warrant Agent and its agents and subcontractors shall not be liable and shall be indemnified by Company for any action
taken, suffered or omitted to be taken by Warrant Agent in reliance upon any Company instructions or upon the advice or opinion of such
counsel. Warrant Agent shall not be held to have notice of any change of authority of any Person, until receipt of written notice thereof
from Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4.5 <U>Rights and Duties of Warrant Agent</U>.
(a) The Warrant Agent may consult with legal counsel (who may be legal counsel for the Company), and the advice or opinion of such counsel
shall be full and complete authorization and protection to the Warrant Agent as to any action taken, suffered or omitted by it in accordance
with such advice or opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) The Warrant Agent shall not be liable for
or by reason of any of the statements of fact or recitals contained in this Warrant Agreement or in the Warrant Certificates (except its
countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been
made by the Company only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) The Warrant Agent shall not be required to
take notice or be deemed to have notice of any event or condition hereunder, including any event or condition that may require action
by the Warrant Agent, unless the Warrant Agent shall be specifically notified in writing of such event or condition by the Company, and
all notices or other instruments required by this Warrant Agreement to be delivered to the Warrant Agent must, in order to be effective,
be received by the Warrant Agent as specified in Section 8.2 hereof, and in the absence of such notice so delivered, the Warrant Agent
may conclusively assume no such event or condition exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) The Warrant Agent and any stockholder, director,
officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or become pecuniarily
interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as
fully and freely as though it were not Warrant Agent under this Warrant Agreement. Nothing herein shall preclude the Warrant Agent from
acting in any other capacity for the Company or for any other legal entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) The Warrant Agent may execute and exercise
any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents, and
the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or
for any loss to the Company resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful
misconduct (each as determined by a final judgment of a court of competent jurisdiction) in the selection and continued employment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) The Warrant Agent may rely on and shall be
held harmless and protected and shall incur no liability for or in respect of any action taken, suffered or omitted to be taken by it
in reliance upon any certificate, statement, instrument, opinion, notice, letter, facsimile transmission or other document, or any security
delivered to it, and believed by it to be genuine and to have been made or signed by the proper party or parties, or upon any written
or oral instructions or statements from the Company with respect to any matter relating to its acting as Warrant Agent hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) The Warrant Agent shall not be obligated to
expend or risk its own funds or to take any action that it believes would expose or subject it to expense or liability or to a risk of
incurring expense or liability, unless it has been furnished with assurances of repayment or indemnity satisfactory to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h) The Warrant Agent shall not be liable or responsible
for any failure of the Company to comply with any of its obligations relating to any registration statement filed with the SEC or this
Warrant Agreement, including without limitation obligations under applicable regulation or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) The Warrant Agent shall not be accountable
or under any duty or responsibility for the use by the Company of any Warrants authenticated by the Warrant Agent and delivered by it
to the Company pursuant to this Warrant Agreement or for the application by the Company of the proceeds of the issue and sale, or exercise,
of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j) The Warrant Agent shall act hereunder solely
as agent for the Company, and its duties shall be determined solely by the express provisions hereof (and no duties or obligations shall
be inferred or implied). The Warrant Agent shall not assume any obligations or relationship of agency or trust with any of the owners
or holders of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(k) The Warrant Agent may rely on and be fully
authorized and protected in acting or failing to act upon (a) any guaranty of signature by an &ldquo;eligible guarantor institution&rdquo;
that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &ldquo;signature guarantee program&rdquo;
or insurance program in addition to, or in substitution for, the foregoing; or (b) any law, act, regulation or any interpretation of the
same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(l) In the event the Warrant Agent believes any
ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document
received by the Warrant Agent hereunder, the Warrant Agent, may, in its sole discretion, refrain from taking any action, and shall be
fully protected and shall not be liable in any way to Company, the holder of any Warrant Certificate or Book-Entry Warrant Certificate
or any other Person for refraining from taking such action, unless the Warrant Agent receives written instructions signed by the Company
which eliminates such ambiguity or uncertainty to the satisfaction of Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(m) Notwithstanding anything contained herein
to the contrary, the Warrant Agent&rsquo;s aggregate liability during any term of this Warrant Agreement with respect to, arising from,
or arising in connection with this Warrant Agreement, or from all services provided or omitted to be provided under this Warrant Agreement,
whether in contract, or in tort, or otherwise, is limited to, and shall not exceed, the amounts paid hereunder by the Company to the Warrant
Agent as fees and charges, but not including reimbursable expenses, during the twelve (12) months immediately preceding the event for
which recovery from the Warrant Agent is being sought. Neither party to this Warrant Agreement shall be liable to the other party for
any consequential, indirect, special, punitive or incidental damages under any provisions of this Warrant Agreement or for any consequential,
indirect, punitive, special or incidental damages arising out of any act or failure to act hereunder even if that party has been advised
of or has foreseen the possibility or likelihood of such damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.5 <U>Acceptance of Agency</U>. The Warrant Agent
hereby accepts the agency established by this Warrant Agreement and agrees to perform the same upon the express terms and conditions herein
set forth and, among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for,
and forward to the Company all moneys received for warrant exercises in a given month by the 5th business day of the following month by
wire transfer to an account designated by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.6 <U>Survival.</U> The Warrant Agent&rsquo;s
indemnities, immunities and protections provided by this Section 7 shall survive the resignation or discharge of the Warrant Agent or
the termination of this Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <U>Miscellaneous Provisions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.1 <U>Successors.</U> All the covenants and provisions
of this Warrant Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective
successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.2 <U>Notices.</U> Any notice, statement or demand
authorized by this Warrant Agreement to be given or made by the Warrant Agent or by the Registered Holder of any Warrant to or on the
Company shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address
is filed in writing by the Company with the Warrant Agent) as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nutriband Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">121 South Orange Ave., Suite 1500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Orlando, Florida 32801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice, statement or demand authorized by
this Warrant Agreement to be given or made by the Registered Holder of any Warrant or by the Company to or on the Warrant Agent shall
be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in
writing by the Warrant Agent with the Company), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">American Stock Transfer&nbsp;&amp; Trust Company,
LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6201 15th Ave</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Brooklyn, NY 11219</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attention: [*]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice, sent by the Warrant Agent pursuant
to this Warrant Agreement shall be effective when sent. Any other notice, sent pursuant to this Warrant Agreement shall be effective,
if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight courier, on the next Business Day
of the delivery to the courier, and if sent by registered or certified mail on the third day after registration or certification thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.3 <U>Applicable Law.</U> The validity, interpretation,
and performance of this Warrant Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York,
without giving effect to conflict of laws. The Company and the Warrant Agent hereby agree that any action, proceeding or claim against
either of them arising out of or relating in any way to this Warrant Agreement shall be brought and enforced in the courts of the State
of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which
jurisdiction shall be exclusive. The Company and the Warrant Agent hereby waive any objection to such exclusive jurisdiction and that
such courts represent an inconvenient forum. Any such process or summons to be served upon the Company or the Warrant Agent may be served
by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address
set forth in Section 8.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company and the
Warrant Agent in any action, proceeding or claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.4 <U>Persons Having Rights under this Warrant
Agreement.</U> Nothing in this Warrant Agreement expressed and nothing that may be implied from any of the provisions hereof is intended,
or shall be construed, to confer upon, or give to, any Person other than the parties hereto and the Registered Holders of the Warrants
and, for the purposes of <U>Sections 6.4, 8.2</U> and <U>8.8</U> hereof, the Underwriter, any right, remedy, or claim under or by reason
of this Warrant Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. The Underwriter shall be deemed to
be a third-party beneficiary of this Warrant Agreement with respect to <U>Sections 6.4</U>, <U>8.2</U> and <U>8.8</U> hereof. All covenants,
conditions, stipulations, promises, and agreements contained in this Warrant Agreement shall be for the sole and exclusive benefit of
the parties hereto (and the Underwriter with respect to the <U>Sections 6.4, 8.2</U> and <U>8.8</U> hereof) and its successors and assigns
and of the Registered Holders of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.5 <U>Examination of the Warrant Agreement.</U>
A copy of this Warrant Agreement shall be available at all reasonable times at the office of the Warrant Agent for inspection by the Registered
Holder of any Warrant. The Warrant Agent may require any such Registered Holder to submit his, her or its Warrant for inspection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.6 <U>Counterparts; Facsimile Signatures.</U>
This Warrant Agreement may be executed in any number of counterparts, and each of such counterparts shall, for all purposes, be deemed
to be an original, and all such counterparts shall together constitute one and the same instrument. Facsimile or electronic signatures
shall constitute original signatures for all purposes of this Warrant Agreement and shall have the same authority, effect and enforceability
as an original signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.7 <U>Effect of Headings.</U> The section headings
herein are for convenience only and are not part of this Warrant Agreement and shall not affect the interpretation thereof</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.8 <U>Amendments.</U> This Warrant Agreement
and any Warrant certificate may be amended by the parties hereto by executing a supplemental warrant agreement (a &ldquo;<B>Supplemental
Agreement</B>&rdquo;), without the consent of any of the Warrant Holders, for the purpose of (i) curing any ambiguity, or curing, correcting
or supplementing any defective provision contained herein, or making any other provisions with respect to matters or questions arising
under this Warrant Agreement that is not inconsistent with the provisions of this Warrant Agreement or the Warrant certificates, (ii)
evidencing the succession of another entity to the Company and the assumption by any such successor of the covenants of the Company contained
in this Warrant Agreement and the Warrants, (iii) evidencing and providing for the acceptance of appointment by a successor Warrant Agent
with respect to the Warrants, (iv) adding to the covenants of the Company for the benefit of the Registered Holders or surrendering any
right or power conferred upon the Company under this Warrant Agreement, or (viii) amending this Warrant Agreement and the Warrants in
any manner that the Company may deem to be necessary or desirable and that will not adversely affect the interests of the Registered Holders
in any material respect. All other modifications or amendments, including any amendment to increase the Warrant Price or shorten the Exercise
Period, shall require the written consent of the Registered Holders representing at least of 50.1% of the Warrant Shares issuable under
the Warrants then outstanding. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise
Period in accordance with <U>Sections 3.1</U> and <U>3.2,</U> respectively, without such consent. As a condition precedent to the Warrant
Agent&rsquo;s execution of any amendment, the Company shall deliver to the Warrant Agent a certificate from a duly authorized officer
of the Company that states that the proposed amendment is in compliance with the terms of this Section 8.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.9 <U>Severability</U>. This Warrant Agreement
shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability
of this Warrant Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or
provision, the parties hereto intend that there shall be added as a part of this Warrant Agreement a provision as similar in terms to
such invalid or unenforceable provision as may be possible and be valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.10 <U>Business Day.</U> For purposes of this
Warrant Agreement, a &ldquo;<B>Business Day</B>&rdquo; is any day other than a Saturday, Sunday or a day on which commercial banks in
The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall
not be deemed to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;,
&ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations at the
direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial
banks in The City of New York generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.11 <U>Bank Accounts.</U> All funds received
by Computershare Inc. under this Warrant Agreement that are to be distributed or applied by Computershare Inc. in the performance of its
services hereunder (the &ldquo;<B>Funds</B>&rdquo;) shall be held by Computershare Inc. as agent for the Company and deposited in one
or more bank accounts to be maintained by Computershare Inc. in its name as agent for the Company. Until paid pursuant to the terms of
this Warrant Agreement, Computershare will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital
exceeding $1 billion or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&rsquo;s (Long
Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). Computershare Inc. shall
have no responsibility or liability for any diminution of the Funds that may result from any deposit made by Computershare Inc. in accordance
with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party. Computershare
Inc. may from time to time receive interest, dividends or other earnings in connection with such deposits. Computershare Inc. shall not
be obligated to pay such interest, dividends or earnings to the Company, any holder of Warrants or any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.12 <U>Force Majeure</U>. Notwithstanding anything
to the contrary contained herein, the Warrant Agent will not be liable for any delays or failures in performance resulting from acts beyond
its reasonable control including, without limitation, acts of God, pandemics, epidemics, terrorist acts, shortage of supply, breakdowns
or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties
with information storage or retrieval systems, labor difficulties, war, or civil unrest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, this Warrant Agreement has
been duly executed by the patties hereto as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUTRIBAND INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMERICAN STOCK TRANSFER&nbsp;&amp; TRUST COMPANY, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Form of Warrant Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[attached hereto]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Agent Fees</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[to be provided]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>ea148206ex23_nutriband.htm
<DESCRIPTION>CONSENT OF SADLER, GIBB & ASSOCIATES, LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nutriband Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Orlando, FL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As independent registered public accountants,
we hereby consent to the use of our report dated April 2, 2021, with respect to the consolidated financial statements of Nutriband Inc.
and subsidiaries as of and for the years ended January 31, 2021 and 2020 in this Registration Statement on Form S-1/A relating to the
registration of up to 1,056,000 Units, each consisting of one share of common stock and a warrant to purchase one share of common stock.
We also consent to the reference of our firm under the caption &ldquo;Experts&rdquo; in this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>/s/ Sadler, Gibb &amp; Associates,
LLC</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Draper, UT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 30, 2021</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ntrb-20210731.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Sep 30 22:42:47 UTC 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" targetNamespace="http://nutriband.com/20210731" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ntrb="http://nutriband.com/20210731" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ntrb-20210731_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ntrb-20210731_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ntrb-20210731_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ntrb-20210731_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://nutriband.com/role/ConsolidatedBalanceSheet" id="ntrb_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals" id="ntrb_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ConsolidatedIncomeStatement" id="ntrb_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ShareholdersEquityType2or3" id="ntrb_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ConsolidatedCashFlow" id="ntrb_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusiness" id="ntrb_r_OrganizationandDescriptionofBusiness">
        <link:definition>006 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/AcquisitionofBusiness" id="ntrb_r_AcquisitionofBusiness">
        <link:definition>007 - Disclosure - Acquisition of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/PropertyandEquipment" id="ntrb_r_PropertyandEquipment">
        <link:definition>008 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/IncomeTaxes" id="ntrb_r_IncomeTaxes">
        <link:definition>009 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/NotesPayableConvertibleDebt" id="ntrb_r_NotesPayableConvertibleDebt">
        <link:definition>010 - Disclosure - Notes Payable/Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/IntangibleAssets" id="ntrb_r_IntangibleAssets">
        <link:definition>011 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/DerivativeLiabilities" id="ntrb_r_DerivativeLiabilities">
        <link:definition>012 - Disclosure - Derivative Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/RelatedPartyTransactions" id="ntrb_r_RelatedPartyTransactions">
        <link:definition>013 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/StockholdersEquity" id="ntrb_r_StockholdersEquity">
        <link:definition>014 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/WarrantsandOptions" id="ntrb_r_WarrantsandOptions">
        <link:definition>015 - Disclosure - Warrants and Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/Leases" id="ntrb_r_Leases">
        <link:definition>016 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/CommitmentsandContigencies" id="ntrb_r_CommitmentsandContigencies">
        <link:definition>017 - Disclosure - Commitments and Contigencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/SubsequentEvents" id="ntrb_r_SubsequentEvents">
        <link:definition>018 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPolicies" id="ntrb_r_SummaryofSignificantAccountingPolicies">
        <link:definition>019 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/AccountingPoliciesByPolicy" id="ntrb_r_AccountingPoliciesByPolicy">
        <link:definition>020 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusinessTables" id="ntrb_r_OrganizationandDescriptionofBusinessTables">
        <link:definition>021 - Disclosure - Organization and Description of Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/AcquisitionofBusinessTables" id="ntrb_r_AcquisitionofBusinessTables">
        <link:definition>022 - Disclosure - Acquisition of Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/PropertyandEquipmentTables" id="ntrb_r_PropertyandEquipmentTables">
        <link:definition>023 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/IncomeTaxesTables" id="ntrb_r_IncomeTaxesTables">
        <link:definition>024 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/NotesPayableConvertibleDebtTables" id="ntrb_r_NotesPayableConvertibleDebtTables">
        <link:definition>025 - Disclosure - Notes Payable/Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/IntangibleAssetsTables" id="ntrb_r_IntangibleAssetsTables">
        <link:definition>026 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/DerivativeLiabilitiesTables" id="ntrb_r_DerivativeLiabilitiesTables">
        <link:definition>027 - Disclosure - Derivative Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/WarrantsandOptionsTables" id="ntrb_r_WarrantsandOptionsTables">
        <link:definition>028 - Disclosure - Warrants and Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables" id="ntrb_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>029 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" id="ntrb_r_OrganizationandDescriptionofBusinessDetails">
        <link:definition>030 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable" id="ntrb_r_ScheduleofdisaggregationofrevenuesTable">
        <link:definition>031 - Disclosure - Organization and Description of Business (Details) - Schedule of disaggregation of revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable" id="ntrb_r_ScheduleofrevenuebygeographicallocationTable">
        <link:definition>032 - Disclosure - Organization and Description of Business (Details) - Schedule of revenue by geographical location</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable" id="ntrb_r_ScheduleofpropertyplantandequipmentTable">
        <link:definition>033 - Disclosure - Organization and Description of Business (Details) - Schedule of property plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/AcquisitionofBusinessDetails" id="ntrb_r_AcquisitionofBusinessDetails">
        <link:definition>034 - Disclosure - Acquisition of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofnetassetsacquiredTable" id="ntrb_r_ScheduleofnetassetsacquiredTable">
        <link:definition>035 - Disclosure - Acquisition of Business (Details) - Schedule of net assets acquired</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable" id="ntrb_r_ScheduleofunauditedproformacondensedfinancialinformationTable">
        <link:definition>036 - Disclosure - Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/PropertyandEquipmentDetails" id="ntrb_r_PropertyandEquipmentDetails">
        <link:definition>037 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofpropertyandequipmentTable" id="ntrb_r_ScheduleofpropertyandequipmentTable">
        <link:definition>038 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/IncomeTaxesDetails" id="ntrb_r_IncomeTaxesDetails">
        <link:definition>039 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/SummaryofprovisionforincometaxesTable" id="ntrb_r_SummaryofprovisionforincometaxesTable">
        <link:definition>040 - Disclosure - Income Taxes (Details) - Summary of provision for income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable" id="ntrb_r_ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable">
        <link:definition>041 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable" id="ntrb_r_ScheduleofdeferredtaxassetandliabilitiesTable">
        <link:definition>042 - Disclosure - Income Taxes (Details) - Schedule of deferred tax asset and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/NotesPayableConvertibleDebtDetails" id="ntrb_r_NotesPayableConvertibleDebtDetails">
        <link:definition>043 - Disclosure - Notes Payable/Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofminimumleasepaymentsTable" id="ntrb_r_ScheduleofminimumleasepaymentsTable">
        <link:definition>044 - Disclosure - Notes Payable/Convertible Debt (Details) - Schedule of minimum lease payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/IntangibleAssetsDetails" id="ntrb_r_IntangibleAssetsDetails">
        <link:definition>045 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" id="ntrb_r_ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable">
        <link:definition>046 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofestimatedamortizationTable" id="ntrb_r_ScheduleofestimatedamortizationTable">
        <link:definition>047 - Disclosure - Intangible Assets (Details) - Schedule of estimated amortization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/DerivativeLiabilitiesDetails" id="ntrb_r_DerivativeLiabilitiesDetails">
        <link:definition>048 - Disclosure - Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable" id="ntrb_r_SchedulereconciliationofderivativeliabilitiesTable">
        <link:definition>049 - Disclosure - Derivative Liabilities (Details) - Schedule reconciliation of derivative liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/RelatedPartyTransactionsDetails" id="ntrb_r_RelatedPartyTransactionsDetails">
        <link:definition>050 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/StockholdersEquityDetails" id="ntrb_r_StockholdersEquityDetails">
        <link:definition>051 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/WarrantsandOptionsDetails" id="ntrb_r_WarrantsandOptionsDetails">
        <link:definition>052 - Disclosure - Warrants and Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable" id="ntrb_r_ScheduleofwarrantsoutstandingTable">
        <link:definition>053 - Disclosure - Warrants and Options (Details) - Schedule of warrants outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZzjdoIf697x9Ebb9RR62VzZ2moDN98hKYJqt0nOEvOJM3ovM/SXTjMP1Ald7slk0jhpkvJNEcZ22oENEU/pa+RGktyuYgAZpSzCvQD/cHd+rIAFOf0qxA58sbmcPw9UpSPh+OrTDXTmJ7VYjFEDe+x4Kv3wGjJ2krmmyw+NNN8s1XXb3twhDh+n/L9ybagyg4=] CSR-->
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" id="ntrb_r_ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable">
        <link:definition>054 - Disclosure - Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofoptionsoutstandingTable" id="ntrb_r_ScheduleofoptionsoutstandingTable">
        <link:definition>055 - Disclosure - Warrants and Options (Details) - Schedule of options outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/LeasesDetails" id="ntrb_r_LeasesDetails">
        <link:definition>056 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/CommitmentsandContigenciesDetails" id="ntrb_r_CommitmentsandContigenciesDetails">
        <link:definition>057 - Disclosure - Commitments and Contigencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/SubsequentEventsDetails" id="ntrb_r_SubsequentEventsDetails">
        <link:definition>058 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" id="ntrb_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>059 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0" id="ntrb_r_ScheduleofdisaggregationofrevenuesTable0">
        <link:definition>060 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0" id="ntrb_r_ScheduleofrevenuebygeographicallocationTable0">
        <link:definition>061 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0" id="ntrb_r_ScheduleofpropertyplantandequipmentTable0">
        <link:definition>062 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofnetassetsacquiredTable0" id="ntrb_r_ScheduleofnetassetsacquiredTable0">
        <link:definition>063 - Disclosure - Acquisition of Business (Details) - Schedule of net assets acquired</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0" id="ntrb_r_ScheduleofunauditedproformacondensedfinancialinformationTable0">
        <link:definition>064 - Disclosure - Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofpropertyandequipmentTable0" id="ntrb_r_ScheduleofpropertyandequipmentTable0">
        <link:definition>065 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable" id="ntrb_r_ScheduleofMinimumleasepaymentsTable">
        <link:definition>066 - Disclosure - Notes Payable/Convertible Debt (Details) - Schedule of Minimum lease payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0" id="ntrb_r_ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0">
        <link:definition>067 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofestimatedamortizationTable0" id="ntrb_r_ScheduleofestimatedamortizationTable0">
        <link:definition>068 - Disclosure - Intangible Assets (Details) - Schedule of estimated amortization:</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0" id="ntrb_r_ScheduleofwarrantsoutstandingTable0">
        <link:definition>069 - Disclosure - Warrants (Details) - Schedule of warrants outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0" id="ntrb_r_ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0">
        <link:definition>070 - Disclosure - Warrants (Details) - Schedule of additional information relating to warrants outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nutriband.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="ScheduleOfDisaggregationOfRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract"/>
  <xs:element name="ScheduleOfRevenueByGeographicalLocationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfRevenueByGeographicalLocationAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfNetAssetsAcquiredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfNetAssetsAcquiredAbstract"/>
  <xs:element name="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="SummaryOfProvisionForIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SummaryOfProvisionForIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfMinimumLeasePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfMinimumLeasePaymentsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract"/>
  <xs:element name="ScheduleOfEstimatedAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfEstimatedAmortizationAbstract"/>
  <xs:element name="ScheduleReconciliationOfDerivativeLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract"/>
  <xs:element name="WarrantsAndOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsAndOptionsAbstract"/>
  <xs:element name="ScheduleOfWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfOptionsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfOptionsOutstandingAbstract"/>
  <xs:element name="LongTermLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_LongTermLiabilitiesAbstract"/>
  <xs:element name="LongTermLiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_LongTermLiabilitiesAbstract0"/>
  <xs:element name="OtherIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OtherIncomeExpenseAbstract"/>
  <xs:element name="OtherComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OtherComprehensiveLossAbstract"/>
  <xs:element name="OtherIncomeExpenseAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OtherIncomeExpenseAbstract0"/>
  <xs:element name="OtherComprehensiveIncomeLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OtherComprehensiveIncomeLossAbstract"/>
  <xs:element name="CashPaidForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CashPaidForAbstract"/>
  <xs:element name="CashPaidForAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CashPaidForAbstract0"/>
  <xs:element name="RevenueByTypeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RevenueByTypeAbstract"/>
  <xs:element name="RevenueByGeographicalLocationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RevenueByGeographicalLocationAbstract"/>
  <xs:element name="RevenueByTypeAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RevenueByTypeAbstract0"/>
  <xs:element name="RevenueByGeographicLocationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RevenueByGeographicLocationAbstract"/>
  <xs:element name="SubscriptionPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SubscriptionPayables"/>
  <xs:element name="CommonStockShareIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockShareIssued"/>
  <xs:element name="CommonStockShareOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockShareOutstanding"/>
  <xs:element name="GainOnForgivenessOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_GainOnForgivenessOfDebt"/>
  <xs:element name="StockIssuedDuringPeriodIssuanceOfWarrantsForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices"/>
  <xs:element name="StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants"/>
  <xs:element name="ReclassificationOfWarrantsFromLiabilityToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity"/>
  <xs:element name="IssuanceOfCommonStockForNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_IssuanceOfCommonStockForNotePayable"/>
  <xs:element name="IssuanceOfCommonStockForNotePayableinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_IssuanceOfCommonStockForNotePayableinShares"/>
  <xs:element name="SubscrptionPayableForCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SubscrptionPayableForCash"/>
  <xs:element name="SubscrptionPayableForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SubscrptionPayableForServices"/>
  <xs:element name="SaleofCommonstockForCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SaleofCommonstockForCash"/>
  <xs:element name="IncreaseDecreaseInDerivativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_IncreaseDecreaseInDerivativeExpense"/>
  <xs:element name="EarlyPrepaymentFeeOnConvertibleDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures"/>
  <xs:element name="GainOnForgivenessOfLoanPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_GainOnForgivenessOfLoanPayment"/>
  <xs:element name="SubscriptionPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SubscriptionPayable"/>
  <xs:element name="IncreaseDecreaseOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_IncreaseDecreaseOperatingLeaseLiability"/>
  <xs:element name="increasedecreaseDepositOnSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_increasedecreaseDepositOnSales"/>
  <xs:element name="CommonStockAndNoteIssuedInAcquisitions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockAndNoteIssuedInAcquisitions"/>
  <xs:element name="AdoptionOfASC842OperatingLeaseAssetAndLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability"/>
  <xs:element name="DerivativeLiabilityWarrantReclassedToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DerivativeLiabilityWarrantReclassedToEquity"/>
  <xs:element name="DebtDiscountOnConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DebtDiscountOnConvertibleNotes"/>
  <xs:element name="CommonStockIssuedForAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockIssuedForAccountsPayable"/>
  <xs:element name="CommonStockIssuedForSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockIssuedForSettlement"/>
  <xs:element name="CommonStockIssuedForSettlementOfNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockIssuedForSettlementOfNotesPayable"/>
  <xs:element name="CommonStockIssuedForPrepaidConsulting" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockIssuedForPrepaidConsulting"/>
  <xs:element name="NoncashPaymentForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_NoncashPaymentForLicenseAgreement"/>
  <xs:element name="CommonIssuedForSubscriptionPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonIssuedForSubscriptionPayable"/>
  <xs:element name="WarrantsAndOptionsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsAndOptionsTextBlock"/>
  <xs:element name="LeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_LeasesTable"/>
  <xs:element name="LeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_LeasesLineItems"/>
  <xs:element name="OrganizationPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OrganizationPolicyTextBlock"/>
  <xs:element name="ReverseStockSplitPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ReverseStockSplitPolicyTextBlock"/>
  <xs:element name="GoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_GoingConcernPolicyTextBlock"/>
  <xs:element name="PerformanceObligationsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PerformanceObligationsPolicyTextBlock"/>
  <xs:element name="DisaggregationOfRevenuesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DisaggregationOfRevenuesPolicyTextBlock"/>
  <xs:element name="DerivativeLiabilitiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DerivativeLiabilitiesPolicyTextBlock"/>
  <xs:element name="UnauditedInterimFinancialStatementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock"/>
  <xs:element name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
  <xs:element name="ScheduleOfAdditionalRelatingWarrantsOutstanding" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding"/>
  <xs:element name="WarrantsandOptionsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_WarrantsandOptionsTablesTable"/>
  <xs:element name="WarrantsandOptionsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsandOptionsTablesLineItems"/>
  <xs:element name="SalesRevenuesGoodsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SalesRevenuesGoodsNet"/>
  <xs:element name="SaleOfGoodsAndServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SaleOfGoodsAndServices"/>
  <xs:element name="DisaggregationOfRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DisaggregationOfRevenues"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems"/>
  <xs:element name="BusinessAcquisitionCommonStockIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessAcquisitionCommonStockIssued"/>
  <xs:element name="NotePayableIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_NotePayableIssued"/>
  <xs:element name="CommonStockAndNoteIssuedInAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockAndNoteIssuedInAcquisition"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks"/>
  <xs:element name="BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic"/>
  <xs:element name="PropertyPlantAndEquipmentsGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PropertyPlantAndEquipmentsGross"/>
  <xs:element name="DeferredTaxAssetAndLiabilityStockIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices"/>
  <xs:element name="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
  <xs:element name="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems"/>
  <xs:element name="DerivativeLiabilityWarrantsReclassedToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DerivativeLiabilityWarrantsReclassedToEquity"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
  <xs:element name="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
  <xs:element name="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice"/>
  <xs:element name="WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable"/>
  <xs:element name="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
  <xs:element name="BusinessAcquisitionsNetLossAsReported" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessAcquisitionsNetLossAsReported"/>
  <xs:element name="LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice"/>
  <xs:element name="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
  <xs:element name="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
  <xs:element name="ShareBasedCompensationNumberOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationNumberOutstanding"/>
  <xs:element name="ShareBasedCompensationNumberExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationNumberExercisable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_OrganizationandDescriptionofBusinessDetailsTable"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentsUsefulLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PropertyPlantAndEquipmentsUsefulLife"/>
  <xs:element name="ConcentrationRiskPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ConcentrationRiskPercentage"/>
  <xs:element name="AcquiredPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_AcquiredPercentage"/>
  <xs:element name="AcquisitionofBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_AcquisitionofBusinessDetailsTable"/>
  <xs:element name="AcquisitionofBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_AcquisitionofBusinessDetailsLineItems"/>
  <xs:element name="BusinessAcquisitionPercentageOfVotingInterestAcquired" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired"/>
  <xs:element name="DebtInstrumentAnnualPrincipalPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DebtInstrumentAnnualPrincipalPayments"/>
  <xs:element name="AnnualMeetingOfShareholdersTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_AnnualMeetingOfShareholdersTerm"/>
  <xs:element name="BusinessAcquisitionRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessAcquisitionRevenue"/>
  <xs:element name="BusinessAcquisitionNetProfit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessAcquisitionNetProfit"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax"/>
  <xs:element name="NotesPayableConvertibleDebtDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_NotesPayableConvertibleDebtDetailsTable"/>
  <xs:element name="NotesPayableConvertibleDebtDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_NotesPayableConvertibleDebtDetailsLineItems"/>
  <xs:element name="NotePayablesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_NotePayablesDescription"/>
  <xs:element name="ProceedsFromLoanOriginationsTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ProceedsFromLoanOriginationsTotal"/>
  <xs:element name="NotePayableConvertibleDebtDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_NotePayableConvertibleDebtDescription"/>
  <xs:element name="FairValueOfConversionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_FairValueOfConversionPrice"/>
  <xs:element name="DiscountRemainingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DiscountRemainingAmount"/>
  <xs:element name="PrepaymentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PrepaymentFee"/>
  <xs:element name="DerivativeLiabilitiesTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DerivativeLiabilitiesTotal"/>
  <xs:element name="InterestExpensesDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_InterestExpensesDebt"/>
  <xs:element name="AmortizationOfDebtDiscountsPremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_AmortizationOfDebtDiscountsPremium"/>
  <xs:element name="GainOnExtinguishmentOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_GainOnExtinguishmentOfDebt"/>
  <xs:element name="DueToRelatedPartyCurrentAndNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DueToRelatedPartyCurrentAndNoncurrent"/>
  <xs:element name="InterestExpenseDebts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_InterestExpenseDebts"/>
  <xs:element name="IntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_IntangibleAssetsDetailsTable"/>
  <xs:element name="IntangibleAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_IntangibleAssetsDetailsLineItems"/>
  <xs:element name="amortizedOverPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_amortizedOverPeriod"/>
  <xs:element name="PaymentForInitialLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PaymentForInitialLicenseFee"/>
  <xs:element name="DerivativeLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_DerivativeLiabilitiesDetailsTable"/>
  <xs:element name="DerivativeLiabilitiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DerivativeLiabilitiesDetailsLineItems"/>
  <xs:element name="FairValueAssumptionsWeightedAverageVolatilityRates" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates"/>
  <xs:element name="FairValueAssumptionsRiskFreeInterestRates" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_FairValueAssumptionsRiskFreeInterestRates"/>
  <xs:element name="ExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ExpectedTerm"/>
  <xs:element name="ExpectedTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ExpectedTerms"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="FairValueOfWarrantExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_FairValueOfWarrantExpense"/>
  <xs:element name="PurchaseOfMaterials" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PurchaseOfMaterials"/>
  <xs:element name="ExpensesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ExpensesPaid"/>
  <xs:element name="RelatedPartyTransactionDescriptionOfTransactions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RelatedPartyTransactionDescriptionOfTransactions"/>
  <xs:element name="CommonStockIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockIssued"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_StockholdersEquityDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_StockholdersEquityDetailsLineItems"/>
  <xs:element name="DesignatedSharesOfPreferredStocks" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DesignatedSharesOfPreferredStocks"/>
  <xs:element name="CommonStockOfDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockOfDescription"/>
  <xs:element name="IncreaseDecreasedInAuthorizedCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_IncreaseDecreasedInAuthorizedCommonStock"/>
  <xs:element name="PrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PrivatePlacement"/>
  <xs:element name="WarrantsToPurchaseOfCommonStockShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsToPurchaseOfCommonStockShare"/>
  <xs:element name="InvestmentWarrantExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_InvestmentWarrantExercisePrice"/>
  <xs:element name="WarrantsToPurchaseOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsToPurchaseOfCommonStockShares"/>
  <xs:element name="CommonStockShareSubscribedButUnissuedSubscriptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares"/>
  <xs:element name="SharesWereRestored" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SharesWereRestored"/>
  <xs:element name="FairValueOfTheCommonStocks" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_FairValueOfTheCommonStocks"/>
  <xs:element name="FundReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_FundReceived"/>
  <xs:element name="WarrantsandOptionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_WarrantsandOptionsDetailsTable"/>
  <xs:element name="WarrantsandOptionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_WarrantsandOptionsDetailsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue"/>
  <xs:element name="InitialPublicOfferingPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_InitialPublicOfferingPricePercentage"/>
  <xs:element name="ReclassOfWarrantsFromLiabilityToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ReclassOfWarrantsFromLiabilityToEquity"/>
  <xs:element name="MonthlyRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_MonthlyRent"/>
  <xs:element name="CommitmentsandContigenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_CommitmentsandContigenciesDetailsTable"/>
  <xs:element name="CommitmentsandContigenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_CommitmentsandContigenciesDetailsLineItems"/>
  <xs:element name="SalaryPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SalaryPayment"/>
  <xs:element name="PublicOrPrivateFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PublicOrPrivateFinancing"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SubsequentEventsDetailsLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="InventoryRawMaterialsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_InventoryRawMaterialsPercentage"/>
  <xs:element name="ActiveIntelligenceLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ActiveIntelligenceLLCMember"/>
  <xs:element name="BPMMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BPMMember"/>
  <xs:element name="BusinessCombinationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_BusinessCombinationMember"/>
  <xs:element name="ConsultingServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ConsultingServicesMember"/>
  <xs:element name="DefendantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DefendantMember"/>
  <xs:element name="FormerIndependentDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_FormerIndependentDirectorsMember"/>
  <xs:element name="HealthsBrandsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_HealthsBrandsIncMember"/>
  <xs:element name="LabEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_LabEquipmentMember"/>
  <xs:element name="LicensingAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_LicensingAgreementMember"/>
  <xs:element name="OneCustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_OneCustomerMember"/>
  <xs:element name="PoconoCoatedProductsLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_PoconoCoatedProductsLLCMember"/>
  <xs:element name="RelatedPartyPayableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RelatedPartyPayableMember"/>
  <xs:element name="RevaluedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_RevaluedMember"/>
  <xs:element name="StockPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_StockPurchaseAgreementMember"/>
  <xs:element name="SubscriptionPayableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_SubscriptionPayableMember"/>
  <xs:element name="TherapeuticsLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_TherapeuticsLLCMember"/>
  <xs:element name="ThreeCustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_ThreeCustomerMember"/>
  <xs:element name="TwoCustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_TwoCustomerMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ntrb_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ntrb-20210731_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Sep 30 22:42:48 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedBalanceSheet" roleURI="http://nutriband.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedIncomeStatement" roleURI="http://nutriband.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedCashFlow" roleURI="http://nutriband.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayables" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="ntrb_SubscriptionPayables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfRevenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnForgivenessOfDebt" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="ntrb_GainOnForgivenessOfDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfDerivatives" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZzjdoIf697x9Ebb9RR62VzZ2moDN98hKYJqt0nOEvOJM3ovM/SXTjMP1Ald7slk0jhpkvJNEcZ22oENEU/pa+RGktyuYgAZpSzCvQD/cHd+rIAFOf0qxA58sbmcPw9UpSPh+OrTDXTmJ7VYjFEDe+x4Kv3wGjJ2krmmyw+NNN8s0DhiCNJwk7CMxROqOFVfNU=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_AccretionExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseDebt" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreaseInDerivativeExpense" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseInDerivativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ntrb_IncreaseDecreaseInDerivativeExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" xlink:href="ntrb-20210731.xsd#ntrb_EarlyPrepaymentFeeOnConvertibleDebentures"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfLeasedAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfLeasedAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfLeasedAsset" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInCustomerDeposits" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnForgivenessOfLoanPayment" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfLoanPayment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ntrb_GainOnForgivenessOfLoanPayment" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ntrb_SubscriptionPayable" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreaseOperatingLeaseLiability" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ntrb_IncreaseDecreaseOperatingLeaseLiability" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ntrb_increasedecreaseDepositOnSales" xlink:href="ntrb-20210731.xsd#ntrb_increasedecreaseDepositOnSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ntrb_increasedecreaseDepositOnSales" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherEquity" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="5" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ntrb-20210731_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Sep 30 22:42:48 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedBalanceSheet" roleURI="http://nutriband.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedIncomeStatement" roleURI="http://nutriband.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ShareholdersEquityType2or3" roleURI="http://nutriband.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedCashFlow" roleURI="http://nutriband.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_OrganizationandDescriptionofBusiness" roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AcquisitionofBusiness" roleURI="http://nutriband.com/role/AcquisitionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_PropertyandEquipment" roleURI="http://nutriband.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IncomeTaxes" roleURI="http://nutriband.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_NotesPayableConvertibleDebt" roleURI="http://nutriband.com/role/NotesPayableConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IntangibleAssets" roleURI="http://nutriband.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_DerivativeLiabilities" roleURI="http://nutriband.com/role/DerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_RelatedPartyTransactions" roleURI="http://nutriband.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_StockholdersEquity" roleURI="http://nutriband.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_WarrantsandOptions" roleURI="http://nutriband.com/role/WarrantsandOptions"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_Leases" roleURI="http://nutriband.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_CommitmentsandContigencies" roleURI="http://nutriband.com/role/CommitmentsandContigencies"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SubsequentEvents" roleURI="http://nutriband.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofSignificantAccountingPolicies" roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AccountingPoliciesByPolicy" roleURI="http://nutriband.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_OrganizationandDescriptionofBusinessTables" roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AcquisitionofBusinessTables" roleURI="http://nutriband.com/role/AcquisitionofBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_PropertyandEquipmentTables" roleURI="http://nutriband.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IncomeTaxesTables" roleURI="http://nutriband.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_NotesPayableConvertibleDebtTables" roleURI="http://nutriband.com/role/NotesPayableConvertibleDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IntangibleAssetsTables" roleURI="http://nutriband.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_DerivativeLiabilitiesTables" roleURI="http://nutriband.com/role/DerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_WarrantsandOptionsTables" roleURI="http://nutriband.com/role/WarrantsandOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofdisaggregationofrevenuesTable" roleURI="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofrevenuebygeographicallocationTable" roleURI="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofnetassetsacquiredTable" roleURI="http://nutriband.com/role/ScheduleofnetassetsacquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofunauditedproformacondensedfinancialinformationTable" roleURI="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyandequipmentTable" roleURI="http://nutriband.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofprovisionforincometaxesTable" roleURI="http://nutriband.com/role/SummaryofprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable" roleURI="http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofdeferredtaxassetandliabilitiesTable" roleURI="http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofminimumleasepaymentsTable" roleURI="http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" roleURI="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofestimatedamortizationTable" roleURI="http://nutriband.com/role/ScheduleofestimatedamortizationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SchedulereconciliationofderivativeliabilitiesTable" roleURI="http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofwarrantsoutstandingTable" roleURI="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" roleURI="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofoptionsoutstandingTable" roleURI="http://nutriband.com/role/ScheduleofoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofdisaggregationofrevenuesTable0" roleURI="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofrevenuebygeographicallocationTable0" roleURI="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyplantandequipmentTable0" roleURI="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofnetassetsacquiredTable0" roleURI="http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofunauditedproformacondensedfinancialinformationTable0" roleURI="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyandequipmentTable0" roleURI="http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofMinimumleasepaymentsTable" roleURI="http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0" roleURI="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofestimatedamortizationTable0" roleURI="http://nutriband.com/role/ScheduleofestimatedamortizationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofwarrantsoutstandingTable0" roleURI="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0" roleURI="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AcquisitionofBusinessDetails" roleURI="http://nutriband.com/role/AcquisitionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_PropertyandEquipmentDetails" roleURI="http://nutriband.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IncomeTaxesDetails" roleURI="http://nutriband.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_NotesPayableConvertibleDebtDetails" roleURI="http://nutriband.com/role/NotesPayableConvertibleDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IntangibleAssetsDetails" roleURI="http://nutriband.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_DerivativeLiabilitiesDetails" roleURI="http://nutriband.com/role/DerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_RelatedPartyTransactionsDetails" roleURI="http://nutriband.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_StockholdersEquityDetails" roleURI="http://nutriband.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_WarrantsandOptionsDetails" roleURI="http://nutriband.com/role/WarrantsandOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_LeasesDetails" roleURI="http://nutriband.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_CommitmentsandContigenciesDetails" roleURI="http://nutriband.com/role/CommitmentsandContigenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SubsequentEventsDetails" roleURI="http://nutriband.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#DocumentAndEntityInformation" roleURI="http://nutriband.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Goodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_LongTermLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_LongTermLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="ntrb_LongTermLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_LongTermLiabilitiesAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_LongTermLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_LongTermLiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayables" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="ntrb_SubscriptionPayables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockShareIssued" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="ntrb_CommonStockShareIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockShareOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="ntrb_CommonStockShareOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_CostsAndExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_OtherIncomeExpenseAbstract" xlink:href="ntrb-20210731.xsd#ntrb_OtherIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="ntrb_OtherIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="us-gaap_AccretionExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnForgivenessOfDebt" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="ntrb_GainOnForgivenessOfDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfDerivatives" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_OtherComprehensiveLossAbstract" xlink:href="ntrb-20210731.xsd#ntrb_OtherComprehensiveLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="ntrb_OtherComprehensiveLossAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayableMember" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="ntrb_SubscriptionPayableMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SaleofCommonstockForCash" xlink:href="ntrb-20210731.xsd#ntrb_SaleofCommonstockForCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_SaleofCommonstockForCash" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:href="ntrb-20210731.xsd#ntrb_ReclassificationOfWarrantsFromLiabilityToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_IssuanceOfCommonStockForNotePayable" xlink:href="ntrb-20210731.xsd#ntrb_IssuanceOfCommonStockForNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_IssuanceOfCommonStockForNotePayable" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_IssuanceOfCommonStockForNotePayableinShares" xlink:href="ntrb-20210731.xsd#ntrb_IssuanceOfCommonStockForNotePayableinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_IssuanceOfCommonStockForNotePayableinShares" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscrptionPayableForCash" xlink:href="ntrb-20210731.xsd#ntrb_SubscrptionPayableForCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_SubscrptionPayableForCash" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscrptionPayableForServices" xlink:href="ntrb-20210731.xsd#ntrb_SubscrptionPayableForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ntrb_SubscrptionPayableForServices" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreaseInDerivativeExpense" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseInDerivativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ntrb_IncreaseDecreaseInDerivativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" xlink:href="ntrb-20210731.xsd#ntrb_EarlyPrepaymentFeeOnConvertibleDebentures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnForgivenessOfLoanPayment" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfLoanPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ntrb_GainOnForgivenessOfLoanPayment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfLeasedAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfLeasedAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfLeasedAsset" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ntrb_SubscriptionPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_increasedecreaseDepositOnSales" xlink:href="ntrb-20210731.xsd#ntrb_increasedecreaseDepositOnSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ntrb_increasedecreaseDepositOnSales" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInCustomerDeposits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreaseOperatingLeaseLiability" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ntrb_IncreaseDecreaseOperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CashPaidForAbstract0" xlink:href="ntrb-20210731.xsd#ntrb_CashPaidForAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ntrb_CashPaidForAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CashPaidForAbstract" xlink:href="ntrb-20210731.xsd#ntrb_CashPaidForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ntrb_CashPaidForAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CashPaidForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CashPaidForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisitions" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisitions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability" xlink:href="ntrb-20210731.xsd#ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForSettlementOfNotesPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForSettlementOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_CommonStockIssuedForSettlementOfNotesPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForPrepaidConsulting" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForPrepaidConsulting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_CommonStockIssuedForPrepaidConsulting" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_NoncashPaymentForLicenseAgreement" xlink:href="ntrb-20210731.xsd#ntrb_NoncashPaymentForLicenseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_NoncashPaymentForLicenseAgreement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilityWarrantReclassedToEquity" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilityWarrantReclassedToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_DerivativeLiabilityWarrantReclassedToEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonIssuedForSubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonIssuedForSubscriptionPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_CommonIssuedForSubscriptionPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DebtDiscountOnConvertibleNotes" xlink:href="ntrb-20210731.xsd#ntrb_DebtDiscountOnConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_DebtDiscountOnConvertibleNotes" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForAccountsPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_CommonStockIssuedForAccountsPayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForSettlement" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ntrb_CommonStockIssuedForSettlement" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/AcquisitionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/NotesPayableConvertibleDebt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/DerivativeLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/WarrantsandOptions">
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsAndOptionsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsAndOptionsTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsAndOptionsAbstract" xlink:to="ntrb_WarrantsAndOptionsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/Leases">
    <loc xlink:type="locator" xlink:label="ntrb_LeasesLineItems" xlink:href="ntrb-20210731.xsd#ntrb_LeasesLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_LeasesTable" xlink:href="ntrb-20210731.xsd#ntrb_LeasesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_LeasesLineItems" xlink:to="ntrb_LeasesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/CommitmentsandContigencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_OrganizationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ReverseStockSplitPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_ReverseStockSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_ReverseStockSplitPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_GoingConcernPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_GoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_GoingConcernPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PerformanceObligationsPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PerformanceObligationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_PerformanceObligationsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenuesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_DisaggregationOfRevenuesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_DerivativeLiabilitiesPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/OrganizationandDescriptionofBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/AcquisitionofBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/NotesPayableConvertibleDebtTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/DerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/WarrantsandOptionsTables">
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsTablesLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsTablesTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_WarrantsandOptionsTablesLineItems" xlink:to="ntrb_WarrantsandOptionsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_WarrantsandOptionsTablesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsTablesLineItems" xlink:to="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDisaggregationOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="ntrb_SalesRevenuesGoodsNet" xlink:href="ntrb-20210731.xsd#ntrb_SalesRevenuesGoodsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="ntrb_SalesRevenuesGoodsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SaleOfGoodsAndServices" xlink:href="ntrb-20210731.xsd#ntrb_SaleOfGoodsAndServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="ntrb_SaleOfGoodsAndServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DisaggregationOfRevenues" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="ntrb_DisaggregationOfRevenues" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable">
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DisaggregationOfRevenues" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="ntrb_DisaggregationOfRevenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ntrb_LabEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofnetassetsacquiredTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfNetAssetsAcquiredAbstract"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionCommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionCommonStockIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_BusinessAcquisitionCommonStockIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotePayableIssued" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_NotePayableIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisition" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_GoodwillGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ntrb_LabEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PropertyPlantAndEquipmentsGross" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="ntrb_PropertyPlantAndEquipmentsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="ntrb_SummaryOfProvisionForIncomeTaxesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_SummaryOfProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryOfProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryOfProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices" xlink:href="ntrb-20210731.xsd#ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable">
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelatedIntangibleAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofestimatedamortizationTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfEstimatedAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilityWarrantsReclassedToEquity" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilityWarrantsReclassedToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="ntrb_DerivativeLiabilityWarrantsReclassedToEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZzjdoIf697x9Ebb9RR62VzZ2moDN98hKYJqt0nOEvOJM3ovM/SXTjMP1Ald7slk0jhpkvJNEcZ22oENEU/pa+RGktyuYgAZpSzCvQD/cHd+rIAFOf0qxA58sbmcPw9UpSPh+OrTDXTmJ7VYjFEDe+x4Kv3wGjJ2krmmyw+NNN8s0BDeZfQ/kG6iSuCTvJiMlQ=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDisaggregationOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="ntrb_SalesRevenuesGoodsNet" xlink:href="ntrb-20210731.xsd#ntrb_SalesRevenuesGoodsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="ntrb_SalesRevenuesGoodsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SaleOfGoodsAndServices" xlink:href="ntrb-20210731.xsd#ntrb_SaleOfGoodsAndServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="ntrb_SaleOfGoodsAndServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0">
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0">
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ntrb_LabEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofnetassetsacquiredTable0">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfNetAssetsAcquiredAbstract"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionCommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionCommonStockIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_BusinessAcquisitionCommonStockIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotePayableIssued" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_NotePayableIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisition" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_GoodwillGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionsNetLossAsReported" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionsNetLossAsReported"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="ntrb_BusinessAcquisitionsNetLossAsReported" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" xlink:href="ntrb-20210731.xsd#ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ntrb_LabEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0">
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelatedIntangibleAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_LicensingAgreementMember" xlink:href="ntrb-20210731.xsd#ntrb_LicensingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ntrb_LicensingAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofestimatedamortizationTable0">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfEstimatedAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0">
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0">
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationNumberOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationNumberOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationNumberOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationNumberExercisable" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationNumberExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationNumberExercisable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_MajorCustomersAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ThreeCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_ThreeCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ntrb_ThreeCustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_TwoCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_TwoCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ntrb_TwoCustomerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_OneCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_OneCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ntrb_OneCustomerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_TherapeuticsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_TherapeuticsLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ntrb_TherapeuticsLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ActiveIntelligenceLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_ActiveIntelligenceLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ntrb_ActiveIntelligenceLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PropertyPlantAndEquipmentsUsefulLife" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentsUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="ntrb_PropertyPlantAndEquipmentsUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_Goodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ConcentrationRiskPercentage" xlink:href="ntrb-20210731.xsd#ntrb_ConcentrationRiskPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="ntrb_ConcentrationRiskPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_AcquiredPercentage" xlink:href="ntrb-20210731.xsd#ntrb_AcquiredPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="ntrb_AcquiredPercentage" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/AcquisitionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_AcquisitionofBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_AcquisitionofBusinessDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_AcquisitionofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="ntrb_AcquisitionofBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_AcquisitionofBusinessDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationMember" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ntrb_BusinessCombinationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DebtInstrumentAnnualPrincipalPayments" xlink:href="ntrb-20210731.xsd#ntrb_DebtInstrumentAnnualPrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="ntrb_DebtInstrumentAnnualPrincipalPayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_AnnualMeetingOfShareholdersTerm" xlink:href="ntrb-20210731.xsd#ntrb_AnnualMeetingOfShareholdersTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="ntrb_AnnualMeetingOfShareholdersTerm" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionRevenue" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="ntrb_BusinessAcquisitionRevenue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionNetProfit" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionNetProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="ntrb_BusinessAcquisitionNetProfit" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" xlink:href="ntrb-20210731.xsd#ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/NotesPayableConvertibleDebtDetails">
    <loc xlink:type="locator" xlink:label="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_NotesPayableConvertibleDebtDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotesPayableConvertibleDebtDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_NotesPayableConvertibleDebtDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_NotesPayableConvertibleDebtDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyPayableMember" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntrb_RelatedPartyPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotePayablesDescription" xlink:href="ntrb-20210731.xsd#ntrb_NotePayablesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_NotePayablesDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvances" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalHomeLoanBankAdvances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_FederalHomeLoanBankAdvances" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ProceedsFromLoanOriginationsTotal" xlink:href="ntrb-20210731.xsd#ntrb_ProceedsFromLoanOriginationsTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_ProceedsFromLoanOriginationsTotal" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotePayableConvertibleDebtDescription" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableConvertibleDebtDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_NotePayableConvertibleDebtDescription" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueOfConversionPrice" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_FairValueOfConversionPrice" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DiscountRemainingAmount" xlink:href="ntrb-20210731.xsd#ntrb_DiscountRemainingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_DiscountRemainingAmount" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PrepaymentFee" xlink:href="ntrb-20210731.xsd#ntrb_PrepaymentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_PrepaymentFee" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesTotal" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_DerivativeLiabilitiesTotal" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_InterestExpensesDebt" xlink:href="ntrb-20210731.xsd#ntrb_InterestExpensesDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_InterestExpensesDebt" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_AmortizationOfDebtDiscountsPremium" xlink:href="ntrb-20210731.xsd#ntrb_AmortizationOfDebtDiscountsPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_AmortizationOfDebtDiscountsPremium" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnExtinguishmentOfDebt" xlink:href="ntrb-20210731.xsd#ntrb_GainOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_GainOnExtinguishmentOfDebt" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DueToRelatedPartyCurrentAndNoncurrent" xlink:href="ntrb-20210731.xsd#ntrb_DueToRelatedPartyCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_DueToRelatedPartyCurrentAndNoncurrent" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_InterestExpenseDebts" xlink:href="ntrb-20210731.xsd#ntrb_InterestExpenseDebts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_InterestExpenseDebts" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="41" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_IntangibleAssetsDetailsLineItems" xlink:to="ntrb_IntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_IntangibleAssetsDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_amortizedOverPeriod" xlink:href="ntrb-20210731.xsd#ntrb_amortizedOverPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsLineItems" xlink:to="ntrb_amortizedOverPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PaymentForInitialLicenseFee" xlink:href="ntrb-20210731.xsd#ntrb_PaymentForInitialLicenseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_IntangibleAssetsDetailsLineItems" xlink:to="ntrb_PaymentForInitialLicenseFee" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/DerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:to="ntrb_DerivativeLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_DerivativeLiabilitiesDetailsTable" xlink:to="srt_RestatementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_RevaluedMember" xlink:href="ntrb-20210731.xsd#ntrb_RevaluedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="ntrb_RevaluedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates" xlink:href="ntrb-20210731.xsd#ntrb_FairValueAssumptionsWeightedAverageVolatilityRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:to="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueAssumptionsRiskFreeInterestRates" xlink:href="ntrb-20210731.xsd#ntrb_FairValueAssumptionsRiskFreeInterestRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:to="ntrb_FairValueAssumptionsRiskFreeInterestRates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ExpectedTerm" xlink:href="ntrb-20210731.xsd#ntrb_ExpectedTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:to="ntrb_ExpectedTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ExpectedTerms" xlink:href="ntrb-20210731.xsd#ntrb_ExpectedTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:to="ntrb_ExpectedTerms" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyTransactionsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="ntrb_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PoconoCoatedProductsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_PoconoCoatedProductsLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ntrb_PoconoCoatedProductsLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_FormerIndependentDirectorsMember" xlink:href="ntrb-20210731.xsd#ntrb_FormerIndependentDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ntrb_FormerIndependentDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueOfWarrantExpense" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfWarrantExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="ntrb_FairValueOfWarrantExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalTransactionsRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrincipalTransactionsRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PrincipalTransactionsRevenue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PurchaseOfMaterials" xlink:href="ntrb-20210731.xsd#ntrb_PurchaseOfMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="ntrb_PurchaseOfMaterials" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ExpensesPaid" xlink:href="ntrb-20210731.xsd#ntrb_ExpensesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="ntrb_ExpensesPaid" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionDescriptionOfTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="ntrb_RelatedPartyTransactionDescriptionOfTransactions" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="ntrb_CommonStockIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssued1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="ntrb_StockholdersEquityDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockholdersEquityDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PoconoCoatedProductsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_PoconoCoatedProductsLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntrb_PoconoCoatedProductsLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_BPMMember" xlink:href="ntrb-20210731.xsd#ntrb_BPMMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntrb_BPMMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ConsultingServicesMember" xlink:href="ntrb-20210731.xsd#ntrb_ConsultingServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntrb_ConsultingServicesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ntrb_ConsultingServicesMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ntrb_BPMMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DesignatedSharesOfPreferredStocks" xlink:href="ntrb-20210731.xsd#ntrb_DesignatedSharesOfPreferredStocks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_DesignatedSharesOfPreferredStocks" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockOfDescription" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockOfDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_CommonStockOfDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreasedInAuthorizedCommonStock" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreasedInAuthorizedCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_IncreaseDecreasedInAuthorizedCommonStock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PrivatePlacement" xlink:href="ntrb-20210731.xsd#ntrb_PrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_PrivatePlacement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShare" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsToPurchaseOfCommonStockShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_InvestmentWarrantExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_InvestmentWarrantExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_InvestmentWarrantExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShares" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsToPurchaseOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromInterestReceived" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharesWereRestored" xlink:href="ntrb-20210731.xsd#ntrb_SharesWereRestored"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_SharesWereRestored" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueOfTheCommonStocks" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfTheCommonStocks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_FairValueOfTheCommonStocks" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_SubscriptionPayable" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PaymentForInitialLicenseFee" xlink:href="ntrb-20210731.xsd#ntrb_PaymentForInitialLicenseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_PaymentForInitialLicenseFee" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_FundReceived" xlink:href="ntrb-20210731.xsd#ntrb_FundReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_FundReceived" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/WarrantsandOptionsDetails">
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_WarrantsandOptionsDetailsLineItems" xlink:to="ntrb_WarrantsandOptionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_WarrantsandOptionsDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_WarrantsandOptionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsLineItems" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_InitialPublicOfferingPricePercentage" xlink:href="ntrb-20210731.xsd#ntrb_InitialPublicOfferingPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsLineItems" xlink:to="ntrb_InitialPublicOfferingPricePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_ReclassOfWarrantsFromLiabilityToEquity" xlink:href="ntrb-20210731.xsd#ntrb_ReclassOfWarrantsFromLiabilityToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_WarrantsandOptionsDetailsLineItems" xlink:to="ntrb_ReclassOfWarrantsFromLiabilityToEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ntrb_MonthlyRent" xlink:href="ntrb-20210731.xsd#ntrb_MonthlyRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ntrb_MonthlyRent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/CommitmentsandContigenciesDetails">
    <loc xlink:type="locator" xlink:label="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_CommitmentsandContigenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommitmentsandContigenciesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_CommitmentsandContigenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="ntrb_CommitmentsandContigenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_CommitmentsandContigenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_CommitmentsandContigenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_CommitmentsandContigenciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_CommitmentsandContigenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_HealthsBrandsIncMember" xlink:href="ntrb-20210731.xsd#ntrb_HealthsBrandsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ntrb_HealthsBrandsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_DefendantMember" xlink:href="ntrb-20210731.xsd#ntrb_DefendantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ntrb_DefendantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PresidentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_PresidentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockPurchaseAgreementMember" xlink:href="ntrb-20210731.xsd#ntrb_StockPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="ntrb_StockPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_SalaryPayment" xlink:href="ntrb-20210731.xsd#ntrb_SalaryPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="ntrb_SalaryPayment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PublicOrPrivateFinancing" xlink:href="ntrb-20210731.xsd#ntrb_PublicOrPrivateFinancing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="ntrb_PublicOrPrivateFinancing" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_PaymentForInitialLicenseFee" xlink:href="ntrb-20210731.xsd#ntrb_PaymentForInitialLicenseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="ntrb_PaymentForInitialLicenseFee" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_OtherCommitmentsDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="ntrb_SubsequentEventsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubsequentEventsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_SubsequentEventsDetailsLineItems" xlink:to="ntrb_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ntrb_InventoryRawMaterialsPercentage" xlink:href="ntrb-20210731.xsd#ntrb_InventoryRawMaterialsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ntrb_InventoryRawMaterialsPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Goodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://nutriband.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ntrb-20210731_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Sep 30 22:42:47 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents - Beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents - End of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDisaggregationOfRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract_lbl" xml:lang="en-US">Schedule of disaggregation of revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="ntrb_ScheduleOfDisaggregationOfRevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfRevenueByGeographicalLocationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfRevenueByGeographicalLocationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfRevenueByGeographicalLocationAbstract_lbl" xml:lang="en-US">Schedule of revenue by geographical location [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfRevenueByGeographicalLocationAbstract" xlink:to="ntrb_ScheduleOfRevenueByGeographicalLocationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property plant and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfNetAssetsAcquiredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfNetAssetsAcquiredAbstract_lbl" xml:lang="en-US">Schedule of net assets acquired [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfNetAssetsAcquiredAbstract" xlink:to="ntrb_ScheduleOfNetAssetsAcquiredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract_lbl" xml:lang="en-US">Schedule of unaudited pro forma condensed financial information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="ntrb_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryOfProvisionForIncomeTaxesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_SummaryOfProvisionForIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SummaryOfProvisionForIncomeTaxesAbstract_lbl" xml:lang="en-US">Summary of provision for income taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SummaryOfProvisionForIncomeTaxesAbstract" xlink:to="ntrb_SummaryOfProvisionForIncomeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract_lbl" xml:lang="en-US">Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of deferred tax asset and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfMinimumLeasePaymentsAbstract_lbl" xml:lang="en-US">Schedule of minimum lease payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="ntrb_ScheduleOfMinimumLeasePaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract_lbl" xml:lang="en-US">Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract" xlink:to="ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfEstimatedAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfEstimatedAmortizationAbstract_lbl" xml:lang="en-US">Schedule of estimated amortization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfEstimatedAmortizationAbstract" xlink:to="ntrb_ScheduleOfEstimatedAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule reconciliation of derivative liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract" xlink:to="ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Balance at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl0" xml:lang="en-US">Balance at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl1" xml:lang="en-US">Derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsAndOptionsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsAndOptionsAbstract_lbl" xml:lang="en-US">Warrants And Options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsAndOptionsAbstract" xlink:to="ntrb_WarrantsAndOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule of warrants outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfWarrantsOutstandingAbstract" xlink:to="ntrb_ScheduleOfWarrantsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Shares, Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Shares, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xml:lang="en-US">Shares Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Exercise Price, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl0" xml:lang="en-US">Exercise Price, Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl1" xml:lang="en-US">Exercise Price Outstanding, Beginning Balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Intrinsic Value, Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Shares, Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xml:lang="en-US">Intrinsic Value Outstanding, Beginning Balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule of additional information relating to warrants outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract" xlink:to="ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfOptionsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfOptionsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfOptionsOutstandingAbstract_lbl" xml:lang="en-US">Schedule of options outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfOptionsOutstandingAbstract" xlink:to="ntrb_ScheduleOfOptionsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price, Outstanding, Beginning Balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise Price, Outstanding, Ending Balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares, Exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY &amp; EQUIPMENT-net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Net Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">OTHER ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use operating lease asset-net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets-net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Notes payable-related party, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liabilities-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible debt- net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_LongTermLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_LongTermLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_LongTermLiabilitiesAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LongTermLiabilitiesAbstract" xlink:to="ntrb_LongTermLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable-net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liabilities-net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockValue_lbl1" xml:lang="en-US">Common stock value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayables" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SubscriptionPayables_lbl" xml:lang="en-US">Subscription payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayables" xlink:to="ntrb_SubscriptionPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_LongTermLiabilitiesAbstract0" xlink:href="ntrb-20210731.xsd#ntrb_LongTermLiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_LongTermLiabilitiesAbstract0_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LongTermLiabilitiesAbstract0" xlink:to="ntrb_LongTermLiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockShareIssued" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockShareIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockShareIssued" xlink:to="ntrb_CommonStockShareIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockShareOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockShareOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockShareOutstanding" xlink:to="ntrb_CommonStockShareOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Net revenue, Reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OtherIncomeExpenseAbstract" xlink:href="ntrb-20210731.xsd#ntrb_OtherIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_OtherIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="ntrb_OtherIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">(Gain) loss on extinguisment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnForgivenessOfDebt" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_GainOnForgivenessOfDebt_lbl" xml:lang="en-US">Gain on forgiveness of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnForgivenessOfDebt" xlink:to="ntrb_GainOnForgivenessOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Gain on change of fair value of derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share of common stock-basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Loss per common share - basic and diluted, Reported (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding - basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OtherComprehensiveLossAbstract" xlink:href="ntrb-20210731.xsd#ntrb_OtherComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_OtherComprehensiveLossAbstract_lbl" xml:lang="en-US">Other Comprehensive Loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherComprehensiveLossAbstract" xlink:to="ntrb_OtherComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OtherIncomeExpenseAbstract0" xlink:href="ntrb-20210731.xsd#ntrb_OtherIncomeExpenseAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_OtherIncomeExpenseAbstract0_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherIncomeExpenseAbstract0" xlink:to="ntrb_OtherIncomeExpenseAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OtherComprehensiveIncomeLossAbstract" xlink:href="ntrb-20210731.xsd#ntrb_OtherComprehensiveIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_OtherComprehensiveIncomeLossAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherComprehensiveIncomeLossAbstract" xlink:to="ntrb_OtherComprehensiveIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices_lbl" xml:lang="en-US">Issuance of warrants for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices" xlink:to="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock for accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Common stock issued, value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock for accounts payable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Common stock issued, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Proceeds from sale of common stock and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" xlink:to="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Proceeds from sale of common stock and warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" xlink:to="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0" xml:lang="en-US">Common stock, value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xml:lang="en-US">Acquired advanced shares of common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for acquisition (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Issued of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xml:lang="en-US">Acquired advanced shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:href="ntrb-20210731.xsd#ntrb_ReclassificationOfWarrantsFromLiabilityToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US">Reclassification of warrants from liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:to="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IssuanceOfCommonStockForNotePayable" xlink:href="ntrb-20210731.xsd#ntrb_IssuanceOfCommonStockForNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_IssuanceOfCommonStockForNotePayable_lbl" xml:lang="en-US">Issuance of common stock for note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IssuanceOfCommonStockForNotePayable" xlink:to="ntrb_IssuanceOfCommonStockForNotePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IssuanceOfCommonStockForNotePayableinShares" xlink:href="ntrb-20210731.xsd#ntrb_IssuanceOfCommonStockForNotePayableinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_IssuanceOfCommonStockForNotePayableinShares_lbl" xml:lang="en-US">Issuance of common stock for note payable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IssuanceOfCommonStockForNotePayableinShares" xlink:to="ntrb_IssuanceOfCommonStockForNotePayableinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscrptionPayableForCash" xlink:href="ntrb-20210731.xsd#ntrb_SubscrptionPayableForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SubscrptionPayableForCash_lbl" xml:lang="en-US">Subscription payable for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscrptionPayableForCash" xlink:to="ntrb_SubscrptionPayableForCash_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscrptionPayableForServices" xlink:href="ntrb-20210731.xsd#ntrb_SubscrptionPayableForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SubscrptionPayableForServices_lbl" xml:lang="en-US">Subscription payable for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscrptionPayableForServices" xlink:to="ntrb_SubscrptionPayableForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued for proceeds and payment for license</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued for proceeds and payment for license (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Issued shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_SaleofCommonstockForCash" xlink:href="ntrb-20210731.xsd#ntrb_SaleofCommonstockForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SaleofCommonstockForCash_lbl" xml:lang="en-US">Common stock issued for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SaleofCommonstockForCash" xlink:to="ntrb_SaleofCommonstockForCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Common stock issued for cash (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of debt for common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of debt for common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Expenses paid on behalf of the Company by related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreaseInDerivativeExpense" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseInDerivativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_IncreaseDecreaseInDerivativeExpense_lbl" xml:lang="en-US">Derivative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreaseInDerivativeExpense" xlink:to="ntrb_IncreaseDecreaseInDerivativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" xlink:href="ntrb-20210731.xsd#ntrb_EarlyPrepaymentFeeOnConvertibleDebentures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures_lbl" xml:lang="en-US">Early prepayment fee on convertible debentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" xlink:to="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfLeasedAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfLeasedAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfLeasedAsset_lbl" xml:lang="en-US">Amortization of right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfLeasedAsset" xlink:to="us-gaap_AmortizationOfLeasedAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits_lbl" xml:lang="en-US">Customer deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:to="us-gaap_IncreaseDecreaseInCustomerDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash received from acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Received proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from stock subscription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CashPaidForAbstract" xlink:href="ntrb-20210731.xsd#ntrb_CashPaidForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CashPaidForAbstract" xlink:to="ntrb_CashPaidForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisitions" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisitions_lbl" xml:lang="en-US">Common stock and note issued for acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockAndNoteIssuedInAcquisitions" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability" xlink:href="ntrb-20210731.xsd#ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability_lbl" xml:lang="en-US">Adoption of ASC 842 Operating lease asset and liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability" xlink:to="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilityWarrantReclassedToEquity" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilityWarrantReclassedToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DerivativeLiabilityWarrantReclassedToEquity_lbl" xml:lang="en-US">Derivative liability warrant reclassed to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilityWarrantReclassedToEquity" xlink:to="ntrb_DerivativeLiabilityWarrantReclassedToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DebtDiscountOnConvertibleNotes" xlink:href="ntrb-20210731.xsd#ntrb_DebtDiscountOnConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DebtDiscountOnConvertibleNotes_lbl" xml:lang="en-US">Debt discount on convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DebtDiscountOnConvertibleNotes" xlink:to="ntrb_DebtDiscountOnConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForAccountsPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockIssuedForAccountsPayable_lbl" xml:lang="en-US">Common stock issued for accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForAccountsPayable" xlink:to="ntrb_CommonStockIssuedForAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForSettlement" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockIssuedForSettlement_lbl" xml:lang="en-US">Common stock issued for settlement of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForSettlement" xlink:to="ntrb_CommonStockIssuedForSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CashPaidForAbstract0" xlink:href="ntrb-20210731.xsd#ntrb_CashPaidForAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CashPaidForAbstract0_lbl" xml:lang="en-US">Cash paid for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CashPaidForAbstract0" xlink:to="ntrb_CashPaidForAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForSettlementOfNotesPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForSettlementOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockIssuedForSettlementOfNotesPayable_lbl" xml:lang="en-US">Common stock issued for settlement of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForSettlementOfNotesPayable" xlink:to="ntrb_CommonStockIssuedForSettlementOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssuedForPrepaidConsulting" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForPrepaidConsulting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockIssuedForPrepaidConsulting_lbl" xml:lang="en-US">Common stock issued for prepaid consulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForPrepaidConsulting" xlink:to="ntrb_CommonStockIssuedForPrepaidConsulting_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_NoncashPaymentForLicenseAgreement" xlink:href="ntrb-20210731.xsd#ntrb_NoncashPaymentForLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_NoncashPaymentForLicenseAgreement_lbl" xml:lang="en-US">Non-cash payment for license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NoncashPaymentForLicenseAgreement" xlink:to="ntrb_NoncashPaymentForLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonIssuedForSubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonIssuedForSubscriptionPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonIssuedForSubscriptionPayable_lbl" xml:lang="en-US">Common issued for subscription payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonIssuedForSubscriptionPayable" xlink:to="ntrb_CommonIssuedForSubscriptionPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US">Early prepayment fee on convertible debentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Derivative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnForgivenessOfLoanPayment" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfLoanPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ntrb_GainOnForgivenessOfLoanPayment_lbl" xml:lang="en-US">Gain on forgiveness of loan payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnForgivenessOfLoanPayment" xlink:to="ntrb_GainOnForgivenessOfLoanPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Gain on change in fair value of derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ntrb_SubscriptionPayable_lbl" xml:lang="en-US">Subscription payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayable" xlink:to="ntrb_SubscriptionPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SubscriptionPayable_lbl0" xml:lang="en-US">Stockholders&#8217; equity subscription payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayable" xlink:to="ntrb_SubscriptionPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreaseOperatingLeaseLiability" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ntrb_IncreaseDecreaseOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreaseOperatingLeaseLiability" xlink:to="ntrb_IncreaseDecreaseOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment on note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Payment on convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Finance payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Payment of related party payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_increasedecreaseDepositOnSales" xlink:href="ntrb-20210731.xsd#ntrb_increasedecreaseDepositOnSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ntrb_increasedecreaseDepositOnSales_lbl" xml:lang="en-US">Deposit on sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_increasedecreaseDepositOnSales" xlink:to="ntrb_increasedecreaseDepositOnSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubscriptionPayableMember" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SubscriptionPayableMember_lbl" xml:lang="en-US">Subscription Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayableMember" xlink:to="ntrb_SubscriptionPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of disaggregation of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RevenueByTypeAbstract" xlink:href="ntrb-20210731.xsd#ntrb_RevenueByTypeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_RevenueByTypeAbstract_lbl" xml:lang="en-US">Revenue by type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByTypeAbstract" xlink:to="ntrb_RevenueByTypeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SalesRevenuesGoodsNet" xlink:href="ntrb-20210731.xsd#ntrb_SalesRevenuesGoodsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SalesRevenuesGoodsNet_lbl" xml:lang="en-US">Sale of goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SalesRevenuesGoodsNet" xlink:to="ntrb_SalesRevenuesGoodsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SaleOfGoodsAndServices" xlink:href="ntrb-20210731.xsd#ntrb_SaleOfGoodsAndServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SaleOfGoodsAndServices_lbl" xml:lang="en-US">Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SaleOfGoodsAndServices" xlink:to="ntrb_SaleOfGoodsAndServices_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DisaggregationOfRevenues" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DisaggregationOfRevenues_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DisaggregationOfRevenues" xlink:to="ntrb_DisaggregationOfRevenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of revenue by geographical location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RevenueByGeographicalLocationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_RevenueByGeographicalLocationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_RevenueByGeographicalLocationAbstract_lbl" xml:lang="en-US">Revenue by geographical location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByGeographicalLocationAbstract" xlink:to="ntrb_RevenueByGeographicalLocationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of property plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment, Usefull life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">ACQUISITION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionCommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionCommonStockIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessAcquisitionCommonStockIssued_lbl" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionCommonStockIssued" xlink:to="ntrb_BusinessAcquisitionCommonStockIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotePayableIssued" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_NotePayableIssued_lbl" xml:lang="en-US">Note payable issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayableIssued" xlink:to="ntrb_NotePayableIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisition" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisition_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockAndNoteIssuedInAcquisition" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_lbl" xml:lang="en-US">Equipment and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase_lbl" xml:lang="en-US">Customer base</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks_lbl" xml:lang="en-US">Intellectual property and trademarks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillGross_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Schedule of unaudited pro forma condensed financial information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Net revenue, Proforma</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl0" xml:lang="en-US">Net revenue Proforma</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss, Reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Net loss, Proforma</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl0" xml:lang="en-US">Net loss Proforma</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl" xml:lang="en-US">Loss per common share - basic and diluted, Proforma (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:to="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl0" xml:lang="en-US">Loss per common share - basic and diluted Proforma (in Dollars per share) | $ / shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:to="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PropertyPlantAndEquipmentsGross" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PropertyPlantAndEquipmentsGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentsGross" xlink:to="ntrb_PropertyPlantAndEquipmentsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Summary of provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Common stock issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US">Impairment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Unused operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax asset and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices" xlink:href="ntrb-20210731.xsd#ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices_lbl" xml:lang="en-US">Stock issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices" xlink:to="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE/CONVERTIBLE DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl" xml:lang="en-US">Years Ending January 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">January 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">January 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">January 31, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">January 31, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of estimated amortization:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Remainder of 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">2924</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">2026 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">DERIVATIVE LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule reconciliation of derivative liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilityWarrantsReclassedToEquity" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilityWarrantsReclassedToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DerivativeLiabilityWarrantsReclassedToEquity_lbl" xml:lang="en-US">Derivative liability warrants reclassed to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilityWarrantsReclassedToEquity" xlink:to="ntrb_DerivativeLiabilityWarrantsReclassedToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in value of embedded conversion option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsAndOptionsTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_WarrantsAndOptionsTextBlock_lbl" xml:lang="en-US">WARRANTS AND OPTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsAndOptionsTextBlock" xlink:to="ntrb_WarrantsAndOptionsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Remaining Life, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Remaining Life Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Shares, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise Price, Granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted_lbl" xml:lang="en-US">Remaining Life, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl0" xml:lang="en-US">Intrinsic Value, Granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Shares, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise Price, Exercised (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess_lbl" xml:lang="en-US">Intrinsic Value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Shares, Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Shares Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" xml:lang="en-US">Shares, Expired (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price, Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise Price, Expired (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl" xml:lang="en-US">Intrinsic Value, Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl0" xml:lang="en-US">Intrinsic Value, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_lbl" xml:lang="en-US">Remaining Life, Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_lbl0" xml:lang="en-US">Remaining Life Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise Price, Exercisable (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Remaining Life, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Intrinsic Value, Exercisable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding_lbl" xml:lang="en-US">Schedule of additional information relating to warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding" xlink:to="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Range of Exercise Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber_lbl" xml:lang="en-US">Number Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Remaining Contractual Life(Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Remaining Contractual Life (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price for Shares Outstanding (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers_lbl" xml:lang="en-US">Number Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price for Shares Exercisable (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices_lbl" xml:lang="en-US">Remaining Life, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices_lbl0" xml:lang="en-US">Intrinsic Value, Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices_lbl" xml:lang="en-US">Remaining Life, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices_lbl0" xml:lang="en-US">Intrinsic Value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTIGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RevenueByTypeAbstract0" xlink:href="ntrb-20210731.xsd#ntrb_RevenueByTypeAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_RevenueByTypeAbstract0_lbl" xml:lang="en-US">Revenue by type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByTypeAbstract0" xlink:to="ntrb_RevenueByTypeAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RevenueByGeographicLocationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_RevenueByGeographicLocationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_RevenueByGeographicLocationAbstract_lbl" xml:lang="en-US">Revenue by geographic location:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByGeographicLocationAbstract" xlink:to="ntrb_RevenueByGeographicLocationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment, Usefull life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property plant and equipment useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US">Net revenue As Reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionsNetLossAsReported" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionsNetLossAsReported"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessAcquisitionsNetLossAsReported_lbl" xml:lang="en-US">Net loss As Reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionsNetLossAsReported" xlink:to="ntrb_BusinessAcquisitionsNetLossAsReported_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" xlink:href="ntrb-20210731.xsd#ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare_lbl" xml:lang="en-US">Loss per common share - basic and diluted As Reported (in Dollars per share) | $ / shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" xlink:to="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice_lbl" xml:lang="en-US">Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice_lbl" xml:lang="en-US">Exercise Price, Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice_lbl" xml:lang="en-US">Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" xlink:to="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice_lbl" xml:lang="en-US">Exercise Price Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal_lbl" xml:lang="en-US">Intrinsic Value Outstanding, Ending Balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice_lbl" xml:lang="en-US">Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationNumberOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationNumberOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationNumberOutstanding_lbl" xml:lang="en-US">Number Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationNumberOutstanding" xlink:to="ntrb_ShareBasedCompensationNumberOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationNumberExercisable" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationNumberExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationNumberExercisable_lbl" xml:lang="en-US">Number Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationNumberExercisable" xlink:to="ntrb_ShareBasedCompensationNumberExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Acounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Less: Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Book income (loss) from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards (expire through 2038)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl" xml:lang="en-US">Intangible impairment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: Accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Foreign [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LabEquipmentMember" xlink:to="ntrb_LabEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_LabEquipmentMember_lbl0" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LabEquipmentMember" xlink:to="ntrb_LabEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRelatedIntangibleAssetsMember_lbl" xml:lang="en-US">Customer base [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:to="us-gaap_CustomerRelatedIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US">Intellectual property and trademarks [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntellectualPropertyMember_lbl0" xml:lang="en-US">Intellectual property	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_LicensingAgreementMember" xlink:href="ntrb-20210731.xsd#ntrb_LicensingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_LicensingAgreementMember_lbl" xml:lang="en-US">License agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LicensingAgreementMember" xlink:to="ntrb_LicensingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xml:lang="en-US">Description of acquired entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Converted per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_PropertyPlantAndEquipmentsUsefulLife" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentsUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PropertyPlantAndEquipmentsUsefulLife_lbl" xml:lang="en-US">Property plant and equipment useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentsUsefulLife" xlink:to="ntrb_PropertyPlantAndEquipmentsUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ConcentrationRiskPercentage" xlink:href="ntrb-20210731.xsd#ntrb_ConcentrationRiskPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ConcentrationRiskPercentage_lbl" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ConcentrationRiskPercentage" xlink:to="ntrb_ConcentrationRiskPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Potential shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_AcquiredPercentage" xlink:href="ntrb-20210731.xsd#ntrb_AcquiredPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_AcquiredPercentage_lbl" xml:lang="en-US">Acquired percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AcquiredPercentage" xlink:to="ntrb_AcquiredPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired_lbl" xml:lang="en-US">Acquired of membership interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired" xlink:to="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xml:lang="en-US">Acquired common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Acquired common stock, shares (in Shares) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DebtInstrumentAnnualPrincipalPayments" xlink:href="ntrb-20210731.xsd#ntrb_DebtInstrumentAnnualPrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DebtInstrumentAnnualPrincipalPayments_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DebtInstrumentAnnualPrincipalPayments" xlink:to="ntrb_DebtInstrumentAnnualPrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Capital raise of no less</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Public offering less</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_AnnualMeetingOfShareholdersTerm" xlink:href="ntrb-20210731.xsd#ntrb_AnnualMeetingOfShareholdersTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_AnnualMeetingOfShareholdersTerm_lbl" xml:lang="en-US">Annual meeting of shareholders, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AnnualMeetingOfShareholdersTerm" xlink:to="ntrb_AnnualMeetingOfShareholdersTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionRevenue" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessAcquisitionRevenue_lbl" xml:lang="en-US">Net revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionRevenue" xlink:to="ntrb_BusinessAcquisitionRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessAcquisitionNetProfit" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionNetProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessAcquisitionNetProfit_lbl" xml:lang="en-US">Net profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionNetProfit" xlink:to="ntrb_BusinessAcquisitionNetProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Net operating loss expire, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" xlink:href="ntrb-20210731.xsd#ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax_lbl" xml:lang="en-US">Corporate rate, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" xlink:to="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotePayablesDescription" xlink:href="ntrb-20210731.xsd#ntrb_NotePayablesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_NotePayablesDescription_lbl" xml:lang="en-US">Notes payable, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayablesDescription" xlink:to="ntrb_NotePayablesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvances" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalHomeLoanBankAdvances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalHomeLoanBankAdvances_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBankAdvances" xlink:to="us-gaap_FederalHomeLoanBankAdvances_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xml:lang="en-US">Additional loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ProceedsFromLoanOriginationsTotal" xlink:href="ntrb-20210731.xsd#ntrb_ProceedsFromLoanOriginationsTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ProceedsFromLoanOriginationsTotal_lbl" xml:lang="en-US">Total loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ProceedsFromLoanOriginationsTotal" xlink:to="ntrb_ProceedsFromLoanOriginationsTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Conversion stock issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_lbl" xml:lang="en-US">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl" xml:lang="en-US">Line of credit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xml:lang="en-US">Line of credit, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xml:lang="en-US">Interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xml:lang="en-US">Assumed amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xml:lang="en-US">Payments of principal interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment_lbl" xml:lang="en-US">Principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment" xlink:to="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Principal and interest payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Balance due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Lease of description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xml:lang="en-US">Borrowing rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Advanced amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Expenses amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Related party payable, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotePayableConvertibleDebtDescription" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableConvertibleDebtDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_NotePayableConvertibleDebtDescription_lbl" xml:lang="en-US">Convertible notes payable, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayableConvertibleDebtDescription" xlink:to="ntrb_NotePayableConvertibleDebtDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Description of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueOfConversionPrice" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_FairValueOfConversionPrice_lbl" xml:lang="en-US">Fair value of conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfConversionPrice" xlink:to="ntrb_FairValueOfConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of the warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Initial derivative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DiscountRemainingAmount" xlink:href="ntrb-20210731.xsd#ntrb_DiscountRemainingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DiscountRemainingAmount_lbl" xml:lang="en-US">Discount remaining amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DiscountRemainingAmount" xlink:to="ntrb_DiscountRemainingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PrepaymentFee" xlink:href="ntrb-20210731.xsd#ntrb_PrepaymentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PrepaymentFee_lbl" xml:lang="en-US">Prepayment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PrepaymentFee" xlink:to="ntrb_PrepaymentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesTotal" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DerivativeLiabilitiesTotal_lbl" xml:lang="en-US">Derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilitiesTotal" xlink:to="ntrb_DerivativeLiabilitiesTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_InterestExpensesDebt" xlink:href="ntrb-20210731.xsd#ntrb_InterestExpensesDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_InterestExpensesDebt_lbl" xml:lang="en-US">Interest expense, debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InterestExpensesDebt" xlink:to="ntrb_InterestExpensesDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_AmortizationOfDebtDiscountsPremium" xlink:href="ntrb-20210731.xsd#ntrb_AmortizationOfDebtDiscountsPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_AmortizationOfDebtDiscountsPremium_lbl" xml:lang="en-US">Interest expenses including amortization debt discount amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AmortizationOfDebtDiscountsPremium" xlink:to="ntrb_AmortizationOfDebtDiscountsPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_GainOnExtinguishmentOfDebt" xlink:href="ntrb-20210731.xsd#ntrb_GainOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_GainOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Forgiveness of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnExtinguishmentOfDebt" xlink:to="ntrb_GainOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DueToRelatedPartyCurrentAndNoncurrent" xlink:href="ntrb-20210731.xsd#ntrb_DueToRelatedPartyCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DueToRelatedPartyCurrentAndNoncurrent_lbl" xml:lang="en-US">Balance due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DueToRelatedPartyCurrentAndNoncurrent" xlink:to="ntrb_DueToRelatedPartyCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_InterestExpenseDebts" xlink:href="ntrb-20210731.xsd#ntrb_InterestExpenseDebts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_InterestExpenseDebts_lbl" xml:lang="en-US">Interest expense, debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InterestExpenseDebts" xlink:to="ntrb_InterestExpenseDebts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Expense including amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_amortizedOverPeriod" xlink:href="ntrb-20210731.xsd#ntrb_amortizedOverPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_amortizedOverPeriod_lbl" xml:lang="en-US">Amortized over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_amortizedOverPeriod" xlink:to="ntrb_amortizedOverPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PaymentForInitialLicenseFee" xlink:href="ntrb-20210731.xsd#ntrb_PaymentForInitialLicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PaymentForInitialLicenseFee_lbl" xml:lang="en-US">IP license</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PaymentForInitialLicenseFee" xlink:to="ntrb_PaymentForInitialLicenseFee_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_PaymentForInitialLicenseFee_lbl0" xml:lang="en-US">License fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PaymentForInitialLicenseFee" xlink:to="ntrb_PaymentForInitialLicenseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ntrb_PaymentForInitialLicenseFee_lbl1" xml:lang="en-US">Initial license fee payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PaymentForInitialLicenseFee" xlink:to="ntrb_PaymentForInitialLicenseFee_lbl1"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates" xlink:href="ntrb-20210731.xsd#ntrb_FairValueAssumptionsWeightedAverageVolatilityRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates" xlink:to="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueAssumptionsRiskFreeInterestRates" xlink:href="ntrb-20210731.xsd#ntrb_FairValueAssumptionsRiskFreeInterestRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueAssumptionsRiskFreeInterestRates" xlink:to="ntrb_FairValueAssumptionsRiskFreeInterestRates_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ExpectedTerm" xlink:href="ntrb-20210731.xsd#ntrb_ExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ExpectedTerm_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpectedTerm" xlink:to="ntrb_ExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ExpectedTerms" xlink:href="ntrb-20210731.xsd#ntrb_ExpectedTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ExpectedTerms_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpectedTerms" xlink:to="ntrb_ExpectedTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueOfWarrantExpense" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfWarrantExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_FairValueOfWarrantExpense_lbl" xml:lang="en-US">Fair value of warrant expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfWarrantExpense" xlink:to="ntrb_FairValueOfWarrantExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl" xml:lang="en-US">Warrant, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:to="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalTransactionsRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrincipalTransactionsRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalTransactionsRevenue_lbl" xml:lang="en-US">Revenue transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalTransactionsRevenue" xlink:to="us-gaap_PrincipalTransactionsRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PurchaseOfMaterials" xlink:href="ntrb-20210731.xsd#ntrb_PurchaseOfMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PurchaseOfMaterials_lbl" xml:lang="en-US">Purchase of materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PurchaseOfMaterials" xlink:to="ntrb_PurchaseOfMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ExpensesPaid" xlink:href="ntrb-20210731.xsd#ntrb_ExpensesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ExpensesPaid_lbl" xml:lang="en-US">Expenses paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpensesPaid" xlink:to="ntrb_ExpensesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionDescriptionOfTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_RelatedPartyTransactionDescriptionOfTransactions_lbl" xml:lang="en-US">Related party transaction, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="ntrb_RelatedPartyTransactionDescriptionOfTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockIssued_lbl" xml:lang="en-US">Common stock issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssued" xlink:to="ntrb_CommonStockIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Issuance of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Stock price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DesignatedSharesOfPreferredStocks" xlink:href="ntrb-20210731.xsd#ntrb_DesignatedSharesOfPreferredStocks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DesignatedSharesOfPreferredStocks_lbl" xml:lang="en-US">Preferred stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DesignatedSharesOfPreferredStocks" xlink:to="ntrb_DesignatedSharesOfPreferredStocks_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockOfDescription" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockOfDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockOfDescription_lbl" xml:lang="en-US">Common stock description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockOfDescription" xlink:to="ntrb_CommonStockOfDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Common stock conversion (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IncreaseDecreasedInAuthorizedCommonStock" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreasedInAuthorizedCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_IncreaseDecreasedInAuthorizedCommonStock_lbl" xml:lang="en-US">Increase decreased in authorized common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreasedInAuthorizedCommonStock" xlink:to="ntrb_IncreaseDecreasedInAuthorizedCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PrivatePlacement" xlink:href="ntrb-20210731.xsd#ntrb_PrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PrivatePlacement_lbl" xml:lang="en-US">Private placement shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PrivatePlacement" xlink:to="ntrb_PrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShare" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsToPurchaseOfCommonStockShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShare_lbl" xml:lang="en-US">Issued price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsToPurchaseOfCommonStockShare" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_InvestmentWarrantExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_InvestmentWarrantExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_InvestmentWarrantExercisePrice_lbl" xml:lang="en-US">Exercise price of warrants (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InvestmentWarrantExercisePrice" xlink:to="ntrb_InvestmentWarrantExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShares" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsToPurchaseOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShares_lbl" xml:lang="en-US">Warrant to purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsToPurchaseOfCommonStockShares" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling and general administrative expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Issued a promissory note, net of debt discount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Payment received (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription payable, value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares_lbl" xml:lang="en-US">Subscription payable, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares" xlink:to="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Extinguish accounts payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SharesWereRestored" xlink:href="ntrb-20210731.xsd#ntrb_SharesWereRestored"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SharesWereRestored_lbl" xml:lang="en-US">Shares were restored</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharesWereRestored" xlink:to="ntrb_SharesWereRestored_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_FairValueOfTheCommonStocks" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfTheCommonStocks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_FairValueOfTheCommonStocks_lbl" xml:lang="en-US">Fair value of the common stocks issuance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfTheCommonStocks" xlink:to="ntrb_FairValueOfTheCommonStocks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_FundReceived" xlink:href="ntrb-20210731.xsd#ntrb_FundReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_FundReceived_lbl" xml:lang="en-US">Balance of the funds received (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FundReceived" xlink:to="ntrb_FundReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue_lbl" xml:lang="en-US">Purchase of warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_InitialPublicOfferingPricePercentage" xlink:href="ntrb-20210731.xsd#ntrb_InitialPublicOfferingPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_InitialPublicOfferingPricePercentage_lbl" xml:lang="en-US">Initial public offering price, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InitialPublicOfferingPricePercentage" xlink:to="ntrb_InitialPublicOfferingPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ReclassOfWarrantsFromLiabilityToEquity" xlink:href="ntrb-20210731.xsd#ntrb_ReclassOfWarrantsFromLiabilityToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ReclassOfWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US">Derivative liability for warrant</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZzjdoIf697x9Ebb9RR62VzZ2moDN98hKYJqt0nOEvOJM3ovM/SXTjMP1Ald7slk0jhpkvJNEcZ22oENEU/pa+RGktyuYgAZpSzCvQD/cHd+rIAFOf0qxA58sbmcPw9UpSPh+OrTDXTmJ7VYjFEDe+x4Kv3wGjJ2krmmyw+NNN8s/U+hZbI8ZQMMO/KbFfuxe0=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ReclassOfWarrantsFromLiabilityToEquity" xlink:to="ntrb_ReclassOfWarrantsFromLiabilityToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_MonthlyRent" xlink:href="ntrb-20210731.xsd#ntrb_MonthlyRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_MonthlyRent_lbl" xml:lang="en-US">Amount of monthly rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_MonthlyRent" xlink:to="ntrb_MonthlyRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Shares cancelled (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SalaryPayment" xlink:href="ntrb-20210731.xsd#ntrb_SalaryPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_SalaryPayment_lbl" xml:lang="en-US">Annual salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SalaryPayment" xlink:to="ntrb_SalaryPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Compensation annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PublicOrPrivateFinancing" xlink:href="ntrb-20210731.xsd#ntrb_PublicOrPrivateFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PublicOrPrivateFinancing_lbl" xml:lang="en-US">Public or private financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PublicOrPrivateFinancing" xlink:to="ntrb_PublicOrPrivateFinancing_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Annual salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Other commitments term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription_lbl" xml:lang="en-US">Purchase commitment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantPurchaseCommitmentDescription" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl" xml:lang="en-US">Note issued transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_InventoryRawMaterialsPercentage" xlink:href="ntrb-20210731.xsd#ntrb_InventoryRawMaterialsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_InventoryRawMaterialsPercentage_lbl" xml:lang="en-US">Inventory raw materials percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InventoryRawMaterialsPercentage" xlink:to="ntrb_InventoryRawMaterialsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_OrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationPolicyTextBlock" xlink:to="ntrb_OrganizationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ReverseStockSplitPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_ReverseStockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ReverseStockSplitPolicyTextBlock" xlink:to="ntrb_ReverseStockSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_GoingConcernPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_GoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GoingConcernPolicyTextBlock" xlink:to="ntrb_GoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Contracts with Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_PerformanceObligationsPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PerformanceObligationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PerformanceObligationsPolicyTextBlock_lbl" xml:lang="en-US">Performance Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PerformanceObligationsPolicyTextBlock" xlink:to="ntrb_PerformanceObligationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenuesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DisaggregationOfRevenuesPolicyTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="ntrb_DisaggregationOfRevenuesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Account receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DerivativeLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilitiesPolicyTextBlock" xlink:to="ntrb_DerivativeLiabilitiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US">Unaudited Interim Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_TherapeuticsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_TherapeuticsLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_TherapeuticsLLCMember_lbl" xml:lang="en-US">4P Therapeutics LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_TherapeuticsLLCMember" xlink:to="ntrb_TherapeuticsLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ThreeCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_ThreeCustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ThreeCustomerMember_lbl" xml:lang="en-US">Three Customers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ThreeCustomerMember" xlink:to="ntrb_ThreeCustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenues [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_TwoCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_TwoCustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_TwoCustomerMember_lbl" xml:lang="en-US">Two Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_TwoCustomerMember" xlink:to="ntrb_TwoCustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OneCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_OneCustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_OneCustomerMember_lbl" xml:lang="en-US">One Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OneCustomerMember" xlink:to="ntrb_OneCustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ActiveIntelligenceLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_ActiveIntelligenceLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ActiveIntelligenceLLCMember_lbl" xml:lang="en-US">Active Intelligence LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ActiveIntelligenceLLCMember" xlink:to="ntrb_ActiveIntelligenceLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BusinessCombinationMember" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BusinessCombinationMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationMember" xlink:to="ntrb_BusinessCombinationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyPayableMember" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_RelatedPartyPayableMember_lbl" xml:lang="en-US">Related Party Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RelatedPartyPayableMember" xlink:to="ntrb_RelatedPartyPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RevaluedMember" xlink:href="ntrb-20210731.xsd#ntrb_RevaluedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_RevaluedMember_lbl" xml:lang="en-US">Revaluation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevaluedMember" xlink:to="ntrb_RevaluedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_RevaluedMember_lbl0" xml:lang="en-US">Re-Valuation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevaluedMember" xlink:to="ntrb_RevaluedMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ntrb_PoconoCoatedProductsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_PoconoCoatedProductsLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_PoconoCoatedProductsLLCMember_lbl" xml:lang="en-US">Pocono Coated Products LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PoconoCoatedProductsLLCMember" xlink:to="ntrb_PoconoCoatedProductsLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_FormerIndependentDirectorsMember" xlink:href="ntrb-20210731.xsd#ntrb_FormerIndependentDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_FormerIndependentDirectorsMember_lbl" xml:lang="en-US">Former Independent Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FormerIndependentDirectorsMember" xlink:to="ntrb_FormerIndependentDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_ConsultingServicesMember" xlink:href="ntrb-20210731.xsd#ntrb_ConsultingServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_ConsultingServicesMember_lbl" xml:lang="en-US">Consulting Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ConsultingServicesMember" xlink:to="ntrb_ConsultingServicesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_ConsultingServicesMember_lbl0" xml:lang="en-US">Consulting services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ConsultingServicesMember" xlink:to="ntrb_ConsultingServicesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_BPMMember" xlink:href="ntrb-20210731.xsd#ntrb_BPMMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_BPMMember_lbl" xml:lang="en-US">BPM [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BPMMember" xlink:to="ntrb_BPMMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ntrb_BPMMember_lbl0" xml:lang="en-US">BPM Inno Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BPMMember" xlink:to="ntrb_BPMMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DefendantMember" xlink:href="ntrb-20210731.xsd#ntrb_DefendantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_DefendantMember_lbl" xml:lang="en-US">Defendants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DefendantMember" xlink:to="ntrb_DefendantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_HealthsBrandsIncMember" xlink:href="ntrb-20210731.xsd#ntrb_HealthsBrandsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_HealthsBrandsIncMember_lbl" xml:lang="en-US">Health Brands, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_HealthsBrandsIncMember" xlink:to="ntrb_HealthsBrandsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PresidentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_PresidentMember_lbl" xml:lang="en-US">President [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockPurchaseAgreementMember" xlink:href="ntrb-20210731.xsd#ntrb_StockPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ntrb_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockPurchaseAgreementMember" xlink:to="ntrb_StockPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_LeasesTable" xlink:href="ntrb-20210731.xsd#ntrb_LeasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_LeasesTable_lbl" xml:lang="en-US">Leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LeasesTable" xlink:to="ntrb_LeasesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_LeasesLineItems" xlink:href="ntrb-20210731.xsd#ntrb_LeasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_LeasesLineItems_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LeasesLineItems" xlink:to="ntrb_LeasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsTablesTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsTablesTable_lbl" xml:lang="en-US">Warrants and Options (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsTablesTable" xlink:to="ntrb_WarrantsandOptionsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsTablesLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsTablesLineItems_lbl" xml:lang="en-US">Warrants and Options (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsTablesLineItems" xlink:to="ntrb_WarrantsandOptionsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable_lbl" xml:lang="en-US">Organization and Description of Business (Details) - Schedule of revenue by geographical location [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems_lbl" xml:lang="en-US">Organization and Description of Business (Details) - Schedule of revenue by geographical location [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable_lbl" xml:lang="en-US">Organization and Description of Business (Details) - Schedule of property plant and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems_lbl" xml:lang="en-US">Organization and Description of Business (Details) - Schedule of property plant and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable_lbl" xml:lang="en-US">Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:to="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems_lbl" xml:lang="en-US">Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable_lbl" xml:lang="en-US">Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems_lbl" xml:lang="en-US">Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable_lbl" xml:lang="en-US">Warrants and Options (Details) - Schedule of options outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" xlink:to="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems_lbl" xml:lang="en-US">Warrants and Options (Details) - Schedule of options outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable_lbl" xml:lang="en-US">Warrants (Details) - Schedule of additional information relating to warrants outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems_lbl" xml:lang="en-US">Warrants (Details) - Schedule of additional information relating to warrants outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Description of Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems_lbl" xml:lang="en-US">Organization and Description of Business (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="ntrb_OrganizationandDescriptionofBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_AcquisitionofBusinessDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_AcquisitionofBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_AcquisitionofBusinessDetailsTable_lbl" xml:lang="en-US">Acquisition of Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AcquisitionofBusinessDetailsTable" xlink:to="ntrb_AcquisitionofBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_AcquisitionofBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_AcquisitionofBusinessDetailsLineItems_lbl" xml:lang="en-US">Acquisition of Business (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AcquisitionofBusinessDetailsLineItems" xlink:to="ntrb_AcquisitionofBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotesPayableConvertibleDebtDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_NotesPayableConvertibleDebtDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_NotesPayableConvertibleDebtDetailsTable_lbl" xml:lang="en-US">Notes Payable/Convertible Debt (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsTable" xlink:to="ntrb_NotesPayableConvertibleDebtDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_NotesPayableConvertibleDebtDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_NotesPayableConvertibleDebtDetailsLineItems_lbl" xml:lang="en-US">Notes Payable/Convertible Debt (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ntrb_NotesPayableConvertibleDebtDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IntangibleAssetsDetailsTable" xlink:to="ntrb_IntangibleAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_IntangibleAssetsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IntangibleAssetsDetailsLineItems_lbl" xml:lang="en-US">Intangible Assets (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IntangibleAssetsDetailsLineItems" xlink:to="ntrb_IntangibleAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DerivativeLiabilitiesDetailsTable_lbl" xml:lang="en-US">Derivative Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilitiesDetailsTable" xlink:to="ntrb_DerivativeLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DerivativeLiabilitiesDetailsLineItems_lbl" xml:lang="en-US">Derivative Liabilities (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilitiesDetailsLineItems" xlink:to="ntrb_DerivativeLiabilitiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyTransactionsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RelatedPartyTransactionsDetailsTable" xlink:to="ntrb_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RelatedPartyTransactionsDetailsLineItems" xlink:to="ntrb_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockholdersEquityDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockholdersEquityDetailsTable" xlink:to="ntrb_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_StockholdersEquityDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockholdersEquityDetailsLineItems" xlink:to="ntrb_StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsDetailsTable_lbl" xml:lang="en-US">Warrants and Options (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsDetailsTable" xlink:to="ntrb_WarrantsandOptionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_WarrantsandOptionsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsandOptionsDetailsLineItems_lbl" xml:lang="en-US">Warrants and Options (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsandOptionsDetailsLineItems" xlink:to="ntrb_WarrantsandOptionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommitmentsandContigenciesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_CommitmentsandContigenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommitmentsandContigenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contigencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommitmentsandContigenciesDetailsTable" xlink:to="ntrb_CommitmentsandContigenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_CommitmentsandContigenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommitmentsandContigenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contigencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommitmentsandContigenciesDetailsLineItems" xlink:to="ntrb_CommitmentsandContigenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubsequentEventsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubsequentEventsDetailsTable" xlink:to="ntrb_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SubsequentEventsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubsequentEventsDetailsLineItems" xlink:to="ntrb_SubsequentEventsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_AcquiredPercentage_lbl0" xml:lang="en-US">Acquired percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AcquiredPercentage" xlink:to="ntrb_AcquiredPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability_lbl0" xml:lang="en-US">Adoption of ASC 842 Operating lease asset and liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability" xlink:to="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_AmortizationOfDebtDiscountsPremium_lbl0" xml:lang="en-US">Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AmortizationOfDebtDiscountsPremium" xlink:to="ntrb_AmortizationOfDebtDiscountsPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_AnnualMeetingOfShareholdersTerm_lbl0" xml:lang="en-US">Annual meeting of shareholders, term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AnnualMeetingOfShareholdersTerm" xlink:to="ntrb_AnnualMeetingOfShareholdersTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_BusinessAcquisitionCommonStockIssued_lbl0" xml:lang="en-US">Common stock issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionCommonStockIssued" xlink:to="ntrb_BusinessAcquisitionCommonStockIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_BusinessAcquisitionNetProfit_lbl0" xml:lang="en-US">Business acquisition net profit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionNetProfit" xlink:to="ntrb_BusinessAcquisitionNetProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl1" xml:lang="en-US">Loss per common share - basic and diluted, Proforma.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:to="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_BusinessAcquisitionRevenue_lbl0" xml:lang="en-US">Business acquisition revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionRevenue" xlink:to="ntrb_BusinessAcquisitionRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase_lbl0" xml:lang="en-US">Customer base.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks_lbl0" xml:lang="en-US">Intellectual property and trademarks.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_CommonIssuedForSubscriptionPayable_lbl0" xml:lang="en-US">Common issued for subscription payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonIssuedForSubscriptionPayable" xlink:to="ntrb_CommonIssuedForSubscriptionPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisition_lbl0" xml:lang="en-US">Common stock and note issued in acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockAndNoteIssuedInAcquisition" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisitions_lbl0" xml:lang="en-US">Common stock and note issued in acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockAndNoteIssuedInAcquisitions" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_CommonStockIssuedForAccountsPayable_lbl0" xml:lang="en-US">Common stock issued for accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForAccountsPayable" xlink:to="ntrb_CommonStockIssuedForAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_CommonStockIssuedForSettlement_lbl0" xml:lang="en-US">Common stock issued for settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForSettlement" xlink:to="ntrb_CommonStockIssuedForSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_CommonStockIssuedForSettlementOfNotesPayable_lbl0" xml:lang="en-US">Common stock issued for settlement of notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForSettlementOfNotesPayable" xlink:to="ntrb_CommonStockIssuedForSettlementOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares_lbl0" xml:lang="en-US">Amount of subscription receivable from investors who have been allocated common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares" xlink:to="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ConcentrationRiskPercentage_lbl0" xml:lang="en-US">For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the &quot;benchmark&quot; (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ConcentrationRiskPercentage" xlink:to="ntrb_ConcentrationRiskPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DebtDiscountOnConvertibleNotes_lbl0" xml:lang="en-US">Debt discount on convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DebtDiscountOnConvertibleNotes" xlink:to="ntrb_DebtDiscountOnConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DebtInstrumentAnnualPrincipalPayments_lbl0" xml:lang="en-US">Amount of the total principal payments made during the annual reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DebtInstrumentAnnualPrincipalPayments" xlink:to="ntrb_DebtInstrumentAnnualPrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices_lbl0" xml:lang="en-US">Stock issued for services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices" xlink:to="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DerivativeLiabilitiesTotal_lbl0" xml:lang="en-US">Fair value of derivative liabilities total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilitiesTotal" xlink:to="ntrb_DerivativeLiabilitiesTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DerivativeLiabilityWarrantReclassedToEquity_lbl0" xml:lang="en-US">Derivative liability warrant reclassed to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilityWarrantReclassedToEquity" xlink:to="ntrb_DerivativeLiabilityWarrantReclassedToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DerivativeLiabilityWarrantsReclassedToEquity_lbl0" xml:lang="en-US">Derivative liability warrants reclassed to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilityWarrantsReclassedToEquity" xlink:to="ntrb_DerivativeLiabilityWarrantsReclassedToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DesignatedSharesOfPreferredStocks_lbl0" xml:lang="en-US">Designated shares to be issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DesignatedSharesOfPreferredStocks" xlink:to="ntrb_DesignatedSharesOfPreferredStocks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DisaggregationOfRevenues_lbl0" xml:lang="en-US">Disaggregation of revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DisaggregationOfRevenues" xlink:to="ntrb_DisaggregationOfRevenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_DiscountRemainingAmount_lbl0" xml:lang="en-US">Discount remaining amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DiscountRemainingAmount" xlink:to="ntrb_DiscountRemainingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures_lbl0" xml:lang="en-US">Early prepayment fee on convertible debenture.&#xd;
&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" xlink:to="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax_lbl0" xml:lang="en-US">Description of effective income tax federal statutory tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" xlink:to="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ExpectedTerms_lbl0" xml:lang="en-US">It represents of expected term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpectedTerms" xlink:to="ntrb_ExpectedTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ExpensesPaid_lbl0" xml:lang="en-US">Expenses paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpensesPaid" xlink:to="ntrb_ExpensesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_FairValueAssumptionsRiskFreeInterestRates_lbl0" xml:lang="en-US">Risk-free interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueAssumptionsRiskFreeInterestRates" xlink:to="ntrb_FairValueAssumptionsRiskFreeInterestRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_FairValueOfConversionPrice_lbl0" xml:lang="en-US">Fair value of conversion price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfConversionPrice" xlink:to="ntrb_FairValueOfConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_FairValueOfTheCommonStocks_lbl0" xml:lang="en-US">Fair value of the common stocks.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfTheCommonStocks" xlink:to="ntrb_FairValueOfTheCommonStocks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_FairValueOfWarrantExpense_lbl0" xml:lang="en-US">Fair value of warrant expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfWarrantExpense" xlink:to="ntrb_FairValueOfWarrantExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_FundReceived_lbl0" xml:lang="en-US">Fund received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FundReceived" xlink:to="ntrb_FundReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_GainOnForgivenessOfDebt_lbl0" xml:lang="en-US">Gain on forgiveness of debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnForgivenessOfDebt" xlink:to="ntrb_GainOnForgivenessOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_GainOnForgivenessOfLoanPayment_lbl0" xml:lang="en-US">Gain on forgiveness of loan payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnForgivenessOfLoanPayment" xlink:to="ntrb_GainOnForgivenessOfLoanPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_GoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">The disclosure of accounting policy for Going Concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GoingConcernPolicyTextBlock" xlink:to="ntrb_GoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_IncreaseDecreaseInDerivativeExpense_lbl0" xml:lang="en-US">The increase (decrease) during the period in the carrying value of derivative expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreaseInDerivativeExpense" xlink:to="ntrb_IncreaseDecreaseInDerivativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_IncreaseDecreaseOperatingLeaseLiability_lbl0" xml:lang="en-US">Amount of increase (decrease) of consideration in operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreaseOperatingLeaseLiability" xlink:to="ntrb_IncreaseDecreaseOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_IncreaseDecreasedInAuthorizedCommonStock_lbl0" xml:lang="en-US">Increase decreased in authorized common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreasedInAuthorizedCommonStock" xlink:to="ntrb_IncreaseDecreasedInAuthorizedCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_InterestExpensesDebt_lbl0" xml:lang="en-US">Amount of the cost of borrowed funds accounted for as interest expense for debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InterestExpensesDebt" xlink:to="ntrb_InterestExpensesDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_InventoryRawMaterialsPercentage_lbl0" xml:lang="en-US">Inventory raw materials percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InventoryRawMaterialsPercentage" xlink:to="ntrb_InventoryRawMaterialsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_InvestmentWarrantExercisePrice_lbl0" xml:lang="en-US">Exercise price of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InvestmentWarrantExercisePrice" xlink:to="ntrb_InvestmentWarrantExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_IssuanceOfCommonStockForNotePayable_lbl0" xml:lang="en-US">Issuance of common stock for note payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IssuanceOfCommonStockForNotePayable" xlink:to="ntrb_IssuanceOfCommonStockForNotePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare_lbl0" xml:lang="en-US">Loss per common share - basic and diluted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" xlink:to="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_MonthlyRent_lbl0" xml:lang="en-US">Amount of monthly rent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_MonthlyRent" xlink:to="ntrb_MonthlyRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_NoncashPaymentForLicenseAgreement_lbl0" xml:lang="en-US">Non-cash payment for license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NoncashPaymentForLicenseAgreement" xlink:to="ntrb_NoncashPaymentForLicenseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_NotePayableConvertibleDebtDescription_lbl0" xml:lang="en-US">Description of convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayableConvertibleDebtDescription" xlink:to="ntrb_NotePayableConvertibleDebtDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_NotePayableIssued_lbl0" xml:lang="en-US">Note payable issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayableIssued" xlink:to="ntrb_NotePayableIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_NotePayablesDescription_lbl0" xml:lang="en-US">Description of notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayablesDescription" xlink:to="ntrb_NotePayablesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_OrganizationPolicyTextBlock_lbl0" xml:lang="en-US">The disclosure of accounting policy for organization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationPolicyTextBlock" xlink:to="ntrb_OrganizationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_PaymentForInitialLicenseFee_lbl2" xml:lang="en-US">Amount paid for initial license fee payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PaymentForInitialLicenseFee" xlink:to="ntrb_PaymentForInitialLicenseFee_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_PropertyPlantAndEquipmentsGross_lbl0" xml:lang="en-US">Amount before accumulated depreciation, depletion and amortization of physical asset used in the normal conduct of business and not intended for resale. Example include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentsGross" xlink:to="ntrb_PropertyPlantAndEquipmentsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_PropertyPlantAndEquipmentsUsefulLife_lbl0" xml:lang="en-US">Property plant and equipment useful life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentsUsefulLife" xlink:to="ntrb_PropertyPlantAndEquipmentsUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_PublicOrPrivateFinancing_lbl0" xml:lang="en-US">Public or private financing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PublicOrPrivateFinancing" xlink:to="ntrb_PublicOrPrivateFinancing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_PurchaseOfMaterials_lbl0" xml:lang="en-US">Purchase of Materials.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PurchaseOfMaterials" xlink:to="ntrb_PurchaseOfMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity_lbl0" xml:lang="en-US">Reclassification of warrants from liability to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:to="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_RelatedPartyTransactionDescriptionOfTransactions_lbl0" xml:lang="en-US">A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="ntrb_RelatedPartyTransactionDescriptionOfTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SalaryPayment_lbl0" xml:lang="en-US">It represents of salary payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SalaryPayment" xlink:to="ntrb_SalaryPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SaleOfGoodsAndServices_lbl0" xml:lang="en-US">The aggregate costs related to services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SaleOfGoodsAndServices" xlink:to="ntrb_SaleOfGoodsAndServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SaleofCommonstockForCash_lbl0" xml:lang="en-US">Sale of Common stock For Cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SaleofCommonstockForCash" xlink:to="ntrb_SaleofCommonstockForCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SalesRevenuesGoodsNet_lbl0" xml:lang="en-US">Aggregate amount of sale of goods during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SalesRevenuesGoodsNet" xlink:to="ntrb_SalesRevenuesGoodsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal_lbl0" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice_lbl0" xml:lang="en-US">Exercise Price, Expired/Cancelled.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice_lbl0" xml:lang="en-US">Gross number of share options (or share units) granted during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice_lbl0" xml:lang="en-US">Exercise Price Outstanding, Ending Balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl2" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue_lbl0" xml:lang="en-US">It represents intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl1" xml:lang="en-US">Expired/Cancelled.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SharesWereRestored_lbl0" xml:lang="en-US">Shares were restored.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharesWereRestored" xlink:to="ntrb_SharesWereRestored_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice_lbl0" xml:lang="en-US">Exercise Price, Exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" xlink:to="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants_lbl0" xml:lang="en-US">Proceeds from sale of common stock and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" xlink:to="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants_lbl0" xml:lang="en-US">Proceeds from sale of common stock and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" xlink:to="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SubscriptionPayable_lbl1" xml:lang="en-US">The amount of subscription payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayable" xlink:to="ntrb_SubscriptionPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SubscriptionPayables_lbl0" xml:lang="en-US">Subscription payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayables" xlink:to="ntrb_SubscriptionPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SubscrptionPayableForCash_lbl0" xml:lang="en-US">Subscrption payable for cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscrptionPayableForCash" xlink:to="ntrb_SubscrptionPayableForCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_SubscrptionPayableForServices_lbl0" xml:lang="en-US">Subscrption payable for services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscrptionPayableForServices" xlink:to="ntrb_SubscrptionPayableForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl0" xml:lang="en-US">Unaudited interim financial statements policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShare_lbl0" xml:lang="en-US">Amount of warrants to purchase of common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsToPurchaseOfCommonStockShare" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShares_lbl0" xml:lang="en-US">Amount of warrants to purchase of common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsToPurchaseOfCommonStockShares" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_StockPurchaseAgreementMember_lbl0" xml:lang="en-US">StockPurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockPurchaseAgreementMember" xlink:to="ntrb_StockPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ActiveIntelligenceLLCMember_lbl0" xml:lang="en-US">ActiveIntelligenceLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ActiveIntelligenceLLCMember" xlink:to="ntrb_ActiveIntelligenceLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ThreeCustomerMember_lbl0" xml:lang="en-US">ThreeCustomerMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ThreeCustomerMember" xlink:to="ntrb_ThreeCustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_GainOnForgivenessOfDebt_lbl1" xml:lang="en-US">GainOnForgivenessOfDebt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnForgivenessOfDebt" xlink:to="ntrb_GainOnForgivenessOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl2" xml:lang="en-US">BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:to="ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IncreaseDecreaseInDerivativeExpense_lbl1" xml:lang="en-US">IncreaseDecreaseInDerivativeExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreaseInDerivativeExpense" xlink:to="ntrb_IncreaseDecreaseInDerivativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShares_lbl1" xml:lang="en-US">WarrantsToPurchaseOfCommonStockShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsToPurchaseOfCommonStockShares" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsToPurchaseOfCommonStockShare_lbl1" xml:lang="en-US">WarrantsToPurchaseOfCommonStockShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsToPurchaseOfCommonStockShare" xlink:to="ntrb_WarrantsToPurchaseOfCommonStockShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessAcquisitionRevenue_lbl1" xml:lang="en-US">BusinessAcquisitionRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionRevenue" xlink:to="ntrb_BusinessAcquisitionRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl1" xml:lang="en-US">UnauditedInterimFinancialStatementsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ExpectedTerms_lbl1" xml:lang="en-US">ExpectedTerms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpectedTerms" xlink:to="ntrb_ExpectedTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SalaryPayment_lbl1" xml:lang="en-US">SalaryPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SalaryPayment" xlink:to="ntrb_SalaryPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ReverseStockSplitPolicyTextBlock_lbl0" xml:lang="en-US">ReverseStockSplitPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ReverseStockSplitPolicyTextBlock" xlink:to="ntrb_ReverseStockSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired_lbl0" xml:lang="en-US">BusinessAcquisitionPercentageOfVotingInterestAcquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired" xlink:to="ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_TwoCustomerMember_lbl0" xml:lang="en-US">TwoCustomerMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_TwoCustomerMember" xlink:to="ntrb_TwoCustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OrganizationPolicyTextBlock_lbl1" xml:lang="en-US">OrganizationPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OrganizationPolicyTextBlock" xlink:to="ntrb_OrganizationPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DerivativeLiabilityWarrantReclassedToEquity_lbl1" xml:lang="en-US">DerivativeLiabilityWarrantReclassedToEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilityWarrantReclassedToEquity" xlink:to="ntrb_DerivativeLiabilityWarrantReclassedToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_FundReceived_lbl1" xml:lang="en-US">FundReceived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FundReceived" xlink:to="ntrb_FundReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl3" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl2" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" xlink:to="ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CashPaidForAbstract_lbl0" xml:lang="en-US">CashPaidForAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CashPaidForAbstract" xlink:to="ntrb_CashPaidForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PaymentForInitialLicenseFee_lbl3" xml:lang="en-US">PaymentForInitialLicenseFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PaymentForInitialLicenseFee" xlink:to="ntrb_PaymentForInitialLicenseFee_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_AnnualMeetingOfShareholdersTerm_lbl1" xml:lang="en-US">AnnualMeetingOfShareholdersTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AnnualMeetingOfShareholdersTerm" xlink:to="ntrb_AnnualMeetingOfShareholdersTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockIssuedForSettlementOfNotesPayable_lbl1" xml:lang="en-US">CommonStockIssuedForSettlementOfNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForSettlementOfNotesPayable" xlink:to="ntrb_CommonStockIssuedForSettlementOfNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockOfDescription_lbl0" xml:lang="en-US">CommonStockOfDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockOfDescription" xlink:to="ntrb_CommonStockOfDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ReclassOfWarrantsFromLiabilityToEquity_lbl0" xml:lang="en-US">ReclassOfWarrantsFromLiabilityToEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ReclassOfWarrantsFromLiabilityToEquity" xlink:to="ntrb_ReclassOfWarrantsFromLiabilityToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_HealthsBrandsIncMember_lbl0" xml:lang="en-US">HealthsBrandsIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_HealthsBrandsIncMember" xlink:to="ntrb_HealthsBrandsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_GainOnForgivenessOfLoanPayment_lbl1" xml:lang="en-US">GainOnForgivenessOfLoanPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnForgivenessOfLoanPayment" xlink:to="ntrb_GainOnForgivenessOfLoanPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_InventoryRawMaterialsPercentage_lbl1" xml:lang="en-US">InventoryRawMaterialsPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InventoryRawMaterialsPercentage" xlink:to="ntrb_InventoryRawMaterialsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RevenueByGeographicLocationAbstract_lbl0" xml:lang="en-US">RevenueByGeographicLocationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByGeographicLocationAbstract" xlink:to="ntrb_RevenueByGeographicLocationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PurchaseOfMaterials_lbl1" xml:lang="en-US">PurchaseOfMaterials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PurchaseOfMaterials" xlink:to="ntrb_PurchaseOfMaterials_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CashPaidForAbstract0_lbl0" xml:lang="en-US">CashPaidForAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CashPaidForAbstract0" xlink:to="ntrb_CashPaidForAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_GoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">GoingConcernPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GoingConcernPolicyTextBlock" xlink:to="ntrb_GoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OtherComprehensiveLossAbstract_lbl0" xml:lang="en-US">OtherComprehensiveLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherComprehensiveLossAbstract" xlink:to="ntrb_OtherComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ExpectedTerm_lbl0" xml:lang="en-US">ExpectedTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpectedTerm" xlink:to="ntrb_ExpectedTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DebtDiscountOnConvertibleNotes_lbl1" xml:lang="en-US">DebtDiscountOnConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DebtDiscountOnConvertibleNotes" xlink:to="ntrb_DebtDiscountOnConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessAcquisitionsNetLossAsReported_lbl0" xml:lang="en-US">BusinessAcquisitionsNetLossAsReported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionsNetLossAsReported" xlink:to="ntrb_BusinessAcquisitionsNetLossAsReported_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonIssuedForSubscriptionPayable_lbl1" xml:lang="en-US">CommonIssuedForSubscriptionPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonIssuedForSubscriptionPayable" xlink:to="ntrb_CommonIssuedForSubscriptionPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SaleofCommonstockForCash_lbl1" xml:lang="en-US">SaleofCommonstockForCash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SaleofCommonstockForCash" xlink:to="ntrb_SaleofCommonstockForCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures_lbl1" xml:lang="en-US">EarlyPrepaymentFeeOnConvertibleDebentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures" xlink:to="ntrb_EarlyPrepaymentFeeOnConvertibleDebentures_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SalesRevenuesGoodsNet_lbl1" xml:lang="en-US">SalesRevenuesGoodsNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SalesRevenuesGoodsNet" xlink:to="ntrb_SalesRevenuesGoodsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase_lbl1" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RelatedPartyTransactionDescriptionOfTransactions_lbl1" xml:lang="en-US">RelatedPartyTransactionDescriptionOfTransactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="ntrb_RelatedPartyTransactionDescriptionOfTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_LongTermLiabilitiesAbstract_lbl0" xml:lang="en-US">LongTermLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LongTermLiabilitiesAbstract" xlink:to="ntrb_LongTermLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisition_lbl1" xml:lang="en-US">CommonStockAndNoteIssuedInAcquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockAndNoteIssuedInAcquisition" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisition_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_AmortizationOfDebtDiscountsPremium_lbl1" xml:lang="en-US">AmortizationOfDebtDiscountsPremium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AmortizationOfDebtDiscountsPremium" xlink:to="ntrb_AmortizationOfDebtDiscountsPremium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_AcquiredPercentage_lbl1" xml:lang="en-US">AcquiredPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AcquiredPercentage" xlink:to="ntrb_AcquiredPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessAcquisitionCommonStockIssued_lbl1" xml:lang="en-US">BusinessAcquisitionCommonStockIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionCommonStockIssued" xlink:to="ntrb_BusinessAcquisitionCommonStockIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PoconoCoatedProductsLLCMember_lbl0" xml:lang="en-US">PoconoCoatedProductsLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PoconoCoatedProductsLLCMember" xlink:to="ntrb_PoconoCoatedProductsLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" xlink:to="ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OtherComprehensiveIncomeLossAbstract_lbl0" xml:lang="en-US">OtherComprehensiveIncomeLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherComprehensiveIncomeLossAbstract" xlink:to="ntrb_OtherComprehensiveIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PropertyPlantAndEquipmentsGross_lbl1" xml:lang="en-US">PropertyPlantAndEquipmentsGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentsGross" xlink:to="ntrb_PropertyPlantAndEquipmentsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IncreaseDecreasedInAuthorizedCommonStock_lbl1" xml:lang="en-US">IncreaseDecreasedInAuthorizedCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreasedInAuthorizedCommonStock" xlink:to="ntrb_IncreaseDecreasedInAuthorizedCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_InvestmentWarrantExercisePrice_lbl1" xml:lang="en-US">InvestmentWarrantExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InvestmentWarrantExercisePrice" xlink:to="ntrb_InvestmentWarrantExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_InterestExpenseDebts_lbl0" xml:lang="en-US">InterestExpenseDebts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InterestExpenseDebts" xlink:to="ntrb_InterestExpenseDebts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ExpensesPaid_lbl1" xml:lang="en-US">ExpensesPaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ExpensesPaid" xlink:to="ntrb_ExpensesPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PerformanceObligationsPolicyTextBlock_lbl0" xml:lang="en-US">PerformanceObligationsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PerformanceObligationsPolicyTextBlock" xlink:to="ntrb_PerformanceObligationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DerivativeLiabilitiesPolicyTextBlock_lbl0" xml:lang="en-US">DerivativeLiabilitiesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilitiesPolicyTextBlock" xlink:to="ntrb_DerivativeLiabilitiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockAndNoteIssuedInAcquisitions_lbl1" xml:lang="en-US">CommonStockAndNoteIssuedInAcquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockAndNoteIssuedInAcquisitions" xlink:to="ntrb_CommonStockAndNoteIssuedInAcquisitions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_amortizedOverPeriod_lbl0" xml:lang="en-US">amortizedOverPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_amortizedOverPeriod" xlink:to="ntrb_amortizedOverPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding_lbl0" xml:lang="en-US">ScheduleOfAdditionalRelatingWarrantsOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding" xlink:to="ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessCombinationMember_lbl0" xml:lang="en-US">BusinessCombinationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationMember" xlink:to="ntrb_BusinessCombinationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DiscountRemainingAmount_lbl1" xml:lang="en-US">DiscountRemainingAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DiscountRemainingAmount" xlink:to="ntrb_DiscountRemainingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RelatedPartyPayableMember_lbl0" xml:lang="en-US">RelatedPartyPayableMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RelatedPartyPayableMember" xlink:to="ntrb_RelatedPartyPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_InterestExpensesDebt_lbl1" xml:lang="en-US">InterestExpensesDebt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InterestExpensesDebt" xlink:to="ntrb_InterestExpensesDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessAcquisitionNetProfit_lbl1" xml:lang="en-US">BusinessAcquisitionNetProfit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessAcquisitionNetProfit" xlink:to="ntrb_BusinessAcquisitionNetProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RevenueByGeographicalLocationAbstract_lbl0" xml:lang="en-US">RevenueByGeographicalLocationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByGeographicalLocationAbstract" xlink:to="ntrb_RevenueByGeographicalLocationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DebtInstrumentAnnualPrincipalPayments_lbl1" xml:lang="en-US">DebtInstrumentAnnualPrincipalPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DebtInstrumentAnnualPrincipalPayments" xlink:to="ntrb_DebtInstrumentAnnualPrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationNumberOutstanding_lbl0" xml:lang="en-US">ShareBasedCompensationNumberOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationNumberOutstanding" xlink:to="ntrb_ShareBasedCompensationNumberOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity_lbl1" xml:lang="en-US">ReclassificationOfWarrantsFromLiabilityToEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity" xlink:to="ntrb_ReclassificationOfWarrantsFromLiabilityToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DefendantMember_lbl0" xml:lang="en-US">DefendantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DefendantMember" xlink:to="ntrb_DefendantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OneCustomerMember_lbl0" xml:lang="en-US">OneCustomerMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OneCustomerMember" xlink:to="ntrb_OneCustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PropertyPlantAndEquipmentsUsefulLife_lbl1" xml:lang="en-US">PropertyPlantAndEquipmentsUsefulLife</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentsUsefulLife" xlink:to="ntrb_PropertyPlantAndEquipmentsUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ProceedsFromLoanOriginationsTotal_lbl0" xml:lang="en-US">ProceedsFromLoanOriginationsTotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ProceedsFromLoanOriginationsTotal" xlink:to="ntrb_ProceedsFromLoanOriginationsTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_InitialPublicOfferingPricePercentage_lbl0" xml:lang="en-US">InitialPublicOfferingPricePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_InitialPublicOfferingPricePercentage" xlink:to="ntrb_InitialPublicOfferingPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_FormerIndependentDirectorsMember_lbl0" xml:lang="en-US">FormerIndependentDirectorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FormerIndependentDirectorsMember" xlink:to="ntrb_FormerIndependentDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DerivativeLiabilitiesTotal_lbl1" xml:lang="en-US">DerivativeLiabilitiesTotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilitiesTotal" xlink:to="ntrb_DerivativeLiabilitiesTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DesignatedSharesOfPreferredStocks_lbl1" xml:lang="en-US">DesignatedSharesOfPreferredStocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DesignatedSharesOfPreferredStocks" xlink:to="ntrb_DesignatedSharesOfPreferredStocks_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_MonthlyRent_lbl1" xml:lang="en-US">MonthlyRent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_MonthlyRent" xlink:to="ntrb_MonthlyRent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockIssuedForAccountsPayable_lbl1" xml:lang="en-US">CommonStockIssuedForAccountsPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForAccountsPayable" xlink:to="ntrb_CommonStockIssuedForAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SaleOfGoodsAndServices_lbl1" xml:lang="en-US">SaleOfGoodsAndServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SaleOfGoodsAndServices" xlink:to="ntrb_SaleOfGoodsAndServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ConcentrationRiskPercentage_lbl1" xml:lang="en-US">ConcentrationRiskPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ConcentrationRiskPercentage" xlink:to="ntrb_ConcentrationRiskPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_FairValueOfConversionPrice_lbl1" xml:lang="en-US">FairValueOfConversionPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfConversionPrice" xlink:to="ntrb_FairValueOfConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OtherIncomeExpenseAbstract_lbl0" xml:lang="en-US">OtherIncomeExpenseAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherIncomeExpenseAbstract" xlink:to="ntrb_OtherIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockShareIssued_lbl0" xml:lang="en-US">CommonStockShareIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockShareIssued" xlink:to="ntrb_CommonStockShareIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DisaggregationOfRevenues_lbl1" xml:lang="en-US">DisaggregationOfRevenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DisaggregationOfRevenues" xlink:to="ntrb_DisaggregationOfRevenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DerivativeLiabilityWarrantsReclassedToEquity_lbl1" xml:lang="en-US">DerivativeLiabilityWarrantsReclassedToEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DerivativeLiabilityWarrantsReclassedToEquity" xlink:to="ntrb_DerivativeLiabilityWarrantsReclassedToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockIssued_lbl0" xml:lang="en-US">CommonStockIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssued" xlink:to="ntrb_CommonStockIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IssuanceOfCommonStockForNotePayable_lbl1" xml:lang="en-US">IssuanceOfCommonStockForNotePayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IssuanceOfCommonStockForNotePayable" xlink:to="ntrb_IssuanceOfCommonStockForNotePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PublicOrPrivateFinancing_lbl1" xml:lang="en-US">PublicOrPrivateFinancing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PublicOrPrivateFinancing" xlink:to="ntrb_PublicOrPrivateFinancing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RevenueByTypeAbstract_lbl0" xml:lang="en-US">RevenueByTypeAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByTypeAbstract" xlink:to="ntrb_RevenueByTypeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_GainOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">GainOnExtinguishmentOfDebt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_GainOnExtinguishmentOfDebt" xlink:to="ntrb_GainOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_NotePayableIssued_lbl1" xml:lang="en-US">NotePayableIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayableIssued" xlink:to="ntrb_NotePayableIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_increasedecreaseDepositOnSales_lbl0" xml:lang="en-US">increasedecreaseDepositOnSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_increasedecreaseDepositOnSales" xlink:to="ntrb_increasedecreaseDepositOnSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SubscrptionPayableForServices_lbl1" xml:lang="en-US">SubscrptionPayableForServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscrptionPayableForServices" xlink:to="ntrb_SubscrptionPayableForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BPMMember_lbl1" xml:lang="en-US">BPMMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BPMMember" xlink:to="ntrb_BPMMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockIssuedForSettlement_lbl1" xml:lang="en-US">CommonStockIssuedForSettlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForSettlement" xlink:to="ntrb_CommonStockIssuedForSettlement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_LongTermLiabilitiesAbstract0_lbl0" xml:lang="en-US">LongTermLiabilitiesAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LongTermLiabilitiesAbstract0" xlink:to="ntrb_LongTermLiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_LicensingAgreementMember_lbl0" xml:lang="en-US">LicensingAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LicensingAgreementMember" xlink:to="ntrb_LicensingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SharesWereRestored_lbl1" xml:lang="en-US">SharesWereRestored</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharesWereRestored" xlink:to="ntrb_SharesWereRestored_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DisaggregationOfRevenuesPolicyTextBlock_lbl0" xml:lang="en-US">DisaggregationOfRevenuesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="ntrb_DisaggregationOfRevenuesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_WarrantsAndOptionsTextBlock_lbl0" xml:lang="en-US">WarrantsAndOptionsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_WarrantsAndOptionsTextBlock" xlink:to="ntrb_WarrantsAndOptionsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax_lbl1" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" xlink:to="ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_LabEquipmentMember_lbl1" xml:lang="en-US">LabEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LabEquipmentMember" xlink:to="ntrb_LabEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationNumberExercisable_lbl0" xml:lang="en-US">ShareBasedCompensationNumberExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationNumberExercisable" xlink:to="ntrb_ShareBasedCompensationNumberExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DueToRelatedPartyCurrentAndNoncurrent_lbl0" xml:lang="en-US">DueToRelatedPartyCurrentAndNoncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DueToRelatedPartyCurrentAndNoncurrent" xlink:to="ntrb_DueToRelatedPartyCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices_lbl0" xml:lang="en-US">StockIssuedDuringPeriodIssuanceOfWarrantsForServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices" xlink:to="ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability_lbl1" xml:lang="en-US">AdoptionOfASC842OperatingLeaseAssetAndLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability" xlink:to="ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_OtherIncomeExpenseAbstract0_lbl0" xml:lang="en-US">OtherIncomeExpenseAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_OtherIncomeExpenseAbstract0" xlink:to="ntrb_OtherIncomeExpenseAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SubscrptionPayableForCash_lbl1" xml:lang="en-US">SubscrptionPayableForCash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscrptionPayableForCash" xlink:to="ntrb_SubscrptionPayableForCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares_lbl1" xml:lang="en-US">CommonStockShareSubscribedButUnissuedSubscriptionsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares" xlink:to="ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IncreaseDecreaseOperatingLeaseLiability_lbl1" xml:lang="en-US">IncreaseDecreaseOperatingLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IncreaseDecreaseOperatingLeaseLiability" xlink:to="ntrb_IncreaseDecreaseOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks_lbl1" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:to="ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_TherapeuticsLLCMember_lbl0" xml:lang="en-US">TherapeuticsLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_TherapeuticsLLCMember" xlink:to="ntrb_TherapeuticsLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PrivatePlacement_lbl0" xml:lang="en-US">PrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PrivatePlacement" xlink:to="ntrb_PrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_FairValueOfTheCommonStocks_lbl1" xml:lang="en-US">FairValueOfTheCommonStocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfTheCommonStocks" xlink:to="ntrb_FairValueOfTheCommonStocks_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RevenueByTypeAbstract0_lbl0" xml:lang="en-US">RevenueByTypeAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevenueByTypeAbstract0" xlink:to="ntrb_RevenueByTypeAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" xlink:to="ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices_lbl1" xml:lang="en-US">DeferredTaxAssetAndLiabilityStockIssuedForServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices" xlink:to="ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" xlink:to="ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_NotePayablesDescription_lbl1" xml:lang="en-US">NotePayablesDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayablesDescription" xlink:to="ntrb_NotePayablesDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_NoncashPaymentForLicenseAgreement_lbl1" xml:lang="en-US">NoncashPaymentForLicenseAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NoncashPaymentForLicenseAgreement" xlink:to="ntrb_NoncashPaymentForLicenseAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl0" xml:lang="en-US">PropertyPlantAndEquipmentUsefulLifeTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates_lbl0" xml:lang="en-US">FairValueAssumptionsWeightedAverageVolatilityRates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates" xlink:to="ntrb_FairValueAssumptionsWeightedAverageVolatilityRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_NotePayableConvertibleDebtDescription_lbl1" xml:lang="en-US">NotePayableConvertibleDebtDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_NotePayableConvertibleDebtDescription" xlink:to="ntrb_NotePayableConvertibleDebtDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_RevaluedMember_lbl1" xml:lang="en-US">RevaluedMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_RevaluedMember" xlink:to="ntrb_RevaluedMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare_lbl1" xml:lang="en-US">LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" xlink:to="ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_FairValueAssumptionsRiskFreeInterestRates_lbl1" xml:lang="en-US">FairValueAssumptionsRiskFreeInterestRates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueAssumptionsRiskFreeInterestRates" xlink:to="ntrb_FairValueAssumptionsRiskFreeInterestRates_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_PrepaymentFee_lbl0" xml:lang="en-US">PrepaymentFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_PrepaymentFee" xlink:to="ntrb_PrepaymentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SubscriptionPayableMember_lbl0" xml:lang="en-US">SubscriptionPayableMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayableMember" xlink:to="ntrb_SubscriptionPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockIssuedForPrepaidConsulting_lbl0" xml:lang="en-US">CommonStockIssuedForPrepaidConsulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockIssuedForPrepaidConsulting" xlink:to="ntrb_CommonStockIssuedForPrepaidConsulting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SubscriptionPayable_lbl2" xml:lang="en-US">SubscriptionPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayable" xlink:to="ntrb_SubscriptionPayable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" xlink:to="ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_FairValueOfWarrantExpense_lbl1" xml:lang="en-US">FairValueOfWarrantExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_FairValueOfWarrantExpense" xlink:to="ntrb_FairValueOfWarrantExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_CommonStockShareOutstanding_lbl0" xml:lang="en-US">CommonStockShareOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_CommonStockShareOutstanding" xlink:to="ntrb_CommonStockShareOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_SubscriptionPayables_lbl1" xml:lang="en-US">SubscriptionPayables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_SubscriptionPayables" xlink:to="ntrb_SubscriptionPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_IssuanceOfCommonStockForNotePayableinShares_lbl0" xml:lang="en-US">IssuanceOfCommonStockForNotePayableinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_IssuanceOfCommonStockForNotePayableinShares" xlink:to="ntrb_IssuanceOfCommonStockForNotePayableinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ntrb_ConsultingServicesMember_lbl1" xml:lang="en-US">ConsultingServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntrb_ConsultingServicesMember" xlink:to="ntrb_ConsultingServicesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl0" xml:lang="en-US">Line of Credit Facility, Frequency of Payment and Payment Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl0" xml:lang="en-US">Proceeds from Interest Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl0" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_lbl0" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl0" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Next Rolling 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl1" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl0" xml:lang="en-US">Subordinated Borrowing, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl1" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl0" xml:lang="en-US">Revenue Recognition, Deferred Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl1" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl0" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl3" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl0" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl4" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0" xml:lang="en-US">Notes Payable, Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl0" xml:lang="en-US">Accretion Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl2" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl0" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl0" xml:lang="en-US">Debt Instrument, Debt Default, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl0" xml:lang="en-US">Other Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl1" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl0" xml:lang="en-US">Convertible Debt, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl0" xml:lang="en-US">Chief Operating Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_lbl0" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl0" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl1" xml:lang="en-US">Intellectual Property [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl0" xml:lang="en-US">Class of Warrant or Right, Expense or Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:to="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl2" xml:lang="en-US">Derivative Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl0" xml:lang="en-US">Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_lbl0" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl0" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PresidentMember_lbl0" xml:lang="en-US">President [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl1" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Finance Lease, Liability, Payment, Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_lbl0" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalHomeLoanBankAdvances_lbl0" xml:lang="en-US">Federal Home Loan Bank Advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBankAdvances" xlink:to="us-gaap_FederalHomeLoanBankAdvances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Public Utilities, Property, Plant and Equipment, Other Property Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl1" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl0" xml:lang="en-US">Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl0" xml:lang="en-US">Other Commitments, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl0" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits_lbl0" xml:lang="en-US">Increase (Decrease) in Customer Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:to="us-gaap_IncreaseDecreaseInCustomerDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl0" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl0" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl0" xml:lang="en-US">Cash Acquired from Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl0" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription_lbl0" xml:lang="en-US">Purchase Commitment, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantPurchaseCommitmentDescription" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl0" xml:lang="en-US">Costs and Expenses, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment_lbl0" xml:lang="en-US">Line of Credit Facility, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment" xlink:to="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl0" xml:lang="en-US">Deposit Liabilities, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl0" xml:lang="en-US">Common Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalTransactionsRevenue_lbl0" xml:lang="en-US">Principal Transactions Revenue, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalTransactionsRevenue" xlink:to="us-gaap_PrincipalTransactionsRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillGross_lbl0" xml:lang="en-US">Goodwill, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl0" xml:lang="en-US">Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelatedIntangibleAssetsMember_lbl0" xml:lang="en-US">Customer-Related Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:to="us-gaap_CustomerRelatedIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_lbl0" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl0" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl0" xml:lang="en-US">Proceeds from Loan Originations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl0" xml:lang="en-US">Other General Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl2" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl0" xml:lang="en-US">Non-US [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl1" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl0" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl0" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfLeasedAsset_lbl0" xml:lang="en-US">Amortization of Leased Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfLeasedAsset" xlink:to="us-gaap_AmortizationOfLeasedAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ntrb-20210731_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Sep 30 22:42:48 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedBalanceSheet" roleURI="http://nutriband.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedIncomeStatement" roleURI="http://nutriband.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ShareholdersEquityType2or3" roleURI="http://nutriband.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ConsolidatedCashFlow" roleURI="http://nutriband.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_OrganizationandDescriptionofBusiness" roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AcquisitionofBusiness" roleURI="http://nutriband.com/role/AcquisitionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_PropertyandEquipment" roleURI="http://nutriband.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IncomeTaxes" roleURI="http://nutriband.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_NotesPayableConvertibleDebt" roleURI="http://nutriband.com/role/NotesPayableConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IntangibleAssets" roleURI="http://nutriband.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_DerivativeLiabilities" roleURI="http://nutriband.com/role/DerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_RelatedPartyTransactions" roleURI="http://nutriband.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_StockholdersEquity" roleURI="http://nutriband.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_WarrantsandOptions" roleURI="http://nutriband.com/role/WarrantsandOptions"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_Leases" roleURI="http://nutriband.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_CommitmentsandContigencies" roleURI="http://nutriband.com/role/CommitmentsandContigencies"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SubsequentEvents" roleURI="http://nutriband.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofSignificantAccountingPolicies" roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AccountingPoliciesByPolicy" roleURI="http://nutriband.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_OrganizationandDescriptionofBusinessTables" roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AcquisitionofBusinessTables" roleURI="http://nutriband.com/role/AcquisitionofBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_PropertyandEquipmentTables" roleURI="http://nutriband.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IncomeTaxesTables" roleURI="http://nutriband.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_NotesPayableConvertibleDebtTables" roleURI="http://nutriband.com/role/NotesPayableConvertibleDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IntangibleAssetsTables" roleURI="http://nutriband.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_DerivativeLiabilitiesTables" roleURI="http://nutriband.com/role/DerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_WarrantsandOptionsTables" roleURI="http://nutriband.com/role/WarrantsandOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofdisaggregationofrevenuesTable" roleURI="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofrevenuebygeographicallocationTable" roleURI="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofnetassetsacquiredTable" roleURI="http://nutriband.com/role/ScheduleofnetassetsacquiredTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofunauditedproformacondensedfinancialinformationTable" roleURI="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyandequipmentTable" roleURI="http://nutriband.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofprovisionforincometaxesTable" roleURI="http://nutriband.com/role/SummaryofprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable" roleURI="http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofdeferredtaxassetandliabilitiesTable" roleURI="http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofminimumleasepaymentsTable" roleURI="http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" roleURI="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofestimatedamortizationTable" roleURI="http://nutriband.com/role/ScheduleofestimatedamortizationTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SchedulereconciliationofderivativeliabilitiesTable" roleURI="http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofwarrantsoutstandingTable" roleURI="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" roleURI="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofoptionsoutstandingTable" roleURI="http://nutriband.com/role/ScheduleofoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofdisaggregationofrevenuesTable0" roleURI="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofrevenuebygeographicallocationTable0" roleURI="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyplantandequipmentTable0" roleURI="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofnetassetsacquiredTable0" roleURI="http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofunauditedproformacondensedfinancialinformationTable0" roleURI="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofpropertyandequipmentTable0" roleURI="http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofMinimumleasepaymentsTable" roleURI="http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0" roleURI="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofestimatedamortizationTable0" roleURI="http://nutriband.com/role/ScheduleofestimatedamortizationTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofwarrantsoutstandingTable0" roleURI="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0" roleURI="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_AcquisitionofBusinessDetails" roleURI="http://nutriband.com/role/AcquisitionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_PropertyandEquipmentDetails" roleURI="http://nutriband.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IncomeTaxesDetails" roleURI="http://nutriband.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_NotesPayableConvertibleDebtDetails" roleURI="http://nutriband.com/role/NotesPayableConvertibleDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_IntangibleAssetsDetails" roleURI="http://nutriband.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_DerivativeLiabilitiesDetails" roleURI="http://nutriband.com/role/DerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_RelatedPartyTransactionsDetails" roleURI="http://nutriband.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_StockholdersEquityDetails" roleURI="http://nutriband.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_WarrantsandOptionsDetails" roleURI="http://nutriband.com/role/WarrantsandOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_LeasesDetails" roleURI="http://nutriband.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_CommitmentsandContigenciesDetails" roleURI="http://nutriband.com/role/CommitmentsandContigenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SubsequentEventsDetails" roleURI="http://nutriband.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#ntrb_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ntrb-20210731.xsd#DocumentAndEntityInformation" roleURI="http://nutriband.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_LongTermLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="LongTermLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermLiabilitiesAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermLiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionPayables" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="SubscriptionPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockShareIssued" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="CommonStockShareIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockShareOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="CommonStockShareOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_CostsAndExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpenseAbstract" xlink:href="ntrb-20210731.xsd#ntrb_OtherIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_AccretionExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnForgivenessOfDebt" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="GainOnForgivenessOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfDerivatives" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveLossAbstract" xlink:href="ntrb-20210731.xsd#ntrb_OtherComprehensiveLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherComprehensiveLossAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionPayableMember" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SubscriptionPayableMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodIssuanceOfWarrantsForServices" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodIssuanceOfWarrantsForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleofCommonstockForCash" xlink:href="ntrb-20210731.xsd#ntrb_SaleofCommonstockForCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SaleofCommonstockForCash" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfWarrantsFromLiabilityToEquity" xlink:href="ntrb-20210731.xsd#ntrb_ReclassificationOfWarrantsFromLiabilityToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ReclassificationOfWarrantsFromLiabilityToEquity" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForNotePayable" xlink:href="ntrb-20210731.xsd#ntrb_IssuanceOfCommonStockForNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForNotePayable" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForNotePayableinShares" xlink:href="ntrb-20210731.xsd#ntrb_IssuanceOfCommonStockForNotePayableinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForNotePayableinShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscrptionPayableForCash" xlink:href="ntrb-20210731.xsd#ntrb_SubscrptionPayableForCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SubscrptionPayableForCash" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscrptionPayableForServices" xlink:href="ntrb-20210731.xsd#ntrb_SubscrptionPayableForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SubscrptionPayableForServices" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInDerivativeExpense" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseInDerivativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInDerivativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarlyPrepaymentFeeOnConvertibleDebentures" xlink:href="ntrb-20210731.xsd#ntrb_EarlyPrepaymentFeeOnConvertibleDebentures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="EarlyPrepaymentFeeOnConvertibleDebentures" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnForgivenessOfLoanPayment" xlink:href="ntrb-20210731.xsd#ntrb_GainOnForgivenessOfLoanPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainOnForgivenessOfLoanPayment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfLeasedAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfLeasedAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfLeasedAsset" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="SubscriptionPayable" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="increasedecreaseDepositOnSales" xlink:href="ntrb-20210731.xsd#ntrb_increasedecreaseDepositOnSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="increasedecreaseDepositOnSales" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInCustomerDeposits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseOperatingLeaseLiability" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreaseOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseOperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAbstract0" xlink:href="ntrb-20210731.xsd#ntrb_CashPaidForAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="CashPaidForAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAbstract" xlink:href="ntrb-20210731.xsd#ntrb_CashPaidForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashPaidForAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAndNoteIssuedInAcquisitions" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockAndNoteIssuedInAcquisitions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdoptionOfASC842OperatingLeaseAssetAndLiability" xlink:href="ntrb-20210731.xsd#ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="AdoptionOfASC842OperatingLeaseAssetAndLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForSettlementOfNotesPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForSettlementOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedForSettlementOfNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForPrepaidConsulting" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForPrepaidConsulting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedForPrepaidConsulting" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashPaymentForLicenseAgreement" xlink:href="ntrb-20210731.xsd#ntrb_NoncashPaymentForLicenseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashPaymentForLicenseAgreement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeLiabilityWarrantReclassedToEquity" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilityWarrantReclassedToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DerivativeLiabilityWarrantReclassedToEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonIssuedForSubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonIssuedForSubscriptionPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonIssuedForSubscriptionPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountOnConvertibleNotes" xlink:href="ntrb-20210731.xsd#ntrb_DebtDiscountOnConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DebtDiscountOnConvertibleNotes" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForAccountsPayable" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedForAccountsPayable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForSettlement" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssuedForSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedForSettlement" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/AcquisitionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/NotesPayableConvertibleDebt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/DerivativeLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/WarrantsandOptions">
    <loc xlink:type="locator" xlink:label="WarrantsAndOptionsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsAndOptionsTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndOptionsAbstract" xlink:to="WarrantsAndOptionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTable" xlink:href="ntrb-20210731.xsd#ntrb_LeasesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesLineItems" xlink:href="ntrb-20210731.xsd#ntrb_LeasesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesTable" xlink:to="LeasesLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/CommitmentsandContigencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_ReverseStockSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ReverseStockSplitPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GoingConcernPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_GoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GoingConcernPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PerformanceObligationsPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PerformanceObligationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PerformanceObligationsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisaggregationOfRevenuesPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenuesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DisaggregationOfRevenuesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeLiabilitiesPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DerivativeLiabilitiesPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="UnauditedInterimFinancialStatementsPolicyTextBlock" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/OrganizationandDescriptionofBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/AcquisitionofBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/NotesPayableConvertibleDebtTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/DerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/WarrantsandOptionsTables">
    <loc xlink:type="locator" xlink:label="WarrantsAndOptionsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsTablesTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsTablesTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsTablesLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndOptionsAbstract" xlink:to="WarrantsandOptionsTablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsTablesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsTablesTable" xlink:to="WarrantsandOptionsTablesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalRelatingWarrantsOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsTablesLineItems" xlink:to="ScheduleOfAdditionalRelatingWarrantsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDisaggregationOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesRevenuesGoodsNet" xlink:href="ntrb-20210731.xsd#ntrb_SalesRevenuesGoodsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="SalesRevenuesGoodsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfGoodsAndServices" xlink:href="ntrb-20210731.xsd#ntrb_SaleOfGoodsAndServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="SaleOfGoodsAndServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisaggregationOfRevenues" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="DisaggregationOfRevenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueByGeographicalLocationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfRevenueByGeographicalLocationAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByGeographicalLocationAbstract" xlink:to="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DisaggregationOfRevenues" xlink:href="ntrb-20210731.xsd#ntrb_DisaggregationOfRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="DisaggregationOfRevenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable" xlink:to="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofnetassetsacquiredTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetAssetsAcquiredAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfNetAssetsAcquiredAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionCommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionCommonStockIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="BusinessAcquisitionCommonStockIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableIssued" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="NotePayableIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAndNoteIssuedInAcquisition" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="CommonStockAndNoteIssuedInAcquisition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_GoodwillGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentsGross" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="SummaryOfProvisionForIncomeTaxesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_SummaryOfProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetAndLiabilityStockIssuedForServices" xlink:href="ntrb-20210731.xsd#ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetAndLiabilityStockIssuedForServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract" xlink:to="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelatedIntangibleAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IntellectualPropertyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:to="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofestimatedamortizationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfEstimatedAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleReconciliationOfDerivativeLiabilitiesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleReconciliationOfDerivativeLiabilitiesAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeLiabilityWarrantsReclassedToEquity" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilityWarrantsReclassedToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="DerivativeLiabilityWarrantsReclassedToEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_0" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZzjdoIf697x9Ebb9RR62VzZ2moDN98hKYJqt0nOEvOJM3ovM/SXTjMP1Ald7slk0jhpkvJNEcZ22oENEU/pa+RGktyuYgAZpSzCvQD/cHd+rIAFOf0qxA58sbmcPw9UpSPh+OrTDXTmJ7VYjFEDe+x4Kv3wGjJ2krmmyw+NNN8s1PZLCaZ2c9yZ+ljIOMZdLE=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract" xlink:to="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingAbstract" xlink:to="WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable" xlink:to="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfDisaggregationOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesRevenuesGoodsNet" xlink:href="ntrb-20210731.xsd#ntrb_SalesRevenuesGoodsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="SalesRevenuesGoodsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfGoodsAndServices" xlink:href="ntrb-20210731.xsd#ntrb_SaleOfGoodsAndServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="SaleOfGoodsAndServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDisaggregationOfRevenuesAbstract" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueByGeographicalLocationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfRevenueByGeographicalLocationAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByGeographicalLocationAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofnetassetsacquiredTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetAssetsAcquiredAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfNetAssetsAcquiredAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionCommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionCommonStockIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="BusinessAcquisitionCommonStockIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableIssued" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="NotePayableIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAndNoteIssuedInAcquisition" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockAndNoteIssuedInAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="CommonStockAndNoteIssuedInAcquisition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_GoodwillGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetAssetsAcquiredAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionsNetLossAsReported" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionsNetLossAsReported"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="BusinessAcquisitionsNetLossAsReported" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" xlink:href="ntrb-20210731.xsd#ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract" xlink:to="BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="ntrb-20210731.xsd#ntrb_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract" xlink:to="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelatedIntangibleAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensingAgreementMember" xlink:href="ntrb-20210731.xsd#ntrb_LicensingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="LicensingAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IntellectualPropertyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable" xlink:to="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofestimatedamortizationTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedAmortizationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfEstimatedAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract" xlink:href="ntrb-20210731.xsd#ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract" xlink:to="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable" xlink:to="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationNumberOutstanding" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationNumberOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationNumberOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="ntrb-20210731.xsd#ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationNumberExercisable" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationNumberExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationNumberExercisable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationandDescriptionofBusinessDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TherapeuticsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_TherapeuticsLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="TherapeuticsLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ActiveIntelligenceLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_ActiveIntelligenceLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="ActiveIntelligenceLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="srt_MajorCustomersAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThreeCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_ThreeCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ThreeCustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_TwoCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="TwoCustomerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneCustomerMember" xlink:href="ntrb-20210731.xsd#ntrb_OneCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="OneCustomerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="OrganizationandDescriptionofBusinessDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentsUsefulLife" xlink:href="ntrb-20210731.xsd#ntrb_PropertyPlantAndEquipmentsUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="PropertyPlantAndEquipmentsUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskPercentage" xlink:href="ntrb-20210731.xsd#ntrb_ConcentrationRiskPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="ConcentrationRiskPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquiredPercentage" xlink:href="ntrb-20210731.xsd#ntrb_AcquiredPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="AcquiredPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/AcquisitionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="AcquisitionofBusinessDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_AcquisitionofBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AcquisitionofBusinessDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_AcquisitionofBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="AcquisitionofBusinessDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationMember" xlink:href="ntrb-20210731.xsd#ntrb_BusinessCombinationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="BusinessCombinationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsTable" xlink:to="AcquisitionofBusinessDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionPercentageOfVotingInterestAcquired" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="BusinessAcquisitionPercentageOfVotingInterestAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentAnnualPrincipalPayments" xlink:href="ntrb-20210731.xsd#ntrb_DebtInstrumentAnnualPrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="DebtInstrumentAnnualPrincipalPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualMeetingOfShareholdersTerm" xlink:href="ntrb-20210731.xsd#ntrb_AnnualMeetingOfShareholdersTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="AnnualMeetingOfShareholdersTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionRevenue" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="BusinessAcquisitionRevenue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionNetProfit" xlink:href="ntrb-20210731.xsd#ntrb_BusinessAcquisitionNetProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionofBusinessDetailsLineItems" xlink:to="BusinessAcquisitionNetProfit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" xlink:href="ntrb-20210731.xsd#ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/NotesPayableConvertibleDebtDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableConvertibleDebtDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_NotesPayableConvertibleDebtDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotesPayableConvertibleDebtDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_NotesPayableConvertibleDebtDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotesPayableConvertibleDebtDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyPayableMember" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefOperatingOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsTable" xlink:to="NotesPayableConvertibleDebtDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="NotePayablesDescription" xlink:href="ntrb-20210731.xsd#ntrb_NotePayablesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="NotePayablesDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvances" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalHomeLoanBankAdvances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_FederalHomeLoanBankAdvances" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromLoanOriginationsTotal" xlink:href="ntrb-20210731.xsd#ntrb_ProceedsFromLoanOriginationsTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="ProceedsFromLoanOriginationsTotal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityAnnualPrincipalPayment" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableConvertibleDebtDescription" xlink:href="ntrb-20210731.xsd#ntrb_NotePayableConvertibleDebtDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="NotePayableConvertibleDebtDescription" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfConversionPrice" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="FairValueOfConversionPrice" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DiscountRemainingAmount" xlink:href="ntrb-20210731.xsd#ntrb_DiscountRemainingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="DiscountRemainingAmount" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentFee" xlink:href="ntrb-20210731.xsd#ntrb_PrepaymentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="PrepaymentFee" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositLiabilitiesAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeLiabilitiesTotal" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="DerivativeLiabilitiesTotal" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpensesDebt" xlink:href="ntrb-20210731.xsd#ntrb_InterestExpensesDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="InterestExpensesDebt" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfDebtDiscountsPremium" xlink:href="ntrb-20210731.xsd#ntrb_AmortizationOfDebtDiscountsPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="AmortizationOfDebtDiscountsPremium" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnExtinguishmentOfDebt" xlink:href="ntrb-20210731.xsd#ntrb_GainOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="GainOnExtinguishmentOfDebt" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToRelatedPartyCurrentAndNoncurrent" xlink:href="ntrb-20210731.xsd#ntrb_DueToRelatedPartyCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="DueToRelatedPartyCurrentAndNoncurrent" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseDebts" xlink:href="ntrb-20210731.xsd#ntrb_InterestExpenseDebts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="InterestExpenseDebts" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableConvertibleDebtDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_IntangibleAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="IntangibleAssetsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="amortizedOverPeriod" xlink:href="ntrb-20210731.xsd#ntrb_amortizedOverPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="amortizedOverPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForInitialLicenseFee" xlink:href="ntrb-20210731.xsd#ntrb_PaymentForInitialLicenseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="PaymentForInitialLicenseFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/DerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="DerivativeLiabilitiesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DerivativeLiabilitiesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_DerivativeLiabilitiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="DerivativeLiabilitiesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilitiesDetailsTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RevaluedMember" xlink:href="ntrb-20210731.xsd#ntrb_RevaluedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="RevaluedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilitiesDetailsTable" xlink:to="DerivativeLiabilitiesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionsWeightedAverageVolatilityRates" xlink:href="ntrb-20210731.xsd#ntrb_FairValueAssumptionsWeightedAverageVolatilityRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilitiesDetailsLineItems" xlink:to="FairValueAssumptionsWeightedAverageVolatilityRates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionsRiskFreeInterestRates" xlink:href="ntrb-20210731.xsd#ntrb_FairValueAssumptionsRiskFreeInterestRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilitiesDetailsLineItems" xlink:to="FairValueAssumptionsRiskFreeInterestRates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedTerm" xlink:href="ntrb-20210731.xsd#ntrb_ExpectedTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilitiesDetailsLineItems" xlink:to="ExpectedTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedTerms" xlink:href="ntrb-20210731.xsd#ntrb_ExpectedTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilitiesDetailsLineItems" xlink:to="ExpectedTerms" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilitiesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FormerIndependentDirectorsMember" xlink:href="ntrb-20210731.xsd#ntrb_FormerIndependentDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="FormerIndependentDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PoconoCoatedProductsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_PoconoCoatedProductsLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PoconoCoatedProductsLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfWarrantExpense" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfWarrantExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="FairValueOfWarrantExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalTransactionsRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrincipalTransactionsRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PrincipalTransactionsRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfMaterials" xlink:href="ntrb-20210731.xsd#ntrb_PurchaseOfMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="PurchaseOfMaterials" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpensesPaid" xlink:href="ntrb-20210731.xsd#ntrb_ExpensesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ExpensesPaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionDescriptionOfTransactions" xlink:href="ntrb-20210731.xsd#ntrb_RelatedPartyTransactionDescriptionOfTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="RelatedPartyTransactionDescriptionOfTransactions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssued" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="CommonStockIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssued1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConsultingServicesMember" xlink:href="ntrb-20210731.xsd#ntrb_ConsultingServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ConsultingServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BPMMember" xlink:href="ntrb-20210731.xsd#ntrb_BPMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BPMMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PoconoCoatedProductsLLCMember" xlink:href="ntrb-20210731.xsd#ntrb_PoconoCoatedProductsLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="PoconoCoatedProductsLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BPMMember_0" xlink:href="ntrb-20210731.xsd#ntrb_BPMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BPMMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingServicesMember_0" xlink:href="ntrb-20210731.xsd#ntrb_ConsultingServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ConsultingServicesMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityDetailsLineItems" order="8.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DesignatedSharesOfPreferredStocks" xlink:href="ntrb-20210731.xsd#ntrb_DesignatedSharesOfPreferredStocks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="DesignatedSharesOfPreferredStocks" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockOfDescription" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockOfDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockOfDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreasedInAuthorizedCommonStock" xlink:href="ntrb-20210731.xsd#ntrb_IncreaseDecreasedInAuthorizedCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="IncreaseDecreasedInAuthorizedCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacement" xlink:href="ntrb-20210731.xsd#ntrb_PrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PrivatePlacement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOfCommonStockShare" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsToPurchaseOfCommonStockShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseOfCommonStockShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentWarrantExercisePrice" xlink:href="ntrb-20210731.xsd#ntrb_InvestmentWarrantExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="InvestmentWarrantExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOfCommonStockShares" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsToPurchaseOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseOfCommonStockShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromInterestReceived" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockShareSubscribedButUnissuedSubscriptionsShares" xlink:href="ntrb-20210731.xsd#ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockShareSubscribedButUnissuedSubscriptionsShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesWereRestored" xlink:href="ntrb-20210731.xsd#ntrb_SharesWereRestored"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="SharesWereRestored" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfTheCommonStocks" xlink:href="ntrb-20210731.xsd#ntrb_FairValueOfTheCommonStocks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="FairValueOfTheCommonStocks" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionPayable" xlink:href="ntrb-20210731.xsd#ntrb_SubscriptionPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="SubscriptionPayable" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForInitialLicenseFee" xlink:href="ntrb-20210731.xsd#ntrb_PaymentForInitialLicenseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PaymentForInitialLicenseFee" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FundReceived" xlink:href="ntrb-20210731.xsd#ntrb_FundReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="FundReceived" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/WarrantsandOptionsDetails">
    <loc xlink:type="locator" xlink:label="WarrantsAndOptionsAbstract" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsAndOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsandOptionsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_WarrantsandOptionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndOptionsAbstract" xlink:to="WarrantsandOptionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsTable" xlink:to="WarrantsandOptionsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" xlink:href="ntrb-20210731.xsd#ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingPricePercentage" xlink:href="ntrb-20210731.xsd#ntrb_InitialPublicOfferingPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsLineItems" xlink:to="InitialPublicOfferingPricePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassOfWarrantsFromLiabilityToEquity" xlink:href="ntrb-20210731.xsd#ntrb_ReclassOfWarrantsFromLiabilityToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsandOptionsDetailsLineItems" xlink:to="ReclassOfWarrantsFromLiabilityToEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="MonthlyRent" xlink:href="ntrb-20210731.xsd#ntrb_MonthlyRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="MonthlyRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/CommitmentsandContigenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContigenciesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_CommitmentsandContigenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContigenciesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_CommitmentsandContigenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContigenciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DefendantMember" xlink:href="ntrb-20210731.xsd#ntrb_DefendantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="DefendantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PresidentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_PresidentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HealthsBrandsIncMember" xlink:href="ntrb-20210731.xsd#ntrb_HealthsBrandsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HealthsBrandsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockPurchaseAgreementMember" xlink:href="ntrb-20210731.xsd#ntrb_StockPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="StockPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsTable" xlink:to="CommitmentsandContigenciesDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalaryPayment" xlink:href="ntrb-20210731.xsd#ntrb_SalaryPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="SalaryPayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOrPrivateFinancing" xlink:href="ntrb-20210731.xsd#ntrb_PublicOrPrivateFinancing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="PublicOrPrivateFinancing" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForInitialLicenseFee" xlink:href="ntrb-20210731.xsd#ntrb_PaymentForInitialLicenseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="PaymentForInitialLicenseFee" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_OtherCommitmentsDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContigenciesDetailsLineItems" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ntrb-20210731.xsd#ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="InventoryRawMaterialsPercentage" xlink:href="ntrb-20210731.xsd#ntrb_InventoryRawMaterialsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="InventoryRawMaterialsPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://nutriband.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="ntrb-20210731.xsd#ntrb_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>ea148206-s1a2_nutriband_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ntrb="http://nutriband.com/20210731"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ntrb-20210731.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ntrb:SubscriptionPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:TherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-25</startDate>
            <endDate>2018-08-01</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:ThreeCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:TwoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:TwoCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:TwoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-22</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-21</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-30</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-06</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">ntrb:RevaluedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2019-02-02</startDate>
            <endDate>2019-02-19</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:PoconoCoatedProductsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ntrb:FormerIndependentDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2016-01-15</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-02</startDate>
            <endDate>2019-05-24</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-20</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-25</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-27</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-27</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-22</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:PoconoCoatedProductsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:BPMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:BPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-27</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ntrb:DefendantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:HealthsBrandsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-29</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-12-05</startDate>
            <endDate>2020-12-09</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ntrb:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-25</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:ActiveIntelligenceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-15</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ntrb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:RelatedPartyPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:RelatedPartyPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-21</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:RelatedPartyPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:PoconoCoatedProductsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-22</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:BPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:BPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:BPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ntrb:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2021-02-25</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-15</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-25</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ntrb:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentDescription contextRef="c0">AMENDMENT NO. 2</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0">Nutriband Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">true</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">151993</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">10181</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c1" decimals="0" unitRef="usd">109347</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" unitRef="usd">12833</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c1" decimals="0" unitRef="usd">52848</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="0" unitRef="usd">20167</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" unitRef="usd">314188</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">43181</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" unitRef="usd">1076626</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">111029</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="c1" decimals="0" unitRef="usd">7529875</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c2" decimals="0" unitRef="usd">1719235</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" unitRef="usd">9610</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c1" decimals="0" unitRef="usd">1006730</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c2" decimals="0" unitRef="usd">314700</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Assets contextRef="c1" decimals="0" unitRef="usd">9927419</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">2197755</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">940612</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">771931</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">928774</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" unitRef="usd">10050</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c1" decimals="0" unitRef="usd">86846</us-gaap:DeferredRevenueCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="c1" decimals="0" unitRef="usd">1402523</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="c2" decimals="0" unitRef="usd">29067</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c1" decimals="0" unitRef="usd">24740</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c1" decimals="0" unitRef="usd">113885</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="0" unitRef="usd">215000</us-gaap:NotesPayableCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c2" decimals="0" unitRef="usd">67500</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">2568606</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">2022322</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c1" decimals="0" unitRef="usd">150063</us-gaap:LongTermNotesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c1" decimals="0" unitRef="usd">96804</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="0" unitRef="usd">2815473</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" unitRef="usd">2022322</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c1" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c1" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c1" decimals="INF" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c1" decimals="INF" unitRef="shares">6256772</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">6256772</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">5441100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">5441100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" unitRef="usd">6257</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">5441</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" unitRef="usd">18871098</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">9072573</us-gaap:AdditionalPaidInCapital>
    <ntrb:SubscriptionPayables contextRef="c1" decimals="0" unitRef="usd">70000</ntrb:SubscriptionPayables>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" unitRef="usd">-304</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" unitRef="usd">-304</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" unitRef="usd">-11835105</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">-8902277</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">7111946</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">175433</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" unitRef="usd">9927419</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">2197755</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">943702</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">370647</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c4" decimals="0" unitRef="usd">582378</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c5" decimals="0" unitRef="usd">549107</us-gaap:CostOfRevenue>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="usd">2957269</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">1790980</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c4" decimals="0" unitRef="usd">3539647</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c5" decimals="0" unitRef="usd">2340087</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-2595945</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-1969440</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c4" decimals="0" unitRef="usd">-12500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AccretionExpense contextRef="c4" decimals="0" unitRef="usd">69131</us-gaap:AccretionExpense>
    <ntrb:GainOnForgivenessOfDebt contextRef="c4" decimals="0" unitRef="usd">3338</ntrb:GainOnForgivenessOfDebt>
    <us-gaap:OtherNonoperatingExpense contextRef="c5" decimals="0" unitRef="usd">767650</us-gaap:OtherNonoperatingExpense>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="c4" decimals="0" unitRef="usd">22096</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="c5" decimals="0" unitRef="usd">88876</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:InterestExpenseDebt contextRef="c4" decimals="0" unitRef="usd">280686</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c5" decimals="0" unitRef="usd">73413</us-gaap:InterestExpenseDebt>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c4" decimals="0" unitRef="usd">-336883</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="0" unitRef="usd">-752187</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">-2932828</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">-2721627</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-2932828</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-2721627</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c4" decimals="2" unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c5" decimals="2" unitRef="usdPershares">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c4" decimals="INF" unitRef="shares">5770944</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c5" decimals="INF" unitRef="shares">5423956</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c4" decimals="0" unitRef="usd">-2932828</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c5" decimals="0" unitRef="usd">-2721627</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c5" decimals="0" unitRef="usd">-252</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">-2932828</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">-2721879</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" unitRef="usd">2404612</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c10" decimals="INF" unitRef="shares">5423956</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" unitRef="usd">5424</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" unitRef="usd">8579890</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="0" unitRef="usd">-52</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="0" unitRef="usd">-6180650</us-gaap:StockholdersEquity>
    <ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices contextRef="c5" decimals="0" unitRef="usd">252700</ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices>
    <ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices contextRef="c16" decimals="0" unitRef="usd">252700</ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="0" unitRef="usd">240000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c15" decimals="INF" unitRef="shares">17144</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c15" decimals="0" unitRef="usd">17</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c16" decimals="0" unitRef="usd">239983</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c5" decimals="0" unitRef="usd">-252</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c17" decimals="0" unitRef="usd">-252</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-2721627</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="0" unitRef="usd">-2721627</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">175433</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c20" decimals="INF" unitRef="shares">5441100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">5441</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">9072573</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" unitRef="usd">-8902277</us-gaap:StockholdersEquity>
    <ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants contextRef="c4" decimals="0" unitRef="usd">515108</ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants>
    <ntrb:StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants contextRef="c25" decimals="INF" unitRef="shares">46828</ntrb:StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants>
    <ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants contextRef="c25" decimals="0" unitRef="usd">47</ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants>
    <ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants contextRef="c26" decimals="0" unitRef="usd">515061</ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c4" decimals="0" unitRef="usd">6085180</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c25" decimals="INF" unitRef="shares">608519</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c25" decimals="0" unitRef="usd">609</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c26" decimals="0" unitRef="usd">6084571</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c4" decimals="0" unitRef="usd">2004875</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c25" decimals="INF" unitRef="shares">135325</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c25" decimals="0" unitRef="usd">135</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c26" decimals="0" unitRef="usd">2004740</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity contextRef="c4" decimals="0" unitRef="usd">906678</ntrb:ReclassificationOfWarrantsFromLiabilityToEquity>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity contextRef="c26" decimals="0" unitRef="usd">906678</ntrb:ReclassificationOfWarrantsFromLiabilityToEquity>
    <ntrb:IssuanceOfCommonStockForNotePayable contextRef="c4" decimals="0" unitRef="usd">287500</ntrb:IssuanceOfCommonStockForNotePayable>
    <ntrb:IssuanceOfCommonStockForNotePayableinShares contextRef="c25" decimals="INF" unitRef="shares">25000</ntrb:IssuanceOfCommonStockForNotePayableinShares>
    <ntrb:IssuanceOfCommonStockForNotePayable contextRef="c25" decimals="0" unitRef="usd">25</ntrb:IssuanceOfCommonStockForNotePayable>
    <ntrb:IssuanceOfCommonStockForNotePayable contextRef="c26" decimals="0" unitRef="usd">287475</ntrb:IssuanceOfCommonStockForNotePayable>
    <ntrb:SubscrptionPayableForCash contextRef="c4" decimals="0" unitRef="usd">60000</ntrb:SubscrptionPayableForCash>
    <ntrb:SubscrptionPayableForCash contextRef="c29" decimals="0" unitRef="usd">60000</ntrb:SubscrptionPayableForCash>
    <ntrb:SubscrptionPayableForServices contextRef="c4" decimals="0" unitRef="usd">10000</ntrb:SubscrptionPayableForServices>
    <ntrb:SubscrptionPayableForServices contextRef="c29" decimals="0" unitRef="usd">10000</ntrb:SubscrptionPayableForServices>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-2932828</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c28" decimals="0" unitRef="usd">-2932828</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">7111946</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c30" decimals="INF" unitRef="shares">6256772</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">6257</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" unitRef="usd">18871098</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="0" unitRef="usd">-11835105</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="0" unitRef="usd">70000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-2932828</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-2721627</us-gaap:NetIncomeLoss>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c4" decimals="0" unitRef="usd">12627</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c5" decimals="0" unitRef="usd">23817</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="0" unitRef="usd">160108</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="0" unitRef="usd">72188</us-gaap:DepreciationDepletionAndAmortization>
    <ntrb:IncreaseDecreaseInDerivativeExpense contextRef="c5" decimals="0" unitRef="usd">767650</ntrb:IncreaseDecreaseInDerivativeExpense>
    <ntrb:EarlyPrepaymentFeeOnConvertibleDebentures contextRef="c4" decimals="0" unitRef="usd">69131</ntrb:EarlyPrepaymentFeeOnConvertibleDebentures>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c4" decimals="0" unitRef="usd">-12500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <ntrb:GainOnForgivenessOfLoanPayment contextRef="c4" decimals="0" unitRef="usd">3338</ntrb:GainOnForgivenessOfLoanPayment>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c4" decimals="0" unitRef="usd">22096</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c5" decimals="0" unitRef="usd">88876</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c4" decimals="0" unitRef="usd">272130</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c5" decimals="0" unitRef="usd">67500</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfLeasedAsset contextRef="c4" decimals="0" unitRef="usd">9610</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:AmortizationOfLeasedAsset contextRef="c5" decimals="0" unitRef="usd">19217</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">2004875</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">252700</us-gaap:ShareBasedCompensation>
    <ntrb:SubscriptionPayable contextRef="c4" decimals="0" unitRef="usd">-10000</ntrb:SubscriptionPayable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c4" decimals="0" unitRef="usd">94753</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" unitRef="usd">-255</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c4" decimals="0" unitRef="usd">-20167</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c5" decimals="0" unitRef="usd">-82558</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c4" decimals="0" unitRef="usd">10235</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInCustomerDeposits contextRef="c4" decimals="0" unitRef="usd">59995</us-gaap:IncreaseDecreaseInCustomerDeposits>
    <us-gaap:IncreaseDecreaseInCustomerDeposits contextRef="c5" decimals="0" unitRef="usd">-71225</us-gaap:IncreaseDecreaseInCustomerDeposits>
    <ntrb:IncreaseDecreaseOperatingLeaseLiability contextRef="c4" decimals="0" unitRef="usd">10050</ntrb:IncreaseDecreaseOperatingLeaseLiability>
    <ntrb:IncreaseDecreaseOperatingLeaseLiability contextRef="c5" decimals="0" unitRef="usd">18777</ntrb:IncreaseDecreaseOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="0" unitRef="usd">145102</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" unitRef="usd">720150</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="usd">-297055</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">-894470</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c4" decimals="0" unitRef="usd">66994</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="0" unitRef="usd">66994</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c4" decimals="0" unitRef="usd">515108</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c4" decimals="0" unitRef="usd">194870</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c5" decimals="0" unitRef="usd">175000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c5" decimals="0" unitRef="usd">250000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromOtherEquity contextRef="c4" decimals="0" unitRef="usd">60000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c4" decimals="0" unitRef="usd">8935</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfDebt contextRef="c4" decimals="0" unitRef="usd">339131</us-gaap:RepaymentsOfDebt>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c4" decimals="0" unitRef="usd">8345</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c4" decimals="0" unitRef="usd">5500</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c5" decimals="0" unitRef="usd">34980</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c4" decimals="0" unitRef="usd">47194</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c5" decimals="0" unitRef="usd">29730</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="0" unitRef="usd">371873</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">430250</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c5" decimals="0" unitRef="usd">-252</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="0" unitRef="usd">141812</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">-464472</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">10181</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c9" decimals="0" unitRef="usd">474653</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">151993</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">10181</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="0" unitRef="usd">11555</us-gaap:InterestPaidNet>
    <ntrb:CommonStockAndNoteIssuedInAcquisitions contextRef="c4" decimals="0" unitRef="usd">7418073</ntrb:CommonStockAndNoteIssuedInAcquisitions>
    <ntrb:AdoptionOfASC842OperatingLeaseAssetAndLiability contextRef="c5" decimals="0" unitRef="usd">28827</ntrb:AdoptionOfASC842OperatingLeaseAssetAndLiability>
    <ntrb:DerivativeLiabilityWarrantReclassedToEquity contextRef="c4" decimals="0" unitRef="usd">906678</ntrb:DerivativeLiabilityWarrantReclassedToEquity>
    <ntrb:DebtDiscountOnConvertibleNotes contextRef="c5" decimals="0" unitRef="usd">270000</ntrb:DebtDiscountOnConvertibleNotes>
    <ntrb:CommonStockIssuedForAccountsPayable contextRef="c5" decimals="0" unitRef="usd">240000</ntrb:CommonStockIssuedForAccountsPayable>
    <ntrb:CommonStockIssuedForSettlement contextRef="c4" decimals="0" unitRef="usd">287500</ntrb:CommonStockIssuedForSettlement>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Nutriband Inc. (the &#x201c;Company&#x201d;)
is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which
was formed by the Company&#x2019;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 1, 2018, the Company acquired
4P Therapeutics LLC (&#x201c;4P Therapeutics&#x201d;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000,
and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been
developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of
the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#x2019;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#x201c;FDA&#x201d;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;With the acquisition of 4P Therapeutics,
4P Therapeutics&#x2019; drug development business became the Company&#x2019;s principal business. The Company&#x2019;s approach is to use
generic drugs that are off patent and incorporate them into the Company&#x2019;s transdermal drug delivery system. Although these medications
have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will
include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical
products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 25, 2020, the Company formed
Pocono Pharmaceuticals Inc. (&#x201c;Pocono Pharmaceuticals&#x201d;), a wholly owned subsidiary of the Company. On August 31, 2020, the
Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono
Coated Products LLC (&#x201c;PCP&#x201d;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company
also acquired 100% of the membership interests of Active Intelligence LLC (&#x201c;Active Intelligence&#x201d;). See Note 2 for further
details of the acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Pocono Pharmaceuticals is a coated products
manufacturing entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product
design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#x2019;s
competitive edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is the same as traditional kinesiology
tape.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In December 2019, COVID-19 emerged and
has subsequently spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local
governments and private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay
at home orders and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed
quarantines and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business
and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Reverse Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 25, 2019, the Company effected
one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock. The
reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements
retroactively reflect the reverse split.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Going Concern&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of January 31, 2021, the Company
believes the substantial doubt about going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current year net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to alleviate
the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses, equity
funding that has been received and the net revenue and positive cash flow from its recent acquisition. These factors did not exist in
prior years during its start-up operations. The Company&#x2019;s recent history of losses has changed from prior periods due to its current
management&#x2019;s plans including its acquisition in the latter part of 2020 to alleviate the substantial doubt about the Company&#x2019;s
ability to continue as a going concern. Management&#x2019;s plans have been currently implemented. The plans enable the Company to meet
its obligations for at least one year from the date when the financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The consolidated financial statements
of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated.
The operations of 4P Therapeutics are included in the Company&#x2019;s financial statements from the date of acquisition of August 1, 2018
and the operations of Pocono and Active Intelligence are included in the Company&#x2019;s financial statements from the date of acquisition
of September 1, 2020. The wholly owned subsidiaries are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Nutriband Ltd.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;4P Therapeutics LLC&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pocono Pharmaceuticals Inc.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related&#160;disclosure
of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related
to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Cash equivalents include short-term
investments in money-market funds and certificate of deposits with an original maturity of three months or less when purchased.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The functional currency of the Company&#x2019;s
Irish subsidiary is the Euro. The assets and liabilities of the subsidiary are translated into US dollars using the prevailing exchange
rate as of the balance sheet date and income and expenses are translated into US dollars using the average exchange rate during the reporting
period. Translation adjustments are recorded in other comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In May 2014, the FASB issued ASU No.
2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606) (&#x201c;ASU 2014-09&#x201d;), which amends the accounting standards for
revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled
when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Types&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following is a description of the
Company&#x2019;s revenue types, which include professional services and sale of goods:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 96px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Service revenues include the contract of research and development related services with the Company&#x2019;s clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Product revenues are derived from the sale of the Company&#x2019;s consumer transdermal and coated products. Upon the reception of a purchase order, we have the order filled and shipped.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A contract with a customer exists when
(i) we enter into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be
transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii)
we determine that collection of substantially all consideration for services that are transferred is probable based on the customer&#x2019;s
intent and ability to pay the promised consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Deferred Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Deferred revenue is a liability related
to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration
from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Performance Obligations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A performance obligation is a promise
in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract
transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation
is satisfied. For the Company&#x2019;s different revenue service types, the performance obligation is satisfied at different times. The
Company&#x2019;s performance obligations include providing products and professional services in the area of research. The Company recognizes
product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service
work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on
a monthly basis for the work performed during that month.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;All revenue recognized in the income
statement is considered to be revenue from contracts with customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company disaggregates its revenue
from contracts with customers by type and by geographical location. See the tables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended &lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by type&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Sale of goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;737,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;124,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;206,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;245,679&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;370,637&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended &lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by geographical location&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;360,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;245,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;583,324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124,958&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;370,637&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Trade accounts receivable are recorded
at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from
the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer
accounts where appropriate and the application of historical loss to non-specific accounts. For the years ended January 31, 2021 and 2020,
the Company recorded no bad debt expense and no allowance for doubtful accounts related to accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Inventories are valued at the lower
of cost and realizable value determined using the first-in, first-out (FIFO) method. Net realizable value is the estimated selling price
in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in progress is comprised
of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Property and equipment represent an
important component of the Company&#x2019;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated
useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and
replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements
are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range
from 3 to 10 years as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Lab Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-20 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Intangible assets include trademarks,
intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under
the guidance of ASC 350, &#x201c;Intangibles-Goodwill and Other.&#x201d; The Company capitalizes certain costs related to patent technology.
A substantial component of the purchase price related to the Company&#x2019;s acquisition has also been assigned to intellectual property
and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives.
Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being
amortized over their estimated useful lives of ten years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Goodwill represents the difference between
the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is
reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which
the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August
31, 2020, in connection with the Company&#x2019;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $5,810,640. As of January 31, 2021, Goodwill amounted to $7,529,875.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Long-lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Management reviews long-lived assets
for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The
carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result
from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between
fair market value of the long-lived asset and the related net book value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;ASC 718, &#x201c;Compensation - Stock
Compensation,&#x201d; prescribes accounting and reporting standards for all share-based payment transactions in which employee services,
and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue
shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments
to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on
their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for
the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718
was applied to stock-based compensation for both employees and non-employees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Business Combinations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company recognizes the assets acquired,
the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values
as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related
costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That
replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated
to the individual assets acquired and liabilities assumed based on their estimated fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In February 2016, the FASB issued ASU
2016-02, &#x201c;Leases&#x201d; (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and
lessors should apply a &#x201c;right-of-use&#x201d; model in accounting for all leases (including subleases) and eliminate the concept of
operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as
a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company adopted ASU 2016-02 as amended
effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize
the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under
ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates
the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company
completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Research and developments costs are
expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Taxes are calculated in accordance with
taxation principles currently effective in the United States and Ireland.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company accounts for income taxes
under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are
determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company records net deferred tax
assets to the extent they believe these assets will more-likely-than-not be realized. In making such determination, the Company considers
all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable
income, tax planning strategies and recent financial operations. In the event the Company was to determine that it would be able to realize
its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation
allowance which would reduce the provision for income taxes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Financial instruments which potentially
subject the Company to concentrations of credit risk consist principally of cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company&#x2019;s cash and cash equivalents
are concentrated primarily in banks. At times, such deposits could be in excess of insured limits. Management believes that the financial
institutions that hold the Company&#x2019;s financial instruments are financially sound and, accordingly, minimal credit risk is believed
to exist with respect to these financial instruments. As of and for the year ended January 31, 2020, three customers accounted for 100%
of the Company&#x2019;s revenues and two customers accounted for 100% of accounts receivable. As of and for the year ended January 31,
2021, one customer accounted for 62% of the Company&#x2019;s revenues and two customers accounted for 67% and 13% of accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Earnings Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Basic earnings per share of common stock
is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings
per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common
stock outstanding during the period.&#160;Potential shares of common stock consist of outstanding common stock purchase warrants. For
the years ended January 31, 2021 and 2020 there were 141,830 and 70,000 potential shares of common stock that were not included in the
calculation of diluted earnings per share as their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;FASB ASC 820, &#x201c;Fair Value Measurements
and Disclosure&#x201d; (&#x201c;ASC 820&#x201d;), defines fair value as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs
that may be to measure fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company utilizes the accounting
guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities
that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.
The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier
value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 -&#160;Observable inputs such
as quoted market prices in active markets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 -&#160;Inputs other than quoted
prices in active markets that are either directly or indirectly observable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 -&#160;Unobservable inputs
about which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The carrying value of the Company&#x2019;s
financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their
fair value due to the short maturities of these financial instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Derivative liabilities are determined
based on &#x201c;Level 3&#x201d; inputs, which are significant and unobservable and have the lowest priority. The recorded values of all
other financial instruments approximate their current fair value because of their nature and respective short maturity dates or durations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Derivative Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company accounts for derivative
instruments in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; and all derivative instruments are reflected as either
assets or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments.
Fair value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market
participants. In general, the Company&#x2019;s policy in estimating fair values is to first look at observable market prices for identical
assets and liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such
as prices of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable
data from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of January 31, 2021, and 2020, the Company had a $-0-
and $928,774 derivative liability, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Fair value estimates are made at a specific
point in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve
uncertainties and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly
affect the estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In August 2018, the FASB issued ASU
2018-13, &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements&#x201d;. The updated
guidance improves the disclosure requirements on fair value measurement. The updated guidance is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. The Company adopted the provisions effective February 1, 2020. The
adoption did not have a material impact on the Company&#x2019;s consolidated financial position or consolidated results of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In December 2019, the FASB issued ASU
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which modifies ASC 740 to reduce complexity while maintaining
or improving the usefulness of the information provided to the users of financial statements. ASU 209-12 is effective for annual reporting
periods beginning after December 15, 2021. The Company is currently assessing the impact of ASU 209-12, but it is not expected to have
a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company has reviewed all other FASB-issued
ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods.
The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles
will have a material impact on the company&#x2019;s reported financial position or operations in the near term. The applicability of any
standard is subject to the formal review of the Company&#x2019;s financial management and certain standards are under consideration.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ntrb:OrganizationPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Nutriband Inc. (the &#x201c;Company&#x201d;)
is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which
was formed by the Company&#x2019;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 1, 2018, the Company acquired
4P Therapeutics LLC (&#x201c;4P Therapeutics&#x201d;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000,
and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been
developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of
the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#x2019;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#x201c;FDA&#x201d;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;With the acquisition of 4P Therapeutics,
4P Therapeutics&#x2019; drug development business became the Company&#x2019;s principal business. The Company&#x2019;s approach is to use
generic drugs that are off patent and incorporate them into the Company&#x2019;s transdermal drug delivery system. Although these medications
have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will
include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical
products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 25, 2020, the Company formed
Pocono Pharmaceuticals Inc. (&#x201c;Pocono Pharmaceuticals&#x201d;), a wholly owned subsidiary of the Company. On August 31, 2020, the
Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono
Coated Products LLC (&#x201c;PCP&#x201d;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company
also acquired 100% of the membership interests of Active Intelligence LLC (&#x201c;Active Intelligence&#x201d;). See Note 2 for further
details of the acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Pocono Pharmaceuticals is a coated products
manufacturing entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product
design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#x2019;s
competitive edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is the same as traditional kinesiology
tape.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In December 2019, COVID-19 emerged and
has subsequently spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local
governments and private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay
at home orders and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed
quarantines and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business
and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:OrganizationPolicyTextBlock>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="c78">the Company acquired
4P Therapeutics LLC (&#x201c;4P Therapeutics&#x201d;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000,
and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been
developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of
the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <ntrb:ReverseStockSplitPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Reverse Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 25, 2019, the Company effected
one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock. The
reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements
retroactively reflect the reverse split.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:ReverseStockSplitPolicyTextBlock>
    <us-gaap:SharesIssuedPricePerShare contextRef="c79" decimals="2" unitRef="usdPershares">0.25</us-gaap:SharesIssuedPricePerShare>
    <ntrb:GoingConcernPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Going Concern&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of January 31, 2021, the Company
believes the substantial doubt about going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current year net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to alleviate
the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses, equity
funding that has been received and the net revenue and positive cash flow from its recent acquisition. These factors did not exist in
prior years during its start-up operations. The Company&#x2019;s recent history of losses has changed from prior periods due to its current
management&#x2019;s plans including its acquisition in the latter part of 2020 to alleviate the substantial doubt about the Company&#x2019;s
ability to continue as a going concern. Management&#x2019;s plans have been currently implemented. The plans enable the Company to meet
its obligations for at least one year from the date when the financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:GoingConcernPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The consolidated financial statements
of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated.
The operations of 4P Therapeutics are included in the Company&#x2019;s financial statements from the date of acquisition of August 1, 2018
and the operations of Pocono and Active Intelligence are included in the Company&#x2019;s financial statements from the date of acquisition
of September 1, 2020. The wholly owned subsidiaries are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Nutriband Ltd.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;4P Therapeutics LLC&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pocono Pharmaceuticals Inc.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related&#160;disclosure
of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related
to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Cash equivalents include short-term
investments in money-market funds and certificate of deposits with an original maturity of three months or less when purchased.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The functional currency of the Company&#x2019;s
Irish subsidiary is the Euro. The assets and liabilities of the subsidiary are translated into US dollars using the prevailing exchange
rate as of the balance sheet date and income and expenses are translated into US dollars using the average exchange rate during the reporting
period. Translation adjustments are recorded in other comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In May 2014, the FASB issued ASU No.
2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606) (&#x201c;ASU 2014-09&#x201d;), which amends the accounting standards for
revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled
when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Types&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following is a description of the
Company&#x2019;s revenue types, which include professional services and sale of goods:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 96px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Service revenues include the contract of research and development related services with the Company&#x2019;s clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Product revenues are derived from the sale of the Company&#x2019;s consumer transdermal and coated products. Upon the reception of a purchase order, we have the order filled and shipped.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A contract with a customer exists when
(i) we enter into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be
transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii)
we determine that collection of substantially all consideration for services that are transferred is probable based on the customer&#x2019;s
intent and ability to pay the promised consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueRecognitionDeferredRevenue contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Deferred Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Deferred revenue is a liability related
to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration
from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
    <ntrb:PerformanceObligationsPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Performance Obligations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A performance obligation is a promise
in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract
transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation
is satisfied. For the Company&#x2019;s different revenue service types, the performance obligation is satisfied at different times. The
Company&#x2019;s performance obligations include providing products and professional services in the area of research. The Company recognizes
product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service
work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on
a monthly basis for the work performed during that month.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;All revenue recognized in the income
statement is considered to be revenue from contracts with customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:PerformanceObligationsPolicyTextBlock>
    <ntrb:DisaggregationOfRevenuesPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company disaggregates its revenue
from contracts with customers by type and by geographical location. See the tables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended &lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by type&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Sale of goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;737,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;124,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;206,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;245,679&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;370,637&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended &lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by geographical location&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;360,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;245,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;583,324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124,958&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;370,637&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:DisaggregationOfRevenuesPolicyTextBlock>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended &lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by type&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Sale of goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;737,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;124,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;206,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;245,679&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;370,637&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <ntrb:SalesRevenuesGoodsNet contextRef="c4" decimals="0" unitRef="usd">737519</ntrb:SalesRevenuesGoodsNet>
    <ntrb:SalesRevenuesGoodsNet contextRef="c5" decimals="0" unitRef="usd">124958</ntrb:SalesRevenuesGoodsNet>
    <ntrb:SaleOfGoodsAndServices contextRef="c4" decimals="0" unitRef="usd">206183</ntrb:SaleOfGoodsAndServices>
    <ntrb:SaleOfGoodsAndServices contextRef="c5" decimals="0" unitRef="usd">245679</ntrb:SaleOfGoodsAndServices>
    <ntrb:DisaggregationOfRevenues contextRef="c4" decimals="0" unitRef="usd">943702</ntrb:DisaggregationOfRevenues>
    <ntrb:DisaggregationOfRevenues contextRef="c5" decimals="0" unitRef="usd">370637</ntrb:DisaggregationOfRevenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended &lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by geographical location&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;360,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;245,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;583,324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124,958&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;370,637&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <ntrb:DisaggregationOfRevenues contextRef="c88" decimals="0" unitRef="usd">360378</ntrb:DisaggregationOfRevenues>
    <ntrb:DisaggregationOfRevenues contextRef="c89" decimals="0" unitRef="usd">245679</ntrb:DisaggregationOfRevenues>
    <ntrb:DisaggregationOfRevenues contextRef="c90" decimals="0" unitRef="usd">583324</ntrb:DisaggregationOfRevenues>
    <ntrb:DisaggregationOfRevenues contextRef="c91" decimals="0" unitRef="usd">124958</ntrb:DisaggregationOfRevenues>
    <ntrb:DisaggregationOfRevenues contextRef="c4" decimals="0" unitRef="usd">943702</ntrb:DisaggregationOfRevenues>
    <ntrb:DisaggregationOfRevenues contextRef="c5" decimals="0" unitRef="usd">370637</ntrb:DisaggregationOfRevenues>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Trade accounts receivable are recorded
at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from
the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer
accounts where appropriate and the application of historical loss to non-specific accounts. For the years ended January 31, 2021 and 2020,
the Company recorded no bad debt expense and no allowance for doubtful accounts related to accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Inventories are valued at the lower
of cost and realizable value determined using the first-in, first-out (FIFO) method. Net realizable value is the estimated selling price
in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in progress is comprised
of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Property and equipment represent an
important component of the Company&#x2019;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated
useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and
replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements
are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range
from 3 to 10 years as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Lab Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-20 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <ntrb:PropertyPlantAndEquipmentsUsefulLife contextRef="c80">P3Y</ntrb:PropertyPlantAndEquipmentsUsefulLife>
    <ntrb:PropertyPlantAndEquipmentsUsefulLife contextRef="c81">P10Y</ntrb:PropertyPlantAndEquipmentsUsefulLife>
    <ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Lab Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-20 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife contextRef="c92">P5Y</us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife contextRef="c93">P10Y</us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife contextRef="c94">P3Y</us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife contextRef="c95">P10Y</us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife contextRef="c96">P20Y</us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Intangible assets include trademarks,
intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under
the guidance of ASC 350, &#x201c;Intangibles-Goodwill and Other.&#x201d; The Company capitalizes certain costs related to patent technology.
A substantial component of the purchase price related to the Company&#x2019;s acquisition has also been assigned to intellectual property
and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives.
Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being
amortized over their estimated useful lives of ten years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Goodwill represents the difference between
the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is
reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which
the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August
31, 2020, in connection with the Company&#x2019;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $5,810,640. As of January 31, 2021, Goodwill amounted to $7,529,875.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:Goodwill contextRef="c82" decimals="0" unitRef="usd">5810640</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c1" decimals="0" unitRef="usd">7529875</us-gaap:Goodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Long-lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Management reviews long-lived assets
for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The
carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result
from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between
fair market value of the long-lived asset and the related net book value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;ASC 718, &#x201c;Compensation - Stock
Compensation,&#x201d; prescribes accounting and reporting standards for all share-based payment transactions in which employee services,
and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue
shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments
to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on
their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for
the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718
was applied to stock-based compensation for both employees and non-employees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:BusinessCombinationsPolicy contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Business Combinations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company recognizes the assets acquired,
the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values
as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related
costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That
replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated
to the individual assets acquired and liabilities assumed based on their estimated fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In February 2016, the FASB issued ASU
2016-02, &#x201c;Leases&#x201d; (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and
lessors should apply a &#x201c;right-of-use&#x201d; model in accounting for all leases (including subleases) and eliminate the concept of
operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as
a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company adopted ASU 2016-02 as amended
effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize
the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under
ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates
the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company
completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Research and developments costs are
expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Taxes are calculated in accordance with
taxation principles currently effective in the United States and Ireland.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company accounts for income taxes
under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are
determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company records net deferred tax
assets to the extent they believe these assets will more-likely-than-not be realized. In making such determination, the Company considers
all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable
income, tax planning strategies and recent financial operations. In the event the Company was to determine that it would be able to realize
its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation
allowance which would reduce the provision for income taxes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Financial instruments which potentially
subject the Company to concentrations of credit risk consist principally of cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company&#x2019;s cash and cash equivalents
are concentrated primarily in banks. At times, such deposits could be in excess of insured limits. Management believes that the financial
institutions that hold the Company&#x2019;s financial instruments are financially sound and, accordingly, minimal credit risk is believed
to exist with respect to these financial instruments. As of and for the year ended January 31, 2020, three customers accounted for 100%
of the Company&#x2019;s revenues and two customers accounted for 100% of accounts receivable. As of and for the year ended January 31,
2021, one customer accounted for 62% of the Company&#x2019;s revenues and two customers accounted for 67% and 13% of accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <ntrb:ConcentrationRiskPercentage contextRef="c83" decimals="2" unitRef="pure">1</ntrb:ConcentrationRiskPercentage>
    <ntrb:ConcentrationRiskPercentage contextRef="c84" decimals="2" unitRef="pure">1</ntrb:ConcentrationRiskPercentage>
    <ntrb:ConcentrationRiskPercentage contextRef="c85" decimals="2" unitRef="pure">0.62</ntrb:ConcentrationRiskPercentage>
    <ntrb:ConcentrationRiskPercentage contextRef="c86" decimals="2" unitRef="pure">0.67</ntrb:ConcentrationRiskPercentage>
    <ntrb:ConcentrationRiskPercentage contextRef="c87" decimals="2" unitRef="pure">0.13</ntrb:ConcentrationRiskPercentage>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Earnings Per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Basic earnings per share of common stock
is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings
per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common
stock outstanding during the period.&#160;Potential shares of common stock consist of outstanding common stock purchase warrants. For
the years ended January 31, 2021 and 2020 there were 141,830 and 70,000 potential shares of common stock that were not included in the
calculation of diluted earnings per share as their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c4" decimals="INF" unitRef="shares">141830</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c5" decimals="INF" unitRef="shares">70000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;FASB ASC 820, &#x201c;Fair Value Measurements
and Disclosure&#x201d; (&#x201c;ASC 820&#x201d;), defines fair value as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs
that may be to measure fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company utilizes the accounting
guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities
that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.
The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier
value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 -&#160;Observable inputs such
as quoted market prices in active markets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 -&#160;Inputs other than quoted
prices in active markets that are either directly or indirectly observable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 -&#160;Unobservable inputs
about which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The carrying value of the Company&#x2019;s
financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their
fair value due to the short maturities of these financial instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Derivative liabilities are determined
based on &#x201c;Level 3&#x201d; inputs, which are significant and unobservable and have the lowest priority. The recorded values of all
other financial instruments approximate their current fair value because of their nature and respective short maturity dates or durations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <ntrb:DerivativeLiabilitiesPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Derivative Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company accounts for derivative
instruments in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; and all derivative instruments are reflected as either
assets or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments.
Fair value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market
participants. In general, the Company&#x2019;s policy in estimating fair values is to first look at observable market prices for identical
assets and liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such
as prices of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable
data from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of January 31, 2021, and 2020, the Company had a $-0-
and $928,774 derivative liability, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Fair value estimates are made at a specific
point in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve
uncertainties and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly
affect the estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:DerivativeLiabilitiesPolicyTextBlock>
    <us-gaap:DerivativeLiabilities contextRef="c1" decimals="0" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c2" decimals="0" unitRef="usd">928774</us-gaap:DerivativeLiabilities>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c4">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In August 2018, the FASB issued ASU
2018-13, &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements&#x201d;. The updated
guidance improves the disclosure requirements on fair value measurement. The updated guidance is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. The Company adopted the provisions effective February 1, 2020. The
adoption did not have a material impact on the Company&#x2019;s consolidated financial position or consolidated results of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In December 2019, the FASB issued ASU
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which modifies ASC 740 to reduce complexity while maintaining
or improving the usefulness of the information provided to the users of financial statements. ASU 209-12 is effective for annual reporting
periods beginning after December 15, 2021. The Company is currently assessing the impact of ASU 209-12, but it is not expected to have
a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company has reviewed all other FASB-issued
ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods.
The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles
will have a material impact on the company&#x2019;s reported financial position or operations in the near term. The applicability of any
standard is subject to the formal review of the Company&#x2019;s financial management and certain standards are under consideration.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ACQUISITION OF BUSINESS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 31, 2020, the Company entered
into a Purchase Agreement (&#x201c;Agreement&#x201d;), with Pocono Coated Products (&#x201c;PCP&#x201d;), pursuant to which PCP agreed to
sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business,
including: (1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free
and clear of all liens, except for certain lease obligations, and (2), a 100% membership interest in Active Intelligence, LLC (collectively
the &#x201c;Assets&#x201d;). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary
of the Company. The purchase price for the Assets was (i) $6,085,180 paid with the issuance of 608,519 shares in the Company&#x2019;s common
stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the &#x201c;Shares&#x201d;), and (ii)
a promissory note of the Company, net of debt discount, in the principal amount, of $1,332,893 (the Note&#x201d;) which is due upon the
earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $4,000,000 and/or a public
offering of no less than $4,000,000. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period
of one year at the annual meeting of shareholders of the Company held in October 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Agreement provides that it is effective
August 31, 2020, on which date the parties also entered into an escrow agreement (the &#x201c;Escrow Agreement&#x201d;), with legal counsel
serving as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special
purpose subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also
entered into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The purpose of the Company entering
into the transaction is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated
to the net tangible assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and,
as such, the transaction was accounted for under the acquisition method of accounting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Details of the net assets acquired are
as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt; Recognized&lt;br/&gt; on&lt;br/&gt; Acquisition&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Common stock issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,085,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Note payable issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,332,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;66,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equipment and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Customer base&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intellectual property and trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,810,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Acounts payable and accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,104&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,851&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(268,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following unaudited pro forma condensed
financial information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and
Active Intelligence, as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed
financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would
have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation
of the future consolidated results of operations of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Proforma&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Proforma&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,369,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;370,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,993,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,932,828&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,001,178&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,766,627&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,732,727&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.51&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Since the date of acquisition, Pocono
and Active Intelligence had net revenues of $154,195 and incurred a net loss of $40,068.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired contextRef="c82" decimals="2" unitRef="pure">1</ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="c97" decimals="0" unitRef="usd">6085180</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c98" decimals="INF" unitRef="shares">608519</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <ntrb:DebtInstrumentAnnualPrincipalPayments contextRef="c82" decimals="0" unitRef="usd">1332893</ntrb:DebtInstrumentAnnualPrincipalPayments>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c99" decimals="0" unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c99" decimals="0" unitRef="usd">4000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <ntrb:AnnualMeetingOfShareholdersTerm contextRef="c100">P1Y</ntrb:AnnualMeetingOfShareholdersTerm>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt; Recognized&lt;br/&gt; on&lt;br/&gt; Acquisition&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Common stock issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,085,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Note payable issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,332,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;66,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equipment and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Customer base&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intellectual property and trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,810,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Acounts payable and accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,104&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,851&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(268,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <ntrb:BusinessAcquisitionCommonStockIssued contextRef="c5" decimals="0" unitRef="usd">6085180</ntrb:BusinessAcquisitionCommonStockIssued>
    <ntrb:NotePayableIssued contextRef="c5" decimals="0" unitRef="usd">1332893</ntrb:NotePayableIssued>
    <ntrb:CommonStockAndNoteIssuedInAcquisition contextRef="c5" decimals="0" unitRef="usd">7418073</ntrb:CommonStockAndNoteIssuedInAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c2" decimals="0" unitRef="usd">66994</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c2" decimals="0" unitRef="usd">1761</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c2" decimals="0" unitRef="usd">42613</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment contextRef="c2" decimals="0" unitRef="usd">1056935</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment>
    <ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase contextRef="c2" decimals="0" unitRef="usd">177600</ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase>
    <ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks contextRef="c2" decimals="0" unitRef="usd">583200</ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks>
    <us-gaap:GoodwillGross contextRef="c2" decimals="0" unitRef="usd">5810640</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c2" decimals="0" unitRef="usd">26104</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c2" decimals="0" unitRef="usd">26851</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c2" decimals="0" unitRef="usd">268715</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c2" decimals="0" unitRef="usd">7418073</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Proforma&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Proforma&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;943,702&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,369,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;370,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,993,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,932,828&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,001,178&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,766,627&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,732,727&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.51&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">943702</us-gaap:Revenues>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c4" decimals="0" unitRef="usd">1369761</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">370647</us-gaap:Revenues>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c5" decimals="0" unitRef="usd">1993472</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">-2932828</us-gaap:ProfitLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-3001178</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">-2766627</us-gaap:ProfitLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-2732727</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c4" decimals="2" unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareBasicAndDiluted>
    <ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic contextRef="c4" decimals="2" unitRef="usdPershares">0.52</ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c5" decimals="2" unitRef="usdPershares">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.45</ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic>
    <ntrb:BusinessAcquisitionRevenue contextRef="c4" decimals="0" unitRef="usd">154195</ntrb:BusinessAcquisitionRevenue>
    <ntrb:BusinessAcquisitionNetProfit contextRef="c4" decimals="0" unitRef="usd">40068</ntrb:BusinessAcquisitionNetProfit>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,053,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,221,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,076,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;111,029&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Depreciation expense amounted to $91,338
and $35,118 for the years ended January 31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,053,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,221,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,076,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;111,029&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <ntrb:PropertyPlantAndEquipmentsGross contextRef="c101" decimals="0" unitRef="usd">144585</ntrb:PropertyPlantAndEquipmentsGross>
    <ntrb:PropertyPlantAndEquipmentsGross contextRef="c102" decimals="0" unitRef="usd">144585</ntrb:PropertyPlantAndEquipmentsGross>
    <ntrb:PropertyPlantAndEquipmentsGross contextRef="c103" decimals="0" unitRef="usd">1053966</ntrb:PropertyPlantAndEquipmentsGross>
    <ntrb:PropertyPlantAndEquipmentsGross contextRef="c94" decimals="0" unitRef="usd">22612</ntrb:PropertyPlantAndEquipmentsGross>
    <ntrb:PropertyPlantAndEquipmentsGross contextRef="c105" decimals="0" unitRef="usd">19643</ntrb:PropertyPlantAndEquipmentsGross>
    <ntrb:PropertyPlantAndEquipmentsGross contextRef="c4" decimals="0" unitRef="usd">1221163</ntrb:PropertyPlantAndEquipmentsGross>
    <ntrb:PropertyPlantAndEquipmentsGross contextRef="c5" decimals="0" unitRef="usd">164228</ntrb:PropertyPlantAndEquipmentsGross>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c1" decimals="0" unitRef="usd">144537</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c2" decimals="0" unitRef="usd">53199</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" unitRef="usd">1076626</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">111029</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c4" decimals="0" unitRef="usd">91338</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">35118</us-gaap:Depreciation>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;INCOME TAXES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company adopted the provisions of
ASC 740, &#x201c;Income Taxes, (&#x201c;ASC 740&#x201d;). As a result of the implementation of ASC 740, the Company recognized no adjustment
in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all
tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize
the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will
also setup a liability for interest and penalties. The Company&#x2019;s policy is to recognize interest and penalties related to uncertain
tax positions as a component of the current provision for income taxes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;There is no U.S. tax provision due to
losses from U.S. operations for the years ended January 31, 2021 and 2020. Deferred income taxes are provided for the temporary differences
between the financial reporting and tax basis of the Company&#x2019;s assets and liabilities. The principal item giving rise to deferred
taxes is the net operating loss carryforward in the U.S. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes
may not be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The provision for income taxes consists
of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Years Ended&lt;br/&gt; January&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A reconciliation of taxes on income
computed at the federal statutory rate to amounts provided is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended&lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Book income (loss) from operations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(615,894&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(580,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Common stock issued for services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;421,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impairment expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unused operating losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;194,870&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;528,061&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of January 31, 2021, the Company
recorded a deferred tax asset associated with a net operating loss (&#x201c;NOL&#x201d;) carryforward of approximately $5,300,000 that was
fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize
those benefits in the foreseeable future. The Company&#x2019;s NOL expires in 2038. The valuation allowance increased by approximately
$810,000 during the year ended January 31, 2021. On December 22, 2017, the Tax Cuts and Jobs Act (the &#x201c;Tax Act&#x201d;) significantly
revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%. Because the Company recognizes
a valuation allowance for the entire balance, there is no net impact to the Company&#x2019;s balance sheet or results of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The types of temporary differences between
tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax
asset and their approximate tax effects are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carryforwards (expire through 2038)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,106,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(698,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock issued for services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(844,520&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(436,904&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible impairment expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,475,859&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,660,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Years Ended&lt;br/&gt; January&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended&lt;br/&gt; January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Book income (loss) from operations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(615,894&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(580,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Common stock issued for services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;421,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impairment expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unused operating losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;194,870&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;528,061&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c4" decimals="0" unitRef="usd">615894</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c5" decimals="0" unitRef="usd">580992</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c4" decimals="0" unitRef="usd">421024</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c5" decimals="0" unitRef="usd">52931</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c4" decimals="0" unitRef="usd">194870</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c5" decimals="0" unitRef="usd">528061</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c1" decimals="0" unitRef="usd">5300000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="c4">The Company&#x2019;s NOL expires in 2038.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c4" decimals="0" unitRef="usd">810000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <ntrb:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax contextRef="c106">On December 22, 2017, the Tax Cuts and Jobs Act (the &#x201c;Tax Act&#x201d;) significantly
revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%.</ntrb:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carryforwards (expire through 2038)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,106,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(698,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock issued for services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(844,520&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(436,904&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible impairment expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,475,859&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,660,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c1" decimals="0" unitRef="usd">1106339</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" unitRef="usd">698308</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <ntrb:DeferredTaxAssetAndLiabilityStockIssuedForServices contextRef="c1" decimals="0" unitRef="usd">-844520</ntrb:DeferredTaxAssetAndLiabilityStockIssuedForServices>
    <ntrb:DeferredTaxAssetAndLiabilityStockIssuedForServices contextRef="c2" decimals="0" unitRef="usd">-436904</ntrb:DeferredTaxAssetAndLiabilityStockIssuedForServices>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense contextRef="c1" decimals="0" unitRef="usd">525000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense contextRef="c2" decimals="0" unitRef="usd">525000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="0" unitRef="usd">2475859</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="0" unitRef="usd">1660212</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DebtDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES PAYABLE/CONVERTIBLE DEBT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Notes Payable&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On March 21, 2020, the Coronavirus Aid
Relief and Economic Security Act (&#x201c;CARES ACT&#x201d; was enacted. The CARES ACT established the Paycheck Protection Program (&#x201c;PPP&#x201d;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#x2019;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was outstanding as of January 31, 2021. The note matures June 17, 2022
and accrues interest at 0.98% per year.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In March 2020, a minority shareholder
who had previously made loans of $215,000 as of January 31, 2020, made an additional loan to the Company in the amount of $60,000, increasing
the total loans from the stockholder to $275,000. The loans are interest free and due upon demand. On March 27, 2020, the Company issued
25,000 shares of common stock upon reaching a settlement with the noteholder to convert the notes in the principal balance of $275,000.
The transaction resulted in a loss on extinguishment of $12,500. In July 2020, the minority shareholder made an additional loan to the
Company in the amount of $100,000. The loan is interest free and due upon demand. The loan was outstanding as of January 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Active Intelligence, the Company&#x2019;s
newly acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000
due October 16, 2029 with interest of 5% per year. The amount assumed in Note 2 was $139,184. The loan requires monthly payments of principal
and interest of $1,697. During the year ended January 31, 2021, Active Intelligence made payments of $3,351, and $2,217 were principal
payments advanced under the Cares Act. As of January 31, 2020, the amount due was $129,078, of which $13,885 is current.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Pocono has two finance leases secured
by equipment. The leases mature in 2025 and 2026. The incremental borrowing rate is 5.0%. As of January 31, 2021, the minimum lease payments
are as follow:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right; width: 13%"&gt;Years Ending&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 75%"&gt;January 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;24,738&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,295&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: right; padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;121,543&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Related Party Payable&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of January 31, 2020, the Company
owed its chief financial officer and chief operating officer $29,067 from advances made to the Company. During the year ended January
31, 2021, the Company&#x2019;s chief financial officer paid expenses of $12,628 on behalf of the Company, the Company&#x2019;s chief executive
officer and chief operating officer advanced the Company $5,500 and the officers were repaid $40,194. As of January 31, 2021, the amount
the officers were fully repaid.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 31, 2020, in connection with
the Company&#x2019;s acquisition of Pocono Products LLC, the Company issued to Pocono Coated Products LLC a promissory note, net of debt
discount, in the amount of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021 or immediately following
the earlier of a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products
LLC, a related party, is a shareholder of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Convertible Debt&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On October 30, 2019, the Company entered
into a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible
promissory notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise
price equal to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price
of the common stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from
this financing of $250,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The notes are convertible at a conversion
price equal to the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion
price, which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion.
The conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply
with the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the
notes at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which
percentage increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after
the closing of the first to occur of (a) the next public offering of the Company&#x2019;s securities or (b) the next private placement
of the Company&#x2019;s equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of
securities pursuant to an equity line of credit or (d) a financing with a bank or other institutional lender.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The embedded conversion option qualified
for derivative accounting and bifurcation under ASC 815-15 Derivative and Hedging. The initial fair of the conversion feature was $128,870
and the fair value of the warrants in connection with the notes were valued at $888,789 and were recorded based on their relative fair
values. A debt discount to the note payables of $270,000 and an initial derivative discount of $767,650 was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The debt discount will be amortized
over the life of the note. Amortization of the debt discount for the year ended January 31, 2020 was $67,500. As of January 31, 2020,
the debt discount remaining was $202,500.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On March 25, 2020, the Company prepaid
the convertible notes in the principal amount of $270,000 from the proceeds of a private placement. The total payments, including a prepayment
fee of $69,131 and accrued interest, was $345,565. As a result of the payment of the notes, the derivative liability, which was $928,774
as of January 31, 2021, was reduced to zero. The warrants are no longer a derivative liability based on the notes being paid in full.
See Note 7 for further information. The total loss of $81,631 was recorded as a result of early prepayment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Interest expense for the year ended
January 31, 2021 was $280,686 including the amortization of the debt discounts of was $272,130 and interest expense of $8,566.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <ntrb:NotePayablesDescription contextRef="c107">the Coronavirus Aid
Relief and Economic Security Act (&#x201c;CARES ACT&#x201d; was enacted. The CARES ACT established the Paycheck Protection Program (&#x201c;PPP&#x201d;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#x2019;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was outstanding as of January 31, 2021. The note matures June 17, 2022
and accrues interest at 0.98% per year.</ntrb:NotePayablesDescription>
    <us-gaap:FederalHomeLoanBankAdvances contextRef="c2" decimals="0" unitRef="usd">215000</us-gaap:FederalHomeLoanBankAdvances>
    <us-gaap:ProceedsFromLoanOriginations1 contextRef="c108" decimals="0" unitRef="usd">60000</us-gaap:ProceedsFromLoanOriginations1>
    <ntrb:ProceedsFromLoanOriginationsTotal contextRef="c108" decimals="0" unitRef="usd">275000</ntrb:ProceedsFromLoanOriginationsTotal>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c109" decimals="INF" unitRef="shares">25000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConvertibleDebt contextRef="c110" decimals="0" unitRef="usd">275000</us-gaap:ConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost contextRef="c109" decimals="0" unitRef="usd">12500</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:ProceedsFromLoanOriginations1 contextRef="c111" decimals="0" unitRef="usd">100000</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="c4" decimals="0" unitRef="usd">160000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms contextRef="c4">October 16, 2029</us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c1" decimals="2" unitRef="pure">0.05</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtDefaultLongtermDebtAmount contextRef="c1" decimals="0" unitRef="usd">139184</us-gaap:DebtDefaultLongtermDebtAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c4" decimals="0" unitRef="usd">1697</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:LineOfCreditFacilityAnnualPrincipalPayment contextRef="c4" decimals="0" unitRef="usd">3351</us-gaap:LineOfCreditFacilityAnnualPrincipalPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal contextRef="c4" decimals="0" unitRef="usd">2217</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">129078</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c2" decimals="0" unitRef="usd">13885</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c5">The leases mature in 2025 and 2026.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:SubordinatedBorrowingInterestRate contextRef="c5" decimals="3" unitRef="pure">0.050</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right; width: 13%"&gt;Years Ending&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 75%"&gt;January 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;24,738&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,295&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: right; padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;121,543&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths contextRef="c1" decimals="0" unitRef="usd">24738</us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c1" decimals="0" unitRef="usd">26295</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c1" decimals="0" unitRef="usd">27948</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c1" decimals="0" unitRef="usd">26361</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c1" decimals="0" unitRef="usd">16202</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c1" decimals="0" unitRef="usd">121543</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:ConvertibleNotesPayable contextRef="c112" decimals="0" unitRef="usd">29067</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OtherGeneralExpense contextRef="c113" decimals="0" unitRef="usd">12628</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense contextRef="c114" decimals="0" unitRef="usd">5500</us-gaap:OtherGeneralExpense>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="c115" decimals="0" unitRef="usd">40194</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c99">the Company issued to Pocono Coated Products LLC a promissory note, net of debt
discount, in the amount of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021 or immediately following
the earlier of a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products
LLC, a related party, is a shareholder of the Company.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <ntrb:NotePayableConvertibleDebtDescription contextRef="c116">the Company entered
into a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible
promissory notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise
price equal to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price
of the common stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from
this financing of $250,000.</ntrb:NotePayableConvertibleDebtDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c116">the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion
price, which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion.
The conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply
with the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the
notes at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which
percentage increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after
the closing of the first to occur of (a) the next public offering of the Company&#x2019;s securities or (b) the next private placement
of the Company&#x2019;s equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of
securities pursuant to an equity line of credit or (d) a financing with a bank or other institutional lender.</us-gaap:DebtInstrumentDescription>
    <ntrb:FairValueOfConversionPrice contextRef="c4" decimals="0" unitRef="usd">128870</ntrb:FairValueOfConversionPrice>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c4" decimals="0" unitRef="usd">888789</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c4" decimals="0" unitRef="usd">270000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c4" decimals="0" unitRef="usd">767650</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c5" decimals="0" unitRef="usd">67500</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <ntrb:DiscountRemainingAmount contextRef="c5" decimals="0" unitRef="usd">202500</ntrb:DiscountRemainingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c117" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <ntrb:PrepaymentFee contextRef="c118" decimals="0" unitRef="usd">69131</ntrb:PrepaymentFee>
    <us-gaap:DepositLiabilitiesAccruedInterest contextRef="c117" decimals="0" unitRef="usd">345565</us-gaap:DepositLiabilitiesAccruedInterest>
    <ntrb:DerivativeLiabilitiesTotal contextRef="c4" decimals="0" unitRef="usd">928774</ntrb:DerivativeLiabilitiesTotal>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c4" decimals="0" unitRef="usd">81631</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <ntrb:InterestExpensesDebt contextRef="c4" decimals="0" unitRef="usd">280686</ntrb:InterestExpensesDebt>
    <ntrb:AmortizationOfDebtDiscountsPremium contextRef="c4" decimals="0" unitRef="usd">272130</ntrb:AmortizationOfDebtDiscountsPremium>
    <us-gaap:InterestExpense contextRef="c4" decimals="0" unitRef="usd">8566</us-gaap:InterestExpense>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of January 31, 2021, and 2020, intangible
assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Customer base&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;314,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;136,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intellectual property and trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;817,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;234,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,131,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(124,770&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(56,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,006,730&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;314,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The value of the intangible assets,
consisting of intellectual property and customer base has been recorded at their fair value by the Company after completing a valuation
and are being amortized over a period of ten years. Amortization expense for the year ended January 31, 2021 and 2020 was $68,770 and
$37,070, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Estimated Amortization:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Year Ended January 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;2026 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;554,130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,006,730&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;January&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Customer base&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;314,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;136,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intellectual property and trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;817,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;234,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,131,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(124,770&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(56,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,006,730&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;314,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c119" decimals="0" unitRef="usd">314100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c120" decimals="0" unitRef="usd">136500</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c121" decimals="0" unitRef="usd">817400</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c122" decimals="0" unitRef="usd">234200</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c1" decimals="0" unitRef="usd">1131500</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c2" decimals="0" unitRef="usd">370700</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c1" decimals="0" unitRef="usd">124770</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c2" decimals="0" unitRef="usd">56000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c1" decimals="0" unitRef="usd">1006730</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="0" unitRef="usd">314700</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ntrb:amortizedOverPeriod contextRef="c4">P10Y</ntrb:amortizedOverPeriod>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c4" decimals="0" unitRef="usd">68770</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" unitRef="usd">37070</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Year Ended January 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;2026 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;554,130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,006,730&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c1" decimals="0" unitRef="usd">113150</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c1" decimals="0" unitRef="usd">113150</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c1" decimals="0" unitRef="usd">113150</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c1" decimals="0" unitRef="usd">113150</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c1" decimals="0" unitRef="usd">554130</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c1" decimals="0" unitRef="usd">1006730</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;DERIVATIVE LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The embedded conversion option of the
convertible debentures described in Note 4 contain conversion features that qualify for embedded derivative classification. The fair value
of the liabilities will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement
of operations as a gain or loss on derivative financial instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The table below sets forth a summary
in the fair value of the Company&#x2019;s Level 3 financial liabilities:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Balance at the beginning of the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;928,774&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Derivative liability warrants reclassed to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(906,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in value of embedded conversion option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22,096&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance at the end of the period&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company uses Level 3 inputs for
its valuation methodology for the embedded conversion option and warrant liabilities as their fair value were determined by using the
Monte Carlo Model based on various assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;At issuance, the expected volatility
was 158.3%; risk-free interest rate of 1.58%; and expected term of one year. For the revaluation at January 31, 2020, the expected volatility
was 184.4%; risk-free rate of return of 1.43%; and expected term of nine months.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Reclassification at March 25, 2020 to
settle the liabilities, the expected volatility was 147.47%; risk-free rate of return of 0.36%; exercise price of $11; and expected term
of 2.6 months.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Balance at the beginning of the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;928,774&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Derivative liability warrants reclassed to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(906,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in value of embedded conversion option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22,096&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance at the end of the period&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c125" decimals="0" unitRef="usd">928774</us-gaap:DerivativeLiabilitiesCurrent>
    <ntrb:DerivativeLiabilityWarrantsReclassedToEquity contextRef="c126" decimals="0" unitRef="usd">-906678</ntrb:DerivativeLiabilityWarrantsReclassedToEquity>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="c126" decimals="0" unitRef="usd">-22096</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <ntrb:FairValueAssumptionsWeightedAverageVolatilityRates contextRef="c4" decimals="3" unitRef="pure">1.583</ntrb:FairValueAssumptionsWeightedAverageVolatilityRates>
    <ntrb:FairValueAssumptionsRiskFreeInterestRates contextRef="c4" decimals="4" unitRef="pure">0.0158</ntrb:FairValueAssumptionsRiskFreeInterestRates>
    <ntrb:ExpectedTerm contextRef="c4">P1Y</ntrb:ExpectedTerm>
    <ntrb:FairValueAssumptionsWeightedAverageVolatilityRates contextRef="c123" decimals="3" unitRef="pure">1.844</ntrb:FairValueAssumptionsWeightedAverageVolatilityRates>
    <ntrb:FairValueAssumptionsRiskFreeInterestRates contextRef="c123" decimals="4" unitRef="pure">0.0143</ntrb:FairValueAssumptionsRiskFreeInterestRates>
    <ntrb:ExpectedTerms contextRef="c123">nine months</ntrb:ExpectedTerms>
    <ntrb:FairValueAssumptionsWeightedAverageVolatilityRates contextRef="c124" decimals="4" unitRef="pure">1.4747</ntrb:FairValueAssumptionsWeightedAverageVolatilityRates>
    <ntrb:FairValueAssumptionsRiskFreeInterestRates contextRef="c124" decimals="4" unitRef="pure">0.0036</ntrb:FairValueAssumptionsRiskFreeInterestRates>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c117" decimals="0" unitRef="usdPershares">11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ntrb:ExpectedTerm contextRef="c124">P2Y7M6D</ntrb:ExpectedTerm>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company&#x2019;s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The fair value of the warrant on the
date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired
unexercised on May 19, 2019.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company had related party notes with its Chief Financial Officer and Chief Operating Officer. See footnote 5 for further discussion.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In connection with the acquisition of Pocono, the Company recorded various transactions and operations through Pocono Coated Products LLC, a related entity. The transactions included revenue of $68,780, purchase of materials of $33,479, paid expenses of $23,310, and finance payments of $6,763. As of January 31, 2021, Pocono Coated Products LLC owed the Company $5,228. The Company also issued a note in the amount $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the years ended January 31, 2021, the Company issued 51,825 shares of common stock, valued at $777,375, to executive officers of the Company, based on the market price at the date of issuance, and 78,500 shares of common stock, valued at 1,221,500, to the Company&#x2019;s current and former independent directors, based on the market price at the date of issuance. The shares were issued on December 31, 2020 at a stock price of $15 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c128">a)On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company&#x2019;s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <ntrb:FairValueOfWarrantExpense contextRef="c129" decimals="0" unitRef="usd">252700</ntrb:FairValueOfWarrantExpense>
    <us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized contextRef="c4">The warrant expired
unexercised on May 19, 2019.</us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized>
    <us-gaap:PrincipalTransactionsRevenue contextRef="c130" decimals="0" unitRef="usd">68780</us-gaap:PrincipalTransactionsRevenue>
    <ntrb:PurchaseOfMaterials contextRef="c130" decimals="0" unitRef="usd">33479</ntrb:PurchaseOfMaterials>
    <ntrb:ExpensesPaid contextRef="c130" decimals="0" unitRef="usd">23310</ntrb:ExpensesPaid>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c130" decimals="0" unitRef="usd">6763</us-gaap:FinanceLeasePrincipalPayments>
    <ntrb:RelatedPartyTransactionDescriptionOfTransactions contextRef="c130">Pocono Coated Products LLC owed the Company $5,228. The Company also issued a note in the amount $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.</ntrb:RelatedPartyTransactionDescriptionOfTransactions>
    <ntrb:CommonStockIssued contextRef="c1" decimals="INF" unitRef="shares">51825</ntrb:CommonStockIssued>
    <us-gaap:StockIssued1 contextRef="c4" decimals="0" unitRef="usd">777375</us-gaap:StockIssued1>
    <us-gaap:SharesIssued contextRef="c131" decimals="INF" unitRef="shares">78500</us-gaap:SharesIssued>
    <us-gaap:CommonStockValue contextRef="c131" decimals="0" unitRef="usd">1221500</us-gaap:CommonStockValue>
    <us-gaap:SaleOfStockPricePerShare contextRef="c132" decimals="0" unitRef="usdPershares">15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;STOCKHOLDER&#x2019;S EQUITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On January 15, 2016, the board of directors
of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company
to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On May 24, 2019, the board of directors
created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (&#x201c;Series
A Preferred Stock&#x201d;). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the
status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated
as part of a particular series by the board of directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 25, 2019, the Company effected
a one-for four reverse split, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the
Company decreased its authorized common stock from 100,000,000 to 25,000,000 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On January 27, 2020, the Company amended
its articles of incorporation to increase its authorized common shares from 25,000,000 shares to 250,000,000 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Activity during the Year Ended January
31, 2021&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On March 22, 2020, the Company issued
in a private placement 46,828 units at a price of $11 per unit. Each unit consisted of one share of common stock and a warrant to purchase
one share of common stock at an exercise price of $14 per share. The warrants expire April 30, 2023. The Company issued a total of 46,828
shares of common stock and warrants to purchase 46,828 shares of common stock. The Company received proceeds of $515,108.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In March 2020, a minority shareholder
who had previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 30, 2020, the Company issued
5,000 shares to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $50,000,
all of which is included in selling and general administrative expense for the year ended January 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 31, 2020, the Company acquired
the membership interests in Pocono Coated Products LLC and issued 608,519 shares of its common stock, valued at $6,085,180, and issued
a promissory note, net of debt discount, in the amount of $1,332,893. See Note 2 for further information.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On December 31, 2020, the Company issued
130,325 shares of common stock for services, valued at $1,954,875, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;51,825 shares of common stock, valued at $777,375, issued to executive officers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;78,500 shares of common stock, valued at $1,177,500, issued to the Company&#x2019;s current and former independent directors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Subscription Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 25, 2021, in connection with the Company&#x2019;s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (&#x201c;BPM&#x201d;), the Company issued 81,396 shares of common stock to BPM and received proceeds of $700,000 to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $60,000 which is included in Stockholders&#x2019; Equity as Subscription in the Company&#x2019;s consolidated balance sheet as of January 31, 2021. The balance of the funds was received in February 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 25,2021, the Company issued 5,602 shares of common stock, valued at $60,000, for consulting services pursuant to a consultant agreement commencing December 1, 2020. The Company has reflected $10,000 representing 934 shares as Subscription Payable in the Stockholders&#x2019; Equity in the Company&#x2019;s consolidated balance sheet as of January 31, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Activity during the Year Ended January
31, 2020&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;During the year ended January 31, 2020,
the Company issued 17,144 shares of common stock to extinguish accounts payable in the amount of $240,000.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c133" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c133" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ntrb:DesignatedSharesOfPreferredStocks contextRef="c134" decimals="INF" unitRef="shares">2500000</ntrb:DesignatedSharesOfPreferredStocks>
    <ntrb:DesignatedSharesOfPreferredStocks contextRef="c135" decimals="INF" unitRef="shares">2500000</ntrb:DesignatedSharesOfPreferredStocks>
    <ntrb:CommonStockOfDescription contextRef="c136">On June 25, 2019, the Company effected
a one-for four reverse split, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the
Company decreased its authorized common stock from 100,000,000 to 25,000,000 shares.&#160;</ntrb:CommonStockOfDescription>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c137" decimals="2" unitRef="usdPershares">0.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c138" decimals="INF" unitRef="shares">100000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c139" decimals="INF" unitRef="shares">25000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c140" decimals="INF" unitRef="shares">25000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c141" decimals="INF" unitRef="shares">250000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:PrivatePlacement contextRef="c142" decimals="INF" unitRef="shares">46828</ntrb:PrivatePlacement>
    <ntrb:WarrantsToPurchaseOfCommonStockShare contextRef="c142" decimals="0" unitRef="usdPershares">11</ntrb:WarrantsToPurchaseOfCommonStockShare>
    <ntrb:InvestmentWarrantExercisePrice contextRef="c142" decimals="0" unitRef="usdPershares">14</ntrb:InvestmentWarrantExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c142" decimals="INF" unitRef="shares">46828</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ntrb:WarrantsToPurchaseOfCommonStockShares contextRef="c142" decimals="INF" unitRef="shares">46828</ntrb:WarrantsToPurchaseOfCommonStockShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c142" decimals="0" unitRef="usd">515108</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ntrb:CommonStockOfDescription contextRef="c143">In March 2020, a minority shareholder
who had previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.&#160;</ntrb:CommonStockOfDescription>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c144" decimals="INF" unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="usd">50000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c145" decimals="INF" unitRef="shares">608519</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c145" decimals="0" unitRef="usd">6085180</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c145" decimals="0" unitRef="usd">1332893</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c146" decimals="INF" unitRef="shares">130325</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c146" decimals="0" unitRef="usd">1954875</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c147" decimals="INF" unitRef="shares">51825</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c147" decimals="0" unitRef="usd">777375</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c148" decimals="INF" unitRef="shares">78500</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c148" decimals="0" unitRef="usd">1177500</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c149" decimals="INF" unitRef="shares">81396</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c149" decimals="0" unitRef="usd">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromInterestReceived contextRef="c150" decimals="0" unitRef="usd">60000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c151" decimals="INF" unitRef="shares">5602</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c151" decimals="0" unitRef="usd">60000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c1" decimals="0" unitRef="usd">10000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <ntrb:CommonStockShareSubscribedButUnissuedSubscriptionsShares contextRef="c1" decimals="INF" unitRef="shares">934</ntrb:CommonStockShareSubscribedButUnissuedSubscriptionsShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c15" decimals="INF" unitRef="shares">17144</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c2" decimals="0" unitRef="usd">240000</us-gaap:AccountsPayableOtherCurrent>
    <ntrb:WarrantsAndOptionsTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;WARRANTS AND OPTIONS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes the changes
in warrants outstanding and the related price of the shares of the Company&#x2019;s common stock issued to non-employees of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;b&gt;Remaining&lt;/b&gt; &lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;182,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,101,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;3.00&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(162,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;2.08 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;3.00 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding-period ending January 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.16&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;853,311&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercisable - period ending January 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.16&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;853,311&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As a result of a completed private placement,
the warrants to purchase 50,000 shares at the lesser of (i) $20.90 or, (ii) if the Company completes its public offering of its common
stock, 110% of the initial public offering price of the Common Stock in the public offering, became a warrant to purchase 95,000 warrants
at $11 per share, subject to adjustment pursuant to the antidilution provisions of the warrant. The Company recorded a derivative liability
for the warrants in the amount of $906,678 and reclassed the derivative liability to additional paid-in capital as of January 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes additional
information relating to the warrants outstanding at January31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Range of &lt;br/&gt; Exercise &lt;br/&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price &lt;br/&gt; for Shares &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number &lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price &lt;br/&gt; for Shares &lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;11.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes the changes
in options outstanding and the related price of the shares of the Company&#x2019;s common stock issued to non-employees of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.05 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;232,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding-period ending January 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercisable - period ending January 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ntrb:WarrantsAndOptionsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;b&gt;Remaining&lt;/b&gt; &lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;182,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,101,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;3.00&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(162,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;2.08 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;3.00 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding-period ending January 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.16&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;853,311&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercisable - period ending January 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.16&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;853,311&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c155" decimals="INF" unitRef="shares">182500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice contextRef="c155" decimals="2" unitRef="usdPershares">6.32</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c156">P0Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c155" decimals="0" unitRef="usd">4101000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c156" decimals="INF" unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c156" decimals="2" unitRef="usdPershares">20.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted contextRef="c156">P3Y</ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c156" decimals="INF" unitRef="shares">-162500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="c156" decimals="2" unitRef="usdPershares">5.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c157" decimals="INF" unitRef="shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice contextRef="c157" decimals="2" unitRef="usdPershares">18.93</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne contextRef="c156">P2Y29D</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c158" decimals="INF" unitRef="shares">91828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c158" decimals="2" unitRef="usdPershares">12.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted contextRef="c158">P3Y</ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c158" decimals="INF" unitRef="shares">-20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="c158" decimals="2" unitRef="usdPershares">14.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c159" decimals="INF" unitRef="shares">141828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice contextRef="c159" decimals="2" unitRef="usdPershares">11.99</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne contextRef="c158">P2Y1M28D</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c159" decimals="0" unitRef="usd">853311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c159" decimals="INF" unitRef="shares">141828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c159" decimals="2" unitRef="usdPershares">11.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c158">P2Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c159" decimals="0" unitRef="usd">853311</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue contextRef="c152" decimals="INF" unitRef="shares">50000</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">20.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ntrb:InitialPublicOfferingPricePercentage contextRef="c4" decimals="2" unitRef="pure">1.10</ntrb:InitialPublicOfferingPricePercentage>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue contextRef="c153" decimals="INF" unitRef="shares">95000</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue>
    <us-gaap:SharesIssuedPricePerShare contextRef="c154" decimals="0" unitRef="usdPershares">11</us-gaap:SharesIssuedPricePerShare>
    <ntrb:ReclassOfWarrantsFromLiabilityToEquity contextRef="c4" decimals="0" unitRef="usd">906678</ntrb:ReclassOfWarrantsFromLiabilityToEquity>
    <ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Range of &lt;br/&gt; Exercise &lt;br/&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price &lt;br/&gt; for Shares &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number &lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price &lt;br/&gt; for Shares &lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;11.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c159" decimals="INF" unitRef="shares">11.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef="c159" decimals="INF" unitRef="shares">95000</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber>
    <ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c158">P1Y9M</ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c158" decimals="2" unitRef="usdPershares">11.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef="c159" decimals="INF" unitRef="shares">95000</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef="c159" decimals="2" unitRef="usdPershares">11.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c1" decimals="INF" unitRef="shares">14.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber contextRef="c1" decimals="INF" unitRef="shares">46828</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber>
    <ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c4">P2Y2M26D</ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">14.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers contextRef="c1" decimals="INF" unitRef="shares">46828</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef="c1" decimals="2" unitRef="usdPershares">14.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c160">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.05 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;232,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding-period ending January 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercisable - period ending January 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c163" decimals="INF" unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c163" decimals="2" unitRef="usdPershares">25.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted contextRef="c163">P0Y18D</ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue contextRef="c163" decimals="0" unitRef="usd">232750</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c163" decimals="INF" unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="c163" decimals="2" unitRef="usdPershares">25.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LEASES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company had operating leases for
its facilities used for research and development, sales and administration. These leases have been terminated. The Company is currently
operating its manufacturing operations on a month-to-month basis in a North Carolina facility under a verbal commitment. The monthly rent
is $4,200.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;See financing leases for equipment in
Note 5.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ntrb:MonthlyRent contextRef="c4" decimals="0" unitRef="usd">4200</ntrb:MonthlyRent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;COMMITMENTS AND CONTIGENCIES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On July 27, 2018, the Company commenced
an action in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc.,
Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without
Notice and a Motion for Prejudgment Writ of Replevin arising from the Company&#x2019;s decision to seek to rescind for misrepresentation
the agreement by which the Company acquired advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and
seek return of the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against
the defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker filed a Motion to Dismiss the Company&#x2019;s Verified Complaint, Motion
to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019,
the court dismissed the Company&#x2019;s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the
six patents never duly transferred to the Company. On February 1, 2019, the Company appealed the court&#x2019;s order. Pursuant to a settlement
agreement with one of the defendants, that defendant returned the 50,000 shares which had been issued to her, and the shares were cancelled
as of January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom the Company has a settlement agreement),
filed a motion for sanctions and civil contempt against us, which generally claimed that we failed to comply with the Court&#x2019;s January
4, 2019 order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer their shares of common stock. On
October 29, 2019, the Court denied the Defendants motion. On March 20, 2020, the Florida district court of appeal reversed the lower court
ruling in the Florida state court action that dismissed our complaint, with prejudice, and gave us leave to file an amended complaint.
On July 7, 2020, Defendants filed Notice for Trial, requesting the court to set a trial date. The Company and defendants have served their
first set of interrogatories on each other and have filed answers and responses to each other&#x2019;s first set of interrogatories.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 22, 2018, four of the defendants
in the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of
Common Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition
agreement. The parties have agreed to a stay pending the outcome of the Florida litigation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On April 29, 2019, the Company filed
a securities fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle
Polly-Murphy, Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently
and deceitfully obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud the Company. The Company is
seeking the return of the shares of common stock and monetary damages resulting from the defendants&#x2019; fraudulent conduct. The defendants
filed a motion to dismiss the complaint on August 23, 2019, and on September 13, 2019 the Company filed its response. On July 20, 2020,
the Court denied the defendant&#x2019;s motion to dismiss the complaint, and the parties have recently commenced the discovery phase of
the litigation. No trial date has been scheduled by the Court.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Employment
Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company entered into a three-year
employment agreement with Gareth Sheridan, our CEO, effective April 25, 2019. The agreement also provides that the executive will continue
as a director. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31,
2024., and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#x2019; notice given
prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement,
Mr. Sheridan receives an annual salary $42,000 per annum, commencing on the effective date of the agreement and increasing to $170,000
per annum in the month in which the Company shall have received not less than $2,500,000 from one or more public or private financings
of the Company&#x2019;s equity securities subsequent to the date of the agreement. During the year ended January 31, 2021, the salary was
increased to $60,000 per anum.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;Rambam Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On December 9, 2020, the Company entered
into a License Agreement (the &#x201c;License Agreement&#x201d;) with Rambam Med-Tech Ltd. (&#x201c;Rambam&#x201d;), Haifa, Israel, to develop
the RAMBAM Closed System Transfer Device (&#x201c;CTSD&#x201d;) and such other products as the parties agree to develop/commercialize. The
Company will license from Rambam the full technology, IP, and title to CTSD in the field, with an Initial license fee of $50,000 and running
royalties on net sales. The $50,000 license fee was paid in February 2021, at which time the agreement became effective.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company had entered into a prior
agreement, dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#x201c;BPM&#x201d;), that, in consideration of BPM&#x2019;s introduction
of Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#x2019;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;BPM Distribution and Stock Purchase
Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 10, 2021, the Company finalized the Distribution Agreement with BPM, providing for distribution of the medical products developed and produced under the License Agreement. Under the Distribution Agreement, BPM&#160;has the right to distribute the medical products in Israel and has a right of first refusal in relation to all other countries/states, other than United States, Korea, China, Vietnam, Canada and Ecuador, which are termed excluded countries.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company and BPM entered into a Stock Purchase Agreement (&#x201c;SPA&#x201d;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#x2019; Equity in the Company&#x2019;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#x2019;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c164" decimals="INF" unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c164" decimals="0" unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="c165" decimals="INF" unitRef="shares">50000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c166" decimals="INF" unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ntrb:SalaryPayment contextRef="c167" decimals="0" unitRef="usd">42000</ntrb:SalaryPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c1" decimals="0" unitRef="usd">170000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <ntrb:PublicOrPrivateFinancing contextRef="c4" decimals="0" unitRef="usd">2500000</ntrb:PublicOrPrivateFinancing>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c168" decimals="0" unitRef="usd">60000</us-gaap:SalariesWagesAndOfficersCompensation>
    <ntrb:PaymentForInitialLicenseFee contextRef="c169" decimals="0" unitRef="usd">50000</ntrb:PaymentForInitialLicenseFee>
    <ntrb:PaymentForInitialLicenseFee contextRef="c170" decimals="0" unitRef="usd">50000</ntrb:PaymentForInitialLicenseFee>
    <us-gaap:OtherCommitmentsDescription contextRef="c4">The Company had entered into a prior
agreement, dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#x201c;BPM&#x201d;), that, in consideration of BPM&#x2019;s introduction
of Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#x2019;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.&#160;</us-gaap:OtherCommitmentsDescription>
    <us-gaap:SignificantPurchaseCommitmentDescription contextRef="c171">The Company and BPM entered into a Stock Purchase Agreement (&#x201c;SPA&#x201d;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#x2019; Equity in the Company&#x2019;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#x2019;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.</us-gaap:SignificantPurchaseCommitmentDescription>
    <us-gaap:SubsequentEventsTextBlock contextRef="c4">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 10, 2021, the Company issued 12,500 shares of common stock, valued at $350,000, for consulting fee in connection with Rambam License Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 25,2021, the Company issued 5,602 shares of common stock, valued at $60,000, for consulting services pursuant to a consultant agreement commencing December 1, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued contextRef="c172" decimals="INF" unitRef="shares">12500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c172" decimals="0" unitRef="usd">350000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued contextRef="c173" decimals="INF" unitRef="shares">5602</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c173" decimals="0" unitRef="usd">60000</us-gaap:CommonStockValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">304258</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">151993</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">13765</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c1" decimals="0" unitRef="usd">109347</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">72600</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c1" decimals="0" unitRef="usd">52848</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">216127</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">606750</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" unitRef="usd">314188</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">1035109</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" unitRef="usd">1076626</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="c3" decimals="0" unitRef="usd">7529875</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c1" decimals="0" unitRef="usd">7529875</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">991821</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c1" decimals="0" unitRef="usd">1006730</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">10163555</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="0" unitRef="usd">9927419</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">975596</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">940612</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="0" unitRef="usd">64704</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c1" decimals="0" unitRef="usd">86846</us-gaap:DeferredRevenueCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="c3" decimals="0" unitRef="usd">1475631</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="c1" decimals="0" unitRef="usd">1402523</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">25506</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c1" decimals="0" unitRef="usd">24740</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">114119</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c1" decimals="0" unitRef="usd">113885</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">2655556</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">2568606</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c3" decimals="0" unitRef="usd">108077</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c1" decimals="0" unitRef="usd">150063</us-gaap:LongTermNotesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c3" decimals="0" unitRef="usd">83856</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c1" decimals="0" unitRef="usd">96804</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">2847489</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="0" unitRef="usd">2815473</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c1" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c1" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c1" decimals="INF" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <ntrb:CommonStockShareIssued contextRef="c3" decimals="INF" unitRef="shares">6356270</ntrb:CommonStockShareIssued>
    <ntrb:CommonStockShareOutstanding contextRef="c3" decimals="INF" unitRef="shares">6356270</ntrb:CommonStockShareOutstanding>
    <ntrb:CommonStockShareIssued contextRef="c1" decimals="INF" unitRef="shares">6256770</ntrb:CommonStockShareIssued>
    <ntrb:CommonStockShareOutstanding contextRef="c1" decimals="INF" unitRef="shares">6256770</ntrb:CommonStockShareOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">6356</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" unitRef="usd">6257</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">19980999</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" unitRef="usd">18871098</us-gaap:AdditionalPaidInCapital>
    <ntrb:SubscriptionPayables contextRef="c1" decimals="0" unitRef="usd">70000</ntrb:SubscriptionPayables>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" unitRef="usd">-304</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" unitRef="usd">-304</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-12670985</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" unitRef="usd">-11835105</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">7316066</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">7111946</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">10163555</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" unitRef="usd">9927419</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c6" decimals="0" unitRef="usd">213739</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" unitRef="usd">84450</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">647227</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="0" unitRef="usd">203814</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c6" decimals="0" unitRef="usd">186762</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="0" unitRef="usd">116937</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">355606</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c8" decimals="0" unitRef="usd">191876</us-gaap:CostOfRevenue>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c6" decimals="0" unitRef="usd">509219</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c7" decimals="0" unitRef="usd">193331</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">1088827</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c8" decimals="0" unitRef="usd">385248</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c6" decimals="0" unitRef="usd">695981</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c7" decimals="0" unitRef="usd">310268</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c0" decimals="0" unitRef="usd">1444433</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c8" decimals="0" unitRef="usd">577124</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" unitRef="usd">-482242</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" unitRef="usd">-225818</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-797206</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c8" decimals="0" unitRef="usd">-373310</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c6" decimals="0" unitRef="usd">3338</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="0" unitRef="usd">43214</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c8" decimals="0" unitRef="usd">-12500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AccretionExpense contextRef="c8" decimals="0" unitRef="usd">69131</us-gaap:AccretionExpense>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="c8" decimals="0" unitRef="usd">22096</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:InterestExpenseDebt contextRef="c6" decimals="0" unitRef="usd">41019</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c7" decimals="0" unitRef="usd">51</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="0" unitRef="usd">81888</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c8" decimals="0" unitRef="usd">205218</us-gaap:InterestExpenseDebt>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="0" unitRef="usd">-37681</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="0" unitRef="usd">-51</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-38674</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c8" decimals="0" unitRef="usd">-264753</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="0" unitRef="usd">-519923</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" unitRef="usd">-225869</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-835880</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c8" decimals="0" unitRef="usd">-638063</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" unitRef="usd">-519923</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" unitRef="usd">-225869</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-835880</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" unitRef="usd">-638063</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c6" decimals="2" unitRef="usdPershares">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c7" decimals="2" unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c0" decimals="2" unitRef="usdPershares">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c8" decimals="2" unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c6" decimals="INF" unitRef="shares">6356269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c7" decimals="INF" unitRef="shares">5513782</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c0" decimals="INF" unitRef="shares">6343076</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c8" decimals="INF" unitRef="shares">5496274</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c6" decimals="0" unitRef="usd">-519923</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c7" decimals="0" unitRef="usd">-225869</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="0" unitRef="usd">-835880</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c8" decimals="0" unitRef="usd">-638063</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c6" decimals="0" unitRef="usd">-519923</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="0" unitRef="usd">-225869</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-835880</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="0" unitRef="usd">-638063</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">7111946</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c30" decimals="INF" unitRef="shares">6256772</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">6257</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" unitRef="usd">18871098</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="0" unitRef="usd">-11835105</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="0" unitRef="usd">70000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" unitRef="usd">640000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c35" decimals="INF" unitRef="shares">81396</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c35" decimals="0" unitRef="usd">81</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c36" decimals="0" unitRef="usd">699919</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c39" decimals="0" unitRef="usd">-60000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="0" unitRef="usd">400000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c35" decimals="INF" unitRef="shares">18102</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c35" decimals="0" unitRef="usd">18</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c36" decimals="0" unitRef="usd">409982</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c39" decimals="0" unitRef="usd">-10000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-835880</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="0" unitRef="usd">-835880</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">7316066</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c40" decimals="INF" unitRef="shares">6356270</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="0" unitRef="usd">6356</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="0" unitRef="usd">19980999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="0" unitRef="usd">-12670985</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">175433</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c20" decimals="INF" unitRef="shares">5441100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">5441</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">9072573</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" unitRef="usd">-8902277</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c8" decimals="0" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c45" decimals="INF" unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c45" decimals="0" unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c46" decimals="0" unitRef="usd">49995</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ntrb:SaleofCommonstockForCash contextRef="c8" decimals="0" unitRef="usd">515108</ntrb:SaleofCommonstockForCash>
    <us-gaap:CommonStockDividendsShares contextRef="c45" decimals="INF" unitRef="shares">46828</us-gaap:CommonStockDividendsShares>
    <ntrb:SaleofCommonstockForCash contextRef="c45" decimals="0" unitRef="usd">47</ntrb:SaleofCommonstockForCash>
    <ntrb:SaleofCommonstockForCash contextRef="c46" decimals="0" unitRef="usd">515061</ntrb:SaleofCommonstockForCash>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c8" decimals="0" unitRef="usd">287500</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c45" decimals="INF" unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c45" decimals="0" unitRef="usd">25</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c46" decimals="0" unitRef="usd">287475</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity contextRef="c8" decimals="0" unitRef="usd">906678</ntrb:ReclassificationOfWarrantsFromLiabilityToEquity>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity contextRef="c46" decimals="0" unitRef="usd">906678</ntrb:ReclassificationOfWarrantsFromLiabilityToEquity>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" unitRef="usd">-638063</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c48" decimals="0" unitRef="usd">-638063</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="0" unitRef="usd">1296656</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c51" decimals="INF" unitRef="shares">5517928</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="0" unitRef="usd">5518</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="0" unitRef="usd">10831782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c53" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c54" decimals="0" unitRef="usd">-9540340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c56" decimals="0" unitRef="usd">7835989</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c57" decimals="INF" unitRef="shares">6356270</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c57" decimals="0" unitRef="usd">6356</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c58" decimals="0" unitRef="usd">19980999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c59" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="0" unitRef="usd">-12151062</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" unitRef="usd">-519923</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c65" decimals="0" unitRef="usd">-519923</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">7316066</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c40" decimals="INF" unitRef="shares">6356270</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="0" unitRef="usd">6356</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="0" unitRef="usd">19980999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="0" unitRef="usd">-12670985</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c67" decimals="0" unitRef="usd">1472525</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c68" decimals="INF" unitRef="shares">5512928</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c68" decimals="0" unitRef="usd">5513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c69" decimals="0" unitRef="usd">10781787</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c70" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c71" decimals="0" unitRef="usd">-9314471</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c7" decimals="0" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c73" decimals="INF" unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c73" decimals="0" unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c74" decimals="0" unitRef="usd">49995</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" unitRef="usd">-225869</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c76" decimals="0" unitRef="usd">-225869</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="0" unitRef="usd">1296656</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c51" decimals="INF" unitRef="shares">5517928</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="0" unitRef="usd">5518</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="0" unitRef="usd">10831782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c53" decimals="0" unitRef="usd">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c54" decimals="0" unitRef="usd">-9540340</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-835880</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" unitRef="usd">-638063</us-gaap:NetIncomeLoss>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c8" decimals="0" unitRef="usd">3628</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">155822</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c8" decimals="0" unitRef="usd">36094</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="0" unitRef="usd">73108</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c8" decimals="0" unitRef="usd">202500</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c8" decimals="0" unitRef="usd">22096</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ntrb:EarlyPrepaymentFeeOnConvertibleDebentures contextRef="c8" decimals="0" unitRef="usd">69131</ntrb:EarlyPrepaymentFeeOnConvertibleDebentures>
    <us-gaap:AmortizationOfLeasedAsset contextRef="c8" decimals="0" unitRef="usd">9610</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="0" unitRef="usd">43214</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c8" decimals="0" unitRef="usd">-12500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">225000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="0" unitRef="usd">38000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">-95582</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c8" decimals="0" unitRef="usd">1811</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" unitRef="usd">41127</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c8" decimals="0" unitRef="usd">4358</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">19752</us-gaap:IncreaseDecreaseInInventories>
    <ntrb:increasedecreaseDepositOnSales contextRef="c0" decimals="0" unitRef="usd">22142</ntrb:increasedecreaseDepositOnSales>
    <ntrb:increasedecreaseDepositOnSales contextRef="c8" decimals="0" unitRef="usd">-29725</ntrb:increasedecreaseDepositOnSales>
    <ntrb:IncreaseDecreaseOperatingLeaseLiability contextRef="c8" decimals="0" unitRef="usd">10050</ntrb:IncreaseDecreaseOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">44659</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c8" decimals="0" unitRef="usd">-38462</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-367944</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c8" decimals="0" unitRef="usd">-313652</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">49396</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" unitRef="usd">583000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c8" decimals="0" unitRef="usd">515108</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c8" decimals="0" unitRef="usd">194870</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfDebt contextRef="c8" decimals="0" unitRef="usd">339131</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c0" decimals="0" unitRef="usd">1213</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="0" unitRef="usd">12182</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c8" decimals="0" unitRef="usd">5500</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c8" decimals="0" unitRef="usd">33628</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">569605</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c8" decimals="0" unitRef="usd">342719</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">152265</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c8" decimals="0" unitRef="usd">29067</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">151993</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">10181</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">304258</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c50" decimals="0" unitRef="usd">39248</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" unitRef="usd">4060</us-gaap:InterestPaidNet>
    <ntrb:CommonStockIssuedForSettlementOfNotesPayable contextRef="c8" decimals="0" unitRef="usd">287500</ntrb:CommonStockIssuedForSettlementOfNotesPayable>
    <ntrb:CommonStockIssuedForPrepaidConsulting contextRef="c0" decimals="0" unitRef="usd">400000</ntrb:CommonStockIssuedForPrepaidConsulting>
    <ntrb:CommonStockIssuedForPrepaidConsulting contextRef="c8" decimals="0" unitRef="usd">12500</ntrb:CommonStockIssuedForPrepaidConsulting>
    <ntrb:NoncashPaymentForLicenseAgreement contextRef="c0" decimals="0" unitRef="usd">57000</ntrb:NoncashPaymentForLicenseAgreement>
    <ntrb:DerivativeLiabilityWarrantReclassedToEquity contextRef="c8" decimals="0" unitRef="usd">906678</ntrb:DerivativeLiabilityWarrantReclassedToEquity>
    <ntrb:CommonIssuedForSubscriptionPayable contextRef="c0" decimals="0" unitRef="usd">70000</ntrb:CommonIssuedForSubscriptionPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ORGANIZATION AND DESCRIPTION OF BUSINESS &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Nutriband Inc. (the &#x201c;Company&#x201d;) is
a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was
formed by the Company&#x2019;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 1, 2018, the Company acquired 4P Therapeutics
LLC (&#x201c;4P Therapeutics&#x201d;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000,
and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by
4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company
since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#x2019;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#x201c;FDA&#x201d;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;With the acquisition of 4P Therapeutics, 4P Therapeutics&#x2019;
drug development business became the Company&#x2019;s principal business. The Company&#x2019;s approach is to use generic drugs that are
off patent and incorporate them into the Company&#x2019;s transdermal drug delivery system. Although these medications have received FDA
approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical
and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 25, 2020, the Company formed Pocono
Pharmaceuticals Inc. (&#x201c;Pocono Pharmaceuticals&#x201d;), a wholly owned subsidiary of the Company. On August 31, 2020, the Company
acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated
Products LLC (&#x201c;PCP&#x201d;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company also
acquired 100% of the membership interests of Active Intelligence LLC (&#x201c;Active Intelligence&#x201d;). See Note 2 for further details
of the acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pocono Pharmaceuticals is a coated products manufacturing
entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product design and
development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#x2019;s competitive
edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is used as the same as traditional
kinesiology tape.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, COVID-19 emerged and has subsequently
spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and
private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders
and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed quarantines
and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business and could
delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="c78">the Company acquired 4P Therapeutics
LLC (&#x201c;4P Therapeutics&#x201d;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000,
and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by
4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company
since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <ntrb:AcquiredPercentage contextRef="c174" decimals="2" unitRef="pure">1</ntrb:AcquiredPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Unaudited Interim Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated balance sheet as of July 31,
2021, and the consolidated statements of operations, stockholders&#x2019; equity, and cash flows for the periods presented have been prepared
by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary
to present fairly the financial position, results of operations, changes in stockholders&#x2019; equity and cash flows for all periods
presented have been made. The results for the six months ended July 31, 2021, are not necessarily indicative of the results to be expected
for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and
footnotes thereto included in Nutriband&#x2019;s Annual Report on Form 10-K for the year ended January 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain information and footnote disclosures required
under generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted
from these consolidated financial statements pursuant to the rules and regulations, including the interim reporting requirements of the
U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The preparation of consolidated financial statements in accordance with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts
in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s significant accounting policies
are summarized in Note 1 in the Company&#x2019;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant
changes to these accounting policies during the six months July 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Going Concern &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of July 31, 2021, the Company believes the
substantial doubt about its status as a going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current quarter net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to
alleviate the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses,
equity funding that has been received and additional funding expected to be received, and the net revenue from its recent acquisitions.
These factors did not exist in prior years during its start-up operations. The Company&#x2019;s recent history of losses has continued
but future positive cash flow projections due to revenue commitments and decreases in overhead as well as expected equity funding will
enable the Company to alleviate the substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s
plans have been currently implemented. The plans enable the Company to meet its obligations for at least one year from the date when the
financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements of the Company
include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations
of 4P Therapeutics are included in the Company&#x2019;s financial statements from the date of acquisition of August 1, 2018, and the operations
of Pocono and Active Intelligence are included in the Company&#x2019;s financial statements from the date of acquisition of September 1,
2020. The wholly owned subsidiaries are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Nutriband Ltd.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;4P Therapeutics LLC&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pocono Pharmaceuticals Inc.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates
and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as
income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases
its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s significant policies are summarized
in Note 1 of the Company&#x2019;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant changes to
the accounting policies during the six months ended July 31, 2021, and the Company does not expect that the adoption of other accounting
pronouncements will have a material impact on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2014, the FASB issued ASU No. 2014-09,
&#x201c;Revenue from Contracts with Customers (Topic 606) (&#x201c;ASU 2014-09&#x201d;), which amends the accounting standards for revenue
recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when
products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Types&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a description of the Company&#x2019;s
revenue types, which include professional services and sale of goods:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Service
    revenues include the contract of research and development related services with the Company&#x2019;s clients in the life sciences
    field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for
    each given research project engaged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Product
    revenues are derived from the sale of the Company&#x2019;s consumer transdermal and coated products. Upon the reception of a purchase
    order, we have the order filled and shipped.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A contract with a customer exists when (i) we
enter into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be transferred
and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine
that collection of substantially all consideration for services that are transferred is probable based on the customer&#x2019;s intent
and ability to pay the promised consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Deferred Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred revenue is a liability related to a revenue
producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from
a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Performance Obligations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A performance obligation is a promise in a contract
to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction
price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
For the Company&#x2019;s different revenue service types, the performance obligation is satisfied at different times. The Company&#x2019;s
performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue
performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize
revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for
the work performed during that month.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All revenue recognized in the income statement
is considered to be revenue from contracts with customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company disaggregates its revenue from contracts
with customers by type and by geographical location. See the tables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by type&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Sale of goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;59,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;541,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;120,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,976&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;83,044&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,450&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;647,227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by geographic location:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;560,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;83,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59,450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;86,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,770&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,450&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;647,227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Account receivable &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivables are recorded at the
net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability
of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts
where appropriate and the application of historical loss to non-applicable accounts. For the six months ended July 31, 2021 and 2020,
the Company recorded no bad debt expense for doubtful accounts related to account receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are valued at the lower of cost and
reasonable value determined using the first-in, first-out (FIFO) method. Net reasonable value is the estimated selling price in the ordinary
course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material
costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of July 31,
2021, 100% of the inventory consists of raw materials.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment represent an important
component of the Company&#x2019;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful
life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement
parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are
capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from
3 to 20 years as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Lab Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets include trademarks, intellectual
property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance
of ASC 350, &#x201c;Intangibles-Goodwill and Other.&#x201d; The Company capitalizes certain costs related to patent technology. A substantial
component of the purchase price related to the Company&#x2019;s acquisitions have also been assigned to intellectual property and other
intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible
assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized
over their estimated useful lives of ten years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Goodwill represents the difference between the
total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed
for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the
recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August 31,
2020, in connection with the Company&#x2019;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $5,810,640. As of July 31, 2021, Goodwill amounted to $7,529,875.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Long-lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management reviews long-lived assets for potential
impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount
of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use
and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market
value of the long-lived asset and the related book value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Earnings per Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic earnings per share of common stock is computed
by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per
share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock
outstanding during the period.&#160;Potential shares of common stock consist of shares issuable upon the exercise of outstanding options
and common stock purchase warrants. As of July 31, 2021, and 2020, there were 141,830 common stock equivalents outstanding, that were
not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 718, &#x201c;Compensation - Stock Compensation,&#x201d;
prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February
1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and
other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including
grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That
expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the
requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based
compensation for both employees and non-employees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 820, &#x201c;Fair Value Measurements and
Disclosure&#x201d; (&#x201c;ASC 820&#x201d;), defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of
observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that
may be used to measure fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company utilizes the accounting guidance for
fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized
or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is
an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data
or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy,
which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable inputs such as quoted market prices in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than quoted prices in active markets that are either directly or indirectly observable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying value of the Company&#x2019;s financial
instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their fair value
due to the short maturities of these financial instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Derivative Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value estimates are made at a specific point
in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve uncertainties
and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect
the estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for derivative instruments
in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; and all 	derivative instruments are reflected as either assets
or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments. Fair
value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market participants.
In general, the Company&#x2019;s policy in estimating fair values is to first look at observable market prices for identical assets and
liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such as prices
of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable data
from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of July 31, 2021, and January 31, 2021, the Company had
no derivative liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has implemented all new pronouncements,
including the adoption of ASU 2018-13 and ASU 2019-12, that are in effect and that may impact its consolidated financial statements and
does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its
consolidated financial statements or results of operations.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <ntrb:UnauditedInterimFinancialStatementsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Unaudited Interim Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated balance sheet as of July 31,
2021, and the consolidated statements of operations, stockholders&#x2019; equity, and cash flows for the periods presented have been prepared
by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary
to present fairly the financial position, results of operations, changes in stockholders&#x2019; equity and cash flows for all periods
presented have been made. The results for the six months ended July 31, 2021, are not necessarily indicative of the results to be expected
for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and
footnotes thereto included in Nutriband&#x2019;s Annual Report on Form 10-K for the year ended January 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain information and footnote disclosures required
under generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted
from these consolidated financial statements pursuant to the rules and regulations, including the interim reporting requirements of the
U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The preparation of consolidated financial statements in accordance with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts
in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s significant accounting policies
are summarized in Note 1 in the Company&#x2019;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant
changes to these accounting policies during the six months July 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:UnauditedInterimFinancialStatementsPolicyTextBlock>
    <ntrb:GoingConcernPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Going Concern &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of July 31, 2021, the Company believes the
substantial doubt about its status as a going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current quarter net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to
alleviate the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses,
equity funding that has been received and additional funding expected to be received, and the net revenue from its recent acquisitions.
These factors did not exist in prior years during its start-up operations. The Company&#x2019;s recent history of losses has continued
but future positive cash flow projections due to revenue commitments and decreases in overhead as well as expected equity funding will
enable the Company to alleviate the substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s
plans have been currently implemented. The plans enable the Company to meet its obligations for at least one year from the date when the
financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:GoingConcernPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements of the Company
include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations
of 4P Therapeutics are included in the Company&#x2019;s financial statements from the date of acquisition of August 1, 2018, and the operations
of Pocono and Active Intelligence are included in the Company&#x2019;s financial statements from the date of acquisition of September 1,
2020. The wholly owned subsidiaries are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Nutriband Ltd.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;4P Therapeutics LLC&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pocono Pharmaceuticals Inc.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates
and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as
income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases
its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s significant policies are summarized
in Note 1 of the Company&#x2019;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant changes to
the accounting policies during the six months ended July 31, 2021, and the Company does not expect that the adoption of other accounting
pronouncements will have a material impact on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2014, the FASB issued ASU No. 2014-09,
&#x201c;Revenue from Contracts with Customers (Topic 606) (&#x201c;ASU 2014-09&#x201d;), which amends the accounting standards for revenue
recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when
products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Types&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a description of the Company&#x2019;s
revenue types, which include professional services and sale of goods:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Service
    revenues include the contract of research and development related services with the Company&#x2019;s clients in the life sciences
    field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for
    each given research project engaged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Product
    revenues are derived from the sale of the Company&#x2019;s consumer transdermal and coated products. Upon the reception of a purchase
    order, we have the order filled and shipped.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A contract with a customer exists when (i) we
enter into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be transferred
and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine
that collection of substantially all consideration for services that are transferred is probable based on the customer&#x2019;s intent
and ability to pay the promised consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueRecognitionDeferredRevenue contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Deferred Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred revenue is a liability related to a revenue
producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from
a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
    <ntrb:PerformanceObligationsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Performance Obligations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A performance obligation is a promise in a contract
to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction
price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
For the Company&#x2019;s different revenue service types, the performance obligation is satisfied at different times. The Company&#x2019;s
performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue
performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize
revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for
the work performed during that month.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All revenue recognized in the income statement
is considered to be revenue from contracts with customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:PerformanceObligationsPolicyTextBlock>
    <ntrb:DisaggregationOfRevenuesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company disaggregates its revenue from contracts
with customers by type and by geographical location. See the tables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by type&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Sale of goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;59,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;541,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;120,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,976&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;83,044&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,450&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;647,227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by geographic location:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;560,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;83,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59,450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;86,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,770&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,450&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;647,227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:DisaggregationOfRevenuesPolicyTextBlock>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by type&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Sale of goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;59,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;541,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;120,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,976&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;83,044&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,450&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;647,227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <ntrb:SalesRevenuesGoodsNet contextRef="c6" decimals="0" unitRef="usd">213739</ntrb:SalesRevenuesGoodsNet>
    <ntrb:SalesRevenuesGoodsNet contextRef="c7" decimals="0" unitRef="usd">59450</ntrb:SalesRevenuesGoodsNet>
    <ntrb:SalesRevenuesGoodsNet contextRef="c0" decimals="0" unitRef="usd">541251</ntrb:SalesRevenuesGoodsNet>
    <ntrb:SalesRevenuesGoodsNet contextRef="c8" decimals="0" unitRef="usd">120770</ntrb:SalesRevenuesGoodsNet>
    <ntrb:SaleOfGoodsAndServices contextRef="c7" decimals="0" unitRef="usd">25000</ntrb:SaleOfGoodsAndServices>
    <ntrb:SaleOfGoodsAndServices contextRef="c0" decimals="0" unitRef="usd">105976</ntrb:SaleOfGoodsAndServices>
    <ntrb:SaleOfGoodsAndServices contextRef="c8" decimals="0" unitRef="usd">83044</ntrb:SaleOfGoodsAndServices>
    <us-gaap:Revenues contextRef="c6" decimals="0" unitRef="usd">213739</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" unitRef="usd">84450</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">647227</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="0" unitRef="usd">203814</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Revenue by geographic location:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;560,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;83,044&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59,450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;86,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,770&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,739&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,450&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;647,227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c177" decimals="0" unitRef="usd">213739</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c178" decimals="0" unitRef="usd">25000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c179" decimals="0" unitRef="usd">560627</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c180" decimals="0" unitRef="usd">83044</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c182" decimals="0" unitRef="usd">59450</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c183" decimals="0" unitRef="usd">86600</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c184" decimals="0" unitRef="usd">120770</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" unitRef="usd">213739</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" unitRef="usd">84450</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">647227</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="0" unitRef="usd">203814</us-gaap:Revenues>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Account receivable &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivables are recorded at the
net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability
of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts
where appropriate and the application of historical loss to non-applicable accounts. For the six months ended July 31, 2021 and 2020,
the Company recorded no bad debt expense for doubtful accounts related to account receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are valued at the lower of cost and
reasonable value determined using the first-in, first-out (FIFO) method. Net reasonable value is the estimated selling price in the ordinary
course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material
costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of July 31,
2021, 100% of the inventory consists of raw materials.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <ntrb:InventoryRawMaterialsPercentage contextRef="c0" decimals="2" unitRef="pure">1</ntrb:InventoryRawMaterialsPercentage>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment represent an important
component of the Company&#x2019;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful
life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement
parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are
capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from
3 to 20 years as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Lab Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c175">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c176">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Lab Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c185">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c186">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c187">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c188">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c189">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c0">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:Goodwill contextRef="c82" decimals="0" unitRef="usd">5810640</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c3" decimals="0" unitRef="usd">7529875</us-gaap:Goodwill>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c0" decimals="INF" unitRef="shares">141830</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c8" decimals="INF" unitRef="shares">141830</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ACQUISITION OF BUSINESS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 31, 2020, the Company entered into a
Purchase Agreement (&#x201c;Agreement&#x201d;), with Pocono Coated Products (&#x201c;PCP&#x201d;), pursuant to which PCP agreed to sell the
Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business, including:
(1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free and clear
of all liens, except for certain lease obligations, and (2), a 100% membership interest in Active Intelligence, LLC (collectively the
&#x201c;Assets&#x201d;). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary
of the Company. The purchase price for the Assets was (i) $6,085,180 paid with the issuance of 608,519 shares in the Company&#x2019;s common
stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the &#x201c;Shares&#x201d;), and (ii)
a promissory note of the Company, net of debt discount, in the principal amount, of $1,332,893 (the Note&#x201d;) which is due upon the
earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $4,000,000 and/or a public
offering of no less than $4,000,000. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period
of one year at the annual meeting of shareholders of the Company held in October 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Agreement provides that it is effective August
31, 2020, on which date the parties also entered into an escrow agreement (the &#x201c;Escrow Agreement&#x201d;), with legal counsel serving
as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special purpose
subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also entered
into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The purpose of the Company entering into the transaction
is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated to the net tangible
assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and, as such, the transaction
was accounted for under the acquisition method of accounting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Details of the net assets acquired are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Recognized on&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Acquisition&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%; text-align: left"&gt;Common stock issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;6,085,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Note payable issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,332,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;66,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Equipment and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer base&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Intellectual property and trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,810,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts payable and accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,104&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,851&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(268,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following unaudited pro forma condensed financial
information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and Active Intelligence,
as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed financial information
is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had
the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated
results of operations of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As Reported&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Proforma&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;629,873&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(638,063&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(702,975&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired contextRef="c82" decimals="2" unitRef="pure">1</ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="c97" decimals="0" unitRef="usd">6085180</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c98" decimals="INF" unitRef="shares">608519</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <ntrb:DebtInstrumentAnnualPrincipalPayments contextRef="c82" decimals="0" unitRef="usd">1332893</ntrb:DebtInstrumentAnnualPrincipalPayments>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c99" decimals="0" unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c99" decimals="0" unitRef="usd">4000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <ntrb:AnnualMeetingOfShareholdersTerm contextRef="c100">P1Y</ntrb:AnnualMeetingOfShareholdersTerm>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Recognized on&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Acquisition&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%; text-align: left"&gt;Common stock issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;6,085,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Note payable issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,332,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;66,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Equipment and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer base&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Intellectual property and trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,810,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts payable and accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,104&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,851&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(268,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,418,073&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <ntrb:BusinessAcquisitionCommonStockIssued contextRef="c190" decimals="0" unitRef="usd">6085180</ntrb:BusinessAcquisitionCommonStockIssued>
    <ntrb:NotePayableIssued contextRef="c190" decimals="0" unitRef="usd">1332893</ntrb:NotePayableIssued>
    <ntrb:CommonStockAndNoteIssuedInAcquisition contextRef="c190" decimals="0" unitRef="usd">7418073</ntrb:CommonStockAndNoteIssuedInAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c82" decimals="0" unitRef="usd">66994</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c82" decimals="0" unitRef="usd">1761</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c82" decimals="0" unitRef="usd">42613</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment contextRef="c82" decimals="0" unitRef="usd">1056935</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment>
    <ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase contextRef="c82" decimals="0" unitRef="usd">177600</ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase>
    <ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks contextRef="c82" decimals="0" unitRef="usd">583200</ntrb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks>
    <us-gaap:GoodwillGross contextRef="c82" decimals="0" unitRef="usd">5810640</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c82" decimals="0" unitRef="usd">26104</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c82" decimals="0" unitRef="usd">26851</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c82" decimals="0" unitRef="usd">268715</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c82" decimals="0" unitRef="usd">7418073</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;b&gt;July 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As Reported&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Proforma&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;203,814&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;629,873&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(638,063&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(702,975&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share - basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c8" decimals="0" unitRef="usd">203814</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c8" decimals="0" unitRef="usd">629873</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <ntrb:BusinessAcquisitionsNetLossAsReported contextRef="c8" decimals="0" unitRef="usd">-638063</ntrb:BusinessAcquisitionsNetLossAsReported>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c8" decimals="0" unitRef="usd">-702975</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <ntrb:LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare contextRef="c8" decimals="2" unitRef="usdPershares">-0.12</ntrb:LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare>
    <ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic contextRef="c8" decimals="2" unitRef="usdPershares">-0.12</ntrb:BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;January&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,097,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,442&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,270,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,221,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(235,450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,035,109&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,076,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense amounted to $90,913 and 17,558
for the six months ended July 31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;January&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;144,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,097,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,442&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,270,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,221,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(235,450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,035,109&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,076,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c191" decimals="0" unitRef="usd">144585</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c192" decimals="0" unitRef="usd">144585</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c193" decimals="0" unitRef="usd">1097532</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c194" decimals="0" unitRef="usd">1056935</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c195" decimals="0" unitRef="usd">28442</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c196" decimals="0" unitRef="usd">19643</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">1270559</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="0" unitRef="usd">1221163</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c3" decimals="0" unitRef="usd">235450</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c1" decimals="0" unitRef="usd">144537</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">1035109</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" unitRef="usd">1076626</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">90913</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c8" decimals="0" unitRef="usd">17558</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES PAYABLE/CONVERTIBLE DEBT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Notes Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 21, 2020, the Coronavirus Aid Relief
and Economic Security Act (&#x201c;CARES ACT&#x201d; was enacted. The CARES ACT established the Paycheck Protection Program (&#x201c;PPP&#x201d;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#x2019;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was forgiven as of April 30, 2021. The Company recorded a gain on the
extinguishment of debt of $34,870 during the six months ended July 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2020, a minority shareholder made an additional
loan to the Company in the amount of $100,000. The loan is interest-free and due upon demand. The loan was outstanding as July 31, 2021,
and January 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Active Intelligence, the Company&#x2019;s newly
acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due
October 16, 2029, with interest of 5% per year. The amount assumed in Note 3 was $139,184. The loan requires monthly payments of principal
and interest of $1,697. During the six months ended July 31, 2021, principal and interest payments of $8,344 were forgiven under the Cares
Act. The amount, $8,344, has been recorded as a gain on the forgiveness of debt. As of July 31, 2021, the amount due was $122,196, of
which $14,119 is current.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pocono has two finance leases secured by equipment.
The leases mature in 2025 and 2026. The incremental borrowing rate is 5.0%. As of July 31, 2021, the minimum lease payments are as follow:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 75%"&gt;January 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;12,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,295&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,362&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Related Party Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 31, 2020, in connection with the Company&#x2019;s
acquisition of Pocono Products LLC, the Company issued to Pocono Coated Products LLC a promissory note, net of debt discount, in the amount
of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021, or immediately following the earlier of a capital
raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products LLC, a related party, is
a shareholder of the Company. During the six months ended July 31, 2021, the Company recorded amortization of debt discount of $71,308.
As of July 31, 2021, the amount due was $1,475,631. The due date for the note has been extended to September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Convertible Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 30, 2019, the Company entered into
a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible promissory
notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise price equal
to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price of the common
stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from this financing
of $250,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The notes are convertible at a conversion price
equal to the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion price,
which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion. The
conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply with
the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the notes
at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which percentage
increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after the closing
of the first to occur of (a) the next public offering of the Company&#x2019;s securities or (b) the next private placement of the Company&#x2019;s
equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of securities pursuant to
an equity line of credit or (d) a financing with a bank or other institutional lender.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The embedded conversion option qualified for derivative
accounting and bifurcation under ASC 815-15 Derivative and Hedging. The initial fair of the conversion feature was $128,870 and the fair
value of the warrants in connection with the notes were valued at $888,789 and were recorded based on their relative fair values. A debt
discount to the note payables of $270,000 and an initial derivative expense of $767,650 was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The debt discount will be amortized over the life
of the note. Amortization of the debt discount for the six months ended July 31, 2020, was $202,500.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 25, 2020, the Company prepaid the convertible
notes in the principal amount of $270,000 from the proceeds of a private placement. The total payments, including a prepayment fee of
$69,131 and accrued interest, was $345,565. As a result of the payment of the notes, the derivative liability, which was $928,774 as of
January 31, 2020, was reduced to zero. The warrants are no longer a derivative liability based on the notes being paid in full.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Interest expense for
the six months ended July 31, 2021was $81,888 including the amortization of the debt discount of $73,108 and interest expense of $8,780.
Interest expense for the six months ended July 31, 2020, was $205,218 including the amortization of debt discount of $202,500 and interest
expense of $2,718.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <ntrb:NotePayablesDescription contextRef="c200">the Coronavirus Aid Relief
and Economic Security Act (&#x201c;CARES ACT&#x201d; was enacted. The CARES ACT established the Paycheck Protection Program (&#x201c;PPP&#x201d;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#x2019;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was forgiven as of April 30, 2021. The Company recorded a gain on the
extinguishment of debt of $34,870 during the six months ended July 31, 2021.</ntrb:NotePayablesDescription>
    <us-gaap:ProceedsFromLoanOriginations1 contextRef="c197" decimals="0" unitRef="usd">100000</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="c0" decimals="0" unitRef="usd">160000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms contextRef="c0">October 16, 2029</us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c3" decimals="2" unitRef="pure">0.05</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtDefaultLongtermDebtAmount contextRef="c3" decimals="0" unitRef="usd">139184</us-gaap:DebtDefaultLongtermDebtAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c0" decimals="0" unitRef="usd">1697</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal contextRef="c0" decimals="0" unitRef="usd">8344</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <ntrb:GainOnExtinguishmentOfDebt contextRef="c0" decimals="0" unitRef="usd">8344</ntrb:GainOnExtinguishmentOfDebt>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">122196</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">14119</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c0">The leases mature in 2025 and 2026.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:SubordinatedBorrowingInterestRate contextRef="c0" decimals="3" unitRef="pure">0.050</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 75%"&gt;January 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;12,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,295&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;January 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,362&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths contextRef="c3" decimals="0" unitRef="usd">12557</us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c3" decimals="0" unitRef="usd">26295</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c3" decimals="0" unitRef="usd">27948</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c3" decimals="0" unitRef="usd">26361</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c3" decimals="0" unitRef="usd">16202</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" unitRef="usd">109362</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c201">the Company issued to Pocono Coated Products LLC a promissory note, net of debt discount, in the amount
of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021, or immediately following the earlier of a capital
raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products LLC, a related party, is
a shareholder of the Company.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c198" decimals="0" unitRef="usd">71308</us-gaap:AmortizationOfDebtDiscountPremium>
    <ntrb:DueToRelatedPartyCurrentAndNoncurrent contextRef="c199" decimals="0" unitRef="usd">1475631</ntrb:DueToRelatedPartyCurrentAndNoncurrent>
    <ntrb:NotePayableConvertibleDebtDescription contextRef="c116">the Company entered into
a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible promissory
notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise price equal
to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price of the common
stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from this financing
of $250,000.</ntrb:NotePayableConvertibleDebtDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c116">the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion price,
which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion. The
conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply with
the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the notes
at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which percentage
increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after the closing
of the first to occur of (a) the next public offering of the Company&#x2019;s securities or (b) the next private placement of the Company&#x2019;s
equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of securities pursuant to
an equity line of credit or (d) a financing with a bank or other institutional lender.</us-gaap:DebtInstrumentDescription>
    <ntrb:FairValueOfConversionPrice contextRef="c0" decimals="0" unitRef="usd">128870</ntrb:FairValueOfConversionPrice>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" unitRef="usd">888789</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c0" decimals="0" unitRef="usd">270000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c0" decimals="0" unitRef="usd">767650</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c8" decimals="0" unitRef="usd">202500</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c117" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <ntrb:PrepaymentFee contextRef="c124" decimals="0" unitRef="usd">69131</ntrb:PrepaymentFee>
    <us-gaap:DepositLiabilitiesAccruedInterest contextRef="c117" decimals="0" unitRef="usd">345565</us-gaap:DepositLiabilitiesAccruedInterest>
    <ntrb:DerivativeLiabilitiesTotal contextRef="c5" decimals="0" unitRef="usd">928774</ntrb:DerivativeLiabilitiesTotal>
    <ntrb:InterestExpenseDebts contextRef="c0" decimals="0" unitRef="usd">81888</ntrb:InterestExpenseDebts>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="0" unitRef="usd">73108</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" unitRef="usd">8780</us-gaap:InterestExpense>
    <ntrb:InterestExpenseDebts contextRef="c8" decimals="0" unitRef="usd">205218</ntrb:InterestExpenseDebts>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c8" decimals="0" unitRef="usd">202500</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpense contextRef="c8" decimals="0" unitRef="usd">2718</us-gaap:InterestExpense>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of July 31, 2021, and January 31, 2021, intangible
assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;January&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Customer base&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;314,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;314,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;License agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intellectual property&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;817,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;817,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,181,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,131,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(189,679&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(124,770&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;991,821&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,006,730&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2021, the Company acquired an IP license
for $50,000, see Note 10- &#x201c;Rambam Agreement&#x201d; for further discussion regarding the license agreement. The value of the intangible
assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company
and are being amortized over a period of three to ten years. Amortization expense for the six months ended July 31, 2021, and 2020 was
$64,909 and $18,534, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Estimated Amortization:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year Ended January 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; width: 89%; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;64,870&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;129,776&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2924&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;129,776&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;113,109&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;554,290&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;991,821&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;July&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;January&#160;31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Customer base&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;314,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;314,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;License agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intellectual property&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;817,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;817,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,181,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,131,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(189,679&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(124,770&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;991,821&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,006,730&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c203" decimals="0" unitRef="usd">314100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c119" decimals="0" unitRef="usd">314100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c204" decimals="0" unitRef="usd">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c206" decimals="0" unitRef="usd">817400</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c121" decimals="0" unitRef="usd">817400</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" unitRef="usd">1181500</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c1" decimals="0" unitRef="usd">1131500</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" unitRef="usd">189679</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c1" decimals="0" unitRef="usd">124770</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">991821</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c1" decimals="0" unitRef="usd">1006730</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ntrb:PaymentForInitialLicenseFee contextRef="c202" decimals="0" unitRef="usd">50000</ntrb:PaymentForInitialLicenseFee>
    <ntrb:amortizedOverPeriod contextRef="c175">P3Y</ntrb:amortizedOverPeriod>
    <ntrb:amortizedOverPeriod contextRef="c176">P10Y</ntrb:amortizedOverPeriod>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">64909</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c8" decimals="0" unitRef="usd">18534</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year Ended January 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; width: 89%; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;64,870&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;129,776&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2924&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;129,776&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;113,109&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;554,290&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-left: 0"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;991,821&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c3" decimals="0" unitRef="usd">64870</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c3" decimals="0" unitRef="usd">129776</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c3" decimals="0" unitRef="usd">129776</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c3" decimals="0" unitRef="usd">113109</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c3" decimals="0" unitRef="usd">554290</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" unitRef="usd">991821</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company had related party notes with its former Chief Financial Officer and Chief Operating Officer. See footnote 5 for further discussion.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In connection with the acquisition of Pocono, the Company recorded various transactions and operations through Pocono Coated Products LLC, a related entity. During the six months ended July 31, 2021, the Company was advanced $7,862 in finance payments. As of July 31, 2021, the Company owed Pocono $2,634. The Company also issued a note in the amount of $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c207" decimals="0" unitRef="usd">7862</us-gaap:FinanceLeasePrincipalPayments>
    <ntrb:RelatedPartyTransactionDescriptionOfTransactions contextRef="c207">As of July 31, 2021, the Company owed Pocono $2,634. The Company also issued a note in the amount of $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.</ntrb:RelatedPartyTransactionDescriptionOfTransactions>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 15, 2016, the board of directors of
the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company
to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 24, 2019, the board of directors created
a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (&#x201c;Series A Preferred
Stock&#x201d;). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of
authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part
of a particular series by the board of directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 25, 2019, the Company effected a one-for
four reverse stock splits, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the Company
decreased its authorized common stock from 100,000,000 to 25,000,000 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 27, 2020, the Company amended its articles
of incorporation to increase its authorized common shares from 25,000,000 shares to 250,000,000 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Activity during the Six Months Ended July 31,
2020&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 22, 2020, the Company issued in a private
placement 46,828 units at a price of $11 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share
of common stock at an exercise price of $14 per share. The warrants expire April 30, 2023. The Company issued a total of 46,828 shares
of common stock and warrants to purchase 46,828 shares of common stock. The Company received proceeds of $515,108.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2020, a minority shareholder who had
previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 30,2020, the Company issued 5,000 shares
to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $50,000, of which
$38,000 is included in selling and general administrative expenses and $12,000 is included in prepaid expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Activity during the Six Months Ended July 31,
2021&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 25, 2021, in connection with the Company&#x2019;s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (&#x201c;BPM&#x201d;), the Company issued 81,396 shares of common stock to BPM and received proceeds of $700,000 to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $60,000 which is included in Stockholders&#x2019; Equity as Subscription Payable in the Company&#x2019;s consolidated balance sheet as of January 31, 2021. In February 2021, BPM advanced a payment for the Company to Rambam in the amount of $57,000 for the license fee. The balance of the funds of $583,000 was received in February 2021. See footnote 10 for further discussion.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 25,2021, the Company issued 5,602 shares of common stock, valued at $60,000, for consulting services pursuant to a consultant agreement commencing December 1, 2020. The Company has reflected $10,000 representing 934 shares as Subscription Payable in the Stockholders&#x2019; Equity in the Company&#x2019;s consolidated balance sheet as of January 31, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 15, 2021, the Company issued 12,500
shares of common stock, valued at $350,000, for consulting fees in connection with the Rambam License Agreement discussed in Note 10.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c133" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c133" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ntrb:DesignatedSharesOfPreferredStocks contextRef="c134" decimals="INF" unitRef="shares">2500000</ntrb:DesignatedSharesOfPreferredStocks>
    <ntrb:SharesWereRestored contextRef="c134" decimals="INF" unitRef="shares">2500000</ntrb:SharesWereRestored>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c208" decimals="2" unitRef="usdPershares">0.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c209" decimals="INF" unitRef="shares">100000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c210" decimals="INF" unitRef="shares">25000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c140" decimals="INF" unitRef="shares">25000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:IncreaseDecreasedInAuthorizedCommonStock contextRef="c141" decimals="INF" unitRef="shares">250000000</ntrb:IncreaseDecreasedInAuthorizedCommonStock>
    <ntrb:PrivatePlacement contextRef="c142" decimals="INF" unitRef="shares">46828</ntrb:PrivatePlacement>
    <ntrb:WarrantsToPurchaseOfCommonStockShare contextRef="c142" decimals="0" unitRef="usdPershares">11</ntrb:WarrantsToPurchaseOfCommonStockShare>
    <ntrb:InvestmentWarrantExercisePrice contextRef="c142" decimals="0" unitRef="usdPershares">14</ntrb:InvestmentWarrantExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c142" decimals="INF" unitRef="shares">46828</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ntrb:WarrantsToPurchaseOfCommonStockShares contextRef="c142" decimals="INF" unitRef="shares">46828</ntrb:WarrantsToPurchaseOfCommonStockShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c142" decimals="0" unitRef="usd">515108</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ntrb:CommonStockOfDescription contextRef="c211">In March 2020, a minority shareholder who had
previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.&#160;</ntrb:CommonStockOfDescription>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c212" decimals="INF" unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <ntrb:FairValueOfTheCommonStocks contextRef="c213" decimals="0" unitRef="usd">50000</ntrb:FairValueOfTheCommonStocks>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c213" decimals="0" unitRef="usd">38000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c214" decimals="0" unitRef="usd">12000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c215" decimals="INF" unitRef="shares">81396</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c215" decimals="0" unitRef="usd">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ntrb:SubscriptionPayable contextRef="c216" decimals="0" unitRef="usd">60000</ntrb:SubscriptionPayable>
    <ntrb:PaymentForInitialLicenseFee contextRef="c217" decimals="0" unitRef="usd">57000</ntrb:PaymentForInitialLicenseFee>
    <ntrb:FundReceived contextRef="c218" decimals="0" unitRef="usd">583000</ntrb:FundReceived>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c219" decimals="INF" unitRef="shares">5602</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c219" decimals="0" unitRef="usd">60000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c220" decimals="0" unitRef="usd">10000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <ntrb:CommonStockShareSubscribedButUnissuedSubscriptionsShares contextRef="c220" decimals="INF" unitRef="shares">934</ntrb:CommonStockShareSubscribedButUnissuedSubscriptionsShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c221" decimals="INF" unitRef="shares">12500</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c221" decimals="0" unitRef="usd">350000</us-gaap:StockIssuedDuringPeriodValueOther>
    <ntrb:WarrantsAndOptionsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;WARRANTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the changes in
warrants outstanding and the related price of the shares of the Company&#x2019;s common stock issued to non-employees of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Remaining&lt;br/&gt; Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Intrinsic&lt;br/&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.16 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;285,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding-period ending July 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable - period ending July 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes additional information
relating to the warrants outstanding as of July 31, 2021:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
    of Exercise Prices&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt;

    Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
    Contractual&lt;br/&gt;
 Life&#160;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
    &lt;br/&gt;
Price for&lt;br/&gt;
 Shares&lt;br/&gt;
 Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt;

    Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
    &lt;br/&gt;
Price for&lt;br/&gt;
 Shares&lt;br/&gt;
 Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;br/&gt;

    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,828&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.75&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,828&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ntrb:WarrantsAndOptionsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Remaining&lt;br/&gt; Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Intrinsic&lt;br/&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.16 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;285,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding-period ending July 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable - period ending July 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;141,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">141828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice contextRef="c3" decimals="2" unitRef="usdPershares">11.99</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0">P2Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="0" unitRef="usd">285000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">141828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice contextRef="c3" decimals="INF" unitRef="shares">11.99</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne contextRef="c0">P1Y4M28D</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c3" decimals="INF" unitRef="shares">141828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice contextRef="c3" decimals="INF" unitRef="shares">11.99</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P1Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
    of Exercise Prices&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt;

    Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
    Contractual&lt;br/&gt;
 Life&#160;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
    &lt;br/&gt;
Price for&lt;br/&gt;
 Shares&lt;br/&gt;
 Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt;

    Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
    &lt;br/&gt;
Price for&lt;br/&gt;
 Shares&lt;br/&gt;
 Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;br/&gt;

    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,828&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.75&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,828&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c222" decimals="INF" unitRef="shares">11.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ntrb:ShareBasedCompensationNumberOutstanding contextRef="c222" decimals="INF" unitRef="shares">95000</ntrb:ShareBasedCompensationNumberOutstanding>
    <ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c223">P1Y3M</ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c223" decimals="2" unitRef="usdPershares">11.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationNumberExercisable contextRef="c223" decimals="INF" unitRef="shares">95000</ntrb:ShareBasedCompensationNumberExercisable>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef="c222" decimals="2" unitRef="usdPershares">11.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c3" decimals="INF" unitRef="shares">14.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ntrb:ShareBasedCompensationNumberOutstanding contextRef="c3" decimals="INF" unitRef="shares">46828</ntrb:ShareBasedCompensationNumberOutstanding>
    <ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0">P1Y9M</ntrb:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">14.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationNumberExercisable contextRef="c0" decimals="INF" unitRef="shares">46828</ntrb:ShareBasedCompensationNumberExercisable>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">14.00</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;COMMITMENTS AND CONTIGENCIES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2018, the Company commenced an action
in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar,
Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a
Motion for Prejudgment Writ of Replevin arising from the Company&#x2019;s decision to seek to rescind for misrepresentation the agreement
by which the Company acquired advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of
the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants.
Defendants Kalmar, Murphy, Polly-Murphy, and Baker filed a Motion to Dismiss the Company&#x2019;s Verified Complaint, Motion to Dissolve
Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court
dismissed the Company&#x2019;s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the six patents
never duly transferred to the Company. On February 1, 2019, the Company appealed the court&#x2019;s order. Pursuant to a settlement agreement
with one of the defendants, that defendant returned the 50,000 shares which had been issued to her, and the shares were cancelled as of
January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom the Company has a settlement agreement), filed
a motion for sanctions and civil contempt against us, which generally claimed that we failed to comply with the Court&#x2019;s January
4, 2019, order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer their shares of common stock. On
October 29, 2019, the Court denied the Defendants motion. On March 20, 2020, the Florida district court of appeal reversed the lower court
ruling in the Florida state court action that dismissed our complaint, with prejudice, and gave us leave to file an amended complaint.
On July 7, 2020, Defendants filed Notice for Trial, requesting the court to set a trial date. The Company and defendants have served their
first set of interrogatories on each other and have filed answers and responses to each other&#x2019;s first set of interrogatories.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 22, 2018, four of the defendants in
the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of Common
Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement.
The parties have agreed to a stay pending the outcome of the Florida litigation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 29, 2019, the Company filed a securities
fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy,
Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently and deceitfully
obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud the Company. The Company is seeking the return
of the shares of common stock and monetary damages resulting from the defendants&#x2019; fraudulent conduct. The defendants filed a motion
to dismiss the complaint on August 23, 2019, and on September 13, 2019, the Company filed its response. On July 20, 2020, the Court denied
the defendant&#x2019;s motion to dismiss the complaint, and the parties have recently commenced the discovery phase of the litigation.
The Court has scheduled a trial date in November 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company entered into a three-year employment
agreement with Gareth Sheridan, our CEO, effective April 25, 2019. The agreement also provides that the executive will continue as a director.
The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2024, and continuing
on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#x2019; notice given prior to the expiration
of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Sheridan receives
an annual salary $42,000 per annum, commencing on the effective date of the agreement and increasing to $170,000 per annum in the month
in which the Company shall have received not less than $2,500,000 from one or more public or private financings of the Company&#x2019;s
equity securities subsequent to the date of the agreement. During the year ended January 31, 2021, the salary was increased to $60,000
per annum.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Rambam Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 9, 2020, the Company entered into
a License Agreement (the &#x201c;License Agreement&#x201d;) with Rambam Med-Tech Ltd. (&#x201c;Rambam&#x201d;), Haifa, Israel, to develop
the RAMBAM Closed System Transfer Device (&#x201c;CTSD&#x201d;) and such other products as the parties agree to develop/commercialize. The
Company will license from Rambam the full technology, IP, and title to CTSD in the field, with an Initial license fee of $50,000 and running
royalties on net sales. The $50,000 license fee was paid by a third party at the direction of the Company in February 2021, at which time
the agreement became effective.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had entered into a prior agreement,
dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#x201c;BPM&#x201d;), that, in consideration of BPM&#x2019;s introduction of
Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#x2019;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;BPM Distribution and Stock Purchase Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 10, 2021, the Company finalized the Distribution Agreement with BPM, providing for distribution of the medical products developed and produced under the License Agreement. Under the Distribution Agreement, BPM&#160;has the right to distribute the medical products in Israel and has a right of first refusal in relation to all other countries/states, other than United States, Korea, China, Vietnam, Canada and Ecuador, which are termed excluded countries.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company and BPM entered into a Stock Purchase Agreement (&#x201c;SPA&#x201d;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#x2019; Equity in the Company&#x2019;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#x2019;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c164" decimals="INF" unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c164" decimals="0" unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="c165" decimals="INF" unitRef="shares">50000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c166" decimals="INF" unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ntrb:SalaryPayment contextRef="c224" decimals="0" unitRef="usd">42000</ntrb:SalaryPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c225" decimals="0" unitRef="usd">170000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <ntrb:PublicOrPrivateFinancing contextRef="c226" decimals="0" unitRef="usd">2500000</ntrb:PublicOrPrivateFinancing>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c168" decimals="0" unitRef="usd">60000</us-gaap:SalariesWagesAndOfficersCompensation>
    <ntrb:PaymentForInitialLicenseFee contextRef="c169" decimals="0" unitRef="usd">50000</ntrb:PaymentForInitialLicenseFee>
    <ntrb:PaymentForInitialLicenseFee contextRef="c218" decimals="0" unitRef="usd">50000</ntrb:PaymentForInitialLicenseFee>
    <us-gaap:SignificantPurchaseCommitmentDescription contextRef="c227">The Company and BPM entered into a Stock Purchase Agreement (&#x201c;SPA&#x201d;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#x2019; Equity in the Company&#x2019;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#x2019;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.</us-gaap:SignificantPurchaseCommitmentDescription>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 31, 2020, the Company entered into a
Purchase Agreement (&#x201c;Agreement&#x201d;), with Pocono Coated Products (&#x201c;PCP&#x201d;), pursuant to which PCP agreed to sell the
Company all of the assets associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the &#x201c;Assets&#x201d;). PCP
is the manufacturer of our transdermal products, and we bought that business from them. The purchase price for the Assets was (i) $6,000,000
paid in shares of the Company&#x2019;s common stock at a value of the average price of the previous 90 days at the date of Closing (the
&#x201c;Shares&#x201d;); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a)
twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of
no less than $4,000,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 31, 2021 we entered into an amendment
to the Agreement with the parties to the Agreement that provides for an extension of the August 31, 2021 due date of the $1,500,000 note
issued in the transaction to September 30, 2021, and extends the time limit set forth in Section 5.3(a) of the Agreement for completion
of the Listing and for payment of the Note in full until September 30, 2021.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventDescription contextRef="c99">(i) $6,000,000
paid in shares of the Company&#x2019;s common stock at a value of the average price of the previous 90 days at the date of Closing (the
&#x201c;Shares&#x201d;); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a)
twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of
no less than $4,000,000.</us-gaap:SubsequentEventDescription>
    <us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares contextRef="c99" decimals="INF" unitRef="shares">1500000</us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-1/A</dei:DocumentType>
    <us-gaap:InventoryNet
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="c1"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c1"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c1"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c1"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenueCurrent
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="c1"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="c2"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="hidden-fact-15"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="hidden-fact-16"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="hidden-fact-17"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="hidden-fact-18"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="hidden-fact-19"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="hidden-fact-20"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="hidden-fact-21"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="hidden-fact-22"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c14"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices
      contextRef="c15"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices
      contextRef="c17"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices
      contextRef="c18"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodIssuanceOfWarrantsForServices
      contextRef="c19"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c17"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c18"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c19"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c15"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c16"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c18"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c19"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c24"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants
      contextRef="c27"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants
      contextRef="c28"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants
      contextRef="c29"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c27"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c28"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c29"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c27"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c28"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c29"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c25"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c27"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c28"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c29"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:IssuanceOfCommonStockForNotePayable
      contextRef="c27"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:IssuanceOfCommonStockForNotePayable
      contextRef="c28"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:IssuanceOfCommonStockForNotePayable
      contextRef="c29"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForCash
      contextRef="c25"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForCash
      contextRef="c26"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForCash
      contextRef="c27"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForCash
      contextRef="c28"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForServices
      contextRef="c25"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForServices
      contextRef="c26"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForServices
      contextRef="c27"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscrptionPayableForServices
      contextRef="c28"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c37"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c38"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c37"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c38"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c35"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c39"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c44"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c24"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c47"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c48"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c49"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SaleofCommonstockForCash
      contextRef="c47"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SaleofCommonstockForCash
      contextRef="c48"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SaleofCommonstockForCash
      contextRef="c49"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c47"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c48"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c49"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c45"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c47"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c48"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ReclassificationOfWarrantsFromLiabilityToEquity
      contextRef="c49"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c46"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c47"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c49"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c55"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c61"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c62"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c63"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c64"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c66"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c44"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c72"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c75"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c76"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c77"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c73"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c74"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c75"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c77"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c55"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:IncreaseDecreaseInDerivativeExpense
      contextRef="c4"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:EarlyPrepaymentFeeOnConvertibleDebentures
      contextRef="c5"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c5"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:GainOnForgivenessOfLoanPayment
      contextRef="c5"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SubscriptionPayable
      contextRef="c5"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c5"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="c5"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c5"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c5"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c4"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c5"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c5"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="c5"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c5"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="c4"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c5"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c4"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c5"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:CommonStockAndNoteIssuedInAcquisitions
      contextRef="c5"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:AdoptionOfASC842OperatingLeaseAssetAndLiability
      contextRef="c4"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:DerivativeLiabilityWarrantReclassedToEquity
      contextRef="c5"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:DebtDiscountOnConvertibleNotes
      contextRef="c4"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:CommonStockIssuedForAccountsPayable
      contextRef="c4"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:CommonStockIssuedForSettlement
      contextRef="c5"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="c0"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c0"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:EarlyPrepaymentFeeOnConvertibleDebentures
      contextRef="c0"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfLeasedAsset
      contextRef="c0"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c8"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:IncreaseDecreaseOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c8"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c0"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="c0"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c8"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c8"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c0"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c0"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="c0"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="c8"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c8"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c8"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:CommonStockIssuedForSettlementOfNotesPayable
      contextRef="c0"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:NoncashPaymentForLicenseAgreement
      contextRef="c8"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:DerivativeLiabilityWarrantReclassedToEquity
      contextRef="c0"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:CommonIssuedForSubscriptionPayable
      contextRef="c8"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:PropertyPlantAndEquipmentsGross
      contextRef="c104"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="c4"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="c5"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c1"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c127"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue
      contextRef="c156"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c156"
      id="hidden-fact-177"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c156"
      id="hidden-fact-178"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess
      contextRef="c156"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess
      contextRef="c156"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c157"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue
      contextRef="c158"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess
      contextRef="c158"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c158"
      id="hidden-fact-184"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c158"
      id="hidden-fact-185"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess
      contextRef="c158"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c161"
      id="hidden-fact-187"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c162"
      id="hidden-fact-188"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c163" id="hidden-fact-189" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c162"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices contextRef="c163" id="hidden-fact-191" xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess
      contextRef="c163"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c163"
      id="hidden-fact-193"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c163"
      id="hidden-fact-194"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices contextRef="c163" id="hidden-fact-195" xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess
      contextRef="c163"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c161"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c161"
      id="hidden-fact-198"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne contextRef="c163" id="hidden-fact-199" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c161"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c161"
      id="hidden-fact-201"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c161"
      id="hidden-fact-202"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c163" id="hidden-fact-203" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c161"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:SaleOfGoodsAndServices
      contextRef="c6"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c181"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c205"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      id="hidden-fact-208"
      unitRef="shares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice
      contextRef="c0"
      id="hidden-fact-209"
      unitRef="shares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue
      contextRef="c0"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c0"
      id="hidden-fact-211"
      unitRef="shares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice
      contextRef="c0"
      id="hidden-fact-212"
      unitRef="shares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices contextRef="c0" id="hidden-fact-213" xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-214"
      unitRef="shares"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice
      contextRef="c0"
      id="hidden-fact-215"
      unitRef="shares"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices contextRef="c0" id="hidden-fact-216" xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal
      contextRef="c3"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c3"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue
      contextRef="c222"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue
      contextRef="c3"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0">0001676047</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321724996424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Nutriband Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">AMENDMENT NO. 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001676047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321723438408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 304,258<span></span>
</td>
<td class="nump">$ 151,993<span></span>
</td>
<td class="nump">$ 10,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">13,765<span></span>
</td>
<td class="nump">109,347<span></span>
</td>
<td class="nump">12,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">72,600<span></span>
</td>
<td class="nump">52,848<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">216,127<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">606,750<span></span>
</td>
<td class="nump">314,188<span></span>
</td>
<td class="nump">43,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY &amp; EQUIPMENT-net</a></td>
<td class="nump">1,035,109<span></span>
</td>
<td class="nump">1,076,626<span></span>
</td>
<td class="nump">111,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,529,875<span></span>
</td>
<td class="nump">7,529,875<span></span>
</td>
<td class="nump">1,719,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use operating lease asset-net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets-net</a></td>
<td class="nump">991,821<span></span>
</td>
<td class="nump">1,006,730<span></span>
</td>
<td class="nump">314,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">10,163,555<span></span>
</td>
<td class="nump">9,927,419<span></span>
</td>
<td class="nump">2,197,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">975,596<span></span>
</td>
<td class="nump">940,612<span></span>
</td>
<td class="nump">771,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">928,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">64,704<span></span>
</td>
<td class="nump">86,846<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Notes payable-related party, net</a></td>
<td class="nump">1,475,631<span></span>
</td>
<td class="nump">1,402,523<span></span>
</td>
<td class="nump">29,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities-current portion</a></td>
<td class="nump">25,506<span></span>
</td>
<td class="nump">24,740<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable-current portion</a></td>
<td class="nump">114,119<span></span>
</td>
<td class="nump">113,885<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debt- net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,655,556<span></span>
</td>
<td class="nump">2,568,606<span></span>
</td>
<td class="nump">2,022,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_LongTermLiabilitiesAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable-net of current portion</a></td>
<td class="nump">108,077<span></span>
</td>
<td class="nump">150,063<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities-net of current portion</a></td>
<td class="nump">83,856<span></span>
</td>
<td class="nump">96,804<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,847,489<span></span>
</td>
<td class="nump">2,815,473<span></span>
</td>
<td class="nump">2,022,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Value</a></td>
<td class="nump">6,356<span></span>
</td>
<td class="nump">6,257<span></span>
</td>
<td class="nump">5,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">19,980,999<span></span>
</td>
<td class="nump">18,871,098<span></span>
</td>
<td class="nump">9,072,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubscriptionPayables', window );">Subscription payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(304)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(12,670,985)<span></span>
</td>
<td class="num">(11,835,105)<span></span>
</td>
<td class="num">(8,902,277)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">7,316,066<span></span>
</td>
<td class="nump">7,111,946<span></span>
</td>
<td class="nump">175,433<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 10,163,555<span></span>
</td>
<td class="nump">$ 9,927,419<span></span>
</td>
<td class="nump">$ 2,197,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_LongTermLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_LongTermLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SubscriptionPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SubscriptionPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321735752920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,256,772<span></span>
</td>
<td class="nump">5,441,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,256,772<span></span>
</td>
<td class="nump">5,441,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockShareIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,356,270<span></span>
</td>
<td class="nump">6,256,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockShareOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,356,270<span></span>
</td>
<td class="nump">6,256,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640436744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 213,739<span></span>
</td>
<td class="nump">$ 84,450<span></span>
</td>
<td class="nump">$ 647,227<span></span>
</td>
<td class="nump">$ 203,814<span></span>
</td>
<td class="nump">$ 943,702<span></span>
</td>
<td class="nump">$ 370,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">186,762<span></span>
</td>
<td class="nump">116,937<span></span>
</td>
<td class="nump">355,606<span></span>
</td>
<td class="nump">191,876<span></span>
</td>
<td class="nump">582,378<span></span>
</td>
<td class="nump">549,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">509,219<span></span>
</td>
<td class="nump">193,331<span></span>
</td>
<td class="nump">1,088,827<span></span>
</td>
<td class="nump">385,248<span></span>
</td>
<td class="nump">2,957,269<span></span>
</td>
<td class="nump">1,790,980<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Costs and Expenses</a></td>
<td class="nump">695,981<span></span>
</td>
<td class="nump">310,268<span></span>
</td>
<td class="nump">1,444,433<span></span>
</td>
<td class="nump">577,124<span></span>
</td>
<td class="nump">3,539,647<span></span>
</td>
<td class="nump">2,340,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(482,242)<span></span>
</td>
<td class="num">(225,818)<span></span>
</td>
<td class="num">(797,206)<span></span>
</td>
<td class="num">(373,310)<span></span>
</td>
<td class="num">(2,595,945)<span></span>
</td>
<td class="num">(1,969,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OtherIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">3,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,214<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Early prepayment fee on convertible debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,131)<span></span>
</td>
<td class="num">(69,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_GainOnForgivenessOfDebt', window );">Gain on forgiveness of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Derivative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(767,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Gain on change of fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,096<span></span>
</td>
<td class="nump">22,096<span></span>
</td>
<td class="nump">88,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(41,019)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(81,888)<span></span>
</td>
<td class="num">(205,218)<span></span>
</td>
<td class="num">(280,686)<span></span>
</td>
<td class="num">(73,413)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(37,681)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(38,674)<span></span>
</td>
<td class="num">(264,753)<span></span>
</td>
<td class="num">(336,883)<span></span>
</td>
<td class="num">(752,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(519,923)<span></span>
</td>
<td class="num">(225,869)<span></span>
</td>
<td class="num">(835,880)<span></span>
</td>
<td class="num">(638,063)<span></span>
</td>
<td class="num">(2,932,828)<span></span>
</td>
<td class="num">(2,721,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (519,923)<span></span>
</td>
<td class="num">$ (225,869)<span></span>
</td>
<td class="num">$ (835,880)<span></span>
</td>
<td class="num">$ (638,063)<span></span>
</td>
<td class="num">$ (2,932,828)<span></span>
</td>
<td class="num">$ (2,721,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock-basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding - basic and diluted (in Shares)</a></td>
<td class="nump">6,356,269<span></span>
</td>
<td class="nump">5,513,782<span></span>
</td>
<td class="nump">6,343,076<span></span>
</td>
<td class="nump">5,496,274<span></span>
</td>
<td class="nump">5,770,944<span></span>
</td>
<td class="nump">5,423,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OtherComprehensiveLossAbstract', window );"><strong>Other Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net loss</a></td>
<td class="num">$ (519,923)<span></span>
</td>
<td class="num">$ (225,869)<span></span>
</td>
<td class="num">$ (835,880)<span></span>
</td>
<td class="num">$ (638,063)<span></span>
</td>
<td class="num">$ (2,932,828)<span></span>
</td>
<td class="num">$ (2,721,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total Comprehensive Income (Loss)</a></td>
<td class="num">$ (519,923)<span></span>
</td>
<td class="num">$ (225,869)<span></span>
</td>
<td class="num">$ (835,880)<span></span>
</td>
<td class="num">$ (638,063)<span></span>
</td>
<td class="num">$ (2,932,828)<span></span>
</td>
<td class="num">$ (2,721,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_GainOnForgivenessOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_GainOnForgivenessOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_OtherComprehensiveLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_OtherComprehensiveLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_OtherIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_OtherIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321636899256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Subscription Payable</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2019</a></td>
<td class="nump">$ 5,424<span></span>
</td>
<td class="nump">$ 8,579,890<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="num">$ (6,180,650)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,404,612<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jan. 31, 2019</a></td>
<td class="nump">5,423,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices', window );">Issuance of warrants for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">252,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">252,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock for accounts payable</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">239,983<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock for accounts payable (in Shares)</a></td>
<td class="nump">17,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,721,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,721,627)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2020</a></td>
<td class="nump">$ 5,441<span></span>
</td>
<td class="nump">9,072,573<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(8,902,277)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,433<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jan. 31, 2020</a></td>
<td class="nump">5,441,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">49,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SaleofCommonstockForCash', window );">Common stock issued for cash</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">515,061<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">515,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock issued for cash (in Shares)</a></td>
<td class="nump">46,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of debt for common stock</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">287,475<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">287,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of debt for common stock (in Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ReclassificationOfWarrantsFromLiabilityToEquity', window );">Reclassification of warrants from liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">906,678<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">906,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(638,063)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(638,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jul. 31, 2020</a></td>
<td class="nump">$ 5,518<span></span>
</td>
<td class="nump">10,831,782<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(9,540,340)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,296,656<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jul. 31, 2020</a></td>
<td class="nump">5,517,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2020</a></td>
<td class="nump">$ 5,441<span></span>
</td>
<td class="nump">9,072,573<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(8,902,277)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,433<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jan. 31, 2020</a></td>
<td class="nump">5,441,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants', window );">Proceeds from sale of common stock and warrants</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">515,061<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">515,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants', window );">Proceeds from sale of common stock and warrants (in Shares)</a></td>
<td class="nump">46,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisition</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">6,084,571<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,085,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition (in Shares)</a></td>
<td class="nump">608,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">2,004,740<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,004,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in Shares)</a></td>
<td class="nump">135,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ReclassificationOfWarrantsFromLiabilityToEquity', window );">Reclassification of warrants from liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">906,678<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">906,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IssuanceOfCommonStockForNotePayable', window );">Issuance of common stock for note payable</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">287,475<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">287,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IssuanceOfCommonStockForNotePayableinShares', window );">Issuance of common stock for note payable (in Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubscrptionPayableForCash', window );">Subscription payable for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubscrptionPayableForServices', window );">Subscription payable for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,932,828)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,932,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2021</a></td>
<td class="nump">$ 6,257<span></span>
</td>
<td class="nump">18,871,098<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(11,835,105)<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">7,111,946<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jan. 31, 2021</a></td>
<td class="nump">6,256,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2020</a></td>
<td class="nump">$ 5,513<span></span>
</td>
<td class="nump">10,781,787<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(9,314,471)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,472,525<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Apr. 30, 2020</a></td>
<td class="nump">5,512,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">49,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(225,869)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(225,869)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jul. 31, 2020</a></td>
<td class="nump">$ 5,518<span></span>
</td>
<td class="nump">10,831,782<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(9,540,340)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,296,656<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jul. 31, 2020</a></td>
<td class="nump">5,517,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jan. 31, 2021</a></td>
<td class="nump">$ 6,257<span></span>
</td>
<td class="nump">18,871,098<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(11,835,105)<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">7,111,946<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jan. 31, 2021</a></td>
<td class="nump">6,256,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for proceeds and payment for license</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">699,919<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for proceeds and payment for license (in Shares)</a></td>
<td class="nump">81,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">409,982<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in Shares)</a></td>
<td class="nump">18,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(835,880)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(835,880)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jul. 31, 2021</a></td>
<td class="nump">$ 6,356<span></span>
</td>
<td class="nump">19,980,999<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(12,670,985)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,316,066<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jul. 31, 2021</a></td>
<td class="nump">6,356,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2021</a></td>
<td class="nump">$ 6,356<span></span>
</td>
<td class="nump">19,980,999<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(12,151,062)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,835,989<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Apr. 30, 2021</a></td>
<td class="nump">6,356,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(519,923)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(519,923)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jul. 31, 2021</a></td>
<td class="nump">$ 6,356<span></span>
</td>
<td class="nump">$ 19,980,999<span></span>
</td>
<td class="num">$ (304)<span></span>
</td>
<td class="num">$ (12,670,985)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,316,066<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jul. 31, 2021</a></td>
<td class="nump">6,356,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IssuanceOfCommonStockForNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IssuanceOfCommonStockForNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IssuanceOfCommonStockForNotePayableinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IssuanceOfCommonStockForNotePayableinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ReclassificationOfWarrantsFromLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrants from liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ReclassificationOfWarrantsFromLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SaleofCommonstockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Common stock For Cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SaleofCommonstockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SubscrptionPayableForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscrption payable for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SubscrptionPayableForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SubscrptionPayableForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscrption payable for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SubscrptionPayableForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321635013064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (835,880)<span></span>
</td>
<td class="num">$ (638,063)<span></span>
</td>
<td class="num">$ (2,932,828)<span></span>
</td>
<td class="num">$ (2,721,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Expenses paid on behalf of the Company by related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,628<span></span>
</td>
<td class="nump">12,627<span></span>
</td>
<td class="nump">23,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">155,822<span></span>
</td>
<td class="nump">36,094<span></span>
</td>
<td class="nump">160,108<span></span>
</td>
<td class="nump">72,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IncreaseDecreaseInDerivativeExpense', window );">Derivative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">767,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_EarlyPrepaymentFeeOnConvertibleDebentures', window );">Early prepayment fee on convertible debentures</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">69,131<span></span>
</td>
<td class="nump">69,131<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on extinguisment of debt</a></td>
<td class="num">(43,214)<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_GainOnForgivenessOfLoanPayment', window );">Gain on forgiveness of loan payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,338)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on change in fair value of derivative</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(22,096)<span></span>
</td>
<td class="num">(22,096)<span></span>
</td>
<td class="num">(88,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">73,108<span></span>
</td>
<td class="nump">202,500<span></span>
</td>
<td class="nump">272,130<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfLeasedAsset', window );">Amortization of right of use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,610<span></span>
</td>
<td class="nump">9,610<span></span>
</td>
<td class="nump">19,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">2,004,875<span></span>
</td>
<td class="nump">252,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubscriptionPayable', window );">Subscription payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">95,582<span></span>
</td>
<td class="num">(1,811)<span></span>
</td>
<td class="num">(94,753)<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(41,127)<span></span>
</td>
<td class="num">(4,358)<span></span>
</td>
<td class="nump">20,167<span></span>
</td>
<td class="nump">82,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(19,752)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,235)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_increasedecreaseDepositOnSales', window );">Deposit on sales</a></td>
<td class="num">(22,142)<span></span>
</td>
<td class="nump">29,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerDeposits', window );">Customer deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,995<span></span>
</td>
<td class="num">(71,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IncreaseDecreaseOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,050)<span></span>
</td>
<td class="num">(10,050)<span></span>
</td>
<td class="num">(18,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">44,659<span></span>
</td>
<td class="num">(38,462)<span></span>
</td>
<td class="nump">145,102<span></span>
</td>
<td class="nump">720,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(367,944)<span></span>
</td>
<td class="num">(313,652)<span></span>
</td>
<td class="num">(297,055)<span></span>
</td>
<td class="num">(894,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(49,396)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash received from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,994<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,994<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">583,000<span></span>
</td>
<td class="nump">515,108<span></span>
</td>
<td class="nump">515,108<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">194,870<span></span>
</td>
<td class="nump">194,870<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from stock subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment on note payable</a></td>
<td class="num">(1,213)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,935)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payment on convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(339,131)<span></span>
</td>
<td class="num">(339,131)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment on finance leases</a></td>
<td class="num">(12,182)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,345)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">34,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment of related party payables</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(33,628)<span></span>
</td>
<td class="num">(47,194)<span></span>
</td>
<td class="num">(29,730)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">569,605<span></span>
</td>
<td class="nump">342,719<span></span>
</td>
<td class="nump">371,873<span></span>
</td>
<td class="nump">430,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="nump">152,265<span></span>
</td>
<td class="nump">29,067<span></span>
</td>
<td class="nump">141,812<span></span>
</td>
<td class="num">(464,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - Beginning of period</a></td>
<td class="nump">151,993<span></span>
</td>
<td class="nump">10,181<span></span>
</td>
<td class="nump">10,181<span></span>
</td>
<td class="nump">474,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - End of period</a></td>
<td class="nump">304,258<span></span>
</td>
<td class="nump">39,248<span></span>
</td>
<td class="nump">151,993<span></span>
</td>
<td class="nump">10,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CashPaidForAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,555<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockAndNoteIssuedInAcquisitions', window );">Common stock and note issued for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,418,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability', window );">Adoption of ASC 842 Operating lease asset and liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockIssuedForSettlementOfNotesPayable', window );">Common stock issued for settlement of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">287,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockIssuedForPrepaidConsulting', window );">Common stock issued for prepaid consulting</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NoncashPaymentForLicenseAgreement', window );">Non-cash payment for license agreement</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DerivativeLiabilityWarrantReclassedToEquity', window );">Derivative liability warrant reclassed to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">906,678<span></span>
</td>
<td class="nump">906,678<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonIssuedForSubscriptionPayable', window );">Common issued for subscription payable</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DebtDiscountOnConvertibleNotes', window );">Debt discount on convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockIssuedForAccountsPayable', window );">Common stock issued for accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockIssuedForSettlement', window );">Common stock issued for settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adoption of ASC 842 Operating lease asset and liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CashPaidForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CashPaidForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonIssuedForSubscriptionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common issued for subscription payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonIssuedForSubscriptionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockAndNoteIssuedInAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock and note issued in acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockAndNoteIssuedInAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockIssuedForAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockIssuedForAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockIssuedForPrepaidConsulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockIssuedForPrepaidConsulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockIssuedForSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockIssuedForSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockIssuedForSettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for settlement of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockIssuedForSettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DebtDiscountOnConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt discount on convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DebtDiscountOnConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DerivativeLiabilityWarrantReclassedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liability warrant reclassed to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DerivativeLiabilityWarrantReclassedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_EarlyPrepaymentFeeOnConvertibleDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early prepayment fee on convertible debenture.



..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_EarlyPrepaymentFeeOnConvertibleDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_GainOnForgivenessOfLoanPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of loan payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_GainOnForgivenessOfLoanPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IncreaseDecreaseInDerivativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IncreaseDecreaseInDerivativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IncreaseDecreaseOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IncreaseDecreaseOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_NoncashPaymentForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash payment for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_NoncashPaymentForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SubscriptionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subscription payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SubscriptionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_increasedecreaseDepositOnSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_increasedecreaseDepositOnSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfLeasedAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123406127&amp;loc=d3e45031-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfLeasedAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCustomerDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634832952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORGANIZATION AND DESCRIPTION OF BUSINESS </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Organization</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nutriband Inc. (the &#8220;Company&#8221;) is
a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was
formed by the Company&#8217;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2018, the Company acquired 4P Therapeutics
LLC (&#8220;4P Therapeutics&#8221;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000,
and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by
4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company
since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#8217;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#8220;FDA&#8221;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the acquisition of 4P Therapeutics, 4P Therapeutics&#8217;
drug development business became the Company&#8217;s principal business. The Company&#8217;s approach is to use generic drugs that are
off patent and incorporate them into the Company&#8217;s transdermal drug delivery system. Although these medications have received FDA
approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical
and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2020, the Company formed Pocono
Pharmaceuticals Inc. (&#8220;Pocono Pharmaceuticals&#8221;), a wholly owned subsidiary of the Company. On August 31, 2020, the Company
acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated
Products LLC (&#8220;PCP&#8221;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company also
acquired 100% of the membership interests of Active Intelligence LLC (&#8220;Active Intelligence&#8221;). See Note 2 for further details
of the acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pocono Pharmaceuticals is a coated products manufacturing
entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product design and
development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#8217;s competitive
edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is used as the same as traditional
kinesiology tape.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, COVID-19 emerged and has subsequently
spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and
private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders
and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed quarantines
and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business and could
delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Organization</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Nutriband Inc. (the &#8220;Company&#8221;)
is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which
was formed by the Company&#8217;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 1, 2018, the Company acquired
4P Therapeutics LLC (&#8220;4P Therapeutics&#8221;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000,
and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been
developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of
the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#8217;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#8220;FDA&#8221;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">With the acquisition of 4P Therapeutics,
4P Therapeutics&#8217; drug development business became the Company&#8217;s principal business. The Company&#8217;s approach is to use
generic drugs that are off patent and incorporate them into the Company&#8217;s transdermal drug delivery system. Although these medications
have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will
include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical
products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 25, 2020, the Company formed
Pocono Pharmaceuticals Inc. (&#8220;Pocono Pharmaceuticals&#8221;), a wholly owned subsidiary of the Company. On August 31, 2020, the
Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono
Coated Products LLC (&#8220;PCP&#8221;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company
also acquired 100% of the membership interests of Active Intelligence LLC (&#8220;Active Intelligence&#8221;). See Note 2 for further
details of the acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Pocono Pharmaceuticals is a coated products
manufacturing entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product
design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#8217;s
competitive edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is the same as traditional kinesiology
tape.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, COVID-19 emerged and
has subsequently spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local
governments and private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay
at home orders and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed
quarantines and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business
and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Reverse Stock Split</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 25, 2019, the Company effected
one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock. The
reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements
retroactively reflect the reverse split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Going Concern</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2021, the Company
believes the substantial doubt about going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current year net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to alleviate
the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses, equity
funding that has been received and the net revenue and positive cash flow from its recent acquisition. These factors did not exist in
prior years during its start-up operations. The Company&#8217;s recent history of losses has changed from prior periods due to its current
management&#8217;s plans including its acquisition in the latter part of 2020 to alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s plans have been currently implemented. The plans enable the Company to meet
its obligations for at least one year from the date when the financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The consolidated financial statements
of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated.
The operations of 4P Therapeutics are included in the Company&#8217;s financial statements from the date of acquisition of August 1, 2018
and the operations of Pocono and Active Intelligence are included in the Company&#8217;s financial statements from the date of acquisition
of September 1, 2020. The wholly owned subsidiaries are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Nutriband Ltd.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">4P Therapeutics LLC</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pocono Pharmaceuticals Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of the consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related&#160;disclosure
of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related
to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Cash and Cash Equivalents</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Cash equivalents include short-term
investments in money-market funds and certificate of deposits with an original maturity of three months or less when purchased.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Foreign Currency Translation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The functional currency of the Company&#8217;s
Irish subsidiary is the Euro. The assets and liabilities of the subsidiary are translated into US dollars using the prevailing exchange
rate as of the balance sheet date and income and expenses are translated into US dollars using the average exchange rate during the reporting
period. Translation adjustments are recorded in other comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Revenue Recognition</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In May 2014, the FASB issued ASU No.
2014-09, &#8220;Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which amends the accounting standards for
revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled
when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a description of the
Company&#8217;s revenue types, which include professional services and sale of goods:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service revenues include the contract of research and development related services with the Company&#8217;s clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product revenues are derived from the sale of the Company&#8217;s consumer transdermal and coated products. Upon the reception of a purchase order, we have the order filled and shipped.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A contract with a customer exists when
(i) we enter into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be
transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii)
we determine that collection of substantially all consideration for services that are transferred is probable based on the customer&#8217;s
intent and ability to pay the promised consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Deferred Revenue</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Deferred revenue is a liability related
to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration
from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A performance obligation is a promise
in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract
transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation
is satisfied. For the Company&#8217;s different revenue service types, the performance obligation is satisfied at different times. The
Company&#8217;s performance obligations include providing products and professional services in the area of research. The Company recognizes
product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service
work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on
a monthly basis for the work performed during that month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All revenue recognized in the income
statement is considered to be revenue from contracts with customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company disaggregates its revenue
from contracts with customers by type and by geographical location. See the tables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">737,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">124,958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">245,679</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographical location</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">360,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">245,679</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Accounts receivable</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Trade accounts receivable are recorded
at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from
the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer
accounts where appropriate and the application of historical loss to non-specific accounts. For the years ended January 31, 2021 and 2020,
the Company recorded no bad debt expense and no allowance for doubtful accounts related to accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Inventories are valued at the lower
of cost and realizable value determined using the first-in, first-out (FIFO) method. Net realizable value is the estimated selling price
in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in progress is comprised
of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Property and equipment represent an
important component of the Company&#8217;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated
useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and
replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements
are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range
from 3 to 10 years as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Intangible Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Intangible assets include trademarks,
intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under
the guidance of ASC 350, &#8220;Intangibles-Goodwill and Other.&#8221; The Company capitalizes certain costs related to patent technology.
A substantial component of the purchase price related to the Company&#8217;s acquisition has also been assigned to intellectual property
and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives.
Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being
amortized over their estimated useful lives of ten years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Goodwill</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Goodwill represents the difference between
the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is
reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which
the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August
31, 2020, in connection with the Company&#8217;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $5,810,640. As of January 31, 2021, Goodwill amounted to $7,529,875.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Long-lived Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Management reviews long-lived assets
for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The
carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result
from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between
fair market value of the long-lived asset and the related net book value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Stock-Based Compensation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ASC 718, &#8220;Compensation - Stock
Compensation,&#8221; prescribes accounting and reporting standards for all share-based payment transactions in which employee services,
and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue
shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments
to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on
their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for
the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718
was applied to stock-based compensation for both employees and non-employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Business Combinations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company recognizes the assets acquired,
the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values
as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related
costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That
replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated
to the individual assets acquired and liabilities assumed based on their estimated fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Leases</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February 2016, the FASB issued ASU
2016-02, &#8220;Leases&#8221; (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and
lessors should apply a &#8220;right-of-use&#8221; model in accounting for all leases (including subleases) and eliminate the concept of
operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as
a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company adopted ASU 2016-02 as amended
effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize
the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under
ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates
the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company
completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Research and Development</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Research and developments costs are
expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Income Taxes</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Taxes are calculated in accordance with
taxation principles currently effective in the United States and Ireland.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounts for income taxes
under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are
determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company records net deferred tax
assets to the extent they believe these assets will more-likely-than-not be realized. In making such determination, the Company considers
all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable
income, tax planning strategies and recent financial operations. In the event the Company was to determine that it would be able to realize
its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation
allowance which would reduce the provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Concentration of Credit Risk</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial instruments which potentially
subject the Company to concentrations of credit risk consist principally of cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s cash and cash equivalents
are concentrated primarily in banks. At times, such deposits could be in excess of insured limits. Management believes that the financial
institutions that hold the Company&#8217;s financial instruments are financially sound and, accordingly, minimal credit risk is believed
to exist with respect to these financial instruments. As of and for the year ended January 31, 2020, three customers accounted for 100%
of the Company&#8217;s revenues and two customers accounted for 100% of accounts receivable. As of and for the year ended January 31,
2021, one customer accounted for 62% of the Company&#8217;s revenues and two customers accounted for 67% and 13% of accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Earnings Per Share</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Basic earnings per share of common stock
is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings
per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common
stock outstanding during the period.&#160;Potential shares of common stock consist of outstanding common stock purchase warrants. For
the years ended January 31, 2021 and 2020 there were 141,830 and 70,000 potential shares of common stock that were not included in the
calculation of diluted earnings per share as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements
and Disclosure&#8221; (&#8220;ASC 820&#8221;), defines fair value as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs
that may be to measure fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company utilizes the accounting
guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities
that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.
The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier
value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 -&#160;Observable inputs such
as quoted market prices in active markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 -&#160;Inputs other than quoted
prices in active markets that are either directly or indirectly observable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 -&#160;Unobservable inputs
about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The carrying value of the Company&#8217;s
financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their
fair value due to the short maturities of these financial instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Derivative liabilities are determined
based on &#8220;Level 3&#8221; inputs, which are significant and unobservable and have the lowest priority. The recorded values of all
other financial instruments approximate their current fair value because of their nature and respective short maturity dates or durations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Derivative Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounts for derivative
instruments in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; and all derivative instruments are reflected as either
assets or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments.
Fair value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market
participants. In general, the Company&#8217;s policy in estimating fair values is to first look at observable market prices for identical
assets and liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such
as prices of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable
data from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of January 31, 2021, and 2020, the Company had a $-0-
and $928,774 derivative liability, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Fair value estimates are made at a specific
point in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve
uncertainties and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly
affect the estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Recent Accounting Standards</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August 2018, the FASB issued ASU
2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements&#8221;. The updated
guidance improves the disclosure requirements on fair value measurement. The updated guidance is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. The Company adopted the provisions effective February 1, 2020. The
adoption did not have a material impact on the Company&#8217;s consolidated financial position or consolidated results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, the FASB issued ASU
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which modifies ASC 740 to reduce complexity while maintaining
or improving the usefulness of the information provided to the users of financial statements. ASU 209-12 is effective for annual reporting
periods beginning after December 15, 2021. The Company is currently assessing the impact of ASU 209-12, but it is not expected to have
a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has reviewed all other FASB-issued
ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods.
The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles
will have a material impact on the company&#8217;s reported financial position or operations in the near term. The applicability of any
standard is subject to the formal review of the Company&#8217;s financial management and certain standards are under consideration.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634634344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION OF BUSINESS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACQUISITION OF BUSINESS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2020, the Company entered into a
Purchase Agreement (&#8220;Agreement&#8221;), with Pocono Coated Products (&#8220;PCP&#8221;), pursuant to which PCP agreed to sell the
Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business, including:
(1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free and clear
of all liens, except for certain lease obligations, and (2), a 100% membership interest in Active Intelligence, LLC (collectively the
&#8220;Assets&#8221;). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary
of the Company. The purchase price for the Assets was (i) $6,085,180 paid with the issuance of 608,519 shares in the Company&#8217;s common
stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the &#8220;Shares&#8221;), and (ii)
a promissory note of the Company, net of debt discount, in the principal amount, of $1,332,893 (the Note&#8221;) which is due upon the
earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $4,000,000 and/or a public
offering of no less than $4,000,000. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period
of one year at the annual meeting of shareholders of the Company held in October 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement provides that it is effective August
31, 2020, on which date the parties also entered into an escrow agreement (the &#8220;Escrow Agreement&#8221;), with legal counsel serving
as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special purpose
subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also entered
into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of the Company entering into the transaction
is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated to the net tangible
assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and, as such, the transaction
was accounted for under the acquisition method of accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the net assets acquired are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Fair value</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Recognized on</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Acquisition</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">Common stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">6,085,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Note payable issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">66,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,761</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,613</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equipment and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer base</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intellectual property and trademarks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">583,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,810,640</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,104</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,851</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(268,715</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following unaudited pro forma condensed financial
information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and Active Intelligence,
as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed financial information
is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had
the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated
results of operations of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>July 31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As Reported</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Proforma</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">203,814</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">629,873</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(638,063</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(702,975</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACQUISITION OF BUSINESS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 31, 2020, the Company entered
into a Purchase Agreement (&#8220;Agreement&#8221;), with Pocono Coated Products (&#8220;PCP&#8221;), pursuant to which PCP agreed to
sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business,
including: (1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free
and clear of all liens, except for certain lease obligations, and (2), a 100% membership interest in Active Intelligence, LLC (collectively
the &#8220;Assets&#8221;). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary
of the Company. The purchase price for the Assets was (i) $6,085,180 paid with the issuance of 608,519 shares in the Company&#8217;s common
stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the &#8220;Shares&#8221;), and (ii)
a promissory note of the Company, net of debt discount, in the principal amount, of $1,332,893 (the Note&#8221;) which is due upon the
earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $4,000,000 and/or a public
offering of no less than $4,000,000. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period
of one year at the annual meeting of shareholders of the Company held in October 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Agreement provides that it is effective
August 31, 2020, on which date the parties also entered into an escrow agreement (the &#8220;Escrow Agreement&#8221;), with legal counsel
serving as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special
purpose subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also
entered into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The purpose of the Company entering
into the transaction is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated
to the net tangible assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and,
as such, the transaction was accounted for under the acquisition method of accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Details of the net assets acquired are
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/> Recognized<br/> on<br/> Acquisition</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,085,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Note payable issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">66,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,761</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,613</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equipment and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Customer base</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intellectual property and trademarks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">583,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,810,640</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,104</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,851</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(268,715</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following unaudited pro forma condensed
financial information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and
Active Intelligence, as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed
financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would
have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation
of the future consolidated results of operations of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proforma</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proforma</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">943,702</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,369,761</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">370,647</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,993,472</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,932,828</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,001,178</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,766,627</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,732,727</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.51</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.50</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.45</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Since the date of acquisition, Pocono
and Active Intelligence had net revenues of $154,195 and incurred a net loss of $40,068.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321632974568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPERTY AND EQUIPMENT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>July&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>January&#160;31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,097,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,643</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,270,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,221,163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(235,450</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144,537</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Property and Equipment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,035,109</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,076,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense amounted to $90,913 and 17,558
for the six months ended July 31, 2021 and 2020, respectively.</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPERTY AND EQUIPMENT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,053,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,643</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,221,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,228</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144,537</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,199</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Property and Equipment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,076,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">111,029</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expense amounted to $91,338
and $35,118 for the years ended January 31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634761592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCOME TAXES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company adopted the provisions of
ASC 740, &#8220;Income Taxes, (&#8220;ASC 740&#8221;). As a result of the implementation of ASC 740, the Company recognized no adjustment
in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all
tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize
the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will
also setup a liability for interest and penalties. The Company&#8217;s policy is to recognize interest and penalties related to uncertain
tax positions as a component of the current provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">There is no U.S. tax provision due to
losses from U.S. operations for the years ended January 31, 2021 and 2020. Deferred income taxes are provided for the temporary differences
between the financial reporting and tax basis of the Company&#8217;s assets and liabilities. The principal item giving rise to deferred
taxes is the net operating loss carryforward in the U.S. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes
may not be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The provision for income taxes consists
of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Years Ended<br/> January&#160;31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A reconciliation of taxes on income
computed at the federal statutory rate to amounts provided is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended<br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Book income (loss) from operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(615,894</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(580,992</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Common stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">421,024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,931</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Unused operating losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">194,870</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">528,061</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2021, the Company
recorded a deferred tax asset associated with a net operating loss (&#8220;NOL&#8221;) carryforward of approximately $5,300,000 that was
fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize
those benefits in the foreseeable future. The Company&#8217;s NOL expires in 2038. The valuation allowance increased by approximately
$810,000 during the year ended January 31, 2021. On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) significantly
revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%. Because the Company recognizes
a valuation allowance for the entire balance, there is no net impact to the Company&#8217;s balance sheet or results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The types of temporary differences between
tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax
asset and their approximate tax effects are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforwards (expire through 2038)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,106,339</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(698,308</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(844,520</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(436,904</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(525,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(525,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,475,859</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,660,212</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640029448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable/Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE/CONVERTIBLE DEBT</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES PAYABLE/CONVERTIBLE DEBT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Notes Payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2020, the Coronavirus Aid Relief
and Economic Security Act (&#8220;CARES ACT&#8221; was enacted. The CARES ACT established the Paycheck Protection Program (&#8220;PPP&#8221;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#8217;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was forgiven as of April 30, 2021. The Company recorded a gain on the
extinguishment of debt of $34,870 during the six months ended July 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2020, a minority shareholder made an additional
loan to the Company in the amount of $100,000. The loan is interest-free and due upon demand. The loan was outstanding as July 31, 2021,
and January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Active Intelligence, the Company&#8217;s newly
acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due
October 16, 2029, with interest of 5% per year. The amount assumed in Note 3 was $139,184. The loan requires monthly payments of principal
and interest of $1,697. During the six months ended July 31, 2021, principal and interest payments of $8,344 were forgiven under the Cares
Act. The amount, $8,344, has been recorded as a gain on the forgiveness of debt. As of July 31, 2021, the amount due was $122,196, of
which $14,119 is current.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Finance Leases</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pocono has two finance leases secured by equipment.
The leases mature in 2025 and 2026. The incremental borrowing rate is 5.0%. As of July 31, 2021, the minimum lease payments are as follow:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ending</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 75%">January 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">12,557</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,295</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,361</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">January 31, 2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,362</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Related Party Payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2020, in connection with the Company&#8217;s
acquisition of Pocono Products LLC, the Company issued to Pocono Coated Products LLC a promissory note, net of debt discount, in the amount
of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021, or immediately following the earlier of a capital
raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products LLC, a related party, is
a shareholder of the Company. During the six months ended July 31, 2021, the Company recorded amortization of debt discount of $71,308.
As of July 31, 2021, the amount due was $1,475,631. The due date for the note has been extended to September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Convertible Debt</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2019, the Company entered into
a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible promissory
notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise price equal
to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price of the common
stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from this financing
of $250,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The notes are convertible at a conversion price
equal to the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion price,
which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion. The
conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply with
the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the notes
at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which percentage
increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after the closing
of the first to occur of (a) the next public offering of the Company&#8217;s securities or (b) the next private placement of the Company&#8217;s
equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of securities pursuant to
an equity line of credit or (d) a financing with a bank or other institutional lender.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The embedded conversion option qualified for derivative
accounting and bifurcation under ASC 815-15 Derivative and Hedging. The initial fair of the conversion feature was $128,870 and the fair
value of the warrants in connection with the notes were valued at $888,789 and were recorded based on their relative fair values. A debt
discount to the note payables of $270,000 and an initial derivative expense of $767,650 was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The debt discount will be amortized over the life
of the note. Amortization of the debt discount for the six months ended July 31, 2020, was $202,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2020, the Company prepaid the convertible
notes in the principal amount of $270,000 from the proceeds of a private placement. The total payments, including a prepayment fee of
$69,131 and accrued interest, was $345,565. As a result of the payment of the notes, the derivative liability, which was $928,774 as of
January 31, 2020, was reduced to zero. The warrants are no longer a derivative liability based on the notes being paid in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Interest expense for
the six months ended July 31, 2021was $81,888 including the amortization of the debt discount of $73,108 and interest expense of $8,780.
Interest expense for the six months ended July 31, 2020, was $205,218 including the amortization of debt discount of $202,500 and interest
expense of $2,718.</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES PAYABLE/CONVERTIBLE DEBT</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notes Payable</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 21, 2020, the Coronavirus Aid
Relief and Economic Security Act (&#8220;CARES ACT&#8221; was enacted. The CARES ACT established the Paycheck Protection Program (&#8220;PPP&#8221;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#8217;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was outstanding as of January 31, 2021. The note matures June 17, 2022
and accrues interest at 0.98% per year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2020, a minority shareholder
who had previously made loans of $215,000 as of January 31, 2020, made an additional loan to the Company in the amount of $60,000, increasing
the total loans from the stockholder to $275,000. The loans are interest free and due upon demand. On March 27, 2020, the Company issued
25,000 shares of common stock upon reaching a settlement with the noteholder to convert the notes in the principal balance of $275,000.
The transaction resulted in a loss on extinguishment of $12,500. In July 2020, the minority shareholder made an additional loan to the
Company in the amount of $100,000. The loan is interest free and due upon demand. The loan was outstanding as of January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Active Intelligence, the Company&#8217;s
newly acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000
due October 16, 2029 with interest of 5% per year. The amount assumed in Note 2 was $139,184. The loan requires monthly payments of principal
and interest of $1,697. During the year ended January 31, 2021, Active Intelligence made payments of $3,351, and $2,217 were principal
payments advanced under the Cares Act. As of January 31, 2020, the amount due was $129,078, of which $13,885 is current.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Pocono has two finance leases secured
by equipment. The leases mature in 2025 and 2026. The incremental borrowing rate is 5.0%. As of January 31, 2021, the minimum lease payments
are as follow:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; width: 13%">Years Ending</td>
    <td style="width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 75%">January 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">24,738</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,295</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,361</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">January 31, 2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right; padding-left: 0.125in; padding-bottom: 4pt">Total</td>
    <td>&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">121,543</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Related Party Payable</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2020, the Company
owed its chief financial officer and chief operating officer $29,067 from advances made to the Company. During the year ended January
31, 2021, the Company&#8217;s chief financial officer paid expenses of $12,628 on behalf of the Company, the Company&#8217;s chief executive
officer and chief operating officer advanced the Company $5,500 and the officers were repaid $40,194. As of January 31, 2021, the amount
the officers were fully repaid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 31, 2020, in connection with
the Company&#8217;s acquisition of Pocono Products LLC, the Company issued to Pocono Coated Products LLC a promissory note, net of debt
discount, in the amount of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021 or immediately following
the earlier of a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products
LLC, a related party, is a shareholder of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Convertible Debt</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On October 30, 2019, the Company entered
into a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible
promissory notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise
price equal to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price
of the common stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from
this financing of $250,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The notes are convertible at a conversion
price equal to the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion
price, which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion.
The conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply
with the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the
notes at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which
percentage increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after
the closing of the first to occur of (a) the next public offering of the Company&#8217;s securities or (b) the next private placement
of the Company&#8217;s equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of
securities pursuant to an equity line of credit or (d) a financing with a bank or other institutional lender.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The embedded conversion option qualified
for derivative accounting and bifurcation under ASC 815-15 Derivative and Hedging. The initial fair of the conversion feature was $128,870
and the fair value of the warrants in connection with the notes were valued at $888,789 and were recorded based on their relative fair
values. A debt discount to the note payables of $270,000 and an initial derivative discount of $767,650 was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The debt discount will be amortized
over the life of the note. Amortization of the debt discount for the year ended January 31, 2020 was $67,500. As of January 31, 2020,
the debt discount remaining was $202,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 25, 2020, the Company prepaid
the convertible notes in the principal amount of $270,000 from the proceeds of a private placement. The total payments, including a prepayment
fee of $69,131 and accrued interest, was $345,565. As a result of the payment of the notes, the derivative liability, which was $928,774
as of January 31, 2021, was reduced to zero. The warrants are no longer a derivative liability based on the notes being paid in full.
See Note 7 for further information. The total loss of $81,631 was recorded as a result of early prepayment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Interest expense for the year ended
January 31, 2021 was $280,686 including the amortization of the debt discounts of was $272,130 and interest expense of $8,566.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321639794904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTANGIBLE ASSETS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 31, 2021, and January 31, 2021, intangible
assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>July&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>January&#160;31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">314,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">314,100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">License agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Intellectual property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">817,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">817,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,181,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,131,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(189,679</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">991,821</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,006,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2021, the Company acquired an IP license
for $50,000, see Note 10- &#8220;Rambam Agreement&#8221; for further discussion regarding the license agreement. The value of the intangible
assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company
and are being amortized over a period of three to ten years. Amortization expense for the six months ended July 31, 2021, and 2020 was
$64,909 and $18,534, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimated Amortization:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0; text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended January 31,</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 89%; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remainder of 2022</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,870</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129,776</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2924</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129,776</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,109</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 and thereafter</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">554,290</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">991,821</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTANGIBLE ASSETS AND GOODWILL</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2021, and 2020, intangible
assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">January&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">January&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">314,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Intellectual property and trademarks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">817,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">234,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,131,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,006,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">314,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The value of the intangible assets,
consisting of intellectual property and customer base has been recorded at their fair value by the Company after completing a valuation
and are being amortized over a period of ten years. Amortization expense for the year ended January 31, 2021 and 2020 was $68,770 and
$37,070, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Estimated Amortization:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Year Ended January 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">113,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2026 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">554,130</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,006,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634984408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE LIABILITIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DERIVATIVE LIABILITIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The embedded conversion option of the
convertible debentures described in Note 4 contain conversion features that qualify for embedded derivative classification. The fair value
of the liabilities will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement
of operations as a gain or loss on derivative financial instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The table below sets forth a summary
in the fair value of the Company&#8217;s Level 3 financial liabilities:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Balance at the beginning of the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">928,774</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative liability warrants reclassed to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(906,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in value of embedded conversion option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,096</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company uses Level 3 inputs for
its valuation methodology for the embedded conversion option and warrant liabilities as their fair value were determined by using the
Monte Carlo Model based on various assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At issuance, the expected volatility
was 158.3%; risk-free interest rate of 1.58%; and expected term of one year. For the revaluation at January 31, 2020, the expected volatility
was 184.4%; risk-free rate of return of 1.43%; and expected term of nine months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Reclassification at March 25, 2020 to
settle the liabilities, the expected volatility was 147.47%; risk-free rate of return of 0.36%; exercise price of $11; and expected term
of 2.6 months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634028488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RELATED PARTY TRANSACTIONS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had related party notes with its former Chief Financial Officer and Chief Operating Officer. See footnote 5 for further discussion.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisition of Pocono, the Company recorded various transactions and operations through Pocono Coated Products LLC, a related entity. During the six months ended July 31, 2021, the Company was advanced $7,862 in finance payments. As of July 31, 2021, the Company owed Pocono $2,634. The Company also issued a note in the amount of $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.</span></td></tr> </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RELATED PARTY TRANSACTIONS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company&#8217;s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the warrant on the
date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired
unexercised on May 19, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had related party notes with its Chief Financial Officer and Chief Operating Officer. See footnote 5 for further discussion.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisition of Pocono, the Company recorded various transactions and operations through Pocono Coated Products LLC, a related entity. The transactions included revenue of $68,780, purchase of materials of $33,479, paid expenses of $23,310, and finance payments of $6,763. As of January 31, 2021, Pocono Coated Products LLC owed the Company $5,228. The Company also issued a note in the amount $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended January 31, 2021, the Company issued 51,825 shares of common stock, valued at $777,375, to executive officers of the Company, based on the market price at the date of issuance, and 78,500 shares of common stock, valued at 1,221,500, to the Company&#8217;s current and former independent directors, based on the market price at the date of issuance. The shares were issued on December 31, 2020 at a stock price of $15 per share.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321632968696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDERS&#8217; EQUITY</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Preferred Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 15, 2016, the board of directors of
the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company
to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2019, the board of directors created
a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (&#8220;Series A Preferred
Stock&#8221;). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of
authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part
of a particular series by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2019, the Company effected a one-for
four reverse stock splits, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the Company
decreased its authorized common stock from 100,000,000 to 25,000,000 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2020, the Company amended its articles
of incorporation to increase its authorized common shares from 25,000,000 shares to 250,000,000 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Activity during the Six Months Ended July 31,
2020</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 22, 2020, the Company issued in a private
placement 46,828 units at a price of $11 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share
of common stock at an exercise price of $14 per share. The warrants expire April 30, 2023. The Company issued a total of 46,828 shares
of common stock and warrants to purchase 46,828 shares of common stock. The Company received proceeds of $515,108.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, a minority shareholder who had
previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30,2020, the Company issued 5,000 shares
to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $50,000, of which
$38,000 is included in selling and general administrative expenses and $12,000 is included in prepaid expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Activity during the Six Months Ended July 31,
2021</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (&#8220;BPM&#8221;), the Company issued 81,396 shares of common stock to BPM and received proceeds of $700,000 to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $60,000 which is included in Stockholders&#8217; Equity as Subscription Payable in the Company&#8217;s consolidated balance sheet as of January 31, 2021. In February 2021, BPM advanced a payment for the Company to Rambam in the amount of $57,000 for the license fee. The balance of the funds of $583,000 was received in February 2021. See footnote 10 for further discussion.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25,2021, the Company issued 5,602 shares of common stock, valued at $60,000, for consulting services pursuant to a consultant agreement commencing December 1, 2020. The Company has reflected $10,000 representing 934 shares as Subscription Payable in the Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2021, the Company issued 12,500
shares of common stock, valued at $350,000, for consulting fees in connection with the Rambam License Agreement discussed in Note 10.</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDER&#8217;S EQUITY</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Preferred Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 15, 2016, the board of directors
of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company
to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On May 24, 2019, the board of directors
created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (&#8220;Series
A Preferred Stock&#8221;). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the
status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated
as part of a particular series by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 25, 2019, the Company effected
a one-for four reverse split, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the
Company decreased its authorized common stock from 100,000,000 to 25,000,000 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 27, 2020, the Company amended
its articles of incorporation to increase its authorized common shares from 25,000,000 shares to 250,000,000 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Activity during the Year Ended January
31, 2021</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 22, 2020, the Company issued
in a private placement 46,828 units at a price of $11 per unit. Each unit consisted of one share of common stock and a warrant to purchase
one share of common stock at an exercise price of $14 per share. The warrants expire April 30, 2023. The Company issued a total of 46,828
shares of common stock and warrants to purchase 46,828 shares of common stock. The Company received proceeds of $515,108.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2020, a minority shareholder
who had previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 30, 2020, the Company issued
5,000 shares to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $50,000,
all of which is included in selling and general administrative expense for the year ended January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 31, 2020, the Company acquired
the membership interests in Pocono Coated Products LLC and issued 608,519 shares of its common stock, valued at $6,085,180, and issued
a promissory note, net of debt discount, in the amount of $1,332,893. See Note 2 for further information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On December 31, 2020, the Company issued
130,325 shares of common stock for services, valued at $1,954,875, as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,825 shares of common stock, valued at $777,375, issued to executive officers.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,500 shares of common stock, valued at $1,177,500, issued to the Company&#8217;s current and former independent directors.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Subscription Payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (&#8220;BPM&#8221;), the Company issued 81,396 shares of common stock to BPM and received proceeds of $700,000 to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $60,000 which is included in Stockholders&#8217; Equity as Subscription in the Company&#8217;s consolidated balance sheet as of January 31, 2021. The balance of the funds was received in February 2021.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25,2021, the Company issued 5,602 shares of common stock, valued at $60,000, for consulting services pursuant to a consultant agreement commencing December 1, 2020. The Company has reflected $10,000 representing 934 shares as Subscription Payable in the Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Activity during the Year Ended January
31, 2020</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the year ended January 31, 2020,
the Company issued 17,144 shares of common stock to extinguish accounts payable in the amount of $240,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634643736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Options<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsAndOptionsAbstract', window );"><strong>Warrants And Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsAndOptionsTextBlock', window );">WARRANTS AND OPTIONS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANTS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the changes in
warrants outstanding and the related price of the shares of the Company&#8217;s common stock issued to non-employees of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Shares</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Exercise<br/> Price</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Remaining<br/> Life</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Intrinsic<br/> Value</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">141,828</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11.99</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16 years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">285,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding-period ending July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41 years</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable - period ending July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41 years</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes additional information
relating to the warrants outstanding as of July 31, 2021:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
    of Exercise Prices</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/>

    Outstanding</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
    Contractual<br/>
 Life&#160;(Years)</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    <br/>
Price for<br/>
 Shares<br/>
 Outstanding</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/>

    Exercisable</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    <br/>
Price for<br/>
 Shares<br/>
 Exercisable</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic<br/>

    Value</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,828</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,828</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANTS AND OPTIONS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes the changes
in warrants outstanding and the related price of the shares of the Company&#8217;s common stock issued to non-employees of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">&#160;&#160;<b>Remaining</b> </span></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Life</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">182,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,101,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;3.00&#160;years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(162,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">5.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;2.08 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;3.00 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Expired/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding-period ending January 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.16</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">853,311</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable - period ending January 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.16</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">853,311</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As a result of a completed private placement,
the warrants to purchase 50,000 shares at the lesser of (i) $20.90 or, (ii) if the Company completes its public offering of its common
stock, 110% of the initial public offering price of the Common Stock in the public offering, became a warrant to purchase 95,000 warrants
at $11 per share, subject to adjustment pursuant to the antidilution provisions of the warrant. The Company recorded a derivative liability
for the warrants in the amount of $906,678 and reclassed the derivative liability to additional paid-in capital as of January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes additional
information relating to the warrants outstanding at January31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Range of <br/> Exercise <br/> Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining <br/> Contractual <br/> Life(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price <br/> for Shares <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price <br/> for Shares <br/> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">95,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">95,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">11.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes the changes
in options outstanding and the related price of the shares of the Company&#8217;s common stock issued to non-employees of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">0.05 years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">232,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding-period ending January 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable - period ending January 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsAndOptionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsAndOptionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634802632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_LeasesLineItems', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEASES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company had operating leases for
its facilities used for research and development, sales and administration. These leases have been terminated. The Company is currently
operating its manufacturing operations on a month-to-month basis in a North Carolina facility under a verbal commitment. The monthly rent
is $4,200.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">See financing leases for equipment in
Note 5.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321632860824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contigencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTIGENCIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMITMENTS AND CONTIGENCIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal Proceedings</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2018, the Company commenced an action
in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar,
Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a
Motion for Prejudgment Writ of Replevin arising from the Company&#8217;s decision to seek to rescind for misrepresentation the agreement
by which the Company acquired advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of
the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants.
Defendants Kalmar, Murphy, Polly-Murphy, and Baker filed a Motion to Dismiss the Company&#8217;s Verified Complaint, Motion to Dissolve
Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court
dismissed the Company&#8217;s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the six patents
never duly transferred to the Company. On February 1, 2019, the Company appealed the court&#8217;s order. Pursuant to a settlement agreement
with one of the defendants, that defendant returned the 50,000 shares which had been issued to her, and the shares were cancelled as of
January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom the Company has a settlement agreement), filed
a motion for sanctions and civil contempt against us, which generally claimed that we failed to comply with the Court&#8217;s January
4, 2019, order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer their shares of common stock. On
October 29, 2019, the Court denied the Defendants motion. On March 20, 2020, the Florida district court of appeal reversed the lower court
ruling in the Florida state court action that dismissed our complaint, with prejudice, and gave us leave to file an amended complaint.
On July 7, 2020, Defendants filed Notice for Trial, requesting the court to set a trial date. The Company and defendants have served their
first set of interrogatories on each other and have filed answers and responses to each other&#8217;s first set of interrogatories.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 22, 2018, four of the defendants in
the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of Common
Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement.
The parties have agreed to a stay pending the outcome of the Florida litigation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2019, the Company filed a securities
fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy,
Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently and deceitfully
obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud the Company. The Company is seeking the return
of the shares of common stock and monetary damages resulting from the defendants&#8217; fraudulent conduct. The defendants filed a motion
to dismiss the complaint on August 23, 2019, and on September 13, 2019, the Company filed its response. On July 20, 2020, the Court denied
the defendant&#8217;s motion to dismiss the complaint, and the parties have recently commenced the discovery phase of the litigation.
The Court has scheduled a trial date in November 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employment Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a three-year employment
agreement with Gareth Sheridan, our CEO, effective April 25, 2019. The agreement also provides that the executive will continue as a director.
The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2024, and continuing
on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#8217; notice given prior to the expiration
of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Sheridan receives
an annual salary $42,000 per annum, commencing on the effective date of the agreement and increasing to $170,000 per annum in the month
in which the Company shall have received not less than $2,500,000 from one or more public or private financings of the Company&#8217;s
equity securities subsequent to the date of the agreement. During the year ended January 31, 2021, the salary was increased to $60,000
per annum.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rambam Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2020, the Company entered into
a License Agreement (the &#8220;License Agreement&#8221;) with Rambam Med-Tech Ltd. (&#8220;Rambam&#8221;), Haifa, Israel, to develop
the RAMBAM Closed System Transfer Device (&#8220;CTSD&#8221;) and such other products as the parties agree to develop/commercialize. The
Company will license from Rambam the full technology, IP, and title to CTSD in the field, with an Initial license fee of $50,000 and running
royalties on net sales. The $50,000 license fee was paid by a third party at the direction of the Company in February 2021, at which time
the agreement became effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had entered into a prior agreement,
dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#8220;BPM&#8221;), that, in consideration of BPM&#8217;s introduction of
Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#8217;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>BPM Distribution and Stock Purchase Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 10, 2021, the Company finalized the Distribution Agreement with BPM, providing for distribution of the medical products developed and produced under the License Agreement. Under the Distribution Agreement, BPM&#160;has the right to distribute the medical products in Israel and has a right of first refusal in relation to all other countries/states, other than United States, Korea, China, Vietnam, Canada and Ecuador, which are termed excluded countries.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and BPM entered into a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.</span></td></tr> </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMITMENTS AND CONTIGENCIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Legal Proceedings</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On July 27, 2018, the Company commenced
an action in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc.,
Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without
Notice and a Motion for Prejudgment Writ of Replevin arising from the Company&#8217;s decision to seek to rescind for misrepresentation
the agreement by which the Company acquired advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and
seek return of the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against
the defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker filed a Motion to Dismiss the Company&#8217;s Verified Complaint, Motion
to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019,
the court dismissed the Company&#8217;s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the
six patents never duly transferred to the Company. On February 1, 2019, the Company appealed the court&#8217;s order. Pursuant to a settlement
agreement with one of the defendants, that defendant returned the 50,000 shares which had been issued to her, and the shares were cancelled
as of January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom the Company has a settlement agreement),
filed a motion for sanctions and civil contempt against us, which generally claimed that we failed to comply with the Court&#8217;s January
4, 2019 order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer their shares of common stock. On
October 29, 2019, the Court denied the Defendants motion. On March 20, 2020, the Florida district court of appeal reversed the lower court
ruling in the Florida state court action that dismissed our complaint, with prejudice, and gave us leave to file an amended complaint.
On July 7, 2020, Defendants filed Notice for Trial, requesting the court to set a trial date. The Company and defendants have served their
first set of interrogatories on each other and have filed answers and responses to each other&#8217;s first set of interrogatories.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 22, 2018, four of the defendants
in the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of
Common Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition
agreement. The parties have agreed to a stay pending the outcome of the Florida litigation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 29, 2019, the Company filed
a securities fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle
Polly-Murphy, Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently
and deceitfully obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud the Company. The Company is
seeking the return of the shares of common stock and monetary damages resulting from the defendants&#8217; fraudulent conduct. The defendants
filed a motion to dismiss the complaint on August 23, 2019, and on September 13, 2019 the Company filed its response. On July 20, 2020,
the Court denied the defendant&#8217;s motion to dismiss the complaint, and the parties have recently commenced the discovery phase of
the litigation. No trial date has been scheduled by the Court.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><i>Employment
Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company entered into a three-year
employment agreement with Gareth Sheridan, our CEO, effective April 25, 2019. The agreement also provides that the executive will continue
as a director. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31,
2024., and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#8217; notice given
prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement,
Mr. Sheridan receives an annual salary $42,000 per annum, commencing on the effective date of the agreement and increasing to $170,000
per annum in the month in which the Company shall have received not less than $2,500,000 from one or more public or private financings
of the Company&#8217;s equity securities subsequent to the date of the agreement. During the year ended January 31, 2021, the salary was
increased to $60,000 per anum.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Rambam Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On December 9, 2020, the Company entered
into a License Agreement (the &#8220;License Agreement&#8221;) with Rambam Med-Tech Ltd. (&#8220;Rambam&#8221;), Haifa, Israel, to develop
the RAMBAM Closed System Transfer Device (&#8220;CTSD&#8221;) and such other products as the parties agree to develop/commercialize. The
Company will license from Rambam the full technology, IP, and title to CTSD in the field, with an Initial license fee of $50,000 and running
royalties on net sales. The $50,000 license fee was paid in February 2021, at which time the agreement became effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company had entered into a prior
agreement, dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#8220;BPM&#8221;), that, in consideration of BPM&#8217;s introduction
of Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#8217;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>BPM Distribution and Stock Purchase
Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 10, 2021, the Company finalized the Distribution Agreement with BPM, providing for distribution of the medical products developed and produced under the License Agreement. Under the Distribution Agreement, BPM&#160;has the right to distribute the medical products in Israel and has a right of first refusal in relation to all other countries/states, other than United States, Korea, China, Vietnam, Canada and Ecuador, which are termed excluded countries.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and BPM entered into a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634630200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUBSEQUENT EVENTS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2020, the Company entered into a
Purchase Agreement (&#8220;Agreement&#8221;), with Pocono Coated Products (&#8220;PCP&#8221;), pursuant to which PCP agreed to sell the
Company all of the assets associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the &#8220;Assets&#8221;). PCP
is the manufacturer of our transdermal products, and we bought that business from them. The purchase price for the Assets was (i) $6,000,000
paid in shares of the Company&#8217;s common stock at a value of the average price of the previous 90 days at the date of Closing (the
&#8220;Shares&#8221;); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a)
twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of
no less than $4,000,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2021 we entered into an amendment
to the Agreement with the parties to the Agreement that provides for an extension of the August 31, 2021 due date of the $1,500,000 note
issued in the transaction to September 30, 2021, and extends the time limit set forth in Section 5.3(a) of the Agreement for completion
of the Listing and for payment of the Note in full until September 30, 2021.</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUBSEQUENT EVENTS</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 10, 2021, the Company issued 12,500 shares of common stock, valued at $350,000, for consulting fee in connection with Rambam License Agreement.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25,2021, the Company issued 5,602 shares of common stock, valued at $60,000, for consulting services pursuant to a consultant agreement commencing December 1, 2020.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321632912936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Unaudited Interim Financial Statements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated balance sheet as of July 31,
2021, and the consolidated statements of operations, stockholders&#8217; equity, and cash flows for the periods presented have been prepared
by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary
to present fairly the financial position, results of operations, changes in stockholders&#8217; equity and cash flows for all periods
presented have been made. The results for the six months ended July 31, 2021, are not necessarily indicative of the results to be expected
for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and
footnotes thereto included in Nutriband&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain information and footnote disclosures required
under generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted
from these consolidated financial statements pursuant to the rules and regulations, including the interim reporting requirements of the
U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The preparation of consolidated financial statements in accordance with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts
in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s significant accounting policies
are summarized in Note 1 in the Company&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant
changes to these accounting policies during the six months July 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Going Concern </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 31, 2021, the Company believes the
substantial doubt about its status as a going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current quarter net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to
alleviate the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses,
equity funding that has been received and additional funding expected to be received, and the net revenue from its recent acquisitions.
These factors did not exist in prior years during its start-up operations. The Company&#8217;s recent history of losses has continued
but future positive cash flow projections due to revenue commitments and decreases in overhead as well as expected equity funding will
enable the Company to alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans have been currently implemented. The plans enable the Company to meet its obligations for at least one year from the date when the
financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of the Company
include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations
of 4P Therapeutics are included in the Company&#8217;s financial statements from the date of acquisition of August 1, 2018, and the operations
of Pocono and Active Intelligence are included in the Company&#8217;s financial statements from the date of acquisition of September 1,
2020. The wholly owned subsidiaries are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nutriband Ltd.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4P Therapeutics LLC</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pocono Pharmaceuticals Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates
and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as
income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases
its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s significant policies are summarized
in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant changes to
the accounting policies during the six months ended July 31, 2021, and the Company does not expect that the adoption of other accounting
pronouncements will have a material impact on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Revenue Recognition </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
&#8220;Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which amends the accounting standards for revenue
recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when
products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a description of the Company&#8217;s
revenue types, which include professional services and sale of goods:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
    revenues include the contract of research and development related services with the Company&#8217;s clients in the life sciences
    field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for
    each given research project engaged.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    revenues are derived from the sale of the Company&#8217;s consumer transdermal and coated products. Upon the reception of a purchase
    order, we have the order filled and shipped.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A contract with a customer exists when (i) we
enter into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred
and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine
that collection of substantially all consideration for services that are transferred is probable based on the customer&#8217;s intent
and ability to pay the promised consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Deferred Revenue</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue is a liability related to a revenue
producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from
a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A performance obligation is a promise in a contract
to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction
price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
For the Company&#8217;s different revenue service types, the performance obligation is satisfied at different times. The Company&#8217;s
performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue
performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize
revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for
the work performed during that month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All revenue recognized in the income statement
is considered to be revenue from contracts with customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disaggregates its revenue from contracts
with customers by type and by geographical location. See the tables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">59,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">541,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">120,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,976</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,044</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographic location:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">560,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">83,044</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,770</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Account receivable </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivables are recorded at the
net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability
of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts
where appropriate and the application of historical loss to non-applicable accounts. For the six months ended July 31, 2021 and 2020,
the Company recorded no bad debt expense for doubtful accounts related to account receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are valued at the lower of cost and
reasonable value determined using the first-in, first-out (FIFO) method. Net reasonable value is the estimated selling price in the ordinary
course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material
costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of July 31,
2021, 100% of the inventory consists of raw materials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment represent an important
component of the Company&#8217;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful
life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement
parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are
capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from
3 to 20 years as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Intangible Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets include trademarks, intellectual
property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance
of ASC 350, &#8220;Intangibles-Goodwill and Other.&#8221; The Company capitalizes certain costs related to patent technology. A substantial
component of the purchase price related to the Company&#8217;s acquisitions have also been assigned to intellectual property and other
intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible
assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized
over their estimated useful lives of ten years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Goodwill</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill represents the difference between the
total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed
for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the
recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August 31,
2020, in connection with the Company&#8217;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $5,810,640. As of July 31, 2021, Goodwill amounted to $7,529,875.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Long-lived Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management reviews long-lived assets for potential
impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount
of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use
and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market
value of the long-lived asset and the related book value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Earnings per Share</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic earnings per share of common stock is computed
by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per
share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock
outstanding during the period.&#160;Potential shares of common stock consist of shares issuable upon the exercise of outstanding options
and common stock purchase warrants. As of July 31, 2021, and 2020, there were 141,830 common stock equivalents outstanding, that were
not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Stock-Based Compensation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, &#8220;Compensation - Stock Compensation,&#8221;
prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February
1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and
other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including
grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That
expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the
requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based
compensation for both employees and non-employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements and
Disclosure&#8221; (&#8220;ASC 820&#8221;), defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of
observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that
may be used to measure fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilizes the accounting guidance for
fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized
or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is
an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data
or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy,
which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs such as quoted market prices in active markets.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying value of the Company&#8217;s financial
instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their fair value
due to the short maturities of these financial instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Derivative Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates are made at a specific point
in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve uncertainties
and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect
the estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for derivative instruments
in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; and all 	derivative instruments are reflected as either assets
or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments. Fair
value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market participants.
In general, the Company&#8217;s policy in estimating fair values is to first look at observable market prices for identical assets and
liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such as prices
of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable data
from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of July 31, 2021, and January 31, 2021, the Company had
no derivative liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Recent Accounting Standards</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has implemented all new pronouncements,
including the adoption of ASU 2018-13 and ASU 2019-12, that are in effect and that may impact its consolidated financial statements and
does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its
consolidated financial statements or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321745901544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Organization</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Nutriband Inc. (the &#8220;Company&#8221;)
is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which
was formed by the Company&#8217;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches.
References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 1, 2018, the Company acquired
4P Therapeutics LLC (&#8220;4P Therapeutics&#8221;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000,
and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been
developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of
the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">4P Therapeutics is engaged in the development
of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics,
the Company&#8217;s business was the development and marketing of a range of transdermal consumer patches. Most of these products are
considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration
(the &#8220;FDA&#8221;). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its
consumer products are not being marketed in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">With the acquisition of 4P Therapeutics,
4P Therapeutics&#8217; drug development business became the Company&#8217;s principal business. The Company&#8217;s approach is to use
generic drugs that are off patent and incorporate them into the Company&#8217;s transdermal drug delivery system. Although these medications
have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will
include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical
products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 25, 2020, the Company formed
Pocono Pharmaceuticals Inc. (&#8220;Pocono Pharmaceuticals&#8221;), a wholly owned subsidiary of the Company. On August 31, 2020, the
Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono
Coated Products LLC (&#8220;PCP&#8221;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction the Company
also acquired 100% of the membership interests of Active Intelligence LLC (&#8220;Active Intelligence&#8221;). See Note 2 for further
details of the acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Pocono Pharmaceuticals is a coated products
manufacturing entity organized to take advantage of unique process capabilities and experience. Pocono helps their customer with product
design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical&#8217;s
competitive edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence
manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is the same as traditional kinesiology
tape.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, COVID-19 emerged and
has subsequently spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local
governments and private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay
at home orders and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed
quarantines and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business
and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions
and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines,
shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of
business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities
in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Reverse Stock Split</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 25, 2019, the Company effected
one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock. The
reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements
retroactively reflect the reverse split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Going Concern </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 31, 2021, the Company believes the
substantial doubt about its status as a going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current quarter net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to
alleviate the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses,
equity funding that has been received and additional funding expected to be received, and the net revenue from its recent acquisitions.
These factors did not exist in prior years during its start-up operations. The Company&#8217;s recent history of losses has continued
but future positive cash flow projections due to revenue commitments and decreases in overhead as well as expected equity funding will
enable the Company to alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans have been currently implemented. The plans enable the Company to meet its obligations for at least one year from the date when the
financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Going Concern</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of January 31, 2021, the Company
believes the substantial doubt about going concern has been resolved. The going concern conditions that caused substantial doubt consisted
of current year net loss, negative working capital, negative cash flow, and accumulated deficit. Management has implemented plans to alleviate
the substantial doubt. These plans include a substantial increase in sales commitments, a decrease in planned overhead expenses, equity
funding that has been received and the net revenue and positive cash flow from its recent acquisition. These factors did not exist in
prior years during its start-up operations. The Company&#8217;s recent history of losses has changed from prior periods due to its current
management&#8217;s plans including its acquisition in the latter part of 2020 to alleviate the substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s plans have been currently implemented. The plans enable the Company to meet
its obligations for at least one year from the date when the financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of the Company
include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations
of 4P Therapeutics are included in the Company&#8217;s financial statements from the date of acquisition of August 1, 2018, and the operations
of Pocono and Active Intelligence are included in the Company&#8217;s financial statements from the date of acquisition of September 1,
2020. The wholly owned subsidiaries are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nutriband Ltd.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4P Therapeutics LLC</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pocono Pharmaceuticals Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The consolidated financial statements
of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated.
The operations of 4P Therapeutics are included in the Company&#8217;s financial statements from the date of acquisition of August 1, 2018
and the operations of Pocono and Active Intelligence are included in the Company&#8217;s financial statements from the date of acquisition
of September 1, 2020. The wholly owned subsidiaries are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Nutriband Ltd.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">4P Therapeutics LLC</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pocono Pharmaceuticals Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates
and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as
income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases
its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s significant policies are summarized
in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant changes to
the accounting policies during the six months ended July 31, 2021, and the Company does not expect that the adoption of other accounting
pronouncements will have a material impact on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of the consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related&#160;disclosure
of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related
to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The
Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Cash and Cash Equivalents</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Cash equivalents include short-term
investments in money-market funds and certificate of deposits with an original maturity of three months or less when purchased.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Foreign Currency Translation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The functional currency of the Company&#8217;s
Irish subsidiary is the Euro. The assets and liabilities of the subsidiary are translated into US dollars using the prevailing exchange
rate as of the balance sheet date and income and expenses are translated into US dollars using the average exchange rate during the reporting
period. Translation adjustments are recorded in other comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Revenue Recognition </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
&#8220;Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which amends the accounting standards for revenue
recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when
products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a description of the Company&#8217;s
revenue types, which include professional services and sale of goods:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
    revenues include the contract of research and development related services with the Company&#8217;s clients in the life sciences
    field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for
    each given research project engaged.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    revenues are derived from the sale of the Company&#8217;s consumer transdermal and coated products. Upon the reception of a purchase
    order, we have the order filled and shipped.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Revenue Recognition</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In May 2014, the FASB issued ASU No.
2014-09, &#8220;Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which amends the accounting standards for
revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled
when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective
method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic
606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The
Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2)
identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance
obligations, and 5) recognize revenue as the performance obligations are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a description of the
Company&#8217;s revenue types, which include professional services and sale of goods:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service revenues include the contract of research and development related services with the Company&#8217;s clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product revenues are derived from the sale of the Company&#8217;s consumer transdermal and coated products. Upon the reception of a purchase order, we have the order filled and shipped.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Contracts with Customers</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A contract with a customer exists when (i) we
enter into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred
and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine
that collection of substantially all consideration for services that are transferred is probable based on the customer&#8217;s intent
and ability to pay the promised consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A contract with a customer exists when
(i) we enter into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be
transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii)
we determine that collection of substantially all consideration for services that are transferred is probable based on the customer&#8217;s
intent and ability to pay the promised consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Deferred Revenue</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue is a liability related to a revenue
producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from
a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Deferred Revenue</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Deferred revenue is a liability related
to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration
from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PerformanceObligationsPolicyTextBlock', window );">Performance Obligations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A performance obligation is a promise in a contract
to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction
price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
For the Company&#8217;s different revenue service types, the performance obligation is satisfied at different times. The Company&#8217;s
performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue
performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize
revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for
the work performed during that month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All revenue recognized in the income statement
is considered to be revenue from contracts with customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A performance obligation is a promise
in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract
transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation
is satisfied. For the Company&#8217;s different revenue service types, the performance obligation is satisfied at different times. The
Company&#8217;s performance obligations include providing products and professional services in the area of research. The Company recognizes
product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service
work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on
a monthly basis for the work performed during that month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All revenue recognized in the income
statement is considered to be revenue from contracts with customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DisaggregationOfRevenuesPolicyTextBlock', window );">Disaggregation of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disaggregates its revenue from contracts
with customers by type and by geographical location. See the tables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">59,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">541,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">120,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,976</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,044</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographic location:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">560,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">83,044</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,770</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company disaggregates its revenue
from contracts with customers by type and by geographical location. See the tables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">737,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">124,958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">245,679</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographical location</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">360,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">245,679</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Account receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Account receivable </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivables are recorded at the
net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability
of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts
where appropriate and the application of historical loss to non-applicable accounts. For the six months ended July 31, 2021 and 2020,
the Company recorded no bad debt expense for doubtful accounts related to account receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Accounts receivable</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Trade accounts receivable are recorded
at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from
the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer
accounts where appropriate and the application of historical loss to non-specific accounts. For the years ended January 31, 2021 and 2020,
the Company recorded no bad debt expense and no allowance for doubtful accounts related to accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are valued at the lower of cost and
reasonable value determined using the first-in, first-out (FIFO) method. Net reasonable value is the estimated selling price in the ordinary
course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material
costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of July 31,
2021, 100% of the inventory consists of raw materials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Inventories are valued at the lower
of cost and realizable value determined using the first-in, first-out (FIFO) method. Net realizable value is the estimated selling price
in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in progress is comprised
of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment represent an important
component of the Company&#8217;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful
life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement
parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are
capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from
3 to 20 years as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Property and equipment represent an
important component of the Company&#8217;s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated
useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and
replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements
are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range
from 3 to 10 years as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Intangible Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Intangible assets include trademarks,
intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under
the guidance of ASC 350, &#8220;Intangibles-Goodwill and Other.&#8221; The Company capitalizes certain costs related to patent technology.
A substantial component of the purchase price related to the Company&#8217;s acquisition has also been assigned to intellectual property
and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives.
Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being
amortized over their estimated useful lives of ten years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Goodwill</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Goodwill represents the difference between
the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is
reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which
the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August
31, 2020, in connection with the Company&#8217;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded
Goodwill of $5,810,640. As of January 31, 2021, Goodwill amounted to $7,529,875.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Long-lived Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Management reviews long-lived assets
for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The
carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result
from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between
fair market value of the long-lived asset and the related net book value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Stock-Based Compensation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ASC 718, &#8220;Compensation - Stock
Compensation,&#8221; prescribes accounting and reporting standards for all share-based payment transactions in which employee services,
and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue
shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments
to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on
their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for
the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718
was applied to stock-based compensation for both employees and non-employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Business Combinations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company recognizes the assets acquired,
the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values
as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related
costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That
replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated
to the individual assets acquired and liabilities assumed based on their estimated fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Leases</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February 2016, the FASB issued ASU
2016-02, &#8220;Leases&#8221; (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and
lessors should apply a &#8220;right-of-use&#8221; model in accounting for all leases (including subleases) and eliminate the concept of
operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as
a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company adopted ASU 2016-02 as amended
effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize
the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under
ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates
the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company
completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Research and Development</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Research and developments costs are
expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Income Taxes</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Taxes are calculated in accordance with
taxation principles currently effective in the United States and Ireland.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounts for income taxes
under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are
determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities
is recognized in income in the period that includes the enactment date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company records net deferred tax
assets to the extent they believe these assets will more-likely-than-not be realized. In making such determination, the Company considers
all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable
income, tax planning strategies and recent financial operations. In the event the Company was to determine that it would be able to realize
its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation
allowance which would reduce the provision for income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i><span style="text-decoration:underline">Concentration of Credit Risk</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial instruments which potentially
subject the Company to concentrations of credit risk consist principally of cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s cash and cash equivalents
are concentrated primarily in banks. At times, such deposits could be in excess of insured limits. Management believes that the financial
institutions that hold the Company&#8217;s financial instruments are financially sound and, accordingly, minimal credit risk is believed
to exist with respect to these financial instruments. As of and for the year ended January 31, 2020, three customers accounted for 100%
of the Company&#8217;s revenues and two customers accounted for 100% of accounts receivable. As of and for the year ended January 31,
2021, one customer accounted for 62% of the Company&#8217;s revenues and two customers accounted for 67% and 13% of accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Earnings Per Share</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Basic earnings per share of common stock
is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings
per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common
stock outstanding during the period.&#160;Potential shares of common stock consist of outstanding common stock purchase warrants. For
the years ended January 31, 2021 and 2020 there were 141,830 and 70,000 potential shares of common stock that were not included in the
calculation of diluted earnings per share as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements
and Disclosure&#8221; (&#8220;ASC 820&#8221;), defines fair value as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs
that may be to measure fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company utilizes the accounting
guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities
that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.
The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company
utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier
value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 -&#160;Observable inputs such
as quoted market prices in active markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 -&#160;Inputs other than quoted
prices in active markets that are either directly or indirectly observable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 -&#160;Unobservable inputs
about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The carrying value of the Company&#8217;s
financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their
fair value due to the short maturities of these financial instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Derivative liabilities are determined
based on &#8220;Level 3&#8221; inputs, which are significant and unobservable and have the lowest priority. The recorded values of all
other financial instruments approximate their current fair value because of their nature and respective short maturity dates or durations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DerivativeLiabilitiesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Derivative Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounts for derivative
instruments in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; and all derivative instruments are reflected as either
assets or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments.
Fair value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market
participants. In general, the Company&#8217;s policy in estimating fair values is to first look at observable market prices for identical
assets and liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such
as prices of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable
data from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially
different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes
its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency
utilized in measuring financial instruments at fair value as discussed above. As of January 31, 2021, and 2020, the Company had a $-0-
and $928,774 derivative liability, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Fair value estimates are made at a specific
point in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve
uncertainties and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly
affect the estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration:underline">Recent Accounting Standards</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August 2018, the FASB issued ASU
2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements&#8221;. The updated
guidance improves the disclosure requirements on fair value measurement. The updated guidance is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. The Company adopted the provisions effective February 1, 2020. The
adoption did not have a material impact on the Company&#8217;s consolidated financial position or consolidated results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, the FASB issued ASU
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which modifies ASC 740 to reduce complexity while maintaining
or improving the usefulness of the information provided to the users of financial statements. ASU 209-12 is effective for annual reporting
periods beginning after December 15, 2021. The Company is currently assessing the impact of ASU 209-12, but it is not expected to have
a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has reviewed all other FASB-issued
ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods.
The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles
will have a material impact on the company&#8217;s reported financial position or operations in the near term. The applicability of any
standard is subject to the formal review of the Company&#8217;s financial management and certain standards are under consideration.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Unaudited Interim Financial Statements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated balance sheet as of July 31,
2021, and the consolidated statements of operations, stockholders&#8217; equity, and cash flows for the periods presented have been prepared
by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary
to present fairly the financial position, results of operations, changes in stockholders&#8217; equity and cash flows for all periods
presented have been made. The results for the six months ended July 31, 2021, are not necessarily indicative of the results to be expected
for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and
footnotes thereto included in Nutriband&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain information and footnote disclosures required
under generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted
from these consolidated financial statements pursuant to the rules and regulations, including the interim reporting requirements of the
U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The preparation of consolidated financial statements in accordance with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts
in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s significant accounting policies
are summarized in Note 1 in the Company&#8217;s Annual Report on Form 10-K for the year ended January 31, 2021. There were no significant
changes to these accounting policies during the six months July 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DerivativeLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DerivativeLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DisaggregationOfRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DisaggregationOfRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for Going Concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PerformanceObligationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PerformanceObligationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial statements policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321639932776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of disaggregation of revenues</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">59,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">541,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">120,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,976</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,044</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">737,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">124,958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">245,679</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of revenue by geographical location</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographic location:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">560,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">83,044</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,770</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographical location</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">360,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">245,679</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321639620232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Fair value</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Recognized on</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Acquisition</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">Common stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">6,085,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Note payable issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">66,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,761</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,613</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equipment and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer base</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intellectual property and trademarks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">583,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,810,640</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,104</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,851</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(268,715</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/> Recognized<br/> on<br/> Acquisition</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,085,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Note payable issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">66,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,761</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,613</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equipment and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Customer base</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intellectual property and trademarks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">583,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,810,640</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,104</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,851</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(268,715</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,418,073</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of unaudited pro forma condensed financial information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>July 31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As Reported</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Proforma</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">203,814</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">629,873</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(638,063</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(702,975</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proforma</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proforma</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">943,702</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,369,761</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">370,647</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,993,472</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,932,828</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,001,178</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,766,627</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,732,727</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.51</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.50</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.45</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321632933224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>July&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>January&#160;31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,097,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,643</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,270,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,221,163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(235,450</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144,537</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Property and Equipment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,035,109</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,076,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144,585</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,053,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,643</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,221,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,228</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144,537</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,199</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Property and Equipment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,076,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">111,029</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321636566760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of provision for income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Years Ended<br/> January&#160;31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended<br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Book income (loss) from operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(615,894</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(580,992</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Common stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">421,024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,931</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Unused operating losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">194,870</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">528,061</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax asset and Liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforwards (expire through 2038)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,106,339</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(698,308</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(844,520</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(436,904</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(525,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(525,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,475,859</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,660,212</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634899432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable/Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of Minimum lease payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ending</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 75%">January 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">12,557</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,295</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,361</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">January 31, 2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,362</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; width: 13%">Years Ending</td>
    <td style="width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 75%">January 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">24,738</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,295</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>January 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,361</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">January 31, 2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right; padding-left: 0.125in; padding-bottom: 4pt">Total</td>
    <td>&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">121,543</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321635080728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>July&#160;31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>January&#160;31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">314,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">314,100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">License agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Intellectual property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">817,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">817,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,181,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,131,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(189,679</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">991,821</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,006,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">January&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">January&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">314,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Intellectual property and trademarks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">817,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">234,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,131,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,006,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">314,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0; text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended January 31,</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 89%; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remainder of 2022</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,870</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129,776</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2924</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129,776</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,109</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 and thereafter</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">554,290</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">991,821</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Year Ended January 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">113,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2026 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">554,130</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,006,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321723422328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule reconciliation of derivative liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Balance at the beginning of the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">928,774</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative liability warrants reclassed to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(906,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in value of embedded conversion option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,096</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321639822488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsTablesLineItems', window );"><strong>Warrants and Options (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Shares</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Exercise<br/> Price</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Remaining<br/> Life</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Intrinsic<br/> Value</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">141,828</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11.99</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16 years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">285,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding-period ending July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41 years</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable - period ending July 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41 years</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">&#160;&#160;<b>Remaining</b> </span></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Life</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">182,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,101,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;3.00&#160;years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(162,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">5.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;2.08 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#160;&#160;3.00 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Expired/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding-period ending January 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.16</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">853,311</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable - period ending January 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">141,828</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.16</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">853,311</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding', window );">Schedule of additional information relating to warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
    of Exercise Prices</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/>

    Outstanding</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
    Contractual<br/>
 Life&#160;(Years)</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    <br/>
Price for<br/>
 Shares<br/>
 Outstanding</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/>

    Exercisable</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    <br/>
Price for<br/>
 Shares<br/>
 Exercisable</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic<br/>

    Value</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,828</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,828</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Range of <br/> Exercise <br/> Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining <br/> Contractual <br/> Life(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price <br/> for Shares <br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price <br/> for Shares <br/> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">95,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">95,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">11.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsTablesLineItems', window );"><strong>Warrants and Options (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, January 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">0.05 years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">232,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding-period ending January 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable - period ending January 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsandOptionsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsandOptionsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321632736376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of disaggregation of revenues</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">59,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">541,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">120,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,976</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,044</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by type</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Sale of goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">737,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">124,958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">245,679</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of revenue by geographical location</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Six Months Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>July 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographic location:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">213,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">560,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">83,044</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,770</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">213,739</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,450</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">647,227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended <br/> January&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue by geographical location</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">360,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">245,679</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">943,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">370,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lab Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321635470136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2018</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jun. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Converted per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,810,640<span></span>
</td>
<td class="nump">$ 7,529,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,529,875<span></span>
</td>
<td class="nump">$ 1,719,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,830<span></span>
</td>
<td class="nump">141,830<span></span>
</td>
<td class="nump">141,830<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 928,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ntrb_ThreeCustomerMember', window );">Three Customers [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ConcentrationRiskPercentage', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ntrb_TwoCustomerMember', window );">Two Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ConcentrationRiskPercentage', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ntrb_TwoCustomerMember', window );">Two Customer [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ConcentrationRiskPercentage', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ntrb_OneCustomerMember', window );">One Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ConcentrationRiskPercentage', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ntrb_TherapeuticsLLCMember', window );">4P Therapeutics LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Description of acquired entity</a></td>
<td class="text">the Company acquired
4P Therapeutics LLC (&#8220;4P Therapeutics&#8221;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000,
and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been
developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of
the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ntrb_ActiveIntelligenceLLCMember', window );">Active Intelligence LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_AcquiredPercentage', window );">Acquired percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentsUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentsUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_AcquiredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_AcquiredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ConcentrationRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ConcentrationRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_OrganizationandDescriptionofBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_OrganizationandDescriptionofBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PropertyPlantAndEquipmentsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PropertyPlantAndEquipmentsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ntrb_ThreeCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ntrb_ThreeCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ntrb_TwoCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ntrb_TwoCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ntrb_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ntrb_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ntrb_TherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ntrb_TherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ntrb_ActiveIntelligenceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ntrb_ActiveIntelligenceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321641763384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - Schedule of disaggregation of revenues - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfDisaggregationOfRevenuesAbstract', window );"><strong>Schedule of disaggregation of revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SalesRevenuesGoodsNet', window );">Sale of goods</a></td>
<td class="nump">$ 213,739<span></span>
</td>
<td class="nump">$ 59,450<span></span>
</td>
<td class="nump">$ 541,251<span></span>
</td>
<td class="nump">$ 120,770<span></span>
</td>
<td class="nump">$ 737,519<span></span>
</td>
<td class="nump">$ 124,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SaleOfGoodsAndServices', window );">Services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 105,976<span></span>
</td>
<td class="nump">$ 83,044<span></span>
</td>
<td class="nump">206,183<span></span>
</td>
<td class="nump">245,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DisaggregationOfRevenues', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943,702<span></span>
</td>
<td class="nump">$ 370,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DisaggregationOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disaggregation of revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DisaggregationOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SaleOfGoodsAndServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SaleOfGoodsAndServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SalesRevenuesGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of sale of goods during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SalesRevenuesGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfDisaggregationOfRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfDisaggregationOfRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321639977768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - Schedule of revenue by geographical location - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of revenue by geographical location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DisaggregationOfRevenues', window );">Total</a></td>
<td class="nump">$ 943,702<span></span>
</td>
<td class="nump">$ 370,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of revenue by geographical location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DisaggregationOfRevenues', window );">Total</a></td>
<td class="nump">360,378<span></span>
</td>
<td class="nump">245,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of revenue by geographical location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DisaggregationOfRevenues', window );">Total</a></td>
<td class="nump">$ 583,324<span></span>
</td>
<td class="nump">$ 124,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DisaggregationOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disaggregation of revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DisaggregationOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640017672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - Schedule of property plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Organization and Description of Business (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of other property, plant and equipment (PPE) owned by public utility, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640116600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_AcquisitionofBusinessDetailsLineItems', window );"><strong>Acquisition of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired', window );">Acquired of membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DebtInstrumentAnnualPrincipalPayments', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,332,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Capital raise of no less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Public offering less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_AnnualMeetingOfShareholdersTerm', window );">Annual meeting of shareholders, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionRevenue', window );">Net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionNetProfit', window );">Net profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ntrb_BusinessCombinationMember', window );">Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_AcquisitionofBusinessDetailsLineItems', window );"><strong>Acquisition of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Acquired common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,085,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Acquired common stock, shares (in Shares) (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_AcquisitionofBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_AcquisitionofBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_AnnualMeetingOfShareholdersTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual meeting of shareholders, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_AnnualMeetingOfShareholdersTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionNetProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition net profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionNetProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DebtInstrumentAnnualPrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DebtInstrumentAnnualPrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ntrb_BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ntrb_BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321723437064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Business (Details) - Schedule of net assets acquired - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfNetAssetsAcquiredAbstract', window );"><strong>Schedule of net assets acquired [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionCommonStockIssued', window );">Common stock issued</a></td>
<td class="nump">$ 6,085,180<span></span>
</td>
<td class="nump">$ 6,085,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotePayableIssued', window );">Note payable issued</a></td>
<td class="nump">1,332,893<span></span>
</td>
<td class="nump">1,332,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockAndNoteIssuedInAcquisition', window );">Total</a></td>
<td class="nump">7,418,073<span></span>
</td>
<td class="nump">7,418,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">66,994<span></span>
</td>
<td class="nump">66,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">1,761<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">42,613<span></span>
</td>
<td class="nump">42,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment', window );">Equipment and fixtures</a></td>
<td class="nump">1,056,935<span></span>
</td>
<td class="nump">1,056,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase', window );">Customer base</a></td>
<td class="nump">177,600<span></span>
</td>
<td class="nump">177,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks', window );">Intellectual property and trademarks</a></td>
<td class="nump">583,200<span></span>
</td>
<td class="nump">583,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">5,810,640<span></span>
</td>
<td class="nump">5,810,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Acounts payable and accrued expenses</a></td>
<td class="num">(26,104)<span></span>
</td>
<td class="num">(26,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(26,851)<span></span>
</td>
<td class="num">(26,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt</a></td>
<td class="num">(268,715)<span></span>
</td>
<td class="num">(268,715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 7,418,073<span></span>
</td>
<td class="nump">$ 7,418,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer base.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intellectual property and trademarks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockAndNoteIssuedInAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock and note issued in acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockAndNoteIssuedInAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_NotePayableIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note payable issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_NotePayableIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfNetAssetsAcquiredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfNetAssetsAcquiredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640060936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract', window );"><strong>Schedule of unaudited pro forma condensed financial information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue, Reported</a></td>
<td class="nump">$ 213,739<span></span>
</td>
<td class="nump">$ 84,450<span></span>
</td>
<td class="nump">$ 647,227<span></span>
</td>
<td class="nump">$ 203,814<span></span>
</td>
<td class="nump">$ 943,702<span></span>
</td>
<td class="nump">$ 370,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenue, Proforma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,873<span></span>
</td>
<td class="nump">1,369,761<span></span>
</td>
<td class="nump">1,993,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss, Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,932,828)<span></span>
</td>
<td class="num">(2,766,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss, Proforma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (702,975)<span></span>
</td>
<td class="num">$ (3,001,178)<span></span>
</td>
<td class="num">$ (2,732,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share - basic and diluted, Reported (in Dollars per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic', window );">Loss per common share - basic and diluted, Proforma (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss per common share - basic and diluted, Proforma.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321635056728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 90,913<span></span>
</td>
<td class="nump">$ 17,558<span></span>
</td>
<td class="nump">$ 91,338<span></span>
</td>
<td class="nump">$ 35,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640298248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of property and equipment - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentsGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,221,163<span></span>
</td>
<td class="nump">$ 164,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Less: Accumulated depreciation</a></td>
<td class="num">(144,537)<span></span>
</td>
<td class="num">(53,199)<span></span>
</td>
<td class="num">$ (235,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Property and Equipment</a></td>
<td class="nump">1,076,626<span></span>
</td>
<td class="nump">111,029<span></span>
</td>
<td class="nump">$ 1,035,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentsGross', window );">Property and equipment, gross</a></td>
<td class="nump">144,585<span></span>
</td>
<td class="nump">144,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentsGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,053,966<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PropertyPlantAndEquipmentsGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 22,612<span></span>
</td>
<td class="nump">$ 19,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PropertyPlantAndEquipmentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical asset used in the normal conduct of business and not intended for resale. Example include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PropertyPlantAndEquipmentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634091992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss expire, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s NOL expires in 2038.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax', window );">Corporate rate, description</a></td>
<td class="text">On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) significantly
revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of effective income tax federal statutory tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634308664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Summary of provision for income taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634339064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract', window );"><strong>Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Book income (loss) from operations</a></td>
<td class="num">$ (615,894)<span></span>
</td>
<td class="num">$ (580,992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Common stock issued for services</a></td>
<td class="nump">421,024<span></span>
</td>
<td class="nump">52,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairment expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Unused operating losses</a></td>
<td class="nump">194,870<span></span>
</td>
<td class="nump">528,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634178072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax asset and liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract', window );"><strong>Schedule of deferred tax asset and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards (expire through 2038)</a></td>
<td class="num">$ (1,106,339)<span></span>
</td>
<td class="num">$ (698,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices', window );">Stock issued for services</a></td>
<td class="num">(844,520)<span></span>
</td>
<td class="num">(436,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Intangible impairment expense</a></td>
<td class="num">(525,000)<span></span>
</td>
<td class="num">(525,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">2,475,859<span></span>
</td>
<td class="nump">1,660,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321626439512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable/Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Mar. 21, 2020</div></th>
<th class="th"><div>Mar. 21, 2020</div></th>
<th class="th"><div>Oct. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotesPayableConvertibleDebtDetailsLineItems', window );"><strong>Notes Payable/Convertible Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotePayablesDescription', window );">Notes payable, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Coronavirus Aid
Relief and Economic Security Act (&#8220;CARES ACT&#8221; was enacted. The CARES ACT established the Paycheck Protection Program (&#8220;PPP&#8221;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#8217;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was outstanding as of January 31, 2021. The note matures June 17, 2022
and accrues interest at 0.98% per year.<span></span>
</td>
<td class="text">the Coronavirus Aid Relief
and Economic Security Act (&#8220;CARES ACT&#8221; was enacted. The CARES ACT established the Paycheck Protection Program (&#8220;PPP&#8221;)
which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and
interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company&#8217;s subsidiary,
4P Therapeutics, was advanced $34,870 under the PPP, all of which was forgiven as of April 30, 2021. The Company recorded a gain on the
extinguishment of debt of $34,870 during the six months ended July 31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvances', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Additional loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ProceedsFromLoanOriginationsTotal', window );">Total loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion stock issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Line of credit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms', window );">Line of credit, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">October 16, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">October 16, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Assumed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Payments of principal interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAnnualPrincipalPayment', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal and interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Balance due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Lease of description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases mature in 2025 and 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases mature in 2025 and 2026.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Borrowing rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party payable, description</a></td>
<td class="text">the Company issued to Pocono Coated Products LLC a promissory note, net of debt
discount, in the amount of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021 or immediately following
the earlier of a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products
LLC, a related party, is a shareholder of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotePayableConvertibleDebtDescription', window );">Convertible notes payable, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered
into a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible
promissory notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise
price equal to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price
of the common stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from
this financing of $250,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Description of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion
price, which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion.
The conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply
with the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the
notes at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which
percentage increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after
the closing of the first to occur of (a) the next public offering of the Company&#8217;s securities or (b) the next private placement
of the Company&#8217;s equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of
securities pursuant to an equity line of credit or (d) a financing with a bank or other institutional lender.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FairValueOfConversionPrice', window );">Fair value of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">$ 67,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Initial derivative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DiscountRemainingAmount', window );">Discount remaining amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,131<span></span>
</td>
<td class="nump">69,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,565<span></span>
</td>
<td class="nump">$ 345,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DerivativeLiabilitiesTotal', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">928,774<span></span>
</td>
<td class="nump">928,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for Debt Extinguishment or Debt Prepayment Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_InterestExpensesDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_AmortizationOfDebtDiscountsPremium', window );">Interest expenses including amortization debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,780<span></span>
</td>
<td class="nump">$ 2,718<span></span>
</td>
<td class="nump">8,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_GainOnExtinguishmentOfDebt', window );">Forgiveness of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,108<span></span>
</td>
<td class="nump">202,500<span></span>
</td>
<td class="nump">272,130<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_InterestExpenseDebts', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,888<span></span>
</td>
<td class="nump">205,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Expense including amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotesPayableConvertibleDebtDetailsLineItems', window );"><strong>Notes Payable/Convertible Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Balance due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Advanced amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Expenses amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotesPayableConvertibleDebtDetailsLineItems', window );"><strong>Notes Payable/Convertible Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Expenses amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_RelatedPartyPayableMember', window );">Related Party Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotesPayableConvertibleDebtDetailsLineItems', window );"><strong>Notes Payable/Convertible Debt (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party payable, description</a></td>
<td class="text">the Company issued to Pocono Coated Products LLC a promissory note, net of debt discount, in the amount
of $1,332,893 with interest accruing at an annual rate of 0.17%, due on August 28, 2021, or immediately following the earlier of a capital
raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products LLC, a related party, is
a shareholder of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DueToRelatedPartyCurrentAndNoncurrent', window );">Balance due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,475,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_AmortizationOfDebtDiscountsPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_AmortizationOfDebtDiscountsPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DerivativeLiabilitiesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative liabilities total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DerivativeLiabilitiesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DiscountRemainingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount remaining amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DiscountRemainingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DueToRelatedPartyCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DueToRelatedPartyCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_FairValueOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_FairValueOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_GainOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_GainOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_InterestExpenseDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_InterestExpenseDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_InterestExpensesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_InterestExpensesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_NotePayableConvertibleDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_NotePayableConvertibleDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_NotePayablesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_NotePayablesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_NotesPayableConvertibleDebtDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_NotesPayableConvertibleDebtDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ProceedsFromLoanOriginationsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ProceedsFromLoanOriginationsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Federal Home Loan Bank (FHLBank) advances to member financial institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoanOriginations1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoanOriginations1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123395306&amp;loc=d3e36975-112693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919370-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123417830&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_RelatedPartyPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_RelatedPartyPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634109512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable/Convertible Debt (Details) - Schedule of minimum lease payments - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfMinimumLeasePaymentsAbstract', window );"><strong>Schedule of minimum lease payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths', window );">Years Ending January 31, 2022</a></td>
<td class="nump">$ 12,557<span></span>
</td>
<td class="nump">$ 24,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo', window );">January 31, 2023</a></td>
<td class="nump">26,295<span></span>
</td>
<td class="nump">26,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree', window );">January 31, 2024</a></td>
<td class="nump">27,948<span></span>
</td>
<td class="nump">27,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour', window );">January 31, 2025</a></td>
<td class="nump">26,361<span></span>
</td>
<td class="nump">26,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive', window );">January 31, 2026</a></td>
<td class="nump">16,202<span></span>
</td>
<td class="nump">16,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 109,362<span></span>
</td>
<td class="nump">$ 121,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfMinimumLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfMinimumLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321635262872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Dec. 09, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_amortizedOverPeriod', window );">Amortized over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,909<span></span>
</td>
<td class="nump">$ 18,534<span></span>
</td>
<td class="nump">$ 68,770<span></span>
</td>
<td class="nump">$ 37,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PaymentForInitialLicenseFee', window );">IP license</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_amortizedOverPeriod', window );">Amortized over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_amortizedOverPeriod', window );">Amortized over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IntangibleAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IntangibleAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PaymentForInitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid for initial license fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PaymentForInitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_amortizedOverPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_amortizedOverPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640744024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems', window );"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 1,181,500<span></span>
</td>
<td class="nump">$ 1,131,500<span></span>
</td>
<td class="nump">$ 370,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(189,679)<span></span>
</td>
<td class="num">(124,770)<span></span>
</td>
<td class="num">(56,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible Assets</a></td>
<td class="nump">991,821<span></span>
</td>
<td class="nump">1,006,730<span></span>
</td>
<td class="nump">314,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember', window );">Customer base [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems', window );"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">314,100<span></span>
</td>
<td class="nump">314,100<span></span>
</td>
<td class="nump">136,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual property and trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems', window );"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 817,400<span></span>
</td>
<td class="nump">$ 817,400<span></span>
</td>
<td class="nump">$ 234,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634787832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of estimated amortization - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfEstimatedAmortizationAbstract', window );"><strong>Schedule of estimated amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 64,870<span></span>
</td>
<td class="nump">$ 113,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">129,776<span></span>
</td>
<td class="nump">113,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">129,776<span></span>
</td>
<td class="nump">113,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">113,109<span></span>
</td>
<td class="nump">113,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2026 and thereafter</a></td>
<td class="nump">554,290<span></span>
</td>
<td class="nump">554,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total</a></td>
<td class="nump">$ 991,821<span></span>
</td>
<td class="nump">$ 1,006,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfEstimatedAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfEstimatedAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634054472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DerivativeLiabilitiesDetailsLineItems', window );"><strong>Derivative Liabilities (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FairValueAssumptionsWeightedAverageVolatilityRates', window );">Expected volatility</a></td>
<td class="nump">147.47%<span></span>
</td>
<td class="nump">158.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FairValueAssumptionsRiskFreeInterestRates', window );">Risk-free interest rate</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ExpectedTerm', window );">Expected term</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=ntrb_RevaluedMember', window );">Re-Valuation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DerivativeLiabilitiesDetailsLineItems', window );"><strong>Derivative Liabilities (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FairValueAssumptionsWeightedAverageVolatilityRates', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FairValueAssumptionsRiskFreeInterestRates', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ExpectedTerms', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">nine months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DerivativeLiabilitiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DerivativeLiabilitiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ExpectedTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of expected term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ExpectedTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_FairValueAssumptionsRiskFreeInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_FairValueAssumptionsRiskFreeInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_FairValueAssumptionsWeightedAverageVolatilityRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_FairValueAssumptionsWeightedAverageVolatilityRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=ntrb_RevaluedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=ntrb_RevaluedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718532200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Details) - Schedule reconciliation of derivative liabilities - Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 928,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DerivativeLiabilityWarrantsReclassedToEquity', window );">Derivative liability warrants reclassed to equity</a></td>
<td class="num">(906,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in value of embedded conversion option</a></td>
<td class="num">(22,096)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance at the end of the period</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DerivativeLiabilityWarrantsReclassedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liability warrants reclassed to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DerivativeLiabilityWarrantsReclassedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321727112440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2019</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Stock, description</a></td>
<td class="text">a)On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company&#8217;s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FairValueOfWarrantExpense', window );">Fair value of warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized', window );">Warrant, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The warrant expired
unexercised on May 19, 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,182<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,345<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockIssued', window );">Common stock issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 777,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,257<span></span>
</td>
<td class="nump">$ 5,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ntrb_PoconoCoatedProductsLLCMember', window );">Pocono Coated Products LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrincipalTransactionsRevenue', window );">Revenue transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PurchaseOfMaterials', window );">Purchase of materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ExpensesPaid', window );">Expenses paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_RelatedPartyTransactionDescriptionOfTransactions', window );">Related party transaction, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of July 31, 2021, the Company owed Pocono $2,634. The Company also issued a note in the amount of $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pocono Coated Products LLC owed the Company $5,228. The Company also issued a note in the amount $1,500,000 to Pocono Coated Products LLC. See footnote 5 for further discussion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ntrb_FormerIndependentDirectorsMember', window );">Former Independent Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issuance of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,221,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ExpensesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ExpensesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_FairValueOfWarrantExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_FairValueOfWarrantExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PurchaseOfMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of Materials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PurchaseOfMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_RelatedPartyTransactionDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_RelatedPartyTransactionDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of expense or revenue offset related to the warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalTransactionsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) resulting from the difference between acquisition price and selling price or fair value of trading assets and trading liabilities, and from the firm's direct investment activity, conducted separately from customer trading activities, including, but not limited to, investments in private equity, alternative investment products, real estate, and exchanges and memberships.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=35711157&amp;loc=d3e42567-110969<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalTransactionsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ntrb_PoconoCoatedProductsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ntrb_PoconoCoatedProductsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ntrb_FormerIndependentDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ntrb_FormerIndependentDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321621281176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Dec. 09, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 22, 2020</div></th>
<th class="th"><div>Jun. 20, 2019</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Feb. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 25, 2019</div></th>
<th class="th"><div>May 24, 2019</div></th>
<th class="th"><div>Jul. 27, 2018</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 27, 2020</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
<th class="th"><div>Jan. 15, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockOfDescription', window );">Common stock description</a></td>
<td class="text">In March 2020, a minority shareholder who had
previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In March 2020, a minority shareholder
who had previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder
to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert
the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 25, 2019, the Company effected
a one-for four reverse split, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the
Company decreased its authorized common stock from 100,000,000 to 25,000,000 shares.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PrivatePlacement', window );">Private placement shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsToPurchaseOfCommonStockShare', window );">Issued price per unit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_InvestmentWarrantExercisePrice', window );">Exercise price of warrants (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsToPurchaseOfCommonStockShares', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 583,000<span></span>
</td>
<td class="nump">$ 515,108<span></span>
</td>
<td class="nump">$ 515,108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Selling and general administrative expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issued of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Common stock, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,085,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription payable, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares', window );">Subscription payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Extinguish accounts payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FairValueOfTheCommonStocks', window );">Fair value of the common stocks issuance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubscriptionPayable', window );">Stockholders&#8217; equity subscription payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PaymentForInitialLicenseFee', window );">License fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_FundReceived', window );">Balance of the funds received (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PaymentForInitialLicenseFee', window );">License fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_PoconoCoatedProductsLLCMember', window );">Pocono Coated Products LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issued of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Common stock, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,085,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Issued a promissory note, net of debt discount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,332,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_BPMMember', window );">BPM Inno Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Payment received (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_BPMMember', window );">BPM Inno Ltd [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_ConsultingServicesMember', window );">Consulting services [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ntrb_ConsultingServicesMember', window );">Consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ntrb_BPMMember', window );">BPM Inno Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubscriptionPayable', window );">Stockholders&#8217; equity subscription payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PaymentForInitialLicenseFee', window );">License fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 777,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,177,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_DesignatedSharesOfPreferredStocks', window );">Preferred stock, shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SharesWereRestored', window );">Shares were restored</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,954,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock conversion (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issued of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Common stock, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued, value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IncreaseDecreasedInAuthorizedCommonStock', window );">Increase decreased in authorized common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IncreaseDecreasedInAuthorizedCommonStock', window );">Increase decreased in authorized common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockOfDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockOfDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_DesignatedSharesOfPreferredStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Designated shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_DesignatedSharesOfPreferredStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_FairValueOfTheCommonStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the common stocks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_FairValueOfTheCommonStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_FundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fund received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_FundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IncreaseDecreasedInAuthorizedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decreased in authorized common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IncreaseDecreasedInAuthorizedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_InvestmentWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_InvestmentWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PaymentForInitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid for initial license fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PaymentForInitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SharesWereRestored">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares were restored.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SharesWereRestored</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SubscriptionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subscription payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SubscriptionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsToPurchaseOfCommonStockShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants to purchase of common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsToPurchaseOfCommonStockShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsToPurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants to purchase of common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsToPurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_PoconoCoatedProductsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_PoconoCoatedProductsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_BPMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_BPMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ntrb_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ntrb_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ntrb_BPMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ntrb_BPMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718541640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsDetailsLineItems', window );"><strong>Warrants and Options (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 20.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_InitialPublicOfferingPricePercentage', window );">Initial public offering price, percentage</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ReclassOfWarrantsFromLiabilityToEquity', window );">Derivative liability for warrant</a></td>
<td class="nump">$ 906,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsDetailsLineItems', window );"><strong>Warrants and Options (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue', window );">Purchase of warrants shares</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsDetailsLineItems', window );"><strong>Warrants and Options (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue', window );">Purchase of warrants shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_InitialPublicOfferingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_InitialPublicOfferingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ReclassOfWarrantsFromLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ReclassOfWarrantsFromLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsandOptionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsandOptionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321635533896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Options (Details) - Schedule of warrants outstanding - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">182,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice', window );">Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 18.93<span></span>
</td>
<td class="nump">$ 6.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Life, Outstanding, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,101,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">91,828<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price, Granted</a></td>
<td class="nump">$ 12.53<span></span>
</td>
<td class="nump">$ 20.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted', window );">Remaining Life, Granted</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess', window );">Intrinsic Value, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares, Expired/Cancelled</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(162,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercise Price, Expired/Cancelled</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess', window );">Intrinsic Value, Expired/Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance</a></td>
<td class="nump">141,828<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice', window );">Exercise Price, Outstanding, Ending Balance</a></td>
<td class="nump">$ 11.99<span></span>
</td>
<td class="nump">$ 18.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne', window );">Remaining Life, Outstanding, Ending Balance</a></td>
<td class="text">2 years 1 month 28 days<span></span>
</td>
<td class="text">2 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 853,311<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable</a></td>
<td class="nump">141,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price, Exercisable</a></td>
<td class="nump">$ 11.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining Life, Exercisable</a></td>
<td class="text">2 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 853,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expired/Cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640050648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems', window );"><strong>Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Range of Exercise Prices</a></td>
<td class="nump">14.00<span></span>
</td>
<td class="nump">14.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life(Years)</a></td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">2 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise Price for Shares Outstanding (in Dollars per share)</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers', window );">Number Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice', window );">Exercise Price for Shares Exercisable (in Dollars per share)</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems', window );"><strong>Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Range of Exercise Prices</a></td>
<td class="nump">11.00<span></span>
</td>
<td class="nump">11.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life(Years)</a></td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise Price for Shares Outstanding (in Dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers', window );">Number Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice', window );">Exercise Price for Shares Exercisable (in Dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321735838216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Options (Details) - Schedule of options outstanding - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems', window );"><strong>Warrants and Options (Details) - Schedule of options outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price, Outstanding, Beginning Balance (in Dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Life, Outstanding, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted (in Shares) | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price, Granted (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted', window );">Remaining Life, Granted</a></td>
<td class="text">18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value, Granted</a></td>
<td class="nump">$ 232,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares, Expired (in Shares) | shares</a></td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercise Price, Expired (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices', window );">Remaining Life, Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess', window );">Intrinsic Value, Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise Price, Exercised (in Dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices', window );">Remaining Life, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess', window );">Intrinsic Value, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Shares, Outstanding, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price, Outstanding, Ending Balance (in Dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne', window );">Remaining Life, Outstanding, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price, Exercisable (in Dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining Life, Exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expired/Cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321634080776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_MonthlyRent', window );">Amount of monthly rent</a></td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_MonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of monthly rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_MonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321729433688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contigencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Dec. 09, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Apr. 29, 2019</div></th>
<th class="th"><div>Apr. 25, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Jul. 27, 2018</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommitmentsandContigenciesDetailsLineItems', window );"><strong>Commitments and Contigencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquired advanced shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquired advanced shares of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,085,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Compensation annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PublicOrPrivateFinancing', window );">Public or private financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PaymentForInitialLicenseFee', window );">Initial license fee payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Other commitments term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company had entered into a prior
agreement, dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (&#8220;BPM&#8221;), that, in consideration of BPM&#8217;s introduction
of Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties
similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting
from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM&#8217;s payment
of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within
36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed
products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the
right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights
of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommitmentsandContigenciesDetailsLineItems', window );"><strong>Commitments and Contigencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_PaymentForInitialLicenseFee', window );">Initial license fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ntrb_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommitmentsandContigenciesDetailsLineItems', window );"><strong>Commitments and Contigencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantPurchaseCommitmentDescription', window );">Purchase commitment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company and BPM entered into a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.<span></span>
</td>
<td class="text">The Company and BPM entered into a Stock Purchase Agreement (&#8220;SPA&#8221;), dated December 7, 2020, providing for the purchase by BPM of 81,396 shares of common stock at a price of $8.60 per share, or $700,000. In December 2020, the Company received an initial payment of $60,000 under the SPA, which is included in Stockholders&#8217; Equity in the Company&#8217;s consolidated balance sheet as of January 31, 2021. On February 25, 2021, in connection with the Company&#8217;s License Agreement with Rambam, pursuant to the SPA, the Company issued 81,395 shares of common stock to BPM and received the balance of the proceeds of $700,000 to be applied to product development expenses under the License Agreement.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_HealthsBrandsIncMember', window );">Health Brands, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommitmentsandContigenciesDetailsLineItems', window );"><strong>Commitments and Contigencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquired advanced shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ntrb_DefendantMember', window );">Defendants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommitmentsandContigenciesDetailsLineItems', window );"><strong>Commitments and Contigencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares cancelled (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommitmentsandContigenciesDetailsLineItems', window );"><strong>Commitments and Contigencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SalaryPayment', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommitmentsandContigenciesDetailsLineItems', window );"><strong>Commitments and Contigencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommitmentsandContigenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommitmentsandContigenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PaymentForInitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid for initial license fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PaymentForInitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_PublicOrPrivateFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public or private financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_PublicOrPrivateFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SalaryPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of salary payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SalaryPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ntrb_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ntrb_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_HealthsBrandsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_HealthsBrandsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ntrb_DefendantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ntrb_DefendantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718971608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,256,772<span></span>
</td>
<td class="nump">5,441,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,257<span></span>
</td>
<td class="nump">$ 5,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, Description</a></td>
<td class="text">(i) $6,000,000
paid in shares of the Company&#8217;s common stock at a value of the average price of the previous 90 days at the date of Closing (the
&#8220;Shares&#8221;); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a)
twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of
no less than $4,000,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares', window );">Note issued transaction</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,602<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718466296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_InventoryRawMaterialsPercentage', window );">Inventory raw materials percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (in Dollars)</a></td>
<td class="nump">$ 7,529,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,529,875<span></span>
</td>
<td class="nump">$ 1,719,235<span></span>
</td>
<td class="nump">$ 5,810,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock (in Shares)</a></td>
<td class="nump">141,830<span></span>
</td>
<td class="nump">141,830<span></span>
</td>
<td class="nump">141,830<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_InventoryRawMaterialsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_InventoryRawMaterialsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321636503384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenues - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfDisaggregationOfRevenuesAbstract', window );"><strong>Schedule of disaggregation of revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SalesRevenuesGoodsNet', window );">Sale of goods</a></td>
<td class="nump">$ 213,739<span></span>
</td>
<td class="nump">$ 59,450<span></span>
</td>
<td class="nump">$ 541,251<span></span>
</td>
<td class="nump">$ 120,770<span></span>
</td>
<td class="nump">$ 737,519<span></span>
</td>
<td class="nump">$ 124,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SaleOfGoodsAndServices', window );">Services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">105,976<span></span>
</td>
<td class="nump">83,044<span></span>
</td>
<td class="nump">206,183<span></span>
</td>
<td class="nump">245,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 213,739<span></span>
</td>
<td class="nump">$ 84,450<span></span>
</td>
<td class="nump">$ 647,227<span></span>
</td>
<td class="nump">$ 203,814<span></span>
</td>
<td class="nump">$ 943,702<span></span>
</td>
<td class="nump">$ 370,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SaleOfGoodsAndServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SaleOfGoodsAndServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SalesRevenuesGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of sale of goods during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SalesRevenuesGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfDisaggregationOfRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfDisaggregationOfRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718965224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 213,739<span></span>
</td>
<td class="nump">$ 84,450<span></span>
</td>
<td class="nump">$ 647,227<span></span>
</td>
<td class="nump">$ 203,814<span></span>
</td>
<td class="nump">$ 943,702<span></span>
</td>
<td class="nump">$ 370,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">213,739<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">560,627<span></span>
</td>
<td class="nump">83,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 59,450<span></span>
</td>
<td class="nump">$ 86,600<span></span>
</td>
<td class="nump">$ 120,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718459848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, Usefull life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640256824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Business (Details) - Schedule of net assets acquired - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfNetAssetsAcquiredAbstract', window );"><strong>Schedule of net assets acquired [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionCommonStockIssued', window );">Common stock issued</a></td>
<td class="nump">$ 6,085,180<span></span>
</td>
<td class="nump">$ 6,085,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_NotePayableIssued', window );">Note payable issued</a></td>
<td class="nump">1,332,893<span></span>
</td>
<td class="nump">1,332,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_CommonStockAndNoteIssuedInAcquisition', window );">Total</a></td>
<td class="nump">7,418,073<span></span>
</td>
<td class="nump">7,418,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">66,994<span></span>
</td>
<td class="nump">66,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">1,761<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">42,613<span></span>
</td>
<td class="nump">42,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment', window );">Equipment and fixtures</a></td>
<td class="nump">1,056,935<span></span>
</td>
<td class="nump">1,056,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase', window );">Customer base</a></td>
<td class="nump">177,600<span></span>
</td>
<td class="nump">177,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks', window );">Intellectual property and trademarks</a></td>
<td class="nump">583,200<span></span>
</td>
<td class="nump">583,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">5,810,640<span></span>
</td>
<td class="nump">5,810,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(26,104)<span></span>
</td>
<td class="num">(26,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(26,851)<span></span>
</td>
<td class="num">(26,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt</a></td>
<td class="num">(268,715)<span></span>
</td>
<td class="num">(268,715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 7,418,073<span></span>
</td>
<td class="nump">$ 7,418,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer base.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intellectual property and trademarks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_CommonStockAndNoteIssuedInAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock and note issued in acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_CommonStockAndNoteIssuedInAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_NotePayableIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note payable issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_NotePayableIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfNetAssetsAcquiredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfNetAssetsAcquiredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321729298888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract', window );"><strong>Schedule of unaudited pro forma condensed financial information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Net revenue As Reported</a></td>
<td class="nump">$ 203,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenue Proforma</a></td>
<td class="nump">629,873<span></span>
</td>
<td class="nump">$ 1,369,761<span></span>
</td>
<td class="nump">$ 1,993,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionsNetLossAsReported', window );">Net loss As Reported</a></td>
<td class="num">(638,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss Proforma</a></td>
<td class="num">$ (702,975)<span></span>
</td>
<td class="num">$ (3,001,178)<span></span>
</td>
<td class="num">$ (2,732,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare', window );">Loss per common share - basic and diluted As Reported (in Dollars per share) | $ / shares (in Dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic', window );">Loss per common share - basic and diluted Proforma (in Dollars per share) | $ / shares (in Dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss per common share - basic and diluted, Proforma.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_BusinessAcquisitionsNetLossAsReported">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_BusinessAcquisitionsNetLossAsReported</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss per common share - basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640709448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of property and equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,270,559<span></span>
</td>
<td class="nump">$ 1,221,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Less: Accumulated depreciation</a></td>
<td class="num">(235,450)<span></span>
</td>
<td class="num">(144,537)<span></span>
</td>
<td class="num">$ (53,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Property and Equipment</a></td>
<td class="nump">1,035,109<span></span>
</td>
<td class="nump">1,076,626<span></span>
</td>
<td class="nump">$ 111,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">144,585<span></span>
</td>
<td class="nump">144,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,097,532<span></span>
</td>
<td class="nump">1,056,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 28,442<span></span>
</td>
<td class="nump">$ 19,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntrb_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321632663800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable/Convertible Debt (Details) - Schedule of Minimum lease payments - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfMinimumLeasePaymentsAbstract', window );"><strong>Schedule of minimum lease payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths', window );">Years Ending January 31, 2022</a></td>
<td class="nump">$ 12,557<span></span>
</td>
<td class="nump">$ 24,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo', window );">January 31, 2023</a></td>
<td class="nump">26,295<span></span>
</td>
<td class="nump">26,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree', window );">January 31, 2024</a></td>
<td class="nump">27,948<span></span>
</td>
<td class="nump">27,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour', window );">January 31, 2025</a></td>
<td class="nump">26,361<span></span>
</td>
<td class="nump">26,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive', window );">January 31, 2026</a></td>
<td class="nump">16,202<span></span>
</td>
<td class="nump">16,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 109,362<span></span>
</td>
<td class="nump">$ 121,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfMinimumLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfMinimumLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321640004472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems', window );"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 1,181,500<span></span>
</td>
<td class="nump">$ 1,131,500<span></span>
</td>
<td class="nump">$ 370,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(189,679)<span></span>
</td>
<td class="num">(124,770)<span></span>
</td>
<td class="num">(56,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible Assets</a></td>
<td class="nump">991,821<span></span>
</td>
<td class="nump">1,006,730<span></span>
</td>
<td class="nump">314,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember', window );">Customer base [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems', window );"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">314,100<span></span>
</td>
<td class="nump">314,100<span></span>
</td>
<td class="nump">136,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ntrb_LicensingAgreementMember', window );">License agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems', window );"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems', window );"><strong>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 817,400<span></span>
</td>
<td class="nump">$ 817,400<span></span>
</td>
<td class="nump">$ 234,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ntrb_LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ntrb_LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321639608984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of estimated amortization: - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfEstimatedAmortizationAbstract', window );"><strong>Schedule of estimated amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Remainder of 2022</a></td>
<td class="nump">$ 64,870<span></span>
</td>
<td class="nump">$ 113,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">129,776<span></span>
</td>
<td class="nump">113,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2924</a></td>
<td class="nump">129,776<span></span>
</td>
<td class="nump">113,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">113,109<span></span>
</td>
<td class="nump">113,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2026 and thereafter</a></td>
<td class="nump">554,290<span></span>
</td>
<td class="nump">554,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total</a></td>
<td class="nump">$ 991,821<span></span>
</td>
<td class="nump">$ 1,006,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfEstimatedAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfEstimatedAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718321752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - Schedule of warrants outstanding<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ScheduleOfWarrantsOutstandingAbstract', window );"><strong>Schedule of warrants outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance</a></td>
<td class="nump">141,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice', window );">Exercise Price Outstanding, Beginning Balance (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Life Outstanding, Beginning Balance</a></td>
<td class="text">2 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value Outstanding, Beginning Balance (in Dollars) | $</a></td>
<td class="nump">$ 285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice', window );">Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value, Granted (in Dollars) | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares Expired/Cancelled</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice', window );">Exercise Price, Expired/Cancelled</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices', window );">Intrinsic Value, Expired/Cancelled</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice', window );">Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices', window );">Intrinsic Value, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding, Ending Balance</a></td>
<td class="nump">141,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice', window );">Exercise Price Outstanding, Ending Balance</a></td>
<td class="nump">11.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne', window );">Remaining Life Outstanding, Ending Balance</a></td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal', window );">Intrinsic Value Outstanding, Ending Balance (in Dollars) | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable</a></td>
<td class="nump">141,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice', window );">Exercise Price, Exercisable</a></td>
<td class="nump">11.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining Life, Exercisable</a></td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Exercisable (in Dollars) | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ScheduleOfWarrantsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ScheduleOfWarrantsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Expired/Cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price Outstanding, Ending Balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140321718922856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - Schedule of additional information relating to warrants outstanding - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems', window );"><strong>Warrants (Details) - Schedule of additional information relating to warrants outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Range of Exercise Prices</a></td>
<td class="nump">14.00<span></span>
</td>
<td class="nump">14.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationNumberOutstanding', window );">Number Outstanding</a></td>
<td class="nump">46,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">2 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise Price for Shares Outstanding (in Dollars per share)</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationNumberExercisable', window );">Number Exercisable</a></td>
<td class="nump">46,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice', window );">Exercise Price for Shares Exercisable (in Dollars per share)</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue', window );">Intrinsic Value (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems', window );"><strong>Warrants (Details) - Schedule of additional information relating to warrants outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Range of Exercise Prices</a></td>
<td class="nump">11.00<span></span>
</td>
<td class="nump">11.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationNumberOutstanding', window );">Number Outstanding</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise Price for Shares Outstanding (in Dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationNumberExercisable', window );">Number Exercisable</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice', window );">Exercise Price for Shares Exercisable (in Dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue', window );">Intrinsic Value (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationNumberExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationNumberExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_ShareBasedCompensationNumberOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_ShareBasedCompensationNumberOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ntrb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-F#;!NS0!LZV@=-$9@.EB<.,5_S\M)#/J%#6X$T]-,%L6@/\)%=Y7U0%?)M
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M([6'\&0^- ZCT)KV!('1,.$6U],^C =!Z(562A!O"8TC"S;OPX*8\2BV4H+
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MTC:]^E17SUZMJ(&;^M!9OQL-]LI+Y2AW;0V_YC"NO?I6IOMUWLJUMZS*-3A
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MM:P5 ?R^J2 (AB]*P.$MSZO_ U!+ P04    " "ZF#Y3$9V-_?(H  !"AP
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M  #X&C;<.@K[O94:DTEIXV!=/,/D'48B3JF@A&RQ;MJZ79% 3G"$B5-B*#S
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MRTS8BD\;Q9Y2*R<($8*/T*C1:6(O\%RGYB ,M\WP*DNK5'#*Y;(YICKU.PV
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M2C"GH05X/]?@_OJ&-FB_R#G[-U!+ P04    " "ZF#Y3.Q="[T8#  !5"
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M?/Q1"%S:?ES;FD"6RL5R;LP.J6RY\; C,5^[W[EJ CE@SO268!H*@-;SI9*
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M ;Q?:7Q1M#?DH/^/R/4?4$L#!!0    ( +J8/E/GUXUF-0X  -LU   9
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M7UJ ]PL#5;DO=$#S>Z[G_P%02P,$%     @ NI@^4]ZO]!+8!   *PT  !D
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M::98MHAG"<)82E1RT% $JS<;80EQ44#X)R#:\)EG:BGA*HLP.F(_.6_O^6<
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M]F$<AGF:)TR7H9H'O/.Z/:?=Z<%[&OI-I]-QX;UU2QF_[*4:]'J>TZ6T:N2
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M5-PEQ'8CP03!T0[T!^J0.,&.:"D2R"#$#B( 1,@"R,)1/&LYL$VQ"U2='JE
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MH04472C;L;/$@.MF6X<U"9*N?1CV0$NTS582-9**D_WZ'5*7V([M)AVPAR%
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MDA0U=UK3CF*ZEE<+N*$71)7]5AM',;S%MRQ^/)@<C :CT4CZA<(NI#Q! /N
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M"W@^L[9*'VB#Y@]@O/X'4$L#!!0    ( +J8/E-/BAO<"@4  , +   9
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M_P7Q^$WF ]#W9'0WV5:VR)Y$?=RR':H2U\*@@_R =WX?&O;J:]LOM[5OYT+
M*Z"B[>$(P%=XIS- HVV*:L##PL*_#GUG9_"<<-FIRZ898)6/9M5VO8+],!2H
MH^GA?P:NX5D\OS0\W4663=25Z7J(C+ XQT\*1" S3X<JK2NJU@W -3@?"!55
M>8#5.K4P#:A#!4S616%6>"X='=8*M*^PJXI5! GYU)!]DS63.EW6H :%5L_Q
M.,?3[S]-[B;JE\O+6_KWT?<'B58 ^TH(M? ^'*NM;4\RZ]H:EW;?PM[5T+D!
M8P<PE?1@0-KPL)U9#)77:^8WG@ ?LN*,.F(P?BI,"*X#GLJ(\#LT.; 96?3M
M(UL(&GQM'8$$?]"[MU?^B*QE["28_;#FUP]C&^)U5Y+S(R5#(C+DGB?1)>X#
M#UWKSZ#OX#!J$@ Y( =@9T4GAX-H<*#S.9B#V D>&85:HTQ=\*.I2C"QR!C<
M1)[,@+IVZ+Y-Y>D<Y!*1NT'_)Q#B^X$\&9MK05966B"P4R3X<!3FH3C68!HN
M@0NI7DH@S=!;,-2S?XIYH<(?>77=7.__:FKW:-!J;<A)I=1EWI6R8H(R[R!7
ME4/GE3+Q@R,/",;3XC-7+2A%UZC+4304)YG&H)FIK'E@9Y.Y 8 %D(,B*MMA
M!ER; 4I6%GT<B&QP&%ZU6M >A>RQA,_(0$%.;?6 80R%,7X(C=<F6E;H 2UY
M>T<):6#:J%@0P5"K_@!&@A6"6^\5Z!W8:&,6[-(14=-&>F5[727?A*"3>R4;
M:C1RV!8P,;"TGZCWT3SP&+8&;U5S.%H!JD"!9.#?S(.%]YCSFQ33:4%B_+SX
M:F!2^B!\"I'!&0J5&IU.@2Z!8S*0!P3%!W"A!KW<@^F6&$\P0('?<WDF(74.
MWI<U0?<I^PL#YR[YM"6S&S;W3_LX)V'//Q[1$7*W V5H!L/FA7+'Q\A\8&O&
M VZ2\8GG $';#O32EA1TS2,(CDX H;TC4PA**RK4]8?#*@$1N^U6]ES"<BT#
M?Q0Z< W/RLYF0#@%JCD?>O!"@E52H0,1[>^<5R$1!D_M#Y<PGP[ON4].-; =
M]EH;1%PNLFY# &M;59EI]*PR(ZN"O;ZB-6)9N[R,GMD*-X%%_%EWF%VJN_[5
MC'4P"9EL/PB"HF9+O*%'=]->(Y!&B;6SRBY84@S<P/R 4>C[Q-7Y^*O0Q:OU
MTI#GS':[>A 4A,$!2;B-V #$>Q7"!(:_;P-=@N6$[,P;WB; QF.L 9DB-EXW
MXG)L:<'G4X@! 6,$Z=A,X8_">T9.*R3H=< M+=H4^0O.$Q)>'9@:%1N]U^DM
M>7R],D-O"SE_@N5V"7_G4<=,AI43:R04-2P X"MR\$<7T:#'Y-RVP-26OKRD
M0@/E615(V"""^-NHNT-@6,_ ?7,^-F5>[14*4:)1X2K,&%Y'S*O>]<#H3;:^
M>W?ESW:[U !A"_I"5PX.6$S4)T=4O0VP9P?<V@_/LS'D@H<0)J-]$N3:#7=W
MX.*O(>" V#9M<039LK\,V5 >X#LQS%2670OP./>^D-4[1!@!PQ(E \K;!'FT
M(-&2K#E1'S!S -_ CFJF(9"/T89YT-5 )T>SC$ T(.Y<H5/'8(*6Q<$*EVB=
M"60!4]Q0+&$)4R,@0=-O:[!\_8@'85B:(^<[0&OP5VE VB!+\'0O '5 >@>K
M/] SJ&&$G]&[D6/&;T6HS!LFF;(B__0X;%')#:@8G0@>Y_"%BDC\!=4F,X,E
M4><PN8.U(5(2JMJ4:&<\-(OQ6KN6W34G7Z2SM@-4@Z&E,,SK+$G6UTL+?$)]
MI8=)('124"J4T.]#N1#7'*)1H;N.<#B>VT3U41O2CG2BM##OQ5Q;K[#2 8"6
MG (?TD$B4'P3G&<Y_P50'Z#Q&,EG$<F/H\3?C^151/(9KO+M.'YW/4,\N5>U
MLH7W&6NMV.0UBTV7[<H[,V9[W#D#*-3 WX6X,40M',1T$OM@@X)8@8J\R]%/
M@%V,GSZ:HH43TWXW#0"1)PP\IVSKUY=W;R3,J\N[3R"("7U[.'V59Y+]?DQ1
M)@1_JF8Z]JA75%$V !V?W[<K6ZB7TY<'(6_&%64UGS_GHN<:J"S9?R9<1]LH
M=5>RXHO7 R,))YBH9$T@G,R9;#1QZ,3G!4+#1MQLY !PW -+M(A&7"_^!6S#
M2,'""O4F_+""+1 MH6S*H1!T1# #S*%CJ]=27C?=V.&0L UKQF*P7 &(3J$Q
MZT!1//[@O-+5+1B=->CH^ZYU2!NXPZPV8'\0"RB8(#RX-K..]%Z A6!E4!@
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MUO0G#N28#A^ [_$W6OP_<(/P WT__2]02P,$%     @ NI@^4_ 8[)F-+P
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MS;*S)JP4,=L>;X$2AFIO8N\-LL&%&&V5;663=O(XJ7>VD1=*0*%WB2[ZM+*
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MHWU,JH3Z"\"01@T(UCJ0R!E;= ZSA<#HDN5BBL;>DB:,P]K4Z WY9\*[!G]
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M(.]!Y9*U=BTVY*I3Z*$4^>&>KFM0/\X]C6&-LY</(:[Z$.$+(5)R([BN%/G
M"RB.^%^?]@_"$P >\AU)AWO25^%)Q)^[^IQ$@4M"/PR.)?0==\I?<C]()QI[
M$%F\Z 6\RSP7'=>,E^16U"QGH,@?EVNE)8K\SQ,!XC% ; /$+P18X7^_Z&HP
M#2V8HF4IH:3[%DMX -Z!.M;9D[CF#7.A6IK#PL%7B +Y ,[ROI( !QTC*_9X
ML#'!!NQL!??&Q)32U-,GHS6YZQ,CZQW1NQ8F*]I3*(4H%'E'PB!RLVB&5C)S
MX\0W1ARX81*@%82^FV7^9(59L1PK>D;"Q/5]GP1^XLZRE$PCUX_CR;W0M#Y
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ML6:%LRE(<P'/-T+H_<($&*?=Y=]02P,$%     @ NI@^4S -R)$B!   *0L
M !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULY59+;]LX$+[K5Q!"#@G
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M:GAQ27VD^HG6;XQLW1392$,SR2TK^@A 907H_59*<]A8 ^-GQ>IO4$L#!!0
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MOH+^ 6?R$/R/<I*^\XGG2P[P^?Y><Y,+91H-Y/OEPEB-U_K'$?*T)T\]>7J
M_ Z_]J+!4U1+<L,EKYJ*",#K3FKVC!^A-?M.]"BG\Y,+4[,<I@$:A@']"$'V
M#9CV1\3EBF"+&K2"39<H>45B.A@.QR<[*PFAHP$]'^[&4T+'@_/T;#<^=/G)
M*-Z-CTB,/!$]N5>6";===(YYE.P[WA=01]/!./FKVI=31^/!,$W(O@L2;GE
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M5VB\[SK31BWPZ+\_0./66/SB72(:6]T[8-X)^+^Q^)GM4?O;LB.K^X%%[G!
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M*%%/S-I0O+1#9\&5'F%VF>NO#!#&09\O.5<;PUS0?K>,_@%02P,$%     @
MNI@^4PQ3P;[4 @  @PP  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
MU5=;3]LP%/XK5IXVB9$XO0%J*U$N&A/5*A#; ]J#FYPT%HX=;&=MI_WXV4Z:
M=!.DFU U>&E\.><[W_'GG)X,ET(^J!1 HU7&N!IYJ=;YB>^K*(6,J$.1 S<[
MB9 9T68J%[[*)9#8.67,#X.@[V>$<F\\=&LS.1Z*0C/*82:1*K*,R/4$F%B.
M/.QM%F[H(M5VP1\/<[* 6]!W^4R:F5^CQ#0#KJC@2$(R\D[QR00/K(.S^$)A
MJ;;&R*8R%^+!3J[BD1=81L @TA:"F,=W. /&+)+A\5B!>G5,Z[@]WJ!?NN1-
M,G.BX$RPKS36Z<@[\E ,"2F8OA'+CU EU+-XD6#*_:)E91MX*"J4%EGE;!AD
ME)=/LJH.8LL!]Y]Q""N'T/$N SF6YT23\5"*)9+6VJ#9@4O5>1MRE%M5;K4T
MN]3XZ?%GN2"<_B#E$?$8G8.*),W=7"1H4BCCH11Z=PZ:4*;>HP_HUMR-N&!@
M#7)I;HC4:Y0SPK6#@,>"YD8Y/?2UH6@#^5%%9U+2"9^A@T,T%5RG"EWP&.+?
M 7R36YU@N$EP$K8B?B+\$'7P 0J#$+?@=>H#ZSB\[C-XEX7D5!<27*H)7=FQ
M0O=3R.8@O[5$Z-81NBY"YW](@NZOC3.ZTI"I-K*]FFRO]3AF+;$.T)V"I& ,
M,9K 4Y>A';N#UD"D:F'9KUGV6Y&FE-.LR&J5T$]T3>;HHCF5W?(-ZEB#UR_?
M44WV:(_RM6/W=LIW7+,\_E?YIB1*C95<_WD^NX7$05,;@]<O)=XJY7B/8NX
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M5&7\/SFV>_-11(K&6"4Z,%H@N&R?[%,7B#, \@P#T@Z0O@9<4L@Z0/8:,+X
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M)FBW =_OE+(O$R?0]ZV+OP%02P,$%     @ NI@^4YC7;M'8 P  A@T  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULC9?=CZ,V$,#_%0OUX4[J+1@2
M2$Y)I'Q<VZMTI]5MKWVH^N# )$$+F+--LOO?=VQ8$CX"]Y)@F(_?C,W,L+AP
M\2Q/ (J\I$DFE]9)J?RC;<OP!"F3#SR'#)\<N$B9PJ4XVC(7P"*CE":VZSB^
MG;(XLU8+<^]1K!:\4$F<P:,@LDA3)EXWD/#+TJ+6VXUO\?&D] U[M<C9$9Y
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MCGB[81^1?]SX%X+_?04PV84C?[<&%=[^"_'=4=!^(?V!]0@V%CD-86JI+B.
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M[03S/!=";SIV ?^SD_P%4$L#!!0    ( +J8/E.]XOS[#0,  -@(   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;+56VV[;, S]%<'80PML]24WIT@,
M-.F&=4"!HEFWAV$/BLTD0BW)D^0F_?M1LN.EJ6-L*/9B2S+/T2$ID9YLI7K4
M&P!#=CP7>NIMC"DN?5^G&^!47\@"!'Y92<6IP:E:^[I00#,'XKD?!<'0YY0)
M+YFXM3N53&1I<B;@3A%=<D[5\PQRN9UZH;=?N&?KC;$+?C(IZ!H68!Z*.X4S
MOV')& >AF11$P6KJ7867\]C:.X-O#+;Z8$RL)TLI'^WD)IMZ@14$.:3&,E!\
M/<$<\MP2H8Q?-:?7;&F!A^,]^R?G._JRI!KF,O_.,K.9>K%',EC1,C?W<OL9
M:G\&EB^5N79/LJUM X^DI3:2UV!4P)FHWG17Q^$ $ Y/ *(:$!T#^B< O1K0
M<XY6RIQ;U]309*+DEBAKC6QVX&+CT.@-$S:+"Z/P*T.<26Y$*CF0KW0'FIQ=
M@Z$LU^?D UG@><G*'(A<8;92*5*6,^I"CRO&V>.857A\%*6!C%!#S ;("C)0
M-"?:4%,:J9Z)H@:(D81R60JC<8>'Q34Y>W<^\0WZ8=7X::UY5FF.3F@.(W(K
MA=EH\E%DD+TD\#$ 312B?11F42?C%RHN2"]\3Z(@"EL$S?\>'G3(Z35)Z3F^
MW@F^_QW['U=+;13>H)\=8ON-V+X3VS\A=H97="_E+)<:3\]*24ZPT"BG6;=E
MN.(<.$Y;:9Z2#\-P$(_[$__I,/ M=H,X&(^CQNZ%Z$$C>M I>BXYQPCB]4I1
MO-8EA@]+(M&@GE@*K9(KQN&!E'X4!M&QXM=F@VC<"]OU#AN]PTZ]-[R@3&'U
M- 1V6,$UM"GLY+#]X%(7-(6IAP7?>@I>0MI.^]MY7C@Y:IP<=3KY($J->:@/
MCE@3>YK:<S%Z%>1PW(]'P5$N7IL-HC@8GDA&W.B,NY-1'7:\AUW)Z.3XAV2\
MG:=RTC]H$AS4VO5.C=4#2T)5*9O5ICU?N:YTM#[#MEUUV3\T5<^_I6K-A"8Y
MK) RN!CA75!5'ZTF1A:N%2VEP<;FAAO\]0!E#?#[2DJSG]@-FI^9Y#=02P,$
M%     @ NI@^4R^$^5[6 @  JP<  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&ULI55=3]LP%/TK5K0'D ;Y3@MJ([&B:4S:A.A@#],>W.2VL7#LS';:
M\N]WG82HA;0P[26QDWO./>?:OIYLI'K4!8 AVY(+/74*8ZI+U]59 275Y[("
M@7^64I74X%2M7%TIH'D#*KD;>%[BEI0))YTTWVY5.I&UX4S K2*Z+DNJGCX!
MEYNIXSO/'^[8JC#V@YM.*KJ".9C[ZE;AS.U9<E:"T$P*HF Y=:[\R]G(QC<!
M#PPV>F=,K).%E(]V<I-/'<\* @Z9L0P47VN8 >>6"&7\Z3B=/J4%[HZ?V3\W
MWM'+@FJ82?Z3Y::8.F.'Y+"D-3=W<O,%.C^QY<LDU\V3;+I8SR%9K8TL.S J
M*)EHWW3;U6$'X$<' $$'"-X+"#M V!AME36VKJFAZ43)#5$V&MGLH*E-@T8W
M3-A5G!N%?QGB3'HC,ED"^4&WH,G)-1C*N#XE9V2.^R6O.1"YM&4!I2 GAFX)
MU1HW%Q4YX8PN&&>&(?2,W,^OR<F'TXEK4)8E=[-.PJ=60G! PE<JSDGH?R2!
M%_@#\-G[X=X^W,5B]!4)^HH$#5]X@.\?C?^Z6FBC<#?^/I([['.'3>[H0.[O
MF  /J**&B17A4FN24:6>\+1NJ,IQA6!;,07$%$K6JP(]A^/!DK=YXB://<GK
M],SWO20,+R;N>K>X X')Q3CTQGW<GI.H=Q(==3(W,GLD3.L:JX?RB0:U9AGH
M(;$M5;*K81Q%L5W./:T#<5&87'C1L-:XUQH?U7HC#!4KML U9V5%F<(N90A6
M&IL5#.F-7^N(@]CS7NI].VY/;]+K38[J?:"\IFT3Y-B%J<@&52:OL@?1*!['
M+W? ZS@_2? H!L,J1[W*T9M[>??\#"_]40Y[A5WJBF8P=?".LEL(G)0,]8C_
MYVE-NCNMU%YCWZA:,:$)AR4R>^<C7%/57@WMQ,BJZ:X+:;!7-\,";U-0-@#_
M+Z4TSQ/;L/O[.?T+4$L#!!0    ( +J8/E-3<+I 4PT  +HX   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;.T;67/;-OI=OP+C37:2&=4B>$IIXAG%
M=M*T/C1)NOO0V0>8A"0V/%20M./]]?M] $^1A)1UFX>=G6EJD<1WWP#Y^B$5
M7[(MYSGY&D=)]N9DF^>[5[-9YF]YS++3=,<3>+).1<QRN!2;6;83G 42*(YF
MIF&XLYB%R<G9:WEO)<Y>IT4>A0E?"9(5<<S$XUL>I0]O3NA)=>-CN-GF>&-V
M]GK'-OP3SW_=K01<S6HL01CS) O3A B^?G.RI*]N'1L!Y(I_A/PA:_TF*,I=
MFG[!BP_!FQ,#.>(1]W-$P>#//3_G4828@(\_2J0G-4T$;/^NL+^3PH,P=RSC
MYVGTSS#(MV].YB<DX&M61/G'].$G7@KD(#X_C3+Y?_*@UKKF"?&++$_C$A@X
MB,-$_65?2T6T .;&"(!9 IA[ -0> ;!* .M8 +L$L(\%<$H YU@ MP1PCP7P
M2@#O6(!Y"3 _5JV+$F!Q+  U*LL91X/4QMZWMN6.@53FID?;FU8&ISV+>V,@
ME<GIOLW'&:N,KAQ^ICQ>ALL%R]G9:Y$^$('K 1_^D#$GX2%*P@33PZ=<P-,0
MX/*SFS3G&5FQ1W87\=EYFMQSD8?PFUSPNYR\N. Y"Z/L)?F!_/KI@KQX]O+U
M+ >Z"#WS2QIO%0USA 8EUVF2;S-RF00\&("_TL.[A^!O#M W-0AFH+!::V:E
MM;>F%N.RV)P2BTZ):9C& $/G>O"?BT@+?O$T\$L]^#436O!W1X";WBCX^V/
MG5'PGYX&_N$8\''9?WX:^"]Z\%L_!\T;"$X70W%PO-WI /CUT]SFY@ X2[34
M;X\'-S0A:-6)RY+XK*<FKM^N ))\R'F<_4M#UZ[IVI*NK:6[4W2GT(EDO@AW
MV.H,>:,>5[[EY#P5:<+N0U%D9!D&DX\\"OF:L"0@EWZ:I''HDT_<+T28/Y*E
M#Y+]_6]STS1^/%]^O/Q$EN>?Y37]D3RPC/ $^BT>G)+/B+I:07B6 [LAE(F
M(%%0&_29_A>R$B".:M3@YT:PN,:_6JU*S"\G#]O0WY)UD009R6(61>2NR$"8
M+ -=Y%N1%AMXS ,NX-DCV11,L"3G0"U*69*=DE\A\0I%>K6:$C^-=RP) 9@)
M3D#BC;0<=+OX;P,-(^(FZ9KL1)CXX8Y%J)%)"$@%"$/"M42V$ZD/5!2:(@-Z
MB*+&!U82*3#KIUF>3:&;37*IV"(/(U2GO']*;A/R<P$^0LND-B7*,,CC(^J
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M2U-?+=^F F"PRSTF2Q] -I:E;[\=KBM.4U)-?2&# 1#$",#[!(PH1^Z!O#V
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M&&22\ P)F'6<2_]BX%O 6GPGL)&E,3*IC#E_-I/AM.-X)B*@,%%& NO'&GI
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M 400Y>17+A1?F5EHQA44TUPN85JF0@-@?\ZY>EWH\:J>O\=_ 5!+ P04
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M11#&0.]7G*N7B6F]_4U;_ -02P,$%     @ NI@^4Q*MU=@* P  B@H  !D
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M]WSS%1I!/<.7<2;M$VWJLTG?0]E**EXT8.U!0<OZ35Z:0.P HF0/(&H T3L
MWF<A;@#Q>\ ^"TD#2&QD:BDV#BE19#(2?(.$.:W9S, &TZ*U?%J:>W]00N]2
MC5.3% 1=$Q-[=$/)C#*J*$ATG((BE,D3=(H^H0#))1$@1X'2)@TPR!KZRYH^
MVD./T2TOU5*BJS*'O ,_/8"/' 2!UMH*CEX%7T9.QELB?!3U/J,HC,(NA]SP
M;Z3T48PM''? TX_#0X>:N+V^V/+%?WI]3S<:@:X5%/*GPU[2VDNLO62/O:N7
M2B<LY&C-F3:KS6V[/@HW"4X&?C(XZ@K^ 6!OZ,?AD4-'K]71<S+=4_E\.A<
MB)8*]*>MD" *NK2XB4(_[G<J<<.PWQNZ=/1;'?V/W8<6471Y[X9': M$2#1
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M8JMLN^XX-ILQ'TS;H6 2>S6+$S2+\P1,AH6G#*7+,,B F/,DS2E8"4ZYGP>
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M=%JG546MNCY4>S#)0:PF=F8[T'[[V4X(61NRK0]]@=CQ[\_=.6>/=UP\RAA
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ML7<_5,[ OE]):?8+%Z"^3<Z^ U!+ P04    " "ZF#Y3#H'PE0L$  #5%
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MF3G5[%IF_^&)22][DQY)V(*6F?DB5^]9I5"(^\4RT_9_LG)KPU&/Q*4V,J_
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M^4'HP;^+X?( O;.:WMF/H;>D6<D.$7/[AUO$'*^&F'/V_KK(FX3^Y(@"8:U
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MT#>4*+FFF5GC[H[#@,QV;;O [H7OT39,Q9"\_$_GIIPE/(9<+IPN&LXR\S]
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MU!_ZN\/F.H?UXCC!QZC).2J-LS#,CF'3%I\XZ@7Q,6QV#NO'48;#8]C=.<R
MC-\&=I2PI$E8TIFP1TXU%&BNB39E_'P/Y0)D5R721CC]4YHG:T+.?JYY*EKZ
M4O.TP!*,3YOG')6D.#UKGG-8+\)QW%[M7G/"7N<)S71B9@]^29W[C63_3ZES
M@'^\U/'/5;J;9^?>@=J0'$:>&6P5R!UX8]3VEJJ%#F_7I'_^)&F!]=+TM&>F
M+; @Q%F&3]K!/QAT2I K-\,JY$I1/40;:S,G7[OI\,1^$PQN@Q;[)!A,V^PS
M.V^[@>N'VVI8OR=R1;E"#)8F!'R5F4/(:OZM-EILW/BU$-H,<VZY-M\,("W
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MI8U($P#OET+HW< D:*^!XS]02P,$%     @ NI@^4Z0W[],> P  ,PL  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULO5913]LP$/XK5K0'D"B)G3AM
M4%L)Z-"88*JHV!ZF/;B)VUHX<;$="O]^=AK2M VADV OB>W<=_[N/OMR_960
M#VI!J0;/*<_4P%EHO3QS714O:$K4J5C2S'R9"9D2;:9R[JJEI"0I0"EWD>>%
M;DI8Y@S[Q=I8#OLBUYQE="R!RM.4R)<+RL5JX$#G=>&.S1?:+KC#_I+,Z83J
M^^58FIE;>4E82C/%1 8DG0V<<W@V@H$%%!8_&5VIVAC84*9"/-C)=3)P/,N(
M<AIKZX*8UQ.]I)Q;3X;'8^G4J?:TP/KXU?M5$;P)9DH4O13\%TOT8N#T')#0
M&<FYOA.K;[0,"%M_L>"J>()5:>LY(,Z5%FD)-@Q2EJW?Y+E,1 U@ FT&H!*
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M!N;[3 C].K%M4-4G#_\"4$L#!!0    ( +J8/E.T>"-/F@(  +('   9
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MT )87W'8:)N)WK?;8SK]!U!+ P04    " "ZF#Y3L>3LF$(#  !X#0  &0
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MK:QQ\WC>?V/-PQ6F2"XU).I7AT"O$NCE OT= K\+S7B;RP6ME]/,BVL]H71
M>PY6=5VWLPWG-7'3)LX+G* &>Y6^7Z7O=Z9_!4J=DK,PS)*,,U/K>K':=!7Q
M^K4\CNE@V ^&;W2UX5P_"-[J:L'U^LXN7;U*5Z]3US=TOM%[;7)ZC<</AW1@
MELXK-4T8Q4TI\-ZJ:>(\ZN]TJ5^IZ7>JN7C5Y0_7D,Q =G5O4 4./N;R'%0"
M!^];GH,VHVAC=>X'FS9AU.OW=MD^K)(?=B_..,3#"=9M(0'PG*+WL9XZVUW3
M^9CFT]K!@+[/_I)7=PSM:MC?'=Z<9T_5BH4PMO# JD"NP9J0KLRW^R9U.S._
M;*OI7OYO=R[J?5#_M[L;[=[>=OOO-[;3 0W\9@/LAYNVX%S/=QMO +MVRC7?
M)-=,+N)4$0YS)#HG 4:0Q3&_&&BQR@^^,Z&QF/GE$C^-0!H SL^%T"\#<Y:N
M/K8F?P%02P,$%     @ NI@^4TK@;4:3 @  @P<  !D   !X;"]W;W)K<VAE
M971S+W-H965T-CDN>&ULC95=;],P%(;_BA5QL4FP?#4?G=)(6R<$2$C3RN "
M<>$V)XTU)R[VZ3KX]=A.%KHU:7?3V/%YW_.<4\?.=D(^J H R5/-&S5S*L3-
MI>NJ504U51=B XU>*86L*>JI7+MJ(X$65E1S-_"\V*TI:YP\L^]N99Z)+7+6
MP*TD:EO75/ZY!BYV,\=WGE_<L76%YH6;9QNZA@7@_>96ZIG;NQ2LAD8QT1 )
MY<RY\B_GJ8FW =\9[-3>F)A*ED(\F,GG8N9X!@@XK- X4/UXA#EP;HPTQN_.
MT^E3&N'^^-G]HZU=U[*D"N:"_V %5C,G=4@!)=URO!.[3]#5$QF_E>#*_I)=
M&YO$#EEM%8JZ$VN"FC7MDSYU?=@3^),10= )@K<*PDX0VD);,EO6#46:9U+L
MB#31VLT,;&^L6E?#&O,O+E#J5:9UF']ND#9KMN1 KI0"5.3L!I RKL[)![+0
MFZ;8ZC51$E#(=-N@(+06$ME?:OZ'2QUUO[@A9^_.,Q<UD+%U5UWRZS9Y,)+\
MRY9?D-!_3P(O\ ?D\Q-RVHS)7=V&OA=!WXO ^H4C?J>K)3^OE@JEWGN_CN0+
M^WRAS3<9R7<'YC,K0)J$NH9@J(.M160MS"?YF,>3-/$R]W&_48=1OA_ZT?^P
M%X"3'G!R%% SA4-,K2K>SQ9,DR1^!340=@0JZJ&BXU#38#($%;T-:B#L"%3<
M0\6G.A4-0<6#V;SI*ZCAL#&HI(=*3D'%A#8%P0KT"5\BR"'&Y"!Y%$V"Z>LM
M-ACFAR.,:<^8'F7\)I#R(:KT8$=/IWYJOO,75(=AOKZ_D@,L=^^(--?35RK7
MK%&$0ZF5WD6B+61[Y+<3%!M[:BX%ZC/8#BM]2X(T 7J]% *?)^8@[N_=_!]0
M2P,$%     @ NI@^4^^];QC6 P  JA$  !D   !X;"]W;W)K<VAE971S+W-H
M965T-S N>&ULK9C;;N,V$(9?92#L10*DD4@?8@>V@3A)VRVZ:)!@=R^*7M#2
MV!:6(EV2CA.@#U]2DB6GD&G)Z(VM _G/Q^%0/Z7)3JH?>HUHX"WC0D^#M3&;
MVS#4\1HSIJ_E!H6]LY0J8\:>JE6H-PI9DG?*>$BC:!AF+!7!;))?>U*SB=P:
MG@I\4J"W6<;4^QRYW$T#$NPO/*>KM7$7PMEDPU;X@N;KYDG9L[!22=(,A4ZE
M (7+:7!';N>T[SKD+;ZEN-,'Q^"&LI#RASOYG$R#R!$AQ]@X"6;_7O$>.7=*
MEN/O4C2H8KJ.A\=[]9_SP=O!+)C&>\F_IXE93X-1  DNV9:;9[G[%<L!#9Q>
M++G.?V%7MHT"B+?:R*SL; FR5!3_[*U,Q$&'WLV1#K3L0'/N(E!.^< ,FTV4
MW(%RK:V:.\B'FO>V<*EPL_)BE+V;VGYF]ITIQ831</& AJ5<7\)/\&+G/MER
M!+F$W;Z!G5)MF$A2L9J$QH9V F%<AID78>B1,$/X(H59:W@4"28?^X<6N>*F
M>^XY]0K^MN77T"-70"-*OKX\P,6GRT\0@EXSA;KX]83I5>GIY6%Z1\*<R@3\
M>;?01MG:^LL3K5]%Z^?1^L>BY=A7\$<=X KFN$J%<+'FC#,18U/V"]UAKNL6
MXNN,],F(CB;A:P//H.(9>'D>WU#%J49X4FF,)[#@(A7P(#EG2L,&53$5E_ /
MU//2A%X@C [1R?5XW$P^K,B'7O)G=$\D1_=[NCQ%WD3EEZ?PCFZ8!#)7UD!'
MD+!W7\'=5. W7N7/PJC4/O-B^,;XMDO.\TPW#:4(.#A(,!T-HBAJSO"H AVU
MJM5?W)KX[Y(N GL%G-W<Z@V+<1I8/]&H7C&8@2>%XXILW*%JO81>H>Z$)*J?
MNE&7::X@6TVH7_L,[ .S("TF'1[?-JG")+QW-<AY<V[]4F=0TIJ2=BJ =KA>
MS3-P:XLAO6ZUT([7*WH&;VU2I)U+[=/<C.?5. .O]BS2Q;1.87JUSL"L#8KX
M+:1AUGV<7K$S.&L_(GY#*I?\!Q]Z+/8^'OLL1=MN2$CM.L1O.[XM20NL0GS<
M;K-!:L<A?LOQ;3=:4/G%2;[9@'ZQU] M-ANT]B':R8=\Y*VLR1^N>YW2VIIH
M&VNJEA%;\,9<ERIM"Y/6ID.[FHZ?@W:I1%J;"?6;R<=*/(WA5SNC]&H;H7X;
M.?8 =*CM:NW_LICPX/4Y0[7*/Q)HB.56F.)-NKI:?8BX*UZ_Z^;%5XPO3-DM
MN@:.2]LUNKZQ_J**#P/%B9&;_&5\(8U]M<\/U\@25*Z!O;^4TNQ/7(#J\\SL
M7U!+ P04    " "ZF#Y3YG!F3+H#  "'#P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970W,2YX;6S-5VUOVS80_BL'81]28(U$^25V8!MHG Y+T6Q!C+88BGV@
MI;,ME"(]DHJ3?S^2DB6KE1FG"(9]L4CJ[KGGCN<[W60GY#>U0=3PF#.NIL%&
MZ^UE&*ID@SE5YV*+W+Q9"9E3;;9R':JM1)HZI9R%<10-PYQF/)A-W-F=G$U$
MH5G&\4Z"*O*<RJ<K9&(W#4BP/[C/UAMM#\+99$O7N$#]:7LGS2ZL4=(L1ZXR
MP4'B:AJ\(Y=S,K8*3N)SACMUL ;KRE*(;W9SDTZ#R#)"AHFV$-0\'G".C%DD
MP^.?"C2H;5K%P_4>_3?GO'%F217.!?N2I7HS#48!I+BB!=/W8O<[5@X-+%XB
MF'*_L*MDHP"20FF15\J&09[Q\DD?JT <*)#A$86X4HB_4X@'1Q1ZE4+/.5HR
M<VY=4TUG$REV(*VT0;,+%QNG;;S)N+W&A9;F;6;T].P+E9)RK>#L&C7-F'H#
M;V%ADB4M&()8 4W3S :<,LAXF3;E#3*SX&O0 G9[#),F2E.>VO.W\&EQ#6>_
MO)F$VO"TUL*DXG15<HJ/<!K"K>!ZH^ ]3S'MT)_[]4GL 0A-@.HHQ?LH7<5>
MQ \%.X<>^17B*"9=A)Y1I_R8>HM.K[ZTGL/K_=>7]O6CL00W&G/UMX=GO^;9
M=SS[1WC>4[YV?-X_HDPRA7 GLP155TJ42$.'9&O/PXST)^'#89"](BV"@YK@
MP$OPCR)?HH0_FQ!T41O\8+<_',6C;M/#VO30'QNT1=8&?6YR59IR5IC;^IBM
M$,[^0BI5YQ_'CTG@R6C"&'*7_EV)Z@>('8""N$* > @I?5*>7+BH_;WP0K=3
M $Q2PF)#):K#Z,-9QN%:,&9);,W-*"O2&8G2VL"7+UZ1EA.CVHG1*?E2^4*7
M#+NHC5Z2+^/:]/@GXW? Y@7Q&S\?/Z](RPD2->TF\KIQ8W(],Q\!"7RFK&@1
M[NX47CC[D7.IMC3!:6"^8A3*!PQFX$E7<M 8B9=I563AZRW:2_?50Q(WH/'_
MNG*3IL60WJO5[@JJ59G)=\GDEVF3;/H+\3>8T^HW^;%QC =1%!VQWC0/XN\>
M/U?"GP&M:GC/4\-/0^CN FU7FV9%_(WAM:MW96[@S1BO3-N1I@L1?QLZK8)7
M(*=F3-,^B+]_O'81K\SYP^B5:3O2-"/B[T8O+N->N!>4\?!@U,E1KMT$J" 1
M!=?EU%.?UE/F.S=;A8UX.:+>4KDV/@##E5&-SB],B&0Y]94;+;9N<%H*;<8P
MM]R821FE%3#O5T+H_<8:J&?OV;]02P,$%     @ NI@^4]0K19$1 P  ,!$
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M/251E"1N!#"W@BC"$'@:<013 !HP)(JZ<_#@/ HVYU2P_8UD]@M02P,$%
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M   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:34[#,! %X*M4V:+&]6\!43;
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M;W!S+V%P<"YX;6Q02P$"% ,4    " "ZF#Y3Q4S%9>\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "ZF#Y3
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( +J8/E.?64E?^@(  *@)   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "ZF#Y3
MMA4^EW '   N(   &               @($^"P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ NI@^4RKKC+H* P  ; L  !@
M     ("!Y!(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M +J8/E-" >4P*P<  - >   8              " @206  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " "ZF#Y3M.3#/UP*   82@  &
M            @(&%'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ NI@^4]V8A[(:"P  \3D  !@              ("!%R@  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +J8/E,1G8W]\B@  $*'
M   8              " @6<S  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " "ZF#Y3@X<ML?8)  "=(P  &               @(&/7
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ NI@^4SL70N]&
M P  50@  !@              ("!NV8  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( +J8/E.YH<6?+P<  !T1   9              "
M@3=J  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ NI@^
M4^?7C68U#@  VS4  !D              ("!G7$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " "ZF#Y3WJ_T$M@$   K#0  &0
M        @($)@   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( +J8/E,&GK0*:@0  .L)   9              " @1B%  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ NI@^4^.\7-WX!   QPT
M !D              ("!N8D  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " "ZF#Y3OMH:;5X)  !*)0  &0              @('HC@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +J8/E,4]9RV
M; 4  %\0   9              " @7V8  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ NI@^4^Y5;#^A @  F04  !D
M ("!()X  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "Z
MF#Y3#IG,VEP/   ,0P  &0              @('XH   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( +J8/E-/BAO<"@4  , +   9
M          " @8NP  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#
M%     @ NI@^4]_W/1=O&P  K$\  !D              ("!S+4  'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "ZF#Y3\!CLF8TO
MM   &0              @(%RT0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+ 0(4 Q0    ( +J8/E/NQ7;TL ,  /D*   9              " @38!
M 0!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ NI@^4S -
MR)$B!   *0L  !D              ("!'04! 'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " "ZF#Y3ZFP!A_,"  !]!P  &0
M    @(%V"0$ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M +J8/E,V-U2:F0,  &((   9              " @: , 0!X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ NI@^4UZ3B>N, @  GP8  !D
M             ("!<! ! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " "ZF#Y3LQH@U)(#  "P"0  &0              @($S$P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +J8/E,/0ME5G0(
M ($%   9              " @?P6 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ NI@^4_UT@9T-!   DPT  !D              ("!
MT!D! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "ZF#Y3
MP8>H;:P#  #["@  &0              @($4'@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( +J8/E.#G-(>? 4  -@7   9
M      " @?<A 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ NI@^4PYD^I8@ P  /@H  !D              ("!JB<! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "ZF#Y3BA:Z[KP"  ##"
M&0              @($!*P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( +J8/E,,4\&^U (  (,,   9              " @?0M 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ NI@^4^: 7MM:
M P  PPH  !D              ("!_S ! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " "ZF#Y3F-=NT=@#  "&#0  &0
M@(&0- $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +J8
M/E-*AI+<L ,  # -   9              " @9\X 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ NI@^4[25_*QM @  C@8  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( +J8/E,OA/E>U@(  *L'   9
M  " @0E, 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MNI@^4U-PND!3#0  NC@  !D              ("!%D\! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " "ZF#Y3"F_-])8"  "R!P  &0
M            @(&@7 $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( +J8/E.5"EP4T0(  -(*   9              " @6U? 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ NI@^4U.MJ_,# P
MBPL  !D              ("!=6(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " "ZF#Y37\#K-(4"  !U!P  &0              @(&O
M90$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +J8/E,2
MK=78"@,  (H*   9              " @6MH 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ NI@^4^6>F#+O @  X08  !D
M     ("!K&L! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +J8/E.N$*9=B@,  %D.   9              "
M@:>' 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ NI@^
M4PZ!\)4+!   U10  !D              ("!:(L! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " "ZF#Y3-[6TYP<"  !"!   &0
M        @(&JCP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( +J8/E-](\^<U@<  "X>   9              " @>B1 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ NI@^4PA8FM\5!   @0P
M !D              ("!]9D! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " "ZF#Y3#8]S 78#  !Q#   &0              @(%!G@$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( +J8/E,KZ^S!
M/ ,  -L*   9              " @>ZA 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ NI@^4[4L)<52 P  D0P  !D
M ("!8:4! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " "Z
MF#Y3@2)O&-8"  ".#   &0              @('JJ $ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( +J8/E.R1EKXUP,  (<-   9
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M970V."YX;6Q02P$"% ,4    " "ZF#Y32N!M1I,"  "#!P  &0
M    @($9O0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M +J8/E/OO6\8U@,  *H1   9              " @>._ 0!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ NI@^4^9P9DRZ P  AP\  !D
M             ("!\,,! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " "ZF#Y3U"M%D1$#   P$0  #0              @ 'AQP$ >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +J8/E.7BKL<P    !,"   +
M      "  1W+ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +J8/E.RJ_G4" 4
M "(O   /              "  0;, 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "ZF#Y3L 4 O38"   <*@  &@              @ $[T0$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "ZF#Y3X<M&R/T!   ]
M*0  $P              @ &ITP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    3P!/ * 5  #7U0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>228</ContextCount>
  <ElementCount>492</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Unaudited Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Acquisition of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/AcquisitionofBusiness</Role>
      <ShortName>Acquisition of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Notes Payable/Convertible Debt</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://nutriband.com/role/NotesPayableConvertibleDebt</Role>
      <ShortName>Notes Payable/Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Warrants and Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/WarrantsandOptions</Role>
      <ShortName>Warrants and Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Commitments and Contigencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/CommitmentsandContigencies</Role>
      <ShortName>Commitments and Contigencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://nutriband.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Organization and Description of Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/OrganizationandDescriptionofBusinessTables</Role>
      <ShortName>Organization and Description of Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Acquisition of Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/AcquisitionofBusinessTables</Role>
      <ShortName>Acquisition of Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/AcquisitionofBusiness</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/PropertyandEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Notes Payable/Convertible Debt (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://nutriband.com/role/NotesPayableConvertibleDebtTables</Role>
      <ShortName>Notes Payable/Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/NotesPayableConvertibleDebt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/IntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/DerivativeLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Warrants and Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/WarrantsandOptionsTables</Role>
      <ShortName>Warrants and Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/WarrantsandOptions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nutriband.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/OrganizationandDescriptionofBusinessTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Organization and Description of Business (Details) - Schedule of disaggregation of revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable</Role>
      <ShortName>Organization and Description of Business (Details) - Schedule of disaggregation of revenues</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/OrganizationandDescriptionofBusinessTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Organization and Description of Business (Details) - Schedule of revenue by geographical location</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable</Role>
      <ShortName>Organization and Description of Business (Details) - Schedule of revenue by geographical location</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/OrganizationandDescriptionofBusinessTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Organization and Description of Business (Details) - Schedule of property plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable</Role>
      <ShortName>Organization and Description of Business (Details) - Schedule of property plant and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/OrganizationandDescriptionofBusinessTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Acquisition of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/AcquisitionofBusinessDetails</Role>
      <ShortName>Acquisition of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/AcquisitionofBusinessTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Acquisition of Business (Details) - Schedule of net assets acquired</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofnetassetsacquiredTable</Role>
      <ShortName>Acquisition of Business (Details) - Schedule of net assets acquired</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/AcquisitionofBusinessTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable</Role>
      <ShortName>Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/AcquisitionofBusinessTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Income Taxes (Details) - Summary of provision for income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/SummaryofprovisionforincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Summary of provision for income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Income Taxes (Details) - Schedule of deferred tax asset and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax asset and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Notes Payable/Convertible Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://nutriband.com/role/NotesPayableConvertibleDebtDetails</Role>
      <ShortName>Notes Payable/Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/NotesPayableConvertibleDebtTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Notes Payable/Convertible Debt (Details) - Schedule of minimum lease payments</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://nutriband.com/role/ScheduleofminimumleasepaymentsTable</Role>
      <ShortName>Notes Payable/Convertible Debt (Details) - Schedule of minimum lease payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/NotesPayableConvertibleDebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IntangibleAssetsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IntangibleAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Intangible Assets (Details) - Schedule of estimated amortization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofestimatedamortizationTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of estimated amortization</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IntangibleAssetsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/DerivativeLiabilitiesDetails</Role>
      <ShortName>Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Derivative Liabilities (Details) - Schedule reconciliation of derivative liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable</Role>
      <ShortName>Derivative Liabilities (Details) - Schedule reconciliation of derivative liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/RelatedPartyTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/StockholdersEquity</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Warrants and Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/WarrantsandOptionsDetails</Role>
      <ShortName>Warrants and Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/WarrantsandOptionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Warrants and Options (Details) - Schedule of warrants outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofwarrantsoutstandingTable</Role>
      <ShortName>Warrants and Options (Details) - Schedule of warrants outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/WarrantsandOptionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable</Role>
      <ShortName>Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/WarrantsandOptionsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Warrants and Options (Details) - Schedule of options outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofoptionsoutstandingTable</Role>
      <ShortName>Warrants and Options (Details) - Schedule of options outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/WarrantsandOptionsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/Leases</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Commitments and Contigencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/CommitmentsandContigenciesDetails</Role>
      <ShortName>Commitments and Contigencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/CommitmentsandContigencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenues</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Acquisition of Business (Details) - Schedule of net assets acquired</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofnetassetsacquiredTable0</Role>
      <ShortName>Acquisition of Business (Details) - Schedule of net assets acquired</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/AcquisitionofBusinessTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0</Role>
      <ShortName>Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/AcquisitionofBusinessTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofpropertyandequipmentTable0</Role>
      <ShortName>Property and Equipment (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Notes Payable/Convertible Debt (Details) - Schedule of Minimum lease payments</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable</Role>
      <ShortName>Notes Payable/Convertible Debt (Details) - Schedule of Minimum lease payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/NotesPayableConvertibleDebtTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0</Role>
      <ShortName>Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IntangibleAssetsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Intangible Assets (Details) - Schedule of estimated amortization:</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofestimatedamortizationTable0</Role>
      <ShortName>Intangible Assets (Details) - Schedule of estimated amortization:</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/IntangibleAssetsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Warrants (Details) - Schedule of warrants outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0</Role>
      <ShortName>Warrants (Details) - Schedule of warrants outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/WarrantsandOptionsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea148206-s1a2_nutriband.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Warrants (Details) - Schedule of additional information relating to warrants outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0</Role>
      <ShortName>Warrants (Details) - Schedule of additional information relating to warrants outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nutriband.com/role/WarrantsandOptionsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" original="ea148206-s1a2_nutriband.htm">ea148206-s1a2_nutriband.htm</File>
    <File>ea148206ex1-1_nutriband.htm</File>
    <File>ea148206ex23_nutriband.htm</File>
    <File>ea148206ex4-12_nutriband.htm</File>
    <File>ea148206ex4-13_nutriband.htm</File>
    <File>ea148206ex5-1_nutriband.htm</File>
    <File>ntrb-20210731.xsd</File>
    <File>ntrb-20210731_cal.xml</File>
    <File>ntrb-20210731_def.xml</File>
    <File>ntrb-20210731_lab.xml</File>
    <File>ntrb-20210731_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea148206-s1a2_nutriband.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 228,
   "dts": {
    "calculationLink": {
     "local": [
      "ntrb-20210731_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ntrb-20210731_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea148206-s1a2_nutriband.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ntrb-20210731_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ntrb-20210731_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ntrb-20210731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 592,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 153,
    "http://nutriband.com/20210731": 67,
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 223
   },
   "keyCustom": 125,
   "keyStandard": 367,
   "memberCustom": 18,
   "memberStandard": 26,
   "nsprefix": "ntrb",
   "nsuri": "http://nutriband.com/20210731",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://nutriband.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Income Taxes",
     "role": "http://nutriband.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Notes Payable/Convertible Debt",
     "role": "http://nutriband.com/role/NotesPayableConvertibleDebt",
     "shortName": "Notes Payable/Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Intangible Assets",
     "role": "http://nutriband.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Derivative Liabilities",
     "role": "http://nutriband.com/role/DerivativeLiabilities",
     "shortName": "Derivative Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Related Party Transactions",
     "role": "http://nutriband.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Stockholders' Equity",
     "role": "http://nutriband.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:WarrantsAndOptionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Warrants and Options",
     "role": "http://nutriband.com/role/WarrantsandOptions",
     "shortName": "Warrants and Options",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:WarrantsAndOptionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Leases",
     "role": "http://nutriband.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Commitments and Contigencies",
     "role": "http://nutriband.com/role/CommitmentsandContigencies",
     "shortName": "Commitments and Contigencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Subsequent Events",
     "role": "http://nutriband.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://nutriband.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://nutriband.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://nutriband.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Organization and Description of Business (Tables)",
     "role": "http://nutriband.com/role/OrganizationandDescriptionofBusinessTables",
     "shortName": "Organization and Description of Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Acquisition of Business (Tables)",
     "role": "http://nutriband.com/role/AcquisitionofBusinessTables",
     "shortName": "Acquisition of Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Property and Equipment (Tables)",
     "role": "http://nutriband.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Income Taxes (Tables)",
     "role": "http://nutriband.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Notes Payable/Convertible Debt (Tables)",
     "role": "http://nutriband.com/role/NotesPayableConvertibleDebtTables",
     "shortName": "Notes Payable/Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Intangible Assets (Tables)",
     "role": "http://nutriband.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Derivative Liabilities (Tables)",
     "role": "http://nutriband.com/role/DerivativeLiabilitiesTables",
     "shortName": "Derivative Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Warrants and Options (Tables)",
     "role": "http://nutriband.com/role/WarrantsandOptionsTables",
     "shortName": "Warrants and Options (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "role": "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c79",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c1",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:SalesRevenuesGoodsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Organization and Description of Business (Details) - Schedule of disaggregation of revenues",
     "role": "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable",
     "shortName": "Organization and Description of Business (Details) - Schedule of disaggregation of revenues",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:DisaggregationOfRevenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Organization and Description of Business (Details) - Schedule of revenue by geographical location",
     "role": "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable",
     "shortName": "Organization and Description of Business (Details) - Schedule of revenue by geographical location",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c88",
      "decimals": "0",
      "lang": null,
      "name": "ntrb:DisaggregationOfRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c94",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Organization and Description of Business (Details) - Schedule of property plant and equipment",
     "role": "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
     "shortName": "Organization and Description of Business (Details) - Schedule of property plant and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c94",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c82",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Acquisition of Business (Details)",
     "role": "http://nutriband.com/role/AcquisitionofBusinessDetails",
     "shortName": "Acquisition of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c82",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ntrb:BusinessAcquisitionPercentageOfVotingInterestAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c190",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:BusinessAcquisitionCommonStockIssued",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Acquisition of Business (Details) - Schedule of net assets acquired",
     "role": "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
     "shortName": "Acquisition of Business (Details) - Schedule of net assets acquired",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information",
     "role": "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable",
     "shortName": "Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Property and Equipment (Details)",
     "role": "http://nutriband.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:PropertyPlantAndEquipmentsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment",
     "role": "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
     "shortName": "Property and Equipment (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:PropertyPlantAndEquipmentsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "role": "http://nutriband.com/role/ConsolidatedIncomeStatement",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c6",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Income Taxes (Details)",
     "role": "http://nutriband.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Income Taxes (Details) - Summary of provision for income taxes",
     "role": "http://nutriband.com/role/SummaryofprovisionforincometaxesTable",
     "shortName": "Income Taxes (Details) - Summary of provision for income taxes",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationTaxCredits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts",
     "role": "http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable",
     "shortName": "Income Taxes (Details) - Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationTaxCredits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Income Taxes (Details) - Schedule of deferred tax asset and liabilities",
     "role": "http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax asset and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c107",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:NotePayablesDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Notes Payable/Convertible Debt (Details)",
     "role": "http://nutriband.com/role/NotesPayableConvertibleDebtDetails",
     "shortName": "Notes Payable/Convertible Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c107",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:NotePayablesDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Notes Payable/Convertible Debt (Details) - Schedule of minimum lease payments",
     "role": "http://nutriband.com/role/ScheduleofminimumleasepaymentsTable",
     "shortName": "Notes Payable/Convertible Debt (Details) - Schedule of minimum lease payments",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:amortizedOverPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Intangible Assets (Details)",
     "role": "http://nutriband.com/role/IntangibleAssetsDetails",
     "shortName": "Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ntrb:amortizedOverPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization",
     "role": "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
     "shortName": "Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Intangible Assets (Details) - Schedule of estimated amortization",
     "role": "http://nutriband.com/role/ScheduleofestimatedamortizationTable",
     "shortName": "Intangible Assets (Details) - Schedule of estimated amortization",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c124",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ntrb:FairValueAssumptionsWeightedAverageVolatilityRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Derivative Liabilities (Details)",
     "role": "http://nutriband.com/role/DerivativeLiabilitiesDetails",
     "shortName": "Derivative Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c124",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ntrb:FairValueAssumptionsWeightedAverageVolatilityRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://nutriband.com/role/ShareholdersEquityType2or3",
     "shortName": "Unaudited Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c125",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Derivative Liabilities (Details) - Schedule reconciliation of derivative liabilities",
     "role": "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable",
     "shortName": "Derivative Liabilities (Details) - Schedule reconciliation of derivative liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c125",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c128",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockDescriptionOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Related Party Transactions (Details)",
     "role": "http://nutriband.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c128",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockDescriptionOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://nutriband.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c133",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Warrants and Options (Details)",
     "role": "http://nutriband.com/role/WarrantsandOptionsDetails",
     "shortName": "Warrants and Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c157",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Warrants and Options (Details) - Schedule of warrants outstanding",
     "role": "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
     "shortName": "Warrants and Options (Details) - Schedule of warrants outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c155",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding",
     "role": "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
     "shortName": "Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c1",
      "decimals": "INF",
      "lang": null,
      "name": "ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c163",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Warrants and Options (Details) - Schedule of options outstanding",
     "role": "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
     "shortName": "Warrants and Options (Details) - Schedule of options outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c163",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:MonthlyRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Leases (Details)",
     "role": "http://nutriband.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:MonthlyRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c164",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Commitments and Contigencies (Details)",
     "role": "http://nutriband.com/role/CommitmentsandContigenciesDetails",
     "shortName": "Commitments and Contigencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c225",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentAnnualPrincipalPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Subsequent Events (Details)",
     "role": "http://nutriband.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c99",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "role": "http://nutriband.com/role/ConsolidatedCashFlow",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c8",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ntrb:InventoryRawMaterialsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ntrb:InventoryRawMaterialsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:SalesRevenuesGoodsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenues",
     "role": "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenues",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location",
     "role": "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c177",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c187",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment",
     "role": "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ntrb:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c187",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c190",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ntrb:BusinessAcquisitionCommonStockIssued",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Acquisition of Business (Details) - Schedule of net assets acquired",
     "role": "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0",
     "shortName": "Acquisition of Business (Details) - Schedule of net assets acquired",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information",
     "role": "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0",
     "shortName": "Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment",
     "role": "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0",
     "shortName": "Property and Equipment (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Notes Payable/Convertible Debt (Details) - Schedule of Minimum lease payments",
     "role": "http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable",
     "shortName": "Notes Payable/Convertible Debt (Details) - Schedule of Minimum lease payments",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization",
     "role": "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0",
     "shortName": "Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c204",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Intangible Assets (Details) - Schedule of estimated amortization:",
     "role": "http://nutriband.com/role/ScheduleofestimatedamortizationTable0",
     "shortName": "Intangible Assets (Details) - Schedule of estimated amortization:",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Organization and Description of Business",
     "role": "http://nutriband.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Warrants (Details) - Schedule of warrants outstanding",
     "role": "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0",
     "shortName": "Warrants (Details) - Schedule of warrants outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "2",
      "lang": null,
      "name": "ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Warrants (Details) - Schedule of additional information relating to warrants outstanding",
     "role": "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0",
     "shortName": "Warrants (Details) - Schedule of additional information relating to warrants outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ntrb:ScheduleOfAdditionalRelatingWarrantsOutstanding",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "lang": null,
      "name": "ntrb:ShareBasedCompensationNumberOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Acquisition of Business",
     "role": "http://nutriband.com/role/AcquisitionofBusiness",
     "shortName": "Acquisition of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Property and Equipment",
     "role": "http://nutriband.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea148206-s1a2_nutriband.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable",
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description",
        "terseLabel": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nutriband.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "ntrb_AcquiredPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired percentage.",
        "label": "AcquiredPercentage",
        "terseLabel": "Acquired percentage"
       }
      }
     },
     "localname": "AcquiredPercentage",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ntrb_AcquisitionofBusinessDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of Business (Details) [Line Items]"
       }
      }
     },
     "localname": "AcquisitionofBusinessDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_AcquisitionofBusinessDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of Business (Details) [Table]"
       }
      }
     },
     "localname": "AcquisitionofBusinessDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_ActiveIntelligenceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ActiveIntelligenceLLCMember",
        "terseLabel": "Active Intelligence LLC [Member]"
       }
      }
     },
     "localname": "ActiveIntelligenceLLCMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_AdoptionOfASC842OperatingLeaseAssetAndLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adoption of ASC 842 Operating lease asset and liability.",
        "label": "AdoptionOfASC842OperatingLeaseAssetAndLiability",
        "terseLabel": "Adoption of ASC 842 Operating lease asset and liability"
       }
      }
     },
     "localname": "AdoptionOfASC842OperatingLeaseAssetAndLiability",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_AmortizationOfDebtDiscountsPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "AmortizationOfDebtDiscountsPremium",
        "terseLabel": "Interest expenses including amortization debt discount amount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountsPremium",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_AnnualMeetingOfShareholdersTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual meeting of shareholders, term.",
        "label": "AnnualMeetingOfShareholdersTerm",
        "terseLabel": "Annual meeting of shareholders, term"
       }
      }
     },
     "localname": "AnnualMeetingOfShareholdersTerm",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_BPMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BPMMember",
        "terseLabel": "BPM [Member]",
        "verboseLabel": "BPM Inno Ltd [Member]"
       }
      }
     },
     "localname": "BPMMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_BusinessAcquisitionCommonStockIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued.",
        "label": "BusinessAcquisitionCommonStockIssued",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "BusinessAcquisitionCommonStockIssued",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_BusinessAcquisitionNetProfit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition net profit.",
        "label": "BusinessAcquisitionNetProfit",
        "terseLabel": "Net profit"
       }
      }
     },
     "localname": "BusinessAcquisitionNetProfit",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_BusinessAcquisitionPercentageOfVotingInterestAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessAcquisitionPercentageOfVotingInterestAcquired",
        "terseLabel": "Acquired of membership interests"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestAcquired",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss per common share - basic and diluted, Proforma.",
        "label": "BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic",
        "terseLabel": "Loss per common share - basic and diluted, Proforma (in Dollars per share)",
        "verboseLabel": "Loss per common share - basic and diluted Proforma (in Dollars per share) | $ / shares (in Dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable",
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "ntrb_BusinessAcquisitionRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition revenue.",
        "label": "BusinessAcquisitionRevenue",
        "terseLabel": "Net revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionRevenue",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_BusinessAcquisitionsNetLossAsReported": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessAcquisitionsNetLossAsReported",
        "terseLabel": "Net loss As Reported"
       }
      }
     },
     "localname": "BusinessAcquisitionsNetLossAsReported",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_BusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessCombinationMember",
        "terseLabel": "Business Combination [Member]"
       }
      }
     },
     "localname": "BusinessCombinationMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer base.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase",
        "terseLabel": "Customer base"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerBase",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellectual property and trademarks.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks",
        "terseLabel": "Intellectual property and trademarks"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualPropertyAndTrademarks",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CashPaidForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashPaidForAbstract",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "CashPaidForAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_CashPaidForAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashPaidForAbstract0",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "CashPaidForAbstract0",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_CommitmentsandContigenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contigencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContigenciesDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_CommitmentsandContigenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contigencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsandContigenciesDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_CommonIssuedForSubscriptionPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common issued for subscription payable.",
        "label": "CommonIssuedForSubscriptionPayable",
        "terseLabel": "Common issued for subscription payable"
       }
      }
     },
     "localname": "CommonIssuedForSubscriptionPayable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CommonStockAndNoteIssuedInAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and note issued in acquisition.",
        "label": "CommonStockAndNoteIssuedInAcquisition",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "CommonStockAndNoteIssuedInAcquisition",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CommonStockAndNoteIssuedInAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and note issued in acquisition.",
        "label": "CommonStockAndNoteIssuedInAcquisitions",
        "terseLabel": "Common stock and note issued for acquisition"
       }
      }
     },
     "localname": "CommonStockAndNoteIssuedInAcquisitions",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CommonStockIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockIssued",
        "terseLabel": "Common stock issued (in Shares)"
       }
      }
     },
     "localname": "CommonStockIssued",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_CommonStockIssuedForAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for accounts payable.",
        "label": "CommonStockIssuedForAccountsPayable",
        "terseLabel": "Common stock issued for accounts payable"
       }
      }
     },
     "localname": "CommonStockIssuedForAccountsPayable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CommonStockIssuedForPrepaidConsulting": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockIssuedForPrepaidConsulting",
        "terseLabel": "Common stock issued for prepaid consulting"
       }
      }
     },
     "localname": "CommonStockIssuedForPrepaidConsulting",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CommonStockIssuedForSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for settlement.",
        "label": "CommonStockIssuedForSettlement",
        "terseLabel": "Common stock issued for settlement of debt"
       }
      }
     },
     "localname": "CommonStockIssuedForSettlement",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CommonStockIssuedForSettlementOfNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for settlement of notes payable.",
        "label": "CommonStockIssuedForSettlementOfNotesPayable",
        "terseLabel": "Common stock issued for settlement of notes payable"
       }
      }
     },
     "localname": "CommonStockIssuedForSettlementOfNotesPayable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_CommonStockOfDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockOfDescription",
        "terseLabel": "Common stock description"
       }
      }
     },
     "localname": "CommonStockOfDescription",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_CommonStockShareIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockShareIssued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockShareIssued",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_CommonStockShareOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockShareOutstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockShareOutstanding",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_CommonStockShareSubscribedButUnissuedSubscriptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock shares.",
        "label": "CommonStockShareSubscribedButUnissuedSubscriptionsShares",
        "terseLabel": "Subscription payable, shares"
       }
      }
     },
     "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsShares",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ConcentrationRiskPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "ConcentrationRiskPercentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ntrb_ConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConsultingServicesMember",
        "terseLabel": "Consulting Services [Member]",
        "verboseLabel": "Consulting services [Member]"
       }
      }
     },
     "localname": "ConsultingServicesMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_DebtDiscountOnConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt discount on convertible notes.",
        "label": "DebtDiscountOnConvertibleNotes",
        "terseLabel": "Debt discount on convertible notes"
       }
      }
     },
     "localname": "DebtDiscountOnConvertibleNotes",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DebtInstrumentAnnualPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "DebtInstrumentAnnualPrincipalPayments",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayments",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DefendantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DefendantMember",
        "terseLabel": "Defendants [Member]"
       }
      }
     },
     "localname": "DefendantMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_DeferredTaxAssetAndLiabilityStockIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued for services.",
        "label": "DeferredTaxAssetAndLiabilityStockIssuedForServices",
        "terseLabel": "Stock issued for services"
       }
      }
     },
     "localname": "DeferredTaxAssetAndLiabilityStockIssuedForServices",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DerivativeLiabilitiesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities (Details) [Line Items]"
       }
      }
     },
     "localname": "DerivativeLiabilitiesDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_DerivativeLiabilitiesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities (Details) [Table]"
       }
      }
     },
     "localname": "DerivativeLiabilitiesDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_DerivativeLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DerivativeLiabilitiesPolicyTextBlock",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesPolicyTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_DerivativeLiabilitiesTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of derivative liabilities total.",
        "label": "DerivativeLiabilitiesTotal",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesTotal",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DerivativeLiabilityWarrantReclassedToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability warrant reclassed to equity.",
        "label": "DerivativeLiabilityWarrantReclassedToEquity",
        "terseLabel": "Derivative liability warrant reclassed to equity"
       }
      }
     },
     "localname": "DerivativeLiabilityWarrantReclassedToEquity",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DerivativeLiabilityWarrantsReclassedToEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability warrants reclassed to equity.",
        "label": "DerivativeLiabilityWarrantsReclassedToEquity",
        "terseLabel": "Derivative liability warrants reclassed to equity"
       }
      }
     },
     "localname": "DerivativeLiabilityWarrantsReclassedToEquity",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DesignatedSharesOfPreferredStocks": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated shares to be issued.",
        "label": "DesignatedSharesOfPreferredStocks",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "localname": "DesignatedSharesOfPreferredStocks",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_DisaggregationOfRevenues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disaggregation of revenues.",
        "label": "DisaggregationOfRevenues",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DisaggregationOfRevenues",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable",
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DisaggregationOfRevenuesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisaggregationOfRevenuesPolicyTextBlock",
        "terseLabel": "Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenuesPolicyTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_DiscountRemainingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount remaining amount.",
        "label": "DiscountRemainingAmount",
        "terseLabel": "Discount remaining amount"
       }
      }
     },
     "localname": "DiscountRemainingAmount",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_DueToRelatedPartyCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DueToRelatedPartyCurrentAndNoncurrent",
        "terseLabel": "Balance due"
       }
      }
     },
     "localname": "DueToRelatedPartyCurrentAndNoncurrent",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_EarlyPrepaymentFeeOnConvertibleDebentures": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early prepayment fee on convertible debenture.\r     \n\r \n.",
        "label": "EarlyPrepaymentFeeOnConvertibleDebentures",
        "terseLabel": "Early prepayment fee on convertible debentures"
       }
      }
     },
     "localname": "EarlyPrepaymentFeeOnConvertibleDebentures",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of effective income tax federal statutory tax rate.",
        "label": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax",
        "terseLabel": "Corporate rate, description"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTax",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_ExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExpectedTerm",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "ExpectedTerm",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_ExpectedTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of expected term.",
        "label": "ExpectedTerms",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "ExpectedTerms",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_ExpensesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses paid.",
        "label": "ExpensesPaid",
        "terseLabel": "Expenses paid"
       }
      }
     },
     "localname": "ExpensesPaid",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_FairValueAssumptionsRiskFreeInterestRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk-free interest rate.",
        "label": "FairValueAssumptionsRiskFreeInterestRates",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "FairValueAssumptionsRiskFreeInterestRates",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ntrb_FairValueAssumptionsWeightedAverageVolatilityRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FairValueAssumptionsWeightedAverageVolatilityRates",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "FairValueAssumptionsWeightedAverageVolatilityRates",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ntrb_FairValueOfConversionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of conversion price.",
        "label": "FairValueOfConversionPrice",
        "terseLabel": "Fair value of conversion price"
       }
      }
     },
     "localname": "FairValueOfConversionPrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_FairValueOfTheCommonStocks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the common stocks.",
        "label": "FairValueOfTheCommonStocks",
        "terseLabel": "Fair value of the common stocks issuance (in Dollars)"
       }
      }
     },
     "localname": "FairValueOfTheCommonStocks",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_FairValueOfWarrantExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant expense.",
        "label": "FairValueOfWarrantExpense",
        "terseLabel": "Fair value of warrant expense"
       }
      }
     },
     "localname": "FairValueOfWarrantExpense",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_FormerIndependentDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FormerIndependentDirectorsMember",
        "terseLabel": "Former Independent Directors [Member]"
       }
      }
     },
     "localname": "FormerIndependentDirectorsMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_FundReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund received.",
        "label": "FundReceived",
        "terseLabel": "Balance of the funds received (in Dollars)"
       }
      }
     },
     "localname": "FundReceived",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_GainOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GainOnExtinguishmentOfDebt",
        "terseLabel": "Forgiveness of debt"
       }
      }
     },
     "localname": "GainOnExtinguishmentOfDebt",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_GainOnForgivenessOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on forgiveness of debt.",
        "label": "GainOnForgivenessOfDebt",
        "terseLabel": "Gain on forgiveness of debt"
       }
      }
     },
     "localname": "GainOnForgivenessOfDebt",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_GainOnForgivenessOfLoanPayment": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on forgiveness of loan payment.",
        "label": "GainOnForgivenessOfLoanPayment",
        "negatedLabel": "Gain on forgiveness of loan payment"
       }
      }
     },
     "localname": "GainOnForgivenessOfLoanPayment",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for Going Concern.",
        "label": "GoingConcernPolicyTextBlock",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_HealthsBrandsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HealthsBrandsIncMember",
        "terseLabel": "Health Brands, Inc [Member]"
       }
      }
     },
     "localname": "HealthsBrandsIncMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_IncreaseDecreaseInDerivativeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative expense.",
        "label": "IncreaseDecreaseInDerivativeExpense",
        "terseLabel": "Derivative expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeExpense",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_IncreaseDecreaseOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration in operating lease liability.",
        "label": "IncreaseDecreaseOperatingLeaseLiability",
        "negatedLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseLiability",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_IncreaseDecreasedInAuthorizedCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decreased in authorized common stock.",
        "label": "IncreaseDecreasedInAuthorizedCommonStock",
        "terseLabel": "Increase decreased in authorized common stock"
       }
      }
     },
     "localname": "IncreaseDecreasedInAuthorizedCommonStock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_InitialPublicOfferingPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "InitialPublicOfferingPricePercentage",
        "terseLabel": "Initial public offering price, percentage"
       }
      }
     },
     "localname": "InitialPublicOfferingPricePercentage",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ntrb_IntangibleAssetsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Table]"
       }
      }
     },
     "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_IntangibleAssetsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Table]"
       }
      }
     },
     "localname": "IntangibleAssetsDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_InterestExpenseDebts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "InterestExpenseDebts",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebts",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_InterestExpensesDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "InterestExpensesDebt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpensesDebt",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_InventoryRawMaterialsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory raw materials percentage.",
        "label": "InventoryRawMaterialsPercentage",
        "terseLabel": "Inventory raw materials percentage"
       }
      }
     },
     "localname": "InventoryRawMaterialsPercentage",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ntrb_InvestmentWarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of warrants.",
        "label": "InvestmentWarrantExercisePrice",
        "terseLabel": "Exercise price of warrants (in Dollars per share)"
       }
      }
     },
     "localname": "InvestmentWarrantExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ntrb_IssuanceOfCommonStockForNotePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for note payable.",
        "label": "IssuanceOfCommonStockForNotePayable",
        "terseLabel": "Issuance of common stock for note payable"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForNotePayable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_IssuanceOfCommonStockForNotePayableinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfCommonStockForNotePayableinShares",
        "terseLabel": "Issuance of common stock for note payable (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForNotePayableinShares",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LabEquipmentMember",
        "terseLabel": "Lab Equipment [Member]",
        "verboseLabel": "Lab equipment [Member]"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/Leases"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/Leases"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_LicensingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LicensingAgreementMember",
        "terseLabel": "License agreement [Member]"
       }
      }
     },
     "localname": "LicensingAgreementMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_LongTermLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LongTermLiabilitiesAbstract",
        "terseLabel": "LONG-TERM LIABILITIES:"
       }
      }
     },
     "localname": "LongTermLiabilitiesAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss per common share - basic and diluted.",
        "label": "LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare",
        "terseLabel": "Loss per common share - basic and diluted As Reported (in Dollars per share) | $ / shares (in Dollars per share)"
       }
      }
     },
     "localname": "LossPerCommonShareBasicAndDilutedReportedinDollarsPerShare",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "ntrb_MonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of monthly rent.",
        "label": "MonthlyRent",
        "terseLabel": "Amount of monthly rent"
       }
      }
     },
     "localname": "MonthlyRent",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_NoncashPaymentForLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash payment for license agreement.",
        "label": "NoncashPaymentForLicenseAgreement",
        "terseLabel": "Non-cash payment for license agreement"
       }
      }
     },
     "localname": "NoncashPaymentForLicenseAgreement",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_NotePayableConvertibleDebtDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of convertible notes payable.",
        "label": "NotePayableConvertibleDebtDescription",
        "terseLabel": "Convertible notes payable, description"
       }
      }
     },
     "localname": "NotePayableConvertibleDebtDescription",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_NotePayableIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note payable issued.",
        "label": "NotePayableIssued",
        "terseLabel": "Note payable issued"
       }
      }
     },
     "localname": "NotePayableIssued",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_NotePayablesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of notes payable.",
        "label": "NotePayablesDescription",
        "terseLabel": "Notes payable, description"
       }
      }
     },
     "localname": "NotePayablesDescription",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_NotesPayableConvertibleDebtDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable/Convertible Debt (Details) [Line Items]"
       }
      }
     },
     "localname": "NotesPayableConvertibleDebtDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_NotesPayableConvertibleDebtDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable/Convertible Debt (Details) [Table]"
       }
      }
     },
     "localname": "NotesPayableConvertibleDebtDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OneCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OneCustomerMember",
        "terseLabel": "One Customer [Member]"
       }
      }
     },
     "localname": "OneCustomerMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for organization.",
        "label": "OrganizationPolicyTextBlock",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_OrganizationandDescriptionofBusinessDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) [Line Items]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) - Schedule of property plant and equipment [Line Items]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) - Schedule of property plant and equipment [Table]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsScheduleofpropertyplantandequipmentTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) - Schedule of revenue by geographical location [Line Items]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) - Schedule of revenue by geographical location [Table]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsScheduleofrevenuebygeographicallocationTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OrganizationandDescriptionofBusinessDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) [Table]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OtherComprehensiveLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherComprehensiveLossAbstract",
        "terseLabel": "Other Comprehensive Loss:"
       }
      }
     },
     "localname": "OtherComprehensiveLossAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_OtherIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeExpenseAbstract",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherIncomeExpenseAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_PaymentForInitialLicenseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount paid for initial license fee payment.",
        "label": "PaymentForInitialLicenseFee",
        "netLabel": "Initial license fee payment",
        "terseLabel": "IP license",
        "verboseLabel": "License fee (in Dollars)"
       }
      }
     },
     "localname": "PaymentForInitialLicenseFee",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/IntangibleAssetsDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_PerformanceObligationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PerformanceObligationsPolicyTextBlock",
        "terseLabel": "Performance Obligations"
       }
      }
     },
     "localname": "PerformanceObligationsPolicyTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_PoconoCoatedProductsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PoconoCoatedProductsLLCMember",
        "terseLabel": "Pocono Coated Products LLC [Member]"
       }
      }
     },
     "localname": "PoconoCoatedProductsLLCMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_PrepaymentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PrepaymentFee",
        "terseLabel": "Prepayment fee"
       }
      }
     },
     "localname": "PrepaymentFee",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_PrivatePlacement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PrivatePlacement",
        "terseLabel": "Private placement shares issued"
       }
      }
     },
     "localname": "PrivatePlacement",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ProceedsFromLoanOriginationsTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsFromLoanOriginationsTotal",
        "terseLabel": "Total loan"
       }
      }
     },
     "localname": "ProceedsFromLoanOriginationsTotal",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
        "terseLabel": "Schedule of property plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessTables",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_PropertyPlantAndEquipmentsGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical asset used in the normal conduct of business and not intended for resale. Example include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "PropertyPlantAndEquipmentsGross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentsGross",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_PropertyPlantAndEquipmentsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment useful life.",
        "label": "PropertyPlantAndEquipmentsUsefulLife",
        "terseLabel": "Property plant and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentsUsefulLife",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_PublicOrPrivateFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public or private financing.",
        "label": "PublicOrPrivateFinancing",
        "terseLabel": "Public or private financing"
       }
      }
     },
     "localname": "PublicOrPrivateFinancing",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_PurchaseOfMaterials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of Materials.",
        "label": "PurchaseOfMaterials",
        "terseLabel": "Purchase of materials"
       }
      }
     },
     "localname": "PurchaseOfMaterials",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ReclassOfWarrantsFromLiabilityToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ReclassOfWarrantsFromLiabilityToEquity",
        "terseLabel": "Derivative liability for warrant"
       }
      }
     },
     "localname": "ReclassOfWarrantsFromLiabilityToEquity",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ReclassificationOfWarrantsFromLiabilityToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of warrants from liability to equity.",
        "label": "ReclassificationOfWarrantsFromLiabilityToEquity",
        "terseLabel": "Reclassification of warrants from liability to equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantsFromLiabilityToEquity",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_RelatedPartyPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RelatedPartyPayableMember",
        "terseLabel": "Related Party Payable [Member]"
       }
      }
     },
     "localname": "RelatedPartyPayableMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_RelatedPartyTransactionDescriptionOfTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "RelatedPartyTransactionDescriptionOfTransactions",
        "terseLabel": "Related party transaction, description"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransactions",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_RevaluedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevaluedMember",
        "terseLabel": "Revaluation [Member]",
        "verboseLabel": "Re-Valuation [Member]"
       }
      }
     },
     "localname": "RevaluedMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ReverseStockSplitPolicyTextBlock",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_SalaryPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of salary payment.",
        "label": "SalaryPayment",
        "terseLabel": "Annual salary"
       }
      }
     },
     "localname": "SalaryPayment",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_SaleOfGoodsAndServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to services.",
        "label": "SaleOfGoodsAndServices",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "SaleOfGoodsAndServices",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable",
      "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_SaleofCommonstockForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Common stock For Cash.",
        "label": "SaleofCommonstockForCash",
        "terseLabel": "Common stock issued for cash"
       }
      }
     },
     "localname": "SaleofCommonstockForCash",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_SalesRevenuesGoodsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of sale of goods during the period.",
        "label": "SalesRevenuesGoodsNet",
        "terseLabel": "Sale of goods"
       }
      }
     },
     "localname": "SalesRevenuesGoodsNet",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable",
      "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of additional information relating to warrants outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAdditionalInformationRelatingToWarrantsOutstandingAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfAdditionalRelatingWarrantsOutstanding",
        "terseLabel": "Schedule of additional information relating to warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfAdditionalRelatingWarrantsOutstanding",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax asset and liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfDisaggregationOfRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of disaggregation of revenues [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDisaggregationOfRevenuesAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfEstimatedAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated amortization [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfEstimatedAmortizationAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsConsistedOfIntellectualPropertyCustomerBaseAndTrademarksNetOfAmortizationAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfMinimumLeasePaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of minimum lease payments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMinimumLeasePaymentsAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfNetAssetsAcquiredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of net assets acquired [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfNetAssetsAcquiredAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfOptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of options outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOptionsOutstandingAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property plant and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfTaxesOnIncomeComputedAtTheFederalStatutoryRateToAmountsAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfRevenueByGeographicalLocationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of revenue by geographical location [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRevenueByGeographicalLocationAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unaudited pro forma condensed financial information [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfUnauditedProFormaCondensedFinancialInformationAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleOfWarrantsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWarrantsOutstandingAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ScheduleReconciliationOfDerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule reconciliation of derivative liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleReconciliationOfDerivativeLiabilitiesAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal",
        "terseLabel": "Intrinsic Value Outstanding, Ending Balance (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicVal",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice",
        "terseLabel": "Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers",
        "terseLabel": "Number Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price, Expired/Cancelled.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice",
        "terseLabel": "Exercise Price, Expired/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue",
        "terseLabel": "Intrinsic Value, Granted",
        "verboseLabel": "Intrinsic Value, Granted (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice",
        "terseLabel": "Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Outstanding, Ending Balance.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice",
        "terseLabel": "Exercise Price Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue",
        "terseLabel": "Purchase of warrants shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingShareIssue",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice",
        "periodEndLabel": "Exercise Price, Outstanding, Ending Balance",
        "periodStartLabel": "Exercise Price, Outstanding, Beginning Balance",
        "terseLabel": "Exercise Price Outstanding, Beginning Balance (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne",
        "terseLabel": "Remaining Life, Outstanding, Ending Balance",
        "verboseLabel": "Remaining Life Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice",
        "terseLabel": "Exercise Price for Shares Exercisable (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents intrinsic value.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue",
        "terseLabel": "Intrinsic Value (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber",
        "terseLabel": "Number Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
        "terseLabel": "Exercise Price for Shares Outstanding (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices",
        "terseLabel": "Remaining Life, Exercised",
        "verboseLabel": "Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess",
        "terseLabel": "Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePricess",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices",
        "terseLabel": "Remaining Life, Expired",
        "verboseLabel": "Intrinsic Value, Expired/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expired/Cancelled.",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess",
        "terseLabel": "Intrinsic Value, Expired/Cancelled",
        "verboseLabel": "Intrinsic Value, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePricess",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_ShareBasedCompensationNumberExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationNumberExercisable",
        "terseLabel": "Number Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationNumberExercisable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_ShareBasedCompensationNumberOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationNumberOutstanding",
        "terseLabel": "Number Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationNumberOutstanding",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted",
        "terseLabel": "Remaining Life, Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2",
        "terseLabel": "Remaining Contractual Life(Years)",
        "verboseLabel": "Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_SharesWereRestored": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares were restored.",
        "label": "SharesWereRestored",
        "terseLabel": "Shares were restored"
       }
      }
     },
     "localname": "SharesWereRestored",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodIssuanceOfWarrantsForServices",
        "terseLabel": "Issuance of warrants for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodIssuanceOfWarrantsForServices",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price, Exercised.",
        "label": "StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice",
        "terseLabel": "Exercise Price, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedExercisePrice",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of common stock and warrants.",
        "label": "StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants",
        "terseLabel": "Proceeds from sale of common stock and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOfProceedsFromSaleOfCommonStockAndWarrants",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of common stock and warrants.",
        "label": "StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants",
        "terseLabel": "Proceeds from sale of common stock and warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareOfProceedsFromSaleOfCommonStockAndWarrants",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockPurchaseAgreementMember",
        "terseLabel": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_StockholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_StockholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SubscriptionPayable": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subscription payable.",
        "label": "SubscriptionPayable",
        "negatedLabel": "Subscription payable",
        "terseLabel": "Stockholders\u2019 equity subscription payable (in Dollars)"
       }
      }
     },
     "localname": "SubscriptionPayable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_SubscriptionPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SubscriptionPayableMember",
        "terseLabel": "Subscription Payable"
       }
      }
     },
     "localname": "SubscriptionPayableMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_SubscriptionPayables": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription payable.",
        "label": "SubscriptionPayables",
        "terseLabel": "Subscription payable"
       }
      }
     },
     "localname": "SubscriptionPayables",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_SubscrptionPayableForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscrption payable for cash.",
        "label": "SubscrptionPayableForCash",
        "terseLabel": "Subscription payable for cash"
       }
      }
     },
     "localname": "SubscrptionPayableForCash",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_SubscrptionPayableForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscrption payable for services.",
        "label": "SubscrptionPayableForServices",
        "terseLabel": "Subscription payable for services"
       }
      }
     },
     "localname": "SubscrptionPayableForServices",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ntrb_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SummaryOfProvisionForIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of provision for income taxes [Abstract]"
       }
      }
     },
     "localname": "SummaryOfProvisionForIncomeTaxesAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographical location [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofrevenuebygeographicallocationTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_TherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TherapeuticsLLCMember",
        "terseLabel": "4P Therapeutics LLC [Member]"
       }
      }
     },
     "localname": "TherapeuticsLLCMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_ThreeCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ThreeCustomerMember",
        "terseLabel": "Three Customers [Member]"
       }
      }
     },
     "localname": "ThreeCustomerMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_TwoCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoCustomerMember",
        "terseLabel": "Two Customer [Member]"
       }
      }
     },
     "localname": "TwoCustomerMember",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ntrb_UnauditedInterimFinancialStatementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial statements policy.",
        "label": "UnauditedInterimFinancialStatementsPolicyTextBlock",
        "terseLabel": "Unaudited Interim Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimFinancialStatementsPolicyTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_WarrantsAndOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Options [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndOptionsAbstract",
     "nsuri": "http://nutriband.com/20210731",
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsAndOptionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsAndOptionsTextBlock",
        "terseLabel": "WARRANTS AND OPTIONS"
       }
      }
     },
     "localname": "WarrantsAndOptionsTextBlock",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) - Schedule of additional information relating to warrants outstanding [Line Items]"
       }
      }
     },
     "localname": "WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) - Schedule of additional information relating to warrants outstanding [Table]"
       }
      }
     },
     "localname": "WarrantsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsToPurchaseOfCommonStockShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrants to purchase of common stock shares.",
        "label": "WarrantsToPurchaseOfCommonStockShare",
        "terseLabel": "Issued price per unit (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantsToPurchaseOfCommonStockShare",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ntrb_WarrantsToPurchaseOfCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrants to purchase of common stock shares.",
        "label": "WarrantsToPurchaseOfCommonStockShares",
        "terseLabel": "Warrant to purchase of common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseOfCommonStockShares",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ntrb_WarrantsandOptionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Details) [Line Items]"
       }
      }
     },
     "localname": "WarrantsandOptionsDetailsLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding [Line Items]"
       }
      }
     },
     "localname": "WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Details) - Schedule of additional information relating to warrants outstanding [Table]"
       }
      }
     },
     "localname": "WarrantsandOptionsDetailsScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Details) - Schedule of options outstanding [Line Items]"
       }
      }
     },
     "localname": "WarrantsandOptionsDetailsScheduleofoptionsoutstandingLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Details) - Schedule of options outstanding [Table]"
       }
      }
     },
     "localname": "WarrantsandOptionsDetailsScheduleofoptionsoutstandingTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsandOptionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Details) [Table]"
       }
      }
     },
     "localname": "WarrantsandOptionsDetailsTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsandOptionsTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Tables) [Line Items]"
       }
      }
     },
     "localname": "WarrantsandOptionsTablesLineItems",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_WarrantsandOptionsTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Options (Tables) [Table]"
       }
      }
     },
     "localname": "WarrantsandOptionsTablesTable",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ntrb_amortizedOverPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "amortizedOverPeriod",
        "terseLabel": "Amortized over period"
       }
      }
     },
     "localname": "amortizedOverPeriod",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ntrb_increasedecreaseDepositOnSales": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "increasedecreaseDepositOnSales",
        "negatedLabel": "Deposit on sales"
       }
      }
     },
     "localname": "increasedecreaseDepositOnSales",
     "nsuri": "http://nutriband.com/20210731",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Officers [Member]"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [
      "r181",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "terseLabel": "Chief Operating Officer [Member]"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Directors [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r180",
      "r315",
      "r317",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r258",
      "r288",
      "r330",
      "r332",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r505",
      "r559",
      "r562",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails",
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0",
      "http://nutriband.com/role/StockholdersEquityDetails",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r258",
      "r288",
      "r330",
      "r332",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r505",
      "r559",
      "r562",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails",
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0",
      "http://nutriband.com/role/StockholdersEquityDetails",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r180",
      "r315",
      "r317",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PresidentMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "President [Member]",
        "terseLabel": "President [Member]"
       }
      }
     },
     "localname": "PresidentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r258",
      "r288",
      "r319",
      "r330",
      "r332",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r505",
      "r559",
      "r562",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails",
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0",
      "http://nutriband.com/role/StockholdersEquityDetails",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r258",
      "r288",
      "r319",
      "r330",
      "r332",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r505",
      "r559",
      "r562",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails",
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0",
      "http://nutriband.com/role/StockholdersEquityDetails",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r144",
      "r196",
      "r197",
      "r349",
      "r368",
      "r420",
      "r421",
      "r422",
      "r423",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r144",
      "r196",
      "r197",
      "r349",
      "r368",
      "r420",
      "r421",
      "r422",
      "r423",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r315",
      "r316",
      "r560",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable",
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r315",
      "r316",
      "r560",
      "r575",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable",
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r181",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails",
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails",
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r11",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Extinguish accounts payable (in Dollars)"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r235",
      "r236",
      "r237"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "negatedLabel": "Early prepayment fee on convertible debentures"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r57",
      "r58",
      "r59",
      "r548",
      "r568",
      "r572"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r56",
      "r59",
      "r65",
      "r66",
      "r67",
      "r119",
      "r120",
      "r121",
      "r406",
      "r563",
      "r564",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r349",
      "r471"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r346",
      "r347",
      "r348",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r77",
      "r96",
      "r271",
      "r442"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow",
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r96",
      "r271",
      "r280",
      "r281",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r96",
      "r218",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfLeasedAsset": {
     "auth_ref": [
      "r96",
      "r448"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.",
        "label": "Amortization of Leased Asset",
        "terseLabel": "Amortization of right of use asset"
       }
      }
     },
     "localname": "AmortizationOfLeasedAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r165",
      "r168",
      "r174",
      "r194",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r400",
      "r409",
      "r431",
      "r469",
      "r471",
      "r528",
      "r545"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r50",
      "r113",
      "r194",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r400",
      "r409",
      "r431",
      "r469",
      "r471"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r329",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails",
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r329",
      "r331",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails",
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business Acquisition, Description of Acquired Entity",
        "terseLabel": "Description of acquired entity"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Acquired common stock value"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Acquired common stock, shares (in Shares) (in Shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of unaudited pro forma condensed financial information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss, Proforma",
        "verboseLabel": "Net loss Proforma"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable",
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net revenue, Proforma",
        "verboseLabel": "Net revenue Proforma"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable",
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r391",
      "r392",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Capital raise of no less"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITION OF BUSINESS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Net revenue As Reported"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Acounts payable and accrued expenses",
        "negatedTerseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "negatedLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "negatedLabel": "Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment",
        "terseLabel": "Equipment and fixtures"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash received from acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r32",
      "r98"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents - End of period",
        "periodStartLabel": "Cash and cash equivalents - Beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet",
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r432"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r113",
      "r135",
      "r136",
      "r137",
      "r139",
      "r141",
      "r147",
      "r148",
      "r149",
      "r194",
      "r243",
      "r248",
      "r249",
      "r250",
      "r254",
      "r255",
      "r286",
      "r287",
      "r290",
      "r294",
      "r431",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of expense or revenue offset related to the warrants or rights.",
        "label": "Class of Warrant or Right, Expense or Revenue Recognized",
        "terseLabel": "Warrant, description"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpenseOrRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r305",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r241",
      "r534",
      "r553"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r242",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTIGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsShares": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.",
        "label": "Common Stock Dividends, Shares",
        "terseLabel": "Common stock issued for cash (in Shares)"
       }
      }
     },
     "localname": "CommonStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock.",
        "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable",
        "terseLabel": "Subscription payable, value (in Dollars)"
       }
      }
     },
     "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r471"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "netLabel": "Common stock value (in Dollars)",
        "terseLabel": "Common Stock Value",
        "verboseLabel": "Common stock value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet",
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r63",
      "r72",
      "r397",
      "r412",
      "r537",
      "r556"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r180",
      "r429",
      "r430",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r180",
      "r429",
      "r430",
      "r573",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r152",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r19",
      "r530",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt amount"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible debt- net"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r19",
      "r530",
      "r546",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Advanced amount"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Convertible notes payable current"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r74",
      "r113",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r431"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total Costs and Expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Expenses paid on behalf of the Company by related party"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r364",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofprovisionforincometaxesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.",
        "label": "Customer-Related Intangible Assets [Member]",
        "terseLabel": "Customer base [Member]"
       }
      }
     },
     "localname": "CustomerRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Conversion stock issued (in Shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.",
        "label": "Debt Instrument, Debt Default, Amount",
        "terseLabel": "Assumed amount"
       }
      }
     },
     "localname": "DebtDefaultLongtermDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r272",
      "r273",
      "r275",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "NOTES PAYABLE/CONVERTIBLE DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Compensation annual rate"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r257",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Common stock conversion (in Dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r17",
      "r19",
      "r302",
      "r529",
      "r530",
      "r542",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description",
        "terseLabel": "Description of convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r256",
      "r278",
      "r279",
      "r443",
      "r445",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt Instrument, Maturity Date, Description",
        "terseLabel": "Lease of description"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to interest.",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Payments of principal interest"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Issued a promissory note, net of debt discount (in Dollars)"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r365",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r365",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r114",
      "r365",
      "r371",
      "r372",
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofprovisionforincometaxesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "negatedLabel": "Net operating loss carryforwards (expire through 2038)"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpense": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense",
        "negatedLabel": "Intangible impairment expense"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofdeferredtaxassetandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositLiabilitiesAccruedInterest": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued but unpaid interest on deposit liabilities.",
        "label": "Deposit Liabilities, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DepositLiabilitiesAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r96",
      "r163"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails",
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Initial derivative expense"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r53",
      "r414",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/WarrantsandOptionsDetails",
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r419",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE LIABILITIES"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability (in Dollars)"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet",
      "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r117",
      "r246",
      "r248",
      "r249",
      "r253",
      "r254",
      "r255",
      "r463",
      "r532",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Balance due"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share of common stock-basic and diluted (in Dollars per share)",
        "verboseLabel": "Loss per common share - basic and diluted, Reported (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement",
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r65",
      "r66",
      "r67",
      "r119",
      "r120",
      "r121",
      "r123",
      "r130",
      "r133",
      "r146",
      "r195",
      "r301",
      "r303",
      "r346",
      "r347",
      "r348",
      "r367",
      "r368",
      "r421",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r563",
      "r564",
      "r565",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0",
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r96",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of the warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r266",
      "r278",
      "r279",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r425",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r266",
      "r278",
      "r279",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r425",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule reconciliation of derivative liabilities"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/DerivativeLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalHomeLoanBankAdvances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Federal Home Loan Bank (FHLBank) advances to member financial institutions.",
        "label": "Federal Home Loan Bank Advances",
        "terseLabel": "Loan amount"
       }
      }
     },
     "localname": "FederalHomeLoanBankAdvances",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities-current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities-net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable",
      "http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.",
        "label": "Finance Lease, Liability, Payments, Due in Next Rolling 12 Months",
        "terseLabel": "Years Ending January 31, 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable",
      "http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "January 31, 2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable",
      "http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "January 31, 2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable",
      "http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "January 31, 2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable",
      "http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "January 31, 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofMinimumleasepaymentsTable",
      "http://nutriband.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r452",
      "r454"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment on finance leases",
        "terseLabel": "Finance payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow",
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r274",
      "r299",
      "r419",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable",
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022",
        "verboseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable",
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated amortization",
        "verboseLabel": "Schedule of estimated amortization:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable",
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024",
        "verboseLabel": "2924"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable",
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable",
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r224",
      "r227",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r224",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r219",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r224",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures [Member]",
        "verboseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "Gain on change in fair value of derivative"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "auth_ref": [
      "r96",
      "r538"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.",
        "label": "Gain (Loss) on Sale of Derivatives",
        "terseLabel": "Gain on change of fair value of derivative"
       }
      }
     },
     "localname": "GainLossOnSaleOfDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r96",
      "r282",
      "r283"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on extinguisment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow",
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r212",
      "r213",
      "r471",
      "r527"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill (in Dollars)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet",
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r216",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable",
      "http://nutriband.com/role/ScheduleofnetassetsacquiredTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r70",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r525",
      "r535",
      "r540",
      "r557"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r355",
      "r356",
      "r361",
      "r369",
      "r374",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r132",
      "r133",
      "r164",
      "r353",
      "r370",
      "r375",
      "r558"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement",
      "http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r351",
      "r352",
      "r356",
      "r357",
      "r360",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Impairment expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Unused operating losses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Common stock issued for services"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Book income (loss) from operations"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofreconciliationoftaxesonincomecomputedatthefederalstatutoryratetoamountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r93",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInCustomerDeposits": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.",
        "label": "Increase (Decrease) in Customer Deposits",
        "terseLabel": "Customer deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInCustomerDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in value of embedded conversion option"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SchedulereconciliationofderivativeliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r106",
      "r223",
      "r507",
      "r508",
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r217",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable",
      "http://nutriband.com/role/ScheduleofestimatedamortizationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual property and trademarks [Member]",
        "verboseLabel": "Intellectual property\t[Member]"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable",
      "http://nutriband.com/role/ScheduleofintangibleassetsconsistedofintellectualpropertycustomerbaseandtrademarksnetofamortizationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r162",
      "r441",
      "r444",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r77",
      "r269",
      "r277",
      "r280",
      "r281"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r79",
      "r270",
      "r280",
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Expense including amortization of debt discount"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r89",
      "r92",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r48",
      "r471"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r49",
      "r107",
      "r145",
      "r207",
      "r208",
      "r209",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r113",
      "r169",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r401",
      "r409",
      "r410",
      "r431",
      "r469",
      "r470"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r113",
      "r194",
      "r431",
      "r471",
      "r531",
      "r550"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r113",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r401",
      "r409",
      "r410",
      "r431",
      "r469",
      "r470",
      "r471"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAnnualPrincipalPayment": {
     "auth_ref": [
      "r16",
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Line of Credit Facility, Annual Principal Payment",
        "terseLabel": "Principal payment"
       }
      }
     },
     "localname": "LineOfCreditFacilityAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average amount borrowed under the credit facility during the period.",
        "label": "Line of Credit Facility, Average Outstanding Amount",
        "terseLabel": "Line of credit amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityAverageOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.",
        "label": "Line of Credit Facility, Frequency of Payment and Payment Terms",
        "terseLabel": "Line of credit, term"
       }
      }
     },
     "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate, percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payment applied to principal.",
        "label": "Line of Credit Facility, Periodic Payment, Principal",
        "terseLabel": "Principal and interest payments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Notes payable-net of current portion"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment [Member]",
        "verboseLabel": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used in Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r60",
      "r62",
      "r67",
      "r71",
      "r97",
      "r113",
      "r122",
      "r124",
      "r125",
      "r127",
      "r128",
      "r132",
      "r133",
      "r138",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r423",
      "r431",
      "r536",
      "r555"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow",
      "http://nutriband.com/role/ConsolidatedIncomeStatement",
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable",
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "verboseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable-current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r36",
      "r117",
      "r464"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Notes payable-related party, net"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use operating lease asset-net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Net operating loss expire, description"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Abstract]",
        "terseLabel": "OTHER ASSETS:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Other Commitments, Description",
        "terseLabel": "Other commitments term, description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r397",
      "r398",
      "r405"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r55",
      "r57"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralExpense": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.",
        "label": "Other General Expense",
        "terseLabel": "Expenses amount"
       }
      }
     },
     "localname": "OtherGeneralExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets-net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Derivative expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses (in Dollars)"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense classified as other.",
        "label": "Other Selling, General and Administrative Expense",
        "terseLabel": "Selling and general administrative expenses (in Dollars)"
       }
      }
     },
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Payment for Debt Extinguishment or Debt Prepayment Cost"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r82",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Public offering less"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)",
        "verboseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r471"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r210",
      "r211"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalTransactionsRevenue": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) resulting from the difference between acquisition price and selling price or fair value of trading assets and trading liabilities, and from the firm's direct investment activity, conducted separately from customer trading activities, including, but not limited to, investments in private equity, alternative investment products, real estate, and exchanges and memberships.",
        "label": "Principal Transactions Revenue, Net",
        "terseLabel": "Revenue transactions"
       }
      }
     },
     "localname": "PrincipalTransactionsRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Payment received (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock",
        "verboseLabel": "Received proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoanOriginations1": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.",
        "label": "Proceeds from Loan Originations",
        "terseLabel": "Additional loan"
       }
      }
     },
     "localname": "ProceedsFromLoanOriginations1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Proceeds from stock subscription"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from related parties"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r60",
      "r62",
      "r67",
      "r90",
      "r113",
      "r122",
      "r132",
      "r133",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r397",
      "r403",
      "r404",
      "r411",
      "r412",
      "r423",
      "r431",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss, Reported"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r234",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r232",
      "r471",
      "r541",
      "r551"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "PROPERTY &amp; EQUIPMENT-net",
        "verboseLabel": "Net Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r232",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property plant and equipment, Usefull life",
        "verboseLabel": "Property plant and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable0",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of other property, plant and equipment (PPE) owned by public utility, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Public Utilities, Property, Plant and Equipment, Other Property Plant and Equipment, Useful Life",
        "terseLabel": "Property plant and equipment, Usefull life"
       }
      }
     },
     "localname": "PublicUtilitiesPropertyPlantAndEquipmentOtherPropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r184",
      "r186",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Account receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r327",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r327",
      "r462",
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "auth_ref": [
      "r20",
      "r447",
      "r456",
      "r458",
      "r459",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "Related Party Transaction, Description of Transaction",
        "terseLabel": "Related party payable, description"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r327",
      "r462",
      "r466",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r460",
      "r461",
      "r463",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Payment on convertible debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment on note payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Payment of related party payables"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r303",
      "r349",
      "r471",
      "r549",
      "r567",
      "r572"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r119",
      "r120",
      "r121",
      "r123",
      "r130",
      "r133",
      "r195",
      "r346",
      "r347",
      "r348",
      "r367",
      "r368",
      "r421",
      "r563",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Contracts with Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of revenue by geographical location"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessTables",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionDeferredRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.",
        "label": "Revenue Recognition, Deferred Revenue [Policy Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r69",
      "r113",
      "r160",
      "r161",
      "r166",
      "r171",
      "r172",
      "r176",
      "r177",
      "r180",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r431",
      "r540"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Total",
        "terseLabel": "Revenue",
        "verboseLabel": "Net revenue, Reported"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement",
      "http://nutriband.com/role/ScheduleofdisaggregationofrevenuesTable0",
      "http://nutriband.com/role/ScheduleofrevenuebygeographicallocationTable0",
      "http://nutriband.com/role/ScheduleofunauditedproformacondensedfinancialinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "terseLabel": "Annual salary"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r399",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Stock, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock price (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r155",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenues [Member]",
        "verboseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax asset and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of taxes on income computed at the federal statutory rate to amounts"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.",
        "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]",
        "terseLabel": "Schedule of Minimum lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable",
      "http://nutriband.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of net assets acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AcquisitionofBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessTables",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r336",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of options outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r305",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Shares, Exercisable (in Shares)",
        "terseLabel": "Shares, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price, Exercisable",
        "verboseLabel": "Exercise Price, Exercisable (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Shares, Expired (in Shares)",
        "terseLabel": "Shares, Expired/Cancelled",
        "verboseLabel": "Shares Expired/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares, Granted",
        "verboseLabel": "Shares, Granted (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Intrinsic Value, Outstanding, Ending Balance",
        "periodStartLabel": "Intrinsic Value, Outstanding, Beginning Balance",
        "terseLabel": "Shares, Outstanding, Ending Balance",
        "verboseLabel": "Intrinsic Value Outstanding, Beginning Balance (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r338",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "netLabel": "Shares Outstanding, Ending Balance",
        "periodEndLabel": "Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance",
        "terseLabel": "Shares, Outstanding, Beginning Balance (in Shares)",
        "verboseLabel": "Shares, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Exercise Price, Outstanding, Ending Balance (in Dollars per share)",
        "periodStartLabel": "Exercise Price, Outstanding, Beginning Balance (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price, Exercised",
        "verboseLabel": "Exercise Price, Exercised (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price, Expired/Cancelled",
        "verboseLabel": "Exercise Price, Expired (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "netLabel": "Exercise price",
        "terseLabel": "Exercise Price, Granted",
        "verboseLabel": "Exercise Price, Granted (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Range of Exercise Prices"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic Value, Exercisable",
        "verboseLabel": "Intrinsic Value, Exercisable (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining Life, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining Life, Outstanding, Beginning Balance",
        "verboseLabel": "Remaining Life Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Issuance of shares (in Shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Converted per share (in Dollars per share)",
        "verboseLabel": "Per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantPurchaseCommitmentDescription": {
     "auth_ref": [
      "r45",
      "r534",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Description",
        "terseLabel": "Purchase commitment, description"
       }
      }
     },
     "localname": "SignificantPurchaseCommitmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r111",
      "r113",
      "r135",
      "r136",
      "r137",
      "r139",
      "r141",
      "r147",
      "r148",
      "r149",
      "r194",
      "r243",
      "r248",
      "r249",
      "r250",
      "r254",
      "r255",
      "r286",
      "r287",
      "r290",
      "r294",
      "r301",
      "r431",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r47",
      "r65",
      "r66",
      "r67",
      "r119",
      "r120",
      "r121",
      "r123",
      "r130",
      "r133",
      "r146",
      "r195",
      "r301",
      "r303",
      "r346",
      "r347",
      "r348",
      "r367",
      "r368",
      "r421",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r563",
      "r564",
      "r565",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r146",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock value"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r22",
      "r23",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "netLabel": "Acquired advanced shares of common stock (in Shares)",
        "terseLabel": "Issuance of common stock for acquisition (in Shares)",
        "verboseLabel": "Issued of shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r46",
      "r268",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of debt for common stock (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Common stock issued for services (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock issued for proceeds and payment for license (in Shares)",
        "verboseLabel": "Issued shares of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock for accounts payable (in Shares)",
        "verboseLabel": "Common stock issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited",
        "terseLabel": "Shares cancelled (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r301",
      "r303",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Shares, Exercised",
        "verboseLabel": "Shares, Exercised (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r47",
      "r301",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "netLabel": "Acquired advanced shares of common stock value",
        "terseLabel": "Issuance of common stock for acquisition",
        "verboseLabel": "Common stock, value (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r301",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of debt for common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Common stock issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r301",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock issued for proceeds and payment for license"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock for accounts payable",
        "verboseLabel": "Common stock issued, value (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ShareholdersEquityType2or3",
      "http://nutriband.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofoptionsoutstandingTable",
      "http://nutriband.com/role/WarrantsandOptionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r28",
      "r29",
      "r113",
      "r185",
      "r194",
      "r431",
      "r471"
     ],
     "calculation": {
      "http://nutriband.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet",
      "http://nutriband.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement.",
        "label": "Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares",
        "terseLabel": "Note issued transaction"
       }
      }
     },
     "localname": "StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r303",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated interest rate of the subordinated debt.",
        "label": "Subordinated Borrowing, Interest Rate",
        "terseLabel": "Borrowing rate, percentage"
       }
      }
     },
     "localname": "SubordinatedBorrowingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/NotesPayableConvertibleDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent Event, Description",
        "terseLabel": "Subsequent event, Description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r439",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/StockholdersEquityDetails",
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r439",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/StockholdersEquityDetails",
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r439",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails",
      "http://nutriband.com/role/StockholdersEquityDetails",
      "http://nutriband.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r274",
      "r299",
      "r419",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/CommitmentsandContigenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r150",
      "r151",
      "r153",
      "r154",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable",
      "http://nutriband.com/role/ScheduleofadditionalinformationrelatingtowarrantsoutstandingTable0",
      "http://nutriband.com/role/ScheduleofwarrantsoutstandingTable",
      "http://nutriband.com/role/WarrantsandOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Potential shares of common stock (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding - basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://nutriband.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406127&loc=d3e45031-112735"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918703-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123417830&loc=SL77919784-209982"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42567-110969"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r592": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r593": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r594": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r597": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r598": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r599": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r600": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001213900-21-050881-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-050881-xbrl.zip
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M)]W!ZMXQ7;_<:C?>'EP:AWL=TKN9964R#G-,3\M2^@_E6?F9FE@:K+#4.+
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M$B4W.0_QR((Q#T_'"#R>3M6T4J;&<!.2;"&H!X$*T2<S 3:<D7F#F1YPK>9
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MK, (6DF@F8&DL8IGI&VQ*7:^I0.WF\'(Z?02JH;O.$_'>;ZL]0KF ]%-;K$
MZ2\4=@FRC))3)1 @:%GSR)(,=7E_K<^'J#DSP5LWALU2JN(6S%HX+>'"Z;Q>
M4!X1 ,*8W- $!E 2BT%D $P=M.62F'31T7Q'\[6&9U4L#!-,QE[^DE5M)5N.
M*<LTA2U2E@6.\B+.ECFS!$'-$R&45LPUA:E"EGK3S#Y61VK'FZ<7)><"55E\
MF$422S*=/_..PCL*_Z(O@TLV?10!OS:H*L6+*O5%- VKTK6,.M2IQLI"=S%J
M]48L,:86PZ,JI'7FD]."*O K'XJ(:H1 ^>,*>RZCA!O RM",BET;:=Y8(>I-
MX7*F;6.G-E%4]0JI36\DQ5B7VD8X\78B# (:F./KU+OA=S1QE\/FN N\'79O
M[A#_EN&$&UEZ$^^N='>E5Z\T6A%-$P*%AV ,X9U,U"6;))(RTFRFX0LCYT6Q
M"55B#V$QYEA)4J"G<XFIQN!+B"Q(C]/G%F&-&FE50":<4NUE;WJSBL)"?59<
M>TWE>UDB3I0,-42+BJ.Q8'&.<$%5PI7UKI#T6Q&O7AS-I1_8[W_IKE5WK9K7
M"G%#4RO1//^(;:$1^AHCVRC4^DPMXD*Y0NK*&X!(4>R[]QKN22IT.NU(<','
M&MXA,=T].?MER[:@7O+2?1!,EW_ #0UK[+-%Q9.L+ARMBA1X"8DNU:L61ZCJ
MU:N4W#Q"FP=FM&1TH_H+6H:,^.%6!WT=)*'C\1V/7Y]"6RO\E\(UQX^;A6W(
M[,=QPNDYJP[D2Y5CVKE4(+$]TJS4X0QYSHJW&HBG1XU+AX^-,VN.O.'TG>\8
M8^"@2_211)^=+M'G@<,)8-3(KX]]&" !$NM4,,H%V)BAQ7@E*]"#?"7\IW^H
MM 1U(M@EU)5]PNN2S^B#J ;E^[9$K0;U[]?%&(,2X:L<4W><,\?5)&,J CM1
M_P:3 1OZ'&M?Q[@B"G3.8CU!T#;$^*;@ \7.(NPI *_=KA(-D&M+T33'0)(D
MY=H,4GZ&2T]#:0'[Y]!@!7,+0XVQ)I(:BN(V4?TN.KX*N'R#\!Q^D*/)'1Q?
MZ%YX7L;PH\%>OQ_!YPG,((O"E]AV #9V9_M@?P_T)YWHQ0S;DC[>[1\\"7<.
M#K;V]X_V^-67>FABAOGZ-?[]\O*RE]I-[,&V_?HT_ATWO:W?,KGWO'8"%A8J
M\X:MZ:#V0[\KE,7HY(XU[9TZ'T;CHO>L=+RT2L<#P?QX5^:F5*FTC3PG  WX
M;#3#$O5C%[=^+" >Y^^.!;KC210PL-(+V!A"?3IP+6RL]UD@L:+P^;LW0(5I
MAA>[%X7_%>=+543A*Y,K#3;"0EXX#@\'T<[1GM>-OMX:MB",.[*.)N%/A[W]
M/B8F!?0XU<_^=- G4%>!B\(;*YUUD6W8BL$QCX3I#F1ZI.%+/<R9*^W3*@8/
M@&C/4FP/"QQS>]N>C'<HP#),R9 MM*<7<)@!U6W3@>_N1X?;AR'B%)KFO@\&
MN.OT72\\19 Y_"=W?S/$^4%/3Z7![^HA8K:%594I6FW)S?UFM2=PP7UU$/6/
M4D_<5'9I*O0K/G.K@Z.;!\-XC/NUTZ<MV.%G&EN@8!8%8S++LJ]H3>S&]V=>
M^UESQ?5W5OT9.-V#'O]I;[ 7#08[#X#J7CFJ(XI3X3Q.,T).H,V890DFR%S.
MLG"FQ@&&^[':GI*+QB@O%1MJ/VW#CO11,-+G*O4]<?B4K5!V9\FN;34G,$D<
M8;_/ X!2 KJR<08;G36_R :] G]N,/!/VP=[S$;.M0[?9B#A=MT;B@)('J'G
M'33"N<LE0F!.N_Z#*V[=-@UO"89ZIQ" =DX="<6<Y#:!KL>+ZS*C$DI5IEV2
M>7[_=%/MVZ!MWX!0P$X?6[0'\J2 UA*LV2./#+8/B ZJ *=_\>17%Q16M<Q/
MA ?1R4(M6ULXTGR6G+>E@2:+92"X[SES54XJC4CN_+2SNQ?M[8/.=ER/=3($
M];*J6I=#CZ1 G6:&&JS#@/>1>7XZVCZ,#@YVD3U:K7IG$ 4BA2GDR2#;0-+_
MUGG6^G[G6FG=BZCFV*@QO;V^3\.$=&P,HS\^5D^"G[;[O:,^"N7'PR?B-G3'
M:26QJ82/!RPP&/1_MC.*0;0P8+YTCW?,7_ )/. OH0+J!ET-%TBOIG:A<[37
M6(45;Z)4^&VUQTBMTON[4INN[W+J!9:=&. G2"^#_O78RH.XWV>C(D-%D84Q
MH4QIML/XQG#BK,WN#-P1-3-H+S-!:,,6XOY)N)HZX;)R./9A\N3]M"UT^SA^
M$N[_C$K'%L+L^EREQGF#*[D*'N+C&(8"\TG+2&UD5K\LU])O])^8Z2!KX+N%
MD@'G[=TM?#=GT7EX&#68CK;;U+@C7[I4==@/ M$*7-MZ0N3[J\.R-K?=Z_?]
MR^?R"G\"W6B[W]3U4ET$CIL+?X^-[QC&?!(,17RF,"!H&;!S.ZP64&H(]?.2
MYF"?J/,BAP1E?"(#@E?WB(-M!R>M>9%!RVF%<EJ"<B3ZL-N3%>!"V@N8CS0!
ML:>+/[]0><QE:HWW6GE C1LFU. 9^/Y!=>))=HE!)3"%QE>?B.?3AIVVSX_5
MTE"?&^U$WYB9M3<5B[#2V!(;R2>$I]3VI2O8,/-F4X>:1+BG2VJG4+';6MX"
MD'I;&@4:*JV9V*0C;!J(>NB8J/,*W%,7_&'G@A<7_&[G@K\K%WS;?=G<JU[-
MO9Z!P(*>:VG4=SK7.37<_5N>70(/$?7T8;CV2-=WOG-DD2B6&%#HIT&O?Q""
M29$@NZ;8/?#64@<B!0CP!7OC3+#)3D*-"$A=0RD'HTLK#_$*:KN-4]Y&>:D%
M^55.-EE&_H]ROC"%RHO0[P>/"F]>E L3'#.6'_KJ'2S>/\Z>GV.A#Q@QH"JU
MO['"5%+C"^5$CC6#N+J'(0Z]C!]7Z$=^[LO8=KCC?KM59A[I<Z3@\.L(M$_9
M_D^4QFKF\","*;1OJC)1N3&O(C7C*Z:'_OL 2\MBQ#+.(]GZ-3N A]1!#G?%
M\U\W [PVDAS-78/0QN+F(ZA!EV,J[:NP0!O%<Q924TH(,1.:M:\WKE^<*TU\
M <]@KU@R',9PEU6R-&0(>);OB<4:I6?>"QXI/%)!KA-?>//B/]5\\<MQES#4
M)0Q5,["H9K8<1TKBJ/.($FQZ^#1%,YV\:Q[=CH4\108B5]6I0"B+(R AK%:R
M5^#'? -T4JLE!9K^-PXQRRY!NF!1K7L :RVJABMN1&E%9 ?US#HVTKC85]K6
M9B@#1/;69CBN7RXEETL$<7=+NEMR]2UQF:+HCD3L%,>#_3Z=E"N',@'];X)R
M/5_E]%B:8XP/KRI9K(FM%N#2]$JL5 I0T[]ZKO*A AUQZ^QSHI>ATP_[VQU1
M=T1]/:(F_/MAS/W10 &/#68J7V!PSY&U%P<DTJYRB&I\-D- <WB(\.+5:$8I
M,#EE]C"7?[R.:R,Q"^<V:KD%,UJHI6N'4OL&9L4NB<J0@HM8_S'/8LO-PCZ)
MJS)/NKO1W8WZW0!ZGB^$C=L^$FMHW%.*O( 67RQN# J4NS7)\BW!!J*@]#17
M"\ZE6Y.$A[\*28?WWM 1:D>HU0Q<^2UU$ZT8N>WR@-X/:5];]2:]OFY1I@5&
M#YR%JR8V$Y2+\<DBD!@'UU"WP<94+40:Z8ZHLRO" KH'90";2P*FCO=CU\*V
MYM 2U 3&"1+O5K#&^4;6$W$E*IH._YY=8E.3* 0;;$3]=*FV5278!6@)[\D6
MZ&IP37!@&5E.36<QE"?-9*4M4#I6^=BX-F2#_8-?!OT#FUYC'8I1&Q+VZJ(X
M(R-12\S=HIAN[%H)7&,6#R"$_X?#-JIM7;O/%0-O:@B7$%&>1GD\) ?GE7[8
M.BE06+9<,(P34(!_6?G"<\S9(NQ*,!,'+):^ 1&H=5?8M;:J+GZ%W^3A3(FY
M,3C:V6'W*_QZ3# ?.:/4P=22&'\'>^I0!-+,(OO/M2X"II\)39O9UGHO+@=4
M[2Y;YX6I  HH+LY]I C#X=K.^(!S!>A.4:>!]G" @\.BJ #HL[AJBL=*O#Q.
M)UP%_B1:&>R@WP_GU5B22X\<V\:]@UKD>:83RN5'_5Q-$/.,42SP-9C(49NH
M/\NVS P<Q(_6C_6P8%F@_!P-T%GB;-P+F*9MLU[OS)$8';[8"4PW)K\*S>K\
M]"0*\Y(<03/+KRQNA,.PAX/QHR5.<U\7(K GA-MKF':H?Y:<EHXI"Q\3"I2-
M0TR2# CB<=S3/=OAJK[7]4O1OM%/\$$O-+2]YXX/<PEL'@%&@QSJQU@Y:,<Y
MMB=R4!]5BK7!NO^Q#2!)581+:F@26'T* X^"X"""QH+K#WODMNDH_WW!RS[J
M8O@2P]_K8OBWC9>MPGC\VR/U__K];21;==-I+4PS%+C_\/?3\.SER]/WK][^
M;6-!>>]]&\Y)<&^ZK=BIN^*C+$G4P@")VW_]E;#JSN#G)AD.Z%;38F,0J3C7
M+;;F;LHN_ 45T+@P-">;*@?"K#3/KK)5P48K]!9N*(R39I>Y6E1;]/,WAX;W
M#]?]]@;7.XCZ>_N8K4B3H-5'H&M2ZS^JM9'$R:N+;?#;CYR2*K^^G&6)^\RF
MG1(Q4JW[NM%Z- W43#_:?' 'Z^IJOO[@BB'V-;EQX_E<CV-*P11]L;V>YZ"W
MYV5YBD5 =3QD SS>>\)V ,W$9?1;:QVU1?1""?KLFEQ;&-/-WZ5^H+UN59UJ
M"=ZT09]!+RLLYD: O59OS]54UT;%=^W ND&7STDM#[8LR&R6#%$&VZ]E"S\+
M?S7EXO?'@R=P%B6*VJ]D /?,Y[8?[<!%W]X_$J+=#(6U\^<?ENI^:9 =&](^
M\6%=%L^TZA[)?V<3_E^D2ON)D"93YO:#H$S8HH-H=[#MD6;X^"#:.^A'^_M'
M/"NIE<1I29$/^5 NP8[6N9%H,%G@,,TDXX3NC!O^QL8) <H-G)1)\N1&^:LH
MSH.#5<VY[4KT>X.][_%2?.VEOT$".:.CI(GX!2]>N>8J3_LN;\*'!FF3'D.3
M@#<(01-DG#B7J)YXCRLH_)UAGV:]HG6P=QCMUNJ#5JI#@"<]A=$_MI3BT21X
M6#O0RO:WCOG85:T,]ES%2%I2.3_\=1T-BG8D60+1,0DX_0GL3Y?O:YGCDXB5
MME*:WI"_:!@SL!D^F>MLLB']ZF%(OSN\Z'\(H0$YV**KK[>\[MNEKD6R2NI^
MP:M,==&H%*X5P5ED28:2J)>8[?4.G?<2]->YRF%NQ!HPQ9:*G D=?[7_M!KB
M%,:ZT.2/9BL'2Z?295+#GS%+4^@Y#=-2O59K+V^Q:8!98 L>PS7MXHS^@U'0
MW\E">^*#[F[@_;N!CWY_$6,42/!U1\OO_/+1W9.&]%YSZX5:<G$.R 9E9N%8
M%NTR#>O0&A^YY\2(,<XCUV\-_;E&:W9J$#AW1&/"]4NIPPK%:BC!@,N#60&M
M 9EWM^ ^WH+7XO>BZE*I(S7+^3!+OOL+@<50O!3;_^3LP\E_/T<SZ>V']\\K
M9'TJ2I)(;.+Y 5MTQDI3DR'?'I^_./[O\$1$Q1N.&'I]BV@"+K\<7]R2?X@?
M?W1YBW#7%AQ !T%';6\Q*BXS,P(8-W)%'9C+P]A+W1V[EW?L?6P^A2_5"#.\
MO_M;]<^L!$N&,R: $M''@&FY:LQIBNA)M[0?>TAYAL'GBYEW-Q#?#^^:7 )_
MF]Q=&.IIG*:"*X8!Q?"P!12/ZS,P3TKPG=M>;$$2O)]QI!(S5^*Q] -@^66E
M5TT\WF8"F@UN?7?E@3=):^R1OJO$R6.R5,[UHF!$OH'#LOMV)GN3F[-]EYOS
MH=6U47E[ X=K*4&M<+ [B YWG%.&LSVEW8 @S!!REXMCD0BNW,=W @?=B#%O
M=/"61)@KDE8&_2YK1;)6]KNLE5M&GFB53E4FR\ZF,UG.3U^?GGPX?1&>G+T]
M/WO]ZL4Q_O'RU=OCMR>OCE^'\/?Q#>:=K$L(;N&QS"J_Z1T?R-!.DNP2V9VO
MPW#>H =*1X*(E![!A63/5<!9O04V^9*<VIE"+0?^)O@[-')J-8>:538D$[6V
M*)U9-5A)F.JI$Z,OT;7<HD]QIH!;0_ M:PA-_#D$G:N8&5Y#^(\R:?W!^J65
M:=OB@K^XN(W*@%O"73[W"RZJ\G\?U/K9+>.U?)52NS8!JY&H==WY?DG?979_
M=951\PA1+5DU-YW@Z*T-B<):4+/Y[='^H_7OV93$OB;CA<OYAB_G*5Y.2ROA
MYEY9O_Z/_[!W^XE]]]?O^(,]GG\B$[NU@V%>SEL%!_07SN/+5M1?OXADPEQJ
M5J*&63*NM*BO.?SM1U<,^&WT@(1]K4T3.\Q_YW>YVOX/M=KN;+]AM=?E"# K
MF,4TS\ITC&I!!A90/AT^WN[O1ML[A]'VWMZ3M1ZKO>V?VWR_;:E-CWY_S\4U
MS>6YY.?KY#DW4Z1Q_$>__[1FS*/&TV0 /OI]?_<@VMX^6#N1ME>T$]+MSQWQ
M8@\'N]_EW(]V=Z*#_O9W.?<=S#'<_7::N?YU7".BK[Q@UG-\@L5O!.%7NVK7
MC79<M>5M>[*W%^WW]Z]ZLFW$#<UF<#2(#@_NRVSV#K>CG8/#^S*;W:-HT%^A
MWILBV6^1(,UW7U^.G(-E2TE/@HK)L:OQ/$ZEJ/I"NZ:ZFZ:YJ']X&!VNRI([
M.N>=P[UH>_>^4-UV=+1W@+G:]V0^@^C@J!\=':YH6!MFW=]$Y2^J;AM"S!O>
MG:U[<DK=/.KS.-@_B/;W-D:SM\N[W^HB?)QDQCS9\*X]/MS9BPZO<]4W/I-]
MV,?^_LX]F DPY)UM; UV+^9RL#V(]J\C.I_<)1^N*-8K!&V6(#P>*A./.(T:
MV^Z0<_5;]F_%*FG;NGYO<!^HJ3=8,>5N;!;7W(>]%=?0K<_@^ASFOO+DC^1#
MPM(!F _&TM?4V7BY)+R3-T;UUZ:Y_6AG=R?JWQ\K+]H]VH^V#U;\,7<VGX,#
MT'!W[\]\=K=WP KXRO-JYB1]US!EOPY_?RXM$L]G&J1)%RK^;B)4UW6]MX?X
M;."U.<U[$K[8O_GPQ6I$\R96W@4W[RD%=:O]L<)]^[LM<8[K*YHG FN(2/R%
M::[[#N* _?WH8%6!_S[B48/=:'"X8LA_%W,'%7YPN'++;R^4]FU64J.F&;%3
M1S'"X6_>4]+?/8P.KQ-HNP6OS?;>;K0[N \>I$%T=' 4#7:O[P.XKQ;X\6A4
MSDMI6D5T56Q\\[:C?305#_?NPTEB8<M>-.C?A\D<1D=](/.#^^Z8//=Z@UA8
M(P;6W71 (MH9[$?]_?OBA#F(!D! 1[OW93Z#@[UH=^<:'MK-NCP:IO_=HP0/
M!EW!E11<'3S @JN;I->54J[?O>*H72F.VD0/:R\[^_VK\_\*7QZ??#A[?^XR
MLS?8/GNUD.5VFG7'OQ^G4K1MFYNO #? UUD"3P0JG &3 R5EFFMN%AN;3[VP
MM::]5LJ.SV'?7=M[8:@3;$:83345G!->:]6GHZ4,W4&[QFFPI@I]+LUL:\O!
MTG3J0$BOR/44>[EC&RX$MW#X^@+16E4U(6R^JGH$-UJJ\%P0&A];PV\E6?9)
MNFL4S2:^7BMYW@,,EY2I- PA;']Z=B2[AXA+"MY":/3<:!2[T,<(]10BI%,>
M8R-@BS:;&1W4*O2Q2\&<X3B&A/*T9H:\8IY2-0 ?B^T^0B=!7</HL0FYB$,L
M4SNN\-S<JH+ZJK R67^.3>&O3R4FP\8<H+,0-@<UNJC!W$1NHPVN)7,E5KWP
MU80P<X1$JDH_F0%M6K(,,M"F<^S74!NUJEVK@#\8 LLV<ZU>)9,=(KQ)/M=C
M['DLJU!&<VL#B_7BP(*;ER;@0;"I!TR!R_.6<$]P7Q+LP4GDCOA\!FYD#%H_
MHA];X-\E]Q2Q9-S[]6F\<0[4$C.X'18TK-?5TT.P;QD?QS/&](--9"00@_UX
M@=)2VQ75-NQV=>V;9]9WN57Q[\\U\PELVA*2^@/_FL VF<CUYS E7"(L9 JX
MLVM&O:IJ(&_5U6+J>KC;=N:Q H0OXN8W-;P[#\XN8#@[X]"[QCJ)@641ZUD@
M2U C79*!)VRT,5;]&;OY]&84GXE@B1'2GX&1F3G,!1 L66X9;%L4C/-R6AO:
M]7DG#EVFMCM4KA#NP903=DD5/#RU*./V)RL+)K0J[9":X.LXK^;)S7^IH14(
M3'1,9#FUGL^S"Y5$%;HZ<T]FC?#WTG:%D1\C20KR#&U?F4[419;SM&&KX1!=
MTR#;3<T=$U8R:V:1";#8E,$0XSS ;4L2S3(2I@1D7"SQ'2O#]T+OIN UL'>%
M]H?V !:AAH:T[XS%B\^-16A@LG'[O:KM*2).<;<>ZD N>#CXF(^5N(8X:G.E
M:3D0NK&;M^M/PTWC9$X!@K?2X6 O,+GIMC<3K,.VX;$+IK90+2U)7[XX#KU#
MIKIN_#EUTR+JI/)X[K)54IN=9&EQ\,#02>)B&3AR!$$(!"&(JPM*9M5XF-(Z
M1WH R=3@<U)_\4Z @A#^*X-_ -&D")4GVPF,:A8O1%6T78IXG3-I92H\$$$S
M$5 /3H!(J3IIFB/U\"J1QFN46MUWV()_60P_RRZL'B>G4YL@Z0=O"$F3*^NI
M^5(Q&^?Z<GV[+Y](%!%RAKC3LC\6VY/4'ND(5[_O/.<K=RX*8UI $G^"HPKL
M/:7;$?I]#;V+DY&"]Y$HA\ 0#37=1-7%]?L2L,*V^5!K6[N&W!V\NTGP8; R
M2SB@*(S=.BO.-L[ IG=MW9A9U.36PY17=3%O3S_UI8.[ $AH 18_S*L&5EP2
M <+&(.>F!E49MK^FSR\KC,JLUAX,S!HTBLHAIGE1,SOYU54HEI<-0@E\0D'N
M@7BP#7KA$Z1[-HG1X;5\\!H(@HO&8[IN7+:"+9K3I3LPK[&$MMW) H;O.!L5
M&<)$<0G_X) 1#:D=)0*55**)S@]9NCULF.+N.U10<K4@>6/<R\=LV,VSL29&
MSK/@1KS8L12$F8,'#IKPP$;G%R"2'?:'ZW+-(0P1>@U!5Y.!JH#?.633\#@!
M2[:<SHC4*_#5&H9JD&)M/G*N]N9VTO9W/:BQFS4/&.=CLK9BS1)-L%^KJ^'.
MR=<(9*<"VBEY)3?-:VS:U:\G8S&)79])>X35\=BK1Y LE64J9C_P=+=[P8N2
M.B CY5 S04%]J2/%L%3"U>48M<1TS]K"Q$X-2>?SJ*%!0#;2D #-(^6,@,"S
MN<Y[P4=_]BI,]92K5Z9@SANY([16]PUI81-T.*RL4A@.P_&TKT> ; 9')*P\
M5TL@MXC= F*2PV? U?)BJUR@AT%OV462\(3;9Y ,V+%#^IZ:8\-#]D--!%.1
MH1<E AS_FR8;\3+,+,N1+<-#23R'[VDA@3B=C*4I6*+)TE0GOD.B@L>&)X$R
M1L*HFUI?+WRQWB(HE@N\9LERE8T'0DOCBD[:[$%\):J UB[@KK*B[SBUG,@Z
MJS.RAEI:=3 F"P:5,VS(B!!#P1H=4]00%B'C2)QDU!AY5HDZ'(E.D9D,F0?>
M:JS6$DZ1NM*,AU/,*'V!1,IAB'TR\:6F',&.FTF9D/*"C<(OV+/#THEU1JM#
MDBH5SS)NJ$!>1/X]J\1#[?R>[#M,,"AD'R7Y'1II2AOXSJVO4KA6!2B*67<>
MH$C&]1MFM4C["EJDKB\Q"D3-&I*D'TF7ZX;.5?-CH<G)K4RS0M2%=N?5PQ3J
M7Q?^VN["7Q+^.NS"7_>5HLGPJ+G++.]A&Y*XD/7?!^R_YU #,L>3L_]Y]6)K
M< 1G I)R'H\>O%[_H6W53EB@Y,]2=G"A"NL>H$UMB7ZP^5SAPEZJ95TM&9:%
MT[=)T2 N'=4C(L_N?+>_!Z#E;VZV>>7/;PXA^#__XVC_X.B7.\0H/JO\>IZ;
MQWERK"'34 [@R2M\>0HCQZ1OBJKA\Q!@UNQ8;GKO["S0N9X5FKT3U4Q\K;GZ
MOOYBM/52[)-5PRA7:4.IQXE4H4BT#T=E0FH;!G39=WJ)^*"D>*Z="^ICK>^G
M9:>:E2M0OV&$$/M35:H_[M]GZ:* /=GA6L>9I^DW1VY"0:<\/(:$[*1NI*_!
MU]Z6FW[^3N?]D*XU1ZPD+6*XE-L !BYVX@TO*6Q=W1#?Y]APZ7C69\;22"))
MU6W0$TPL,#88)4_;Y(BQ5@E!DZ.9[,)/%/D19XGG4W)B=ARK:0HF#CU9@"YH
MK8SUL.8LG1Z4++R&=MX0F%=?G#6K"M;)OT<K.)57B$=.>-SH);K5^Q-HT=TF
MY-I ]QXE2DDXRSK3I,>-+\VP+[2[;T#5<PRNJ;8,+"\[J<8LB+8W0M@=#?]0
M-%QY(&? AX$#BY>JTFJ<5UOXL7/W=B39D>0&K(W LS9L/*=)@QWI=:2W8=*3
MI! ,.4RS;%S72-G8$E>Y->0Z8NV(]39%M^</08F-CG!X'5A&ILCC86F5RY4D
MOI786XL3AAV7U2^F&I0$F.$TIK"8"C%B2_D*DN_E##=JLXA]2B@5.C4E: H<
MZ^\N0G<1;DV'?8Z>BY-9!ORWH[J.ZFZ8ZEY-@A9^BEF6S&TY['^>E4",_P5\
M67%P!B:%MCVP2TEZ$/YH&D]C8_019UY4>?L=]^SH>"->K 914DS#T=^D(<B]
M,H:Z$A#&A9Y3. C(-UN4G*V-WF2#:8]FD1FBGC@=97-6G"G;;:Q'.::7C .%
M0THU ;S7N7IM(-44>F$H$3VU*HIW9U)0TX$6TKDL9E3F0_[9@AKKDL\-%1R8
MU6W=I"L#[/:2W7)L_.OR57:Z?!7)5SGJ\E6^#_INILU+HB(WJ7=)CYP'%XBO
M7BI4_D@IEX+Z^QD_K1U8R#C&7V'0%Y/99U*R+&EY/V8R.VTI;H\M,1NW%=51
MS15PX$"VWEJ=L9&:(3RG,?R:@<$F\!^5+NNYXER,%]DTZ=J1ILNKZIW:3K87
M-,JL4I1M66G65F<K8S(P,' (/TSI+W6U"N+*[$WY9<!%?U*:M:S%/VV")OZS
M(!N^EJK95A1D*YFN2,^(_-H/;W+!:N6';:"!YOREKA+M:0O65912 _LD3B7?
M/Z;ZR)=ECO?%K^]QM6=#4J 3>!X645.K0;9G'/SRTI_HP"B#&">%&52FR@_F
M\J4VQP7&T^C*CK(RA6GQ1S4_GM'Z$T?C\#@J<O5<>Z: .?!/E52_<UI7QKQF
MQ.AVF"CB*ABX"-WM)1$"K(:4'J"(908;QN?AY\]PB1[V?Y62Q"H@8W?=F1WB
MOQGK1"VQ4/VX4J2B;ZCT:<_/#]87 #W8W-YC+PO/Y?\W$O&\)#Q;=.!R\"(Z
M&B_%S_,ORYVI9_Y1%<"*+'FPJ7R=X7=7AE_6&NQ(-18Q8(&-K=IN$&I5H"IR
MZI?.)]&1YLV2)N9(VW(:+-.OZQ).H^DHL*/ 6V6.?M4:46%I*FW1*N\U[FB3
MN!;Q0MNZRA5CI*/?CGYOF'Z!%@,R!DQ8#_SF^B*&42B9WE(R9M-7Y.I9<AUA
M=H1YPX093["\M(V?5HS4D^U1TV;2!DDB-IBRD)9HD7$U,W<?DK0' G6KJE$L
M-@H^1\4HM9\&*S]UM2F&_1Q_EK ?DYA\6QY<0'<[NMMQP[=#_$X*5-]%H=(*
M4;!3=3N:NQU5MV*P"#1$?BMT AJ5B%^0:91YZ217P#=+Y*2Z(\V.-#=+FL $
M"^M&;47_ZTBP(\$;)D&,*0&W0[V0P9ZJFEPO3I?JR^IO"JD1[/%<Y]..+W9$
MN0G_J,<7$=M*YYC]"L]TZF)'>YND/1>$MM'Q,(DM+8X2%<\%J8'!81!=*^WH
ML*/#3>N&:JS_+%6!T$2F7"!>AF0F(/#@93'[!:FRH\*."C=+A067_2$'S#7Y
M.#_I907WR$[.E'#__*0/9V=3UN!=)B;?:^B\W2X565*1!_TN%_F^DK3#SINH
M.$$)U,B@::2[!E>DNTJJX'RAXKP9"7&)?,!D' CP0T\Y/I-,XBI@>74*<7!%
M"C$C#UUDA6T@4V%O+?(89@,2P3L[3CSE#E <FO+@ZM=VV*#TXMAXF<\59K4D
M+.N5!)<J"8M U$AI*,VZ1 0!6Y/@60T(MTH/IIQDS*YM3?5RR<+5<B/_797/
MM_96]\IJ5SP8W63I$/M=JK:@(?(V!][%4%4G*6N\NH.R(WBYTVN(_V$2O:UG
MH.YF7\YM#_Q\>)=H#[:9,1S%E,HIR:!6!,]<=?.X\MA_" ;CDGAJ6/6N*T[.
M@-9;0+KQ2 =P]8=P?SC4["#-//1G;[N!<H?\:V-K("0)OKI8U>/43X1TE;7=
M6;BOA[O)@==!1R'X! $%8GJ'=CRFGIVOC45E2R=Q/G<]?'P&:]2$6TDX-;47
MGEX0]B&A]>/C<ZR.49P-#T,$B$ROD7*D:1(%SW-Z?*43#G4!<-6 *L%BO:7#
M"F^L>%COAB'#VZJ VC3H=0$5 'Z*TXKU6K0.R[0CVW !WB3 ]KCH(C:8)$#@
M[BIQ/0E=U4)M$[FK'E4G(E.;P_$7W#4 -J]8!K)]\/QHV0N/)5L,\1LC1QW2
M&\]\$F9O2PX\WLCGQ2TB<CW!C#*V-<8(L8G?NHJ.&4E)H-&L--2&40IT>L$'
M/EZ;7LF$A0NHB16>S6K3'\R(6 55MVM@1%ON0E2711\LR\'>?U1N8L_!?[R>
MU6%G:>LAZM]B(T(J@WFHS(@9_\<ZQHSMMJ0X&V4+LU&6#G$F<(TGLGRJ4NE.
MX'?68O_P.G[ U3H/G<O[C4:&P$'TA>L-$#D^U6AY$05.@QFI!2OB@GEIM];?
M5ELG1!??P_M?>0!X.LS%Z*@))F0/NDHZ^M(QFY5SCB\(D?]+YQWZYHHM\K%_
M3J2XJMG9Q'^S+WBX+28ILK VXCLQ,0IB'<@")!_1Z[$)\M;$V+\ 9 *\EPO6
M6OD2:X7\*RL[F5TB$Q3=IUIMEJ]HUZ[B2Q9:NRAJC#V4@)/#:#\&7]$IU</I
M/*P21D584$<;V;V =\^J+18>5HK8&"' 2!L;&LBJJ& %Y3]$+2QWNK6-==IW
MT[?V@A5K#U/*?5HGH6G<4/@" 4>@4+1:K4USJ")TJ:@A2X'7@YZGGBEV%O3R
M$&\NK)6N27V6R)Z6C$./3V"3*)6F6,!9(49) V3W\JPL/+B((L]@!>?4H>J+
MK TX(947HO,^67)_X:K!)#60(26@J3?"N97&MF>V?(=4JMQU,;D 4YY*>X%4
M;5NA4@"VW7$IH=HX#2K&4S/.;==E4VN:2)L*'!YWO<9HOG:C3NIL*D KKRKI
M)&:EL<D4E2 SR$9U_+(TOTB6EY/Y;JBNBK +@-QT (3N2M#B2^IBOAVQ;8;8
MVG"W;!H,LW)BH1T!=@1XPP28HYP/JMXE:#!PKKYK-NW00:C9'^$G7&DYD<Q&
MS/=XJD@W6+7/0A,3&(UMV8M>FZ"&VVF[$I-*(]W$$< A*V(Q:V#0"V3/7J]'
MA*B@[H;C&-NW<2_B5JN2-2\WD^YB=1=K,YP]3F'DHA1GI]0J#C.5>]6*2K1M
M),6.$CM*O&%*U&D2FR(P9<Q'"U8F]^=%ASSU@>*FQ&P9=WI&1X0;($+T- >.
M\EQR@;)>&\Q5*,H\)3_ (C/%ENM_)-!#6^6BH\N.+F^<.2*J75#%,% =#+,A
MMCFP+D6LTLI&&;O>,Z\Q>\<\.R*]#2*%4P0[1M)@F(=*%![I<:3S*D\#&UEZ
M[=!'69DS)&1'G1UU;IXZ,>DFB4<69P*K"!&KPE88)NK2L*QWX=*.(#N"O'F"
M#%1H2DQ.(EY9197:W%"_ $5V1-@1X4T#G]C$+D3^<Z3X9XFXM(5D,?IIB2.5
MCN,QZI(<S26=<C6-Z8[I]*^/_'4%,GM=@8PMD!ET!3*W2*AK.-T[4;]UFF<)
M-[4UG "J_$B$Y$4$-HF#\TUL0@J">:V"@&), @?S.I91FNHJ2#.GLV!I/,%:
MJ\++:K/V0=6N) J$S7Q&1&=N->^Y .NFK_3T@57'M@0ZCRE+)+18V9(+PG4A
MN&:74-?(%A&DB=64*R\B%*O42(8R-[F7F=G/%CK':!0';8Q-:ZYPP]7X K8;
M:,OQ4\JLX4QM3D@<,V!@XO)&U86*$RH=40DL#3/=+^IP[+CMJ+M27GNM&;<'
MAC&T*>Z2O8(OCU.;K6UL/G<5"^-^]0\Z6XQNPFK^'9J?=>K ='I3FH5.QRNI
M0$#X);Q=R@9@2S4]1M&\*G[B#MP+L7CX]]2RSY);KH4B)*-3C^WP3)$N1Q[D
MK[*F]3Q+8[AX^#-Z8833]&L9SJDK8 7H3SL@BZHM*<Q22DB;9WG5?:B1'#5F
MGU)+!IQ/F%F]"&]]R14YI$8C$'M5HBK< 8VWI8Z>28E?3-K L-PHUNE%K^?(
M;[;FIC>0"2O5VB\4X30_!MGB8YLO,A/;43WZF&7). K*5##Y4WL>L3&EYB82
M L6 ]2A2P@'3K!4G5N4*"HX^U9-84@RQM&KJ2H1&,Y5..66YZK1$@3IGH ;T
M0LZAS8E5A%Q#05,A10+G+]7Z/LAXY2M<V;('RP>X/J\]:53E^9*)N*BG9P9?
MR&^FW$"O!,RIRB*N*K@8EZ9@&CB#WF\L\YZI?(Z,@/H35)6HF/@]!8HAXJ%\
M4Z0Z3D]-EW(#3(O>;EP_%->TXE754B.B7[>FT+:P ]>]I)&,'(4&^Y.-L\NT
M?74K;4M<E-FO//F7SA; T2RX3A-Y!\_-53\B3!X5^ZQL2B\\]C<D&W&GD)'E
MA+7$#-SMU;X059=+9&6T48U=FU>;'MAD4Q+!5#1%/)G*9XLL\C)>*[* Z7!B
M2_X%]<N)+V13<P;>D)%%UTF)U[5W25Q+;0_VIE=5X1[Y\'GJ1GL>/.I@]4ZQ
M7#><-NUQ2"Z'<%?:P\W_RMY*[FISEQPYG,"[L42#E=RPW8E(>;#OE0H[[AT#
M1('%ZU*-\D-5J3O6VE1(5L\_6#W_5?81"0'8\Z_JK.LMJ-JN6YU$;*E+.X5<
M!4?@^G851B<3JPV96@<AE_\;^>V95LC*O_-4&KB&GH,&/;?($>]BM.J#EB?R
MW%F[I99+7OJ]=TA=DGSGW=P 7I]?6]R"[ZQR-<<KR.I;VR5FFYQUY?:;T.0T
MKH[=L[.C@+$ML.YK3/7'6,D+%XQLFBA<^78.*E5I31ZN-79S6ZAB=@D:6A>5
MZJ[,K5X9Z=@XQ'(T]JI%Y.&+*O0#= ^B DLFJB_O&IIL)'@$?NI*57".,,/Y
M J&\J,H5AB"?!]DW;=6^J^98=S>ZNW'K=\.%T$9+Y^A%NB6D(H+-9A)N8@'X
M1>NV=KQI^6'-(R,L,K1&.9S'QCC'%"[C!3J5C[FC)]NEGU*TP1%M)@W?OCAF
M& GT;+ .24XF'P'H*@='=Z.Z&W7K"EK3CD[4$(X;Z7:-7M9B]WW9$@_8SNHH
MO*/P&Z9P;%N.G9>(7;,[!OAP6"ZRM.'I:]61FNA(Z.4!*B#/) J$T4R/RP0C
MK!ANB U:!VC$QT6A$96)7+<$EE<U>HZ"570!JF #:X>" PPE,<*PA3@]F@Y$
M6,+=WY7;3O+8[Y(\;)+'=I?D\3TR==B0J_GZ(]FS:_%IX9:M')<W CG#38RW
M45G0G.%M3XFQ[3@*-%9^_+JF&:UP]R97]Q'=2.^I[ "G]5.W=)N:X])"G$X%
MQOP"^/[$.:T:K?TXX:^>$6@HN,5A<M2XR-F<:_S9:#5UFN0$DN$/JE9MY ;^
MQ0MW]_?KAI'A_5 /PTDN*:Q-J1GC,%>QJ<.#4N:5 97,:&M-$*0CVN[7(-\?
MB'X[LV SAJ^/>EK!;TE*D8]ANCX>=_<*>4>E#Y!*$<Q.)8SO W1H-*+^<GYN
MO=<0QK.R44RYD43!'9EV9'IK9"K>#")1RTLI5,I8SN12)(F_BNE*P("DTV*S
MAV%"2="2I>LG9+<X:#IB[HAY(XW:!82]@<"+%&CS<H X-;!6=H$O9DO#50JU
M\@10A-'J0U5"LHOAQ7Z6L"!4E49WW+HC\%LST/S6762-^4'(D5K$!4'DKF*\
MQ5Y?!IL%Z5<75'"8':/NZ/@6FL%RC181<\158-0ZPZOWXM0MU"*(5@T!$'L5
M73;O4FK0JA*NCF0[DMT R;I>,JF7W>L:#D5<2<$A0-_WRV5*4]:PJYSICD@[
M(MVL?N#:HH$&S+5#W $M3JDMD_)RUL'^NXB)'.:MW6RH("<VKC5&P7X*K@<J
MPFF6C>N_#!9H'\:C3@_NZ'S3=,Y(K!'EPFI)I-5872IU2I@12QF$)2?, @N&
M'^;Q=-:I"AUU;IHZAYPJFDI1L4T>(AA,51# 1#K!9[B,$1'>7 TMAXLG,67M
MP5_';U\<&W3&4:U5/")^K%+,?S5:?ZIUNRRR0-K9V(?1Y<QES9-FVE\]',[9
M)0P4\7D1YU7HA"9LNL[DW<6YA<[D%UD\KKN=$Q7/C>";K-R<;!VGOX@S*?7_
ML3J5<ZD^5K_Z3A^IY2;T?81%D=:,"(X W$13AOQH!BJA)N"$!6(TI!B94D-X
MYOJUB2U=F+1T>?+0 WQ(':F=)RR ($[]5 2O0V^M+'2=\[47'A,V!A ']O3%
M,)NT/6YK1URU(JZSQ4L=M#3R=76N'NJ7*WFVG?@X!IWH)J]=:8_L,"0:Y<8/
ML\R8:\I=@ZUQ5O59]@K"">&G;D[X_0MM!VNDO3*UQZ(-7N38S!HFC+3<I-])
M3R_NBH@'@1@VP#00EJ7^JZIA!ADZ_M<Z#\@<FBEL& N$Y;+!/.R8AUXO?ISZ
M%[&V.RLDC^  :UNAHNYR2:W/Z' ^62P,'_"#A['@&U[GD'KGN7?8UJQ*L;,U
MV%8S@H>#+UQY-'%7T@>]!.ZKV[VZYJZAWZP3XU'<N62,2$@C$$G8-Z(^3+T]
MI]=U6(W^+.,*1>==!OPB$PPO2_"V:WN3ANU\0FEVFZ _H.H$!SH>IBB841X3
M_I;7B=@M'O8#Y,*2O*_(2*E_?)DF!)O@F*F%Q&&0+'C;HLRQC)>:/7/;Q:%N
M- V4;G;I5$UUH&IB_G*6T>7RQ$1L&FMKZZI7[T6HQ^Y8>^'S)37P(S6ZV8?6
MI]THL!V7">7%PE)1S4']\+FM8&:DX)*:' ON3-6<QE:L"9)*6_?;^M615P>2
M4Q<C;\-E_0D*36Q_E3'B 'XN90I$*C[24R]\U:161.O*8)>0X>+/Z#=V7,1"
M&!/FEC3#Q [5)JBD%IZJ<&OWXV;&JW!74)1G6$@$3R2Q%>(XV2'U(K+LX5+E
M<(9BP>.5!]8"^D=> V%P P06(FBLYD Q]:Z!JIA%%6R;WV\2MX!09+B4"<<8
M874&84#-8[.:E-L+W^LI[$0BW -X$^7ELKP)K+0A3J58(P5AH1"CK(5"^%P6
MI=3S"H$@P A=0=QLV;4$2:F"SL$F][R07OBRS'$*%@I)VNG63M9)-4XBMGMI
MQ..'P#=)-B(<^P*;01J8&,+X#!7F<UI\EC:2K%B!D'D(N@^^ _:;((H"^X6;
M***@5:V!Z\H3]> F'F]T<J&-Z_U-E#_5"*QXD>7<QP2,5H34"S]J7IS7&YQ;
MA6?PF/2O"M@9ORJ&L*U].<>_@:2W8'Y;%KRNA8=$]DA E<29RW2765F?J--:
M6,^;:RSF!JM'Y8@FYF!#JNFM7D:97CO#>JAJP]>5#1UT94.V;&BG*QNZKR1-
M)@W;VB*CUFD79(L;;CP^7P 7<^W%UP=20A=(6<=2#<K*FA8+["UF'4%4M0;S
M@5^CJ6\"%\YY^/8*[%&-U1+RZSKXF: F&IP_8 ZCX<Y[6SENP^&\ZA31.$C"
MM:80 \H2#!=,PRNT((U@KHI"NB=G)2A^N@;=F4N/9:N7,8(>J8*JA0[#!ATJ
M5+F<%]A'R&2 8:)3D/FP'[-X&%=-NJMH-QM$3(3-32I(6:Y9XZ):P7^6M'"U
M1BM&D7J95O95<.QCN@VU@UN,KW<&XH8215' !&EY"9=BD=>].A2$(+3E7T@F
MK#4&]:<>KLRV#,[5_%B0&A.^C\VG\)2KGR4E,G@3%Y('')YSZ@/NX0(D[2C6
M%=9GY25@Q"??[68A^;A?N4^D!-SGQI) !>MK;:Z]0&";K7+_T-D<PM*]1,I'
MYL^8)O6<U6,LE>2S.P8C @YAN]\_"*=*,F:INE$0CSG)D*U*N)LM9QVNGO62
M>8)_?\72)TV:M&@_JQ8O$H/U$OIRG"79U.(3DU,7&-VECJ<SMEQ@#H*^A[-%
M+X&4IJW.KW5NQ" =C@5\!]H/+!:LZ%&PBA[8"Y_7**PMMW@%O!;_9N=X\8W3
M)"\$"1M;@V='LD:(]9@"R[,U(_C(-<8F<4!PU0TOG>@$GGLMN/Z9TXT$)CXI
MJ(05=TE<;EX.-CJ#OGROEP^<D9[YFT[[X;><J_R;@?@W!1*=M[9&>+$)IYB-
M]N"YVHO8C#+R0V+HKW("E"F#-*TZ MP&HZ<Q19Q/;N,WOM(J]QRZNN;2)76%
M@DC>,6#(2TJV5Z /3=!H_C+):DYM# U%OK>J%3/=#X[Y=>&^VHK+&.?JLG)0
MNU<"'Q:_.SJZ'^RULL*@_4"F8"?'I/+Q)0M(IM&5<D3BG:Q?GN_8/0VR]"(-
MJ%&CGVBF*]U1+ O3QEPC$EZ>3 S8+R>IHVVAC2R=9HS59-5P"V7+RBM3@%[1
M>Z]G24K]84#UA^BAS/*"W^9U"ZA ?1.G]#/:K_@[X<-Y5M?Z)WSAK)4%?Z$#
M<;O_2S:9;!%: OT]^ 65:$.N/7*K(BZWMWK/K*EV"A[(+S1L5562QEL_L=C?
MWCYPF-NG"=\[CMYX21'CK!MZ5U#U,'#>8S$TY/H/$7N<-J] _TO4%&/\UMHN
M\G%QTY<50[Q.!DPUSNO> $JWJW4.QG8RQ[=9I@#JAL<NFV[&:I&ROQ3F(*)?
MD&J8ZDOXV5BX+YEQ5!'(*.X?JOFHM'U&2[MZ/%ZK2;JX-Z->NO(5]KVZSB_P
M9@P I09N8!18F#^TMA$R']5"Z@XA>!V\,$&-U6.FKH?*\5B1^"@ZHG VVC%I
M:>*7P(-^79>(5(]L=ZPB0&ER4^N\X]<H^\SGJO8"HLM45.VSU >OJAR;RIG"
M\53?@23AJ*9X"'A7#>C?!4V!O\#L!H2*Y6B(WPO%[Y&"0377K43.ZG&N)XC9
MQVIV.2^YB 9Y@&F<ZY->>.9%2:J0'UB-<@W)C033^P27+\[!,&3E'PP&)8N1
MH';5L&<*[^8Z2E%L*+YB)1@E L'T;!>L'(TLGB332R#AF!X8LTS,<RS_08]J
M9-N/,#>E K@:G;(2+>B=R/ZQ:P6&P'%[D1W"H1"QY^Q$7U9!,#P3/^B<!K6V
M!7[G#=BF::[ 0/R(.D"SG#_7(E/Y!$IV:O#'$GTG(6<;1\$O,3+*TM@"^8[B
M'([.$*:C"4#VY9G$V>."T_NY_Y!VCC0TL." Y;Q@8_WD*%%8Z$%5UZ(10PDT
MS7_C(7NM>+BM*PMITE"0C0?#^B)PMS*B\V0IBP8Y/8>[4K5 K!V.X"<UW(PD
M,JI.2RY^[796"!_WT%.+V5+FJ*H_*UB1JGO%:15KHGH4.FQ<UBK.QU3>I'XG
MA6NJE.';Y#'$MBR39A@8^V'5C)0F/6&;EW3I5C6I+^RY7$0;HDZ!FO)DN66P
MC$Y2A)?-6/1*6QQOLA7#&MGD#=>TCEI<$90%LA,* J-S^5\H.K %C!KIDE)@
M WGQPY7"7Q7+/.QBF3:6N=O%,N\I2:_8&RW*BN,)01.UQJ H*(T$'EE&KS S
MPKRCQRDR:7]3:3'8Y3Z<8BVO33)Q(SF1+:WYN&$<Y>ABV81F@[R>>T@&!T>@
ML-&E""KD[9:#7^(OD5F!-43P9JL=-HW(>6]5+:(^6"_J)5T(Y1NE]GD](QDA
MI1+FR,LY*<LA^L\='"$;V%7K+A369(E5P@)M K:GT:%@4[0JZ:S'7R>%22FJ
M/,"@*)+C@0^R_7>NG#L*K+\_IQP^E9*VH4S&:;OHSE\!/_+L!8X%61DD #.\
M &?BR@XI.I4D*QZ;)ZQV*"?( IHIR4[?02:5NBTFBP30DZ1R%Y+BH1P\3DS[
M"2SW MO U1*?5+J6^@/*TDPKWU,E8#T=+$L3ZTJ'2\H6< M\9-T?!"_$^"H;
MUW;T*O^. B>1[_,(I!Z)]._64Z3]H70[FZ/GI;*1K5["B8Q@]^&1!ROFCRN^
M)D<YB5D-QZN@\]3:N+C%=,!I$VJ.2K98@5O9:.<BX<'IY,E5U%37UK358Y?5
M0_=UO+I>[490::Z>E9B%W+$5;5PPHMF<1D.;O1]9JJ5S\](ZU,.)'I/;DT"Q
M"C30$G59:R9$S)A;B@H!Q+FX]3%).F@K47#U*_6P5]O07K4,,!Q=ZU<&BU&)
MI!P\;&_*WS4L=(:-18GK7>#IP0@-S":2XM)1<X'M(97K"95GB;8NB 92,#$P
M/_U]74*"EX#+AXJLV$_QJG ?G 0)O-E2>@OJ*#46/<PS-6:GK!7"DUR5[)'C
M;.7*>3WS]J&5$%WR\XC;XO*2 \<S,#?(L0Q*O)[6^F/).+-X494?.%\-KRKB
M1+,:O$6M_ K=ZMYBJAL4\ WZXB+P"R<WR3]"F@:ROL(FO5$>CN9NH.2>SY(D
MN^QZX'7UJ#=?C_H!.](Z,B[BK4_QZ-,0#6XD:*1^5&G1K, NX(G[5"[C)PQ7
M%)1NDF0IYYZ@Y@!\H<2N1.BNA5%)U4)W)=4JLIL..!G+"M2[L)@DH&KQ923%
MFH82H K6P%G3ADN9D]K +Z%_YWI>IH(W$]40P.*4_,ND39;Y:*:XT^X8F5RB
MY:^*8W)P*H";-Z=Y@T9TP8%$<<^ROYECT Y";U)[DG:%[:)X/L3\_S'YMSDA
MAW=Y5N?WZ&'U8]UOR$<GT5/^(QYW" [=Q=_@Q7\)5U6')UQY?@R7BE(TM%>:
M1!5E*>&E&H2@GF7>=>;F-7Q1R$MK7+!4GK=L0 J=\7%L=#W!]P9<7\18$4M;
MYU<ULJ?*.Y"[[ZQ&Z-("0(AK5G(Y^[OZC2OH8=,.C/4$-)(1L"5/L\37_+07
M[?7[F ?VTV 0]>&?"TH=QOV@>;7%IYN[M4"O!JH9;GM0[<7]2?1X2B8MJ3U1
MZ(>L*-GYSS(."S6'^2%B43R91 $U(,:>/:1 E,@!,0XU4\G$&L?>YOAE6=5F
M.YV(FXQ+3PCVM,A4J,HQE@ $6\FQ\8K0.1]Z97[X4*XO53ZVK@S%GA#"L[,3
M1*:*N4P=W^KXU@WS+3:7@E>8:DN9,.^RO+!<"F4F@B*4J?OH&)U(KL_AWU^]
M.SZ.''_SX)Q]&3S'0M&"VZEPKCYB;1#&*+=(I'X0DK^(#LIIJ0B'05Q7\84:
M+=&6&)6Y<W)BXJW7DK'2DM!5B]6:\831R41!\/)0NFO47:,-B/_SC$SE<TNF
MQR-.M$&)@GU\=8X>0;+R&5-)B1W:DL:I1+JRIXEE+-;2TP<%NBFJ?M816,!P
MU>@FN 1.J_>&OMYK%636+2BY 839,$Z5UPC)Z$JF=ZA-W6W9P&UY [HO>W@,
MER4HH+=LBM=CO><T8L^GLL_4S6O.O'9ZIJ$A2-MD,@?[E/UJF)?AWA&PY)(,
M!4J6KF=B4C"1U#S1[7G8<QS3GZJ?K%C/:?#PUAJ)GS8#"FO6$;[!)M16/CPO
M0;66B_I#05)A<HQ7NE<K/TR7%=.2$PHJ__N7O(?$!5<>0G 2( >8!,PAC\W8
M9="S;YT)%NLJ=5[+>908#",<6),A\IRHF+\JAH^D\*/_V*'[,C:U,K-P G+A
M 8=GOBH)YJA+@K%),'M=$LQ])6F*.-8+_U:S^&P"NBWT^2.EN,0Y"<+5&E8)
M7;:4"E$[$L5Q?#"HL,"@"KU(,*JUS/_!1_]>>0YK.0#NH]7$.X@;W#W(*H2:
M]K.AQ'DY$Z,7BO#\JOP/5\;E6@Q8*>54?_SB G1WKT8'3[4FVH,/,]UZY Z=
M3(H85B9IZV[0_I5\FU!2/VVJ04O7,%J/J[LD 91BJA%FJ01>GQ#LT(C .@^8
M<"JW9(RWE]#J\'H1W%R6)V-0SQF?+#9!E:EEJY/M)1]ZI1(3BHA([((<C!Y.
MK@=!N?(CPH&DB"PY'.F64SJR!?/@@PLJJJ/"G#59.>MI)O,P-X?*Q +L6R#E
M],+3"@/S4K/ZY>K;/%:$8>/&?7%?>R57#DI,ZKK]9]9,'.-/H@G+28#NS:!)
M!"WGC8 E=-4H094KLW[QG"7VUV?TL15C!;W.!$&VCD?8W]@MK<#NJN=8X6W'
M+N7*IG1IBS7#5RWY(PTZ6=_0\NHUK]&(&0+,QUTD/YXD\:,46GU1(*GL7DH^
M58P1YL!,CZLL<^=VK\9UN6\V$?[!,J2S=60;44U+/"KI$A"OTO.ASJU!+?S^
MM$0L8V M\&,;:A%T-"F)KM)8"-B&XQ6NG+(*BK#E@AB"9$^SM>7(/W*CIGJ:
M%;$2<2H%92X PB)16T>3F%V%'LU2Q&_P'5HLZ\9P(XT%9O'FXE,FLLX"\V1;
M\K0P&3*0RD1\X^HU%&@'5Q31#$WEVO+FVO"X=<0N$%3=S<S+*T+S\Y.>90DF
M\P!C"LC"___LO=MRW$:6-GJ/IT#XU^R0(D .BV>V>QQ!T5:WNFU)6Y3'T?OF
M#U0ABX2% FH %.GJI]_KF < 19$V*6M*N)AIN8A#(G/ERG7\/G4__=. X#6#
M6'G:T/)2AU35V  B7;TP*;X7-,Z%A [< 46QQ##6,,]_DQHS;GC',;!"PG @
M[BRJDO'[_Q0^;ULWE;?"?)BY2J)\R.Z3DCQKRDO_Z)WF>]B3G:+%EW-3Y7 =
M(.@[6 +E<F^OX2>,-82,:I'V\W0  0:X@SIUI%2&3H^&-<;C9D-19+ 7>@8O
M9R$95];<T^KPC@TGIR!A7(]BCXY2^JE1XL./CH/#LP-50)UVE:^)ME9J_7I6
M'_[: Q/O56]'N6;T',AJ()@2)K4E-NA2_C;S6*I*@T"\=7N]]4ZC\]NMR[CN
M1G&]C1$%7KK60@7(&_UB>KL<N_'?JUOLA4M4Y7 +)YU0V!(G"^-CT0YA0T0Y
M F0UC/=K6Q+O>+'K3IP&HD,FYHVQ+]82B%5S5_^C:+L(_T;5QNZ- W0D0SU!
M'+! HR,P! ,YQ'NI?+-+0#(XLQ%&^U?:%*NEM_Z.H4@^UK\(K"_5=%3>S\X&
MIU0T(REQQ75NF0?=?G)VMNT( ;WTE4#R:P\I)5A4.PNNMO@ATOZ,IURDV1ON
M'\4;J8&)0:\574MZOAFZU\(*<.]HT,YN5Z$C?,&>LF6%*.ZFUJZ,))*-LX8;
MYV8'"Y^0'(09^?R>>07C_GH":*^"E=#\'!=\!%,C'FPD,B#]+@1[&$XI87B3
M6>,ZHS)&K@+)J/)LARM+"5QQF==L2&2&S&Q"#0GM\I20^35YY@#HFTC:,.0#
M4#C KL;6,6,C8 SN_Y"Q8MV)E/\S9$SJNJ=%Z.6!0O%(Z?=05.?=26VNR8^E
MKJVIZS;T0$$)]Z9PWDI %4$U:>O[->1%=UFMNW%OO7';TK@<,,I<O /+EDH.
MI*G G:/2Q91"0X5!;':WK/[2*/!#1(T-K(K!1<*]BO0)ZR4-S]W UFA+=<4M
MA79NC>$DKTR=G&,T<ZC!<6CQ(B\(/VA194RWLB22-[BE;G>PWHA_B);$94C=
M<H@!J1FXN'(]_?!/@7RWSBBE"Y>IC<I9UQ!=XX(7R/L$Y3_D#Z6"3U!_.V@W
MX+48;-N-?-8'.I^U&!,CM[<I.0B-@JTOT]G'](H+1FQAM(0A0^%0NWM8)!(]
MZN446Z09V/3VV ]U*,/XXZZ0*F[:.X$J&$#/U^-ZHZ+O R<R7!)Z7!*;F(KH
MI;:[EF$2X2V;-I1(A7O /4R8V)HPGB$2>>:,P]4G[8''6+B]/4C^>]GFGDUF
MC2_'4^!UYG##-$++9;Y9]OB'P=,=,P],]^[OC>E>3?<>C^G>(7$BVU.'\DEC
M;,#(X8*D/_!R[_A''4>RA47IZ$'<31CU:P7_B%"O$J,%1@H9[7@6--2Q:3+#
M-NXA7BF?^,9Q]DJB$XY)ESL.(CSJ0:E9'7T&H_9/J182_CE4T'#PLTG#[4UL
M+#BO)-(YZR+/TE%#LY4O39$S/&. \#X8'FCB$!P>[)?,A0[(7MMP( XB"6,N
MV$>00K/KD^]EL #AXUG+LP1Q&,P*4 J9A^N'H?_$<C99]#RVI4LA7Z&C"L4G
MS!9;;,N./8R!ZT:3R)GC()"(27]'Q(,[ DP@JGV+@MV EW &\),;@VE4NU1Z
MVIIJ:R;8SK&H$;IQKPA"88G@^)Y=T&_.0 N,'4],]A)#L,84?-0(K0[$WZ69
M1\<IC;_T)X_QBNO&I""0FU%*P]VQ^'R&!PGP7J5S><$N4DO2,Y-B8]8O^',E
M?[%RE6AV/_&3)&47"[1+>H0US_Z,6ZWGV*T<X6-(<*6XC>*%4R:CG!=8?HE+
MR<!3X'(.YS33E@'_,=MA4)E%E!'CK(?7:.S!@/I@VUZ3\MH1GF,3I%AW\C3I
M>@K4"")YPD*"A":!_2AY7UP8"W4?YC ;Q;W6U*_*V8P<5%<&>!^3=1IDUC!D
MAE-..&^PK:)@4S4.=VSXM&$Z3_(H"&_".X=HDP;SQ9N7!F'/'9ED28Y)J9,P
M'CJ:)F' Y'<0]25E) R&\A%&G/T'CA+IV+<\@O:+RB#RBY$<^9%$[Y@*D*#S
M?_/^7#NU)FM'B<^,=VMP;M3J[5I@=5E4(;6@SE[L*BRH+UF;]&T KC:P&F54
ME8)"M%!O;%.2?^OC9.'2L=YQH.R]<SMZH#.LM$"6%DQR7AV;I.X)3:]@A.2D
M:_*)7QVD)A%AR2NRE^"22>WICV:%S=?GSD_]&#+J$D:7&T.!9,K,$4Z591R0
MBX1^Q;02UIM=I\0=S,?HIGKOP6"77S_'1E;F@[^OL/$+#$+3"6!FPA([!-5I
M-XS,0HB!;%E<+0JN!,@(-[0V,E]=1$;LZR<52'$4^!N:#4RPB3.)"9T>AAG#
MBE)PD#.GG12I'I"^]*7:YA.4A<K)C+L7,3M#F'BF]O.26UY9$BMLW/^*=^IT
MP);KY]<A,I-5AP%4G(I'I]8+2RL&>+09Q 6$#6U7-N@%F,9ENRDSM200UPX#
MJI_]Y_-?3"6V'JBNE+"=HA#QR78>6/.ABQU%E53;K;+=:OKPTCVE*G+?1#U_
M<.7Y#YU:A*&"$.4NV<!CZRPBM]J=).><K"BCH7BRXQ57W>?Y<B0#7OGST/-S
MI:3%3U@6Z<STR\XSLV! H);TKP-.BGI99G%<,$"*9C<H=P1GOTG%/P+KUS#Y
MV*HE"X]4(!4B\=E1FWEAF"O6Q(@7V)N!M.&:IEH+E@E?6-"2M+ZE]P$N'N*,
M\=3;FZH?;5  QD(4M!V4* ('4#8# J[#\M. B#R28$.Q=AEFQY4:I)-U7.AI
MN&'AF;AS7:%ET!_@4&39):OQF0CL HY+9+DE'L)7WU]\QXB>AE5%8*??5O7'
M6-(5[(^;7O519'URRY:B#B*S=E?N(RR!]0;0XU#ZZ%7PY)I) @0D!B;S*BWS
M?VM#%T]8= <=LT7@T+ZQ<(0;X)?9:" \]'OZ9^H.:E6DV3AG<6_.L#/>Y7AD
M_XKSNVIZ,J@]E&[U##7(SSX2<D2=15I1:S>N*KM< P.$]-Z  5KX]0VT86&L
M;E/GI:OSE!@##Q?F\QX?N!M98#0_3@HKTA8VET:TNSTC.MC.J5_J)N\U%J:D
MMY%<3;%>RV7(G7"%5PQ%%9]-:X-+R#X<8!581%1F29;AN*T_/%RG?;W1[4:;
M)6I(;?7I\ 1EEXT(E4#[=H2>=?)KO?W!8 (:YL[Q]*R3X>VW\>S:XN*7!^6S
M)F,^2_-9)V,^ZTL5::_ 5#-(_<"IFLJ1.SW\RMY/-M!M)/)KKP/J6-0D&[L;
MP^%%U==4F_7&IPG;D ?"TTOXO(IUU.\I$U1A'_+*=DI).Y'?XZ/Q!?5D_67;
M$(()NY+0&G-!,M(QBD@H9BK'P_-2FEVEGL66F&MD?H@QS\&T%@8-%'FG9/S
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M!@Y6G%@_ZDR?P_\(=EI5AR!1@43:FRBJ0RA&4=I:3<[$\**.AS1MA]2'7B9
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MW ! 1S5,LXW9#BBV[=Z4&!7"VLJ9'"J8_^1,,?EY*S@PZOS?AODK(IKTQ((
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M<"-I)XA_K^B'F-WI.B!<MX8"H;#CW@&/T-'-]@8O!GP$_[7S5!=%#*$R?D.
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MYPD'4@M&"7/V,)\;QR03"D[+]CI08;)I/J83,%NA'0?.(8R%"<"8)DRVQM"
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MGF$?+)=$<T-U)$!4(SH%.?<)Y>S8RLWM.:QCW,QBCHB/[OW8*8U7\RBV,!+
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M&/!-Q<PWM9)*=X8<E[(5CNIR@&88XM=NL&L0Y&F>'"H-P!L87A ^12UY\ID
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M]=7IF<T<G>3:3MJ9ZUF SDP5N'7;*C=1:"RKBPHT+>#%Z.X=DRI"Y&;)\;6
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M^@Z^'E^1^* ?^B<%P6[:JIHP:"Z.,>DX-.HQF+^18VE+$7VB7I*VJN/E(C'
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M*]IMJ80&<0:T?-J'@1CRX7EM;Y@Q1X2S*+U]?!U<=C?R%DGD+;C.-"86O$*
ME81NG,%6%'+(^Q6,LJS8"U5 \-&!TO!#$4SE1CT.QDN)E@N!7.Y>+,!KF&>P
MV 1*VJEGK(NGEQQZ73")=$(W+0W]UQ>OR-4O)L*QR8NI/:YPVP"4)$!/N?+8
M!O?31#DH<;\(!H6^"V;X'OVPQP1E6>TF%XPE,:M=P%3A(-H28FCCK--J:^/8
ML&C=!2ZJ<1H2J.$[O,.CNDHG^_%3F!8.P^OHX. 6S O @M//=Q Q@ GH;:&7
M?H5?!OCKJ49.O @?-[3I.5U2-<#3Q+#[C:,-I*SJ-P$L8'>),<NV7AJ-@$%8
M($J+%Q5*[)*W%K(YGH/_ACRL<UYV0Y/M;+ WH X?/&![S$$0TR_N\AQ3X$JO
MQ"3"<Y]D.);&/?I49>EX.B7?@J3CY_,3B=?"=CLZ> AK GBT_QXAGY?P;P\?
M)A$M&QV"= EHN6)27::)0=<*5$R= =Y5[:8)QH !Z&?Q(PAB&;1(.T";SLQ(
M'4R+I48!A:V.%II5%/]T6EX@6LR;= Z9:+;79.@V$'C5Y+5=.N93&!0>FWX#
MXHH"O-UW?B1[-PK;LJ$>'E*XYO3(#MDX1&,C4<4! 0T ZE!28:)*=!Q("R2J
M"4PD^'S,0%YU5=)YK^=)W)OIR=EQ?+9_HJ?9=+7,Y@#0Q7GA!5YG>3OI#-*]
M+N+7/4\GY%N$,:SCAJ/PS&5,[W.NEH!V/E_6=;I*XE_;=.8#5& B+/< Y=RN
M^)(K]7X1=T"09C C]S2@+]M0]J.U573Y(#J1O^33C,5(B8X*$IX6-X$!B4I(
M1S5J$W@PCKPD9AA .()C8?'BCR+6P0MY^.#>(90M5K&[6C(YFY$JC$"X,">,
M\;<<:CRQ[X7KJ<$'V;>UB=*K#T#H.%FF$M,]R\JR6167.-;")Q &D5QXMQL_
M!F8F@+\PPF,WNJT]_VO-'HDWE";]A@)-'1VZL*:88C^!Q31L/^ /)Q8SF$C(
M4WBH$S""*/M38E&"<(^#RS)M0][#,V>4)9%>L7SLCHLV2SO#3.(Y>-X=2E,0
M@/TG# ,7YDW,^Z4]9RZMN9'<]8<=O^+1/0F''[E[#=^@)S%!^?/ :S]N970)
MQ SH3O/T=R8%:S*&5!2,,/]F.DPDOW-'NM8)"7O[A"G-:#*G14XGNL""',]7
M--)$DBXUO?"T@#QP%I+N1-*C$HS\O>(XIJR9SW2I3J%%RSBNF&E0E&PG&M;A
MD<1!Z7!55V)(D&J ;0K$JWP!6B)@AM7+B\CQN6V<9)B,IL.&3,Z<M34-QR*N
M'%+UD1C'EK[ID5/A#<3O1SEBW_DXZC/+):0)TXN2) -<LA+)%1U(CW*,MBU2
M-TX, OW'3D4ZREB9CV<U&6IC85CEZ#P98CDM=#/F,#>M"V#K(;0Y:#PK7G@L
MW9"TJG (0EEG5F$0YZ)8CD&K,J<WD_AQVD0Y\^B@G,/*??76]'BJ5Z9 T.(H
MTZU"[D;:H& @7(BQ!73]3CB%R I!4FA0C!-6C&R%/\XK6[U3']$2F_'5LKT
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M%.?NE&MTI)7@'M6[^ K^Q_%;8,R6?F1/.*V@3E$P:*KXTO!BH!(>>,&SJ2K
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MP6>#@!O1>)[XD38PUFR/;;"H4%IQ;H]=<AWQKVQ030+@;C<.<!3XA*\!]8T
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M@=\2'CED^BS]#.2JX6/R'N8*N'3>6BIW*C$+!1P7_X*;7^%'3&Z%B@XUB&4
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M%B$";5>8+ @DI*6=0G0,_,'\71[7V@UQN^G^:.@>XOP0]Q/DBJ*_&N\I71.
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M3[_5-)"5M#6=O9Y$O-[PN8DBO!3:?21:25%+ZU VOJ;J?U%BHF 7O*& IA!
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MU&_-2:I;V^%98*..-K91B72$$W0U$<W&2..&!E@!>V >>.K,KWZ8=+AX9G8
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M-4=]KIHIKO" I<?%.HN4?J=_;0B=CL:";QP^.2:4*IO3Z4/]HS"%TTC30>K
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M1*,3I",+;XP;*N_TFKW34X>)TRV(!)[EXG=; A.,,DRZO"VHH8)[ '2 L'*
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M.L)1IVX==^87W[^Y?(1M)B(OM6/-HQH_CZ]>NU!E0U39$'N>#5%X<9V-1FR
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M"V OEK .:BU"X8Q__,KB8*JQ[OJYJ_Y:DJ!5M[K=/7$N;F&?]E%B5];A:QM
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MJS/M=S[2M3#EO=H14ZXQY6='3/FS#L8AF'_UVJ[MO[,UP8K?\2Z+!=5%W<Y
MVVV"6%SUD'V8E6M@&>5P;1JO30/>':2QFL9^93C'>GWGH-M:F2.SAL3N)SK\
M7VD@9&P8O9D<"(4L:K"7PT"<@.*%_Z41X750_F(<O0,&?Q2G+@-3V*80F(0B
ML- \5DBEN0@IZ,:*[$#A7);6379SC7$::Y!?WQ)NB<LF;T!&Q8V(Z'=E99,W
M&%3%[[S[B RT"\63Q9,C+\3*K8Z:+R\D!D&D)<=A'39L$>R9@L758*CG&2;1
M?/D*\MC PN.?C!X!\D'PHJ(2.QA%@KE ::%'8HPH*6GM&^-[;?;=2^F+W8/T
MUT7I_QZ"BP!#&((?M,F=M^3[!W;=T4AM.=3C1;>>6.T<T5\O@O33*ZM)Z!ZV
ML$])*X6=5V5]N9O.&@C? \4H \;I %0IS =1#F$Z2&QW@'BJ>Y+$(4\IPWG"
M\H7^@QAQ%"K_(1WFD$B"H9O&,C6:?X-$W.)="[=*ROC6)^%&E%V$U8?9JY@+
M1:'H+9P(,/Y"?+MC/WR4B-OA,)VF'*L8B;$W!)5O?W4#\&8H>()S\*:2P!<3
M*;X;4-K!]7WQ@(E5JW!!:*H(9*//*SR%F_N@)YM.XDT5PRT;TV7I4;XBQF3Q
M2&0?P =ASACC.A.,DV+6)8AQSYEUS!J#2J @)*-[]=I+. F%R&0N5@&*Z?(,
M8R^_,@PGQI0&?AF3,D8J4\X+@S!AA/$;X@N%T<#>P#BM&>$+<5_@CQRFH5J$
MQ(V2DW1FQ,F*,3KRE1-X7,AY<=Q:P:AA[L4YX@'RF[@;';Z+0,J$HF/AP R*
MW,8,*61LAQJ:B522Q@?(0T+@Q(AB0IA^S^WYTD-0  NR5*")@3FDV#!8ZN8/
M@REY<T/.PKMR=AQ65'+):\D?%0$CM@TS%=-D0B063C<<P.F7D4JB\$F(;!*I
MM02?)XTF1X:"#'A=9$8Q]I3LQJ.E5.TZV'GM2'TOV.:_#3[>PF\\4)GHVDC"
M'A3F&QGTU]7@+RL3AR<!.X?3UUMKVLJYMZ]I+.NVBDN><6 &\PWC17T&VN<&
M?C2?UY.TG>.DZZN!TI6D5SFH%45]#SM_QWFTY51 5AX8:)O(W/EZSV)L(4$^
M,%ZBD2>$A%/EK@,7C(:A3)89 #O3Y #3?PIC0SO#PE$;N<Z"\BZ.P^21>_-6
M7J$MD;<[L'@DCR'/EPY:RJ#-CT;"?/"/12"_G0P.-^E6S!+&/$B\)IMDI7M"
M(Z$B8Q],[OBW [@I7X.^V3G(N;X:Y5Q)A337T3=;*[ZM5ZC _Y)(6WUM"7BI
M3=\Y,+2^&AE::1];ZVSZULST\DTOJ'1^73N_<SA=O11/5W'#=[Z'2^H.MG=G
ME+_^M=\8C9UGY.OKIN1_Q.)Z? 'KBQ997-6_RG_KP#RJ'S'91'IX1S=J/2'=
M>;J]49IN+Y7&/;E LTC,7)8HA;<TO2*KT!KW:&LPUTN].!#[[V81J%GFWS-E
M!IK@\'<TT4LJPM&]('E!5#\5$N6@KA85&OPA;*$6BK,'<9Q.9T;VPF6$+:>1
M9R$E[MTI4Z2CST U4(Y9H>6H8'Q62Q&HX@$)HF39SEH'4@*$]O&>HO.%E5]4
M0@9G-PPXQ#QP8R^> R\@+0G-!;W';&8Z/.[8@S2A\#XZ@ SGQ$>$L5!CPX4A
M!"G\&7&X]&W98I:1R(@:=G#UHY10E2.!%:4>QJC_DL9BG/HV5LCB9] 30F>4
MXM(44L>_:HYYG"$/V6-B%/XT)Q)T9=R X*3Y&2%8G!(*A!K.ZE48(1IH7#>#
M11=W-4)'F/)?A&@=X/3=..1 .ZE!EELO&J933 H,A61/4-A>C4%&F:4/TX;0
M3*=,$?"O='0O@^HZCS!TH^B)D>=^*C(16JCSRZIP0TSON",/17X&)PLS(>2\
M\N3B,(UHS?I,"J,&J&"N(, Z X#[K!?Q&-^OIFAWCH1HK(N$.'?C";P4_P];
M[8 HX2LV#?-6>=B!62<X6#HQ] ]CV$<S93W)VSW]82E88ETAWL-FDC2);# Z
M.!M/X.8_240TM;(*1#):IF$@GDYDR2(F["5O#9;FC8F,CPE[*"D?2\,&J1\\
M&)=+,=PTJTR)A, G)I,8*QB(WX^RM3-0\1.X!H\YV8I2M_.<;*.YILZ^#",!
MBWQ.R7Z0<",P#V.A'WT.>F^HQS=^P<M1U,HAVVK,MC'*(V5MJ>CM/-W<**)O
MHU=N0XKWY(:",J:!8>6=DJ]\[DV#>9@OUB#OD&74%VD4<M:GQ$B7SS.^B19[
M(I=!8;Q_W(+OX_L(H,+2NGO%PH,%:U2T_R?#H"RB(W+U8V4F#VX? 9?+2!6Y
M2G\L[UQ6?:W[ -[SO=#OM.F=$M>5>;GPD\5 K%/S4-KN"-<X0PI%>*YEYDT5
MYDUA:G!IQ8S]IK&^1\C7A]=V>1U8:5W]6%JG2^OJM6-MW:NOK6OL'&O2:&]0
M7 <_? >UAL7F2Q$E2ZVQE0\Z,(]:CM<V!GSTI=>3M9TC&1JKD0S5Y5=%M=:1
M^/UPC7QUB>Z_Q;'MR_[M)]4RL7_[P_X6GEKXUY/:F:/(6Y7P4I03EAR9SI2S
M?2[)BF+[/3&CV9U:YT-&"P9/E$_+2-TXK@O'&;UY9O[2F0B,!8_<:$2!7DO!
M[J-L]4YMXYEH2&+XFF+21A*#@KO,Z""-+OU]-/XTFC\A'FQ*-^"_)+L36GV2
M*VD@64U\,;(X4F RR))%.$;F<(IRNYJY*4]QZV(W><'8J_L4A!5OTBP(COQ,
M:D39]#.3<AJ.O+$G,+N11&$\X[(_:RJ223@RZ@ OQ2"B>A2)]Y)441A5\1!,
M%82V+-T@SB9.O+#!R>./D(\-/RG<"!E3F+$X8ZE,9V2AAC/>!]IN"[:[, $D
M.2UQV?\MLI0-+2**>Q3ZR@Z'-9UZN(GW(18F4-_.Z,$;ZJ3.4'@SJBN8N4],
MNH(4IN$ LPGY7(9^8ZR75,L'0_*Q;B/R"-A'N80"$<,0/CP:?!;X(N^3%FTX
MDQ_@8*-0C)]T<P@\#[#H'RS]EYAS=,0>0A66N.=&)8%C-S]DF[- UC?#FE+'
M;GV@K,U055 L? 2%5SD\V8NLW(MP#=L?%C?#EG34)2,D"8_AWS$*WVOS+5[J
MDMHY\JJQ&GE5_<IIKGU);0-X5[CW\I=>@"?HMPV"7>J20L=FZWF*-8;\ZD5X
MYQ"R1A&$;%,1;JTMPGNI]J$(&2&5J6HNIN)$W7=%WGS68BT?RW"",JP,)94D
M@1MO##<QA]QR-R360N(CZ?X\ J.K-0S:.<RM<;:,L*.J=!]ZI\JS#G:J7-*9
M6WZNT=IN1\O_^W_..MVSOQ:UM<Q=%@L^^]9&<,M',+-MS5(3916RNQ&#13V<
M+'"W*LXW?9@UX_1"[S3?4QE1*K?UQF";#3WN<3;&J!>U/D)6ZQ-DM,?>1 B7
M.;4_,YT^RA#Q_L,I1Z3+D(O#.7F*-,Q<3C,BLY\I!'$VJ&UDR)I,[@=OE!$E
M\J#(BB9^EGMX49#-%CZ.O/NJ@\MI8<?.BD)7)&#+A&ZIRMK6^]^2,$M:<@-;
M%V&CFH@JX74IC[IH"D6TJ!4+2U*.4?G4_C$+M5LN]'WHZBP\DRLZV/: 2JJH
M9@E_!1+J^[(R'RG*9V52M:T^L-NS\ [IYMLY=K99VRPL? ERIL)+V!=%Q9:>
M%R.N^-3M.3:;^S!EL;4=N3/+Y?J5Q8>;.\<1-NLK#+KUY7<?7#69+<+HJ(Q?
MGCA(."9GO?<^H,*EU*)N$2@0,3X4;("6/86"K4@%@]3'9 @0]6SFU'CW$Z)&
MN7>CD0IJ+H;Z*-IJF2%52L9S0,V3P445 ,2X66QRYC)QV<)3'?N]!Q/+663$
MBQ).8>@,DF=6$L8VT^>]#]:CR 7GD&8GI+:0\K(RJ$P0-NQS@S;LN<92,<[-
M3$&-S<D9(<Q\B%*MJT9/8/6Q;*MDL*+ 2N2#I[D!',-UU4[TSO&9S<:S,Z2?
M!8N,_,OF&=*Y![T<+DT-Q)8C.6+12L5G]XV3BSHGET0IRB5Q#[I&"XT*DG'#
M$4_I1*.^QM6?8:>#^DE*UGQ2S1Q84Q_""X&;03+]%Z=)1ODD'B.QL'_"W# H
MH^4EBC<LSBMBKB1QL]M'MG1SL1OZ U%9R7Y4.BM%U\44B1NP+:=(<FDJ54RC
M!EE4V/5[OW]SO "J2?_.L9[-=:F%;K)TW'66C=N$D+/2DP[![3$&:ALC/7H]
M%<1KYQBOYFH^H?5$5OEIZPKZ7GREXF0XWS72U,;6&89"1^=#VO74GQU[W \3
M<D4,3T3'3)771,X-.S7($\T$.02#44'>(EP(WTGJW=8B'@ '*A$#Y!>1/Z8'
M53([B;)05XH;YRXWZ@#BRE+8XB=8\-H,*F!?RI8A\R%"+I;DR+><EUH=3GB5
MO\$VWX# G>Q9"6YX#@:244&60!N,E-J#-^(*:*-G='&F36X+.'*N&=5?-!,8
M@**ZL6:V2.E@["GV4AE2':YFCU1?I[9/'.R<%Z)3^Q_XZ4?][,*16\CM2M'4
M10C(H_R^CK.2LTZ\H,%#2#MC"NU8;BP^D9#H/K;-5HE*V$0,H"-[$_:TB8EZ
ME;8'?%O+Y<HK_\DHY-7/DN-'3ED%E4<C"+]PM&2JJ>F=PR.;1?#(#33YUKB;
MEFIRWY^'=OT[HS+@L@E+\R.@=E%FNU&Q;J >E<J5D5EU(EY=D?>.;+VU"BT:
MQT*+K-"B?BRT6-]0/PB%NW.H7[.[INL(#W/O[R-Q+]\GXS0;.8\5GW4([F-^
MJ&B;J<$>/<@*4K9SO%]S-=YO7<E5/N3Z$K\G[)_R!T;9 "7)CC0KK*5FA3UX
M(I^(W!'X][W OIVS"='QD'N'21YJK$ZX<(+W')%_E<2QM7/D7W,UP=VRS,WM
M<")&J2^T.']Z^NK^*XPT'.#3TW=517PKF +I#B7 U,K;/6_-#<];8UW\HC3J
M,-OJSK!IN/I7#K#( *8JPKT*VL@FT2*Z<=$,S./'LD\2E.I1H-^,C_-'?[7E
M/#-["XW28I D3 ^OJ/]XUYE?@E*[5J*W\J\L&N\_J:?(18"0O;\-HK]\5!UK
M>"#-NC,_E\*!%[QO72S=P:QR8_NKC)U_MK..KV2VM9>2&EWB(2]'-8ZJBV#.
MA^)<\\N_Y,?M/;?JO,'!A4VZCT*P=%$?AA$\_7[POE%K.8UFSVFTVQ]*4=G=
MSJ_O/MZ:90'SFZ:TZ:]5P-OU7_/2X(LQ3/*7DF>>S7U:KLG25HPMLQ-CK4(G
M1G)2<(:QNH-^QVE^$TE9"\9W'[O-KM.NGRTT7RQ=FZ)9%Y_8 UO.]CZ6L]YH
M.6?MWO:6L_K16!3\$OTH0?H+XK^&.JVL0JO*RGI/VNWIN1[3/H/%JU:J?+\;
MM8Y3[S57[G?)?5!U>=[6UFQ^$M?:FE;;Z717:[:-MF:W-];\D%JXV7=AXOJK
M!M_:1"S@2\24ZXM*.GBM9^SNJ);Y7>42<=9J.MU:8VV):#WGJ+[*'=GLA*Z_
M(\UNS>DTN[O8D6W7O3P_!O3*@J"MG=?$M%;7Q%2L9;GX$SRQP/6-<-#O.CS8
M1Y[ME<&@C6(YS6,LYQC+.:!5/L9RWD@LIS"Y<0SN+ ON%!D$N?X<!QZ?Z/7V
M971U:DZSN\48Q>$NZ=F>EK2JK_F281_)H_RV0PMGM3WM>+O7=)J-UC'PL];N
MU/>T.U7#L,?8STM'&HZQGT/;D6/LYQC[:>V<.**U;@.J[U1+2J"NC;E/RIYP
M8,38?=6L+M(C/A)CKR==.R<Q:)4VF:HDJ/N 7$;N2&2-#S-9RG71L-Q$5M8E
MNKZ)^P02N89L!HA\&[!:6'[M8BU2OL!KZL+?X7^QT4^QI/TB$:/);H C&UMT
MX$>C<&IQ#8JJ7 _'! S-P)^J=Z;D51XIVI,X/Q3-4,+ 4F,\@R<TRR8VDD5C
MFRQ-HS+4$&GU-DL/]W$BL#!]-HO"6>2I;BA4\C:;^<97C<Z0."D<+AR9$_TR
M]<2L$/")HI>"HI<R;FDWB::Z4:>W8"B*^S_FZ^V9MGK@(F_>(%']6.@K\/M5
M_2\-?I@"T7AMI3LOI5YV3D'16K?7UU4 ]A:(X-.&EV/9]U^.$46-R-ME)^A7
M?]'MG*RA5=J8JX+([:5[@Q83NJ[H\J)R:&(%#1]!GU.OXSB11=WPA'_3/<CW
MG-$.(&LP,/:B&(M:'/DO[*7[_O+J\OJ#S4T&3F'\R>+#9/EZ=L7%PO=E.^DA
ME<E+YD;8A @I1].(NYX/\-TBQK[.V()17B_\X(@:'>M'J0Y<JO"=*4O'7L#L
M_$SXA5.E,F*/&C2 9P9/I9+.*0PEAHL?OH-#C)#P"Q^";97A9ATFMN^"4\F_
MX^;&U&5+_C'[M;I*9%4VW80/(IH(%][_7A-X!2'17H8SHG]!=A<7\Z+)TZMK
MSO529WSG?!:M=7L6W42XG<G3C>\&";P=NZD2?^^&MT_5YQV8HZ:&[=@T<#H5
M>NA'EVT]&=QYL7YK=2^CM>5:$[>L?R#V(!%J5-RX40T)R:MY'>'WEC?%LBF4
M7KP:P@!_74)GS!TIYQTN>-;0TZ5\,WT0LO<AG0I,-7(Q^GB"1T?R73 9AGE?
M6FDLT%\A-F\Y#/7:[+05O03)4!*ZC^#J-]PQO*].[0N\,T=>DD;2-84+GRC$
M9B[<[PZ[L")0G)<6_,%WATR$@-2=L>3S&(72'QXBJ(@K#?60'[+VG*IY)Q@D
MPPGLF62>4;X:T:U@AU"P(Y"688JU;#8&.E$H^7J%C8E@@4BL+7J0._,2M#?P
M6Y_5NGM,!(.;ER8Y&R:_XLILN2.N=!HJKKZD*2&3YT\BNM$#S[86[GIJ%DKU
MF<LNBEX^7GP2B^%OHS1"7S=/PU5V7.(?M)A?8/O??6S.ZS%<PZ6OKV_S]?7:
MPOO9:7=CV<?B6%Y:4?/NG!>@M9H7H)P3KDP:,F&HAA[<X/9X%?#!9R%S>KT"
ML,,<:<#)&>9T5*('/_";?8:YLR_NP#2HM@XV68IBF4><*(S8]CH,+)/8L\9*
M7::MYW0 \O4CD2VB2\7P&OVX"M+^[F-[7O.=+!UJ\P6'6J:E<TT0]HS V53<
M+],H(!N%# "XD,E>60K/*WECF6B_H#RW7E!(%BV)93+RDO"/347G*[+G!B*:
ML_7?B.RT#TK!+%>&G1<<:V,]9?BSH"AV'S-:B^RM>21[R\C>&D>RMV>=E(/P
M[W;.E]7JK9T/3=S@W@/%U:>(!KS/2\07[-W%WECUQ.B*!QU83#H;K\T#/L:A
MUY*T]LZIL%JE33#7$=J]I%:U*,FPH&[GB-@B>-@?L4.]>*@/4.KZF O,(LZ:
M(QES@;8[E,B=9 (V\?U$ISPQ=CF ):30YUR;>!,W1&:0O2#?W([<RG62#\=V
M__;<;K9KCHWAZT;MK]GWXA,D$7CT?.[%1X\]I4_5_YI[>Q9PC;.6%)3^-% T
M,Y=:$25B. G R+]_.K7Z9B^DQ;"Z[NG'].3YCDV+07=<MIB;L"/OM>O'(;?E
M@#V!_>)O%FZ"E25OO6SVI_8/ZM]N+IBS\#&UX\3!1YVL0!)EX!B#P^X4R=:0
M/U@%\3T3V67&Q$^M14&BQZ)3L_#@!!Y"C:[@9"!O-NZ\-\4P/1XL$(],](IG
M721Z\-R! (_)6F/8M%VPS&1 'U/5U93GSFO&V^OV451G'5X\KUXW3%97?^*!
MF09JX$>+8#V1VSD8OEW:17$CZ=W#CNH;5.>2&?BD6E ,4>$FCW!-T<6<8/W2
M_,6GH+1CT.T2/H4=/_B">)_=&)@+U7/_0#^K%E<$^F*DUPC1N=0Q1-^7I[8>
MIA=;D7CPQ".V[LW=*-E- VMN G'Q/5/L2S6.R"E-L*LA& )>-$RGW!X1[C$W
MBN">YT\_1EZ"-\8H? S@:?!YB?>">\D+B6F?TJV6;/3+8%X]\SC%?M@\??'G
M4(A1+"^H;(7FDN^AX#9=ZEHC\!=/."#C*6)[B*Y;:1&=VM>!W4_O82LM"3BN
M.;)G5B#;.98VW3:M$1CR30A?"N%3='O>J(8A7[Z<TX+TL<&80),-H6OW)!;P
M-\=\=(9$UYL%#_YE>5UO8]T:I7G=O:2PT^G5:TZGI2-INC#I% Q.'-L\6MO)
MQ SV <Q5-LF63V'M2LCJ,^@Z[<:9T^NV%V=PM&(JJ>.=5X^TUVV!>:7UU74$
M#YZ%L>M?C[^$P3UYA\^R9S9Y]H%9-CC8$Y\:LQ^#'IO(X\X+&MJE/36?*=I[
MV-NO;N#>"PF=0R,BMOU,X/C&MM"JF(48"T"GW[ OL)^40&<3O76J-X)?8G5L
M0FV9P2(*[KF55MZT .\8"XQDKV7J.07&QA,U[J1KAJR=@-\/,WI"2\"2G3#A
M?53/8_<#<RQ&=^NR)S)J/C\[!)BAF6$\F=.,TDI!X-^<C6(5#;;2@STL_3(-
M(#",IFIDAJL.RQ,/Y74[=..)/49$%F'LAO(*!H%-_81A:Q*IQ^/&U<>8P8CD
M39LS&KEW:E_1VBXL'9LN_%R<')I\XH0,OL<P]4?8)*G$#J8%PL %3%O;?(6K
MK0QC%1G"VKQ!&/XAE_=XB5=2.#NOC&FOV\;T=N)&XA/61:#M*X*8WSN3@[D*
M,-\&<H IWGB]+,4&CSZP*_PVP;6E*=CF'(XW^7I"N?-BD791\U-ZY?/D>Q\=
M\, #[M9[.B=@#M,^L4D$+?.7CDH+8)!C&'D#C#=P3H*N-JJ"DFU';-60E+,5
M+KB#,2[("5="R7IEV^A/&NN(@"VF,S]\$KK[9^Q@\-X!FP&OD$LQB,CE)(^S
M?N90<;'Z#JP&1>1E?H5"Y.8K.&7#@',<IQ$\H3ZF7ARG^'OX9XBW%N''0_JU
ML&@*^+E9ADSG7 %BC!(,<<2@D$AJ5 3#F VNJ VWHXBP7R<!]_D9_!>LK-8H
M=B(GB4_MV\55B[&%N3%?GA0.]![#+^26S[^4!^SH:O>LD^O0W':%R9>AFK$Z
M#+;NA!C;JI;-F@_'4+K*S8JPO=A\E2YOD/$?V<>3=QR4HAXQ?4UEQT+9@E7D
MVJR"/42&(LH6Q8_<1Q UQ_XC0-O#C:7!P-&9K(FL?//[-.88%W[J 8TH+$FD
MOWU088U%(9NE$7PMH-ZG>'3@M[V36M>QY3FR'EU9J<CCIH67&Y=;8SP/5'RO
MMU"6JQM"?#1KJFG?G9=)M3MKFC6?9![WW$CCKF>]E#_AP(P4-5#;'.G10EE/
MOG9>#-+NEEDHE41US^WPLO;8N<HQ>9LS T@NWP'W\A0[3!-!2_!$:A2''H5<
M'Z[)6E1W;@6\0.L+\^-)]FOI^V+RQ+&GPL4%5<7S^9O.<F5Q&S8:IX]3DL#W
MID2QBOZZ-!$DZ4G66MBPF& .6 8.;P$7>S%%D4S@*LQ "<803Z0S;,E2]<P"
MP*E&Z3#ARU7^>9H268UY&\=BYL*K!6(*5$# 7 /*X& 0_UZ N4*W)3Q WNRC
M?,T>7OJJ1I"W#=][(MO,>]1Z/ARBHAB)Q/5\7HL91H_"-"Y>$-4R/+,$C.I^
MC/,88^5NS+JKO26Q(Q@R LL!(QMS8K28-6,ITJ;- A3"B.<<;^9*6F?G(,CV
MNB#(+R"!0GS!2M5-DP-+'G%@=S./\7@9KR52G9VC'=M%:,?UQ51A,*J)]%[
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M%^N"U[GIC WF3W[/TM#+5'NW4]_;SAOG\TIEP7_Z3=,KL211T7 Z!5TL#_N
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M+ >PJ)WMKRGRU&QG'5_);&NO6&HJ8\PJ+D<_7N^597&.@A&LGN5QTJ](\^P
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M9L5%WPN7]G5@?W6CX<1N<#:^YJS(QG=S803<,[ECX#/%P\B;42>3CYPICL+
M??"B-+;[WLCZCHS+8^Y8!4\-I_#T6S%,(\P%4JI=IMG/^]_AD/;/[V2BG6 C
M(G"1(5I20JM/Y BH\:4PFN%$P#UY$\'8V-J$?]Y'[E0__^;F1J7PK<>)![,?
M@_45VS'8F+X]2&,O$,0BK>++LA[6?[+O4S=R84'@;7[H!O&I_2,8"<ZCPV,=
MHI!W T_18\-R4W@!(V[P/\R,XK,QSYIQ=L.*6)JYWANKY@I#> L_AN#-^ C]
MO)G[%(4PV&$8)P0>"#AO2A@96$[Z_:D-V_M?:2!LA#CP[A:E\.-T$'LCSXV>
M'*MU@PL<P2T&CQK"HW'MW=$#&M,C^Y<F(7[!E,Y-&I<-9L1KB5\(TP3V)1A1
M:K@0E,7[&, >@<12]]S<2!O4=,<=#N$BC0U:?Y3FL]ZO]@Q>CYB2!2C$&U8<
MK8J*8R]\W5=:<9!8N?;4"T(ZR3%6FDQ"'R0$3E=H3]P12+-X\,(TAA,T=4>"
MSPZ*Q7)PT\:>H<3__&<X%5_@59_<X(\^R_"RAL/UXEA.L03#I&DJ8)B@T8:?
MA*.,$YM#RBB FJ2Z7SGI>JWWC+9JI#0NHW"*\[X&IT!"\.+ZDJQ%,7[+4:@T
M.,74/B0)$SE%V5<!?TE5:KS=JQMX;3 WU?"U=&)W.*HEN]HMWE560#P9U+%:
MQXPCP6V]$<V8SK"CA(#C,B)M*F6^2)W*Y(JU8@'.S 6X^G:Y5KQCD)R' 1CO
M,=5NX;_@2KP*8O W,'1-15XQA^Z+]YL.9PRK4B+J_'<4TJ%9A$C+ *(PG)!&
MQS8,"??H89AL(G5Y)@=#'IW^B\9I9M>>0HZM/A'UVJ8G0BX2WIFX>AN(B44X
M*KCT8SDTQK?)1CB<G:9F=I@J3,$0F8IJI_QLTSG][GI!_(5*G*Z#B]Q[$>PS
M2#X1G<L_0!N+Z_$X P#AWU X<-675_[5&TZ[\,Q<H4$!6CR3_B*]OT(S6IMJ
MQOIS>H%NHAGK)<#H3'D@3K*"ZM ?KV@=O6$SIEW1C&GMI6* L,0@UHGPX4]"
M 6#G;60K$(\@]N[P?U,/@ZF&R6P3]H;T 1+D@-#?@QCD=>.Y"]8ZR)M]2R[&
M)^EBV)_%@_!#ZLUI7X)1348^]L4*2"T.J89]]<'8& 3^!5YT/>92^4MW2+Y#
M'Q2F>R^N,R%=!0"OEQ@0%AZ#M3#X1>.YC)C5ZNEZ#,X=+E4_&,E_W8EH"K?9
M]3 )$<]=[]#Q.5O 1]-&Z&,*ZUD]>]1XYG)>R;<B3+V?W,!XPM%%,-*K>=(P
MEG,&)^'=Q_;"2AH.#ZD2J3%=4.93OHG0$[<;I%YV5&Q"YU6,7;C\OH3!/99W
MX*]6"D?SS*GW%D$!AD[$#::R"3 XD@D<LQGO;MY-)H_0W,.=]8J%6U*;5+QA
MWE *G-K-I7FEL\5V\*?VYTK%$(Y=H)'X.C4799_J(( 1^C=J%^0Z+.E5ZS3;
MBZ6EW!5QC\.>VS<]_F796]#TBQ;QHX@,H]72NZ!C(EDLY)QL9]A :FM9Z#(:
MY@XJQ]7'=?/D:"KNPN_<^/#&C1#5(/MN@/K\%@:RM>$R&_#,J747L6Q.%NK9
MT= -HYV"PC+">+YRQ$VGUUM4GFBBR=D>MEUU8$2;9T>BS8QHLW<DVMP7T>8J
MQZ!3T8'8"[WF38BI#.I-F3R&LC8*[!HLYL1VE:!XQ,@:/-EHXY"AO[S>L;W<
M'/F*L7*XWCZ#6L\E7,B8XI=R/)UK4!MMU<>T4UR,2B$^:K;LXTF-J*DB5QV"
MVJS.9-%<0[_?IJ@3T/T6HT_JG::=O-0X/EUT-'XMN7#K.D3A3=,IKX^VHZQ<
M%=GK*B);[\!T*QZ8;1&67E+Y]5=>]2^XZ-(*BR_#Z-R=>2!L].M767OV?,06
M076R,39_-5A#88K+*RBVTJRJV_Y5EYNIP]+88VE'MZ3]U4X<UTO6R21Q&N2N
M)!+,Y*O@&[X$9 <6_^Y1^ _B*SJBRU)%+:?;?&:9Q[/;Y11L2@7:L/EM;[XD
M\]T.]U3N)QZLN\=PR59VG,;9HM-P""1W6]KAUD^PPY-(+ -F=YVSUNKC>K!G
MM/WV=_ R3)<PEL$A;58@+'M)2'9U3/[60/TEWY@3GL[;KA[8DWAZ#\MJ"> .
MJ;UX(4$EH[-B'S""MQ.R8A/1706.KUB^\,J1^"\BM<OBN76GW6JN+:5OA 1O
M!WYUKZ)?O1?N.QGJMS'6__03P*C/*B[^7KB6EJ5[%/%@^(B9VB2VAQ.$06<L
M2N%X[ U%1($Z_EM&?J'^M@H8L^U<RQ)3[,RI=0KR9 0(E$FQF#.6>1SDBA2H
M54C7J#'*98LV<[V1JMBND!JMUYL;DRTB+]KO(D!@Z<JZX'K#Z306/0Y$B@W$
MQ/7'1,J5S7/9I,6?8IAB4MBJ(BDZ+VE"$U<MRL:IU[46I5T(*E-\7VH&,:=<
M(T%;NVKD&],I/SL_VJHY]8+&',M#T9S[M1:GRP2;/.G#SE(^3VTCE+.2WC[;
M4_E+/[V'GPR=[=&4 ED[@L@AJ^AL$A0L)G0C;K?, ]U$(7)QQ_:7+^?+2VG.
MSN8ETA#&I[L,<&JD>:['QN]5D8T)/D:5*T=R'K(Y8 S(=K&L9 H?Q99NB,IU
MF-YV#&=HD%@CV X43Z< F%EWFLV&TSMKSF&IJ$2#@(P)8=\(+<+Y(_@:^!?=
M7QV".H1ZJ1L]/A%(%NE-IV+D,4DN)V(4V!PN"-\#?8:,A/:0DP;P7&05A%_!
M!'T$T!&!["\MA)_A_U"7_(4@=#.PRV')0R0[9/58]IW3DA6S: M=.)-L6,UP
M7QQJ>)?#NN85^<]4D()PW&KU@[5]'&;#E+%Q1&]YY2M7;NZE=!/4J()@-FM$
MJ7NVHHZPWBFK(YQ#[!=4%;+"DZA;BU&WG&EGIM)9&@TGF.F=!^(^AJ"W'D!K
MA1%]"I'PQ&O+:*9B=9I0DEQ]Z[WWP>[\"LI,G) ).\Q&:\WIUH**!T.?-KI:
M8<%#X:D)AK#YH8]N%,F1Z;FT^>,E]1FL?,%0C(:@(&$D8%D@X@#>*:> FH^5
M%4[AET;M]*R&"IC>[>54&-4P^@)GL*!'';M>K_VJ=)X'!A$:X_/*EMYOR0_E
M!JJ6)/\%LQ8'Y<3U B1HAXN58?H^[X>M+BA>05X1+L? M\*S[R,LQ]"UD^B3
MP&4"*ELZ#GP1_-+@U?RI='75LN/Z7NJ.5?$GUUX9IXA$6?X"JYSF9;FB5BE&
MSRPHD_RI(,F$'^F0L1 3BW4:Y868Q%85 "T8&I$ZS\CT'GD,:)B;CR-5#DCF
M2(Q9VF.[FYTL,(30NDHB=Z0/E%UTH R.]49-?W[D/N$Q$. 'JK^.I$F6#85+
MF[*?Y5N4.P8K@< Z1([)%^='XU'A\+\$4X./PL> >A^X(]QDTKKRL(L'_,%4
M,&/7\V.N$@--\V3I.HD0UO*>JW(,7"T)BBS\ED\@O-5$<*R5%"6Z3D]&N9FQ
M,/5>C5=$6YBLO60IE)R>)>4Q(3-93+UTBG\!%U/OBEFXDRO?SNQAX[6=PK>J
M?9A[NS3'22PL8^E58P!:KGH#QF*\ 48)JM(P0F&F)_!.W#LO'.67#/9+ NWI
M7LNO%EQHNO =1VV[8Y@0&>*H*:3BI#X+7A33BH=#N''IZ+@L[0$<Q"*[N[#D
M/+NN\< ,S"=$W@.NT<QWAW1[6R7/P,DD3_A]]%[,1X+@95<Z(\P$$M,/A?<
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ML VZ!LW;4Y%,PA$<T?LG#49?$A.D]BJR1:(9AN.68'GL/K5A&0EPKJ;496V
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M,EUQ KLOYQ+MJ'QT;DY[TBKE5:72JBPL+MT2;4?5<NO]E&;O2;#?-P[T2&T
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M$\TWU]Q87<L<X1 DVYW%H(;4OW+ZF155E6U:I<DYPY8I\UP8)_^CUKPP)%2
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M--+;L' 5&!;\Q7?.9N9-H1A"49"2TTT;C,<.P_76Q@$[?;6>(LB^9Z,JFWZ
MZ'O1K&>&"L%$,\1D JX>.,8K14;/Y&"5MVUOD0<\>RC5[JTAW#&49/*LK:J/
M:*BU_OXRWG:?SW:+]93,]632VCSD1Q>6RLG#+/$D./$:M;"NUG:9H';J;4@S
M.[0WHDI[AUD/ITZ1S,;41A3IU=5>;X<Y#Z=.E<RR;2.J-&IML&IW3Y:")G9'
M$\[LE6[7$SU5V:.NB*T[V[+C@: EQDIB+$CM[#(7[=0IE3WPNRVE2MFYC[CS
MUO>IIW:Z.\R(.G5*90]];TNI1J>E=ML[3"K<PB]ZAIZ,$ICC#2Z*O#7>?E69
M.?:KX>+-AE^EYN9I/W/WQ^?F9Y"Y-#>./;V$-0W+!PYP'V3H?:&-\^>><*/7
M/SU' ^9H6)KS=NNQJ0N<":%Q;"HND<I_*C&/7:37LZ6BY3!MX4 X)+HILZZ3
M9<3>D6;6'1;=.&RFU]LBZGAL\:/#HKL#++W6V8*9E,I,"<R)*S.)O<D>UNHU
M1VN3+801SZURJD1 B8!=(*"4CR4PYRH?[Y@7FS*\7U:0;H#4@<(R@)J-*G+2
M&OU%=QOO@RB9'0V;$B6M:Z DRA;NB$V)DM:!4!)E"Z?%ID1)ZV8H0RDE,(4'
MYM#:52NJ6RDS!F"\: [E7L.5G,(E=W$D976DN<:8.C/IANE[.-EH]6TKZA3/
M#72PQ@9,3,Y%?V#.$!'X!?$UL/0KCJVU; V^1XAWWWVN7=0VS\5*&.FY5MX<
M)YFZQ2#3YID7YT6F6B'(5-]<53@O,O6*0:;U?5DV(U.ISY7 G*,^)ZZ$@7.L
MO8]*593^)%8$_8/A=IFN:  JSAKF=W)>!51LWW,]T !A":6J%$$AW,!!O\UL
M]YA2>'MWLP&'E+@=<-3>^=,1<^XGQ"WO0WRN8)P!OY2<LJ,VVQVUD<%5E&+L
M^RF2KULH\K75-HZAZ^U,VITZ^6J%(A_<OE93K:48>E"2;U&Y/#CYVFJK#\PS
M0\Y\"O*5"F<)S(DKG+)1V:4]G3GLA5DNSC^Y%?5SZ,#_4(XX*X')_2R7#+0$
MYB@9:*(5/I_?LAF&%KR$^\L^(8$0DP=<''RW' 8 _)OI?[5-W'&DWPH;^X[A
M&<P=.(8+?[J"7ZWG!^88M@Z(N)\\:3^+6+VR/9JWJ^@]#)KW7K6R/9JW*\D]
M#)KW7JVR/9JWJZ<]#)K+*I42F.,#YM!QA=5-Q6YLA\&7%;BA#K/&;XKG:)9K
M4LF9HNE_^*Z'_337^5C.)(V_1$")@#-'0"E#2V#.3H:VUH^_3/2JKKMUQYEY
MM,7\RP7309H \)OI(VX>; ??./ \QQCYG@8@/MFY=\HX[U2R+09G[IN@60MN
MSHN@6TS<W#=!LQ;KG!=!MQC4N6^"9BWT29<6^BN!]_DWW7C]7*G\]BO^^]M,
MKCFQ,7>N7@-4/QE3YBIW[(?R:$\U2^4?J,J0.<;DDS+5G&<#7H*/UN+O1;O7
MF+R%IV26Z^O&#''[[O.0,<6R/5C%LP&E&I &T_N "#IVJZ.?2,'7\..)86G6
MV-#,BNO!!VBGN_N"- DO_U&M*C<&,_6/RH/V#,=\R/[E,VO,/BK]OE*MBL?I
MPO%OP/\DA/R]5<^> 9P-/ OB$WD^.OC9.N/G7:8]+VXR>#O!4UL"3@WYR$TU
MNFFYW4_*T]L,-CUPM)$Q_J3<P8WD*+FS$0V-7O1;O\JO$880J0%NDG U<ICV
M9Y6W5OL(NBGB.@IO9PF\B-,H=B)TCE%T^<NC\.)&0FKF>]3R/M('NNN_C3[?
M?7]ZO/TRN+M2;N\N+Q3\8?C]R_#VZG;P>'L]_.W7T9+-T_\TQ=#!"/IGK=9$
M!&F?\P;U^]W@^]7MT_65<GE_=W5]-^0_#>^_WEX-X./*\ G^^79]]S14[F^4
MX=/]Y?_\]?[KU?7C\+_^L]>H=S\IU__[_?;I_Y9O:K],*J?S V@:&C^5;[#H
MBZM< \_6E;_YYIO2K*M*H]:H[V/O:T\S"4] D6D*Z4N"'']W9]I8_A[78L"4
M-K69"XQ&_O1)^6'HW@N"6_OEDY(6]'>IS/C5)GKD5,H]C@+-8LFGP5H .VS1
MHDJ9':Q;OJUP;QN,Q_[4-S4J:CC%#:9[6UIWV1;W;(T7/*?-;OS6W4#:60%I
M*GUT]/F2U^,,L1ZG #M:?Y-@:339-/,8H*6DA&, M#!'>B^0[H$/'2,3Y^40
M?!U[4BS1L:NW/6B&KMQ:^WI=S,5UPMK&T!^Y8\>8(6L^?2T@I6RE$%S!>6K*
MK?!JI]/8RV!J^Y@Y= I[N=1FQLD<LKGP]"ELZ8I-C+%Q(H?M07M#'\U^=*]L
M*1/"^=-$WP_M,W7/@B^:J5ECIBHW;.3XFO.F!,ZQ^%:E?^F7E:&ZX*E403GQ
M=/>7I>&WE=&W>M;H&YE\+[8)='>O_^4;WEOR/+^N6J_7U7YK?8WRRGTO3['9
M 4)7+IP%J\TM:L2IFMB-E!.O*?]NM#MJM[N^>O\PJ-WE66UFCOUO<E@1H]US
MP.9>KGZ]I_:Z=;767]]![BA0NCJ7H=G(!Z=)T_92-'Q;N?F%E)+"(;2Y5X2"
ME,*DG7JM??1X78W6UE[$?DVMU=:G/Z6^]UM/J4^MS14V8[@$I@2F!.98\^\W
M8T*7T5YWANOZF!MG.SAP<LR8[E*ONYGVA@ER] ?3&&,Z7<Z(SB<[E^3*+6TR
M6D;[=\WTV1W[07]Q5RCMK72RYD"'<[4P;F]A+"Y'&[<A5^--6I"]NMKLK[?,
MBX^Y/1ZW%"/C"XFOS.4MVU[/?E_MU[,T;-@/TB()J%67C:O&S^J+H0.?_JCP
M?ZL3@+C:Z5.Y(>6;'1?DW5K1(%]C]_7W=E*3<OVS"I0MFC*4QDH)3 E,"<P)
M&2LN<U[!+,G81:S 1@G_^,9VAF*'R=I/JU8:)PO&23K\22.EWE/KM?4QKN)C
M\ #'K[X^]%)(O.5BK&QT;<%H2=$6O>BJ?[UHJG]JR!M%@_P01LO*$YL4QRJ-
MEY/2_4I@2F".&IA\C9=5';]2<Z)@YB2:+=X+ ][Z4YGRHE>VK.@UOO^CZYM6
M3C0N*F7.OJ5?:@6QF:@@EBA+0%FK1-FF*&N7*$MG_^QMXGHI-+*?YLYN3W-I
M*I; E,"4P!RIJ9AA/&U0ZK61/5C4YHRK)?I^JL.:]8Y:ZY03+%-2I;7'ZC(:
M[=O=60_3@Y$F_[O2VB[,G+HZ#2A24F,]-?93W881PIK:[Q__[.L]=/IM%:\Z
M[KQ;+[?V7%W74#M=N"V]]=5UITZ7U-9Z-[6UOL$\Z'BGZ9-H/YNZ6VFM[%9:
M=BLMWW9:_<.*B,[C[U.VJ[?N!M*R6VG!H2V[E182TK);Z=*WE=U*RVZE&5]9
M=BLMNY4>RU[*;J4%W4S9K;38FSG+;J6U^:T6K&]93@&$.3=UMZVVFNNG_)U(
MK]+&WJ+)@-967:WOLB5<<4_J7J+!A-%SP.9>HKE]M=9MJ.UN4:_^3CMK-HH7
MC"UZ2\TU"-UO,+6G]FL-M='=LE5Q =":.A;:DR"E_W]"[+1L.7JDR:$E,"4P
M1PW,'KKXE"RG!*8$I@1F9SI,9.53:@N6N5IQ1_V%VL?;%:Q5C*Y@[1-!X"$.
MWW&B[> ]P?IJOU]<W*6UI(^VCW&O<'V,4T.>M0U;:3$<F\)5 E,"<]3 %-%B
M&&ONRU%9"Y;GC#X.08VP)WQ/M"70,BYA)RL4LSK.'SO.EJW;F 4<1Z2F71FO
M!IP6W>4VP4H3H-51>XU3P%:.1ZJU/D942/QLK.QO<>5JG>*.=$FK81:N76YJ
MR)/[N!4=\E:IU9^)4E0"4P)SU, <5JNWX&4NRGA[ E)]Q"<6CB/*_E$I]VG<
MBN&>[R?\9\\8F6S(QO"D9ZQR,S9Z7;5]$J[M'<8&LN%3&@J-,EBPN^-97 _X
M_J,'6U[S5K>XR$RK!"<WR"TZY,G-4(L.>7)CF-+P."V]K02F!.:H@3FDX?'(
MQJ;FNL8$7N<)\^.'YCB:Y;G*Q+&GBFEH(\,TO#?%LQ5&Z?='98J0TW-^F_>3
M?XA-WL >O\HM/MEK:V!J';73+:Q#?6$T1M'%=*]P"D8.+O=S.7VIJ7ZT^37]
MH\VOZ9?Y->>B3Y3 E, <-3#;*,0'F'6WT!7BZ(;CK*[<W=O8H@Z(B5IG?7GY
M&8TM*F?=I=5ODK,[2I0EH*P<#[@QRI+S6<X-96M:YY="XPA.\XXG-Y:FXK%I
MVB4P)3!'#<PN3<5=S;I;:P\6=NK**HG>WDO'MKK:Z'?4S@G,\-I GF]%EOK^
MVA.VZUVUGZ*:I.BDV<-EV4M#/J1(28T4U-A/7]2:V@,)T.TU2I*L-Q#;^VT'
M6 Z[6TN0UEX)TE?;K9K:;.UL=.K1DB6UM9Y^,GWF67>G,.HN& :Q\)[_J%:5
M&X.9^D?E07L&:@S9OWP&^CM-B%.J5?$\'0S^E0AM^"NKGCV#QQN(8?&)Q'H'
M/TO1/#W#=A?W%[R=X*DM :>&Y_VF&MVUW.\GY>EM!KL>.-K(&']2[N ^<YS<
MV8B&1C_ZK5_EUPA#B-4 -TFX&CE,^[,Z8L!#8.$9(3L*;V<)O(C3*'8B)(X=
MG>4OC\*+&PFIN:M3MNQ$'?5%B<Z$?'IQ&$N>"EDOIT)N.A7R=,8DE6_;U=O*
MT8\;.>W67:8U 9K"C)C;":3E?,>"0UO.=RPDI+MB-L?(CLLACN40QXROS'>(
M8Y$GFY63&@NYEW)28T$W4TYJ+/9FSF-2XV#F&":L(-U5\8T6;%Y;>[M.&RD#
MDEVUUVRK_5Z_H//:5BZ<":W=?>5"=-1FNZ,VNN<PJC&.U;P.*V'T'+"Y72^M
MM+D(?;CW-;7?+^K=W^EHP7:_<+D$11\JN!JAG9QR_1(06F^H]79=K7769\X4
M':^I@_E="=*F_R]'-IY6!G,)3 G,40.3KVF83SVW1^D.B17="_;CT96 K9'O
M^RK.:Z,BVBB+\R*4*2NZTZI(R;VA2I0EH"RYL5*)LN4HJ]>26SJ=&\[6"(W,
M;99+J;''XYS<YROGFN[27"R!*8$I@2F4N;BKFNZU%F%AJXM6B?2<:O#FPY#-
M>D>M=<J2[I14:=6*%\8L.FGRORNMG&(B6<*@)35:>RFPWR",>A8D6=/S*Z<R
M^[*D.RM!]EMC7V^HG2[<EM[ZB3VG3I?TYGKZMI5G7=1=W-+86ED:NVEI[#)#
M<=/ZD<+7I91OV]7;RJK9C1PG6]RS->[QPM3T[032LJ"VX-"6!;6;0WJXJMFS
M$.IE06U94)OQE?D6U!9-U)>UML>\E[+6MJ";*6MMB[V9,ZRU7>AV7K""N\Y>
MRA?K:JO;4-N-]:[O$ZFU[?3VV7>\D:KO^%&4,FZ U3S[AJ_/KCP!;.94%[K0
M][O;P[[?W=- Z>J88G>_I:&G7VO;S2F3(;'O=K/> F%5/WJTIH^Q-B5,V?Y?
M5MR>5@9J"4P)S%$#LX<Y>Y%W;VHFWKJNCW:B8D] TE& S$5)1<6W+G->C3'Z
MR7+%ZFJ)NY7 Q>TQ_<IW8.L/S#%L_>^:Z3/^\8WM#,4.5ZC?-;566Y]R>Z #
MN1IUS2VLON78X\9@.O2%)N%I(/ 0A^\XT;;=<)KMT=;JJ_U^<7&76A5N):8;
M%A[TY&&UA0<]>7)/:3D<D^)5 E,"<]3 G&"OGK73=@M?V[_&/[BOK@N-1EOM
M=3:O=#KAK@MEKY[4*DZW[**R,<[*!D>;XZSL<)12;.RMQULI-[(?Y_J.FT^5
M!F,)3 E,"<R1&HR[ZM:SUB8L;-WXRC;W>^E 4E<;_8[:.8$N)!L(]*W(4M]G
M)F0W529DT4FSA\NREP8Q2)&2&BFHD5-KF(5,S%X3,S'7SY$X"Y*LF9JRW^XP
M9;N>M039+LB]>29HNU53FZV=-7\[6K*D-]?3-]<]ZVX]LO)TR)ABV1ZLXMEP
M^C1?-SR&%5>HW;O\)_*B8"&N,C$L4.4-S:R -N2Q*2SB[@O2)+S\1[6JW!C,
MU#\J#]HS')\A^Y?/P.# -]>5:E4\3R>9?R5RF/B+JYX]@\<;>"+$)_*4=/"S
M%)5E&3:]N,O@[01/;0DX-;R@-]7HKN5^/RE/;S/8]<#11L;XDW('#(CCY,Y&
M-#1KT6_]*K]&&$*L!KA)PM7(8=J?U1$#I@<+SPC947@[2^!%G$:Q$R%TC*3+
M7QZ%%S<24C/?LW;P9E';OB[_+41;+GQ_>KS],KB[4F[O+B\4_&'X_<OP]NIV
M\'A[/5S>?8O^IRF&_M_O7O]9PZRGWW[5/N<-ZO>[P?>KVZ?K*^7R_N[J^F[(
M?QK>?[V]&L#'E>$3_//M^NYIJ-S?*)>#X5^5FZ_W_TC81%XMS;#:-;ITU37^
M#5>N&[TT^,P2D,HV8RO;!O%&#\;/6+>XTVCVL(-N2=)#5_C.-#M UPYJR7G7
M\5.HB@^[).Z/Z)\O-?=%F9CV#U>9./94L6?,T3QXG8)6SJOA&<S]N-+CO@8%
M2[WJ:3SY6Z^[EP8!O=K2PC:9GC5/RZ*556;VE6\:_L89V[W>EH.@"U!.N1J=
MF>O2-T5G!\YEK;-E=?J''47#8XL.=%2AR"I%<]9A@*"Q >J0)3,6X5/\>8R<
MQT?SUK RL)TRZI@S@YM_=V)L\?KG#-T4+OS=T!6X$B/VHID3+&S#Q%3L7*99
M;\KH#0X#]1*#!QWO+6>$IO96-;.6'>0'>BXLYM)V/7=@Z9)<CYP8#TB+Y&!!
M4^VD"*3EG&Z3YA1>L1GP&D,CC&F6KFA3&U[R;XUWDCL<P3*+V.B.X&>3X0]
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M)L@").N(F"P(P)0+T66@1"^(V(L)5@68,NX;W+/IA3(P\8X_OPB. I8)*N^
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M")\$ 8T-''@?S;"GFS]#!5O(PPO>SJH"Y$ZTBP3:_\U"2X;R#?"0.[8I=0C
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M63?2R)@OU]@T7^XA3 :X#W,!LC102K52(;2&"*1*!-1S5AXRYLTUUN?-;7;
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MHMFX9\"+,N8UMG/,:TPLV]5#SA.1%Y6$0J G>P:'O5=O!Z& D'-Q7]U?F0[
M/$O?/PDYTU3^O^7O$9Z\B<G3L#&RRU5\[OVK1%P_HF@K6O8E7%B:24"Z+XQY
M<UXI%*F1&Q3[.DA2X;D#.):#=Z$@#Z@$360C[I^(/V^)XVXSAUV0]HU%.C+L
M3[KJ$F_91>764IZ9Q1S-5)>J+C-J+40Q7;[UN%>+.LX"T-1"5S$Q5QP0$U&0
MX_8\U;U1@_-QS"M;B1)FP693><1 >]4,DRPRY1^BCD"4^U+]F?QK6-[,57,G
M$B"P=3 ?(F23S@<.7H7X&E@%FA,EG*J\88J4,O:=5[PIP!PU+TA)(%V,)TL
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MZIMM;7[ZRIX,2Q7P8K >#XCUZ0!*!C=R,NVWG4RKOI,A\&#K54!6ZX,DN(+
M1T$\ EOE=ER1,!FF.PY,'SX:N+Z< 7QMVOX,'C@QQR:<MOP,0DK;$X((N"%_
M!+]E^Z^:^L5R7'-B:*KQ!*&?YZLCB1GV#V98B-H&GY_ EL#Y;VCJ'?@M#CSI
M-\."S6G*K1%8ZE7@+F;PK"MS/,-90>JM8UFO'^2OOQJ!:ZA?3 N^PM?Q3V=F
MJY^-OY@+NW6>&$%9$3J!H5XY=.JXU <V7S@N#JF\M/\=V-Q3^Q,^Y@0^HA-@
M60@^SE!B7[IUV;^#R1/!&?SIFD29.[:PV#,2P34)3GSJ.O/<><OHV"&:%L&,
M,T8X@.!2@9WAU)N;7@C:PMF3,-,D@(+R^"K X>*':(S_$^ PI0B/+8>V]/A2
MMU3O=6H"T1CA CVS0I)*:Q7@3Q3A*%9%TTAM;E-H&DMWQN?1(4)(_K:0OX@1
M7.8'K@W[4Z*IW80X/PJ>0);55EQ\QR23$A_1J,[)-LBG@)6_GSDOZID1>"R4
M34+,9E-F3S!>:"CGX;^E0(:RF!1!?#;)FSHU+5J1D!AX#^@]X&HO5QS^0#V&
MF)'X!PL6X6O);WJ.]<R4JMN[8]["0<01^'+./ODZH^=3'&6I(_?1]#DZ,!%<
M3J[M$,6',8HK$[X7-BD:ILXWP77-@C0%K(V_=P(B2N!222H3>)7G@=).R#0^
M 11*NZE.C%>/K\$SOZD+PT?CHMCL&>'Y4+/#VFUORMP\I/0$O$Y\/Z'N6"Q
M5XA5T2;#[5!960/A-F,H6Q[S?8N#N41:B;;KV.',^6AW^#+#CWXAV%R\;XG$
MU@7FFA])?W'<*3/] H3%$'&M7#UQY3PS)NHC8W9LHOX,;9$<U"\_#-*KCN4
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MH,DWT"D !0*Z ?8UUZ3*054M[F&B-9+V$%HGMC8['!/GV&D$M Y7<6)E.%H
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MNZ&23LUO]9(IAA2$H.V<*;:QN?;!J(JP!6;T)#M%Q>A^\9NM,D5[FSQ1ZCO
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MET$DNGGR(.,"*XFX ,OAYM0DD>M&3 *(Q*B08,(O( LJZ+F#*2Z!T3+Y:"#
M"YU*Y1J[)1:.00"QLT(O, )_YKCF?R.'X@S'<L$B;UR<Y>YH_%7XFR^6@Q-;
MX26<PA+T**JV.R1DVK5Z6$,=G06T7:F]-;>X$)Z$A7!__Z&UT1$-U[\_W%U^
M'EV?JY?79PUUXS61\65OH 924+O7J@0GVOYIH[3Z#%\J*Y&4;^W^E+'6CSG6
M>G,+^^A]I+6DAB=O^C!S?[?!;:1G/Q_:^L]F)INJ%]] I=.=PHT($K:SCSSW
M!I5D557VPZ>4RN8^49UK?DOY>\UGN4S6MRW?ZJ_,-:P)%W/'F<P/4+QI!X>Z
M>B[<45FK%.Z36]>$WRS@5]$?P3>B-8S&&*13.E%\_O3]:(/R.2Y+IJ=LOPQT
M6R]ZB]=?4DL8R^UP;UXF1\##=%[BN4OAJH\-=&MYVM0FYU]>"%*>E?"()T>W
MO,*\J4(WM-VLX.G5/)GF%QY+P\,-/W 9#Z5+?-29Z;,/2%KXONV\N,8B(M9/
M2\ZNV.?M#%:F1)@)V"@A'DS?VA416JNS0SU$. ?13M.@\G2UMS>[YI)WTQVS
MM;\TG3!Z&PUWKR4J!(G;.\CZHRY:!AJ^<W%IL]6-UB#7&7^L/MFN+Z;?#;<=
MKMK8^7;> 0VW'JH+O"I:!\>L.G@ENU,EFM%\^ZWRDG!E1XUWU'C?@<8S;.%<
M"G"N@]=XD4-Y-C-,=\ZQ*&D51V6XBC*,0[8=E>%1&>Z;,MQ>Y'UECF<&L]2K
MUW>@'V]=YID3 =S @35H";<S Y3E'D3>.[T/W96ZW3V+':ZBV/EVW@$-]T?9
MWAF30/T<_!OQX^W@X-7M49=NG>3[P$&'JPEVOIUW0,/]T:;W/K8$J;<-]1ZA
MU8[J]*A.5\X$A"QTOCL6.EQ=L//MO ,:[H\^_<-CSX[E3-1?7?/)P;*=HT(]
M*M352+X?/'2XVF#GVWD'--P?C7IEN'^I_\"G^$?_]*A.UTB=[IZ!#E</['P[
M[X"&^Z-+(52;&HB,8H\-[ZA+C[ITC5A_UPRT+WI@']"NM_6Z^J%8%L7DKRY2
MU2><#*,5;&QK]8*1<RSM@T0C3Y F?&IL)Q/36UC&*\JLS1!IY-O/,V; 9CZI
MJD(_F9,)L^5/\*GK8 XO&M,,)&"8.S;]^P_CY@^J.?G[#_S#'W!"_@?XE6W,
M\17,_/E<3#W$03:@RA![\F\?$\_[%+[@B\MG2"7?T,J^09=O"+P/3X:Q^/G2
MQAE;COMZS?P?U, V^7<#;_*#^LTS?[9-"[C<#7"C'Y,O6_9Z/?OZ5OKUMR[#
M$5L7?/;6&<[=LE=?!_[?RFMII]=RLV#8[6@_?<61^W?FT\R_F?[NL9'GK4&;
M-5;42:_H'$[YV<#JOZ_15+.UB;3R>KKE%))K>GW#L:W,P+TLC:8,I[7=85H_
M6)N%5EY(/[T0WG;--D2:E0]KD%[/F6.3'P9F_YP]^ELCS#"]D*^._?3 W/DU
MXOS<&J_HB&R%5_1FI3.Z=OC OXT3)^>4](P"IJG_/K5EC^P)'!K*%[/'(.F;
MYIH\$F4T\A;7DT>?C%:^=86 W_O.^*\_$-)D.\R3T<9;60G09,+&YMRPO+__
MT,Y95D8I)Y=U:[@W+DW#FM *;YE[/S/<U$KAMQ[^UOOA4[/1;.KKF-36LI5F
M5/6N5KJ4IAE=CD+@V)M=YANIF:/?M[W&]K(U9E3_OIYX*V,9=K72931MY1J,
M[9[[4FKF&I'MKK&3LZR,+;FTQ\Z</1C?1+SQF0\/W[AOW\U93,:<;&LQ>AYI
M,E:$SFKF6#B%\>(_ ;A%-=BV/+J$5L+VW4>^C$N<ICLY)Z2\6P+)P]^@XW8S
M_=-P<?JD]\5Q(7A_-L?KN"7+5]K/66E_+U<ZR%GI8"]7.LQ9Z7 O5YIS^NV,
MQ2A8+"FY&YQ@6H, Y1QV.V,@=K&PG+-M9ZS"+A:6HW+:V<P/OAQ!WETV U5L
M/C.NG+\Z'K(:,Y]L'CZ/7Q^ _SS^)@B/Z">.YS>:8$(:XZ9KYM],0:]O/%SJ
MY>PE8U8.9"]YG)S--QW&7O*8/Q/\',A>\N0E$Q[!VZ/%UR"T>8R>B7_J7D2>
M$<@$.#4OHI7CNW7R+5'-OELKAQP=O8KUYNI]>LM!+;POKC._-RSX32Q( #:7
MIGWC_F\K1]5T6@>Q\AS%TFD?Q,KSN"5CJLH6/QH#(WLF/GKUY:W!$/D!T0X6
MEW?F&6.RJ\7E'6O&.I0MCO_Z+>[[&F>;,1T[76'> 6?LRDY7F.,#=)L)M7/'
MQI;A>2'<3BPR U43WJP\..N;HS58L:OOVR)SN+';VK=%YC!DM[UOB\P[[DYB
MD5&6(&;D0$KPVG']6\<U#KB[^V7E'6EO]\O*4RRIK%KPZ(W=!7Y7K +6=&9X
ML\TO)B?(Z YVM9@\]A[N:C$Y3-UK[FHQ.3S3TY<O9OWTX.ILTVOM<#TYG--K
M[W ]><S3V>%Z\O@GX^S7'<;G,4W&J:][$7F<LNW43IYEZFT[M=/.H\1*+O@U
M>Z&_;#YR;N?(3W^ENX<:UY9#M_Y*UP]UARZYU%OI'J+V%>;HHW[F0J)N <C1
M1_U,>F8'4MC?MF9NY^BC_K8U<R<GR]O/3ZO4G>7-6TE^^J3FE73RN&.OTB2=
M'%TS6$E3U[["'.8>[)6^SCOE0<J;-BSFB"#U_[5WK=UIZTK[K_3T:U=V+'//
M.B=KD5MWVB3PYM*]V[/.!\=6P*VQV;X0Z*]_)1N(P2)@(]D:XR^]</-HGM%H
MYI%FY,V3U&R91@8X:\6(PL*M7HPH+(!2<>71,70O9(UB1]+?KI[*!<A4#'K^
M(K, 3\6KYR\R(XYIK](GQ;.&3.OMR"8DPUX[LM'M+ OMR$:WLVRRDXC^10=S
MC-BZDW> SS+\3MX!/M-F\@[P&RR;8*\&@B/:)J/<I5-(E-]D56WE3<(T&0?)
M.WF?KVDR\AVD)(+XO:78)@;#9R E$:F+%H.5AR*%39_L;:);9&DQZ_D2?C0?
M61@^!"FICK/LGTAMDY%I0JDB=?$R,E8EI*0*S<7+R*IK4OC3Y-O$8$Y%_CXZ
MD^7S]])9#"=9W2M:#%8L@9(5O;GX))9]H%7FA.C"I87.%SCZ^]I^ZR<PKSG*
MH_()H546Y5)SK5G8]V%&3S)?8=RS5VO5R:N!FZVR(X-T"3_^63-MCYH0]GKV
MY936/P>F-Z3"]EYH*7U.@JV>(Z%2]6SB^08$/AM[7N_EQM'H#NHH6^^%#!*M
MU6J%^[AF?".7MS=F2I%PQDE#7W0UR41\9---LCY7\X;A64R7+%@D XZ=R\P'
M+9:;ID+U76=B&M@XFSUYV(B4Y5$K[Y)?GF1DBS((R"K"?3NOS#R@)"!)90F6
M<.EQP=;Z:N2C*D;CG#>)PM(24<DB4YQ$''Z_<.?$+>W;YR.+0 DG'A<H&TP9
MI$B$V_%^(WT2RNKF6+/F+EM(!L>2*A%@7[Z\8)VL99=3?:C9 WRO^70-IO[*
M-NA?U)8FFB5(2*;J&$[=QR0(\/N::?#O3<545,*%+TNTJ3V;!F<9F'I(..W\
M9:BMDL^K)2-T<D=)V+4ML-* A4]ME6_N&LXXXIF[#^?MNKK:G"ILVD7D7?+.
M.1ER;34&3W;PFLU9\3E=CHW,A'@&#=;6A'OV+TQ/=P(2V<9C\-"#<U_8F!+5
M-]G:,M/OZJ& >ZPH&5!L;!7K ?N^A87$WHS.@"A94'KN>&&+IGDJY]UCBS;9
MZ&NNB#" *5/":=,DA69.O5BJ>6U[Y*GABD?\.$G\_ QEJQF$:\N2=3*E2_CY
M[L@AHOR>;YV%/LS(UGGP?6D8NXTH65*:=TK%TM%:>>FZ2!N:$?(.])CZ2H;C
M\YCNT9FG?"0^)_+YL[Y%?#V=I>35<6[>HIX(T./Y@N  G2E0[@$Z$[=$@)YC
MWL(4*.'5\\X8F& E_'K<>N+KC!@VC"E3(CB/0U>03 DG7G!FQ3*Q1L*WRR@D
MHR^QR/2/A68CX=3%IEY,/6QN629$!J8>MH?D;['OOEXS@XI60_,[A_;V'\X]
M))'MQM1I.-P=N#A;=)Y!8TU)<CZFOEH,.-^0%,_AASOE2;%6P_.-X9+WV<VR
MF9<^$VTDG/F\8_(5-DB@:7%HU)<^#VTFG'?.0K$TU4RVI)P+%;4Q*D93R1Z4
M^0K%U%3"G2^ZE<_QX]<#,HO*&/WFBY&.J;M$K+Z4+D*T6-UM[$.?MW1,W24"
M^(5TW,3*H+)$!)^S4$Q-;>;;R6)-8@NR?(>4#(DS#&P$>L@6S>6\'HTUTZ6K
M5'1:(">*.5D.*I?,+#TGRT0+G;[)FM#<Q&$UO4\6@"ZF!A$H) &]V 4@6=*A
M;75_+*$V+@\Y"858%>LH62+*]9:4+2(U6,<L6VOG8F@CZS/*W])VC\28HMZ-
M- ,8A"G)V>SM(_/$I?NJN48O#,-)Q$MBX&L[.O48_N>"9.@D(79-VS/US!</
M9!O;KF5(X9"\\,WY."ZGV-5-,L:8L/,FWX)P2%:J;H/"VX+%8@S> H^_,+T7
M"!O="8F0!GCQ?M\E:><J*&\MS?>?">SA=M*9'=>Q9CE@F660;87W(,>F&WY)
MV#"W#Y3EUQB%N7OZD5[@>[YF&V2*[NL\M@V(13RLU_%"]8K,L=5*:)7,@>Y:
MY9"S^V?*FJQV*(O[9PXW9=0AN_MGU<<A1A4T/Z]X%XR>5YK.<P.,56&'VNG#
MD]W'(L@P8VZ#>8DE8I7QH7:R40=]XO/VD3ZG'ND]'FFF35X_)W)1P0/-HK?-
MJ1N'M[P],Q.*G62+#_G6Z118K55QY[Z4<8").:R4T0>$%9H]4'9-9-$K-%O6
M9#0!;85.,[,:12[0.\RKK!9W"($'HS)?/C>?:D '$WUT4O(BF8>Y*?3HV7C[
M[,N H9KL3 #;*-5DCX-]!S0W/7J006!XSQQ+LE$"O['(-,%41AN&/</[S2/=
M-,<0A[B1B2([1.$SMM4IAK@?!680J*JR%H6$U\!\=AR#U@X(O9B0J=[$OOG\
MWG;NEU@HK,LFDXT<KHAQ^?C&G-!M:.()!W2O--K=RG;R*--14C79VH$+7^J]
M$::K8^'E"IECX;O^,@:RR?V)'!5*N1%1#)V=85P"EN!$JIP71GRW'!@#X6=Y
MS/66.:B"]QIX))+,<16TM9!-V+55-+6D^QM.%M,I-%/?Q7#>1X(5?*(6SSF^
M(?_A3]XQA\)>].6(-;>$5RJ#&U<1IY5_T3AT_]W=]*"HG-9Y7F/8-NDC60UL
MGG3)LXVP"L+2!A]/Z2]NSHFV_]RE[9O^[!S3M,NZM@T\_8IG'T\514'-5E.I
MMQB4!GTETN9R<KOTT!BVB3\X_;=EVK]./'U(<CKRP _3\/]#ESZ;*IOFT$AI
MU= ?TU WX=O^;$P$\LS1V H5M/H;D<9BSU@\U',"E_S_PW1DV1Z!V/?')\?'
MKZ^O?TR?7>L/QQT<JXI2.R;0^+3@COPT?<,\F2LD- RBD/GJ]N'#_&T<:N4T
M?&GYHFG0EU],['X()<,K#_2P_L? F1R?7W]=5=_ZET\7CSI>>U;L^>/0[ZX]
MGPS!#>/'4ZK!(T4]4M#B1][>6XPD-A8C]J7640V]/3EZ)R[-\LD4YQ5=,56'
M8*@NPM^?ZP#%=+!X9P\=J.!TH'#700V<#M;F @<=U&'H8,6-*!G=".+K1AKP
M5(<Z652G<%==$Y[JJ $U)%B\6@!5IV11G<)==6V8JLLT83FKK@-#=6]+)?5T
MG,,%1$/N?!7P9A-X0-.G&.KSMPPBR'1LF;KIWV*ZJ?C!,,DGZ74K<?:*P$^_
M'Y5VTW31L2FITIV:WL?3M[9-RWKZZ+<BP1*/B$EWO":>?*"ADH/6-8RPS1UM
MQ6(:U_:Y-C9]S=H"(!3TU+*CI^O!* @[Q(2M4NGG7#RDOT;;D]'"OZU3$0J6
MM9)C>8]]S;2Q<:FY]%2 5QX?6B\I<IMZA9<'N49)D2LX9)$QIT;-DF-==*0C
M)>BMLH,N58 DI0FT2VX"1<954@+>*2G@,H1C,@*N5L23X-!;P.:B6A%/>1%/
M(M"KB*=BB"<16%;$$U0?6A%/4)&KB"?AX:DLYV#4BGC*CWB2!O2*>"J*>)+&
M!"KBZ< <?44\'1;@M8IX$AUZ\S_97ZN(I]R()P'H5<130<23 "PKX@FJ#ZV(
M)ZC(5<23^/!4DCK.6D4\Y4@\R0)Z13P51CS)8@(5\71@CKXBG@X+\'I%/.40
M>O-N)5 13WD23[S1JXBGXH@GWEA6Q!-4'UH13U"1JX@G2?=%^7?#J%?$D^PG
MG@2 7A%/L$X\"3"!BG@Z,$=?$4^'!7@C?^)IGS!6X1[&-LI.XA3/O D K?3<
MC3S,FP#TRL[6R!58BL6RK/R-#!&B6.3*RM_($.J)12Y_-F9/ZK%^5%-X*J#L
MS$3Q,9L T,K.)4@4LPE KZS$@/0Q&W\LFV4_;"))S"8 N;*2%9+%; *0*SMC
M(<-NJ20W5C1+SV_(M%LJ"^AE)T+D"I"D-(&R,BHRQ%52 E[68S$RA&-2 IX_
M\;0G]<@[C"T[B5,\\R8 M-)S-_(P;_S1:Y6=K9$KL!2+95GY&QDB1+'(E96_
MD2'4$XM<V=D8&9@W22X\;96>A)&)>9,%]++3+G(%2%*:0%F)&!GB*BD!+^L)
M(!G",2D!!TL\G04>F;F>U]4)X%ZX>L>@?B3^7!OCP#=U[^;FO"B849LBIC92
MP4R_U([9!@^8\Z>J]LA6Z'U9S9C6.&0K;7!LC^?Z)_>:/<"15=/_WIJV.0I&
MVXQ9G,>2H9=T&QS7PT)2FU9(MO/G?O:D4-I\#YRWP5$HD>W^=-SSP/-)?N1Z
M*VNNB_'BC=TRIS0+_KECZT1B5Z-+_;WI_3J;G6%;'XXT]]=J5/^@6=B[QQ-L
M!_@.^X5D\;+<^=@&1]V\;V.OSHX6)M"^NKKN!"2UN,<Z-B?5S:+$RL!Q1>]:
M6<_>U8^5W(M)$RJ (Z)X>K'RP@J.;JH6)X!6!H[CHE:V)#0_8V?@:N.AJ6M6
M!'4(L#L[>7HX5+\![N25K(C*$D!V0/)S[R"Z<,=WCOVTP[92R2=L!R1I)SV\
MTLQ><*>X]F37TX1N?=<AZO1G?4NS_:YMT W*,17Y;/8X&^-8_'BC/2_?+/#D
M@10. R0UN@?+7UF4:(L"1X2F@GOQX:O M4T_<#'YX)4YI?\"UGU3 /0@V4F9
MEJ?%AV\U?6C:V)W%/UA%MR#929D6J\J^WK4O<#3I;H>T%N^>.Z-GTPZIS<(J
MDCAO[7? <8X0(%N?G.TLN6^;\^0$<+1.1KTAA5)^P#2'E R:(U_BK#F4O^;R
MS&6JU'4=<+4"/#O@__[7T=&'__YU^ZWQO__^K8^#Z7>[T3%^MR:#[S/[Z2)X
M_=QR.ZVOZL^GQYEGM2;Z;\7ZXA_[#_C+[U;MUQ3I-[[RX^I*??AZ/)F>G7]7
M)L:#^^/W3\.Y?FEV6M/.Y?-SY_Z^J7[[_4,=.1=WG?;PZ_<O__B*W;N<]+[<
MUIS)[?'#WX\_;_NH:QDMS_JE_!R.?TV^W%WJ/U35N;R[?#H>:Y_N/__R9\'W
M0??'^.'W^>3_+H[U/XU/[G7WJO>B_#/M-MK>\TCOOW:>Q@_]X:>>^WCQ]^/H
M2^O;]Y]7EQ?XT[3^=5)[_?SSB_K+'8UFKY_N[N[:GGJ,+\YN;HSOUK>FHPQ^
M*\_F7W^^_N=_'\X?[H^.EKYQQUDA"^F,E%JY9T65%+T/?[V"_W"WG)#2. SX
M92)TY0&_"2QW0*TCE%IST9=4E:OF6L T1\VG1LPNM<W5CE2^-M<^',UQGJV=
MP]&<VN*I.02!(UDE4N,JX$"D(E0 V;&W\;0D*.U&"!YK0#>B'DW?PKV7:]LP
M)Z81+$Y<T;?.AR9^N3)MS=9-S>J]O)CZKI5F K8,$-\M X3@Y;.2XR5EWHK@
MY:V[P-PC>M!\TQY4,$<PP\M/)9_-JQ=)</>^X%+*3H;MJ.A+;XT N5@ZA)0R
M$:3R["Z"$-#<L)DEPVEP-9X"<D-.-!YQA::/;\P)-JYM8D(#\]G"7<_#OG<V
MBXH$+<U;[RHY+Q"\QV'CN?4OEL:=J@5DKA6NXI,4%>[9@TRXDD]BR\*Z3T*A
M!6^?7]L>P7,4'D%0#BQ%S$N8Y,$]]A9%=K&C(/=XHED!-JI=3K4 LH!'8)E>
M<[P#2Q5>_KUT;IKI?J,3X&RV_.>?Y#&:JP]G-WB"UXI0EQ^ZML>![X6?J)4G
MXB@@,3]0(*4DTM0"Z(4#Q5]PN F-))E' >FV@:,OH0[7*0!M SU3_$2_Q'L/
MM :7AI@S"7VBN=FCJ]F>IJ\5X_0=,ECGW D_YCI&H/L[-+LN^7)1@T=0O+/O
M$N)\Y;@C[)*W\)AHB/S^A>F2+-9Q"[R!G??B4(/+1<A]G]!*<(Y4WK 50#OL
MH0+4I):+N.[]U.#MYR<L-R3+>B^A<:YU(27:P%ZW[^(7[+K8V-%^!?(RC2P1
M6>-(K7-=9>"R"R!!)_.VE1KTYI'*=:.[!O"(0&;-<27C:G!S>"BKNX!+4U"M
M@(R=0RR=4V>3@[8,>,<V<NRI=,B648?'N%26L6$CAV\E1QTF,U.M)N(MHP#R
MA\,N-TH76,]WN;F6<]8A\"^<-,>7)Z[#I6VV[PR<.[876+0:@Z3R$U/?6C(N
M;E.@F>4P2)/S$?4Z7+IF ]C>V2S^CL2[0E(T&ZO#/42R U^7*B@0!W7Z#@?K
M6Q)<H(;'-6TIO+J<8CWPS0DNO+1.$H1ATE+O(+S8T*UF;QT>L91YI3[KW^ZR
M*J=:+()G#_\3T#1R0OY(MA-:^T!^Q]]7K UE/"RB<MZ7:, CJT1;6WE=2P,>
M_Y09[&P)8.5IQ'D:N.>;+LA0)QJ-/Z]MSW<#^E/T"LI5N/_27&*8.S0F%)=I
M2G'^L &O$"L^8TW#U-P9O7N8F6E>]WL%361I\(7+&\J&K]@3I0VXG-^.>T$[
MNUPAF-'-8^Z8E8"FDP\S*2M;&_!H.@!0BRW%;, CW@!@)F>8 Y>'DQAJL1%/
M$RZ;M5N.&0:LO7'!MTY),3^;<,DLF;$6NWXVRTX"%0V:B)RD"9?0D1DT*9.2
M)K1V.ZB=H=EX]"6^G>J;\-B6;677%_B%:&:'$%'<I$!9>BAPGQ1P29G4^V9_
M8LWRA]X9^:SA7=MZ4=L9%,=Z%O#K1RK7UB-->#3-+FVL"SQ2)3@'A$?1;,&K
M[V(O?.9A]S5I0NL!-#_WT4BGN>A+7%U8"RXM4OY#%FVN2,,E19;W*KQE:K&P
M)$S1^H&K#S4/=P<N#OG-PW:(+;ADBKS3>C4X48_0L@R'1W#2@DNEP(&,;SEW
M"^YQE[/ ,VWL>5W]G\#TS+42N:X>\6*T);@YP+:.MQ=)O<DGPJNV8XVI"BN4
M:L'D<?8HWY<G'.+=_+(%C[C9L^"^Q%C"Y&&6>_&?L3-PM?'0U!>YO>X$Q!'/
M3IX>\HY@4=A$3@),87(U4F*J9,%4P*6K+7CG9J3%5!;?VX9'($F+:2;V0, \
M;<.CBK9@NDA[[AS[:8?&T&5?7-OPZ"$8 ,NRTK;AD4DP )9FV85'/<$ 6)HU
M^."XIC3TY>*&PKZEV7[7-NAI]C$5^6SVQCZ'5.:-]KQ\LZAST=(XC8/CO"J;
M$FY3\+BW5( O]Z #US;]P,7D@U?FE/XKUQMFY 0?)DDGTR*U^/"MI@]-&[NS
M^ >K.+<-DS*4:<FJ+.Q="^L40&#NI3EZDKDC0]_0#CR:$$RLMWIPI<7Y('0'
M'O\'%#G>1]@[\(@]H(N5X!D(C[\K!8[<YR,\F@YD^BMX-L(CQDJ (O>Y6  5
MM?=F0ROMC9TB-ALZ\'B<S%6L\9?[VDQ[MO"!'Y_LP.-88*(O=!%3%6A$1G1S
M408BHW:D\IP J@*7R( U 62\_H;\*+1Y$U6?U5,O'"KO>0.7C+@R22",;\P)
M-JYMXGH')ID(7<_#/IDZM]I/QPUO%%J[2BCP?&>$W?D<6O]B6>A!58%+3J3"
M-:()39W^B#W8M708#HQPN0G(,').:U4%+CF1R<M&9:=8]P/-6K ;I9F2<$_+
M;+]84ZK+%25)KE4%+K6R8Z_@PF]=COJZ<2WM5Q5XG$AU4WLNEH%@%KQ5-[6+
MMXP":*2]%\GT]XTC[O>-JPCN>110]XUGO%Q>5;F"70!KM+?F9+BI7440.C"O
M=HF/JX"+CX7+:6SW%(7=0BK)19 J@DMU2(RN)'?,JJC,Y ?$N<NSOZB*"B Z
M2J(Y>%P#O.A7EB5.A7!*0VC;3%6%F"=G-![$UWC@YLD[$D/%7SS'>\M'A7M(
M0F+,I-SK4>&=FP!S'\C\_A:^"U$!9()L*B@@X]YKLN]S^0_?M1AN-@OG/H7B
M/'M@FQ'2@6=\7!5[A#4O</&IZ3EU%;5.GAXN%C^R>"L2;_$J_2W6[_:QZPTU
M%WL?EU,C^E#HB/&:8N@W[PA8KN8["XVGE6D%IK4?3#SL MO.B)A*].Z&!\Z!
M"8?!UL+Z(]=^-@[+<MQ;=!?36A*6=R5Z_W?'Y#,?3S?^)GV;J=75'STVIR?D
MV0Z90MB+_CO$FA%.$_)1,LC3Q9_/CC$C?PW]D77Z_U!+!P@9\DBS"C,# 'I[
M' !02P,$%   " @ NI@^4U)4](E=Z@  ]+L$ !L   !E83$T.#(P-F5X,2TQ
M7VYU=')I8F%N9"YH=&WLO6N3VT:2-OJ=$?P/.!.[$\T-=+M;%]MC^?A$Z^;1
M'H^L8\GC?6-C8P,DP6Z,2( #@-WB_/J3UZJL D"R=;6E?M^(':M) G7)RLK+
MDT]^_]=7?_OIA_'H^[\^.7\,_YO@__O^U;-7/SWYX?NO^'_ATZ_DX^\?_OSX
M_R0O7_V?GY[\WW]:5&7[77)VNFZ35\4J;Y+G^77R2[7*RI3_D"8O\[I8_ E^
M"#]]<=/?/4A667U1E-\E^-73!TF;OVF/LV5Q 7^JBXO+]D\_?/_PAR=O+HMI
MT29G)V=_+J?-^L'W7SV$L;_X$&^=Y66;U_3:C_FNY[^^^N79P_/GC]/DV?-'
M)Q_PI?_8-&VQV/[)3>]#3^W7YX^?_/+;+\]>/7O^8W+^XR]/GOSMR?-7G],,
M__L__B?YM2S:YN/(RJ.J; J88GF15(N/\TJ<X<O+K(8G58OD4;5:567RLJUF
MKS_.^\_+^<>;Z&]976=EVR1ME;S8U+/+K,F3OA48CV@)DC^\+(NJA3FFR9W3
M.V=_Z,FXM_R6+9?9[/)AWEXFC[)UT6;+-/GIIT<?^KU_S>II53?%/$^>%F56
MSHILF;Q89O_*DOL?^MUGW]Y/_KJ9-W0\3^"GFZ+-D[-[9Z<?^LW_F==-ODT>
M%>TV39[_9W+ZS=VS#RY(WS_[X;Q)?LG7<"[A$&=M<97C^6PO<SB5S][?J>3_
M>W+G?E$.#^5E?I77L->_EO.\OJYAY6MX?K;*YPGNQ^PRGV^6^7CT++G,Z[RM
MWNL(/^E1^RF;%_",K)PG/\(^+/-57G[W.4Q-_EC CN)#3T]  /X46VMIDL$[
MKK)Y-A[-JGI=U2"(L.-'*(9_7L[_N:D>?/\KW-NK=59NO__JUQ_^7-,?)VFR
MKJMUU>"8FLWT'_FLQ5L'?P?"L^(5G57EO, '-DD#(@[2A.)3P&S@JT73;'+Z
M6I,OE_+C\6AC1; D$2S*!"XXE<+D&=Y:(HCQ2*T XW!3&6]2U4D.*A4F7/9_
M/9C<>+2 'UQ?5JMD2!?#^)-L1K9,UB1U>)"C487'/%Q&&$]V<5'G%[ ^J #^
M^W__5VPR>LIXY!_SM*A7:J[91^#$$O<AKKJWLN#\YDF#U[]J%]G,/]<-_KR!
MKY--U*!!D";_=GIR>GJ6K+,ZN<J6L$'KO.;?CT==J3#&E!\0[2F^]IK-$=S:
MM5HCP7#L$^(U4UO&/)D>C),=C[+N-^T03I)7\#!:RJ;7^(,-6^1U#<*%DEC"
MPL!VO@0A1NG'T;&@9@N0C."[L-?A.''=P9RBM\1CQ6\ZF^R]OC&QRZ-"#LN"
M+ZTN0%;A(=<%B"S^U,N-&Q7]B0>=]CT>!K:!8U'PG$YT4J_TIVY6L+QP>*<Y
M'^<Y;G2S@4_&H[9*^733-RXS.!;X(K+8>"#KNK@JEOD%;$^3MPD<.1@P:H?,
MB4YVD=/_K7-4S&V:S$F-P)+!^9SF\!-^ZJ-EU:# /X:/4_B@O<[SDA6*R#N]
M$?][@[H!9Y[BTH8OZI?!Y%S?WY4Q]_1E4SF5B-MFE%IPK8)NV:RK<H>F-$OA
M!.0>B4>U('U1K?N4],]PA<,=L*Q:'&GR,WTI.)?V'&[6N$.D?>;\9KC^T57H
M/R^IUW"XS)LU/FQ1@+#",H.*F-'JG=W_]XFJ&2-A25,MYRSS>.Q!M/$9\?!I
MO#TGB73D_"O8[]C%<9-YIUG H(,QZQO&(SOLG]VP06CF^:(H00RG^;*ZGO3/
M).E18# 5>!RIZQF.&R\9_"U,!.4&AS&KKO@]5;"=,!KXL-G +QMW-.%I"YC[
MEB6Q=__A6,+RM1TI%.V/.Y,G\Z*9P64*7T]I2/)3V3P4SVA**#JL9%)ZPG(;
M_B;^J_XNQ5.+IP7NG"GH.OJP9<E.CGKN9WTJ3WD;Z5>T699+/"%7\+)8CX6_
M+4*9.O&JS'_!:<?.3TE!VY=9#0UJ-U;1.]2G>6BL.^=%#<^'AT^W]J8^6(N.
M1_,<=K*8YDYL?\DOP!00J^XEVF"L1O&S%W4Q0TE[45?-&EZ\\0M@_M25=UX[
M=XYI=-G2V1=^@N,17'%\K>V^T?1PV<7Z?&WP5]'6XEHT[("-1X$'AFLWQ=-2
M+E!2X8M%[2]#7,<%R&1UW7S&'@M8_N"@GIT,B#+;/%Y>V3-]^,/)Y[LB5G[@
M^@,%D(.Y#D>+5.("=,'<VWZ1=GOR!F[,\H(>L *UT^_LR2>A40]'V&Q HQO@
M;ZSX\./[0L_'^1QF5%:_6(/G:#$1FV>"YM[3"E7U\5ER]!0FF#RO3I*[=^\>
M)W?N_^7;NW<G";F-\8S/9RW=FV=_N7N7K#UP)^%[\WC*X4\ZM@=K7' ]>0UA
M'3;+C(VUV-%S7_K%?\D^CX8CNEW7GRY &C^:![/E9DYJ%?=U6:S@FJRW:%FJ
M0H:_9F2^B'$9[3#9"#1/LAO(%,4_]>\>.'7^E6"#M$D.NI@N.?.0":[=*MOR
M_3-%FZ_._[DI1)_C*.;BOI);X^SED^3E\+OMC@3C0,$>'DM*0D^#F.>S)4F^
M_Z*_.F5Y]PS!O-6] LP;C2X<L#B)?)G]7KREY]5LPQ_A7XH2;*H5OWB.RT)K
M!K=^AEYVJ]?FD'IK+^MJ<X'.@ W03,4"R<M9CD95A8.X+M 69F.O!56#CW8C
M+O.F\;96*+9/W+100X7RC]_,.8TI9QJWIY%@C)N]OC=\5,(&;IVS6SO?.$4!
M/D-1S;LCU.,VO(9NJFCN=)=3IPAOYLW+Y_RWHE3A"(][N'SJOZI<]Y[HSF3'
MH[>:;9IX VD&DL-##0)'?4(1V)3/@JC.>(2'@^\ & W^1T/NT71:YU<%.<\#
M>MS.'&>=W/OZSM%T6+/VZ3[\32#)F&@RHP[$JB1)\F(L"V&BB .'0HQAV5Y6
M;[UO]S\Y&8_.4:OTJU0G*#NM9EU0<[L:+=Y=OCOWCK+^Y8/!P/JYO6=Q$0&P
MD:T79KC6Q(E<BOZO[;LH^J]FV##_M?82!/TZ.WB!BA4<1Q2R)2YO@<>!7[T6
M5T-TG?,=P+*%GZZ7+C8,)S1<%O#Q^@Y&UW?Y>+Y#OU46VH/P[O_K^!@<S'PY
M_RYYD5WD#^ %_]R@H,,XDN-C ;1\__C9WW60_.KCMEK#5^ZL6QW,\;1JVVKU
M7?(U_FU:U2!1[F\/E]GL=7)V<A_&"UYW,0>3V4V[FRMVSZ2WG/:\!/YF9_/]
M5S#"GL&"/LE>'W,([CM0O3A#^^BO>QZ-D[+#,VL]^$JSC%_A.O+2O8>]_;V8
M\ 7I:Q1F5"MD>^S3*\,Z.8-G80S,*+<!^SQ-KB^+V:4>;7;)S3T['L&EM2K:
MUEVPE?X+C^>BKE8#=SZ<81[HW=/SP9&*61:/EFS"IF(]B]<C7&A='1D'K/$9
M._1C_(6=X8]L\)H8CT3[X1JA)N0%A+]LDVL8Y >[1M[Q#NE=EU_<M;O*YO;N
MQ?GW7RA#RP8^C5/T9C%==,M;:737\TOF[OK&%WIKSYNY&&^RYH$8<9^Q8\^A
MCCLGP=5,YB8Z]A)$+3BL;>.#(&=9/=<CKL&T$PV%?(8+=H;+A=:55:0NMB\+
M=NU3!>S&4^2LH6.7VJA;F)]!#20+3$ZM^!/T +_T)M\T',*83R1D*HX3_9S"
M_Q)A/NPQ4WU,^@<.^0D.90B&TKO!Q003_\^KY&^P/G6!\=&_@9Y43=J@*OU9
M-"=!&$^2\Y87N-?_=:D0L['N;V$*D?:K'=RL%"X#RKVDNS2]NT^JICWNB1TX
MYWD&(KPLV&>[+D!MTA^V* :H1%<R?1!QTJZ-NSK&(PG$R'K$(7@V"L2G'O!E
M2\P\S).RPO1J!=^@_\(_TU#X7VP?4-8* T%36"(TWK."O#B$;;3U)C?N)!X9
M/_!%)HXVV! 4DL+O=;Y@@TK37#$CZKW#S\M\!MN(UQ)\8Y6]YF2(%PB)W,"7
M8=0)2,8RSU Q<LKBE<C$2\Q6/"Z:&6SH!N[M%V!!HV79D]K;H0NZ4B/ !X$H
M]$D->[Q5-F\NJVL.45SE30O_$2K\.=R_H)HD78)O6X,=<L578I3+HY3=ID'S
M [>D%+7A)02.X>N\[7._NN(2^?1_<S_5$QBG,^40>%Q!;&K9&!\,M-FLUP2R
M:M&^X^5%8,*<ER<,7HE=W.M:[XA,[#_2 [NCL^D<A^ T6,%/WE'NQZ/W(_CZ
MW51MSR4F"'6#9T4-]A5\&^RH1I8M,EY13.:P!'WGINZ:(XJ;*"+L!F_?=16%
M F#T9)_@0W(:!%N'M+1KU'2Z-G*,>=:5ZO:$W(U]"<U]YUN2SR]LX >C) 6N
M2X*HC%0L4TJY5>C^@&IC>P$/&XP]"$4N-G59-)<^"JZF2,\IQ5<6BP(M]*T]
MLAP>P0Q.D Y7]ZSGM916#3*]:BI\<[20[.S A222V]"MHE%=3ANX@&XDB^RJ
M]$9.V? ?NEA.$KBX*5:!\[L2S 6I %B+TMFK8?Q7%F9G4+R[D;0D"*V@9]%(
M2H+CS'(2O(96G *%BK7PJ0Q8C[9H-RU?OYCIE^$A7"'5K7U=5M>P$A<QCBX5
M;( /9,FRU#G\H_1K9U(27X+IQK:;NT# <O,W"!IJ<1835<$<-[N8TE:P'^Y.
MJ@;I_>7E=&S_O3<(4 @BG/S,]C(K#](@+AGX[E?X>!2!OW=?X\F'N\4_MCCN
M"(S>>2#&=O,=OE+TVH/D[PA%A8\_5MST\/F_=83U. AMZA(\2%YMUS#3\SJ;
M%K,'A,'G90)E"I._$\1#]5?X"2_R\6W(]L-K-E9MYS,X;W">QB.O*%BU'9U/
M.NH-SWXQI]C<K%IO^Y"A+CCP#.%@=?*TSO/D-SS2892RQTT!O3%WX4G5=5XA
M=+4MW^IH!>Q^6=<>T.!L7_0RY<!+^4[W/@YQSPH<>MF/1Q_^MD_V7?;);Y<Y
MV&PM&.UE#S@;K@!GIQ]@P/8[63#_W4LFKA;(",98J?)BKAXK^$0H",UFVI ^
M:<G_0I>"@ ?D0& X(N?T.P]UO9DNBQE?0CL@@ 36$#]*8QL2^!V/CLXF-_2A
M!##C_"CX<?@U[R>1!S'G</,NA\D=FYMZ3$F?PT0(UZ,[D\!-H#0J>A2P8N3V
MZG\W)M[#?V%O(\[%J-U^2&JA3T!N[,9Q%FJW#[?;A4L&/;@]0I[VSH!LZD,T
MPWZ'+GD[?P[_QVCK\>C].73);G_NO"'][HI&\,D7=;:^9&V;+YO\^I+S3TD(
MOWI_,6+ZOV>#)80?XEH>>EOOI0R:Q-N[(F%@Z/>+F(61K_*L;.+4U0JQ7BCP
M):*QAY-UI@!%0U;A!AA\&:8 !@$H/BK6"Q%S(G2 >>!C<2Q2:ZNU06.433:3
M_*Z:)-UHA4%\5%'QW;,_(KKVY@)UQPH4K_AX-+#D77G"K9:?%[Q;"_SIM?S4
MY+M=.4.0^Y'\^=WAS&^Z"]Y#%PY:H<5 .*=7F(.B [[('M(C\C=@[+2LP:.0
M+!41Z6B/YI.C^Q/,VN!OX1_?[HK1!I4P-K/NT&L'#QT,-\K'X%W4]Z,T>'Z=
MAW=I7! )!Q\LAZ8G[ Q3O!B>TA_R4-S0^0&!. ]B] 0X-U&(79FPGMR;O62+
MQA3_P ;!:(KI4JICZITGY?2^% Y_H=OR:)(\B:Z&\:C'/%K"WO3I="ZI;F#7
MFD41)F8.=A9JYRV8%S[F*-AV/'K!$-B!)/=]3.8+W#^E-W!DSM1%"@0=;T6X
M+,'N0MG 6MJ6[","#ME,! >ES[Z^1^-VRI1-VZXRLN!SK*8JYZEH@N/7>;X6
M'Y9'97.N7X)X%5<4\7"<( ;5:Z*Y"T<98C/TD?O<YP"S'PW*.X]R$6ER&*0J
MY4T]-'H;.Q<'9]NMY.W.NS,Z2U]HI,T5X!#RG$I3[NTJ3;'?OTEABL:Z!^I,
M\.N+K*C9LVL(O#LT^S;86W<B8Q12F"I'"W(.2]5J79+$.C9+7JYJG=?&#^5)
MDO\&]L!ELD"(BZ^/)=WA?';-I>5]GEWRZ\G+DP3.+R)[8'K9;):O:12S6;4I
M.1>QKD&PBC4NW)%?ZQ_/SU\$-4_"I,!N .T]965)TU6;-AA;45Y52PSO'SF[
MFLRP39F!8FEIK+BR*[^6X$/Z@X)Q)4.DL<VS^CA'A8N_3K(YGD^-7* 2AJ^C
MN9._P4URYHY-BI# .FH)@GE48?X:MGM152V=/(<D(7\ EV+"&3PZK7UGFRA
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MY$98RTOZ\?.LF6?_5-)UN0ELOHZ_T,F*.@J5CL0F;R6P6,G3^"Q!_Y1(P?.
M$!-,XA@.))!'O3BZ<BFSWB^/,JA;4930R;1A,KP%EIJ5Q5KB1\/59B05J4_Q
MD/6A_^)2;9$7VA@&Z:K<L!&3L:[%Z]\4%3!M5K59SC%&8&R.(%L[R\A,J"4K
MK@9/P[[<OUP&=64FX]#W=3%SQ1)""+V-$_+(T)W-T"^D*A5Z.('TZ96]</TO
MP81^HV[;,RK<8Y9%7;->\Z)P-> @%<2S<U%<X3FT&;J#&)&=1=E)QN5)F5/D
M@JI8'%-CZJO.IWD C].QLY-?;BT^CO0#$>@5 =H*7^-GG9A),Q3EWJF%HOR.
MDDKW;I-*+JET[S:I]&GHAL#>1P[)65[+G<V0 ?*0&=TO,>8.,@JA-[8<&#\,
M*__(\L9(7I,OG1<2?"6FT\JB>AY;S@/#B2CD^UZ:N93_*FOI+T05IZB%Z?:/
M=AO<F&KK[GZJK9!;2Y;SEEKK8U%K[:3-&H]"VI8OD1SK1PP3OVPS*F$ETV4\
MBHU=#@5LR,2] &OR7XS)1./@"EXTAP],6H JE#W3M ,](U*JW;K0="/O-$[Y
M,KMVL/%_@,73S LI-<(_EO%3>2SL3W>##&CE5M=27"JI$'C]D0M,!KS-U-RF
MNBXE+8B )V=O(6)U@UR)2"PSW8#D$-$TJ+M-73.V<YI3/@RDNN"@HLC=C?II
M')IO-Q%/#MZBD8:[\\\-[ ;!6F$R\RJQ8\WP5LA!*&ZV.5ID8[?#4U<6+:X9
M7C_CT1(<%:KV9CY.7$!QB7SAJUM*V60W0"RP%;-3)B&VK4O/I2!B",1-N%01
M'[;(BB6N#]:-5O([I-M!QXDL7G+&J<^3#=UZ9]T[3J9:.)M?83]'M<U=KR4=
M:^JJK_@_15)2@TA./<AY/#HR*>1 X)SG%N.98\@[+R(1[4B6CE.5# [#GT_A
MM,N/]32%5824RY%;B86MTYK*H63[.R[H]W>T6YC8V(I&VY-S64\F>?V4O"&?
MD,;F[Z@F<>?H]GM8\.%ZHC$BOPLNX=?9OV3/]CD0S.[]<Z&S\8AT!OY,E;@F
MC ,:@K7RLR%,">X!EZ4/K-+4E:%+((.'24^F;TYESJ[[3%!BP"_),9T^RSF1
M<H$\4V'^I2<5WE)+&\DC8WB:6J*ILOB.D ;JT+K'\R&28B !.9#%.\W*U_5F
MW<ZV"'AH$(]?XG^#E6$N&TJR"]R#KJR,@^-X \!2%&WE^V-)GR573B"0!$1Z
MA:.16 Q*SZIT^H_*U@EF@=AA2B9@KH$BSN'XS36ZR.=D.E$8@7@.?,LO&K!B
M 0@<H;%LQ-C,:1P.0" ZAL$J7 ?_#X*W"$Q&H/T5-J%#"^N?FZ*5VI9ED2]T
MA%%[3_\UT"-YV6A40S('KI>8HU*H-G4KI=*@W>DN$7(G(>Q@?V-!L2YZXY0J
M++Z(RCT-1A':*YN) F$;3D!-R&(@!Y7/N]G7OI+S7OT2_OE 9>."Z:@7-BNM
MZNC4DKLF%O)<;FAA25)<% NKDNV]C0$)$ C8^ZNB\D%.]J;Y/:@16'[=X6DH
M,,]G2Q06/ OD,<,'NQJG+1Z7E'E 4BJ4XEO;(:I!:+UQ8\)](O+T"M K3F@I
M0.=,(X8&1<X^_'H*?CRSRY!B0>TJQD^8\Z6S2ZI-Z3]2LQXZ&XD^=BP@2D?:
MI1RXLE,JX]8WB(MF?@=C-DM?NQ'L6. C(N/@:@?)LY,VQVP&]Z-99FMA\2NX
M+\H4E W'Q.& SZJ5>=Q$-ZRJN0BBE:HCKJ.O'2^+9D"(UD,Y=%-"82WSVBA<
M/!E+F1'!89AGI:6B+1YDVC]$L($L>?ICF?"Y>47R!*<=U(EQ7\ZMZ5,J]G0J
M-XH&XI%;-)^VQ!J#?4HKO)975=U>$."%50/:Q,ZPQTNT)F[T;I\NIS'L4&IC
M3I)AS\^A)79NP9#<,[AX&XM]\CZD'@&"@V(OHD R,+SH@V<A]@8&CP(N"%9+
MOX4*2FZN@<P*.=UZKF2X#',6JM=')J@(+WUFG>6P/-0(P([?A$E1&*:\-@G>
M^G"+Y@2LB'\H_^F+,_.OE&G\[RH"W''U1XR($H+NL;8H&,P/@3 Y >I3Y&SA
MH<.W>[=Y"YP*@',#%A=8XNSD>3N6/=(+-T+71.%WE+BY?YNX<8F;^[>)FT]]
MSJ_4UF[<21Z/GE>*W\,(-0%2"&5(,H=_"D#ITKZ%> :#DF:),]GJ'./X]E&Z
M]MCW9+]\3/N>OL8<'R9MW2')V/- 2_@GESX:^AUXUV#?HOY,^?X69;;VBL+<
MN3,^T.KEO+I6"+AM<VR\B'0WR!TT(Q!6,Y2UC[$_"&EVN+3E5K-$#IYWV#;
M)- D48NH*XBA *;!DG+P-@BZ6JJ4J.">PPE5[8+))K( ?WT(FCIY^7HK89&
M8*+2%ND:#7U6SN&DU5NMU:I0>L\U4)_BK79BS96GSY[_<A[8J@/'PK1UGWM*
M:.-YFIV1.%=OM@GLFL?1LD9;#^ODH6@.V$O?83J]Q88H$NH9#R87*Y+"+T]V
M;5F_[F"C3\70QL!A9F*0"ULEV?%4@/*.-N^78+Y)D:<@!66U!Y)AV S3QTEG
MP4\Z'$+O*^73*;%D5+[(L[1_IY#<IG5.FM<V,DHXOJAM8G0!O(]#P7Y:-BK,
M3T])EL&3RPKQ/4J0)G#E0#5.EX)U-RRY/"0ZH5C2YR.VB$(P-#A1:#+5C!LE
M-S0F:(@(!=>4:('*AZ$#>%E(QS ;6F9:&LXF:^^[L*F"8VYY;RPB [WG8B@B
M&9],$5.1"7"!%X-@16$UK]!AF'+X*A>X;;3\F,"2^^':W2L^6L_M>BA>8'BL
M.+J-2<(WQ',SH^"+*F F79W1#>+Y6SVJ96M$E**$.\3T1#KQ81=O,V;\AB3U
M#[8V7";,R&M\ #"8C#),<NL,&Y\%,4<.3P277U&0<IKO.#E"-ET>FY,S'A&W
M(\G],L\(_8.'9%GD<!47*RS<C!,R#^@?E]42;PEW)I33)V@V$P;@N7(UPZ=K
MYF&JA2WDL'(FFRXF>?R#PRTK;QCN'PG#4'-DAL3#):+$<9/Q2*>V!Z)J,C$J
MGANLF)6LBQR">.WH@J9LE4(!!*<;<3\2P)=(.!AS:>_BM$<\;F*$FH2<!5A8
MQ4NO?V ,1]J@ #5.8\!S3&EJ\ ?J6>&[G]S0CMQQ')@=K,EK@=JCMI/9([4Q
M;K"SDCNKNL.Q(?G \Z2'2' E>GGTI/NZK@NIF3U3([W'J\/X#*()6R+V@.LG
MXYN;FT+O?&BGJ]EXA&W-N$JK'^7_5AKB00\/W*XL\#ZMI[?K,&%;Q1R-OM@Y
MK-9U3><.(A7O7G>VX\$.=,N787FRZ?DJ>Y,W Q8G@NE\OP7QO%)-\Z:.RWZ>
M+"NLSVRS-\A1NZE+[O5@&[P*=&.RBQLW>\-TT^**H1X;*NY*I&Z*P6'J %&<
M7H/<G!Y1'2IDKWIC'>T"]>"8#)R'TAL%V%<;XN5C5 SI9>6H2UF##;HR$W:\
MIA,Y:4M:JWS'*F&/'K3J$2PAU!#9EA1N56I5%R\T)[%P%K)50DL1O4FO<TZ5
M\1G';_>@'0;7AA)W,([D?2Z-H\#2] 3M&(U9INQQDKPJE;#\?SJN+*8\5.H)
MOJC)O9C-:K7.-B7M ,V$;#<R7.&+TB]JO>%&@J5</_!SQQ9I^PQK;(:= "G.
M)=\=X\>4#>GE93Q1<J#ACB!EQ?> #2;4&=U41QI+\%!#Z38RT9X"?%P-PC&(
MB@AS@\E%J<"Z[44AK%MFPT ICPWU5*XD< LPQ,B3A_EM9"$(@)+Y$$S$YB/O
M$R3+<BG1&AP-O=[/&7.W1",NU-TY<0W'PV%!I>(4'QMJ67V&-.JL+@,MB7E5
MU)&I5Z,>R%+F+:%,5R#J%R!E3?0O*L!;HRN$UA[\SP83M!D9;/"T5<J0A@5F
M[A;(=G)9X!?@3"T*_!6XO AW@?^@U"Y("3+28"I9_H,?B(N(YB]1L<#9JV'1
MT@21$-66#PTH!GHR1ZU*>D*;K=;@PLUFF[78IV $K(K-RH$4M_CH<KX@$=<Q
MS>!NJE88ZYIO-(HG/<WXQ"SRG'#7J*C$$<2-!//F(G?F^>N"[#A8X"M*6P8<
MO1S 1O^T,1UM<SC+;,AD<V5HIF+M[ V]0?^*."8A#.PS0GJE042NAU9_N51Y
M3*6VV<=$D62G22T_*<<Y>#E\A_'>FY/ZAGBYQ[5SY@O___>? -F1-OOZ-FWF
MTF9?WZ;-?@=6KK9SU+:UCR@&Q;GPFT?;,*C-U\6[VQ>N"VE/[V&,V;,5AI<C
M__3#AO?&(S3W^V)\L$AH!+#^=$Z;QG%4=WLHN%8F"\@$\:DTNJH.PH7AXRPH
M3Z$_U-U2IEQA+1-[^9N:(PT>&(^6==_('8L$YB;9QT6R)PR5EO.&:Y3GN?PU
M3-=0,(BOE\BV0!Q$$#!\D!S-)GPON#<S1P#&0)GM06:Q,QY^9&:=^1^RL5LR
M]0=Z/KV1]L#;1VM*K" 7+D'CB;_M*@MLV,8^5>*QA#US$5G\E<-4HCDF"]4_
MG#41[^#2RU1KWQ?!Q81M#-@,&<M\A?HI>#@]B$)KC3LZ=GIXS]?4J$R^FR'?
M5"/U#N%'F[((6$ABL),K*PJ>M%ZBCI*&7F5^/1Y=2#59D!S8):R3%!O,#$F+
M.PZAV,2C6U;EQ3'9'AB'!/.[I7^!+448/2-'[%(P_V6]P=3AP!!MSYC6(<="
M"77OM]O"KR3_-I=YC4?!Q.AU,W8D?/'_%YSU$RXL2_SPPC>!=# MS.0VGOP#
M WQ%FQKX.7K?:!)2<\=IT2H.BVOL11VC^=]Z6*7 KO"^X'HIA;*+>X<GRU$\
M[>"5-9TC)88@]4+83""J.DT.>R1^T]%A8LA9:I)KN4^JVF FG'2]U\MQ,#'W
M!4@E"Z7'1$A0\(DW0SY$36&\TEPYTW.9(R.)\- (6IL<=/S&CU:DGW!!84^O
M67#"8,#<#H=C#_B/LBH[F6*DEO"98MNTX8A"<N%S$:0:(JVZ+U=&T BU;"ED
MB]*H_VA$4<C5XV XXH,1D532V*S82V)JZ^^P$G8A"BP0C9-<Y4@DXQW;_M6P
MF)@'8#\6\137%<<9&\DK4A@"G7\/(PW1)Y2'E,$;>$H$(PI!0Q&L" Q99C(5
M,]IW*"1+P,'O&Y=.L.U#*.>' ;:!_8<G?B6<!V 9;3&<:NM)V7$ E:8%IXB7
M-E"B4$X"3!&/%=\<RA(&X7PUVQ"TQYVG'=!>RN)1Y(XLAX69;(>]]JK?H(Z/
MH#P$K.QBE>ZXIRYA6^D_I/A,2@VBB\I<8MY@E%S>SL-.QF!1SZ4(P!UT;CC#
M90"X&Z96EF0!);U T@GNR]Q!T0\(0?? 2S:"0E(NW.K>3FN\?]PT#.K<,U<Z
M'OFMK*^_R*,+/USX8%69(<_O1(EWL=2IUWF/Y1GH0XGB]E48#*Q-3-_!Y-J8
M+A@FE)(#V#'H_?S!N0&+W90FVC*@V-Z9574MOKPN#+F>3O)4IN2\]^R,%"KN
M.05(WT?'P.UTWR8['K=42(CE"L+09,G1?OS84795'-A.M>TXUMG,X=)F/^:J
M>LT.ZWD$T'M+$611<+8<H4\"(:1?\MA.P/HHQ+?PJU(.6W?@08?FG93?JSV'
MUQ5;>8T&FG,.)V07I*+=Y8AN(_MOJG)J-##8@1L6QQ-SA]G9@UE#T[>16L-3
MPS>WK*:>-)PFE82FH0T]K>94J:MVD_PAFZ^*4JXEE,0+K.@U:LWA3<<C_(%.
M&KYSI,DBQ;JB!5RM4,1G$TQ;X+8$O C$DA_!4\QR6[( 8<_&<;C"_R_"NC6L
M(Z^*=ID/Y+R)A8+IK)&UD:TD_+Z"$UQ%F=LF8IZH:@=QFMS<4J:K^>9IR$90
M4]4UDSDA+X9KLN9#:WPV'>=%G :T_6QW8L)2OH@P5Z&P*,VO-*GC\YAM5E.V
MX:2&B!DKM*2.NC>Y0>[TWFY*O#T4VY05#%Y\(V3R>!0%*31GS9)PF2\5ITX9
MMO@2+!K^"F\0?Y%,NI3:D2J!#1ISAHA >$WX D9"?F9EYG6DN[:/RAXMB6*V
M(8H &@NZ(I78@C";A?1;#^Y\?8:#.AFZE!VB\RD33=_<)II<HNF;VT33I[]>
ME)JSS<F%W@ALGC1$M_)2V(N,ARSV&[MZ@B.%,TT-@O':00.-F'_H/RP/9T/Y
M_WF.-U;C<_KR3_H(+-6,YNN^&#G-P:_BSV;5>LLC2HT3CU9W:=^/MT*=:P\H
M0<?*3(P/W+]$R2_TQ< E-@50HMD/TTLA1=8-R;%N?.D,@_D/ > H5+6FG0XO
M#MBU72L0$%F]RY2C=N=]DT%'<+G47K&.\*#&[)'</$6Y0(=!.)T6PD]-TF+A
MTHCKT*8AV\0*0Q+) B6 T*AH@K/CLPL=HO19[GU_Y_78<1&L1/*2GE7"(Y$.
M'0X'1<<C&(AG_=KEX#;$$; ?++>K((HK$[LR%;!UI^+8<^8@G/NJ:'QG')$Z
M[]>3[&DPHO 8&Q':W4N#!FC,W?E *QG=<"3'8/,!PX?#9A@& DNTDVB2$GB+
M]@8S9S#,\H)R&93:=[L7V&2E<)<Z.=DUP6Y'C0*SAY@6=)&*!96H<(:"A8+
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M&MDU<S59=7(<!.83W8T#W^BPGB0_MP9D[RL<;@*HA(OH+2\:LH!]'AW;ES-
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M1/8#36T8=E#,>LI R&REM&\FQELM9]Q=A7,L'^H6,@=("SJ;_K%.E;@G>R(
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M66S(\K"MO!\3YQT9>%V)4OYATA\R<)F*E>->4K,F9?2L]'08C^B/WK9R/[)
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M+!T^%&MRJ;PTTPM)Z+B9VIOBL)E^R[U:Y\*X V;"<3\G;CB*//3,=J&$,1(
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M<; 8L7$B")SI$BV[UUL%J)O4IZ.2)KX;%-CQZ !KLA%X:=>DA-GG-YQ]GYC
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MP/EU%]=U*>J*_1&%UPOG(/9_R_4[99P3A?<IKP C8BLX$ R-8RB/4US@W)V
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ML7V&-F/%ETA;L4Y^(7Y AZ+)9PRS)NYA"L]FA5B*GW-%)0H7[BQUVF=J5^A
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M0PXUR,,5[;,,#[^];BYR28;(DB@W2P_:XEE16N+?P-^"ZSRBDJ>=[;]:4)[
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M516UJRZOL-KZRM4UVQXT/LE2@'(UQK;-TC0,>RY_11O0%#G$U]24.UBT)[=
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M EN\#R/3C,%72&MV5,YPD#5EB60"]<I4""O)#&!@V>2'E76X^_KCZ1:"ETW
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M+ ,W:IHW_!PEB9]3Z&M!I!_2WW<LK_("P715J'$F4MT4PY7)RNF?:XKL.A6
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M,:50Q!OI&VB\C(0O$:?6$" .GS:%<M16>"B6E[YR[M/B!-:\2.1:/G6]R38
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M/LJQ5/J DJ!"*7I2UK[W6F=^@YT7H*K9^F;MB74Y?7JS!E!D'3PI6Z#RJ8H
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M05Z#4M]^UC<)DKXFG1A+]8;IW8VRN4EO$#E L"S>";HHIROP_BK)\+H?X7K
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MK0PY\YE,HFLQ&<\&856" TPUW26!@):F,Z#I)CFQJ<' %_:%D<2D"C@W1<7
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M/-K^N/F_@)7 NHK/DS@FZN.].1J%O*WDWI>=P LV99=ERUW?DL\RCSN16WN
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MFXZI/\,LISC7CP>6H?\^15G_I<1 #"H^P$/PO[$/1TV4]\ND[:(G/3PC@IP
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M/,66N?6Z_7,A=^UMH;L^V%O&+U!+ P04   (" "ZF#Y3"S1(10I+  !;<@$
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MLT^4S%$Z+Q7NW,/6_1>>Q%?0-21F?4<FJ_7^H5KEOWT[>@MLW<TBJC57PM
M:+7,2<-$*2"4%16,=$^&FN"H38DN$\N5?(J#%1(@.1/+ -W3V2QE5S+<(N!1
MPG)<#:YO?)U<ZP4$P8Z2>;G$G LO3<:YC]<-BD?^S&ZQ'A3=15Z%IL>@YEU6
M4X0H6:YIWF"/0OL59ECEL&0.&9KS#/Q7*FLE?Q&EM$CN0<\=YM.%IBD<KMU1
MY #(5FQ/3-)LT9B7%S0$Z%$OGK>63Q*9DN?2E--,6)4NU+QSDQN2R;NBO,K3
MZ3GK 0DFJ^"U1/@^_)8U<J.S(#BL5A.'1@+U WZ3+"[BEC R^DWH0+8(W<K:
MXATA\&$O;\#K:5[A, K6@\Z!]@5K0Z([B?!(A.'3J8OJ)G$,05!.''?X+6:A
MPQZI5GJ[HWKCK8E-/_@6AI8P](/_SC#TISB!-["-6CH)BWWC/N]D3#W82D:8
M-"IX&[!VZM1Z$EH)6BA'$[CA!6C+A(MU'W12 ;?JD;6QF$FYTM]+CJ3<2+8B
M-%?IX&Q?(@(29:[1.9'5%\ _)CE8".0?==);%VF% ^#'ZDDR#B)8'4L)D:I&
MR*.S>YJV\A5;E'$L,7$^Z=Q(,"B"KCNEV/?$C5345B48)1R&03@5O4D20V<6
M,)42U'>1KW!4<LV+1&#%FX(CK>6(G[A*/:CO!\XV!KW],^>&MBU:FQ%*;K#/
MG67YP<"ES_?>L><$<9++6$5R[+6.VW/CA.H__67[\4Y\7?YW.S4W,"=CZW_Q
MOJ<)D7U?S.+AP/.L14<S :&+>\AQ$"B2D3-?T0$O=Q@O#J=K"SLC58E(K%G<
M!.@4WP"P 32JFR5G:E(F.G%Y,CDU(.$I;_@SS&"W>FE'+90;R3<]9I=QQR]6
M%IQE;BS!MH=L.# N,LX$12*,5^(^)>U4CDG'KZ">ULPUZ#QC<FP@HE.?YW3L
M%JT\X!<$P.A&1MZRL>3O(W='4!:RPW]N[=U_,8JV_C'Z%WZ^M3<2B,@=32DV
M_^ZB*_OZXWM?SB\L+/JKS^^?# =;XDW#<*;JZ&X8+9M3OG"3P@&P42C73+O>
M/96).16VS\$0&PY H;N(C <3C21CMGO"PY/1<K'(F87P$X$GMP)S!YSG@\[$
M3=Y"7H+>U[B#FN(@9*,OTH+"9C,]Z(STL@&UBQ+>H(>]Y7JDE.@?=G:VQJ.M
M'WX<D9U\8I!BT?'K4P\L9A.G9^D4<TE<Y'F>7-4CDSSB3#AFWZFP*<9[ZP;J
M]4\STA6V5O94="*YMW4L<%/^P^]YD4W%$1J*C2J,!0A>3+(%++<55%X?(4Z,
MIJ&LV:[8J#9\*AR*K)T[J"9KS[0Y8Z"UX3PW.1*=\T7Q5L=_99QCXAJG7XL
MX/"#DZ4DKD'W42=&0;E?FY[5]L1&H1LY''AW!>>2!5C+C9A&QQD4)K8WN>&
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M]5906:C5GJ^GF29AJA=K-TK6EC4&FFJ:-05,<?*87:Q9Y'2&T!#'\Q[:HN'
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M=JJQ>'%OY@&$XL4X$SMC!6 2X\LIBCUIEA2H=+U>JMUWS0&QCKG!&[H4R3C
MY#3;85[;-[;]B?[FBM 1ICI;_S#M3:<H.V4IBSR8I& /.<5B0.=]O[).:(U>
ML0R:+:N"N\K"N4,1Z$>$;6O:\Q)XJ>D8TNFS)F&$F9<PE#CE)1 :+]A.J9WA
M5N!W!NA4I.#\"J]R?$N$6Z^]JZS[8BOA;@Q8)0./K=/#3Z^%3^<]!?6/C(;
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M$DN."</!N-,(VGSRJ&-*Z$-:S2\D!]@DT8).(L ;A3M;[Y8F4X2:G!M^=8Y
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M0"AU#=S82G0?<4S63*Z%[4DWXC5AEK23)V&M4G1UFJ/">H_9ZIGM8Q<\(O;
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M\KJK0(AEU3S^Z"]=CZW"2Z_*#C9-W?(0VA6V21ODY[*;5GTY._RG[]'?\23
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M738CQS&%O@<X@P25YBBX$0CB8:WM)MG?8PPQ=U2[PT>> -9\Q/!/]QKH20A
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M[-H>W?27T%I)8@PU>RPLL@3#MVUF:[Y.O/ Y($*XHH]J06#J!2:&_K2>7?I
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M3(P-?N4U#KG&/3VO9Z24KS34Q=!Z\@.L2(AKWDX(-)#,"H4Y[H[P(!(5Y6Z
MK?*<W8>QQY5$"B@.Q6'"-+OER!'84.R']&'TT$%5K#?N"?VM*;P^UY)"FOX7
M7E^9E)T>?*FKI/(LQ]QZMM)' *MW#&'VIE31DVLZZOJ.[!:LH[$M#<:+G#EZ
MAAD5*> YI2DVJ8^NA*SZ=N$,8D9<;[C/;U,/[3H^LVP*1L%E(9+4<,G*,2$:
M)/# ^6!)W1=+ :*YJ)#I.)O,TF-BZ&\"IMZHO%S9H*]\5HX4Y:;>%6F"K/RW
M[ \STWS).'G=)68ME.52N\4:$D;7]8Z/#<^Z%#>G5LM=EV9&D@##%HA0$$Y(
MP[@M>W[0F;BD, 6?E6%R6IJRQC;<&(82D\>";^?MT0$BV"2@/+ELY3<.SY:3
MC^V6TGZ]*7X'+]*TV:^/[F=*K&OH/8R[W^#,D6_#A%Y'K3"C?!"(D6+*3;MQ
M9LFFVA7LR,$L=:*T9IXA!<H= U".-I*+)R$W>GM3;LC#H"MYC54"R[KF0%]1
MJ]6=2(CD'6DRW,>P-7'VP=Y8-Q5!C=#&QPR 7HIDN!Q)N6<#NDQKFI"VJK_,
M995)TV4= YV!Z(X#8[!TZ0.F*X8"AY#BB+Y3;/ <SDO-]NZB75\2R/"Z[$CD
M? 2XCVAHB7560XS"U%IZPIHHW@]*)"$)'!I9H5<NM2.FUT6@5&MIG%B%XK2"
M7=GHY2:UTF+E??'K!"=8IPD30N=WY79<91$5-(]40,6'#R2[&'2%LIY+-@<M
M0B=[HW=LX.2=N&2WND,6;[GP8)]#IT@IPE]R>FUA_6<%^L1GY;P Y3DGMVPI
MH6[CC+6NI5%/* ZOKT,/<GP8$N!8?M7M33LZJW%$Q;N'R15)'F00V;[7OZK7
M6*^2WM&>"9 ?QH5^'Y9TOH3.SM0SNTL(]^M/(5P)X7[]*83[VPOO^2;A37 3
M.:JJ-V-"H86<&.,\*';%$$G0]'S$CPHI=!%KP]U,]LAK50V"%8I]54'-<F?M
M6=1?KE9][M(EZW*@JCI@R/;5$FF.2,$!4:@9><(FV4[U%>+5%N8\ J1XC;T:
M%)Y35^65<SCP&&!RUR!*,R&E];2!9%UB5$!A2!KL6"FRG:Y!I$8OF>/2C5I<
M7F2SMUU1CUQUQNYE@I&[N4H[0XZJ\5FTT#:B=7=$9A]<WFH).WX2,H490DQ.
MD*K_X& ,7!7; >;*8+-+7439)'W&02-X$U6H[USI2MXY+J_0AM!;*7M!C:*/
MDX/-5$8A\;RSBFT"\WS=-0R'8WB5A\,29]-*B6LZ0U#I.$"PB #MC5U9^,5=
M761A=-'K;TK*%C.PM.S<O/%5+@7N:1-H[7D;,9$;#%]5ZW)A&TC%UFX,0EC7
MRCC1(VA^E-<,[:]K%V:LB^M=6>;JUF4VJCZ)59D;-3[L\OO+#5=CW8]]A$'T
MGDDGT?P+:CJ/?03^3I$;+S(+[A::-=GT-=5N&;FO#$)]6I8SYQ806E:\T8N:
M2W.XDMB.^<=P\^[$SOAI\\X(HO.H49?H'2GZ<4*J<PI:0+?Q+3MSBE^BZP$R
MNT/Q;  .@F4XX/"WO@JO>7-N/;*N:GSAQ@K)],K9X7;N*_'(T3:PJ?QZ^<,?
MBVI%6QCM1KYS.JSP8P49I>!=-\2$#0\L/&7Z+NZ1#W?1E[7$+.P04Y0L4)8I
M C4(C!XO#A7]4TE4PF@=SK 4N&,6-A<%(="(\@AJ ;TL63]/. 6U&C,"S98E
M\^!VOK9>X_#=R7IY[*SXKIS!WD$I\E:*[;6>]G&)%4*Q%]*K+37Z7)>XIZQT
MN )^E4<:$%Z/S09'QRQ)9.QT1JOOLH6Y>X2/892+'"F8Y4@>DO 6XT@VG$ X
M:WH'"FLG!HS()ZU>1?*R^!?1H7#O6A92D)A)80S_=SVP1UQR1P.^2="H2I"F
MN\)W=E ?9@%'P/@J<PHN\_@N)]7E6I37=2.@JN%&'/\6%.P 9&JG!5 1=IC3
M/QV%A=F(2.@PU5S68L7O4P,.^8JVA4=,7"H16B*6^(H)G%" &S9V[,N\PUQ>
M-K,X2<9K_7ED2L=%J$?)$#X/@DRU@C1)=\-@YQ9)7IZHWLSVJEMT!N,D8KK/
M9#3.]2@#4N]CQ0",#9$VF>/>(3("JS0T<QVS",<22M10&XH$<UN;=HVH1):4
M,)5LMA-';7FXN6J>#[ES),,IBQQSZ6X2.]EQ[_HRD]ZTG*U=2A=J*UN K./:
MY08@GO/>V@:Y2J<%X8VH'&@>J::U&T>>(??-UK0YW%ZEA&5=-$HO%[@R!U\Z
MA'G*L+:$K6$;'$^$*&C@DS&D/6,5O0R+%.TPFJO0-<RKU^QR(73-70E=;[QI
M6C/S5SO(N2P4OG>X+FNXA Y.[A]B5 WV"3+;E+.*BW9C6*N<Z<,LK@GIP6<.
M*1B(ZM5YB")L&#H,Z/3CW8BQ,XF[L&]JLQ'B%%\19C(+AK*!N\& 8Q@5.GV9
M T'S"'(.5^-'*V+J8<9RF!SB2RAJ![?W=MI=TL]L<"YL&GTIVK8VZ7JQH>T0
MK>\0O6U U1Y:$:1M5'/V!O%<.,\,XI!Z!%DSF!D_1U6G+X6<;=7VSOHD-\\'
M$)N+EJGK2&Q*QW9$ '[%6+=3+A\L>(13LDHVY!PQ/>)$2P[S)25VS"C)-;D_
MPH0?C4$JNLAR'[/I)@5=.+3%^FOO1++G,2#Z+9 9N%D&9D;&4D&YLS29QM<Q
M/T>6?^RR=9X%M<]GV@5A].>JR_3..6$,A/_@&M-3HY<3LQ?&Y$TAV;E'F;LV
MN/X!D3HU+&Y4W#W$?RI!RZQP%N*\K>OV&D^(/HZPNZX,ZHV:HJBFVFDH2'=F
M0W])Z0MKN-ZNBGH#A8Y>TR21R %+_G_/61;A(\TUJ?M:X3U?R?[JJ47&-T0<
ME8Z#- TY03E-5PUY,(SYM,-L!G>)X/[U4P17(KA__13!_<UWZ-=48^$[.+IE
M71=-V:Y[4^-PA\@VOF:J#<=9*+PSIW4MQHY-U+T3XXI@A=1Y.RF;<E[=B=!-
M]=JJF0E64C2\\7NJ3F]KD+JFAKUCH(%1[HJ6]K4EF-3U,4X<'\8BP.*2H;.F
M#-<MV%C6-Q#D9-#8'\6C;/TD\,ZV$RJ__;V0KC( XDY0,><0;R_;IO,O1W C
M^U-*3&"JR$(@5C2J4HG@J(J@EV3(YNC;1'41'C[@_)6B83U0OH"[OI<PW[BL
M>Z %CD9_2/8D:5K];NRHUVNLX8F3_[*9[L@I.;E_DIV#G;C(WG24XG1Z51[!
M&];54&8G#X^/=V.8;SJXCF9MGKVHX7C/BNS!_:^/3W9C;*?HTT0%^)M-C$ [
M,L[MPCLHH4C421\KO&\5TFW*D>;$]D::D=]+>&=&=H.!&PKO1))NE$#GI/<W
M.[)_EO#LM-",;XTG<N-_*98KL"@HH*QAC?V]5Z^>[<;8O[Q_? +B'!89Y/MN
M#.EIU[8?ZAOX[>L?LA.XQ_ZZ&^,RXOS'__C[CHS)BFX1?&,AI#@BB1EM]^%[
MVG1B;>A+K;_!(C!H[0X I?%[T?,^'\MN5ZV \[P'90<4E*R&(*X71"5$$ <5
MTU0,0H<_DNNY7B,-S&#V5-V6SXL;AW%R1?!<3$U^26;?_(YW"K>"E/0S<HHR
M;" N_.8!S P2W:54B*^9<.?4 PQ?$:10O)Y*?9-'^ QQ5T=4F5L<]G'JF]MD
M3%0MR)NZ5J.\UVUDR[N>#U(60.O2&*)L*;(D14P(V]G,84Q<MAQ>$O*'I<FF
M-#1A^- -3D# > (.(OXLI0_;WY/ &_=T&<>=6@/<#H$#MQW""25,\21*H7%?
MXAT3?,+9"2OZB(_D?4/ATG.NCOL<-S=.#-<#4C<+F3ZP%/Y[.]%\KKJNO&JG
M1,/+]8QZ5RG%9A;E2E=F/S1RY6?)/OV();DNJ/HM0>)^\J0#G+*J[PLZ(>]#
M[A]?1JCW5#T9E7^!70+J;R5QU_72U*&GY>ZE;"7RXRC_"%4ROVLQ3TF[Y-]P
M9C0G,@R,VX=^K6ZL[-PFL1#+,JP[+W,%9H,"==6")7!)93N84,[KQ%S\3$BT
MG3O#A[Z2V<9'6(9D0<U2A#E*PU?F?M7!PUQ]SJ<DS%W%L(C1;,ERQ^5\Y'1L
M.7,[(WF)8TB+CWY;D/P2UI Q9,)4*&#QK&FRF_D<) !:*E,3/Q_5I44\JL]A
M'!%C*]JUZND&0,@<XT?<4F.,?NC6A+I@J5MVPH?;=EQ?AG$:KK"(AE<+7ZU#
MJ=F9-#YM@HZPJW0'Y4Z @6J#>1H1 UF/=:=SW-<T:_AV^/+KHZ\-+UDN4M+5
M?.;N4AHL'CG8[UR1E66^P\(Y+HYMSNS6V<[J"L]](!K-]VHE\$4N*TP@%TI$
MU3?H>;P(.YE@QB ;NV"%YAXK8.SUGE9%MXWY+HY>1_.'<Y7SO&V9QB-R^CN'
M?TY%8B3@'@RT=R,5GDPWUKL1E7B6&EEZ@OQQ.K->!=[;S]'1:)<=Z#:S$YHB
M__NXG73H$.;I@ *K3;*/;]_A.R/J'C*K8Q$&J,MD?)J*'/&UN'G#^JI"5W!!
M,2G7( JDXUP=J.MR[VVKGIDNONC79W\OZ05+P?@#.A15)<;N-"[AHA4ALUL+
M0N[(3KA+W/[D^%/@7@+W)\>?(O>_@[3ZDHMI$<,5WAO]H^R%RT,^U_R)WI4?
M3DHH4;&T1HH#SJ\YQV.N)+'4 %^#1.Y@.=GT:RTKJ^5Q5-4Q?*3D*>+JJ%J[
M,R+:&K\0I-!E*>A\24S!4AFET\$(4.?SM(_,-&#F&=)&=&U337T&3*\<<O:-
MTA_SU&@DM[@/^)V4S^'Z98I':NE2;R,+9IISP9I$%W9$H'Y]]!5=K3P!,(G?
ME@5:2Z;Z3U]J_0_^AA&8N!T[UJ"<#4R%4H3.IQ#F'E]+[Y;%H<PU\;XLRCB?
M1PS<79GTK\EIABE$I+7J9*>FB%4^&SLSA @J)30;R?A.C;(Z4<X>]ACTZ]6J
MIG?#AE8(J#<7#@I-]7K\],FY>=:8D(\_?_I$LKT.??E>24[HE4%F1%FE>NK(
MZ,+G,(-WZE,47'X(6T[T!5H^'>4(89E8<JQH]_1GLU*=V<X('652Y!RN=(D\
M EOW1FNLR#-W KERR%_"C/;LHMO?VUIK4K/S!/B/V<7]$,0)[PIJM_-HM@!,
MYD%5'>[O2<D=QP7,!H3CAI:Z/%SY.L8'*\,G9HZN5(=UZJ<OLBG+Z4%9$:CJ
M3C3BD:..!P"+;P;@L%XSK21,W0M@XK:6.)?]2=<"%1[0R"ZSC5\=4F:B+T6Y
M<7P;,&4I2PPW)P*U9ZZ0TOX>>00<+Y8X.[J4+W![J2C,B;RB.:.#STM^I[FF
M^#73@2!G>N9JXUF:-ZHXQ>K AJ)3ZAMELF\2W;,K&#8QN$5"O.S]/(XGBC:*
M\)/ 3!7.@\_> -ZURW;F B@TM843G3'-I/N&JWE,T9P+6=_>=L)NV</U/TCB
MQ9GC,7L+O6AG"MM74PR?T9PW(^(V++YS$E.OAJR&3M#S#X^/3OX<"\5SYFS'
MW'R:7%K[@,:,LAP:# 9HFMC1*&]LL&FS^6A-:]IQR7G0&AH8%EMW@7T=3TO(
ML,LRS'HX'AR=6.?&@Z/[.?WMH9)8/D3O"U$K&XDX]N3-5M9(3FTJF_C$2HJ5
MRW0;551P.R!5KUKKEZ<)AX.KE9V:,"6XIST@1J@<7231X5>H9@F'2-RI0JH?
M*NGJMR5Y0IDYI/*3J !\?P=XC_K7.Z-K_I4WRQ72[Y%^K4D^:<4G=E#V_,NZ
M])S456.K:ZR;4'W7+<'ICN:*5[=T4O4,ZG5$YL!=_+3BG][0)AA!7,=R"8>5
MDH[KJEP'?((RJ&A$=:GOW-]S+\U3^AY[VMTN!/'EW5TS5!.I+,UMFKGI.7++
MHME6<%8E[5/T%F_O;?![K55$"6YR@P2%(<PO=V:_GQSCAK< !-;T7^"^B"S7
M),^/5<7M:XS^3;@(5'R+&QL9*;)SM%-GF-A^#C=*P>R4_)CRNV)2/0IXN'4G
M1?.!M0.*J<KA<9%@8M,V0K"+RT^C1-6:UU3%VM9S6L#E0[5@YQP$Z=QMGH_[
M(&@_R98/*D!^7 ] =!-X7XDK!D1H#-"992ESE[OO%B4R/-RKFGNKNIBZ[_?W
MY $L+XZQ,,HD=1R^N@1!KKV>%'(?"NT*1\15>R$5$[HHI%*4V;JXZ9&W.IL@
M:<8"KFO5=O@,[^\Y<@3]B2_1C:%25TNA;^''S.B&[1@G"U.7N<2\_@:T%CC(
M!UZ!HIQ F[W7'PK_IRS1_I[NDRRY3> :Q?+A>&/BV%8E<PX(@=(43@9,/DY*
MH]FLNY+X!X>=\EB>POQDIYSM:%)9>.XU^9+B^*@XK-&L1/6/</!;M7[!DW1:
M1WE&,(L)^09;H?CR%42B%V\L38MA?,G$]QG,!_BL%SPOL._6XO?7"?%&IIO<
M1*(D/%@@^RIQ:[8-TU7@A4@R0+-%%3"!9UH,^(W#P]!'0VZ]#>T>9>\)V4OI
M_'%=4U6]-F&=\ZA5,GNH%B#^^@4?+.$F%B8-&0'N&QFM_S X4R+V2 V\0%3R
M"1)/5^1P83X"/)I_.LE !ZFU/!03-64%*D279=8Q-*B8@$S "[F42E>7G8"R
MSPF5^S8[>'61O6I1T+Q$*K N>P8"%+KVCEYPF&??M>WLQBG7!Z]:]'!<H-XA
MC]#ZO:@&#$O1)W!.:!'PU?+2YTQ@['[B:(?!,$*;B];Q:=VVZ,N^%)1]F;TZ
M>GMT>)1:X.WEVMHN8B2E^Q#I1M;6F-%E<D4'J#B*PR[H*BF./;W/1O5%:,,@
M1Q+,]6H1FZ-2/3"F>U:*9W6SX!;(B829LPT,SY.GP&&<(87EHTG:WZ/NX:CF
M<84I%3K.&$>>'?*TS R#?%E0%:D^Q>?!DIIGI]^\/*A&$X# \FA"=YU2FVS>
M-1RZI!A!X8EP+.>]<=G17.S,!4)9=B]0"\Z^*WXJ03U@^V@31<R($2;AZ4PE
M*(RXB-R9P1K,O6&WH/U@;XUX(Q/2LKQI,>.O(GB<J5@*G6IK?R#R!%EESJ^
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MWI2X<G3*48K*?ZT4#3KX&R[]YT_?//\!;:7/O[WX[M63_P]02P,$%   " @
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MT/^6%:54/PR0QWII[^T=M.C/ QN#M/A#I?S] 2N]?W)RTF*_ID4C+,*?_E*
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MFIBD*6P1X,S*1&!,JL$9L&(DUB]7 6X8S&=P;TS48!QX+C'KS[]',)S3FNT
M'13X*RG&FP0+'#Y<C<.],'"^)5W_SW^_;.\?_Y\50^#/QPU7BVI[:N/QA1?<
M"_4U*U =@ (?CU;C(^W&HOTTZZB(;5TTLGWX@_5(?C@#V$%P2O\*AN\B#'V
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M-%7J(9?&E.+? 0)W1&P"M 9[;$U1*T50(ORYK5)_#'+#8_+F1P):2&?DNW?
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MF645R@&*K(A.$BA%'^ICRQ.XNCJ]!OE'(2A1;D"OL&^7AS)HPD=G;Z_- +\
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MC&?WP;7C*4^'<>D -CGM>L_3853VO<W(H.WCG@YS'9_9Q$[RH*?#)6 8:]?
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M)"4X@7-"#E@EI#_8%=(\>R1T@+M*%QV7%Q:U6=R)C/*P-I'!AR0)OH3\AH\
M_'9P=PM HF--P'<P *X>AMJ^YG6#F'U<^,MOP^4CN[!^2LMG)AR]EU)TN0*
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M S9:I!J?1T4^X$EZC>(\*"*6T9N4OT\*',!0QMV/'>_#;D4)T&FSW1>KU8^
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M(O?>,_?9A@$2_&T:4X!_#Q6LON372>PSEG8A'G&PO6T6951QXRS U">P=1E
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M $;:G=M++] 2BN1X5L<AFR>;XD^;KR^@N;"AF[&R)1!Z]W_9]R[CN6"*K(8
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M;\/E(WI/%F-NG(A7WUZQ +OUE5G,8L?0+ @*[+RHZ![+;@-;9O(LS=@TV8]
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MS@@5L"K6\]6J6;/(C[0XOXNG_CSV\B#,2+"FR2*A*\]/V$ QXXP1\V(_]-B
MQ3^T"J'T"@/X5--D]YP+/O1I3?.BIGFYHVD8(V!(Q.*BK@DWR%0GWWQ1*0RY
M"V.?-)X5>8.Y67$''&I9]^32_?'13YL4B[ZO#*W7]MKGM4$WK9D=PGZ6T1V%
MA]"^6DBA1@G3Z*+,3I.KA/THO27KA$);VL)&&L$IW5]L.L@!8CAL+T[&Q67,
M#F)RA>5O@U-_B9LW '-(_(1! @$;^X;0*GJHJA0=^LPD/ NC/./7WE+MPO@L
MB2*/\M\N?@^T@GL,_T+VX]XH0R(5;.S1]0S//<JK)6\YJ#ADO!8\FV[<T.%?
MDMC[H P)'W!7XJ1_=1-EP/E5=Z42[)C_'5GS\M];/1*G7Z"]:8")(RZT@^HC
M^L)NU=T&XVFA/L@QN=]B<K_IBC!-V;>6N'K,VC]F[1^S]D><M7_,?AXN^_F8
M38N?36O_,?F8LXZ:LVX]@TK(*EZ,FX+D2#=%Z5U!A:)ZN5F5W3Q[)'3F^_DJ
MCSQVOS\C:TK\T#O,5,06J923X<,;D:0LQWOXR@58D0Y2@B]&FLT8A+&%(%25
MDR+BI61=]OHJVV+UZXI5#7O%AZU:B)EVQ)(.U<>P*%R@I!BWCAO9U 3.<G(9
M7S-8;Y.(?;R\_T*B)_(QB;-'G#/,G!LGIJ2!N%N&B3GV:(_Z:IXJ?OY)/'K_
M)7&D!GM,.(_HMR_Z?9A1ZECJL<%DC./F-F!C%"]+N%(OX4:*#]!BY2+)D>Z9
MVER,(#X$5>HEU&HS"5_FX=,(%GO!Q8N7>0&U.C0 0^9.1/PBK35XD8"!+S<A
MKQBW#!_X[89'BOM)G(8INT\7_[3-^*RC ?PJPY@W/F8C9MOLSYADR<);)30+
M?^O9D_)RRU(9O'Y0[PZ-YX.[J_3^-08^-4T[QWS#N["XYA'M5.ENUS(&5=I_
M=G(M @LA'H9G8IBQ/?RI2'EO(7"R^>C]DM#3B,T7+=!#AS[2S1;6R<&Y?G2>
MPG#9H<0=2#C8T;_V5I@1);H\N&H/VF/% 87>#?D8!(\4?&(@>H=Q*,,*'B,V
MI6:E+KQS2XJWJ -V\![C892=QE(8[HE-40/Q53N^]0./0I^K<KR<+2DANN%'
MHH\=QDGTD(8"$!0G=%?9(<3E)"$W39E!<%1ZD2T?B'AA+DJB[GQ+([OBP<4$
M.#,MZT<CJF/6F,?0&B-BP^'KTO242"C+H3<=K/@<!<FCLF@H"RP*:'@G.4FS
M<,55N-/!W:O6R'D]='-U&(8!R<="<(@UZ9P_KWG:) ]*&2(2J ]+8WA@ LD=
MNL="Q#"TUZ.#*>2H( -.W,5/VEE5Y@JR'SIDO8^>/C>8$41&O+B-BA^%AK3"
MC! R5[0YPHPV,F'%1?C)F#2D%9)D/5-&CY_9(B,4.SS)F)_I:,K^.C/7D#V)
MH-@@'9>(\V<_RH,P7M;EL;%\A6K"X_0::@H=!C',433PU>V+1ZD79VF29RGO
MC<F#Y8TCDW;F^T_5L//=L(:7-ME(YG5)JL)#)#A-5ER\Y?6"4UJ2,M-[]RM5
MF-J,017,UT5AJ@8SUSF:L]T^E^X+A@$4HU7PQ+Z@,)I=6F3S)Q(N'_F]]XE0
M;TG.GPGUPY2D-S3T8;%A@S$S&6T:6$9(+P(%=P_J"3QH3^"6<,#9ST^9Y<O!
MR[V(E]%^C[>M#3R/462\F.Q]0\M;?5-Q?-XR6XN&<1KZ__ BI A\/&Y'D(SA
M[@#>EQSD(6-P3?M0@',9WQ :)@'>2SP&G\X3.0?6K4Y966]G:L5XZ&"UMAJ&
M,^R43$Q%@082B?6^I?;XWK'-_L(+ULN.14QU4C$RAK?$P;5**1U(OU(7I]_Y
M\SJDQ3?;A3'*TZ^+SZEL7JBRPNEIBL#J\*>?DHFI*-! (E%V*\51I52?<8$[
MII@'+%5U>*ZFY)!P)3AUMU:C,S)+_,^7:9J3X"QGI_*RY*7@/2W^<<MPR0[2
M$:C/QI1TI@_:D/ZG^AN/-B,&1U1/&E,2L!U0(1U$79PQE4-_5">,%D\ORYBQ
M+3!U9U"73X#E2^7P%K*"A:_VN:]3'J"&H"-Z2!:]^<QCUZ_*,LZF\V#B4GRU
M+EHJ?V5C*H)WGR%4343Z91V)AO#7JB)V:KOQ.Q9[*P\\&W$\U2&7DSD2$055
M:Y0U9[8E_]8>HRX<CE(6)J,[@\BCUB*IY]I%U%2#<>"1_,THHZ9,YC$E?X13
M>=?:*W.6.U;>]A/DZ'5TG]VO7!4/I%=KG,0Y[B";P N"8DB/?;=M"DMY42(&
M59;(D@WT381:&@=Y^_I<7&D5-D4A;'1)L\@)O/:H=:)X,2+=U40Q%6=K,-D7
MC866KF;O95Y6$.#-:+(-W\J2N*CWC%7B4TX1S24$*^N)M>3:CV92R-'ZE^R1
M0ZS!V4UI@+Z?DCJ;($5OBDD %TH69R<MI"J98N$X;<MJ1SZ892ZKO0&Q_EZ;
M@KOR'-*=HBF#/4CL5J"4>[7*5^A9GCTF-/R-!)^834L;C]*\R5H[Y/>6&^:E
M>V*^:!CYE3T^H%/2/N^.O-_8MM;@*F"W;:;$MU8QL6.AA]/R<"Q7WL=!;&\P
MH-;;8.[(F]S[._P+9IF:,N48FK$7NO$XE+3=!E?]W/L=$RDC<"YCG_)N/V>D
M_*\L(@?W.<8.BR]>C1U*WV[W+N41T/"K]CY3FV-]M6=J"]"19<W5X(C?=1QL
M15!FOD*-PA I)-W.@4H.F;,IH'E4,!T!0;/K!GEUF].E%U<URM@_G)'4IV%Q
M2TT6)WG*4$EK>%^;Q>!H4-![0#,:V"P70(,4_ 5,>U#$U^ON)ZX^HMNN'WWL
M+#Q1:8DXI=G/A<<&^A;%/FBXYMC?]MUR[1&QMD?84Y.I[G(![B$#>3(R A[N
MZX9#C^S=ECX&=6I4"U"X*[L/HK"G'1-,G;SA0&$%O<Z8/!'4ZV7F_YJ':3EM
MK/=K$2VG[2C[;"9*$.TZQ67D^!\IP6P/J:;J9&,"*K)*7'OXX;S'*0DC/5R#
M1.?T#=NF]* OV=K'4-DSK>IF P[S 9U%'4,CVL;#F%E=< $>EG2EPOO7S1<M
M8O!=$"0<,057+7#EVE@+0(*,U5@<*2V+!IM4#HZ,MQY20&TLF\0^X>]C'(K;
M,/U\LCDAL?_(^VZAV7=*HGC+93A;3XTL2OW.0[(U44233TG4=0MPJ)K+!;B/
M)%H<J8HTDOD'$:-#VP]#B,"]5=L"9.BL\I5EYTY[5#<9/0+'U=:6:T\<PVWV
MT7O&P+8UZCBQ;4_<MDE0G'Q%0Z[:_-#H1-[UG8.W,9"=O_7/=T[6^J9>DOJ2
MF*!Z\)6+>AZ:H![.U/(&6YIHL8F:'GXU?D [9FKY=KR- ?8BDMZ2)Q+GY)I@
MAN%W4W+8RPIJ-K="IKOA0DE?F?E^DL<9(^>3\(G?.1"E(R3FLL6<B83$J"$=
MGH1Z:Y)GH9]>79UJ'9]=7[I+3P&_'#3.TLZYVS8 "UHS/PN?>$HWB:)PR=2
MZ*$M^]ZEBNNC+D4"K:MJ!Y\-%\E\43$=G,=9F&V&>JF0L> J3*MO&(DIXI@=
MM-*R7FD1&GA#:/$S'"-!2,UA,0M;$I5 :;>%5,'U#4W6A&8;GJ^5S>* IQ^N
MB\*@GU*RR*.K< &+W (-Y"C4WTK,%@PI=0:)X0I#;2C;;!H[10$=@H33K.C
MU&1KD__ 6\(6B>Q[9P4YK:P.*3+*Q 6CE/!V8'J9+W$61CG[6;F'-HL)!;^P
MFW(5(&E__9CR\@*.*V,QJ%,'3+3BC%!VG^.V[U7H/801PW._CK@EF7=3FKH]
M*< /$)]O<%DK35/-/;3CLPDO(R$2ZB8Q0Z5#-*X6MO(?9$,>P*36!N5(/114
M,#8\I4$]RN Y#%KPM[54#L?060K'&&1=5=4).AXZ=G4P<1V#CH]!QU]'T'&Q
M.=2D3Y/50Q@7IHJ&3US\M9,.I.8N<0D,EC..6N0:#.[LN_GB'TE6MA @[(J4
MU1:@ED3T1G9H))O9&X8 #I8Q4U9JJQDH';9SRO_+#]PBL7F6IN$R1NISUY,E
M=_V#M=7!EA @1:E0E"/=9ZRN@]9T]KM1$AAK4]H\;$L%H2C4&7G(+N.4#5!4
M1HCCW(MN:!C[X9K]H:R7 +O_PD9RYELVV_F!\"A]_'W6<L-*.$V8*<A(%7^Y
MIUZ<+@AE9PU.J7\M!J8C6#-\45X.:@VZ3RJKH>:)I!]HDN*X#91$)W@>JX&$
MU ?2]\L5&\)'0K@!6.W6CTG$**6\CA_,*Z<8P]%#J*%G3@4(3O/ZC@.V"GHT
MO<;4GT\*?1D,.*W>.RA>D^R&)HLP,X5^-\"4;#T '*!>YX,\I-01)%XC>*3Y
MCF)TEHFB4O;;Y]@]S)14#8_F,[*FQ \+2P#IU;9!P*D#"RRY]O-L$Q^8VVH0
MW;Z,V1_)O?=,S)\&ZTENQSH+4SZCG!)4;9;1,W<*S->%11LOKY@E=.I1NEDD
ME-? 2[E7HBR8%T7)%R_>KXUI:5I:#+B,;@;(N[D&]("U'6>NYN(J7(59P48Z
MCS^E0POW@+S37<Z:; ]1Q7'T'NK0&2FOHVP2,W:UR4X?>2;F93Q;\102%.EJ
M,^$N(413P/KP6DYI*RS&\\6"5 D2%?>W7D9NB9_$?AB5Q^LLNR#<*1'Q[C@Y
M&VBS_660C=V7AALS7%.L=M"$!DT/8LE<)QE);[P-=PB?)O$3L]%"]D?NDVQ9
M-OI:IQ[YX(XCU3"=\4ROFFH:\$@HZ%A8,93=P5 &4MEJ/AB=WH%1)D?9+2_N
MS.LOLUM&X59EBY>?GR>;YK^@!4IID'==UD=3RYL'F@[(..$Y33J(@50=9)Q&
M3NEKMTALJ.T%#PDA14MUR\=I>)1M$6'4.^,E%^[#C#>AOHR#\"D,<B^R6IFQ
M>W2GX:(&^YT$)[L7L4Y"/X798Z$/7'T>P_5]4B:T6J[3J$MWB 4F*-XHU5FA
MP%0X6J_JJ,F!Q5J/1K)T5L(;0YQ8V^7I8T@6%V',;N^A%\T7B]#OKK730WHR
M&JXJ\QCN2K7TI+!AU$,K"&X]:HAR$M"8LIQ$L*&4AVE:.M6IK!&@+?[:J>=7
M?"W97I\E\\:(R.963T4F;23J@7T77=\Z?"SOZ[CHA *I/DCE_/M;LB)7B1>?
M>/'G6?#$W;\XO@<9/7>!5H82 X%HO>%NXYW:)R1(+]@\.-DY#9=5X%Z*$P$I
MI^@LY+&G]!0X(D09RRC>)YD7@78^]2@3W0,!\ "JB)A%N3QD);=I&?[*^2;!
M+N2Y&8".L\8T67!5UJ#GFM,%&M)AU;!L=Y-U%(GNTYC>JA2B!8@B-BJIQ":1
M\D #DL[C\V=N[>=A^LCU8K[@E$_((J'D)QIF[#JQX#\KGZJ+_ 2>,\*.WM,D
MQ9&G/>X<1=/VU *+TE&&/YMH#V=^OCAE!,/LPN,/W=FF*H+3K'B#%R2BQ<!4
MK28]E$%%4ZQ(^H*27W,2^YOYHNYO&]>=;GG,/<ZUQHR3::Y_0]25X=ZV-*#.
M(N2Q+K/LAM P"<YCG"Q.'?HO1]I"A&LGA>6'])+7PD%_E<1+1GS%?X2XA<LI
M3G7/5N!82\^VCZF=-5JJ2^A7NT.M2VAB5%.>K-\)"&PM5[$+RIJ9U9D1/)R1
MU4U^LO+5@;@6LMW>9%T<[.G9EI7!Q"QD8*K[LA[*M:2M.[]R<I\T7GY"DI[F
M[-Y6V'+72>R7?\'9J(&TIRIA,+:U<&6>KIZ.KM94$&6J(/DBW&"=6-8RM)9<
MWWW>?_2RG/+'<J94PE=3%$-*1'FR!RT0V%JP=OU5=_D#&Y@_<)#@)*$T^=(H
MG\6O6"@255.=YGT5@&8M1LO>*,&V,.3>.E&9"9&K)26O$:"?(IH]$OJ!Q/S1
M_OQY36*L7- ..E.U8#HQJV,;;$4#*>+36PUT&C]'$9XN#Y,]_+3!KJ4N]A/U
MB0 [F(%Q/)ADI*FM0AV0:O'82LSM-I*&M3BG'=D'0+ 6FC355GM977@A+4IM
MSA>[:(NB=Q5H+4D^GY:AH02CAE_B4S&*KJQ)[OJKS!<_>93MIOME)&W%5THI
M3FW; ^)82\^VTV2V2AB?90^1>9TA$"]Y[$(ZBP.>@5\T*T61))CX=/=#.+ZU
MA!%<*G5;'1[6PJ-:YO'N9]<$ZUU*175:^ZL&FK4D)24/]:OV5HIR2_CL!,$]
MHCJ]@F^GMZKD4-2X2RL>]C<++SR?(+_+=Q*;ZLDF1J\6F,3W81)Y3M;E@](%
M@;8/;7XQT56Q-^TZI-]Z[;$SLD[2,&MT:)OY/ALR0(YR4%&=ZFFB1+.6I*44
M]ZK(>4>G/7A:AN3S:8E!"48-OL31T*<*>!E,W XP+DQ#E$6DICHMZ6F@6<O1
M9HI3O40K5W%ZF%TA6#Z='T[.MRK!H$;;3G>$LCISZQY5\%9?G=C)MPIS8.EU
M]3 32S<"HU,+19I@9%@SMZ4$*'O7/HWI66E"M&K!V&U4P&^GW;DKH(4B^7Q:
MAX02C!I^2[?U;L=/<TEV[E<H'K4NJM.2G@::M1PMA3R4IN%>3-M&'2TH,IE!
M(TWMBJ\#4BT?JY?]O<V4\PNK7]KYX8NPP2H,ZO1QNQ4%.VB=/_M17B7";=?H
M$#: F/B+,0XD^-;R554#&J@#0^;%2S[1HHQVSP[M@M$.@%,M</D@QAM.U[#P
M0L32 1 5M[L ,13JYF8CF?_0/=AYR:Q;7K+=:M',W8A8=T%8I4R(KM6%PQHH
M8)1S*X:W7+ZM.::3:KZ=VM,"%*DBV-[X%@M/[F'JK*0D!%90B4A=6#^R>:[R
ME655;8_JQKP0+,,:V+V)8VP"'[UG#&Q;HXX3V_;$4>HP>J5U1X(YLQG+S#B0
M/='UG2L7IK8UT3EII#* ;1?"/JL#>&,.2#J\INA("@J@N@J@_EM^]:*=T$N.
MC1==A3Z_%X%?]B7?._.U:*\2*0K*VGU#W0$[GU'[701E0^K=!F$CF5T)96/#
M[X7J40:_'&K!+W].'\$UD:29EQ7CV[TL[HWKNIT,6!NW%OD^,!#3L0_\EOLF
M'([LL#."0,LZL 9W/;""MLTK9C?>[JZ:FI #.Q,8%%)_XN'[@5;U]-8G#LQV
MZ=)LU$IO3\UN+ZEVY@JSB?)5D3&4_D3"Y6-&@JKFWC\27D6?%P[A.<ZP<]]@
M6'>/0&;GK0ER*#?8+D9NP_3S!26DF9UN+KGNT1R]:-N3E@ DZU75"P;XRY+/
M5(.7+ 0)HO6!LTN3&=KMR4*N2N9@PM2Z_85##T!_0!N/S'8.@FVMA,A+TVWR
MVYS>\LWL_)D9OV%*BFS&769<]:](W0#,.)G*AM03;TC!\L&\#Z)V?PT'A(%%
M)QU3SP,!'LQ"'Y^.\>&."-! 2"K>[8?0E4-GCQ\Q)C:\$=HWM*^N[:..?L)Z
M/EI]VSIV?3QV?3QV?1QCU\=MU;/:27'^:\X(GB:K=1+SM!^T)N)RBF@K$6<_
M!<)H-2"CIKE'"K%1>#<E-,<:J%DX2'&;(A+ A=(BO),64I=PL7"<=@JW(Q_,
MK4^PUM$V/AD]U^];ION>%$.(J\UFD3^\#5!.T9'UJ*''D*I]X)<SZR)#VA@!
M0G.Z0]J4&W2?- @62MC%/3E-"MHT"7(_2Z^N3C7>X^0C.'B>T]I'=O%"<B P
MVAM?)'1%*+LFD#5WV[%#,:3$9[^<:L"O',3%ZT//IMY =*Q' >SJ#J]627R7
M)?YG>-RN0:WF?2I.7E%!]XUV5>8#=%"L[#N/ZT]!9] "OQ"Z#M^@3!R[6I#B
M'#2-*IO5LTAGY0-UQ=&]K]U%'AA[V"50V T'5KQ5%339W\@3B7-R2_QD&?.X
M\B%?!84\3$NNQDC;[2*^+>Y3=P5J\E]11Y&NE*"CI]T^<I0#:+G+>&E_YM1_
M])B6+#XRKFGH1; GTJ[O7*6R&.^(G9-7/I4;19[P@DLW7@C+$VI]X"R,QQC6
M]GP!3;G-BED7]7G)%?&*P(=6_SFD8M92BI.2$Q!$94-LDRU'L\%#KY -\: 3
M,Z4-D5,WNC:18.,JQANH[YMN A$=?C6I)2.:N;*1M/$;ZI8(3L!<B\ T[=XV
M1H!VSV:2>/0H2;LTW98DF@0F*HD61EBMFQO+K[C)8CO(2B)3LFO%2*G;+O=U
MEQ7AIS>$%KJ [2-K$YO42:*&3MT]N=HC!HG7+3A\3"+&4UJZ:W>1NMJV@W"P
M ZBDQ@1@&*/<)N&X\*!<Q1!X^WMW1"X<\*V5HP+!0A3N,:JL=W0%3%7UX\GL
M/VP=8\J.,67'F+)CR3S3_:N[:)Z]0F3'BGG'BGFCKYAWL%U5CW[%,L*W@ ZH
M(3I0T>V?0^B4+^ ]'L#+P <\HZ>#C),=!ZRA'4_7+8QL)XV):2%9.MT2&8>5
M8R84F'ESS*RT:O/(<RIESJ%C2J5U6^J84GE,J7284GG,*^IC^4$RBFS%51T3
MBCH-D&-"T3&A""6A2$$Y/=DT_V7H#;.+_(O9/SNQ!=0:ZBO>@?;0,5RF];5:
M)#?4=X1#0@-LER.Y6ML6$6IECOPA);_F_+7CB?V_>_8)GN]00&LB-W E9%B1
MS1T$$3<\,;5A; ^9(U&NK HA87L3A221=CZYH%RZ%BV(R;Y_\6O*,\=*+M?&
M^^3FHP:VN]\>-XZ-62'HZ"DS%=C:"N/E':%/H4]T\O"%'X\;4?&<[::B'EMA
M(;<9.[9PTVPS-O)Z),J%J8X2&?D,M39S[05Q_DS\G-=UGB\6##UJ>64(AI]@
ML1496!@[55W&Q;) ]H9UU!:DIQSVL<&)6VJ;_H@5;KHI.32(E!=ZR14):TUL
MR1$:DG1VPP1 *"4!=ODA&3VGYZ0X6*LE'1E<E@,I.W*YOIZZ4#!QB(M"J0_U
M8ZFKMA:7*9RS/'M,*%H]'@5)AUGY>GE24 BQ_/AMNLSTG=,BPB\HLCU1DS"!
MI!V5W[$A1C&<"'USST@:+F-.J]2>^:+-#+1IJFJ4R2PM*"J ,,A>I2WFBT9A
M#: S3O"QJPQR ^#%  #"I,SVLC/RD%W&*1NFB$].XB=",]YSN?PC?X H\J-Q
MRF# J4]#B@:H0KM#Z2VER]BGO*[0&2G_&US&NY.QH6:@I04>S%WY#(/%!H=(
M^=:L_S16=" C-Y'GDRI96RV&@X\F<<H+YJNN;J4-:MUZ[3[9U99KR+'#*!,
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MQQ'%$$-W'($#?O!T+@+!4<>1,U($C;$5LG-YWH8I7KEM*4&G=7-@:MKV%,O
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M5=F3V[T)W=QZ7SYZ&:&A%Z7:Q4[E8SCSEU@Q490(X?@?;VC"SN]L<Q-QMN.
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MIQDD'7X#UO<'< OWX,O7X.W;;_Z _^\K\&%]"MZ^?ONF;/*__ARCY*>[((<
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M9X,/'5)XG"4-.$<$KZUS'SR'$%[]#?PUP<?F^+U7=*CPH3D?1%,UC>0D?1*
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M]#:A%3V$YU2G5G]:I^=8R!=/2CY-W3X=AYIIDL?-C-SMI1MM1MR5<=T3*%(
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MQ),953GHF6TI16C9RRYB^>RJTK3JYN96[&L.J!]099"Y="ZPY7)+@C_V&E@
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M' X)O/<>]=?@^/E,H"/A6^])+7?.HVNIMVM)PSS,4%E+HBXX'9TG!2J>7%U
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MMY2<2ZS7DJR5,#YEJ$2AM2905'E6;!XR@N&<!USP:1&5E4*1W/'FS?,F9.3
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M>+Z:/IL\*_YU>H_@IG$)545OU/4(W$5+A\ _]?4'V1CNQ(B$$MXA4I4!\GZ
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MBI$&.Y@V$QCR+]%4Z+=L>NE95>V*[2?.P?&QW,AC_;'> K@\N&]]!UQD&&D
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MY'ZVTO.11N/1#Q*O?T ;OL\PC6<B$T)WZ"0^TL271]T*(S4.5D39Z=RX7_)
M&D#&B J'C/ULR'LA0N&QUJ@ RM3:0*%2\D%YE;"NUBCBE$H_.>B-%J,^;WI-
MRP6I4 =^ >&46A[/VL&LO/I^PU\-E9>6-7CPJ\\3,"J!9-Q'D,BIK)_2].*7
MN\>&>_615Y04R7FI;[4#V3$U#2/*V<SVA85JF!B*'(U)3#0ELB#\Q.'V0HP9
MF6OM)7"95:[D14'0$&W6HZ3^4V?A&+<]U&6%G4#SQ:VL^E8W<WSO:>;X4>)2
M754*F6&OG^,(Q0J(^]4GNDA?SS:UL:=:#L0X# :&T]USC"Q&#8N1C__>'9A3
M_#GW]DVC'5HR$_NF:):-Q*95^"%BQ9(ROW/!>/HT"J28  KQU12Z"E],HK8E
M]4&?1BON94CG4M[#_YA>9FVN67\PWLX(K/>)X@1Z/6P$"=#[EN>!(9Z5_Z<.
M,R1N@)R%<D-15C@548."J$?1Y$,R6"%[^>C]@M-(Y\:2\)G+S==6[9ED+Y8<
M]Z[>O!,CU5=.S?\@77%'%LJ(G+L_IGE$% ]+:XYI'5Y[X4C-Y*VE_/3JYG&X
M?I"J>4R!4_1)@WP*W1Y9?&4[L4[]Q8G%JTZX?9LPWG[XT35%W0AJBN;EJN-/
M[;1"^W$FH.DOK=_+AA>;'L5#'S90-.;8^ON$3/3DCIU69IG#J$.*;&H^_3!B
M=KGT?F)PWW*8].QPS7MI%/ZBPTE))J%:3>K*H62*D_).8@S+WD<1#\._LK];
M,*H]IRR%PP )Z-JX?2F%A;@I5V)!-V+>1Z%0#'DP"1#'9I"%<CPCD.-4ZE =
M;!)G9AR*.X,^[Q*,3@PX+L*?:B&O</[$2.H:O\/9\OJP',+EC)^Q@>?>1T.Z
M%%J9V,?*H;.RL1G$\2/_MU6F15_Z8?"34-BDFR*8SF+@SOVP5GH]S"S(QL"0
M1[ZU)C8L:HR'Y4/!4JNC1EW(*0G4=9%_*V38Z&W3_?W\L>0;8<"N=I""O]R(
MPYDW87>@',+Z,4P/<AV#&7=*A!1;IDE4YP;':V5^K#[V6AOZ)=3N4^,5Z5$0
M%;!@<HC;A/DIPN/^,0[DD<B:EW__($SQ[N7##_G]JKQ(&5STNL?E\T(,;!BA
MH[\TFEJ(")OY<6+S]LE$'70'@_&!;T2VHE%;BC)G#:<LW4DY)VRGZU*HZ\I!
MM:R^M@<B.UFS0*7;5UKYI%,;CFND\2IK>DTA01DA"C85<PV&@GJHLP\2<-:H
MVJE%"$2_LU2^9#T!QZD0,O_![]K9RPXQ4#&S:/F"$!)/_;#HS5O;;OSK-T7I
MO>3M^ 6#!VF=,'NK]@<8]@C+#,B) ,!7U:[8WC1EM2J?Q0_JYIZ.F"^G8?T\
M1@6@1>!)IA>3UU1N9<_2O(_'3N\GQTYO^5-15N+W$ $#< M![QUOGGZE#YSW
M2V/6VA@LCM@!FU\87E658D]D/</VEO9Y!SZ"BW*[$[]STJ<'-X_O0',VF9J0
MZ1EUI^]Q(Y!^4M+#[4!&8#OG53S-*OT13H_O1'*!D6;I1!W1@HD%(38WVJ4$
MS;%S)U>K9B=#!<%D%#UPG,RJQ[K))20!Z@AE>%@ZB1V94XV>GHNR@<]Q*3[9
M5JRPV"XWU[6P?B&HHT(YB0D@PUR0UVYF WT/YM-Q,Y-]D%;C1*&*'\ 15%\_
MF+-9:QHTTM)=K;.=38XT;S\V^MQ [56#,B6.0SV2#4.A;D8,)C=;(\2A-FP2
M0[(JZWTS#IU9_O[E4_'?=6.PR=KW+[?B:&G 9?6%/ZC5IS5 T3/#)ZKG!E5;
MSMYCNLE2J?X%S+PAE&Y"V@?E4":A.O&16)\Y8RS6-R*&&8EWT)@/V&,J?;A9
M/H4WV9&)=&^=BQ+ (ZMUJ_3G$ J1,)55=^A^S$*;'<010Q\Q>+PP3#I1RF7O
M<]-!I_>\XINRP[)[8]]4GX(Y>!Y-*(N]T?.^77B2KI$OCS M\P"NX/KP*YF<
MN[;*;1ROMJC=#<O4#JQS^+O,RZSZ9-([>#*3T#OW0%;GC6USF:'_46S5IMB*
MB^1L_516)>Q.R$#1.]FK=ZG10DM6X^4E.Y[!"7.3"#2)2E2($_@SD^QKF1-F
MM701YGK#5V4P:2$"&">G''?'L6>E_%8/8@,>\SN8GWD%;RW%E_X'CC*3T.?%
M4[>$F9#,.>1D4AO#$^G'9'T0"_/VG="JA$%F5]OM<UVMA1VWD@UD]-DSN&=@
MR7X5^\-FPU>=)5E0W&X%"]CX'3)!:7C+ +ME><74F]P^Q<0QY^G,"L:G#^7]
M3U0L+.@HM4IZ9278'8I&DZ[O]:^=B<9W?#ZF9]$=05RYTX+[+E:ACCC68_2]
M</;6C-ON"%D_+<2[QO503UJ5H$1X+B9<8JV$^M[(P6ULG^63<N8DP7K%^5J6
MC=MI\J$CPHQ1A?KC;KJC(X/&LO#2XS$@(O13@"\(/68"&KRE&L:AWRE5O428
M]S@/<AOM.F/.RN=M(T!;0RZA/<C$N9S.&B1?BI\J_$N)<2&O5)1IM-Q\^+%Z
M!$T,K*)E)0&5JS7\ [Z ;\46HF)A\PI,9#.+,JZ$@BQ!IF5O!5GV,<Q%JA!-
M(1H3XG2F9;2+T$RNY48JUU8.E]"SRQ4@+ZL<KZG)<5"$X.3%+9B<5<%7JWF)
M/\_#F)&<()?(UJRI\^,*;JNX.XP]CG0$MVOE$Y-]:#I]ABG&+\<D-LW.NQFN
M CY;GE]Y$ATQB,!Y.C#]P($3^9,YWORQKM??R^TVF')E'D*2JRBZQ=E+QCB.
MT)1;D1_UYPT<7J,&Q'-J/>PY?ERRLEBL5GWQ$V\>(+[7U-^[1_B6BLI[.YAZ
M:CV&J4%,CR+:QA%:;,8GD9VOG/VB7LFFBG=B9F^RB7Z&P4,D&WI_I?L,=:G(
M'@;NO0[R0E#97VD.%Q7W4R.HO7$>0F*>%H?F/.P'L(YIZ"0)N"29.>^GP69Z
MC-*\V_T:*48T%PE8H&>="HM\J+S6W+6O=K._0*7A7G0Z+L7$7)1^R DD8Q_+
M9([EKJVY[X8&N].J<&&LU8$XI?J6)MTP3B(FN7369,\J'3)@Q,];KH&E;*2T
M0$E4/Q; &_1HE3EFC2?57E,(Q"66RIC,$C-Y_CHNL6_Y1W"U].!W)C[CN$E(
M(;8FT8C&?=.9DS,'"#NXU5%=KO37WY\&D^\Z,Y$Y(1?#H3D[J (?T:FW79AI
M],G7$E]$_?JR;K[PYIO0L;S>$U4CH1YG:IJ^I=,(:X5MH"F/GHU:NY]$.IHZ
M,YUW6:/?'XNR@B2P9:4@?"[$\K[)'&&_'TP,,9794/RB<8VLD:2?8H BU$T6
M8T#>#E>#A7A=%]6R*1]TJD7[2YIM#,.8/6XNN0@./3$3V<. G >?57ZXG^AB
M*HB#:2Z'E($ZB4M]T78T;2D(04Y<%'H$_J'GZRE$E'&+C8VEO2L_CM.P9TBZ
MZM$\T!H2:(Q;DD'FY-5P^TUD\MC2"WJ'U$*TG)>VFG>/'%Q3#1.?V4(\05*B
M]0= BP"DI% NX(D34$=;1^)XB&W_M)>8_*^2A^IA/;8/<PL^\[Z^W#55V>T:
M+A9\6?Z GRR+'FU6;D;(/67&S"1WP$\.)ML8\=E;,0U9L7;JWX0$U7&*\"@A
M,IZP2M.Q*9EF3(*369;7>R^C;[HX-I*>H&*-IE!X!N#7R-HQ"7A)S*C<ZMS8
MUE>;9?Y.W)M,+0+?QC8!>??HY[KZ&O%PBT?$O\@13P&'-RP7XZ1#3>8S'"]A
M4_5IXI:Y$O15X/2!,NHVG&T90<J?7Y;E ;2CIO:A+,PLZK/5"LI[6R$;T/]4
MNJ'2\ )%Y7((TV-ZZ  ]CMH-'2 )DU24 SFMY4"+JF"Z9;#;UUP0[F+$H=IM
M$D-F(B*DBYCK,4/-$26^+2Z^4<R\QV&:%Z3=:[@R4>Z)7,X+L5-LBT:8PK\7
M#Q*J3>=0M4G-9&#LBS1$83A4SJ^VN[7"_FYEN1&D)\L'=/"+?:FWQ$T 4BA&
M+\9D3F6^"<65W$!O^ NN_KVJ]FX&R/%0&+B6[R-09"EG86_,?&\!!6'_[E0I
M,1HLV)J6NM+D$%9@TGX-4TEB5\YA4ZU-;<#T^)1[DH.XS7RSZX%[ !?"4::)
MS,R>X68'3#X5W:XINY>+HN,);7*=:)(9SV "O&,N>33)0V,\FA1D3E9X80<"
MU0ME8SWYI^*Y;O]BD&%C /E4F3,CLKSI,0CQ>5TM2"PAX@/ @CYM(J;Z3&(U
M 4L_QH_,IYJT7V\:_ER4IJ%EQ)Y73EL]9( "<ZQY*O<M2HS7BQL@/;<7K;\'
M0;>M*RB2ASL1!9"=KEP,DRI5PP_4.V-%8S)GP@K'@8RF3P_5G6=@ WNQ> ,Y
MH6JX=L3-%E57KLY[L24PY:<"W9-XO[#9]@ 5#!+P32/LWHS R\I5Z\!<F.4P
MN1[B0&HFKJ<[[$\D\+P:VV51-C*'^C/OAHQ=:9(9H_OED[#.=PU?+R$Q1%R:
M&N&C_5K5]RUO).#85?6\Z\: F6G7%BS Y*T#QNRP"&47LS?].MXRLQ)(E^[7
M(O%6Q%ZVE\/D>O:03>>6U9F-]Z@3-:_@J?I/J'OB;-<]U@TD-*4TH#!W)AN&
M$9]] 8(PV4;ISVF6?R@::)G8BGM;+B:Q!Y<9!GJ,DL=\T7<B)&(B2N)*[GBO
M%3Q9;J[!)ZL2O[W17COV!-W1Y!!U;A-_,5Y:T#!OF/"L9Y=I)G+)UY!QY+%4
MHLU9]/"@[4<LHC1*<0=D.H_RJE-13;%-4Q5YC^]\*@NA?45OEDFFPBQMA:.*
MX2"3X00;(>LYM8?>!#&!/C:=@@.PCU:UD)GX=H![-F@ J:3B0<XI;,J;E]"[
MQLQY*H[0/AAGA5RG^Q_[:PCN'2N\:1=HS,P8.Y ;89_C 8S-N@5Z(W!H9KW<
M_%[ *>5'NATL=JL%.$C=#"2ND C1%+2$_4S(G^JM2W#@:$@TF$S?TY!U1)<5
M[J<'$TDB$S(CD\HO.+%0T217SJU&$24"M8G\U!)ABLK4Z''2R(3"H3ZS!NXA
M-_DF5CQ$"$R:1C<FPT,XETFX@"IW439\U=41W#SS%'$!GKM@F^,^<O*Z/5'L
M]<3KPPM2G^1VH_")IE"+>D?3V9333YJ2_#BQ^L*708J58] 78X0H1F^HJ0PC
MSX4ZN*[ZJA+ZD#A:)J51':%VOG\OJ6EV$DXFIFL=2V1Y+?L 5I9J<M9*3[?5
M\.P+!/B"6>L)N&/#W"H):6C_-DQ/G%WT&LY,2$^9PFK2U.9#TIFQ_&6J$(*'
M%CQJ$"3<_D+K\?+%_POQ*7N_MJ*3+EWISC$//39\HXAL!962PDW1WDLR]4A!
M[J^__ ??=JWYS3OXS;L___+NMU_^_4>[_C?/*S(?)O:[@5?HX: ?TFX]4LT0
M%\CXJW5H&G^%AVV :W%[7(D?V]-N@N$U69,3]]\>WPKP*)//DN=M^V6$[HLQ
MD9./!C '^[F^K'A5B$OA[$>9M#'$8&M3B/_M;PC_[!GV@_?EONV@'V%_P$,T
M/OZH.(P)[R=,<5:O7NR.?^B=+'XC_@,15"#I_P%02P,$%   " @ NI@^4X($
M]8+<70  ^F,& !4   !N=')B+3(P,C$P-S,Q7W!R92YX;6SMO7MSY+BQ)_K_
M?HK>WG_N#4>[>WJ.S[@=]MDHO=JRU2I=2>TYGHV-"8I$E3##(FOX4*OFTU^
MCRH^0!  $TQ2JH@]ZQY)1";REP 2B7S\]7\_;_PW3R2*:1C\[>UW?_SP]@T)
MW-"CP?IO;[_>O5O<G5Y>OOW?__7FS?_XZ_]\]^[-9Q*0R$F(]^9A]^8TW&SO
M7/KF/G*">!5&FS?_3[+Y?]^\>_.8)-N_O'__[=NW/[KL;V*71B0.T\@E,?_!
MFW?OV(#ED*<1X0/^Y<W]8_KFCFS??/_AS<>/?_D/]O_^_.;K_>F;CQ\^?I=_
M\C_^ZM/@UP<G)F\8WT'\M[<52L\/D?_',%J___CAP_?ORS]\F__E7Y[Y#VI_
M_^W[[*^_^_3IT_OLM_L_C:GH#]FPW[W_[R]7=^XCV3CO:! G3N!R C']2YS]
M\"ITG2239"]?;SK_@O_7N_+/WO$?O?ONX[OOO_OC<^R]S>7VYLU?H] GMV3U
M)N/\+\EN2_[V-J:;K<\9RG[V&)'5W]X&2?3PCDOPPP_Y$/^+_^3GZ.?3,(A#
MGWI<]B>.SZ=R]TA(\O8-'_KK[>5^$D&:1/3!"3R.W7O^V_>='[__+\OL_7SC
M1"1('DE"7<>/!W';',L*\Y=L.6W(7<+^O6'$M!EN?L^9A.'R[I%-_S'T/;;\
MSW]+:;*[9X-\#*/OE9B4?,YX!)?CJ1,_7OCA-VT![C]\#[=XEM':">COV6)G
MA,]([$9TR_\K7)VD,0U(K*::2@-!B7/A,IAB:L"F^$LHOFZB<$NB9,=(<D7:
M*J\3X8> ,.=K[]YY)FIBJOX]E'"NPX3$-\[.>? )4VMV5B>4_?.,/*C)2/8]
MW%YR&;##<,T'7L0Q253%U?@(2F9G)*)/;$T]D2OJ/%"?*:XB@N(OH?BZ)3[?
MD=BQPS9+;C0Y+E]2:JQU?@QV;-TEH?MK;4=7.PC:G^5K$(:K'YV(S3:)&<WE
M5EU<@L\@N;HBS#I3XZ3X4[A#<;.A"=_J^-S8DD[HFMGLJAHN^1R*P[OT(2:_
MI8S$^1.GHZ9%S8_@N-ELG&@7KN[H.J K9NH%R<)UPY3-/%C?,#-!67:*0T'J
M67OXDUWV+[6U*?D<2KXJ)LP]/WW@+*)B.+CC2VC?:# M^QZ.2Y&YH\&DY',H
M7:@80!J,M;^"DYG$_-'@L'\4R#7?M(NT1"G\%$Z>0@-)@T'9]W!<M@]_#18[
M/X8SM)3.$0V6M0:$FX;[2+S4)^'*H[&S7D=D[>1;8$38&9X6%-5FH#B6!>8+
M @^[-0G7D;-]Y-X@OW#EF<Q 84 +T]@6V_O6=_@FX)':'J\YA9[! ._8!YH!
M29QLTW+X:1H1SX3QCD$ O69[4FG@I!YE5S(F+.[]=MR0"2J(B;>BS'1QJ</&
MRWYAJD@F%,#,YI8N0.F4774J=T)&[8GR9PTF'YH9&,G>P-#;4Z4CV5"LB#"<
M778V%CM@1BX,<MK\025E*N$DR2-9$7;I=OPX<9(T":,=?YI)0F?#-WZCS1>4
M-+PJ>HQLQ!8U8RM;Y6P6?L.,T#UM%$:TLMMM:$ WZ<;GSH&ML\LNY"83Z!['
M"MMT;V#FVRQ3EYC&3"FR7Q'?)VZ2.GZYUMTT3ICF1/PMBTT@B1R/L%7U:\SV
MZ7#%M(49TK\;[X^6F;%P2),XH1ONQALZ=<E T,NNN2=X>Q-^T-K3&-:*)G\K
MS/PP3?A++G_R-@&B<Q@+VN-X7N9CJ!W[$?<+,ZI)"#0C4RI64 KS&]C *76-
M GEK5[S!?("\#GVP(_3^"XSN+%1&M#(5^45&=QI]H\%;/.+[C"[?7:/8T7^#
M:XONA(Q(V+#5.R\UIJHUBE9] 3(^N\>9H?&IBYAM;JR(L-MNU)V^;"0;*ZW+
M[M#ENWL<*P(WM*9T9V5,9LQGP#-V#%'%H#V=\6 ?7 5/>3J,2P> Y%3TGJ?#
MJ.Q[R,B@_>.>#G."SR!E)WG0T^%281BP:V#S:4]/FN)O(44J?-G385(Z "2G
M79%4.LSVC0%FL[6"JW2X[/X:\*QKOY?JL-C]-2"+>0B6#EOU+R"UKSL 2X>_
M_E% [W:-X"PM'>SX%I8_E?=O/:YU1H10U;/033F>"W8<,R+)[O)@R*GMG[(!
M]@?Z-B(Q^Z/LIU>,GQJGY#DA[/[IE;SR<8WR0/)#CY'S0[=&(?/YA%%)P'<>
MB/^WMVG\;NTXVY_W:0[+U45YC[\)<V-J\1"S.Y.;U.7(>8L9<UD.S<J)'[)$
MFF*\]US [XF?Q.5/,I&_^_!=D4_SO[0(OS><57[F6N6_0:)$NX'W(JJS[41N
MR0W[9PWL=EY2\1?OMUG2S#OWD?I[/5E%X<8,Q23LEE,8L7/K;V\_\*PT-HW\
MH>XJEVTGFQF/"3OO2/:7AZ5I"-MI&O'YCH!>D])!W1 P%.ML&ZV6>)!!X]D^
M; /D_\,-GB?'YV?.(CEE9L:.[=S_<OR46 %1C7)U9FBP=NAT%5U%.8*A;;1
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M4PE=>K/5"VW!(M6O4S&3%BZ[D>:%WVR]4RH2QT[9&FYRUF4)5A8/W.S$PEQ
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M@)78',ER(9P.8L9>V.:(EB^=G=2P_:=],-8+]W3*;(:>S[MTLW&B7;BZH^N
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M]KBB3."Z!&AB=D9C9[V.R+JH)E&HD!%JJF/-8&=5%@M<S7>SS=0ES/Y_\'L
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M;2?X##O]44.W.2ZBB0-FT1LEVJ910'EY#L;]!7WF_[+IE9*00PW)T01217J
M$59&R'YQV'P#$NVJT[$(K8P><D*0(;I2";XN!Z7ZV6/M]E\(_/MA>:<WZ8-/
MW:])V86H2S.6R2.)%$+P[)@NT$R^##M'Z$&U!^RL/; !DVI6>\4IJH4?/*^F
MOM=KDC0*D)OY7+O'T3=C!/6O3\/-IDALN8SC]" \*7M* ^'&=O3*GR\'-8$@
M&9T\]; H4Z@!3?LK;&^L$A*"R6*9A!4-8)L=9RSGZ#*HJ(D2%FHCS0(?1:$
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M<,O?1D#O=H<1<>"QN=K+>T%%:@BWMHRZN@6KCAIB,URA+M;$+2CY;J3Q7VA
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MKBZMT"A@N\=>:%0O4:2#<!*H:EE*X&%7T$I4"0&JWD_'5JLN-E[?5F:J:9U
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M@SNI3>X^TK^8Q5*#JQ>GA><M<?,6(.6$>&#9%74>J$^3W7V8.\^55I_B4/-
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M+=J=AA[$W5,^_BP,/25!P>5.=OL1__J>\_7@Q(3_U_\/4$L! A0 %  (" @
MZ9@^4QGR2+,*,P, >GL< !L                      &5A,30X,C V+7,Q
M83)?;G5T<FEB86YD+FAT;5!+ 0(4 !0   @( +J8/E-25/2)7>H  /2[!  ;
M                 %,S P!E83$T.#(P-F5X,2TQ7VYU=')I8F%N9"YH=&U0
M2P$"%  4   (" "ZF#Y3*,@4V9$"  !L"   &@                #I'00
M96$Q-#@R,#9E>#(S7VYU=')I8F%N9"YH=&U02P$"%  4   (" "ZF#Y3"S1(
M10I+  !;<@$ '                 "R( 0 96$Q-#@R,#9E>#0M,3)?;G5T
M<FEB86YD+FAT;5!+ 0(4 !0   @( +J8/E-'#@=*\44  .9> 0 <
M         /9K! !E83$T.#(P-F5X-"TQ,U]N=71R:6)A;F0N:'1M4$L! A0
M%   " @ NI@^4S=5DV\U"@  5"D  !L                 (;($ &5A,30X
M,C V97@U+3%?;G5T<FEB86YD+FAT;5!+ 0(4 !0   @( +J8/E,#LA59[1L
M )MB 0 1                 (^\! !N=')B+3(P,C$P-S,Q+GAS9%!+ 0(4
M !0   @( +J8/E.=-3=W; P  /^.   5                 *O8! !N=')B
M+3(P,C$P-S,Q7V-A;"YX;6Q02P$"%  4   (" "ZF#Y3JY5F/6A<  "E&@8
M%0                !*Y00 ;G1R8BTR,#(Q,#<S,5]D968N>&UL4$L! A0
M%   " @ NI@^4S\I)>$FQ   :50* !4                 Y4$% &YT<F(M
M,C R,3 W,S%?;&%B+GAM;%!+ 0(4 !0   @( +J8/E."!/6"W%T  /IC!@ 5
M                 #X&!@!N=')B+3(P,C$P-S,Q7W!R92YX;6Q02P4&
/  L "P " P  360&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
